

0001628280-24-03610410-Q ARROWHEAD PHARMACEUTICALS, INC. 202408082024040808160319160319 0 0001628280-24-036104 10-Q 86 20240630 20240808 20240808
ARROWHEAD PHARMACEUTICALS, INC. 0000879407 2834 460408024 DE 0930 10-04-001-38042 241188083 177 E COLORADO BLVD SUITE 700 PASADENA CA 91105 626-696-4702 177
E COLORADO BLVD SUITE 700 PASADENA CA 91105 ARROWHEAD RESEARCH CORP 20040112 INTERACTIVE GROUP INC 20020509 INTERACTIVE INC 19940224 10-Q 1 arwr-
20240630.htm 10-Q arwr-20240630000087940709-
302024Q3false12/31/202415xbrii:sharesiso42171:USDiso4217:USDxbrii:sharesarwr:obligationxbrii:purearwr:bundlearwr:agreementutr:sgftarwr:option00008794072023-10-012024-06-
3000008794072024-08-0100008794072024-06-3000008794072023-09-3000008794072024-04-012024-06-3000008794072023-04-012023-06-3000008794072022-10-012023-06-
300000879407us-gaap:CommonStockMember2023-09-300000879407us-gaap:AdditionalPaidInCapitalMember2023-09-300000879407us-
gaap:AccumulatedOtherComprehensiveIncomeMember2023-09-300000879407us-gaap:RetainedEarningsMember2023-09-300000879407us-gaap:NoncontrollingInterestMember2023-09-
300000879407us-gaap:AdditionalPaidInCapitalMember2023-10-012023-12-3100008794072023-10-012023-12-310000879407us-gaap:CommonStockMember2023-10-012023-12-
310000879407us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-10-012023-12-310000879407us-gaap:RetainedEarningsMember2023-10-012023-12-310000879407us-
gaap:NoncontrollingInterestMember2023-10-012023-12-310000879407us-gaap:CommonStockMember2023-12-310000879407us-gaap:AdditionalPaidInCapitalMember2023-12-
310000879407us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-12-310000879407us-gaap:RetainedEarningsMember2023-12-310000879407us-
gaap:NoncontrollingInterestMember2023-12-3100008794072023-12-310000879407us-gaap:AdditionalPaidInCapitalMember2024-01-012024-03-3100008794072024-01-012024-03-
310000879407us-gaap:CommonStockMember2024-01-012024-03-310000879407us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-01-012024-03-310000879407us-
gaap:RetainedEarningsMember2024-01-012024-03-310000879407us-gaap:NoncontrollingInterestMember2024-01-012024-03-310000879407us-gaap:CommonStockMember2024-03-
310000879407us-gaap:AdditionalPaidInCapitalMember2024-03-310000879407us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-03-310000879407us-
gaap:RetainedEarningsMember2024-03-310000879407us-gaap:NoncontrollingInterestMember2024-03-3100008794072024-03-310000879407us-gaap:AdditionalPaidInCapitalMember2024-04-
012024-06-300000879407us-gaap:CommonStockMember2024-04-012024-06-300000879407us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-04-012024-06-300000879407us-
gaap:RetainedEarningsMember2024-04-012024-06-300000879407us-gaap:NoncontrollingInterestMember2024-04-012024-06-300000879407us-gaap:CommonStockMember2024-06-
300000879407us-gaap:AdditionalPaidInCapitalMember2024-06-300000879407us-gaap:AccumulatedOtherComprehensiveIncomeMember2024-06-300000879407us-
gaap:RetainedEarningsMember2024-06-300000879407us-gaap:NoncontrollingInterestMember2024-06-300000879407us-gaap:CommonStockMember2022-09-300000879407us-
gaap:AdditionalPaidInCapitalMember2022-09-300000879407us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-09-300000879407us-gaap:RetainedEarningsMember2022-09-
300000879407us-gaap:NoncontrollingInterestMember2022-09-3000008794072022-09-300000879407us-gaap:AdditionalPaidInCapitalMember2022-10-012022-12-3100008794072022-10-012022-
12-310000879407us-gaap:CommonStockMember2022-10-012022-12-310000879407us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-10-012022-12-310000879407us-
gaap:RetainedEarningsMember2022-10-012022-12-310000879407us-gaap:NoncontrollingInterestMember2022-10-012022-12-310000879407us-gaap:CommonStockMember2022-12-
310000879407us-gaap:AdditionalPaidInCapitalMember2022-12-310000879407us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310000879407us-
gaap:RetainedEarningsMember2022-12-310000879407us-gaap:NoncontrollingInterestMember2022-12-3100008794072022-12-310000879407us-gaap:AdditionalPaidInCapitalMember2023-01-
012023-03-3100008794072023-01-012023-03-310000879407us-gaap:CommonStockMember2023-01-012023-03-310000879407us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-
012023-03-310000879407us-gaap:RetainedEarningsMember2023-01-012023-03-310000879407us-gaap:NoncontrollingInterestMember2023-01-012023-03-310000879407us-
gaap:CommonStockMember2023-03-310000879407us-gaap:AdditionalPaidInCapitalMember2023-03-310000879407us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-03-
310000879407us-gaap:RetainedEarningsMember2023-03-310000879407us-gaap:NoncontrollingInterestMember2023-03-3100008794072023-03-310000879407us-
gaap:AdditionalPaidInCapitalMember2023-04-012023-06-300000879407us-gaap:CommonStockMember2023-04-012023-06-300000879407us-
gaap:AccumulatedOtherComprehensiveIncomeMember2023-04-012023-06-300000879407us-gaap:RetainedEarningsMember2023-04-012023-06-300000879407us-
gaap:NoncontrollingInterestMember2023-04-012023-06-300000879407us-gaap:CommonStockMember2023-06-300000879407us-gaap:AdditionalPaidInCapitalMember2023-06-
300000879407us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-06-300000879407us-gaap:RetainedEarningsMember2023-06-300000879407us-
gaap:NoncontrollingInterestMember2023-06-3000008794072023-06-300000879407arwr:AmgenIncorporatedMemberarwr:RoyaltyPharmaAgreementMember2024-06-
300000879407arwr:UnderwritingAgreementMember2024-01-02024-01-020000879407arwr:UnderwritingAgreementMember2024-01-
020000879407arwr:GlaxosmithklineIntellectualPropertyLimitedMember2024-04-012024-06-300000879407arwr:GlaxosmithklineIntellectualPropertyLimitedMember2023-04-012023-06-
300000879407arwr:GlaxosmithklineIntellectualPropertyLimitedMember2023-10-012024-06-300000879407arwr:GlaxosmithklineIntellectualPropertyLimitedMember2022-10-012023-06-
300000879407arwr:HorizonTherapeuticsIrelandDACMember2024-04-012024-06-300000879407arwr:HorizonTherapeuticsIrelandDACMember2023-04-012023-06-
300000879407arwr:HorizonTherapeuticsIrelandDACMember2023-10-012024-06-300000879407arwr:HorizonTherapeuticsIrelandDACMember2022-10-012023-06-
300000879407arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember2024-04-012024-06-
300000879407arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember2023-04-012023-06-
300000879407arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember2023-10-012024-06-
300000879407arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember2022-10-012023-06-
300000879407arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember2022-10-012023-06-300000879407arwr:JanssenPharmaceuticalsIncorporationMember2024-04-012024-
06-300000879407arwr:JanssenPharmaceuticalsIncorporationMember2023-04-012023-06-300000879407arwr:JanssenPharmaceuticalsIncorporationMember2023-10-012024-06-
300000879407arwr:JanssenPharmaceuticalsIncorporationMember2022-10-012023-06-300000879407arwr:AmgenIncorporatedMember2024-04-012024-06-
300000879407arwr:AmgenIncorporatedMember2023-04-012023-06-300000879407arwr:AmgenIncorporatedMember2023-10-012024-06-300000879407arwr:AmgenIncorporatedMember2022-
10-012023-06-300000879407arwr:GlaxosmithklineIntellectualPropertyLimitedMemberarwr:GSKHSDLicenseAgreementMember2023-06-
300000879407arwr:GlaxosmithklineIntellectualPropertyLimitedMemberarwr:GSKHSDLicenseAgreementMember2021-11-
220000879407arwr:GlaxosmithklineIntellectualPropertyLimitedMembersrt:MaximumMemberarwr:GSKHSDLicenseAgreementMember2021-11-
220000879407arwr:GlaxosmithklineIntellectualPropertyLimitedMemberarwr:GSKHBVAgreementMember2023-12-012023-12-
310000879407arwr:GlaxosmithklineIntellectualPropertyLimitedMembersrt:MaximumMemberarwr:GSKHBVAgreementMember2023-12-
110000879407arwr:GlaxosmithklineIntellectualPropertyLimitedMemberarwr:GSKHBVAgreementMember2024-06-
300000879407arwr:HorizonTherapeuticsIrelandDACMemberarwr:HorizonLicenseAgreementMember2021-06-012021-06-
300000879407arwr:HorizonTherapeuticsIrelandDACMemberarwr:HorizonLicenseAgreementMember2021-07-012021-07-
310000879407arwr:HorizonTherapeuticsIrelandDACMemberarwr:HorizonLicenseAgreementMember2023-01-
310000879407arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMembersrt:MinimumMemberarwr:LicenseAndCoFundingAgreementMember2020-10-012020-10-
310000879407arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMembersrt:MaximumMemberarwr:LicenseAndCoFundingAgreementMember2020-10-012020-10-
310000879407arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMemberarwr:LicenseAndCoFundingAgreementMember2020-10-012020-10-
310000879407arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMemberarwr:LicenseAndCoFundingAgreementMember2023-03-
310000879407arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMembersrt:MaximumMemberarwr:LicenseAndCoFundingAgreementMember2024-06-
300000879407arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMemberarwr:LicenseAndCoFundingAgreementMember2024-06-
300000879407arwr:AmgenIncorporatedMemberarwr:OlpasiranAgreementMember2016-09-300000879407arwr:AmgenIncorporatedMemberarwr:OlpasiranAgreementMember2016-09-012016-
09-300000879407arwr:AmgenIncorporatedMemberarwr:OlpasiranAgreementMember2024-06-300000879407arwr:AmgenIncorporatedMemberarwr:OlpasiranAgreementMember2018-09-
300000879407arwr:AmgenIncorporatedMemberarwr:OlpasiranAgreementMember2020-07-310000879407arwr:AmgenIncorporatedMemberarwr:OlpasiranAgreementMember2022-12-
310000879407arwr:AmgenIncorporatedMembersrt:MaximumMemberarwr:OlpasiranAgreementMember2024-06-
300000879407arwr:VisirnaTherapeuticsIncMemberarwr:VisirnaLicenseAgreementMember2023-10-012024-06-
300000879407arwr:VisirnaTherapeuticsIncMemberarwr:VisirnaLicenseAgreementMember2022-10-012023-06-
300000879407arwr:VisirnaTherapeuticsIncMemberarwr:VisirnaLicenseAgreementMember2024-06-300000879407us-gaap:LandMember2024-06-300000879407us-gaap:LandMember2023-09-
300000879407us-gaap:BuildingMember2024-06-300000879407us-gaap:BuildingMember2023-09-300000879407arwr:ResearchEquipmentMember2024-06-300000879407us-gaap:ResearchEquipmentMember2024-06-
300000879407us-gaap:ResearchEquipmentMember2023-09-300000879407us-gaap:FurnitureAndFixturesMember2024-06-300000879407us-gaap:FurnitureAndFixturesMember2023-09-
300000879407arwr:ComputerAndSoftwareMember2024-06-300000879407arwr:ComputerAndSoftwareMember2023-09-300000879407us-gaap:LeaseholdImprovementsMember2024-06-
300000879407us-gaap:LeaseholdImprovementsMember2023-09-300000879407us-gaap:ConstructionInProgressMember2024-06-300000879407us-gaap:ConstructionInProgressMember2023-09-
300000879407us-gaap:ConstructionInProgressMember2023-10-012024-06-300000879407us-gaap:BuildingMember2023-10-012024-06-300000879407us-gaap:BuildingMember2023-12-
310000879407us-gaap:DebtSecuritiesMember2024-06-300000879407us-gaap:DebtSecuritiesMember2023-09-300000879407us-gaap:PatentsMemberarwr:NovartisMember2024-06-
300000879407us-gaap:LicensingAgreementsMemberarwr:NovartisMember2024-06-300000879407arwr:NovartisMember2024-06-300000879407us-
gaap:PatentsMemberarwr:NovartisMember2023-09-300000879407us-gaap:LicensingAgreementsMemberarwr:NovartisMember2023-09-300000879407arwr:NovartisMember2023-09-
300000879407arwr:TwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember2024-06-
300000879407arwr:TwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember2023-09-
300000879407arwr:AtTheMarketAgreementMembersrt:MaximumMember2022-12-020000879407arwr:AtTheMarketAgreementMembersrt:MaximumMember2022-12-022022-12-
020000879407arwr:AtTheMarketAgreementMember2024-06-300000879407stpr:Warwr:DrugManufacturingFacilityMember2021-12-
200000879407stpr:Warwr:LaboratoryAndOfficeFacilityMember2021-12-200000879407arwr:FacilitiesMember2024-06-300000879407srt:MinimumMemberarwr:FacilitiesMember2024-06-
300000879407srt:MaximumMemberarwr:FacilitiesMember2024-06-300000879407stpr:CAarwr:CorporateHeadquartersInPasadenaMember2024-06-
300000879407stpr:CAarwr:ColoradoOwnerLLCMemberarwr:CorporateHeadquartersInPasadenaMember2024-06-300000879407stpr:CAarwr:ResearchFacilityInSanDiegoMember2024-06-
300000879407stpr:CAarwr:MaximumMemberarwr:ResearchFacilityInSanDiegoMember2024-06-300000879407stpr:CAarwr:ResearchFacilityInSanDiegoMember2023-09-
250000879407stpr:CAarwr:ResearchFacilityInSanDiegoMember2023-12-310000879407stpr:Warwr:ResearchFacilityInMadisonMember2023-04-06-300000879407us-
gaap:ResearchAndDevelopmentExpenseMember2024-04-012024-06-300000879407us-gaap:ResearchAndDevelopmentExpenseMember2023-04-012023-06-300000879407us-
gaap:ResearchAndDevelopmentExpenseMember2023-10-012024-06-300000879407us-gaap:ResearchAndDevelopmentExpenseMember2022-10-012023-06-300000879407us-
gaap:GeneralAndAdministrativeExpenseMember2024-04-012024-06-300000879407us-gaap:GeneralAndAdministrativeExpenseMember2023-04-012023-06-300000879407us-
gaap:GeneralAndAdministrativeExpenseMember2023-10-012024-06-300000879407us-gaap:GeneralAndAdministrativeExpenseMember2022-10-012023-06-
300000879407arwr:TwoThousandsThirteenIncentivePlanMember2024-06-300000879407arwr:TwoThousandTwentyOneIncentivePlanMember2021-09-
300000879407arwr:TwoThousandsThirteenIncentivePlanMember2023-10-012024-06-300000879407arwr:TwoThousandTwentyOneIncentivePlanMember2023-10-012024-06-300000879407us-
gaap:EmployeeStockOptionMemberarwr:InducementAwardsMember2024-06-300000879407us-gaap:RestrictedStockUnitsRSUMemberarwr:InducementAwardsMember2024-06-
300000879407arwr:TwoThousandTwentyOneIncentivePlanMember2024-06-300000879407arwr:InducementAwardsMember2024-06-300000879407us-
gaap:RestrictedStockUnitsRSUMemberarwr:TwoThousandsThirteenIncentivePlanMember2024-06-300000879407us-
gaap:RestrictedStockUnitsRSUMemberarwr:TwoThousandTwentyOneIncentivePlanMember2024-06-300000879407us-gaap:RestrictedStockUnitsRSUMember2024-06-300000879407us-
gaap:EmployeeStockOptionMember2024-04-012024-06-300000879407us-gaap:EmployeeStockOptionMember2023-04-012023-06-300000879407us-gaap:EmployeeStockOptionMember2023-10-
012024-06-300000879407us-gaap:EmployeeStockOptionMember2022-10-012023-06-300000879407us-gaap:EmployeeStockOptionMember2024-06-
300000879407arwr:VisirnaESOPMember2023-10-012023-10-010000879407arwr:VisirnaESOPMember2023-10-010000879407arwr:VisirnaESOPMember2024-04-012024-06-
300000879407arwr:VisirnaESOPMember2023-10-012024-06-300000879407us-gaap:RestrictedStockUnitsRSUMember2023-09-300000879407us-gaap:RestrictedStockUnitsRSUMember2023-10-
012024-06-300000879407us-gaap:RestrictedStockUnitsRSUMember2024-04-012024-06-300000879407us-gaap:RestrictedStockUnitsRSUMember2023-04-012023-06-300000879407us-
gaap:RestrictedStockUnitsRSUMember2022-10-012023-06-300000879407us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-
gaap:USGovernmentDebtSecuritiesMember2024-06-300000879407us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-
gaap:USGovernmentDebtSecuritiesMember2024-06-300000879407us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-
gaap:USGovernmentDebtSecuritiesMember2024-06-300000879407us-gaap:FairValueMeasurementsRecurringMemberus-gaap:USGovernmentDebtSecuritiesMember2024-06-300000879407us-
gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberarwr:CommercialNotesMember2024-06-300000879407us-gaap:FairValueInputsLevel2Memberus-
gaap:FairValueMeasurementsRecurringMemberarwr:CommercialNotesMember2024-06-300000879407us-gaap:FairValueInputsLevel3Memberus-
gaap:FairValueMeasurementsRecurringMemberarwr:CommercialNotesMember2024-06-300000879407us-gaap:FairValueMeasurementsRecurringMemberarwr:CommercialNotesMember2024-
06-300000879407us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2024-06-300000879407us-
gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2024-06-300000879407us-
gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2024-06-300000879407us-
gaap:FairValueMeasurementsRecurringMemberus-gaap:CorporateDebtSecuritiesMember2024-06-300000879407us-gaap:FairValueInputsLevel1Memberus-
gaap:FairValueMeasurementsRecurringMember2024-06-300000879407us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-06-300000879407us-
gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2024-06-300000879407us-gaap:FairValueMeasurementsRecurringMember2024-06-300000879407us-
gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-06-300000879407us-gaap:MoneyMarketFundsMemberus-
gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2024-06-300000879407us-gaap:MoneyMarketFundsMemberus-gaap:FairValueInputsLevel3Memberus-
gaap:FairValueMeasurementsRecurringMember2024-06-300000879407us-gaap:MoneyMarketFundsMemberus-gaap:FairValueMeasurementsRecurringMember2024-06-
300000879407arwr:CommercialNotesMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2024-06-

[illegible]

Phase 3 PALISADE study of investigational plazosiran in patients with familial chylomicronemia syndrome (FCS). The Company highlighted recent data for its cardiometabolic pipeline at its June 25, 2024, Cardiometabolic event;â€Presented preclinical data on ARO-INHBE for the treatment of obesity and metabolic diseases at the American Diabetes Association 84th Scientific Sessions. INHBE small interfering RNA (siRNA) administration resulted in multiple promising findings including: (1) 95% reduction in INHBE mRNA expression, (2) 19% suppression of body weight compared to saline controls, (3) 26% loss of fat mass, and (4) preservation of lean mass;â€Announced results from the Phase 2b double blind, randomized ARCHES-2 study of investigational zodosiran in patients with mixed hyperlipidemia;5â€Announced that new interim clinical data on ARO-RAGE achieves high level of gene knockdown in patients with asthma; â€Completed enrollment in Amgenâ€s Phase 3 OCEAN(a - outcome trial of olpasiran, triggering a \$50.0A million milestone payment to the Company, which was paid in the third quarter of fiscal 2024;â€Presented final data from the double-blind treatment period of the Companyâ€s Phase 2 SHASTA-2 study of investigational plazosiran in patients with severe Hypertriglyceridemia. Results from the SHASTA-2 study showed dramatic, consistent, and sustained reductions in Apolipoprotein C-III (APOC3) and triglycerides and improvement in multiple atherogenic lipoprotein levels; â€Announced an Expanded Access Program (â€eEAPâ€) to make investigational plazosiran available outside of a clinical trial for qualifying patients with FCS; â€Initiated a Phase 1/2a clinical trial of ARO-DM1, being developed as a potential treatment for type 1 myotonic dystrophy (DM1), the most common adult-onset muscular dystrophy;â€Filed an application for clearance to initiate a Phase 1/2a clinical trial of ARO-CFB, being developed as a potential treatment for complement mediated renal disease; â€Entered into an Amended and Restated License Agreement with GSK, pursuant to which GSK received a worldwide, exclusive license to develop and commercialize daplusiran/tomligisiran (GSK5637608, formerly JNJ-3989). Daplusiran/tomligisiran had previously been licensed to Janssen Pharmaceuticals, Inc. See Note 2.Consolidation and Basis of PresentationThe interim Consolidated Financial Statements include the accounts of Arrowhead Pharmaceuticals, Inc. and its subsidiaries (wholly-owned subsidiaries and a variable interest entity for which the Company is the primary beneficiary). Subsidiaries refer to Arrowhead Madison, Inc., Visirna Therapeutics, Inc. (â€Visirnaâ€), and Arrowhead Australia Pty Ltd. For subsidiaries in which the Company owns or is exposed to less than 100% of the economics, the Company records net loss attributable to noncontrolling interests in its consolidated statements of operations equal to the percentage of the economic or ownership interests retained in such entity by the respective noncontrolling party.The interim Consolidated Financial Statements have been prepared in conformity with U.S. generally accepted accounting principles (â€GAAPâ€). The financial data of the Company included herein are unaudited. In the opinion of management, all material adjustments of a normal recurring nature have been made to present fairly the Companyâ€s financial position at JuneA 30, 2024 and the results of operations and cash flows for the periods presented. All intercompany transactions and balances have been eliminated. Certain prior period amounts have been reclassified to conform with the current period presentation.Certain financial information that is normally included in annual financial statements prepared in accordance with GAAP, but that is not required for interim reporting purposes, has been omitted from the accompanying interim consolidated financial statements and related notes. Readers are urged to review the Companyâ€s Annual Report on Form 10-K for the year ended SeptemberA 30, 2023 for more complete descriptions and discussions. Operating results and cash flows for the nine months ended JuneA 30, 2024 are not necessarily indicative of the results that may be expected for the fiscal year ending SeptemberA 30, 2024.Liquidity The Companyâ€s primary sources of financing have been through the sale of its equity securities, revenue from its licensing and collaboration agreements and the sale of certain future royalties. Research and development activities have required significant capital investment since the Companyâ€s inception and are expected to continue to require significant cash expenditure in the future, particularly as the Companyâ€s pipeline of drug candidates and its headcount have both expanded. Additionally, significant capital investment will be required as the Companyâ€s pipeline matures into later stage clinical trials.As of JuneA 30, 2024, the Company had \$69.4 million in cash, cash equivalents and restricted cash (\$2.2 million in restricted cash) and \$367.3A million in available-for-sale securities to fund operations. During the nine months ended JuneA 30, 2024, the Companyâ€s cash, cash equivalents and restricted cash and investments balance increased by \$33.0 million which was primarily due to the net proceeds of \$429.3A million from the underwritten offering in January 2024 discussed below, offset by ongoing expenses related to the Companyâ€s research and development programs, general and administrative expenses and capital expenditures. On January 2, 2024, the Company entered into an underwriting agreement with Jefferies LLC, BofA Securities, Inc., 6and Cowen and Company, LLC, as representatives of the several underwriters. The Company issued 15,790,000 shares of common stock at a price of \$28.50 per share. The aggregate purchase price paid by investors was \$450.0A million and the Company received net proceeds of \$429.3A million after deducting advisory fees and offering expenses.In total, the Company is eligible to receive up to \$2.7 billion in developmental, regulatory and sales milestones, and may receive various royalties on net sales from its licensing and collaboration agreements, subject to the terms and conditions of those agreements. The revenue recognition for these collaboration agreements is discussed further in Note 2.Summary of Significant Accounting Policies There have been no changes to the significant accounting policies disclosed in the Companyâ€s most recent Annual Report on Form 10-K for the fiscal year ended SeptemberA 30, 2023.Uncertainty in Income TaxesThe Company recorded an income tax benefit of \$3.3 million and expense of \$0.8A million for the nine months ended JuneA 30, 2024 and 2023, respectively. The income tax benefit is primarily due to the discrete change in the Companyâ€s uncertain tax positions related to the statute of limitation expiration.Recent Accounting Pronouncements In December 2023, the Financial Accounting Standards Board (â€FASBâ€) issued Accounting Standard Update (â€ASUâ€) 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, to improve its income tax disclosure requirements. Under the guidance, entities must annually (1) disclose specific categories in the rate reconciliation and (2) provide additional information for reconciling items that meet a quantitative threshold. This guidance will become effective for the Company beginning on October 1, 2025. The Company does not expect any material impact on its consolidated financial statements and related disclosures resulting from applying this ASU.In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which is intended to improve reportable segment disclosure requirements, primarily through additional disclosures about significant segment expenses. The guidance requires public companies with a single reportable segment to provide all disclosures required under ASC 280. In addition, the guidance requires public companies to include in interim reports all disclosures related to a reportable segmentâ€s profit or loss and assets that are currently required in annual reports. The standard is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The amendments should be applied retrospectively to all prior periods presented in the financial statements. The Company does not expect any material impact on its consolidated financial statements and related disclosures resulting from applying this ASU.NOTE 2. COLLABORATION AND LICENSE AGREEMENTSThe following table provides a summary of revenue recognized:Three Months Ended June 30,Nine Months Ended June 30,2024202320242023(in thousands)GSK\$â€A \$277A \$2,685A \$29,600A Horizonâ€A 1,539A â€A \$23,206A Takedaâ€A 14,009A \$866A 146,477A Janssenâ€A â€A â€A 355A Amgenâ€A â€A â€A 25,000A Total\$â€A following table summarizes the balance of receivables and contract liabilities related to the Companyâ€s 7collaboration and license agreements:June 30, 2024September 30, 2023(in thousands) Receivables included in accounts receivable\$â€A \$â€A Contract liabilities included in deferred revenue\$â€A \$866A Glaxosmithkline Intellectual Property (No. 3) Limited (â€GSKâ€)GSK-HSD License AgreementOn NovemberA 22, 2021, GSK and the Company entered into an Exclusive License Agreement (the â€GSK-HSD License Agreementâ€). Under the GSK-HSD License Agreement, GSK has received an exclusive license for GSK-4532990 (formerly ARO-HSD). The exclusive license is worldwide with the exception of greater China. GSK is wholly responsible for all clinical development and commercialization of GSK-4532990 in its territory. GSK dosed the first patient in a Phase 2b trial in March 2023 and paid a \$30.0A million milestone payment to the Company in the third quarter of fiscal 2023. The Company is eligible for an additional payment of \$100.0 million upon achieving the first patient dosed in a Phase 3 trial. Furthermore, should the Phase 3 trial read out positively, and the potential new medicine receives regulatory approval in major markets, the deal provides for commercial milestone payments to the Company of up to \$190.0 million at first commercial sale, and up to \$590.0 million in sales-related milestone payments. The Company is further eligible to receive tiered royalties on net product sales in a range of mid-teens to twenty percent.GSK-HBV AgreementOn December 11, 2023, the Company entered into an Amended and Restated License Agreement with GSK (the â€GSK-HBV Agreementâ€) pursuant to which GSK received a worldwide, exclusive license to develop and commercialize daplusiran/tomligisiran (GSK5637608, formerly JNJ-3989), the Companyâ€s third-generation subcutaneously administered RNAi therapeutic candidate being developed as a potential therapy for patients with chronic hepatitis B virus infection. GSK5637608 had previously been licensed to Janssen in October 2018. Under the terms of the GSK-HBV Agreement, the Company received \$2.7A million in December 2023, upon signing the amended GSK-HBV Agreement. The Company is eligible to receive up to \$832.5A million in development and sales milestone payments under the GSK-HBV Agreement.There were no contract assets and liabilities recorded as of JuneA 30, 2024. Horizon Therapeutics Ireland DAC (â€Horizonâ€) In June 2021, Horizon and the Company entered into a collaboration and license agreement (the â€Horizon License Agreementâ€). Under the terms of the Horizon License Agreement, Horizon received a worldwide exclusive license for HZN-457, a clinical-stage medicine being developed by Horizon as a potential treatment for people with uncontrolled gout. At the inception of the Horizon License Agreement, the Company identified one distinct performance obligation. The Company determined that the key deliverables included the license and certain R&D services, including the Companyâ€s responsibilities to conduct all activities through the preclinical stages of development of HZN-457 (the â€Horizon R&D Servicesâ€). The Company received a \$40.0A million upfront payment in July 2021. Revenue was recognized on a straight-line basis over the timeframe for completing the Horizon R&D Services, concluding in the first quarter of 2023. Further, the Company received an additional \$15.0A million upon Horizonâ€s initiation of a Phase 1 clinical trial in January 2023.On October 6, 2023, Amgen completed its acquisition of Horizon and subsequently notified the Company of Amgenâ€s intent to terminate the HZN-457 license. Horizon exercised its right to terminate the Horizon License Agreement for convenience, which took effect on December 21, 2023. Takeda Pharmaceutical Company Limited (â€Takedaâ€)In October 2020, Takeda and the Company entered into an Exclusive License and Co-Funding Agreement (the â€Takeda License Agreementâ€). Under the Takeda License Agreement, Takeda and the Company will co-develop the Companyâ€s fazirsiran program (formerly TAK-999 and ARO-AAT), the Companyâ€s second-generation subcutaneously administered RNAi therapeutic candidate being developed as a treatment for liver disease associated with alpha-1 antitrypsin deficiency. Within the United States, fazirsiran, if approved, will be co-commercialized under a 50/50 profit sharing structure. Outside the United States, Takeda received an exclusive license to commercialize fazirsiran and will lead the global commercialization strategy, while the Company will be eligible to receive tiered royalties of 20% to 25% on net \$sales. At the inception of the Takeda License Agreement, the Company identified one distinct performance obligation. The Company determined that the key deliverables included the license and certain R&D services including the Companyâ€s responsibilities to complete the initial portion of the SEQUOIA study, to complete the ongoing Phase 2 AROAAT2002 study and to ensure certain manufacturing of fazirsiran drug product is completed and delivered to Takeda (the â€Takeda R&D Servicesâ€). Due to the specialized and unique nature of these Takeda R&D Services and their direct relationship with the license, the Company determined that these deliverables represent one distinct bundle and, thus, one performance obligation. Beyond the Takeda R&D Services, which are the responsibility of the Company, Takeda will be responsible for managing future clinical development and commercialization outside the United States. Within the United States, the Company will also participate in co-development and co-commercialization efforts and will co-fund these efforts with Takeda as part of the 50/50 profit sharing structure within the United States. The Company considers the collaborative activities, including the co-development and co-commercialization, to be a separate unit of account within Topic 808, and as such, these co-funding amounts are recorded as research and development expenses or general and administrative expenses, as appropriate. Under the terms of the Takeda License Agreement, the Company received \$300.0A million as an upfront payment in January 2021 and an additional \$40.0A million upon Takedaâ€s initiation of a Phase 3 REDWOOD clinical study of fazirsiran in March 2023, and is eligible to receive up to \$527.5A million in additional potential development, regulatory and commercial milestones. The Company allocated the total \$300.0A million initial transaction price to its one distinct performance obligation for the fazirsiran license and the associated Takeda R&D Services. Revenue was recognized using the input method (based on actual patient visits completed versus total estimated visits completed for the ongoing SEQUOIA and AROAAT2002 clinical studies). The Phase 2 study visits for patients in the SEQUOIA and AROAAT2002 studies concluded by December 31, 2023, and the Company has substantially completed its performance obligation under the Takeda License Agreement. As such, all revenue has been fully recognized as of December 31, 2023. There were no further deferred revenue and contract liabilities as of JuneA 30, 2024.The Company recorded \$21.3A million as accrued expenses as of JuneA 30, 2024 that was primarily driven by co-development and co-commercialization activities.Janssen Pharmaceuticals, Inc. (â€Janssenâ€)On April 7, 2023, Janssen voluntarily terminated its collaboration agreement with the Company and the Company regained full rights to ARO-PNPLA3, formerly called JNJ-75220795. ARO-PNPLA3 is in Phase 1 clinical trials, which are now being developed by the Company.Further, on December 11, 2023, the Company entered into the GSK-HBV Agreement, as discussed above, pursuant to which GSK received an exclusive license for daplusiran/tomligisiran (GSK5637608, formerly JNJ-3989). Daplusiran/tomligisiran had previously been licensed to Janssen in October 2018.Amgen Inc. (â€Amgenâ€)In September 2016, Amgen and the Company entered into two collaboration and license agreements and a common stock purchase agreement. Under the Second Collaboration and License Agreement (the â€Olpasiran Agreementâ€), Amgen received a worldwide, exclusive license to the Companyâ€s novel RNAi olpasiran (previously referred to as AMG- 890 or ARO-LPA) program. These RNAi molecules are designed to reduce elevated lipoprotein(a), which is a genetically validated, independent risk factor for atherosclerotic cardiovascular disease. Under the Olpasiran Agreement, Amgen is wholly responsible for clinical development and commercialization. Under the Olpasiran Agreement, the Company has received \$35.0A million in upfront payments and \$21.5A million in the form of an equity investment by Amgen in the Companyâ€s common stock. Further, the Company received an additional \$55.0A million in milestone payments; \$10.0A million upon Amgenâ€s initiation of a Phase 1 study in September 2018, \$20.0A million upon its initiation of a Phase 2 clinical study in July 2020, and \$25.0A million upon its first subject enrollment in a Phase 3 trial in December 2022. The Company has substantially completed its performance obligations under the Olpasiran Agreement. There were no contract assets and liabilities recorded as of JuneA 30, 2024. In November 2022, Royalty Pharma Investments 2019 ICAV (â€Royalty Pharmaâ€) and the Company entered into a Royalty Purchase Agreement with Royalty Pharma (the â€Royalty Pharma Agreementâ€). In consideration for the payments under the Royalty Pharma Agreement, Royalty Pharma is entitled to receive all royalties otherwise payable by Amgen to the Company under the Olpasiran Agreement. The Company remains eligible to receive up to an additional \$485.0A million in remaining development, regulatory and sales milestone payments payable from Amgen and Royalty Pharma. See Note 911.Visirna Therapeutics, Inc. (â€Visirnaâ€)In April 2022, the Company and Visirna, its subsidiary, entered into a License Agreement (the â€Visirna License Agreementâ€), pursuant to which Visirna received an exclusive license to develop, manufacture and commercialize four of the Companyâ€s RNAi-based investigational cardiometabolic medicines in Greater China (including the Peopleâ€s Republic of China, Hong Kong, Macau and Taiwan). The Company also performs manufacturing and development work pursuant to a Clinical Supply Agreement between the parties contemplated by the Visirna License Agreement. The Company received \$0.1A million and \$0.9A million as consideration for this manufacturing and development work for the nine months ended JuneA 30, 2024 and 2023, respectively. There were no contract assets and liabilities recorded as of JuneA 30, 2024. 10NOTE 3. BALANCE SHEET ACCOUNTSProperty, Plant and EquipmentThe following table summarizes the Companyâ€s major classes of property, plant and equipment: June 30, 2024September 30, 2023(in thousands) Land\$2,996A \$2,996A Building75,868A â€A Research equipment64,207A \$6,509A Furniture5,931A 1,540A Computers and software976A 700A Leasehold improvements140,396A 103,813A Construction in progress175,778A 166,655A 429,814A 332,213A Less: Accumulated depreciation and amortization(53,903)(41,951)Property, plant and equipment, net\$375,911A \$290,262A Depreciation and amortization expense for property, plant and equipment for the three months ended JuneA 30, 2024 and 2023 was \$4.4A million and \$2.9A million, respectively. Depreciation and amortization expense for property and equipment for the nine months ended JuneA 30, 2024 and 2023 was \$12.3A million and \$7.4A million, respectively. During the first quarter of fiscal 2024, the Company completed the build out of one of its laboratory and office facilities in Verona, Wisconsin, which resulted in the reclassification of \$75.9A million from construction in progress to building as of JuneA 30, 2024. Further, the Company commenced depreciation on the newly completed facility over a 39-year period. Accrued ExpensesAccrued expenses consist of the following:June 30, 2024September 30, 2023(in thousands) Accrued R&D expenses\$17,911A \$16,125A Accrued R&D expenses; co-development21,280A 5,895A Accrued capital expenditures6,909A 14,044A Other1,799A 3,699A Total accrued expenses\$47,899A \$39,763A 11NOTE 4. INVESTMENTSThe Companyâ€s investments consisted of the following:As of June 30, 2024(in thousands)Adjusted BasisGrossUnrealized GainsGrossUnrealized LossesFair ValueAvailable-for-sale securities\$367,862A \$8A (\$598)\$367,272A As of September 30, 2023(in thousands)Adjusted BasisGrossUnrealized GainsGrossUnrealized LossesFair ValueAvailable-for-sale securities\$367,862A \$8A (\$598)\$367,272A As of September 30, 2023(in thousands)Adjusted BasisGrossUnrealized GainsGrossUnrealized LossesFair ValueAvailable-for-sale securities\$295,699A \$3A (\$2,967)\$292,735A The Company has

determined the available-for-sale securities available in an unrealized loss position at June 30, 2024 and 2023. 12NOTE 5. INTANGIBLE ASSETSIntangible assets subject to amortization include patents and a license agreement capitalized as part of the Novartis RNAi asset acquisition in March 2015. The following table presents the components of intangible assets: Gross Carrying AmountAccumulated AmortizationImpairmentNet Carrying AmountUseful Lives(in thousands)(in years)As of June 30, 2024Patents\$21,728A \$14,485A \$â€”A \$7,243A 14License\$3,129A 1,385A â€”A 1,744A 21Total intangible assets, nets\$24,857A \$15,870A \$â€”A \$8,987A As of September 30, 2023Patents\$21,728A \$13,321A \$â€”A \$8,407A 14License\$3,129A 1,274A â€”A 1,855A 21Total intangible assets, nets\$24,857A \$14,595A \$â€”A \$10,262A Intangible assets are reviewed annually for impairment and more frequently if potential impairment indicators exist. No impairment indicators were identified during the nine months ended June 30, 2024 and 2023. Intangible assets with definite useful lives are amortized on a straight-line basis over their useful lives. Intangible assets amortization expense was \$0.4 million for the three months ended June 30, 2024 and 2023, and \$1.3A million for the nine months ended June 30, 2024 and 2023. None of the intangible assets with definite useful lives are anticipated to have a residual value. The following table presents the estimated future amortization expense related to intangible assets as of June 30, 2024:Amortization ExpenseYear Ending September 30, (in thousands)2024 (remainder)\$425A 20251,700A 20261,700A 20271,700A 20281,700A Thereafter1,762A Totals\$9,987A 13NOTE 6. STOCKHOLDERSâ€™ EQUITYThe following table summarizes the Companyâ€™s shares of common stock and preferred stock:SharesPar ValueAuthorizedIssuedOutstanding(in thousands)As of June 30, 2024Common stock\$0.001A 290,000A 124,227A 124,227A Preferred stock\$0.001A 5,000A â€”A 5,000A â€”A As of September 30, 2023Common stock\$0.001A 290,000A 107,312A 107,312A Preferred stock\$0.001A 5,000A â€”A 5,000A â€”A As of June 30, 2024 and September 30, 2023, respectively, 11,608,148 and 12,709,837 shares of common stock were reserved for issuance upon exercise of options and vesting of restricted stock units granted or available for grant under the Companyâ€™s 2013 and 2021 Incentive Plans, as well as for other inducement grants made to new employees under Rule 5635(c)(4) of the Nasdaq Listing Rules. On January 2, 2024, the Company entered into an underwriting agreement with Jefferies LLC, BofA Securities, Inc., and Cowen and Company, LLC, as representatives of the several underwriters. The Company issued 15,790,000 shares of common stock at an offering price of \$28.50 per share. The aggregate purchase price paid by investors was \$450.0A million and the Company received net proceeds of \$429.3A million after deducting advisory fees and offering expenses. On December 2, 2022, the Company entered into an open market sale agreement (the â€œOpen Market Sale Agreementâ€), pursuant to which the Company may, from time to time, sell up to \$250,000,000 in shares of the Companyâ€™s common stock through Jefferies LLC, acting as the sales agent and/or principal, in an at-the-market offering (â€œATM Offeringâ€). The Company is not required to sell shares under the Open Market Sale Agreement. The Company will pay Jefferies LLC a commission of up to 3.0% of the aggregate gross proceeds received from all sales of the common stock under the Open Market Sale Agreement. Unless otherwise terminated, the ATM Offering shall terminate upon the earlier of (i) the sale of all shares of common stock subject to the Open Market Sale Agreement and (ii) the termination of the Open Market Sale Agreement as permitted therein. The Company and Jefferies may each terminate the Open Market Sale Agreement at any time upon prior notice. As of June 30, 2024, no shares have been issued under the Open Market Sale Agreement. NOTE 7. COMMITMENTS AND CONTINGENCIESLitigationFrom time to time, the Company may be subject to various claims and legal proceedings in the ordinary course of business. If the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount is reasonably estimable, the Company will accrue a liability for the estimated loss. There were no contingent liabilities recorded as of June 30, 2024. CommitmentsThe Company owns land in the Verona Technology Park in Verona, Wisconsin, which is being developed into an approximately 160,000 square foot drug manufacturing facility and an approximately 140,000 square foot laboratory and office facility which will support the Companyâ€™s manufacturing process development and analytical activities. During the first quarter of fiscal 2024, the Company completed the build out of one of its laboratory and office facilities. As of June 30, 2024, the Company has incurred \$266.0 million and intends to spend an additional \$18.0 million to \$32.0 million to complete the build out of the facilities. NOTE 8. LEASESPasadena, California: The Company leases 49,000 square feet of office space located at 177 East Colorado Blvd. for its corporate headquarters from 177 Colorado Owner, LLC, which lease expires on April 30, 2027. The lease contains an option to renew for one additional five-year term. The Company is not reasonably certain that it will exercise this option to 14renew and therefore it is not included in right-of-use assets and liabilities as of June 30, 2024. San Diego, California: The Company leases 144,000 square feet of office and research and development laboratory space located at 10102 Hoyt Park from 11404 & 11408 Sorrento Valley Owner, LLC, which lease expires on April 30, 2038. Pursuant to the lease, within twelve months of the expiration of the initial 15-year term, the Company has the option to extend the lease for up to one additional ten-year term, with certain annual increases in base rent. The Company is not reasonably certain that it will exercise this option to renew and therefore it is not included in right-of-use assets and liabilities as of June 30, 2024. The lease agreement grants the Company the right to receive an Additional Tenant Improvement Allowance (â€œATIAâ€) funded by the lessor, with a maximum amount of \$7.2 million, subject to a 7% interest per annum over the base term. Further, on September 25, 2023, the Company executed the first amendment to the lease, which grants a second ATIA with a maximum amount of \$23.6 million, bearing interest at a rate of 9% per annum over the base term. The Company received \$30.8A million ATIA from the lessor during the first quarter of fiscal 2024. As a result, the Company remeasured its lease liability and right-of-use assets to reflect these additional allowances and the related increased lease payments. The Company has further concluded that these ATIAs have no effects on the classification of the lease. The Company previously subleased additional research and development space in San Diego, California, which sublease ended during the fiscal year of 2023. Madison, Wisconsin: The Company leases 115,000 square feet space located at 502 South Rosa Road for its office and laboratory facilities, which lease expires on September 30, 2031. The lease contains options to renew for two terms of five years. The Company is not reasonably certain that it will exercise this option and therefore it is not included in right-of-use assets and liabilities as of June 30, 2024. The components of lease assets and liabilities along with their classification on the Companyâ€™s consolidated balance sheets were as follows:Lease Assets and LiabilitiesClassificationJune 30, 2024September 30, 2023(in thousands)Operating lease assetsRight-of-use assets\$44,339A \$45,297A Current operating lease liabilitiesLease liabilities\$6,053A 10,563A Non-current operating lease liabilitiesLease liabilities, net of current portion112,040A 104,608A Three Months Ended June 30, Nine Months Ended June 30, Lease Cost Classification2024202320242023(in thousands)Operating lease costResearch and development\$2,965A \$3,323A \$8,531A \$7,735A General and administrative expenses\$374A \$509A 1,504A 1,542A Variable lease cost (1)Research and development\$863A 257A 2,478A 627A General and administrative expenseâ€”A â€”A â€”A â€”A Total \$4,365A \$4,089A \$12,513A \$9,904A (1) Variable lease cost is primarily related to operating expenses associated with the Companyâ€™s operating leases. There was no short-term lease cost during the nine months ended June 30, 2024. There was \$0.6A million and \$1.2A million short-term lease cost during the three and nine months ended June 30, 2023, respectively. 15The following table presents maturities of operating lease liabilities on an undiscounted basis as of June 30, 2024:YearAmounts(in thousands)2024 (remainder of fiscal year)\$3,793A 202515,356A 202615,696A 202714,869A 202813,511A 2029 and thereafter128,356A Totals\$191,581A Less imputed interest\$(73,488)Total operating lease liabilities (includes current portion)\$118,093A Supplemental cash flow and other information related to leases was as follows:Three Months Ended June 30, Nine Months Ended June 30, 2024202320242023(in thousands)Cash received for amounts included in the measurement of lease liabilities:Operating cash flows from operating leases\$5,414A \$3,099A \$23,343A Right-of-use assets adjusted in exchange for new/amended operating lease liabilities\$â€”A \$3,519A \$(64)A \$(19,063)Cash paid for amounts included in the measurement of lease liabilities:Operating cash flows from operating leases\$3,204A \$1,885A \$7,221A \$4,081A June 30, 20242023Weighted-average remaining lease term (in years)12.813A 4Weighted-average discount rate8.0A %8.0A %16NOTE 9. STOCK-BASED COMPENSATIONStock PlansThe Company has two plans that provide for equity-based compensation under the 2013 and the 2021 plans. Under the 2013 Incentive Plan (the â€œ2013 Planâ€), 2,924,586 shares of the Companyâ€™s common stock are reserved for grants of stock options and restricted stock awards to employees and directors as of June 30, 2024. Under the 2021 Incentive Plan (the â€œ2021 Planâ€), 8,000,000 shares (subject to certain adjustments) of the Companyâ€™s common stock are reserved for grants of stock options, stock appreciation rights, restricted and unrestricted stock, performance awards, cash awards and other awards convertible into or otherwise based on shares of the Companyâ€™s common stock. The maximum number of shares authorized under the 2021 Plan will be (i) reduced by any shares subject to awards made under the 2013 Plan after January 1, 2021, and (ii) increased by any shares subject to outstanding awards under the 2013 Plan as of January 1, 2021 that, after January 1, 2021, are canceled, expired, forfeited or otherwise not issued under such awards (other than as a result of being tendered or withheld to pay the exercise price or withholding taxes in connection with any such awards) or settled in cash. As of June 30, 2024, the total number of shares available for issuance was 4,565,727 shares, which includes 158,928 and 154,139 shares that were forfeited under the 2013 and 2021 Plans, respectively, and 3,697,189 shares have been granted under the 2021 Plan. In addition, there were 665,020 shares reserved for options and 616,638 shares reserved for restricted stock units issued as inducement grants to new employees granted outside of the Companyâ€™s equity-based compensation plans under Rule 5635(c)(4) of the Nasdaq Listing Rules. The following table presents a summary of awards outstanding:As of June 30, 2024202313Plan2021PlanInducement AwardsTotalGranted and outstanding awards:Options1,315,326A 32,151A 665,020A 2,012,497A Restricted stock units1,609,260A 2,804,026A 616,638A 5,029,924A Total2,924,586A 2,836,177A 1,281,658A 7,042,421A The following table summarizes stock-based compensation expenses included in operating expenses:Three Months Ended June 30, Nine Months Ended June 30, 2024202320242023Research and development\$6,221A \$8,982A \$21,634A \$26,129A General and administrative\$8,490A 10,965A 27,350A 33,820A Total\$14,711A \$19,947A \$48,984A \$59,949A Stock Option AwardsThe following table presents a summary of the stock option activity for the nine months ended June 30, 2024:SharesWeighted-AverageExercisePricePer ShareWeighted-AverageRemainingContractualTerm (Years)AggregateIntrinsicValueOutstanding at September 30, 20232,263,477\$22.68A Grantedâ€”A â€”A Canceled or expired(53,582)36.62A Exercised(197,398)10.98A Outstanding at June 30, 20242,012,012\$23.22A 3.82\$2,486,304A Exercisable at June 30, 20242,012,012\$23.05A 3.82\$2,486,304A The aggregate intrinsic values represent the amount by which the market price of the underlying stock exceeds the 17exercise price of the option. The total intrinsic value of the options exercised during the three months ended June 30, 2024 and 2023 was \$0.7 million and \$6.5 million, respectively. The total intrinsic value of the options exercised during the nine months ended June 30, 2024 and 2023 was \$3.8A million and \$10.1A million, respectively. Stock-based compensation expense related to stock options outstanding for the three months ended June 30

Operating Expenses Agreement. The Company has evaluated the terms of the Royalty Pharma Agreement and concluded, in accordance with the relevant accounting guidance, that the Company accounted for the transaction as debt and the funding of \$250.0A million and \$50.0A million from Royalty Pharma were recorded as liabilities related to the sale of future royalties on its consolidated balance sheets. The Company is not obligated to repay these funds received under the Royalty Pharma Agreement. The Company records the obligations at their carrying value using the effective interest method. In order to amortize the sale of future royalties, the Company utilizes the prospective method to estimate the future royalties to be paid by the Company to the counterparty over the life of the arrangement. Under the prospective method, a new effective interest rate is determined based on the revised estimate of remaining cash flows. The new rate is the discount rate that equates the present value of the revised estimate of remaining cash flows with the carrying amount of the debt, and it will be used to recognize non-cash interest expense for the remaining periods. The Company periodically assesses the amount and the timing of expected royalty payments using a combination of internal projections and forecasts from external sources. The estimates of future net product sales (and resulting royalty payments) are based on key assumptions including population, penetration, probability of success and sales price, among others. To the extent such payments are greater or less than the Company's initial estimates or the timing of such payments is different than its original estimates, the Company will prospectively adjust the amortization of the royalty financing obligations and the effective interest rate. As of June 30, 2024, the estimated effective interest rate was 6.3%. The following table presents the activity with respect to the liability related to the sale of future royalties. Carrying Amount (in thousands) Carrying value as of September 30, 2023 \$268,326A Milestone payment received \$50,000A Non-cash interest expense recognized \$17,705A Carrying value as of June 30, 2024 \$336,031A NOTE 12. NET LOSS PER SHARE The following table presents the computation of basic and diluted net loss per share for the three and nine months ended June 30, 2024 and 2023. 21 Three Months Ended June 30, Nine Months Ended June 30, 2024 2023 2024 2023 (in thousands, except per share amounts) Numerator: Net loss attributable to Arrowhead Pharmaceuticals, Inc. \$(170,793) \$(102,946) \$(428,957) \$(95,596) Denominator: Weighted-average basic shares outstanding 124,199A 107,004A 118,260A 106,597A Effect of dilutive securities: A A A A A Weighted-average diluted shares outstanding 124,199A 107,004A 118,260A 106,597A Basic net loss per share \$(1.38) \$(0.96) \$(3.63) \$(0.90) Diluted net loss per share \$(1.38) \$(0.96) \$(3.63) \$(0.90) The following table sets forth the potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to include them would be anti-dilutive. Three Months Ended June 30, Nine Months Ended June 30, 2024 2023 2024 2023 (in thousands) Options 753A 637A 711A 768A Restricted stock units 3,976A 2,830A 4,060A 3,256A Total 4,729A 3,467A 4,771A 4,024A NOTE 13. SUBSEQUENT EVENTS Financing Agreement On August 7, 2024 (the "Closing Date"), the Company entered into a financing agreement (the "Financing Agreement") with the guarantors party thereto, the lenders party thereto (the "Lenders"), and Sixth Street Lending Partners, as the administrative agent and collateral agent for the Lenders. The Financing Agreement provides for a senior secured term loan facility of \$500.0 million (the "Credit Facility"), which includes \$400.0 million funded on the Closing Date with an additional \$100.0 million at the Company's option, subject to mutual agreement between Sixth Street and the Company, during the seven-year term of the agreement. The Credit Facility matures on August 7, 2031 (the "Maturity Date") and bears interest at an annual rate equal to 15.0%. The Credit Facility does not provide for scheduled amortization payments during the term, and all principal will be due on the Maturity Date. The Company has the right to prepay loans under the Financing Agreement at any time. See Item 5. Other Information of Part II, for more information. 22 ITEM 2. A A A MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and we intend that such forward-looking statements be subject to the safe harbors created thereby. For this purpose, any statements contained in this Quarterly Report on Form 10-Q except for historical information may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "expect," "anticipate," "believe," "estimate," "forecast," "project," "intend," "plan," "propose," "could," "estimate," "forecast," "continue," or the negative of these words or other variations thereof or comparable terminology are intended to identify forward-looking statements. In addition, any statements that refer to projections of our future financial performance, trends in our business, or other characterizations of future events or circumstances are forward-looking statements. These forward-looking statements include, but are not limited to, statements about the initiation, timing, progress and results of our preclinical studies and clinical trials, including any commercialization efforts, our research and development programs, and our 2025 pipeline goal; our expectations regarding the potential benefits of the partnership, licensing and/or collaboration arrangements and other strategic arrangements and transactions we have entered into or may enter into in the future; our beliefs and expectations regarding the amount and timing of future milestone, royalty or other payments that could be due to or from third parties under existing agreements; and our estimates regarding future revenues, research and development expenses, capital requirements and payments to third parties. The forward-looking statements included herein are based on current expectations of our management based on available information and involve a number of risks and uncertainties, all of which are difficult or impossible to predict accurately, and many of which are beyond our control. As such, our actual results and timing of certain events may differ materially from the results discussed, projected, anticipated or indicated in any forward-looking statements. Forward-looking statements are not guarantees of future performance and our actual results of operations, financial condition and cash flows may differ materially. Factors that may cause or contribute to such differences include, but are not limited to, those discussed in more detail in Item 1. Business and Item 1A. Risk Factors of Part I and Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations of Part II of our most recent Annual Report on Form 10-K. Readers should carefully review these risks, as well as the additional risks described in other documents we file from time to time with the Securities and Exchange Commission (the "SEC"). In light of the significant risks and uncertainties inherent in the forward-looking information included herein, the inclusion of such information should not be regarded as a representation by us or any other person that such results will be achieved, and readers are cautioned not to place undue reliance on such forward-looking information. Statements made herein are as of the date of the filing of this Quarterly Report on Form 10-Q with the SEC and should not be relied upon as of any subsequent date. Except as may be required by law, we disclaim any intent to revise the forward-looking statements contained herein to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. OVERVIEW The Company develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, the Company's therapies trigger the RNAi interference mechanism to induce rapid, deep and durable knockdown of target genes. RNAi is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. RNAi-based therapeutics may leverage this natural pathway of gene silencing to target and shut down specific disease-causing genes. The Company has focused its resources on therapeutics that exclusively utilize its high levels of pharmacologic activity in multiple animal models spanning several therapeutic areas. The Company believes that TRIMTM enabled therapeutics offer several potential advantages over prior generation and competing technologies, including: simplified manufacturing and reduced costs; multiple routes of administration including subcutaneous injection and inhaled administration; the ability to target multiple tissue types including liver, lung, CNS, muscle and adipose tissue; and the potential for improved safety and reduced risk of intracellular buildup, because there are fewer metabolites from smaller, simpler molecules. The Company's clinical pipeline includes: a Hypertriglyceridemia - plozasiran (formerly ARO-APOC3); a Dyslipidemia - zodasiran (formerly ARO-ANG3); a Cardiovascular disease - olpasiran (formerly AMG 890 or ARO-LPA, out-licensed to Amgen); a Muco-obstructive or inflammatory pulmonary conditions - ARO-MUC5AC and ARO-RAGE; a Idiopathic pulmonary fibrosis - ARO-MMP7; a Non-alcoholic steatohepatitis (NASH) - GSK-4532990 (formerly ARO-HSD, out-licensed to GSK); a Alpha-1 antitrypsin deficiency (AATD) - fazirsiran (formerly ARO-AAT, a collaboration with Takeda); a Chronic hepatitis B virus - daplusiran/tomligisiran (GSK5637608, formerly JNJ-3989, out-licensed to GSK); a Complement mediated diseases - ARO-C3; a Non-alcoholic steatohepatitis (NASH) - ARO-PNPLA3 (formerly JNJ-75220795 or ARO-JNJ1); a Facioscapulohumeral muscular dystrophy - ARO-DUX4; a Dystrophia myotonica protein kinase (DMPK) - ARO-DM1; and a Hepatic expression of complement factor B (CFB) - ARO-CFB. The Company operates lab facilities in California and Wisconsin, where its research and development activities, including the development of RNAi therapeutics, take place. The Company's principal executive offices are located in Pasadena, California. The Company continues to develop other clinical candidates for future clinical trials. Clinical candidates are tested internally and through Good Laboratory Practice (GLP) toxicology studies at outside laboratories. Drug materials for such studies and clinical trials are either manufactured internally or contracted to third-party manufacturers. The Company engages third-party contract research organizations (CROs) to manage clinical trials and works cooperatively with such organizations on all aspects of clinical trial management, including plan design, patient recruiting, and follow up. These outside costs, including toxicology/efficacy testing and manufacturing costs, as well as the preparation for and administration of clinical trials, are referred to as candidate costs. As clinical candidates progress through clinical development, candidate costs will increase. The First Three Quarters of Fiscal 2024 Business Highlights Key recent developments through the first three quarters of fiscal 2024 included the following: a Announced plans to advance investigational plozasiran into a Phase 3 cardiovascular outcomes trial called CAPITAN, which is designed to enroll patients with mixed hyperlipidemia and residual risk of atherosclerotic cardiovascular disease; a Announced successful top-line results from the pivotal Phase 3 PALISADE study of investigational plozasiran in patients with familial chylomicronemia syndrome (FCS). The Company highlighted recent data for its cardiometabolic pipeline at its June 25, 2024, Cardiometabolic event; a Presented preclinical data on ARO-INHBE for the treatment of obesity and metabolic diseases at the American Diabetes Association 84th Scientific Sessions. INHBE small interfering RNA (siRNA) administration resulted in multiple promising findings including: (1) 95% reduction in INHBE mRNA expression, (2) 19% suppression of body weight compared to saline controls, (3) 26% loss of fat mass, and (4) preservation of lean mass; a Announced results from the Phase 2b double blind, randomized ARCHES-2 study of investigational zodasiran in patients with mixed hyperlipidemia; a Announced that new interim clinical data on ARO-RAGE achieves high level of gene knockdown in patients with asthma; a Completed enrollment in Amgen's Phase 3 OCEAN(a) - outcome trial of olpasiran, triggering a \$50.0A million milestone payment to the Company, which was paid in the third quarter of fiscal 2024; a Presented final data from the double-blind treatment period of the Company's Phase 2 SHASTA-2 study of investigational plozasiran in patients with severe Hypertriglyceridemia. Results from the SHASTA-2 study showed dramatic, consistent, and sustained reductions in Apolipoprotein C-III (APOC3) and triglycerides and improvement in multiple atherogenic lipoprotein levels; a Announced an Expanded Access Program (aEAP) to make investigational plozasiran available outside of a clinical trial for qualifying patients with familial chylomicronemia syndrome (FCS); a Initiated a Phase 1/2a clinical trial of ARO-DM1, being developed as a potential treatment for type 1 myotonic dystrophy (DM1), the most common adult-onset muscular dystrophy; a Filed an application for clearance to initiate a Phase 1/2a clinical trial of ARO-CFB, being developed as a potential treatment for complement mediated renal disease; a Entered into an underwriting agreement with Jefferies LLC, BofA Securities, Inc., and Cowen and Company, LLC, as representatives of the several underwriters. The Company issued 1,790,000 shares of common stock at a price of \$28.50 per share. The aggregate purchase price paid by investors was \$450.0 million and the Company received net proceeds of \$429.3 million after deducting advisory fees and offering expenses; and a Entered into an Amended and Restated License Agreement with GSK, pursuant to which GSK received a worldwide, exclusive license to develop and commercialize daplusiran/tomligisiran (GSK5637608, formerly JNJ-3989). Daplusiran/tomligisiran had previously been licensed to Janssen Pharmaceuticals, Inc. See Note 2 - Collaboration and License Agreements to Consolidated Financial Statements of Part I, Item 1. Financial Statements. Net loss attributable to Arrowhead Pharmaceuticals, Inc. was \$170.8 million and \$102.9 million for the three months ended June 30, 2024 and 2023, respectively. Net loss attributable to Arrowhead Pharmaceuticals, Inc. was \$429.0 million and \$95.6 million for the nine months ended June 30, 2024 and 2023, respectively. Net loss per share "diluted" was \$1.38 and \$0.96 for the three months ended June 30, 2024 and 2023, respectively. Net loss per share "diluted" was \$3.63 and \$0.90 for the nine months ended June 30, 2024 and 2023, respectively. The changes in net loss attributable to the Company for the three and nine months ended June 30, 2024 were mainly due to a decrease in revenue from the Company's license and collaboration agreements, in conjunction with increased research and development expenses, which have continued to increase as the Company's pipeline of candidates has expanded and progressed through clinical trial phases. The Company had \$69.4 million of cash, cash equivalents and restricted cash, \$367.3 million in available-for-sale securities, and \$883.8 million of total assets as of June 30, 2024, as compared to \$110.9 million of cash, cash equivalents and restricted cash, \$292.7 million in available-for-sale securities and \$765.6 million of total assets as of September 30, 2023. Based upon the Company's current cash and investment resources and operating plan, the Company expects to have sufficient liquidity to fund operations for at least the next twelve months from the date of the issuance of these financial statements. Critical Accounting Estimates There have been no significant changes to the Company's critical accounting estimates disclosed in the most recent Annual Report on Form 10-K for the fiscal year ended September 30, 2023. RESULTS OF OPERATIONS The following data summarizes the Company's results of operations for the following periods indicated: Three Months Ended June 30, Nine Months Ended June 30, 2024 2023 2024 2023 (in thousands, except per share amounts) Revenue \$A \$15,825A \$3,551A \$224,638A Operating loss \$(176,141) \$(102,703) \$(438,877) \$(96,672) Net loss attributable to Arrowhead Pharmaceuticals, Inc. \$(170,793) \$(102,946) \$(428,957) \$(95,596) Net loss per share - diluted \$(1.38) \$(0.96) \$(3.63) \$(0.90) Revenue/Total revenue for the three months ended June 30, 2

operates in a cross-functional manner across projects and does not separately allocate facilities-related costs, candidate costs, discovery costs, compensation costs, compensation expenses, depreciation and amortization expenses, and other expenses related to research and development activities. The following table provides details of research and development expenses for the periods indicated:

	Three Months Ended June 30, 2024	ofExpenseCategory	Three Months Ended June 30, 2023	ofExpenseCategory	Increase (Decrease) %	Candidate							
costs	\$78,367.51A	%\$41,209.44A	%\$37,158.90A	%R&D	discovery costs	\$30,890.20A	%20,253.21A	%\$10,637.53A	%Salaries	24,532.16A	%16,632.18A	%\$7,900.47A	%Facilities
related	7,132.5A	%4,810.5A	%62,322.48A	%Total research and development expense, excluding non-cash expenses	140,921.92A	%\$82,904.88A	%\$58,017.70A	%Stock					
compensation	7,241.5A	%8,982.9A	%1,741.19A	(19)%Depreciation and amortization	4,269.3A	%2,871.3A	%1,398.49A	%Total research and development					
expense	\$152,431.100A	%\$94,757.100A	%\$57,674.61A	%(in thousands)Nine Months Ended June 30, 2024	ofExpenseCategory	Nine Months Ended June 30, 2023	ofExpenseCategory						
Increase (Decrease)%	Candidate costs	\$157,546.43A	%\$110,079.43A	%\$47,467.43A	%R&D	discovery							
costs	\$4,898.23A	%50,377.20A	%34,521.69A	%Salaries	72,048.19A	%47,725.19A	%24,323.51A	%Facilities	related	19,597.5A	%11,601.5A	%7,996.69A	%Total research and development expense, excluding non-cash expense
development expense, excluding non-cash expense	\$334,089.90A	%\$219,782.87A	%\$611,307.52A	%Stock	compensation	23,735.7A	%26,129.10A	%(2,394)					
(9)%Depreciation/amortization	12,220.3A	%7,422.3A	%4,798.65A	%Total research and development expense	\$370,044.100A	%\$253,333.100A	%\$116,711.46A	%Candidate costs					
increased \$37.2 million, or 90%, for the three months ended June 30, 2024 and \$47.5 million, or 43%, for the nine months ended June 30, 2024 compared to the same period of 2023. This increase was primarily due to the additional progression of the Company's pipeline of candidates into and through clinical trials, which resulted in higher manufacturing, outsourced clinical trial, and toxicity study costs.R&D discovery costs increased \$10.6 million, or 53%, for the three months ended June 30, 2024 and \$34.5 million, or 69%, for the nine months ended June 30, 2024 compared to the same period of 2023. This increase was primarily driven by the growth of the Company's discovery efforts and continued advancement into novel therapeutic areas and tissue types, along with rising costs associated with CNS studies and lab supplies. Salaries consist of salary, bonuses, payroll taxes, and related benefits for the Company's R&D personnel. Salaries expense increased \$7.9 million, or 47%, for the three months ended June 30, 2024 and \$24.3 million, or 51%, for the nine months ended June 30, 2024 compared to the same period of 2023. The increase was primarily due to an increase in R&D headcount that has occurred as the Company has expanded its pipeline of candidates, in addition to annual salary increases. Facilities-related expense includes lease costs for the Company's research and development facilities in San Diego, California and Madison, Wisconsin. Facilities-related costs increased \$2.3 million, or 48%, for the three months ended June 30, 2024 and \$8.0 million, or 69%, for the nine months ended June 30, 2024 compared to the same period of 2023. This increase was mainly due to the ATIs on the lease in San Diego, California. See Note 8 to Consolidated Financial Statements of Part I, Financial Statements. Stock compensation expense, a non-cash expense, was based upon the valuation of stock options and restricted stock units granted to employees. Stock compensation expense decreased \$1.7 million, or 19%, for the three months ended June 30, 2024 and \$2.4 million, or 9%, for the nine months ended June 30, 2024 compared to the same period of 2023. The decrease was primarily due to the cancelled awards upon the departure of employees. Depreciation and amortization expense, a non-cash expense, increased \$1.4 million, or 49% for the three months ended June 30, 2024 and \$4.8 million, or 65%, for the nine months ended June 30, 2024 compared to the same period of 2023. The increase was primarily attributed to higher leasehold improvements, due to completion of the development of the San Diego facility. Additionally, as of December 31, 2023, the Company completed the build out of one of its laboratory and office facilities in Verona, Wisconsin, and commenced depreciation. The Company anticipates these R&D expenses to continue to increase as its pipeline of candidates grows and progresses to later phase clinical trials, in addition to inflationary pressure on goods and services and the labor market. General & Administrative Expenses The following table provides details of the Company's general and administrative expenses for the periods indicated: (in thousands)Three Months Ended June 30, 2024 ofExpenseCategoryThree Months Ended June 30, 2023 ofExpenseCategoryIncrease (Decrease)% Salaries\$6,740.28A %\$5,063.21A %\$1,677.07A %Professional, outside services, and other 5,410.23A %\$5,987.25A %\$(577.10)%Facilities related1,238.5A %1,352.6A %\$(114.18)%Total general & administrative expense, excluding non-cash expenses\$13,388.56A %\$12,402.52A %\$986.04A %Stock compensation8,909.42A %10,965.46A %\$(1,156.11)%Depreciation and amortization513.2A %404.2A %\$109.0A %Total general & administrative expenses\$23,710.100A %\$23,771.100A %\$(61.00A)%(in thousands)Nine Months Ended June 30, 2024 ofExpenseCategoryNine Months Ended June 30, 2023 ofExpenseCategoryIncrease (Decrease)% Salaries\$20,087.28A %\$14,275.21A %\$5,812.07A %Professional, outside services, and other 16,910.23A %\$15,293.22A %\$1,617.01A %Facilities related3,278.5A %3,377.5A %\$(99.00)%Total general & administrative expense, excluding non-cash expenses\$40,275.56A %\$32,945.48A %\$7,330.08A %Stock compensation30,759.42A %33,920.50A %\$(3,061.08)%Depreciation and amortization1,350.2A %1,212.2A %\$138.0A %Total general & administrative expenses\$72,384.100A %\$67,977.100A %\$4,407.00A %Salaries expense increased \$1.7 million, or 33%, for the three months ended June 30, 2024 and \$5.8 million, or 41%, for the nine months ended June 30, 2024 compared to the same period of 2023. The increase was driven by the combination of annual salary increases and increased headcount required to support the Company's growth. Professional, outside services, and other expense includes legal, consulting, patent expenses, business insurance expenses, other outside services, travel, and communication and technology expenses. This expense decreased \$0.6 million, or 10%, for the three months ended June 30, 2024 and increased \$1.6 million, or 11%, for the nine months ended June 30, 2024 compared to the same period of 2023. The increase for the nine months ended June 30, 2024 was mainly due to legal services associated with patent applications and intellectual property matters, as well as other professional services. Facilities related expense primarily includes rental costs and other facilities-related costs for the Company's corporate headquarters in Pasadena, California. Stock compensation expense, a non-cash expense, was based upon the valuation of stock options and restricted stock units granted to employees. This expense decreased \$1.2 million, or 11%, for the three months ended June 30, 2024 and \$3.1 million, or 9%, for the nine months ended June 30, 2024 compared to the same period of 2023. The decrease was mainly due to the decreased compensation costs related to performance awards. Depreciation and amortization expense, a non-cash expense, was primarily related to amortization of leasehold improvements for the Company's corporate headquarters. The Company anticipates these general and administrative expenses to continue to increase as its pipeline of candidates grows and progresses to later phase clinical trials including commercialization efforts, in addition to inflationary pressure on goods and services and the labor market. Other Income (Expense)Other income (expense) is primarily related to interest income and expense. Other income increased \$2.8 million for the three months ended June 30, 2024 compared to the same period of 2023. The increase was primarily due to the higher yields on investments due to higher interest rates, offset by the non-cash interest expense on the liability related to the sale of future royalties. The balance remained consistent for the nine months ended June 30, 2024 compared to the same period of 2023. LIQUIDITY AND CAPITAL RESOURCESThe Company has historically financed its operations through the sale of its equity securities, revenue from its licensing and collaboration agreements, and the sale of certain future royalties. Research and development activities have required significant capital investment since the Company's inception and are expected to continue to require significant cash expenditure as the Company's pipeline continues to expand and matures into later stage clinical trials. Additionally, the Company expanded its facilities in Verona, Wisconsin and leased additional facilities in San Diego, California. Each of these expansions is designed to increase the Company's internal manufacturing and discovery capabilities and requires significant capital investment. The Company's cash, cash equivalents and restricted cash decreased to \$69.4 million at June 30, 2024 compared to \$110.9 million at September 30, 2023. Cash invested in available-for-sale securities was \$367.3 million at June 30, 2024 compared to \$292.7 million at September 30, 2023. On December 2, 2022, the Company entered into the Open Market Sale Agreement, pursuant to which the Company may, from time to time, sell up to \$250.0 million in shares of the Company's common stock through Jefferies LLC, acting as the sales agent and/or principal, in an at-the-market offering. As of June 30, 2024, no shares have been issued under the Open Market Sale Agreement. On January 2, 2024, the Company entered into an underwriting agreement with Jefferies LLC, BofA Securities, Inc., and Cowen and Company, LLC, as representatives of the several underwriters. The Company issued 15,790,000 shares of common stock at an offering price of \$28.50 per share. The aggregate purchase price paid by investors was \$450.0 million and the Company received net proceeds of \$429.3 million after deducting advisory fees and offering expenses. The Company believes its current financial resources are sufficient to fund its operations through at least the next twelve months from the date of the issuance of these financial statements. The following table presents a summary of cash flows: Nine Months Ended June 30, 2024 2023 (in thousands) Cash Flow from: Operating activities \$(325,635) \$(127,964) Investing activities \$(197,149) \$(126,664) Financing activities \$481,431.25 \$232.23 Net decrease in cash, cash equivalents and restricted cash \$(41,353) \$(2,396) Cash, cash equivalents and restricted cash at end of period \$69,399.4 \$105,334.4 During the nine months ended June 30, 2024, cash flow used in operating activities was \$325.6 million, which was primarily due to the ongoing expenses related to the Company's research and development programs and general and administrative expenses. Cash used in investing activities amounted to \$197.1 million, which was primarily attributable to capital expenditures of \$117.2 million and investment purchases of \$428.6 million, offset by proceeds from sales and maturities of investments of \$348.6 million. Cash provided by financing activities of \$481.4 million was related to cash received from the issuance of common stock, a milestone payment from Royalty Pharma, and stock option exercises (See Note 6 to Consolidated Financial Statements of Part I, Financial Statements). During the nine months ended June 30, 2023, cash flows used in operating activities was \$128.0 million, which was primarily due to the ongoing expenses related to the Company's research and development programs and general and administrative expenses, partially offset by the receipt of \$110.0 million from collaboration and license agreements. Cash used in investing activities was \$126.7 million, which was primarily related to capital expenditures, \$112.8 million of construction in progress and investment purchases of \$234.0 million, offset by maturities of investments of \$220.2 million. Cash provided by financing activities of \$252.2 million was primarily related to the \$250.0 million payment from Royalty Pharma as													

6.Â 6.1 Â EXHIBITSE ExhibitNumber Document Description 3.1 Amended and Restated Certificate of Incorporation (incorporated by reference from Exhibit 3.3 of the Companyâ€™s Form 8-K filed on April 6, 2016) 3.2 Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Arrowhead Pharmaceuticals, Inc. (incorporated by reference from Exhibit 3.2 of the Companyâ€™s Form 10-Q filed on May 2, 2023) 3.3 Second Amended and Restated Bylaws of Arrowhead Pharmaceuticals, Inc., as amended January 24, 2023 (incorporated by reference from Exhibit 3.3 of the Companyâ€™s Form 10-Q filed on May 2, 2023) 31.1* Certification of Chief Executive Officer pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 31.2* Certification of Chief Financial Officer pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 32.1** Certification of Chief Executive Officer pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 32.2** Certification of Chief Financial Officer pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 101.INS* Inline XBRL Instance Document 101.SCH* Inline XBRL Taxonomy Extension Schema Document 101.CAL* Inline XBRL Taxonomy Extension Calculation Linkbase Document 101.LAB* Inline XBRL Taxonomy Extension Label Linkbase Document 101.PRE* Inline XBRL Taxonomy Extension Presentation Linkbase Document 101.DEF* Inline XBRL Taxonomy Extension Definition Linkbase Document 104* The cover page from this Quarterly Report on Form 10-Q, formatted in Inline XBRL (included as Exhibit 101) *Filed herewith. **Furnished herewith.â€ Certain portions of this exhibit were redacted by means of marking such portions with asterisks because the identified portions are (i) not material and (ii) treated as private or confidential by the Company. 33 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Quarterly Report on Form 10-Q to be signed on its behalf by the undersigned, thereunto duly authorized. Dated: August 4, 2024 ARROWHEAD PHARMACEUTICALS, INC. By: /s/ Kenneth A. Myszkowski Kenneth A. Myszkowski Chief Financial Officer (Principal Financial Officer and Duly Authorized Officer) 34 EX-31.1 2 arwr-2024630xex311.htm EX-31.1 arwr-2024630xex311 Â EX-31.2 3 arwr-2024630xex312.htm EX-31.2 arwr-2024630xex312 Â EX-32.1 4 arwr-2024630xex321.htm EX-32.1 arwr-2024630xex321 Â EX-32.2 5 arwr-2024630xex322.htm EX-32.2 arwr-2024630xex322 Â EX-101.SCH 6 arwr-20240630.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Statement - Cover link: presentationLink link: calculationLink link: definitionLink 9952151 - Statement - Consolidated Balance Sheets link: presentationLink link: calculationLink link: definitionLink 9952152 - Statement - Consolidated Balance Sheets (Parenthetical) link: presentationLink link: calculationLink link: definitionLink 9952153 - Statement - Consolidated Statements of Operations and Comprehensive Loss link: presentationLink link: calculationLink link: definitionLink 9952154 - Statement - Consolidated Statements of Stockholders' Equity link: presentationLink link: calculationLink link: definitionLink 9952155 - Statement - Consolidated Statements of Cash Flows link: presentationLink link: calculationLink link: definitionLink 9952156 - Disclosure - Organization and Significant Accounting Policies link: presentationLink link: calculationLink link: definitionLink 9952157 - Disclosure - Collaboration and License Agreements link: presentationLink link: calculationLink link: definitionLink 9952158 - Disclosure - Balance Sheet Accounts link: presentationLink link: calculationLink link: definitionLink 9952159 - Disclosure - Investments link: presentationLink link: calculationLink link: definitionLink 9952160 - Disclosure - Intangible Assets link: presentationLink link: calculationLink link: definitionLink 9952161 - Disclosure - Stockholders' Equity link: presentationLink link: calculationLink link: definitionLink 9952162 - Disclosure - Commitments and Contingencies link: presentationLink link: calculationLink link: definitionLink 9952163 - Disclosure - Leases link: presentationLink link: calculationLink link: definitionLink 9952164 - Disclosure - Stock-Based Compensation link: presentationLink link: calculationLink link: definitionLink 9952165 - Disclosure - Fair Value Measurements link: presentationLink link: calculationLink link: definitionLink 9952166 - Disclosure - Liability Related to the Sale of Future Royalties link: presentationLink link: calculationLink link: definitionLink 9952167 - Disclosure - Net Loss Per Share link: presentationLink link: calculationLink link: definitionLink 9952168 - Disclosure - Subsequent Events link: presentationLink link: calculationLink link: definitionLink 9954471 - Disclosure - Organization and Significant Accounting Policies (Policies) link: presentationLink link: calculationLink link: definitionLink 9954472 - Disclosure - Organization and Significant Accounting Policies (Tables) link: presentationLink link: calculationLink link: definitionLink 9954473 - Disclosure - Collaboration and License Agreements (Tables) link: presentationLink link: calculationLink link: definitionLink 9954474 - Disclosure - Balance Sheet Accounts (Tables) link: presentationLink link: calculationLink link: definitionLink 9954475 - Disclosure - Investments (Tables) link: presentationLink link: calculationLink link: definitionLink 9954476 - Disclosure - Intangible Assets (Tables) link: presentationLink link: calculationLink link: definitionLink 9954477 - Disclosure - Stockholders' Equity (Tables) link: presentationLink link: calculationLink link: definitionLink 9954478 - Disclosure - Leases (Tables) link: presentationLink link: calculationLink link: definitionLink 9954479 - Disclosure - Stock-Based Compensation (Tables) link: presentationLink link: calculationLink link: definitionLink 9954480 - Disclosure - Fair Value Measurements (Tables) link: presentationLink link: calculationLink link: definitionLink 9954481 - Disclosure - Liability Related to the Sale of Future Royalties (Tables) link: presentationLink link: calculationLink link: definitionLink 9954482 - Disclosure - Net Loss Per Share (Tables) link: presentationLink link: calculationLink link: definitionLink 9954483 - Disclosure - Organization and Significant Accounting Policies - Narrative (Details) link: presentationLink link: calculationLink link: definitionLink 9954484 - Disclosure - Collaboration and License Agreements - Revenue (Details) link: presentationLink link: calculationLink link: definitionLink 9954485 - Disclosure - Collaboration and License Agreements - Receivables and Contract Liabilities (Details) link: presentationLink link: calculationLink link: definitionLink 9954486 - Disclosure - Collaboration and License Agreements - Glaxosmithkline Intellectual Property (No. 3) Limited (Details) link: presentationLink link: calculationLink link: definitionLink 9954487 - Disclosure - Collaboration and License Agreements - Horizon Therapeutics Ireland DAC (Details) link: presentationLink link: calculationLink link: definitionLink 9954488 - Disclosure - Collaboration and License Agreements - Takeda Pharmaceutical Company Limited (Details) link: presentationLink link: calculationLink link: definitionLink 9954489 - Disclosure - Collaboration and License Agreements - Amgen, Inc (Details) link: presentationLink link: calculationLink link: definitionLink 9954490 - Disclosure - Collaboration and License Agreements - Visirma Therapeutics, Inc. (Details) link: presentationLink link: calculationLink link: definitionLink 9954491 - Disclosure - Balance Sheet Accounts - Summary of Property and Equipment (Details) link: presentationLink link: calculationLink link: definitionLink 9954492 - Disclosure - Balance Sheet Accounts - Accrued Expenses (Details) link: presentationLink link: calculationLink link: definitionLink 9954493 - Disclosure - Investments - Summary of Short-term, Long-term Investments and Marketable Securities (Details) link: presentationLink link: calculationLink link: definitionLink 9954494 - Disclosure - Intangible Assets - Schedule of Intangible Assets (Details) link: presentationLink link: calculationLink link: definitionLink 9954495 - Disclosure - Intangible Assets - Expected Future Amortization (Details) link: presentationLink link: calculationLink link: definitionLink 9954496 - Disclosure - Stockholders' Equity (Details) link: presentationLink link: calculationLink link: definitionLink 9954497 - Disclosure - Commitments and Contingencies - Narrative (Details) link: presentationLink link: calculationLink link: definitionLink 9954498 - Disclosure - Leases - Narrative (Details) link: presentationLink link: calculationLink link: definitionLink 9954499 - Disclosure - Leases - Components of Lease Assets and Liabilities (Details) link: presentationLink link: calculationLink link: definitionLink 9954500 - Disclosure - Leases - Summary of Maturities of Operating Lease Liabilities on an Undiscounted Basis (Details) link: presentationLink link: calculationLink link: definitionLink 9954500 - Disclosure - Leases - Summary of Maturities of Operating Lease Liabilities on an Undiscounted Basis (Details) link: presentationLink link: calculationLink link: definitionLink 9954501 - Disclosure - Leases - Supplemental Cash Flow and Other Information Related to Leases (Details) link: presentationLink link: calculationLink link: definitionLink 9954502 - Disclosure - Stock-Based Compensation - Narrative (Details) link: presentationLink link: calculationLink link: definitionLink 9954503 - Disclosure - Stock-Based Compensation - Summary of Granted and Outstanding Shares (Details) link: presentationLink link: calculationLink link: definitionLink 9954504 - Disclosure - Stock-Based Compensation - Expenses Included in Operating Expenses (Details) link: presentationLink link: calculationLink link: definitionLink 9954505 - Disclosure - Stock-Based Compensation - Summarize Information about Stock Options (Details) link: presentationLink link: calculationLink link: definitionLink 9954506 - Disclosure - Stock-Based Compensation - Assumptions Used to Value Stock Options (Details) link: presentationLink link: calculationLink link: definitionLink 9954507 - Disclosure - Stock-Based Compensation - Summary of RSUs Activity (Details) link: presentationLink link: calculationLink link: definitionLink 9954508 - Disclosure - Fair Value Measurements - Fair Value Measurements for Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) link: presentationLink link: calculationLink link: definitionLink 9954509 - Disclosure - Liability Related to the Sale of Future Royalties - Narrative (Details) link: presentationLink link: calculationLink link: definitionLink 9954510 - Disclosure - Liability Related to the Sale of Future Royalties - Activity (Details) link: presentationLink link: calculationLink link: definitionLink 9954511 - Disclosure - Net Loss Per Share - Basic and Diluted Net Loss Per Share (Details) link: presentationLink link: calculationLink link: definitionLink 9954512 - Disclosure - Net Loss Per Share - Antidilutive (Details) link: presentationLink link: calculationLink link: definitionLink 9954513 - Disclosure - Subsequent Events (Details) link: presentationLink link: calculationLink link: definitionLink EX-101.CAL 7 arwr-20240630 cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 8 arwr-20240630 def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 9 arwr-20240630 lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT GSK-HSD License Agreement GSK-HSD License Agreement [Member] GSK-HSD License Agreement Liability related to the sale of future royalties Carrying value as of September 30, 2023 Carrying value as of June 30, 2024 Royalties, Liability, Noncurrent Royalties, Liability, Noncurrent Adjustments to reconcile net loss to net cash flow from operating activities Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Statistical Measurement [Domain] Statistical Measurement [Domain] Contract assets Contract with Customer, Asset, after Allowance for Credit Loss, Current Schedule of Lease Assets and Liabilities and Lease Cost Lease, Cost [Table Text Block] Cover [Abstract] Cover [Abstract] Debt securities Debt Securities [Member] Summary of Maturities of Operating Lease Liabilities on an Undiscounted Basis Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block] Other liabilities Other Liabilities, Current Trading Symbol Trading Symbol Comprehensive loss Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest All Trading Arrangements All Trading Arrangements [Member] Compensation Actually Paid vs. Net Income Compensation Actually Paid vs. Net Income [Text Block] Non-NEOs Non-NEOs [Member] Schedule of Earnings Per Share, Basic and Diluted Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Rule 10b5-1 Arrangement Adopted Rule 10b5-1 Arrangement Adopted [Flag] Awards Close in Time to MNPI Disclosures Awards Close in Time to MNPI Disclosures [Table] Income taxes paid Income Taxes Paid, Net Other Commitments [Line Items] Other Commitments [Line Items] Accrued R&D expenses Accrued Research And Development Expense, Current Accrued Research And Development Expense, Current Planned area of the site (in sq ft) Area of Land Pay vs Performance Disclosure [Line Items] Peer Group Total Shareholder Return Amount Peer Group Total Shareholder Return Amount Accounts receivable Increase (Decrease) in Accounts Receivable Operating lease, net Increase (Decrease) in Operating Lease Liability Non-Rule 10b5-1 Arrangement Adopted Non-Rule 10b5-1 Arrangement Adopted [Flag] Fair Value Measurements Fair Value Disclosures [Text Block] Proceeds from the exercises of stock options Proceeds from Stock Options Exercised Land Land [Member] Award Timing Disclosures [Line Items] Other Performance Measure, Amount Other Performance Measure, Amount 2027 Finite-Lived Intangible Asset, Expected Amortization, Year Three Leases Lessee, Operating Leases [Text Block] Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Operating lease cost Operating Lease, Cost Lease Cost Lease, Cost [Abstract] Common stock, share reserve for issuance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant Lease liabilities, net of current portion Operating Lease, Liability, Noncurrent Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Deferred revenue Contract liabilities Contract with Customer, Liability, Current Plan Name Plan Name [Domain] Common stock offering price (in dollars per share) Sale of Stock, Price Per Share Operating Leased Assets [Line Items] Operating Leased Assets [Line Items] Effect of dilutive securities (in shares) Weighted Average Number of Shares Outstanding, Diluted, Adjustment Upfront payment Cash Received As Due Under Collaboration Agreement Cash received as due under collaboration agreement. Other assets Other Assets, Noncurrent Entity Tax Identification Number Entity Tax Identification Number Leases [Abstract] Leases [Abstract] Gross Carrying Amount Finite-Lived Intangible Assets, Gross Schedule Of Finite Lived Intangible Assets [Table] Intangible Asset, Finite-Lived [Table] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] Amortization (accretion) of note premiums/discounts Investment Income, Net, Amortization of Discount and Premium Money market instruments Money Market Funds [Member] Net cash used in operating activities Net Cash Provided by (Used in) Operating Activities Patents Patents [Member] Net proceeds Sale of Stock, Consideration Received on Transaction CASH FLOWS FROM OPERATING ACTIVITIES: Net Cash Provided by (Used in) Operating Activities [Abstract] Net loss per share attributable to Arrowhead Pharmaceuticals, Inc.: Earnings Per Share Reconciliation [Abstract] Secured Debt Secured Debt [Member] Plan Name Plan Name [Axis] Prepaid expenses Prepaid Expense, Current Equity Components [Axis] Equity Components [Axis] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] Other current assets Other Assets, Current Award Timing Method Award Timing Method [Text Block] Common stock shares value reserved for future issuance Common Stock Capital Shares Value Reserved For Future Issuance Common stock, capital shares value reserved for future issuance, Trading Arrangements, by Individual Trading Arrangements, by Individual [Table] Available-for-sale securities Debt Securities, Available-for-Sale Measurement Frequency Measurement Frequency [Axis] Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Insider Trading Policies and Procedures [Line Items] Financing Agreement Financing Agreement [Member] Financing Agreement Adjustment to Compensation, Amount Adjustment to Compensation Amount Aggregate Intrinsic Value Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value Additional paid-in capital Additional Paid in Capital, Common Stock Compensation Amount Outstanding Recovery Compensation Amount Supplemental disclosure of non-cash investing activities: Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract] Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member] Schedule of Operating Leased Assets [Table] Schedule of Operating Leased Assets [Table] Entity Small Business Entity Small Business Company Selected Measure Amount Company Selected Measure Amount Geographical [Axis] Geographical [Axis] 2013 Incentive Plan Two Thousands Thirteen Incentive Plan [Member] Two thousands thirteen incentive plan. Tabular List, Table Tabular List [Table Text Block] Interest income Investment Income, Interest and Dividend Level 3 Fair Value, Inputs, Level 3 [Member] Sales-related milestone payments Sales Related Milestone Payments Sales-related milestone payments. Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items] Cash paid for amounts included in the measurement of lease liabilities: Cash Flow, Operating Activities, Lessee [Abstract] Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member] Office space leases (in sq ft) Land Subject to Ground Leases Lessee Lease Description [Line Items] Lessee, Lease, Description [Line Items] Contingent liabilities Loss Contingency Accrual Accrued expenses Total accrued expenses Accrued Liabilities, Current Potentially dilutive securities excluded from computation of diluted earnings per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Current investments, Available-for-sale, Gross Unrealized Losses Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, Current Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, Current Asset Acquisition Asset Acquisition [Axis] Credit Facility [Domain] Credit Facility [Domain] Cash, cash equivalents and restricted cash BEGINNING OF PERIOD END OF PERIOD Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents Number of distinct performance obligations Number Of Distinct Performance Obligations Number of distinct performance obligations. Percentage of commission to sales agent Percentage Of Commission On Aggregate Gross Proceeds From Sale Of Common Stock Percentage of commission on aggregate gross proceeds from sale of common stock. Additional tenant improvement allowance interest per annum Additional Tenant Improvement Allowance, Interest Per Annum Additional Tenant Improvement Allowance, Interest Per Annum Current assets: Assets, Current [Abstract] Commercial notes Commercial Notes [Member] Commercial Notes Proceeds from the sale of future royalties Proceeds from Sale of Future Royalties Proceeds from Sale of Future Royalties Forgone Recovery due to Disqualification of Tax Benefits, Amount Forgone Recovery due to Disqualification of Tax Benefits, Amount Options Share-Based Payment Arrangement, Option [Member] Short-term lease cost Short-Term Lease, Cost Vested (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] 2025 Lessee, Operating Lease, Liability, to be Paid, Year One Research Facility in San Diego Research Facility in San Diego [Member] Research Facility in San Diego. Development regulatory and sales milestones payments Development Regulatory And Sales Milestones Payments Development regulatory and sales milestones payments. Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Antidilutive Security, Excluded EPS Calculation [Table] Accrued R&D expenses; co-development Accrued Research And Development Co-Development Expense, Current Accrued Research And Development Co-Development Expense, Current Preferred stock, shares outstanding (in shares) Preferred Stock, Shares Outstanding 2013 and 2021 Incentive Plans and other inducement grants Two Thousand Thirteen Equity Incentive Plan, Two Thousand Twenty One Equity Incentive

Plan And Inducement Grants [Member] Two Thousand Thirteen Equity Incentive Plan, Two Thousand Twenty One Equity Incentive Plan And Inducement Grants Municipal securities Municipal Bonds [Member] Security Exchange Name Security Exchange Name Award Type Award Type [Axis] Corporate debt securities Corporate Debt Securities [Member] Exercised (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price Right-of-use assets adjusted in exchange for new/amended operating lease liabilities Right-Of-Use Asset Adjustment In Exchange For Operating Lease Liability Right-Of-Use Asset Adjustment In Exchange For Operating Lease Liability Victoria Vakieren [Member] Victoria Vakieren Number of RSUs Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Property, plant and equipment, net Property, plant and equipment, net Property, Plant and Equipment, Net Summary of Short-term and Long-term Investments and Marketable Securities Held To Maturity Securities And Marketable Securities Table [Table Text Block] Held to maturity securities and marketable securities. Noncontrolling interest Equity, Attributable to Noncontrolling Interest Additional tenant improvement allowance liability Additional Tenant Improvement Allowance Liability Additional Tenant Improvement Allowance Liability Weighted-Average Exercise Price Per Share, Exercisable (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price Other comprehensive loss, net of tax: Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract] Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Forgone Recovery, Explanation of Impracticability Forgone Recovery, Explanation of Impracticability [Text Block] Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table] Realized gain on investments Realized Investment Gains (Losses) Expiration Date Trading Arrangement Expiration Date CASH FLOWS FROM INVESTING ACTIVITIES: Net Cash Provided by (Used in) Investing Activities [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Wisconsin WISCONSIN Lease liabilities Operating Lease, Liability, Current Total Shareholder Return Amount Total Shareholder Return Amount Common stock, shares issued (in shares) Common Stock, Shares, Issued Equity Awards Adjustments, Footnote Equity Awards Adjustments, Footnote [Text Block] Maximum borrowing capacity Line of Credit Facility, Maximum Borrowing Capacity Insider Trading Policies and Procedures Adopted Insider Trading Policies and Procedures Adopted [Flag] Less: Accumulated depreciation and amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment Subsequent Event [Line Items] Subsequent Event [Line Items] Property, plant and equipment, gross Property, Plant and Equipment, Gross Receivables included in accounts receivable Accounts Receivable, after Allowance for Credit Loss Exercise of stock options (in shares) Exercised (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period Named Executive Officers, Footnote Named Executive Officers, Footnote [Text Block] Weighted- Average Exercise Price Per Share Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Research and development Research and Development Expense [Member] Common stock, shares authorized (in shares) Common Stock, Shares Authorized Schedule of Company's Current Pipeline Schedule of Current Products [Table Text Block] Schedule of Current Products Change in unrealized losses on available-for-sale securities OCI, Debt Securities, Available-for-Sale, Gain (Loss), after Adjustment and Tax Diluted (in shares) Weighted-average diluted shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Diluted Janssen Janssen Pharmaceuticals Incorporation [Member] Janssen Pharmaceuticals, Incorporation. MNPI Disclosure Timed for Compensation Value MNPI Disclosure Timed for Compensation Value [Flag] 2024 (remainder) Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year Inducement Awards Inducement Awards [Member] Inducement Awards Long-Term Debt, Type [Axis] Long-Term Debt, Type [Axis] Total Arrowhead Pharmaceuticals, Inc. stockholders' equity Equity, Attributable to Parent Research equipment Research Equipment [Member] Research Equipment Collaboration and License Agreements Collaborative Arrangement Disclosure [Text Block] Initial transaction price Initial Transaction Price Initial transaction price. Operating lease renewal term Lessee, Operating Lease, Renewal Term Interest expense Interest Expense, Nonoperating Schedule of Liability Related to the Sale of Future Royalties Schedule Of Liability Related To The Sale Of Future Royalties [Table Text Block] Schedule Of Liability Related To The Sale Of Future Royalties Fair Value, Measurements, Recurring Fair Value, Recurring [Member] Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross Commercial milestone payments at first commercial sale Commercial Milestone Payments At First Commercial Sale Commercial milestone payments at first commercial sale. Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Number of shares authorized (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized Sale of Stock [Domain] Sale of Stock [Domain] Pension Adjustments Prior Service Cost Pension Adjustments Prior Service Cost [Member] Document Fiscal Period Focus Document Fiscal Period Focus All Executive Categories All Executive Categories [Member] 2026 Finite-Lived Intangible Asset, Expected Amortization, Year Two Changed Peer Group, Footnote Changed Peer Group, Footnote [Text Block] Weighted- Average Remaining Contractual Term (Years) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term ASSETS Assets [Abstract] Expected dividend yield Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate Document Type Document Type Common stock - restricted stock units vesting Stock Issued During Period, Value, Restricted Stock Award, Gross Pension Benefits Adjustments, Footnote Pension Benefits Adjustments, Footnote [Text Block] Total Shareholder Return Vs Peer Group Total Shareholder Return Vs Peer Group [Text Block] Common stock - restricted stock units vesting (in shares) Stock Issued During Period, Shares, Restricted Stock Award, Gross additional remaining development regulatory and sales milestones payments Additional Remaining Development Regulatory And Sales Milestones Payments Additional remaining development regulatory and sales milestones payments. 2021 Incentive Plan Two Thousand Twenty One Incentive Plan [Member] Two thousand twenty one incentive plan. Weighted-Average Remaining Contractual Term, Exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term Vested (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period Schedule of Receivables and Contract Liabilities Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block] Schedule of Intangible Assets Future Amortization Expense Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block] Risk-free interest rate Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Subsequent Event [Table] Subsequent Event [Table] Lease Assets and Liabilities Assets and Liabilities, Lessee [Abstract] Maximum Maximum [Member] Amortization expense Amortization of Intangible Assets Contract liabilities included in deferred revenue Contract with Customer, Liability Equity Valuation Assumption Difference, Footnote Equity Valuation Assumption Difference, Footnote [Text Block] Furniture Furniture and Fixtures [Member] Intangible assets, net Net Carrying Amount Finite-Lived Intangible Assets, Net Antidilutive Securities [Axis] Antidilutive Securities [Axis] Accounts payable Accounts Payable, Current Accounting Policies [Abstract] Accounting Policies [Abstract] Leasehold improvements Leasehold Improvements [Member] Cancelled (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price Assumptions Used to Value Stock Options Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Current Fiscal Year End Date Current Fiscal Year End Date Less imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Total Lease, Cost Visirma Therapeutics, Inc. Visirma Therapeutics, Inc. [Member] Visirma Therapeutics, Inc. Statistical Measurement [Axis] Statistical Measurement [Axis] PEO Name PEO Name Milestone payment Milestone Payment Earned Milestone payment earned. Non-Rule 10b5-1 Arrangement Terminated Non-Rule 10b5-1 Arrangement Terminated [Flag] Loss before income tax expense (benefit) and noncontrolling interest Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Non-PEO NEO Average Total Compensation Amount Non-PEO NEO Average Total Compensation Amount Award Type Award Type [Domain] Name Outstanding Recovery, Individual Name License Licensing Agreements [Member] Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Variable lease cost Variable Lease, Cost, Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block] Compensation Actually Paid vs. Company Selected Measure Compensation Actually Paid vs. Company Selected Measure [Text Block] Non-PEO NEO Non-PEO NEO [Member] Capital expenditures incurred Commitments, Capital Expenditures Incurred To Date Commitments, Capital Expenditures Incurred To Date Useful Lives Finite-Lived Intangible Asset, Useful Life Net decrease in cash, cash equivalents and restricted cash Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect Additional Paid-In Capital Additional Paid-in Capital [Member] Award Timing Predetermined Award Timing Predetermined [Flag] Subsequent Event Type [Domain] Subsequent Event Type [Domain] Schedule Of Held To Maturity Securities And Marketable Securities [Table] Schedule Of Held To Maturity Securities And Marketable Securities [Table] Schedule of held to maturity securities and marketable securities. Class Of Stock [Line Items] Class of Stock [Line Items] Current investments, Available-for-sale, Adjusted Basis Debt Securities, Available-for-Sale, Amortized Cost, Current Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Diluted (in dollars per share) Diluted net loss per share (in dollars per share) Earnings Per Share, Diluted Finite-Lived Intangible Assets by Major Class Finite-Lived Intangible Assets by Major Class [Axis] Accumulated Amortization Finite-Lived Intangible Assets, Accumulated Amortization Olpasiran Agreement Olpasiran Agreement [Member] Olpasiran agreement. Counterparty Name [Domain] Counterparty Name [Domain] Name Measure Name Entity Interactive Data Current Entity Interactive Data Current Deferred revenue Increase (Decrease) in Contract with Customer, Liability Restatement does not require Recovery Restatement Does Not Require Recovery [Text Block] Preferred stock, shares issued (in shares) Preferred Stock, Shares Issued Customer [Axis] Customer [Axis] Fair Value Measurements for Assets and Liabilities Measured at Fair Value on Recurring Basis Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block] Milestone payment receivable upon achievement of phase two and first patient dosed in phase three Milestone Payment Receivable Upon Achievement Of Phase Two And First Patient Dosed In Phase Three Milestone payment receivable upon achievement of phase two and first patient dosed in phase three. Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Drug Manufacturing Facility Drug Manufacturing Facility [Member] Drug manufacturing facility. Stock-based compensation Share-Based Payment Arrangement, Noncash Expense Summary of Awards Outstanding Share-Based Payment Arrangement, Activity [Table Text Block] Collaboration And License Agreements [Abstract] Collaboration And License Agreements [Abstract] Collaboration and license agreements. Net loss including noncontrolling interest Net income (loss) Net loss Net Income (Loss), Including Portion Attributable to Noncontrolling Interest Income tax expense (benefit) Income Tax Expense (Benefit) Other income (expense): Nonoperating Income (Expense) [Abstract] Interest rate Debt Instrument, Interest Rate, Stated Percentage Available-for-sale securities, at fair value Current investments, Available-for-sale, Fair Value Debt Securities, Available-for-Sale, Current Supplementary disclosure of cash flows: Supplemental Cash Flow Information [Abstract] Schedule Of Held To Maturity Securities And Marketable Securities [Line Items] Schedule Of Held To Maturity Securities And Marketable Securities [Line Items] Schedule of held to maturity securities and marketable securities. Weighted average period to recognize pre-tax compensation expense Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Liability related to the sale of future royalties Liability, Sale of Future Royalties Liability, Sale of Future Royalties Revenue Revenue from Contract with Customer, Excluding Assessed Tax Organization And Significant Accounting Policies [Table] Organization And Significant Accounting Policies [Table] Organization and significant accounting policies. Total other income (expense) Nonoperating Income (Expense) Development and sales milestone payments Development And Sales Milestones Payments Development And Sales Milestones Payments Net cash used in investing activities Net Cash Provided by (Used in) Investing Activities Operating loss Operating Income (Loss) Liability, Sale Of Future Royalties [Roll Forward] Liability, Sale Of Future Royalties [Roll Forward] Liability, Sale Of Future Royalties Research and development Research and Development Expense (Excluding Acquired in Process Cost) Total Liabilities, Noncontrolling Interest and Stockholders' Equity Liabilities and Equity Subsequent Events Subsequent Events [Text Block] All Adjustments to Compensation All Adjustments to Compensation [Member] Rule 10b5-1 Arrangement Terminated Rule 10b5-1 Arrangement Terminated [Flag] Fair Value Hierarchy and NAV Fair Value Hierarchy and NAV [Axis] Accrued payroll and benefits Employee-related Liabilities, Current Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Number of options to renew Number Of Options To Renew Number of options to renew. Takeda Takeda Pharmaceuticals United States Of America Incorporated [Member] Takeda Pharmaceuticals United States of America Incorporated. Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Finite-Lived Intangible Assets, Major Class Name Finite-Lived Intangible Assets, Major Class Name [Domain] Underlying Security Market Price Change Underlying Security Market Price Change, Percent Individual: Individual [Axis] Accumulated Other Comprehensive Loss AOCI Attributable to Parent [Member] Horizon Horizon Therapeutics Ireland DAC [Member] Horizon Therapeutics Ireland DAC. Expected life (in years) Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term Long-Term Debt, Type [Domain] Long-Term Debt, Type [Domain] Entity Address, State or Province Entity Address, State or Province Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Statement [Line Items] Statement [Line Items] Liability Related to the Sale of Future Royalties Liability Related To The Sale Of Future Royalties [Text Block] Liability Related To The Sale Of Future Royalties Erroneous Compensation Analysis Erroneous Compensation Analysis [Text Block] Operating expenses: Operating Expenses [Abstract] Summary of Property and Equipment Property, Plant and Equipment [Table Text Block] Compensation Actually Paid vs. Total Shareholder Return Compensation Actually Paid vs. Total Shareholder Return [Text Block] Financial Instruments [Domain] Financial Instruments [Domain] Beginning balance (in dollars per share) Ending balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value LIABILITIES, NONCONTROLLING INTEREST AND STOCKHOLDERS' EQUITY Liabilities and Equity [Abstract] Milestone payment received Milestone Payment Received, Liability Related To Sale Of Future Royalties Milestone Payment Received, Liability Related To Sale Of Future Royalties Cash received for amounts included in the measurement of lease liabilities: Cash Flow, Operating Activities, Lessee, Cash Received For Amounts Included In Measurement Of Lease Liabilities [Abstract] Cash Flow, Operating Activities, Lessee, Cash Received For Amounts Included In Measurement Of Lease Liabilities Minimum Minimum [Member] Restatement Determination Date Restatement Determination Date Pay vs Performance Disclosure Pay vs Performance Disclosure [Table] Adoption Date Trading Arrangement Adoption Date Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Beginning balance (in dollars per share) Ending balance (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price Right-of-use assets Operating Lease, Right-of-Use Asset Erroneously Awarded Compensation Recovery Erroneously Awarded Compensation Recovery [Table] Number of options outstanding (in shares) Beginning balance (in shares) Ending balance (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member] Liability Related To The Sale Of Future Royalties [Abstract] Liability Related To The Sale Of Future Royalties Exercise Price Award Exercise Price California CALIFORNIA Net Loss Per Share Earnings Per Share [Text Block] Novartis Novartis [Member] Novartis. Arrangement Duration Trading Arrangement Duration Subsequent Event Subsequent Event [Member] Exercise of stock options Stock Issued During Period, Value, Stock Options Exercised Restricted cash Restricted Cash and Cash Equivalents, Current Granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Peer Group Issuers, Footnote Peer Group Issuers, Footnote [Text Block] Increase (decrease) in cash and investments Increase (Decrease) In Cash And Investments Increase decrease in cash and investments. License and Co-Funding Agreement License And Co Funding Agreement [Member] License and co-funding agreement. Material Terms of Trading Arrangement Material Terms of Trading Arrangement [Text Block] Debt instrument term Debt Instrument, Term 2028 Finite-Lived Intangible Asset, Expected Amortization, Year Four All Individuals [Member] Building Building [Member] PEO PEO [Member] Organization And Significant Accounting Policies [Line Items] Organization And Significant Accounting Policies [Line Items] Organization and significant accounting policies. Name Trading Arrangement, Individual Name At The Market Agreement At The Market Agreement [Member] At-the-market agreement. Other, net Other Nonoperating Income (Expense) Corporate Headquarters In Pasadena Corporate Headquarters In Pasadena [Member] Corporate Headquarters In Pasadena Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Axis] Number of distinct bundle Number Of Distinct Bundle Number of distinct bundle. Unrecognized pre-tax compensation expense Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Royalty payment threshold Royalty Payment Threshold Royalty Payment Threshold CASH, CASH EQUIVALENTS AND RESTRICTED CASH: Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including

Disposal Group and Discontinued Operations [Abstract] Property, plant and equipment, reclassification Property, Plant and Equipment, Transfers and Changes Facilities Facilities [Member] Facilities. Awards Close in Time to MNPI Disclosures, Table Awards Close in Time to MNPI Disclosures [Table Text Block] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table] Shares reserve for issuance (in shares) Common Stock, Capital Shares Reserved for Future Issuance Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member] Beginning balance (in shares) Ending balance (in shares) Shares, Outstanding Cash equivalents Cash and Cash Equivalents, Fair Value Disclosure Non-cash interest expense on liability related to the sale of future royalties Non-cash interest expense recognized Non-Cash Interest Expense, Liability Related To Sale Of Future Royalties Non-Cash Interest Expense, Liability Related To Sale Of Future Royalties Total long-term liabilities Liabilities, Noncurrent Aggregate Erroneous Compensation Amount Aggregate Erroneous Compensation Amount Local Phone Number Local Phone Number Aggregate Erroneous Compensation Not Yet Determined Aggregate Erroneous Compensation Not Yet Determined [Text Block] Royalty Pharma Agreement Royalty Pharma Agreement [Member] Royalty Pharma Agreement Total operating expenses Operating Expenses Expected volatility Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate Summary of Share Activity Related to RSUs Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block] Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Operating cash flows from operating leases Operating Lease, Cash Received For Amounts Included In Measurement Of Lease Liabilities Operating Lease, Cash Received For Amounts Included In Measurement Of Lease Liabilities Long-term liabilities: Liabilities, Noncurrent [Abstract] PEO Total Compensation Amount PEO Total Compensation Amount Long-Lived Tangible Asset [Domain] Long-Lived Tangible Asset [Domain] Schedule of Accrued Expenses Schedule of Accrued Liabilities [Table Text Block] Income Statement Location [Axis] Statement of Income Location, Balance [Axis] Commitments and Contingencies Commitments and Contingencies Disclosure [Text Block] Common Stock Common Stock [Member] Measure: Measure [Axis] Amgen Amgen Incorporated [Member] Amgen Incorporated. Preferred stock, shares authorized (in shares) Preferred Stock, Shares Authorized Forgone Recovery due to Expense of Enforcement, Amount Forgone Recovery due to Expense of Enforcement, Amount Common stock issued, net of offering costs (in shares) Stock Issued During Period, Shares, New Issues Line of Credit Line of Credit [Member] Entity Emerging Growth Company Entity Emerging Growth Company Entity Central Index Key Entity Central Index Key General and administrative expense General and Administrative Expense [Member] Lessee Lease Description [Table] Lessee, Lease, Description [Table] Non-GAAP Measure Description Non-GAAP Measure Description [Text Block] Non-PEO NEO Average Compensation Actually Paid Amount Non-PEO NEO Average Compensation Actually Paid Amount Stockholders' Equity Equity [Text Block] Award Timing, How MNPI Considered Award Timing, How MNPI Considered [Text Block] Preferred stock, par value (in dollars per share) Preferred Stock, Par or Stated Value Per Share Equity Component [Domain] Equity Component [Domain] Financial Instrument [Axis] Financial Instrument [Axis] Additional 402(v) Disclosure Additional 402(v) Disclosure [Text Block] Stock-based compensation APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Entity Shell Company Entity Shell Company Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Title Trading Arrangement, Individual Title 2029 and thereafter Lessee Operating Lease Liability Payments Due Year Five And After Year Five Lessee operating lease liability payments due year five and after year five. Statement [Table] Statement [Table] Milestone payment receivable upon FDA approval Milestone Payment Receivable, Upon FDA Approval Milestone Payment Receivable, Upon FDA Approval Measurement Frequency Measurement Frequency [Domain] Counterparty Name [Axis] Counterparty Name [Axis] Numerator: Net Income (Loss) Available to Common Stockholders, Diluted [Abstract] Visirna License Agreement Visirna License Agreement [Member] Visirna License Agreement City Area Code City Area Code Current liabilities: Liabilities, Current [Abstract] Milestone payment receivable upon achievement of enrollment in phase 3 clinical trial Milestone Payment Receivable, Upon Achievement of Enrollment in Phase 3 Clinical Trial Milestone Payment Receivable, Upon Achievement of Enrollment in Phase 3 Clinical Trial Insider Trading Policies and Procedures Not Adopted Insider Trading Policies and Procedures Not Adopted [Text Block] Level 1 Fair Value, Inputs, Level 1 [Member] Impairment Finite-Lived Intangible Assets, Impairment Finite-Lived Intangible Assets, Impairment Foreign currency translation adjustments Foreign currency translation adjustments Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax Total current assets Assets, Current Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Aggregate purchase price paid by investors Sale Of Stock, Aggregate Purchase Price Sale Of Stock, Aggregate Purchase Price Accrued expenses Increase (Decrease) in Accrued Liabilities Incremental Facility Incremental Facility [Member] Incremental Facility Number of Options Outstanding, Exercisable (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number Milestone payments Milestone Payment Received Milestone payment received. Weighted- Average Grant Date Fair Value Per Share Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Weighted average grant date fair value per share of options granted (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Subsequent Event Type [Axis] Subsequent Event Type [Axis] Percentage of eligible to receive tiered royalties on net sales Percentage Of Eligible To Receive Tiered Royalties On Net Sales Percentage of eligible to receive tiered royalties on net sales. Organization and Significant Accounting Policies Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block] 2028 Lessee, Operating Lease, Liability, to be Paid, Year Four Earnings Per Share [Abstract] Equity [Abstract] Equity [Abstract] Accumulated deficit Retained Earnings (Accumulated Deficit) General and administrative General and Administrative Expense Organization, Consolidation and Presentation of Financial Statements [Abstract] Aggregate Available Trading Arrangement, Securities Aggregate Available Amount Equity Awards Adjustments Equity Awards Adjustments [Member] Weighted-average discount rate Operating Lease, Weighted Average Discount Rate, Percent Total operating lease liabilities (includes current portion) Operating Lease, Liability Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Underlying Securities Award Underlying Securities Amount Investments Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block] Total (in shares) Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Equity Instruments Other Than Options, Outstanding Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Equity Instruments Other Than Options, Outstanding Credit Facility [Axis] Credit Facility [Axis] Amendment Flag Amendment Flag Entity Registrant Name Entity Registrant Name Adjustment to Non-PEO NEO Compensation Footnote Adjustment to Non-PEO NEO Compensation Footnote [Text Block] Stock Appreciation Rights (SARs) Stock Appreciation Rights (SARs) [Member] Depreciation and amortization expense for property and equipment Depreciation, Depletion and Amortization Intangible Assets Intangible Assets Disclosure [Text Block] Fair Value as of Grant Date Award Grant Date Fair Value Subsequent Events [Abstract] Subsequent Events [Abstract] Level 2 Fair Value, Inputs, Level 2 [Member] Shares of common stock issued (in shares) Sale of Stock, Number of Shares Issued in Transaction Fair Value Hierarchy and NAV Fair Value Hierarchy and NAV [Domain] Noncontrolling interest and stockholdersâ€™ equity: Equity, Including Portion Attributable to Noncontrolling Interest [Abstract] Geographical [Domain] Geographical [Domain] GSK Glaxosmithkline Intellectual Property Limited [Member] Glaxosmithkline Intellectual Property Limited. Recovery of Erroneously Awarded Compensation Disclosure [Line Items] Summary of Revenue Disaggregation of Revenue [Table Text Block] Common stock issued, net of offering costs Stock Issued During Period, Value, New Issues Computers and software Computer And Software [Member] Computer And Software Colorado Owner, LLC Colorado Owner L L C [Member] Colorado Owner, LLC. Entity Address, Postal Zip Code Entity Address, Postal Zip Code Current investments, Available-for-sale, Gross Unrealized Gains Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, Current Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, Current Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Share-Based Payment Arrangement, Expensed Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block] Restatement Determination Date: Restatement Determination Date [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Number of agreements Number Of Agreements Number of agreements. Title of 12(b) Security Title of 12(b) Security Common stock, \$0.001 par value: Authorized 290,000 shares; issued and outstanding 124,227 and 107,312 shares Common Stock, Value, Issued Share-based Payment Arrangement [Abstract] Share-Based Payment Arrangement [Abstract] U.S. government bonds US Government Debt Securities [Member] Cash, cash equivalents and restricted cash Cash and Cash Equivalents, at Carrying Value Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member] Maximum additional tenant improvement allowance Maximum Additional Tenant Improvement Allowance Maximum Additional Tenant Improvement Allowance Finite Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Forfeited (in dollars per share) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value CASH FLOWS FROM FINANCING ACTIVITIES: Net Cash Provided by (Used in) Financing Activities [Abstract] Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member] Proceeds from sales and maturities of investments Proceeds from Sale, Maturity and Collection of Investments Useful life Property, Plant and Equipment, Useful Life Cash and Cash Equivalents [Domain] Cash and Cash Equivalents [Domain] Shares Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward] Depreciation and amortization Depreciation, Depletion and Amortization, Nonproduction Basic (in dollars per share) Basic net loss per share (in dollars per share) Earnings Per Share, Basic Accounts payable Increase (Decrease) in Accounts Payable Proceeds from the issuance of common stock, net of offering costs Proceeds from Issuance of Common Stock Operating cash flows from operating leases Operating Lease, Payments Adjustment To PEO Compensation, Footnote Adjustment To PEO Compensation, Footnote [Text Block] Award Timing MNPI Disclosure Award Timing MNPI Disclosure [Text Block] Amount intends to invest for buildout of the facilities Amount Intends To Invest For Buildout Of Facilities Amount intends to invest for buildout of facilities. Visirna ESOP Visirna ESOP [Member] Visirna ESOP Capital expenditures included in accrued expenses Capital Expenditures Incurred but Not yet Paid Aggregate Pension Adjustments Service Cost Aggregate Pension Adjustments Service Cost [Member] Milestone payment receivable upon receipt of royalty payments Milestone Payment Receivable, Upon Receipt Of Royalty Payments Milestone Payment Receivable, Upon Receipt Of Royalty Payments Compensation Actually Paid vs. Other Measure Compensation Actually Paid vs. Other Measure [Text Block] Schedule Of Stock By Class [Table] Stock, Class of Stock [Table] Total current liabilities Liabilities, Current Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member] Unrecognized pre-tax compensation expense Share-Based Payment Arrangement, Nonvested Award, Option, Cost not yet Recognized, Amount Total Assets Assets 2025 Finite-Lived Intangible Asset, Expected Amortization, Year One Long-term line of credit Long-Term Line of Credit Liability related to the sale of future royalties, interest rate Liability, Sale Of Future Royalties, Interest Rate Liability, Sale Of Future Royalties, Interest Rate Granted (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period Purchases of property and equipment Payments to Acquire Property, Plant, and Equipment Forgone Recovery due to Violation of Home Country Law, Amount Forgone Recovery due to Violation of Home Country Law, Amount Commitments and contingencies (Note 7) Commitments and Contingencies Termination Date Trading Arrangement Termination Date Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items] 2026 Lessee, Operating Lease, Liability, to be Paid, Year Two Stock-Based Compensation Share-Based Payment Arrangement [Text Block] Entity Address, City or Town Entity Address, City or Town Debt Instrument [Axis] Debt Instrument [Axis] Summarized Information about Stock Options Share-Based Payment Arrangement, Option, Activity [Table Text Block] Intrinsic value of options exercised Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value Stock-based compensation expense Share-Based Payment Arrangement, Expense Net loss attributable to Arrowhead Pharmaceuticals, Inc. Net loss attributable to Arrowhead Pharmaceuticals, Inc. Net Income (Loss) Attributable to Parent Trading Arrangement: Trading Arrangement [Axis] Investments, Debt and Equity Securities [Abstract] Investments, Debt and Equity Securities [Abstract] Granted (in dollars per share) Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Other Commitments [Table] Other Commitments [Table] Pay vs Performance Disclosure, Table Pay vs Performance [Table Text Block] Forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period Schedule of Finite-Lived Intangible Assets Schedule of Finite-Lived Intangible Assets [Table Text Block] Equity Awards Adjustments, Excluding Value Reported in Compensation Table Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member] Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member] Accrued capital expenditures Accrued Capital Expenditure, Current Accrued Capital Expenditure, Current Milestone payment receivable Milestone Payment Receivable Milestone Payment Receivable Entity File Number Entity File Number Cash and Cash Equivalents [Axis] Cash and Cash Equivalents [Axis] Document Fiscal Year Focus Document Fiscal Year Focus Non-controlling Interest Noncontrolling Interest [Member] Income Statement [Abstract] Income Statement [Abstract] Entity Address, Address Line One Entity Address, Address Line One Underwriting Agreement Underwriting Agreement [Member] Underwriting Agreement Weighted-average shares used in calculating Denominator: Weighted Average Number of Shares Outstanding Reconciliation [Abstract] Entity Address, Address Line Two Entity Address, Address Line Two Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Effect of exchange rate on cash, cash equivalents and restricted cash Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations Total financial assets Assets, Fair Value Disclosure Lease term Lessee, Operating Lease, Term of Contract Other Other Accrued Liabilities, Current Name Forgone Recovery, Individual Name Aggregate Intrinsic Value, Exercisable Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value 2024 (remainder of fiscal year) Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Weighted-average remaining lease term (in years) Operating Lease, Weighted Average Remaining Lease Term Document Period End Date Document Period End Date Sale of Stock [Axis] Sale of Stock [Axis] Thereafter Finite-Lived Intangible Asset, Expected Amortization, after Year Four Finite-Lived Intangible Asset, Expected Amortization, after Year Four Award Timing MNPI Considered Award Timing MNPI Considered [Flag] Total Lessee, Operating Lease, Liability, to be Paid Horizon License Agreement Horizon License Agreement [Member] Horizon License Agreement Share-based payment award (in shares) Beginning of period (in shares) End of period (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number Cancelled (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period Insider Trading Arrangements [Line Items] Balance Sheet Accounts Supplemental Balance Sheet Disclosures [Text Block] Outstanding Aggregate Erroneous Compensation Amount Outstanding Aggregate Erroneous Compensation Amount Schedule of Shares of Common Stock and Preferred Stock Schedule of Stock by Class [Table Text Block] 2027 Lessee, Operating Lease, Liability, to be Paid, Year Three PEO Actually Paid Compensation Amount PEO Actually Paid Compensation Amount Adjustment to Compensation: Adjustment to Compensation [Axis] GSK-HBV Agreement GSK-HBV Agreement [Member] GSK-HBV Agreement Net loss attributable to noncontrolling interest, net of tax Net Income (Loss) Attributable to Noncontrolling Interest Document Transition Report Document Transition Report Document Quarterly Report Document Quarterly Report Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table] Fair Value, Recurring and Nonrecurring [Table] Customer [Domain] Customer [Domain] Accumulated other comprehensive loss Accumulated Other Comprehensive Income (Loss), Net of Tax Entity Current Reporting Status Entity Current Reporting Status Laboratory and Office Facility Laboratory And Office Facility [Member] Laboratory and office facility. Accumulated Deficit Retained Earnings [Member] Pension Adjustments Service Cost Pension Adjustments Service Cost [Member] Asset Acquisition Asset Acquisition [Domain] Basic (in shares) Weighted-average basic shares outstanding (in shares) Weighted Average Number of Shares Outstanding, Basic Stock Price or TSR Estimation Method Stock Price or TSR Estimation Method [Text Block] Research Facility in Madison Research Facility In Madison [Member] Research facility in Madison. Total noncontrolling interest and stockholdersâ€™ equity Beginning balance Ending balance Equity, Including Portion Attributable to Noncontrolling Interest Restricted stock units Restricted Stock Units (RSUs) [Member] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Executive Category: Executive Category [Axis] Purchases of investments Payments to Acquire Investments Name Awards Close in Time to MNPI Disclosures, Individual Name Construction in progress Construction in Progress [Member] Number of shares forfeited (in shares) Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period Entity Filer Category Entity Filer Category Shares issued Shares, Issued Income Statement Location [Domain] Statement of Income Location, Balance [Domain] Company Selected Measure Name Company Selected Measure Name EX-101.PRE 10 arwr-

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

YVMUMSSrT0DCV- MQ)h8+H(H(G0G01-M-B3<6-0Z5=-#-VCW8r-!%y9&8J%5PO-2#5<GO-MGUUQJ70Y-0T-M!6!-0KWQ)H)M-M-1K-Y+6B<Q1D-N:ThQ3WQOT+%^B2V7Ll9@W>+6T89Q
M7MZQ<=&%/-3F#V-1-!PS2V0-SI%KWC(2?LW%-R-N:YSfA<~OS-5JC^Y)M-JZ-OB&W@DNDE=-ABK+MHCCQZE=F&MF4P4<.<8+U+H:7HO?L119E!H!)
MLWYQlWQ%YQD9BUET-2#4H-LIG6-W!15MJBEZ#!+!EY80-NV%MXRN23T5T-M-AJ<KQ-3%.@YMQ<3K-V!Q0-ODYH8 DVCIG KQ-0/&T%+HUQ!MQ3P
MY%#A8-DUK>Z7-MU%=-Y/N^Y7H!XN0!>-@HDCY9Xl(0-!53W-U-!-M?/2D?PQ!<+!T:IC-<802\$S^TAU(6!1L2VX%G<F<#H4<+!N-1-PF70V6+78-26XAEV'M'
@-D.VG<5S0TP<KM7XAW+JEHFGVRISICJEK!+Y8<?&5ZC-205F7GP-U-MZK<6-2.PM4C9Y@04!<\$A1Y@<0BN=N8H!HMMQ0U3Q>3>7HEDV%MA-7>6
<5>2<C!8H^U!<@C0<^2-!M9N!LS!OF(2-VYP3T5CW^KM2T-M@<G%-B:5!2V7-OY!G6G6!LX%W!&K!PQ!P2=-QU!UZXG&HSHIUH0W-MWIK<
IGVM996462A^P!12IR>+<4&L>+!<W4-10/W!&H-KD-Z086=9\$4!MKY-O!<CVU!<H!<Y+725O&+!+P!S2HAH!<O-!<C!M%<U56UAHF MRV=AWE!<7FGK<Q0W-ROG/@EF/!S!
T!>@KH-UQF-P!H5U!U!<@L=M-MDC<+D-S!Y74!<I!WQ!<A!P26TYV!<L!OCMAYT!<4!9FC93D!<M7<K-MR-ZQH!+UX3N-22Z-20!<J!<Y%W=-!<DC(TH!H3>+VGB?T!>6W!H!8E
MHX?<00S_VIDL?FSV\$<^C!<M=36=08!<I=WUB-SWF1T!<L8!404-01D-!<545!TJWN<N!<20+5KM-M<.<49U!<820869W<^XS-G!<Q!<2&P2RT04R!<D&AEEB6B10P...71MS!<H!<R!<T!<TJG9>
KCP-P4V?7<?<0MJ-G-92M?<3^<SF0!<R!<H!<D>-W!<S!UJYA<T!<M4!<T!<HOLD-RESN!<Q9C3!<OYC!<Q!<QA!<8!<+A06!<O6PW!<V38-9EMKMX!<Q!<M?<
R<@!<I!<QA!<HFM<+!<NSU-!<H!<GRT<2V2C!<!<PKZC-G-M!<XT!<6T!<4-7RX<@DLN!<I!<A!<5F!<S!<V!<S!<G!<GUK!<O!<H37<G!<00PWT!<V!<N2!<M!<P2C!<G=<H!<I!<F!<@<@<XQ!<Q!<O?<E97<*<972

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible][illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

M5-T1N8B17QV4VTV<U>[W<K<B<H<I<C<I<Q<8AMP<[0<X<Z<QMI<^>]>M<M0<R1MN.%<#8W<90S@M<.%<SOCB1E9@f<I.3MOG<I&6<^<0K<L M/%<K HTFMFW4R1.2+<*<#TP19I<...</p></div>

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

[illegible]

[-Definition](#)

Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.

[+References](#)

No definition available.

[+Details](#)

Name:dei_DocumentFiscalPeriodFocus_Namespace Prefix:dei_Data Type:dei:fiscalPeriodItemType Balance Type:na Period Type:duration

[-Definition](#)

This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.

[+References](#)

No definition available.

[+Details](#)

Name:dei_DocumentFiscalYearFocus_Namespace Prefix:dei_Data Type:xbrli:gYearItemType Balance Type:na Period Type:duration

[-Definition](#)

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

[+References](#)

No definition available.

[+Details](#)

Name:dei_DocumentPeriodEndDate_Namespace Prefix:dei_Data Type:xbrli:dateItemType Balance Type:na Period Type:duration

[-Definition](#)

Boolean flag that is true only for a form used as an quarterly report.

[+References](#)

Reference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher-SEC-Name-Form-10-Q-Number-240-Section-308-Subsection-a>

[+Details](#)

Name:dei_DocumentQuarterlyReport_Namespace Prefix:dei_Data Type:xbrli:booleanItemType Balance Type:na Period Type:duration

[-Definition](#)

Boolean flag that is true only for a form used as a transition report.

[+References](#)

Reference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher-SEC-Name-Forms-10-K,10-Q,20-F-Number-240-Section-13-Subsection-a-1>

[+Details](#)

Name:dei_DocumentTransitionReport_Namespace Prefix:dei_Data Type:xbrli:booleanItemType Balance Type:na Period Type:duration

[-Definition](#)

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".

[+References](#)

No definition available.

[+Details](#)

Name:dei_DocumentType_Namespace Prefix:dei_Data Type:dei:submissionTypeItemType Balance Type:na Period Type:duration

[-Definition](#)

Address Line 1 such as Attn, Building Name, Street Name

[+References](#)

No definition available.

[+Details](#)

Name:dei_EntityAddressAddressLine1_Namespace Prefix:dei_Data Type:xbrli:normalizedStringItemType Balance Type:na Period Type:duration

[-Definition](#)

Address Line 2 such as Street or Suite number

[+References](#)

No definition available.

[+Details](#)

Name:dei_EntityAddressAddressLine2_Namespace Prefix:dei_Data Type:xbrli:normalizedStringItemType Balance Type:na Period Type:duration

[-Definition](#)

Name of the City or Town

[+References](#)

No definition available.

[+Details](#)

Name:dei_EntityAddressCityOrTown_Namespace Prefix:dei_Data Type:xbrli:normalizedStringItemType Balance Type:na Period Type:duration

[-Definition](#)

Code for the postal or zip code

[+ References](#)

No definition available.

[+ Details](#)

Name:dei_EntityAddressPostalZipCode_Namespace-Prefix:dei_Data-Type:xbrli:normalizedStringItemType Balance-Type:na-Period-Type:duration

[-Definition](#)

Name of the state or province.

[+ References](#)

No definition available.

[+ Details](#)

Name:dei_EntityAddressStateOrProvince_Namespace-Prefix:dei_Data-Type:dei:stateOrProvinceItemType Balance-Type:na-Period-Type:duration

[-Definition](#)

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

[+ References](#)

Reference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher-SEC-Name-Exchange-Act-Number-240-Section-12-Subsection-b-2>

[+ Details](#)

Name:dei_EntityCentralIndexKey_Namespace-Prefix:dei_Data-Type:dei:centralIndexKeyItemType Balance-Type:na-Period-Type:duration

[-Definition](#)

Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings. Instrument.

[+ References](#)

No definition available.

[+ Details](#)

Name:dei_EntityCommonStockSharesOutstanding_Namespace-Prefix:dei_Data-Type:xbrli:sharesItemType Balance-Type:na-Period-Type:instant

[-Definition](#)

Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports); and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.

[+ References](#)

No definition available.

[+ Details](#)

Name:dei_EntityCurrentReportingStatus_Namespace-Prefix:dei_Data-Type:dei:yesNoItemType Balance-Type:na-Period-Type:duration

[-Definition](#)

Indicate if registrant meets the emerging growth company criteria.

[+ References](#)

Reference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher-SEC-Name-Exchange-Act-Number-240-Section-12-Subsection-b-2>

[+ Details](#)

Name:dei_EntityEmergingGrowthCompany_Namespace-Prefix:dei_Data-Type:xbrli:booleanItemType Balance-Type:na-Period-Type:duration

[-Definition](#)

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits; the sequence number may contain 1-8 digits; the optional suffix may contain 1-4 characters; and the fields are separated with a hyphen.

[+ References](#)

No definition available.

[+ Details](#)

Name:dei_EntityFileNumber_Namespace-Prefix:dei_Data-Type:dei:fileNumberItemType Balance-Type:na-Period-Type:duration

[-Definition](#)

Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.

[+ References](#)

Reference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher-SEC-Name-Exchange-Act-Number-240-Section-12-Subsection-b-2>

[+ Details](#)

Name:dei_EntityFilerCategory_Namespace-Prefix:dei_Data-Type:dei:filerCategoryItemType Balance-Type:na-Period-Type:duration

[-Definition](#)

Two-character EDGAR code representing the state or country of incorporation.

[+ References](#)

No definition available.

[+ Details](#)

Name:dei_EntityIncorporationStateCountryCode_Namespace Prefix:dei_Data Type:dei:edgarStateCountryItemType Balance Type:na Period Type:duration

[- Definition](#)

Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

[+ References](#)

Reference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher-SEC-Name-Regulation-S-T-Number-232-Section-405>

[+ Details](#)

Name:dei_EntityInteractiveDataCurrent_Namespace Prefix:dei_Data Type:dei:yesNoItemType Balance Type:na Period Type:duration

[- Definition](#)

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

[+ References](#)

Reference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher-SEC-Name-Exchange-Act-Number-240-Section-12-Subsection-b-2>

[+ Details](#)

Name:dei_EntityRegistrantName_Namespace Prefix:dei_Data Type:xbrli:normalizedStringItemType Balance Type:na Period Type:duration

[- Definition](#)

Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.

[+ References](#)

Reference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher-SEC-Name-Exchange-Act-Number-240-Section-12-Subsection-b-2>

[+ Details](#)

Name:dei_EntityShellCompany_Namespace Prefix:dei_Data Type:xbrli:booleanItemType Balance Type:na Period Type:duration

[- Definition](#)

Indicates that the company is a Smaller Reporting Company (SRC).

[+ References](#)

Reference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher-SEC-Name-Exchange-Act-Number-240-Section-12-Subsection-b-2>

[+ Details](#)

Name:dei_EntitySmallBusiness_Namespace Prefix:dei_Data Type:xbrli:booleanItemType Balance Type:na Period Type:duration

[- Definition](#)

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

[+ References](#)

Reference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher-SEC-Name-Exchange-Act-Number-240-Section-12-Subsection-b-2>

[+ Details](#)

Name:dei_EntityTaxIdentificationNumber_Namespace Prefix:dei_Data Type:dei:employerIdItemType Balance Type:na Period Type:duration

[- Definition](#)

Local phone number for entity.

[+ References](#)

No definition available.

[+ Details](#)

Name:dei_LocalPhoneNumber_Namespace Prefix:dei_Data Type:xbrli:normalizedStringItemType Balance Type:na Period Type:duration

[- Definition](#)

Title of a 12(b) registered security.

[+ References](#)

Reference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher-SEC-Name-Exchange-Act-Number-240-Section-12-Subsection-b>

[+ Details](#)

Name:dei_Security12bTitle_Namespace Prefix:dei_Data Type:dei:securityTitleItemType Balance Type:na Period Type:duration

-Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher-SEC-Name-Exchange-Act-Number-240-Section-12-Subsection-d1-1>

+ Details

Name:dei_SecurityExchangeName Namespace Prefix:dei_Data Type:dei:edgarExchangeCodeItemType-Balance Type:na-Period Type:duration

-Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:dei_TradingSymbol Namespace Prefix:dei_Data Type:dei:tradingSymbolItemType-Balance Type:na-Period Type:duration XML-17-R2.htm IDEA: XBRL DOCUMENT Consolidated Balance Sheets - USD (\$) \$ in Thousands Jun. 30, 2024 Sep. 30, 2023 Current assets: Cash, cash equivalents and restricted cash\$ 69,399\$ 110,891 Available-for-sale securities, at fair value367,272292,735 Prepaid expenses9,2078,813 Other current assets4,1844,033 Total current assets450,062416,472 Property, plant and equipment, net375,911290,262 Intangible assets, net0,98710,262 Right-of-use assets44,33945,297 Other assets4,4603,259 Total Assets883,759765,552 Current liabilities: Accounts payable26,53035,866 Accrued expenses47,89939,763 Accrued payroll and benefits15,79517,963 Lease liabilities6,05310,563 Deferred revenue0866 Other liabilities417435 Total current liabilities96,714105,456 Long-term liabilities: Lease liabilities, net of current portion112,040104,608 Liability related to the sale of future royalties336,031268,326 Total long-term liabilities448,071372,934 Commitments and contingencies (Note 7) Noncontrolling interest and stockholders' equity: Common stock, \$0.001 par value: Authorized 290,000 shares; issued and outstanding 124,227 and 107,312 shares217200 Additional paid-in capital1,786,3041,300,395 Accumulated other comprehensive loss(987)(3,222) Accumulated deficit(1,454,987)(1,026,030) Total Arrowhead Pharmaceuticals, Inc. stockholders' equity330,547271,343 Noncontrolling interest8,42715,819 Total noncontrolling interest and stockholders' equity338,974287,162 Total Liabilities, Noncontrolling Interest and Stockholders' Equity\$ 883,759\$ 765,552

-Definition

Royalties, Liability, Noncurrent

+ References

No definition available.

+ Details

Name:arwr_RoyaltiesLiabilityNoncurrent Namespace Prefix:arwr_Data Type:xbrli:monetaryItemType-Balance Type:credit-Period Type:instant

-Definition

Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210.5-02\(19\)\(a\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210.5-02(19)(a))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480566/210-10-S99-1)**Reference 2:** <http://www.xbrl.org/2003/role/exampleRef-Topic-852-SubTopic-10-Name-Accounting-Standards-Codification-Section-55-Paragraph-10-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481372/852-10-55-10>

+ Details

Name:us-gaap_AccountsPayableCurrent Namespace Prefix:us-gaap_Data Type:xbrli:monetaryItemType-Balance Type:credit-Period Type:instant

-Definition

Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210.5-02\(20\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210.5-02(20))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480566/210-10-S99-1)

+ Details

Name:us-gaap_AccruedLiabilitiesCurrent Namespace Prefix:us-gaap_Data Type:xbrli:monetaryItemType-Balance Type:credit-Period Type:instant

-Definition

Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.

+ References

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Name-Accounting-Standards-Codification-Topic-220-SubTopic-10-Section-45-Paragraph-14A-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482790/220-10-45-14A>**Reference 2:** <http://fasb.org/us-gaap/role/ref/legacyRef-Topic-220-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-11-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482790/220-10-45-11>**Reference 3:** [http://www.xbrl.org/2003/role/disclosureRef-Topic-944-SubTopic-40-Name-Accounting-Standards-Codification-Section-65-Paragraph-2-Subparagraph-\(g\)\(2\)\(ii\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480016/944-40-65-2](http://www.xbrl.org/2003/role/disclosureRef-Topic-944-SubTopic-40-Name-Accounting-Standards-Codification-Section-65-Paragraph-2-Subparagraph-(g)(2)(ii)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480016/944-40-65-2)**Reference 4:** [http://www.xbrl.org/2003/role/disclosureRef-Topic-944-SubTopic-40-Name-Accounting-Standards-Codification-Section-65-Paragraph-2-Subparagraph-\(h\)\(2\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480016/944-40-65-2](http://www.xbrl.org/2003/role/disclosureRef-Topic-944-SubTopic-40-Name-Accounting-Standards-Codification-Section-65-Paragraph-2-Subparagraph-(h)(2)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480016/944-40-65-2)**Reference 5:** [http://www.xbrl.org/2003/role/disclosureRef-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210.5-02\(30\)\(a\)\(4\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210.5-02(30)(a)(4))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480566/210-10-S99-1)**Reference 6:** <http://www.xbrl.org/2003/role/disclosureRef-Topic-944-SubTopic-210-Name>

~~Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(23)(a)(3)) -Publisher FASB -URI https://asc.fasb.org/1943274/214748777/944-210-S99-1Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 220 -SubTopic 10 -Section 45 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14~~

+ Details

Name:us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax **Namespace Prefix:**us-gaap_ **Data Type:**xbrli:monetaryItemType **Balance Type:**credit **Period Type:**instant

- Definition

Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(30)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

+ Details

Name:us-gaap_AdditionalPaidInCapitalCommonStock **Namespace Prefix:**us-gaap_ **Data Type:**xbrli:monetaryItemType **Balance Type:**credit **Period Type:**instant

- Definition

Amount of asset recognized for present right to economic benefit.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48**Reference 2:** http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 49 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49**Reference 3:** http://www.xbrl.org/2003/role/disclosureRef -Topic 270 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (i) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1**Reference 4:** http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (ee) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32**Reference 5:** http://fasb.org/us-gaap/role/ref/otherTransitionRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 32 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32**Reference 6:** http://www.xbrl.org/2003/role/disclosureRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 22 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22**Reference 7:** http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (bb) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3**Reference 8:** http://www.xbrl.org/2003/role/disclosureRef -Topic 810 -SubTopic 10 -Name Accounting Standards

Codification –Section 45 –Paragraph 25 –Subparagraph (a) –Publisher FASB –URI <https://asc.fasb.org/1943274/2147481231/810-10-45-25>Reference 9:
[http://www.xbrl.org/2003/role/disclosureRef-Topic-235-SubTopic-10-Name-Accounting-Standards-Codification-Section S99-Paragraph 1-Subparagraph \(SX 210-4-08\(g\)\(1\)\(ii\)\) –Publisher FASB –URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic-235-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210-4-08(g)(1)(ii))-Publisher-FASB-URI)Reference 10: **[http://www.xbrl.org/2003/role/disclosureRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph \(c\) –Publisher FASB –URI https://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic-323-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-3-Subparagraph-(c)-Publisher-FASB-URI)Reference 11:** **[http://www.xbrl.org/2003/role/disclosureRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-Subparagraph \(f\) –Publisher FASB –URI https://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbrl.org/2003/role/disclosureRef-Topic-825-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-28-Subparagraph-(f)-Publisher-FASB-URI)Reference 12:** **[http://www.xbrl.org/2003/role/exampleRef-Topic 852-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 10 –Publisher FASB –URI https://asc.fasb.org/1943274/2147481372/852-10-55-10](http://www.xbrl.org/2003/role/exampleRef-Topic-852-SubTopic-10-Name-Accounting-Standards-Codification-Section-55-Paragraph-10-Publisher-FASB-URI)Reference 13:** **[http://www.xbrl.org/2003/role/exampleRef-Topic 946-SubTopic 830-Name Accounting Standards Codification-Section 55-Paragraph 12 –Publisher FASB –URI https://asc.fasb.org/1943274/2147479168/946-830-55-12](http://www.xbrl.org/2003/role/exampleRef-Topic-946-SubTopic-830-Name-Accounting-Standards-Codification-Section-55-Paragraph-12-Publisher-FASB-URI)Reference 14:** **[http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210-7-03\(a\)\(12\)\) –Publisher FASB –URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic-944-SubTopic-210-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210-7-03(a)(12))-Publisher-FASB-URI)Reference 15:** **[http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210-6-04\(8\)\) –Publisher FASB –URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-210-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210-6-04(8))-Publisher-FASB-URI)Reference 16:** **[http://www.xbrl.org/2003/role/disclosureRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210-5-02\(18\)\) –Publisher FASB –URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210-5-02(18))-Publisher-FASB-URI)Reference 17:** **[http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210-13-01\(a\)\(4\)\(i\)\) –Publisher FASB –URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1A-Subparagraph-(SX-210-13-01(a)(4)(i))-Publisher-FASB-URI)Reference 18:** **[http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210-13-01\(a\)\(4\)\(ii\)\) –Publisher FASB –URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2009/role/commonPracticeRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1A-Subparagraph-(SX-210-13-01(a)(4)(ii))-Publisher-FASB-URI)Reference 19:** **[http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210-13-01\(a\)\(4\)\(iii\)\) –Publisher FASB –URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2009/role/commonPracticeRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1A-Subparagraph-(SX-210-13-01(a)(4)(iii))-Publisher-FASB-URI)Reference 20:** **[http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210-13-01\(a\)\(4\)\(iii\)\(A\)\) –Publisher FASB –URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1A-Subparagraph-(SX-210-13-01(a)(4)(iii)(A))-Publisher-FASB-URI)Reference 21:** **[http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210-13-01\(a\)\(4\)\(iv\)\) –Publisher FASB –URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1A-Subparagraph-(SX-210-13-01(a)(4)(iv))-Publisher-FASB-URI)Reference 22:** **[http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210-13-01\(a\)\(5\)\) –Publisher FASB –URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1A-Subparagraph-(SX-210-13-01(a)(5))-Publisher-FASB-URI)Reference 23:** **[http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210-13-02\(a\)\(4\)\(i\)\) –Publisher FASB –URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1B-Subparagraph-(SX-210-13-02(a)(4)(i))-Publisher-FASB-URI)Reference 24:** **[http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210-13-02\(a\)\(4\)\(iii\)\(A\)\) –Publisher FASB –URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1B-Subparagraph-(SX-210-13-02(a)(4)(iii)(A))-Publisher-FASB-URI)Reference 25:** **[http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210-13-02\(a\)\(4\)\(iii\)\(B\)\) –Publisher FASB –URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1B-Subparagraph-(SX-210-13-02(a)(4)(iii)(B))-Publisher-FASB-URI)Reference 26:** **[http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210-13-02\(a\)\(4\)\(iv\)\) –Publisher FASB –URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1B-Subparagraph-(SX-210-13-02(a)(4)(iv))-Publisher-FASB-URI)Reference 27:** **[http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210-13-02\(a\)\(5\)\) –Publisher FASB –URI https://asc.fasb.org/1943274/2147481404/852-10-50-7](http://www.xbrl.org/2003/role/disclosureRef-Topic-470-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1B-Subparagraph-(SX-210-13-02(a)(5))-Publisher-FASB-URI)Reference 29:** **[http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 30-Subparagraph \(c\) –Publisher FASB –URI https://asc.fasb.org/1943274/2147480280/280-10-50-30](http://www.xbrl.org/2003/role/disclosureRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-30-Subparagraph-(c)-Publisher-FASB-URI)Reference 30:** **[http://fasb.org/us-gaap/role/ref/legacyRef-Topic 942-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210-9-03\(11\)\) –Publisher FASB –URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic-942-SubTopic-210-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210-9-03(11))-Publisher-FASB-URI)**

[+ Details](#)

Name:us-gaap_Assets Namespace Prefix:us-gaap_ Data Type:xbri:monetaryItemType Balance Type:debit Period Type:instant

[- Definition](#)

Amount of asset recognized for present right to economic benefit, classified as current.

[+ References](#)

*Reference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic-810-SubTopic-10-Name> Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (bb)-
Publisher FASB-URI <https://asc.fasb.org/1943274/2147481203/810-10-50-3>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef-Topic-810-SubTopic-10-Name>*

~~Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481231/810-10-45-25>Reference 3: [\(http://www.xbrl.org/2003/role/disclosureRef-Topic 235-SubTopic 10-Name Accounting Standards Codification -Section S99-Paragraph 1-Subparagraph \(SX 210.1-08\(g\)\)\(1\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 235-SubTopic 10-Name Accounting Standards Codification -Section S99-Paragraph 1-Subparagraph (SX 210.1-08(g))(1)) (ii) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480678/235-10-S99-1>Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 323-SubTopic 10-Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 323-SubTopic 10-Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic 825-SubTopic 10-Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbrl.org/2003/role/disclosureRef-Topic 825-SubTopic 10-Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28)Reference 6: <http://www.xbrl.org/2003/role/exampleRef-Topic 852-SubTopic 10-Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 7: <http://www.xbrl.org/2003/role/disclosureRef-Topic 210-SubTopic 10-Name Accounting Standards Codification -Section 45 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1>Reference 8: [http://www.xbrl.org/2003/role/disclosureRef-Topic 210-SubTopic 10-Name Accounting Standards Codification -Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(9\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 210-SubTopic 10-Name Accounting Standards Codification -Section S99-Paragraph 1-Subparagraph (SX 210.5-02(9)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification -Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification -Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 10: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470-SubTopic 10-Name Accounting Standards Codification -Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470-SubTopic 10-Name Accounting Standards Codification -Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 11: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470-SubTopic 10-Name Accounting Standards Codification -Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470-SubTopic 10-Name Accounting Standards Codification -Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(iii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 12: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification -Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification -Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 13: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification -Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification -Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 14: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification -Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification -Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 15: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification -Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(i\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification -Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(i)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 16: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification -Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(A\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification -Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iii)(A)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 17: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification -Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification -Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iii)(B)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 18: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification -Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification -Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iv)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 19: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification -Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(5\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification -Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(5)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 20: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 852-SubTopic 10-Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph \(a\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 852-SubTopic 10-Name Accounting Standards Codification -Section 50 -Paragraph 7 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7)~~

+ Details
Name:us-gaap_AssetsCurrent_Namespace-Prefix:us-gaap_Data-Type:xbrl:monetaryItemType-Balance-Type:debit-Period-Type:instant

-References

No definition available.

+ Details
Name:us-gaap_AssetsCurrentAbstract_Namespace-Prefix:us-gaap_Data-Type:xbrl:stringItemType-Balance-Type:na-Period-Type:duration

-Definition

Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.

+ References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic-320-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-2-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481830/320-10-45-2>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef-Topic-326-SubTopic-30-Name-Accounting-Standards-Codification-Section-45-Paragraph-1-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479130/326-30-45-1>

+ Details
Name:us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_Namespace-Prefix:us-gaap_Data-Type:xbrl:monetaryItemType-Balance-Type:debit-Period-Type:instant

-Definition

Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.

+ References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic-230-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-8-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482913/230-10-50-8>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic-230-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-24-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482740/230-10-45-24>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef-Name-Accounting-Standards-Codification-Topic-230-SubTopic-10-Section-45-Paragraph-4-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482740/230-10-45-4>

+ Details
Name:us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_Namespace-Prefix:us-gaap_Data-Type:xbrl:monetaryItemType-Balance-Type:debit-Period-Type:instant

-Definition

Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.

+ References

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic-942-SubTopic-210-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210.9-03\(17\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147478546/942-210-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic-942-SubTopic-210-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210.9-03(17))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147478546/942-210-S99-1)Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210.5-02\(25\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210.5-02(25))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic-944-SubTopic-210-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210.7-03\(a\)\(19\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147478777/944-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic-944-SubTopic-210-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210.7-03(a)(19))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147478777/944-210-S99-1)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-210-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210.6-04\(15\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479170/946-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-210-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210.6-04(15))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479170/946-210-S99-1)

[+ Details](#)

Name:us-gaap_CommitmentsAndContingencies Namespace Prefix:us-gaap_ Data Type:xbri:monetaryItemType Balance Type:credit Period Type:instant

[- Definition](#)

Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.

[+ References](#)

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(29\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(29))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: <http://www.xbrl.org/2003/role/exampleRef-Topic 852-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 10> -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.7-03\(a\)\(22\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.7-03(a)(22))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478777/944-210-S99-1>

[+ Details](#)

Name:us-gaap_CommonStockValue Namespace Prefix:us-gaap_ Data Type:xbri:monetaryItemType Balance Type:credit Period Type:instant

[- Definition](#)

Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.

[+ References](#)

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1> -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479837/606-10-45-1>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 8-Subparagraph \(a\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 8-Subparagraph (a)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479806/606-10-50-8>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 2> -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479837/606-10-45-2>

[+ Details](#)

Name:us-gaap_ContractWithCustomerLiabilityCurrent **Namespace Prefix:**us-gaap_ **Data Type:**xbri:monetaryItemType **Balance Type:**credit **Period Type:**instant

-Definition

Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+References

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(20\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)

+Details

Name:us-gaap_EmployeeRelatedLiabilitiesCurrent **Namespace Prefix:**us-gaap_ **Data Type:**xbri:monetaryItemType **Balance Type:**credit **Period Type:**instant

-Definition

Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.

+References

Reference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2)**Reference 2:** <http://www.xbrl.org/2003/role/disclosureRef-Topic 926 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 5 -Publisher FASB -URI https://asc.fasb.org/1943274/2147483154/926-20-50-5>

+Details

Name:us-gaap_FiniteLivedIntangibleAssetsNet **Namespace Prefix:**us-gaap_ **Data Type:**xbri:monetaryItemType **Balance Type:**debit **Period Type:**instant

-Definition

Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.

+References

Reference 1: <http://www.xbrl.org/2003/role/exampleRef-Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10>**Reference 2:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.7-03\(a\)\(25\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 944 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03(a)(25)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1)**Reference 3:** [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.4-08\(g\)\(1\)\(ii\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 235 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.4-08(g)(1)(ii)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)**Reference 4:** [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 323 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 3 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3)**Reference 5:** [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph \(f\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 825 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 28 -Subparagraph (f) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28)**Reference 6:** [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.9-03\(23\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 942 -SubTopic 210 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03(23)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1)**Reference 7:** [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(32\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(32)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)

[+ Details](#)

Name:us-gaap_LiabilitiesAndStockholdersEquity **Namespace Prefix:**us-gaap **Data Type:**xbrl:monetaryItemType **Balance Type:**credit **Period Type:**instant

[- Definition](#)

Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.

[+ References](#)

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(21\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(21))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)**Reference 2:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481203/810-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481203/810-10-50-3)**Reference 3:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 25-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481231/810-10-45-25](http://www.xbrl.org/2003/role/disclosureRef-Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 25-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481231/810-10-45-25)**Reference 4:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph \(bb\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481203/810-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (bb)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481203/810-10-50-3)**Reference 5:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.4-08\(g\)\(1\)\(ii\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.4-08(g)(1)(ii))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)**Reference 6:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3)**Reference 7:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-Subparagraph \(f\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbrl.org/2003/role/disclosureRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-Subparagraph (f)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28)**Reference 8:** <http://www.xbrl.org/2003/role/exampleRef-Topic 852-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 10-Publisher FASB-URI https://asc.fasb.org/1943274/2147481372/852-10-55-10>**Reference 9:** <http://www.xbrl.org/2003/role/disclosureRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 5-Publisher FASB-URI https://asc.fasb.org/1943274/2147483467/210-10-45-5>**Reference 10:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(i\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(i))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)**Reference 11:** [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(ii\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(ii))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)**Reference 12:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\(A\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(iii)(A))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)**Reference 13:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(iv))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)**Reference 14:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(5\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(5))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)**Reference 15:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(i\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(i))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)**Reference 16:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(A\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iii)(A))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)**Reference 17:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iii)(B))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)**Reference 18:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iv))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)**Reference 19:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(5\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(5))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)**Reference 20:** [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 852-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 7-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481404/852-10-50-7](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 852-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 7-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481404/852-10-50-7)**Reference 21:** [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 852-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 7-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481404/852-10-50-7](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 852-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 7-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481404/852-10-50-7)

+ Details

Name:us-gaap_LiabilitiesCurrent **Namespace Prefix:**us-gaap_ **Data Type:**xbri:monetaryItemType **Balance Type:**credit **Period Type:**instant

- References

No definition available.

+ Details

Name:us-gaap_LiabilitiesCurrentAbstract **Namespace Prefix:**us-gaap_ **Data Type:**xbri:stringItemType **Balance Type:**na **Period Type:**duration

- Definition

Amount of obligation due after one year or beyond the normal operating cycle, if longer.

+ References

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(22\)\)-SubTopic 10-Topic 210-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(22))-SubTopic 10-Topic 210-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)**Reference 2:** [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(24\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(24))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)**Reference 3:** [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(25\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(25))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)**Reference 4:** [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(26\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(26))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)**Reference 5:** [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(23\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(23))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)**Reference 6:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481203/810-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481203/810-10-50-3)**Reference 7:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 25-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481231/810-10-45-25](http://www.xbrl.org/2003/role/disclosureRef-Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 25-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481231/810-10-45-25)**Reference 8:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph \(bb\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481203/810-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (bb)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481203/810-10-50-3)**Reference 9:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.4-08\(g\)\(1\)\(ii\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.4-08(g)(1)(ii))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)**Reference 10:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3)**Reference 11:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 20-Subparagraph \(f\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbrl.org/2003/role/disclosureRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 20-Subparagraph (f)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28)**Reference 12:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(i\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(i))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)**Reference 13:** [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(ii\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(ii))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)**Reference 14:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\(A\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(iii)(A))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)**Reference 15:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(iv))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)**Reference 16:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(5\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(5))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)**Reference 17:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iii)(B))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)**Reference 18:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(A\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iii)(A))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)**Reference 19:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iii)(B))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)**Reference 20:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iv))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)**Reference 21:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(5\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(5))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)**Reference 22:** [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 852-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 7-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481404/852-10-50-7](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 852-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 7-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481404/852-10-50-7)**Reference 23:** [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 852-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 7-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481404/852-10-50-7](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 852-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 7-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481404/852-10-50-7)

[+ Details](#)

Name:us-gaap_LiabilitiesNoncurrent Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant

[- References](#)

No definition available.

[+ Details](#)

Name:us-gaap_LiabilitiesNoncurrentAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

-Definition

Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity.

+ References

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(31\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(31))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.4-08\(g\)\(1\)\(ii\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.4-08(g)(1)(ii))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480678/235-10-S99-1>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph \(c\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (c)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481687/323-10-50-3>Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-Subparagraph \(f\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-Subparagraph (f)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482907/825-10-50-28>Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.7-03\(a\)\(24\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.7-03(a)(24))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478777/944-210-S99-1>Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.6-04\(19\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.6-04(19))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-1>Reference 7: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(i\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(i))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Reference 8: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(iv))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Reference 9: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(5\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(5))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1A>Reference 10: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(i\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(i))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1B>Reference 11: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iv))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1B>Reference 12: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(5\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(5))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1B>Reference 13: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 942-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.9-03\(22\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 942-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.9-03(22))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478546/942-210-S99-1>

[+ Details](#)

Name:us-gaap_MinorityInterest_Namespace Prefix:us-gaap_Data Type:xbri:monetaryItemType Balance Type:credit Period Type:instant

[- Definition](#)

Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.

[+ References](#)

Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic-842-SubTopic-20-Name-Accounting-Standards-Codification-Section-45-Paragraph-1-Subparagraph-\(b\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479041/842-20-45-1](http://www.xbrl.org/2003/role/disclosureRef-Topic-842-SubTopic-20-Name-Accounting-Standards-Codification-Section-45-Paragraph-1-Subparagraph-(b)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479041/842-20-45-1)

[+ Details](#)

Name:us-gaap_OperatingLeaseLiabilityCurrent_Namespace Prefix:us-gaap_Data Type:xbri:monetaryItemType Balance Type:credit Period Type:instant

[- Definition](#)

Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.

[+ References](#)

Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic-842-SubTopic-20-Name-Accounting-Standards-Codification-Section-45-Paragraph-1-Subparagraph-\(b\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479041/842-20-45-1](http://www.xbrl.org/2003/role/disclosureRef-Topic-842-SubTopic-20-Name-Accounting-Standards-Codification-Section-45-Paragraph-1-Subparagraph-(b)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479041/842-20-45-1)

[+ Details](#)

Name:us-gaap_OperatingLeaseLiabilityNoncurrent_Namespace Prefix:us-gaap_Data Type:xbri:monetaryItemType Balance Type:credit Period Type:instant

[- Definition](#)

Amount of lessee's right to use underlying asset under operating lease.

[+ References](#)

Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic-842-SubTopic-20-Name-Accounting-Standards-Codification-Section-45-Paragraph-1-Subparagraph-\(a\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479041/842-20-45-1](http://www.xbrl.org/2003/role/disclosureRef-Topic-842-SubTopic-20-Name-Accounting-Standards-Codification-Section-45-Paragraph-1-Subparagraph-(a)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479041/842-20-45-1)

[+ Details](#)

Name:us-gaap_OperatingLeaseRightOfUseAsset_Namespace Prefix:us-gaap_Data Type:xbri:monetaryItemType Balance Type:debit Period Type:instant

[- Definition](#)

Amount of current assets classified as other.

[+ References](#)

Reference 1: <http://www.xbrl.org/2003/role/exampleRef-Topic-852-SubTopic-10-Name-Accounting-Standards-Codification-Section-55-Paragraph-10-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481372/852-10-55-10>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph \(SX 210.5-02\(8\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210.5-02(8))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480566/210-10-S99-1)

[+ Details](#)

Name:us-gaap_OtherAssetsCurrent_Namespace-Prefix:us-gaap_Data-Type:xbrli:monetaryItemType-Balance-Type:debit-Period-Type:instant

[-Definition](#)

Amount of noncurrent assets classified as other.

[+ References](#)

Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph \(SX 210.5-02\(17\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210.5-02(17))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480566/210-10-S99-1)

[+ Details](#)

Name:us-gaap_OtherAssetsNoncurrent_Namespace-Prefix:us-gaap_Data-Type:xbrli:monetaryItemType-Balance-Type:debit-Period-Type:instant

[-Definition](#)

Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.

[+ References](#)

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph \(SX 210.5-02\(20\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210.5-02(20))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: [http://www.xbrl.org/2003/role/exampleRef-Topic-852-SubTopic-10-Name-Accounting-Standards-Codification-Section-55-Paragraph-10-Publisher FASB-URI https://asc.fasb.org/1943274/2147481372/852-10-55-10](http://www.xbrl.org/2003/role/exampleRef-Topic-852-SubTopic-10-Name-Accounting-Standards-Codification-Section-55-Paragraph-10-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481372/852-10-55-10)

[+ Details](#)

Name:us-gaap_OtherLiabilitiesCurrent_Namespace-Prefix:us-gaap_Data-Type:xbrli:monetaryItemType-Balance-Type:credit-Period-Type:instant

[-Definition](#)

Amount of asset-related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.

[+ References](#)

Reference 1: [http://www.xbrl.org/2003/role/exampleRef-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-1-Subparagraph \(g\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483467/210-10-45-1](http://www.xbrl.org/2003/role/exampleRef-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-1-Subparagraph-(g))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147483467/210-10-45-1)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph \(SX 210.5-02\(7\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210.5-02(7))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic-340-SubTopic-10-Name-Accounting-Standards-Codification-Section-05-Paragraph-5-Publisher FASB-URI https://asc.fasb.org/1943274/2147482955/340-10-05-5](http://www.xbrl.org/2003/role/disclosureRef-Topic-340-SubTopic-10-Name-Accounting-Standards-Codification-Section-05-Paragraph-5-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482955/340-10-05-5)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic-340-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-1-Publisher FASB-URI https://asc.fasb.org/1943274/2147483032/340-10-45-1](http://www.xbrl.org/2003/role/disclosureRef-Topic-340-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-1-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147483032/340-10-45-1)

+ Details

Name:us-gaap_PrepaidExpenseCurrent **Namespace Prefix:**us-gaap_ **Data Type:**xbrl:monetaryItemType **Balance Type:**debit **Period Type:**instant

- Definition

Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.

+ References

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 50-Paragraph 1-SubTopic 10-Topic 360-Publisher FASB-URI https://asc.fasb.org/1943274/2147482099/360-10-50-1>**Reference 2:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 842-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 7A-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A](http://www.xbrl.org/2003/role/disclosureRef-Topic 842-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 7A-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A)**Reference 3:** <http://www.xbrl.org/2003/role/exampleRef-Topic 852-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 10-Publisher FASB-URI https://asc.fasb.org/1943274/2147481372/852-10-55-10>**Reference 4:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 210-Name Accounting Standards Codification-Section 599-Paragraph 1-Subparagraph \(SX 210.7-03\(a\)\(8\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478777/944-210-599-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 210-Name Accounting Standards Codification-Section 599-Paragraph 1-Subparagraph (SX 210.7-03(a)(8))-Publisher FASB-URI https://asc.fasb.org/1943274/2147478777/944-210-599-1)**Reference 5:** <http://www.xbrl.org/2003/role/disclosureRef-Topic 942-SubTopic 360-Name Accounting Standards Codification-Section 50-Paragraph 1-Publisher FASB-URI https://asc.fasb.org/1943274/2147478451/942-360-50-1>

+ Details

Name:us-gaap_PropertyPlantAndEquipmentNet **Namespace Prefix:**us-gaap_ **Data Type:**xbrl:monetaryItemType **Balance Type:**debit **Period Type:**instant

- Definition

Amount of accumulated undistributed earnings (deficit).

+ References

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1-Subparagraph \(SX 210.5-02\(30\)\(a\)\(3\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-599-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1-Subparagraph (SX 210.5-02(30)(a)(3))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-599-1)**Reference 2:** <http://www.xbrl.org/2003/role/exampleRef-Topic 852-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 10-Publisher FASB-URI https://asc.fasb.org/1943274/2147481372/852-10-55-10>**Reference 3:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 2-Subparagraph \(g\)\(2\)\(i\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480016/944-40-65-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 2-Subparagraph (g)(2)(i)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480016/944-40-65-2)**Reference 4:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 2-Subparagraph \(h\)\(2\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480016/944-40-65-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 2-Subparagraph (h)(2)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480016/944-40-65-2)**Reference 5:** <http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 11-Publisher FASB-URI https://asc.fasb.org/1943274/2147480990/946-20-50-11>**Reference 6:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 210-Name Accounting Standards Codification-Section 599-Paragraph 1-Subparagraph \(SX 210.7-03\(a\)\(23\)\(a\)\(4\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478777/944-210-599-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 210-Name Accounting Standards Codification-Section 599-Paragraph 1-Subparagraph (SX 210.7-03(a)(23)(a)(4))-Publisher FASB-URI https://asc.fasb.org/1943274/2147478777/944-210-599-1)**Reference 7:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section 599-Paragraph 1-Subparagraph \(SX 210.6-04\(17\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479170/946-210-599-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section 599-Paragraph 1-Subparagraph (SX 210.6-04(17))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479170/946-210-599-1)**Reference 8:** [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1-Subparagraph \(SX 210.3-04\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480008/505-10-599-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1-Subparagraph (SX 210.3-04)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480008/505-10-599-1)

+ Details

Name:us-gaap_RetainedEarningsAccumulatedDeficit **Namespace Prefix:**us-gaap_ **Data Type:**xbri:monetaryItemType **Balance Type:**credit **Period Type:**instant

- Definition

Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.

+ References

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(29\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(29))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>**Reference 2:** [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(30\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(30))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>**Reference 3:** [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(31\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(31))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>**Reference 4:** <http://www.xbrl.org/2003/role/exampleRef-Topic 852-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 10> -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481372/052-10-55-10>**Reference 5:** <http://www.xbrl.org/2003/role/exampleRef-Topic 946-SubTopic 830-Name Accounting Standards Codification-Section 55-Paragraph 12> -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479168/946-830-55-12>**Reference 6:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.6-04\(19\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.6-04(19))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-1>**Reference 7:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph \(SX 210.6-05\(4\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph (SX 210.6-05(4))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-2>**Reference 8:** [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph \(SX 210.6-09\(4\)\(b\)\)](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.6-09(4)(b))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3>**Reference 9:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph \(SX 210.6-09\(6\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.6-09(6))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3>**Reference 10:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph \(SX 210.6-09\(7\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.6-09(7))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3>**Reference 11:** [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.4-08\(g\)\(1\)\(ii\)\)](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.4-08(g)(1)(ii))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480678/235-10-S99-1>**Reference 12:** [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph \(c\)](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (c)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481687/323-10-50-3>**Reference 13:** [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-Subparagraph \(f\)](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-Subparagraph (f)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482907/825-10-50-28>**Reference 14:** [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 310-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph \(SAB Topic 4.E\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 310-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph (SAB Topic 4.E)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480418/310-10-S99-2>

+ Details

Name:us-gaap_StockholdersEquity_Namespace Prefix:us-gaap_Data Type:xbrl:monetaryItemType Balance Type:credit Period Type:instant

- Definition

Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.

+ References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 6-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 805-SubTopic 60-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph \(g\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 805-SubTopic 60-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph (g)-Publisher FASB-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 805-SubTopic 60-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph \(d\)\(1\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 805-SubTopic 60-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph (d)(1)-Publisher FASB-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 323-Name Accounting Standards Codification-Section 65-Paragraph 2-Subparagraph \(e\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 323-Name Accounting Standards Codification-Section 65-Paragraph 2-Subparagraph (e)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 323-Name Accounting Standards Codification-Section 65-Paragraph 2-Subparagraph \(g\)\(4\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 323-Name Accounting Standards Codification-Section 65-Paragraph 2-Subparagraph (g)(4)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 323-Name Accounting Standards Codification-Section 65-Paragraph 2-Subparagraph \(d\)\(2\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 323-Name Accounting Standards Codification-Section 65-Paragraph 2-Subparagraph (d)(2)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 323-Name Accounting Standards Codification-Section 65-Paragraph 2-Subparagraph \(d\)\(1\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 323-Name Accounting Standards Codification-Section 65-Paragraph 2-Subparagraph (d)(1)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef-Topic 848-SubTopic 10-Name Accounting Standards Codification-Section 65-Paragraph 2-Subparagraph \(a\)\(3\)\(iii\)\(03\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483550/848-10-65-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 848-SubTopic 10-Name Accounting Standards Codification-Section 65-Paragraph 2-Subparagraph (a)(3)(iii)(03)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483550/848-10-65-2)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef-Topic 842-SubTopic 10-Name Accounting Standards Codification-Section 65-Paragraph 8-Subparagraph \(c\)\(3\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479832/842-10-65-8](http://www.xbrl.org/2003/role/disclosureRef-Topic 842-SubTopic 10-Name Accounting Standards Codification-Section 65-Paragraph 8-Subparagraph (c)(3)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479832/842-10-65-8)Reference 10: <http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 24-Publisher FASB-URI https://asc.fasb.org/1943274/2147483421/250-10-45-24>Reference 11: [http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 23-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483421/250-10-45-23](http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 23-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483421/250-10-45-23)Reference 12: [http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 5-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483421/250-10-45-5](http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 5-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483421/250-10-45-5)Reference 13: [http://www.xbrl.org/2003/role/disclosureRef-Topic 326-SubTopic 10-Name Accounting Standards Codification-Section 65-Paragraph 5-Subparagraph \(c\)\(2\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479634/326-10-65-5](http://www.xbrl.org/2003/role/disclosureRef-Topic 326-SubTopic 10-Name Accounting Standards Codification-Section 65-Paragraph 5-Subparagraph (c)(2)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479634/326-10-65-5)Reference 14: [http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 20-Name Accounting Standards Codification-Section 65-Paragraph 6-Subparagraph \(e\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480528/815-20-65-6](http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 20-Name Accounting Standards Codification-Section 65-Paragraph 6-Subparagraph (e)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480528/815-20-65-6)Reference 15: [http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 20-Name Accounting Standards Codification-Section 65-Paragraph 6-Subparagraph \(h\)\(1\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480528/815-20-65-6](http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 20-Name Accounting Standards Codification-Section 65-Paragraph 6-Subparagraph (h)(1)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480528/815-20-65-6)Reference 16: [http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 20-Name Accounting Standards Codification-Section 65-Paragraph 6-Subparagraph \(h\)\(1\)\(i\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480528/815-20-65-6](http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 20-Name Accounting Standards Codification-Section 65-Paragraph 6-Subparagraph (h)(1)(i)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480528/815-20-65-6)Reference 17: [http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 20-Name Accounting Standards Codification-Section 65-Paragraph 6-Subparagraph \(h\)\(1\)\(iii\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480528/815-20-65-6](http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 20-Name Accounting Standards Codification-Section 65-Paragraph 6-Subparagraph (h)(1)(iii)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480528/815-20-65-6)Reference 18: [http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 20-Name Accounting Standards Codification-Section 65-Paragraph 6-Subparagraph \(h\)\(1\)\(iv\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480528/815-20-65-6](http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 20-Name Accounting Standards Codification-Section 65-Paragraph 6-Subparagraph (h)(1)(iv)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480528/815-20-65-6)Reference 19: [http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 20-Name Accounting Standards Codification-Section 65-Paragraph 6-Subparagraph \(i\)\(3\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480528/815-20-65-6](http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 20-Name Accounting Standards Codification-Section 65-Paragraph 6-Subparagraph (i)(3)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480528/815-20-65-6)Reference 20: [http://www.xbrl.org/2003/role/disclosureRef-Topic 105-SubTopic 10-Name Accounting Standards Codification-Section 65-Paragraph 6-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479343/105-10-65-6](http://www.xbrl.org/2003/role/disclosureRef-Topic 105-SubTopic 10-Name Accounting Standards Codification-Section 65-Paragraph 6-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479343/105-10-65-6)Reference 21: [http://www.xbrl.org/2003/role/disclosureRef-Topic 105-SubTopic 10-Name Accounting Standards Codification-Section 65-Paragraph 6-Subparagraph \(d\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479343/105-10-65-6](http://www.xbrl.org/2003/role/disclosureRef-Topic 105-SubTopic 10-Name Accounting Standards Codification-Section 65-Paragraph 6-Subparagraph (d)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479343/105-10-65-6)Reference 22: [http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 2-Subparagraph \(f\)\(1\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480016/944-40-65-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 2-Subparagraph (f)(1)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480016/944-40-65-2)Reference 23: [http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 2-Subparagraph \(f\)\(2\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480016/944-40-65-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 2-Subparagraph (f)(2)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480016/944-40-65-2)Reference 24: [http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section 65-Paragraph 8-Subparagraph \(d\)\(2\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482615/740-10-65-8](http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section 65-Paragraph 8-Subparagraph (d)(2)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482615/740-10-65-8)Reference 25: [http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section 65-Paragraph 8-Subparagraph \(d\)\(3\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482615/740-10-65-8](http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section 65-Paragraph 8-Subparagraph (d)(3)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482615/740-10-65-8)Reference 26: [http://www.xbrl.org/2003/role/disclosureRef-Topic 326-SubTopic 10-Name Accounting Standards Codification-Section 65-Paragraph 4-Subparagraph \(d\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479654/326-10-65-4](http://www.xbrl.org/2003/role/disclosureRef-Topic 326-SubTopic 10-Name Accounting Standards Codification-Section 65-Paragraph 4-Subparagraph (d)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479654/326-10-65-4)Reference 27: [http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(b\)\(3\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (b)(3)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1)Reference 28: [http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph \(e\)\(3\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph (e)(3)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1)Reference 29: [http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 7-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-7](http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 7-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-7)Reference 30: <http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 5-Publisher FASB-URI https://asc.fasb.org/1943274/2147482765/220-10-50-5>Reference 31: <http://www.xbrl.org/2003/role/disclosureRef-Topic 830-SubTopic 30-Name Accounting Standards Codification-Section 50-Paragraph 1-Publisher FASB-URI https://asc.fasb.org/1943274/2147481674/830-30-50-1>Reference 32: <http://www.xbrl.org/2003/role/disclosureRef-Topic 830-SubTopic 30-Name Accounting Standards Codification-Section 45-Paragraph 17-Publisher FASB-URI https://asc.fasb.org/1943274/2147481694/830-30-45-17>Reference 33: [http://www.xbrl.org/2003/role/disclosureRef-Topic 830-SubTopic 30-Name Accounting Standards Codification-Section 45-Paragraph 20-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481694/830-30-45-20](http://www.xbrl.org/2003/role/disclosureRef-Topic 830-SubTopic 30-Name Accounting Standards Codification-Section 45-Paragraph 20-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481694/830-30-45-20)Reference 34: <http://www.xbrl.org/2003/role/exampleRef-Topic 946-SubTopic 830-Name Accounting Standards Codification-Section 55-Paragraph 11-Publisher FASB-URI https://asc.fasb.org/1943274/2147479168/946-830-55-11>Reference 35: <http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 205-Name Accounting Standards Codification-Section 45-Paragraph 3-Publisher FASB-URI https://asc.fasb.org/1943274/2147478009/946-205-45-3>Reference 36: <http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 505-Name Accounting Standards Codification-Section 50-Paragraph 3-Publisher FASB-URI https://asc.fasb.org/1943274/2147478448/946-505-50-3>Reference 37: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.6-04\(19\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.6-04(19))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1)Reference 38: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph \(SX 210.6-05\(4\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph (SX 210.6-05(4))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2)Reference 39: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph \(SX 210.6-09\(4\)\(b\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.6-09(4)(b))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3)Reference 40: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph \(SX 210.6-09\(6\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.6-09(6))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3)Reference 41: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph \(SX 210.6-09\(7\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.6-09(7))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3)Reference 42: [http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.3-04\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.3-04)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1)Reference 43: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.4-08\(g\)\(1\)\(iii\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.4-08(g)(1)(iii))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)Reference 44: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3)Reference 45: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-Subparagraph \(f\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-Subparagraph (f)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28)Reference 46: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 810-SubTopic 10-Section 45-Paragraph 15-Publisher FASB-URI https://asc.fasb.org/1943274/2147481231/810-10-45-15>Reference 47: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 810-SubTopic 10-Section 45-Paragraph 16-Publisher FASB-URI https://asc.fasb.org/1943274/2147481231/810-10-45-16>Reference 48: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 810-SubTopic 10-Section 55-Paragraph 41-Publisher FASB-URI https://asc.fasb.org/1943274/2147481175/810-10-55-41>Reference 49: [http://www.xbrl.org/2003/role/disclosureRef-Topic 350-SubTopic 60-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147476166/350-60-65-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 350-SubTopic 60-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147476166/350-60-65-1)

No definition available.

+ Details

Name:us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAbstract_Namespace Prefix:us-gaap_Data Type:xbrli:stringItemType Balance Type:na Period Type:duration XML 18-R3.htm IDEA: XBRL DOCUMENT Consolidated Balance Sheets (Parenthetical) - \$ / shares Jun. 30, 2024 Sep. 30, 2023 Statement of Financial Position [Abstract] - Common stock, par value (in dollars per share) \$ 0.001 \$ 0.001 Common stock, shares authorized (in shares) 290,000,000 290,000,000 Common stock, shares issued (in shares) 124,227,000 107,312,000 Common stock, shares outstanding (in shares) 124,227,000 107,312,000

- Definition

Face amount or stated value per share of common stock.

+ References

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(29\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(29))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>

+ Details

Name:us-gaap_CommonStockParOrStatedValuePerShare_Namespace Prefix:us-gaap_Data Type:dtr-types:perShareItemType Balance Type:na Period Type:instant

- Definition

The maximum number of common shares permitted to be issued by an entity's charter and bylaws.

+ References

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(29\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(29))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.6-04\(16\)\(a\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.6-04(16)(a))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-1>

+ Details

Name:us-gaap_CommonStockSharesAuthorized_Namespace Prefix:us-gaap_Data Type:xbrli:sharesItemType Balance Type:na Period Type:instant

- Definition

Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.

+ References

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(29\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(29))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>

+ Details

Name:us-gaap_CommonStockSharesIssued_Namespace Prefix:us-gaap_Data Type:xbrli:sharesItemType Balance Type:na Period Type:instant

- Definition

Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.

+ References

Reference 1: <https://asc.fasb.org/1943274/2147481112/505-10-50-2>Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(29\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(29))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph \(SX 210.6-05\(4\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph (SX 210.6-05(4))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-2>Reference 4: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph \(SX 210.6-09\(4\)\(b\)\)](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.6-09(4)(b))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3>Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.6-04\(16\)\(a\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.6-04(16)(a))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-1>Reference 6: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph \(SX 210.6-09\(7\)\)](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.6-09(7))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3>

[+ Details](#)

Name:us-gaap_CommonStockSharesOutstanding_Namespace Prefix:us-gaap_Data Type:xbrli:stringItemType Balance Type:na Period Type:instant

[-References](#)

No definition available.

[+ Details](#)

Name:us-gaap_StatementOfFinancialPositionAbstract_Namespace Prefix:us-gaap_Data Type:xbrli:stringItemType Balance Type:na Period Type:duration XML 19 R4.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Operations and Comprehensive Loss - USD (\$) shares in Thousands, \$ in Thousands3 Months Ended9 Months Ended

Jun. 30, 2024

Jun. 30, 2023

Jun. 30, 2024

Jun. 30, 2023

Income Statement [Abstract] — Revenue\$ 0\$ 15,825\$ 3,551\$ 224,638Operating expenses: — Research and development152,43194,757370,044253,333General and administrative23,71023,77172,38467,977Total operating expenses176,141118,528442,428321,310Operating loss(176,141)(102,703)(438,877)(96,672)Other income (expense): — Interest income6,4984,17215,55011,414Interest expense(5,094)(5,158)(17,705)(13,064)Other, net7603061,370821Total other income (expense)2,164(680)(785)(829)Loss before income tax expense (benefit) and noncontrolling interest(173,977)(103,383)(439,662)(97,501)Income tax expense (benefit)0742(3,313)759Net loss including noncontrolling interest(173,977)(104,125)(436,349)(98,260)Net loss attributable to noncontrolling interest, net of tax(3,184)(1,179)(7,392)(2,664)Net loss attributable to Arrowhead Pharmaceuticals, Inc.\$ (170,793)\$ (102,946)\$ (428,957)\$ (95,596)Net loss per share attributable to Arrowhead Pharmaceuticals, Inc.: — Basic (in dollars per share)\$ (1.38)\$ (0.96)\$ (3.63)\$ (0.90)Diluted (in dollars per share)\$ (1.38)\$ (0.96)\$ (3.63)\$ (0.90)Weighted-average shares used in calculating — Basic (in shares) 124,199107,004118,260106,597Diluted (in shares) 124,199107,004118,260106,597Other comprehensive loss, net of tax: — Change in unrealized losses on available-for-sale securities\$ 249\$ 0\$ 2,374\$ 0Foreign currency translation adjustments(141)(79)(139)(275)Comprehensive loss\$ (173,869)\$ (104,204)\$ (434,114)\$ (98,535)

[-References](#)

No definition available.

[+ Details](#)

Name:us-gaap_ComprehensiveIncomeNetOfTaxAbstract_Namespace Prefix:us-gaap_Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

[-Definition](#)

Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.

[+ References](#)

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 19-Publisher FASB-URI https://asc.fasb.org/1943274/2147481231/810-10-45-19>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 2-Subparagraph \(SX 210.5-03\(22\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483621/220-10-599-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 2-Subparagraph (SX 210.5-03(22))-Publisher FASB-URI https://asc.fasb.org/1943274/2147483621/220-10-599-2)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 942-SubTopic 220-Name Accounting Standards Codification-Section 599-Paragraph 1-Subparagraph \(SX 210.9-04\(24\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478524/942-220-599-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 942-SubTopic 220-Name Accounting Standards Codification-Section 599-Paragraph 1-Subparagraph (SX 210.9-04(24))-Publisher FASB-URI https://asc.fasb.org/1943274/2147478524/942-220-599-1)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1A-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1A-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1B-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1B-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section 599-Paragraph 1-Subparagraph \(SX 210.7-04\(20\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147477250/944-220-599-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section 599-Paragraph 1-Subparagraph (SX 210.7-04(20))-Publisher FASB-URI https://asc.fasb.org/1943274/2147477250/944-220-599-1)Reference 7: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 810-SubTopic 10-Section 55-Paragraph 4K-Publisher FASB-URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K>

[+ Details](#)

Name:us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest **Namespace Prefix:**us-gaap **Data Type:**xbrl:monetaryItemType **Balance Type:**credit **Period Type:**duration

[- Definition](#)

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

[+ References](#)

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic-250-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-6-Publisher-FASB-URI> <https://asc.fasb.org/1943274/2147483443/250-10-50-6>**Reference 2:** <http://www.xbrl.org/2003/role/exampleRef-Topic-260-SubTopic-10-Name-Accounting-Standards-Codification-Section-55-Paragraph-52-Publisher-FASB-URI> <https://asc.fasb.org/1943274/2147482635/260-10-55-52>**Reference 3:** [http://www.xbrl.org/2003/role/disclosureRef-Topic-805-SubTopic-60-Name-Accounting-Standards-Codification-Section-65-Paragraph-1-Subparagraph-\(g\)-Publisher-FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-805-SubTopic-60-Name-Accounting-Standards-Codification-Section-65-Paragraph-1-Subparagraph-(g)-Publisher-FASB-URI) <https://asc.fasb.org/1943274/2147476176/805-60-65-1>**Reference 4:** [http://www.xbrl.org/2003/role/disclosureRef-Topic-740-SubTopic-323-Name-Accounting-Standards-Codification-Section-65-Paragraph-2-Subparagraph-\(g\)\(3\)-Publisher-FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-740-SubTopic-323-Name-Accounting-Standards-Codification-Section-65-Paragraph-2-Subparagraph-(g)(3)-Publisher-FASB-URI) <https://asc.fasb.org/1943274/2147478666/740-323-65-2>**Reference 5:** <http://www.xbrl.org/2003/role/disclosureRef-Topic-250-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-3-Publisher-FASB-URI> <https://asc.fasb.org/1943274/2147483443/250-10-50-3>**Reference 6:** <http://www.xbrl.org/2003/role/disclosureRef-Topic-260-SubTopic-10-Name-Accounting-Standards-Codification-Section-55-Paragraph-15-Publisher-FASB-URI> <https://asc.fasb.org/1943274/2147482635/260-10-55-15>**Reference 7:** [http://www.xbrl.org/2003/role/disclosureRef-Topic-815-SubTopic-40-Name-Accounting-Standards-Codification-Section-65-Paragraph-1-Subparagraph-\(e\)\(4\)-Publisher-FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-815-SubTopic-40-Name-Accounting-Standards-Codification-Section-65-Paragraph-1-Subparagraph-(e)(4)-Publisher-FASB-URI) <https://asc.fasb.org/1943274/2147480175/815-40-65-1>**Reference 8:** [http://www.xbrl.org/2003/role/disclosureRef-Topic-815-SubTopic-40-Name-Accounting-Standards-Codification-Section-65-Paragraph-1-Subparagraph-\(f\)-Publisher-FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-815-SubTopic-40-Name-Accounting-Standards-Codification-Section-65-Paragraph-1-Subparagraph-(f)-Publisher-FASB-URI) <https://asc.fasb.org/1943274/2147480175/815-40-65-1>**Reference 9:** [http://www.xbrl.org/2003/role/disclosureRef-Topic-250-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-11-Subparagraph-\(a\)-Publisher-FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-250-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-11-Subparagraph-(a)-Publisher-FASB-URI) <https://asc.fasb.org/1943274/2147483443/250-10-50-11>**Reference 10:** [http://www.xbrl.org/2003/role/disclosureRef-Topic-250-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-11-Subparagraph-\(b\)-Publisher-FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-250-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-11-Subparagraph-(b)-Publisher-FASB-URI) <https://asc.fasb.org/1943274/2147483443/250-10-50-11>**Reference 11:** [http://www.xbrl.org/2003/role/disclosureRef-Topic-250-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-7-Subparagraph-\(a\)-Publisher-FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-250-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-7-Subparagraph-(a)-Publisher-FASB-URI) <https://asc.fasb.org/1943274/2147483443/250-10-50-7>**Reference 12:** <http://www.xbrl.org/2003/role/disclosureRef-Topic-260-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-2-Publisher-FASB-URI> <https://asc.fasb.org/1943274/2147482689/260-10-45-2>**Reference 13:** [http://www.xbrl.org/2003/role/disclosureRef-Topic-260-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-60B-Subparagraph-\(d\)-Publisher-FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-260-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-60B-Subparagraph-(d)-Publisher-FASB-URI) <https://asc.fasb.org/1943274/2147482689/260-10-45-60B>**Reference 14:** <http://www.xbrl.org/2003/role/disclosureRef-Topic-250-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-4-Publisher-FASB-URI> <https://asc.fasb.org/1943274/2147483443/250-10-50-4>**Reference 15:** [http://www.xbrl.org/2003/role/disclosureRef-Topic-260-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-1-Subparagraph-\(a\)-Publisher-FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-260-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-1-Subparagraph-(a)-Publisher-FASB-URI) <https://asc.fasb.org/1943274/2147482662/260-10-50-1>**Reference 16:** <http://www.xbrl.org/2003/role/disclosureRef-Topic-260-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-10-Publisher-FASB-URI> <https://asc.fasb.org/1943274/2147482689/260-10-45-10>**Reference 17:** [http://www.xbrl.org/2003/role/disclosureRef-Topic-220-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-2-Subparagraph-\(SX-210.5-03\(25\)\)-Publisher-FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-220-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-2-Subparagraph-(SX-210.5-03(25))-Publisher-FASB-URI) <https://asc.fasb.org/1943274/2147483621/220-10-S99-2>**Reference 18:** [http://www.xbrl.org/2003/role/disclosureRef-Topic-942-SubTopic-220-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210.9-04\(27\)\)-Publisher-FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-942-SubTopic-220-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210.9-04(27))-Publisher-FASB-URI) <https://asc.fasb.org/1943274/2147478524/942-220-S99-1>**Reference 19:** [http://www.xbrl.org/2003/role/disclosureRef-Topic-944-SubTopic-220-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210.7-04\(23\)\)-Publisher-FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-944-SubTopic-220-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210.7-04(23))-Publisher-FASB-URI) <https://asc.fasb.org/1943274/2147477250/944-220-S99-1>**Reference 20:** <http://www.xbrl.org/2003/role/disclosureRef-Topic-260-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-7-Publisher-FASB-URI> <https://asc.fasb.org/1943274/2147482689/260-10-45-7>

+ Details

Name:us-gaap_EarningsPerShareBasic_Namespace-Prefix:us-gaap_Data-Type:dtr-types:perShareItemType-Balance-Type:na-Period-Type:duration

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic-250-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-6-Publisher-FASB-URI>
<https://asc.fasb.org/1943274/2147483443/250-10-50-6>Reference 2: <http://www.xbrl.org/2003/role/exampleRef-Topic-260-SubTopic-10-Name-Accounting-Standards-Codification-Section-55-Paragraph-52-Publisher-FASB-URI>
<https://asc.fasb.org/1943274/2147482635/260-10-55-52>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic-805-SubTopic-60-Name-Accounting-Standards-Codification-Section-65-Paragraph-1-Subparagraph-\(g\)-\(3\)-Publisher-FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-805-SubTopic-60-Name-Accounting-Standards-Codification-Section-65-Paragraph-1-Subparagraph-(g)-(3)-Publisher-FASB-URI)
<https://asc.fasb.org/1943274/2147476176/805-60-65-1>Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic-740-SubTopic-323-Name-Accounting-Standards-Codification-Section-65-Paragraph-2-Subparagraph-\(g\)-\(3\)-Publisher-FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-740-SubTopic-323-Name-Accounting-Standards-Codification-Section-65-Paragraph-2-Subparagraph-(g)-(3)-Publisher-FASB-URI)
<https://asc.fasb.org/1943274/2147478666/740-323-65-2>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef-Topic-250-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-3-Publisher-FASB-URI>
<https://asc.fasb.org/1943274/2147483443/250-10-50-3>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef-Topic-260-SubTopic-10-Name-Accounting-Standards-Codification-Section-55-Paragraph-15-Publisher-FASB-URI>
<https://asc.fasb.org/1943274/2147482635/260-10-55-15>Reference 7: [http://www.xbrl.org/2003/role/disclosureRef-Topic-815-SubTopic-40-Name-Accounting-Standards-Codification-Section-65-Paragraph-1-Subparagraph-\(e\)-\(4\)-Publisher-FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-815-SubTopic-40-Name-Accounting-Standards-Codification-Section-65-Paragraph-1-Subparagraph-(e)-(4)-Publisher-FASB-URI)
<https://asc.fasb.org/1943274/2147480175/815-40-65-1>Reference 8: [http://www.xbrl.org/2003/role/disclosureRef-Topic-815-SubTopic-40-Name-Accounting-Standards-Codification-Section-65-Paragraph-1-Subparagraph-\(f\)-Publisher-FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-815-SubTopic-40-Name-Accounting-Standards-Codification-Section-65-Paragraph-1-Subparagraph-(f)-Publisher-FASB-URI)
<https://asc.fasb.org/1943274/2147480175/815-40-65-1>Reference 9: [http://www.xbrl.org/2003/role/disclosureRef-Topic-250-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-11-Subparagraph-\(a\)-Publisher-FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-250-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-11-Subparagraph-(a)-Publisher-FASB-URI)
<https://asc.fasb.org/1943274/2147483443/250-10-50-11>Reference 10: [http://www.xbrl.org/2003/role/disclosureRef-Topic-250-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-11-Subparagraph-\(b\)-Publisher-FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-250-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-11-Subparagraph-(b)-Publisher-FASB-URI)
<https://asc.fasb.org/1943274/2147483443/250-10-50-11>Reference 11: [http://www.xbrl.org/2003/role/disclosureRef-Topic-250-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-7-Subparagraph-\(a\)-Publisher-FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-250-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-7-Subparagraph-(a)-Publisher-FASB-URI)
<https://asc.fasb.org/1943274/2147483443/250-10-50-7>Reference 12: <http://www.xbrl.org/2003/role/disclosureRef-Topic-260-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-2-Publisher-FASB-URI>
<https://asc.fasb.org/1943274/2147482689/260-10-45-2>Reference 13: [http://www.xbrl.org/2003/role/disclosureRef-Topic-260-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-60B-Subparagraph-\(d\)-Publisher-FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-260-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-60B-Subparagraph-(d)-Publisher-FASB-URI)
<https://asc.fasb.org/1943274/2147482689/260-10-45-60B>Reference 14: <http://www.xbrl.org/2003/role/disclosureRef-Topic-250-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-4-Publisher-FASB-URI>
<https://asc.fasb.org/1943274/2147483443/250-10-50-4>Reference 15: [http://www.xbrl.org/2003/role/disclosureRef-Topic-260-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-1-Subparagraph-\(a\)-Publisher-FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-260-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-1-Subparagraph-(a)-Publisher-FASB-URI)
<https://asc.fasb.org/1943274/2147482662/260-10-50-1>Reference 16: [http://www.xbrl.org/2003/role/disclosureRef-Topic-220-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-2-Subparagraph-\(SX-210.5-03\(25\)\)-Publisher-FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-220-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-2-Subparagraph-(SX-210.5-03(25))-Publisher-FASB-URI)
<https://asc.fasb.org/1943274/2147483621/220-10-S99-2>Reference 17: [http://www.xbrl.org/2003/role/disclosureRef-Topic-942-SubTopic-220-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210.9-04\(27\)\)-Publisher-FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-942-SubTopic-220-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210.9-04(27))-Publisher-FASB-URI)
<https://asc.fasb.org/1943274/2147478524/942-220-S99-1>Reference 18: [http://www.xbrl.org/2003/role/disclosureRef-Topic-944-SubTopic-220-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210.7-04\(23\)\)-Publisher-FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-944-SubTopic-220-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210.7-04(23))-Publisher-FASB-URI)
<https://asc.fasb.org/1943274/2147477250/944-220-S99-1>Reference 19: <http://www.xbrl.org/2003/role/disclosureRef-Topic-260-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-7-Publisher-FASB-URI>
<https://asc.fasb.org/1943274/2147482689/260-10-45-7>

+ Details

Name:us-gaap_EarningsPerShareDiluted_Namespace-Prefix:us-gaap_Data-Type:dtr-types:perShareItemType Balance-Type:na-Period-Type:duration

-References

No definition available.

+ Details

Name:us-gaap_EarningsPerShareReconciliationAbstract_Namespace-Prefix:us-gaap_Data-Type:xbrli:stringItemType Balance-Type:na-Period-Type:duration

-Definition

The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.

+ References

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph \(SX 210.5-03\(4\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph (SX 210.5-03(4))-Publisher FASB-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.6-07\(2\)\(a\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.6-07(2)(a))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1)

+ Details

Name:us-gaap_GeneralAndAdministrativeExpense_Namespace-Prefix:us-gaap_Data-Type:xbrli:monetaryItemType Balance-Type:debit-Period-Type:duration

-Definition

Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.

+ References

Reference 1: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 22-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22>Reference 2: <http://www.xbrl.org/2003/role/exampleRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 48-Publisher FASB-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48>Reference 3: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph \(f\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph (f)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 4: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 30-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 30-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30)Reference 5: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 270-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(i\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 270-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (i)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1)Reference 6: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph \(ee\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph (ee)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 7: [http://fasb.org/us-gaap/role/ref/otherTransitionRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://fasb.org/us-gaap/role/ref/otherTransitionRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.7-04\(11\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.7-04(11))-Publisher FASB-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1)Reference 9: <http://www.xbrl.org/2003/role/exampleRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 31-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-31>Reference 10: [http://www.xbrl.org/2003/role/disclosureRef-Topic 942-SubTopic 235-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.9-03\(b\)\(2\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 942-SubTopic 235-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.9-03(b)(2))-Publisher FASB-URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1)Reference 11: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph \(SX 210.5-03\(10\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph (SX 210.5-03(10))-Publisher FASB-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2)Reference 12: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 942-SubTopic 220-Name>

+Details

Name:us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest Namespace Prefix:us-gaap_ Data Type:xbri:monetaryItemType Balance Type:credit Period Type:duration

-References

No definition available.

+Details

Name:us-gaap_IncomeStatementAbstract Namespace Prefix:us-gaap_ Data Type:xbri:stringItemType Balance Type:na Period Type:duration

-Definition

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.

+References

Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic-270-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-1-Subparagraph-\(i\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482964/270-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic-270-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-1-Subparagraph-(i)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482964/270-10-50-1)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-32-Subparagraph-\(ee\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2003/role/disclosureRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-32-Subparagraph-(ee)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 3: <http://www.xbrl.org/2003/role/disclosureRef-Topic-740-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-12-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482685/740-10-50-12>Reference 4: <http://www.xbrl.org/2003/role/exampleRef-Topic-740-SubTopic-10-Name-Accounting-Standards-Codification-Section-55-Paragraph-231-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482663/740-10-55-231>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef-Topic-250-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-9-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147483443/250-10-50-9>Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic-740-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SAB-Topic-6.I.7\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479360/740-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic-740-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SAB-Topic-6.I.7)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479360/740-10-S99-1)Reference 7: <http://www.xbrl.org/2003/role/disclosureRef-Topic-250-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-8-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147483443/250-10-50-8>Reference 8: <http://www.xbrl.org/2003/role/disclosureRef-Topic-740-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-10-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482685/740-10-50-10>Reference 9: [http://www.xbrl.org/2003/role/disclosureRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-22-Subparagraph-\(h\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482810/280-10-50-22](http://www.xbrl.org/2003/role/disclosureRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-22-Subparagraph-(h)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482810/280-10-50-22)Reference 10: [http://www.xbrl.org/2003/role/disclosureRef-Topic-944-SubTopic-220-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210.7-04\(9\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147477250/944-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic-944-SubTopic-220-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210.7-04(9))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147477250/944-220-S99-1)Reference 11: [http://www.xbrl.org/2003/role/disclosureRef-Name-Accounting-Standards-Codification-Section-45-Paragraph-2-Subparagraph-\(a\)-SubTopic-20-Topic-740-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482659/740-20-45-2](http://www.xbrl.org/2003/role/disclosureRef-Name-Accounting-Standards-Codification-Section-45-Paragraph-2-Subparagraph-(a)-SubTopic-20-Topic-740-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482659/740-20-45-2)Reference 12: [http://www.xbrl.org/2003/role/disclosureRef-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210.4-08\(h\)\)-SubTopic-10-Topic-235-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210.4-08(h))-SubTopic-10-Topic-235-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480678/235-10-S99-1)

[+ Details](#)

Name:*us-gaap_IncomeTaxExpenseBenefit* **Namespace Prefix:***us-gaap_* **Data Type:***xbri:monetaryItemType* **Balance Type:***debit* **Period Type:***duration*

[- Definition](#)

Amount of interest expense classified as nonoperating:

[+ References](#)

Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-22-Subparagraph-\(d\)-Publisher-FASB](http://www.xbrl.org/2003/role/disclosureRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-22-Subparagraph-(d)-Publisher-FASB) **URI** <https://asc.fasb.org/1943274/2147482810/280-10-50-22> **Reference 2:** [http://www.xbrl.org/2009/role/commonPracticeRef-Topic-220-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-2-Subparagraph-\(SX-210.5-03\)-Publisher-FASB](http://www.xbrl.org/2009/role/commonPracticeRef-Topic-220-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-2-Subparagraph-(SX-210.5-03)-Publisher-FASB) **URI** <https://asc.fasb.org/1943274/2147483621/220-10-S99-2>

[+ Details](#)

Name:*us-gaap_InterestExpenseNonoperating* **Namespace Prefix:***us-gaap_* **Data Type:***xbri:monetaryItemType* **Balance Type:***debit* **Period Type:***duration*

[- Definition](#)

Amount before accretion (amortization) of purchase discount (premium) of interest income and dividend income on nonoperating securities:

[+ References](#)

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic-220-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-2-Subparagraph-\(SX-210.5-03\(7\)\(a\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic-220-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-2-Subparagraph-(SX-210.5-03(7)(a))) **Publisher** FASB **URI** <https://asc.fasb.org/1943274/2147483621/220-10-S99-2> **Reference 2:** [http://fasb.org/us-gaap/role/ref/legacyRef-Topic-220-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-2-Subparagraph-\(SX-210.5-03\(7\)\(b\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic-220-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-2-Subparagraph-(SX-210.5-03(7)(b))) **Publisher** FASB **URI** <https://asc.fasb.org/1943274/2147483621/220-10-S99-2>

[+ Details](#)

Name:*us-gaap_InvestmentIncomeInterestAndDividend* **Namespace Prefix:***us-gaap_* **Data Type:***xbri:monetaryItemType* **Balance Type:***credit* **Period Type:***duration*

[- Definition](#)

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent:

[+ References](#)

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic-250-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-6> **Publisher** FASB **URI**

<https://asc.fashb.org/1943274/2147483443/250-10-50-6>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 9-Publisher FASB-URI https://asc.fashb.org/1943274/2147483443/250-10-50-9>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 805-SubTopic 60-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph \(g\)-Publisher FASB-URI https://asc.fashb.org/1943274/2147476176/805-60-65-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 805-SubTopic 60-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph (g)-Publisher FASB-URI https://asc.fashb.org/1943274/2147476176/805-60-65-1)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 323-Name Accounting Standards Codification-Section 65-Paragraph 2-Subparagraph \(g\)\(3\)-Publisher FASB-URI https://asc.fashb.org/1943274/2147478666/740-323-65-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 323-Name Accounting Standards Codification-Section 65-Paragraph 2-Subparagraph (g)(3)-Publisher FASB-URI https://asc.fashb.org/1943274/2147478666/740-323-65-2)Reference 5: [http://fashb.org/us-gaap/role/ref/legacyRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 2-Subparagraph \(SX 210.5-03\(20\)\)-Publisher FASB-URI https://asc.fashb.org/1943274/2147483621/220-10-599-2](http://fashb.org/us-gaap/role/ref/legacyRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 2-Subparagraph (SX 210.5-03(20))-Publisher FASB-URI https://asc.fashb.org/1943274/2147483621/220-10-599-2)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1-Subparagraph \(SX 210.4-08\(g\)\(1\)\(ii\)\)-Publisher FASB-URI https://asc.fashb.org/1943274/2147480678/235-10-599-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1-Subparagraph (SX 210.4-08(g)(1)(ii))-Publisher FASB-URI https://asc.fashb.org/1943274/2147480678/235-10-599-1)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph \(c\)-Publisher FASB-URI https://asc.fashb.org/1943274/2147481687/323-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (c)-Publisher FASB-URI https://asc.fashb.org/1943274/2147481687/323-10-50-3)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-Subparagraph \(f\)-Publisher FASB-URI https://asc.fashb.org/1943274/2147482907/825-10-50-28](http://www.xbrl.org/2003/role/disclosureRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-Subparagraph (f)-Publisher FASB-URI https://asc.fashb.org/1943274/2147482907/825-10-50-28)Reference 9: <http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 6-Publisher FASB-URI https://asc.fashb.org/1943274/2147482765/220-10-50-6>Reference 10: [http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(b\)\(2\)-Publisher FASB-URI https://asc.fashb.org/1943274/2147483443/250-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (b)(2)-Publisher FASB-URI https://asc.fashb.org/1943274/2147483443/250-10-50-1)Reference 12: [http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph \(f\)-Publisher FASB-URI https://asc.fashb.org/1943274/2147480175/815-40-65-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph (f)-Publisher FASB-URI https://asc.fashb.org/1943274/2147480175/815-40-65-1)Reference 13: <http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 8-Publisher FASB-URI https://asc.fashb.org/1943274/2147483443/250-10-50-8>Reference 14: [http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph \(a\)-Publisher FASB-URI https://asc.fashb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph (a)-Publisher FASB-URI https://asc.fashb.org/1943274/2147483443/250-10-50-11)Reference 15: [http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph \(b\)-Publisher FASB-URI https://asc.fashb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph (b)-Publisher FASB-URI https://asc.fashb.org/1943274/2147483443/250-10-50-11)Reference 16: <http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 4-Publisher FASB-URI https://asc.fashb.org/1943274/2147483443/250-10-50-4>Reference 17: <http://www.xbrl.org/2003/role/exampleRef-Topic 946-SubTopic 830-Name Accounting Standards Codification-Section 55-Paragraph 10-Publisher FASB-URI https://asc.fashb.org/1943274/2147479168/946-830-55-10>Reference 18: <http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section 45-Paragraph 7-Publisher FASB-URI https://asc.fashb.org/1943274/2147479105/946-220-45-7>Reference 19: [http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section 599-Paragraph 1-Subparagraph \(f\)-Publisher FASB-URI https://asc.fashb.org/1943274/2147477250/944-220-599-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section 599-Paragraph 1-Subparagraph (f)-Publisher FASB-URI https://asc.fashb.org/1943274/2147477250/944-220-599-1)Reference 20: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section 599-Paragraph 1-Subparagraph \(SX 210.6-07\(9\)\)-Publisher FASB-URI https://asc.fashb.org/1943274/2147479134/946-220-599-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section 599-Paragraph 1-Subparagraph (SX 210.6-07(9))-Publisher FASB-URI https://asc.fashb.org/1943274/2147479134/946-220-599-1)Reference 21: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section 599-Paragraph 3-Subparagraph \(SX 210.6-09\(1\)\(d\)\)-Publisher FASB-URI https://asc.fashb.org/1943274/2147479134/946-220-599-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section 599-Paragraph 3-Subparagraph (SX 210.6-09(1)(d))-Publisher FASB-URI https://asc.fashb.org/1943274/2147479134/946-220-599-3)Reference 22: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(i\)\)-Publisher FASB-URI https://asc.fashb.org/1943274/2147480097/470-10-599-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(i))-Publisher FASB-URI https://asc.fashb.org/1943274/2147480097/470-10-599-1)Reference 23: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(ii\)\)-Publisher FASB-URI https://asc.fashb.org/1943274/2147480097/470-10-599-1](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(ii))-Publisher FASB-URI https://asc.fashb.org/1943274/2147480097/470-10-599-1)Reference 24: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\(A\)\)-Publisher FASB-URI https://asc.fashb.org/1943274/2147480097/470-10-599-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(iii)(A))-Publisher FASB-URI https://asc.fashb.org/1943274/2147480097/470-10-599-1)Reference 25: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\)-Publisher FASB-URI https://asc.fashb.org/1943274/2147480097/470-10-599-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(iv))-Publisher FASB-URI https://asc.fashb.org/1943274/2147480097/470-10-599-1)Reference 26: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(5\)\)-Publisher FASB-URI https://asc.fashb.org/1943274/2147480097/470-10-599-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1A-Subparagraph (SX 210.13-01(a)(5))-Publisher FASB-URI https://asc.fashb.org/1943274/2147480097/470-10-599-1)Reference 27: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(i\)\)-Publisher FASB-URI https://asc.fashb.org/1943274/2147480097/470-10-599-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(i))-Publisher FASB-URI https://asc.fashb.org/1943274/2147480097/470-10-599-1)Reference 28: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(A\)\)-Publisher FASB-URI https://asc.fashb.org/1943274/2147480097/470-10-599-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iii)(A))-Publisher FASB-URI https://asc.fashb.org/1943274/2147480097/470-10-599-1)Reference 29: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\)-Publisher FASB-URI https://asc.fashb.org/1943274/2147480097/470-10-599-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iii)(B))-Publisher FASB-URI https://asc.fashb.org/1943274/2147480097/470-10-599-1)Reference 30: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\)-Publisher FASB-URI https://asc.fashb.org/1943274/2147480097/470-10-599-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iv))-Publisher FASB-URI https://asc.fashb.org/1943274/2147480097/470-10-599-1)Reference 31: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(5\)\)-Publisher FASB-URI https://asc.fashb.org/1943274/2147480097/470-10-599-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1B-Subparagraph (SX 210.13-02(a)(5))-Publisher FASB-URI https://asc.fashb.org/1943274/2147480097/470-10-599-1)Reference 32: [http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 60B-Subparagraph \(a\)-Publisher FASB-URI https://asc.fashb.org/1943274/2147482689/260-10-45-60B](http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 60B-Subparagraph (a)-Publisher FASB-URI https://asc.fashb.org/1943274/2147482689/260-10-45-60B)Reference 33: <http://www.xbrl.org/2003/role/disclosureRef-Topic 205-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 7-Publisher FASB-URI https://asc.fashb.org/1943274/2147483499/205-20-50-7>Reference 34: <http://fashb.org/us-gaap/role/ref/legacyRef-Topic 230-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 28-Publisher FASB-URI https://asc.fashb.org/1943274/2147482740/230-10-45-28>Reference 35: [http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1A-Subparagraph \(a\)-Publisher FASB-URI https://asc.fashb.org/1943274/2147482790/220-10-45-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1A-Subparagraph (a)-Publisher FASB-URI https://asc.fashb.org/1943274/2147482790/220-10-45-1)Reference 36: [http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1B-Subparagraph \(a\)-Publisher FASB-URI https://asc.fashb.org/1943274/2147482790/220-10-45-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1B-Subparagraph (a)-Publisher FASB-URI https://asc.fashb.org/1943274/2147482790/220-10-45-1)Reference 37: [http://fashb.org/us-gaap/role/ref/legacyRef-Topic 942-SubTopic 220-Name Accounting Standards Codification-Section 599-Paragraph 1-Subparagraph \(SX 210.9-04\(22\)\)-Publisher FASB-URI https://asc.fashb.org/1943274/2147478524/942-220-599-1](http://fashb.org/us-gaap/role/ref/legacyRef-Topic 942-SubTopic 220-Name Accounting Standards Codification-Section 599-Paragraph 1-Subparagraph (SX 210.9-04(22))-Publisher FASB-URI https://asc.fashb.org/1943274/2147478524/942-220-599-1)

[+ Details](#)

Name:us-gaap_NetIncomeLoss Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItem Type:Balance Type:credit Period Type:duration

[- Definition](#)

Amount of Net Income (Loss) attributable to noncontrolling interest.

[+ References](#)

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic-250-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-6-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147483443/250-10-50-6>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef-Topic-250-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-9-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147483443/250-10-50-9>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef-Topic-250-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-8-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147483443/250-10-50-8>Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic-944-SubTopic-220-Name-Accounting-Standards-Codification-Section-599-Paragraph-1-Subparagraph-\(SX-210.7-04\(17\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147477250/944-220-599-1](http://www.xbrl.org/2003/role/disclosureRef-Topic-944-SubTopic-220-Name-Accounting-Standards-Codification-Section-599-Paragraph-1-Subparagraph-(SX-210.7-04(17))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147477250/944-220-599-1)Reference 5: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic-220-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-6-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482765/220-10-50-6>Reference 6: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic-810-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-1A-Subparagraph-\(a\)\(2\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481203/810-10-50-1A](http://fasb.org/us-gaap/role/ref/legacyRef-Topic-810-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-1A-Subparagraph-(a)(2)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481203/810-10-50-1A)Reference 7: <http://fasb.org/us-gaap/role/ref/legacyRef-Name-Accounting-Standards-Codification-Topic-810-SubTopic-10-Section-55-Paragraph-4J-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481175/810-10-55-4J>Reference 8: [http://www.xbrl.org/2003/role/disclosureRef-Topic-220-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-1A-Subparagraph-\(a\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482790/220-10-45-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic-220-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-1A-Subparagraph-(a)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482790/220-10-45-1A)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef-Topic-220-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-1B-Subparagraph-\(a\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482790/220-10-45-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic-220-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-1B-Subparagraph-(a)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482790/220-10-45-1B)

[+ Details](#)

Name:us-gaap_NetIncomeLossAttributableToNoncontrollingInterest Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

[- Definition](#)

The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).

[+ References](#)

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph \(SX 210.5-03\(7\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph (SX 210.5-03(7)))-Publisher FASB-URI <https://asc.fasb.org/1943274/2147483621/220-10-S99-2>

[+ Details](#)

Name:us-gaap_NonoperatingIncomeExpense Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

[- References](#)

No definition available.

[+ Details](#)

Name:us-gaap_NonoperatingIncomeExpenseAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

[- Definition](#)

Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.

[+ References](#)

No definition available.

[+ Details](#)

Name:us-gaap_OperatingExpenses Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

[- References](#)

No definition available.

[+ Details](#)

Name:us-gaap_OperatingExpensesAbstract_Namespace-Prefix:us-gaap_Data-Type:xbrli:stringItemType-Balance-Type:na-Period-Type:duration

[- Definition](#)

The net result for the period of deducting operating expenses from operating revenues.

[+ References](#)

Reference 1: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-22-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482810/280-10-50-22>**Reference 2:** [http://www.xbrl.org/2009/role/commonPracticeRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-32-Subparagraph-\(f\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2009/role/commonPracticeRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-32-Subparagraph-(f)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482810/280-10-50-32)**Reference 3:** [http://www.xbrl.org/2009/role/commonPracticeRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-30-Subparagraph-\(b\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482810/280-10-50-30](http://www.xbrl.org/2009/role/commonPracticeRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-30-Subparagraph-(b)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482810/280-10-50-30)**Reference 4:** [http://www.xbrl.org/2009/role/commonPracticeRef-Topic-270-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-1-Subparagraph-\(i\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482964/270-10-50-1](http://www.xbrl.org/2009/role/commonPracticeRef-Topic-270-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-1-Subparagraph-(i)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482964/270-10-50-1)**Reference 5:** [http://www.xbrl.org/2009/role/commonPracticeRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-32-Subparagraph-\(ee\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2009/role/commonPracticeRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-32-Subparagraph-(ee)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482810/280-10-50-32)**Reference 6:** [http://fasb.org/us-gaap/role/ref/otherTransitionRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-32-Subparagraph-\(c\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://fasb.org/us-gaap/role/ref/otherTransitionRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-32-Subparagraph-(c)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482810/280-10-50-32)**Reference 7:** <http://www.xbrl.org/2003/role/exampleRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-31-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482810/280-10-50-31>

[+ Details](#)

Name:us-gaap_OperatingIncomeLoss_Namespace-Prefix:us-gaap_Data-Type:xbrli:monetaryItemType-Balance-Type:credit-Period-Type:duration

[- Definition](#)

Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.

[+ References](#)

Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic-944-SubTopic-220-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210-7-04\(19\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147477250/944-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic-944-SubTopic-220-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210-7-04(19))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147477250/944-220-S99-1)**Reference 2:** [http://www.xbrl.org/2003/role/disclosureRef-Topic-220-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-10A-Subparagraph-\(e\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482790/220-10-45-10A](http://www.xbrl.org/2003/role/disclosureRef-Topic-220-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-10A-Subparagraph-(e)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482790/220-10-45-10A)**Reference 3:** [http://www.xbrl.org/2003/role/disclosureRef-Topic-220-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-10A-Subparagraph-\(f\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482790/220-10-45-10A](http://www.xbrl.org/2003/role/disclosureRef-Topic-220-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-10A-Subparagraph-(f)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482790/220-10-45-10A)**Reference 4:** <http://www.xbrl.org/2003/role/disclosureRef-Topic-220-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-11-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482790/220-10-45-11>

+ Details

Name:us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_Namespace Prefix:us-gaap_Data Type:xbri:monetaryItemType Balance Type:credit Period Type:duration

- Definition

Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term investment nature.

+ References

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 45-Paragraph 10A-Subparagraph \(a\)-SubTopic 10-Topic 220-Publisher FASB-URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 45-Paragraph 10A-Subparagraph (a)-SubTopic 10-Topic 220-Publisher FASB-URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A)**Reference 2:** [http://www.xbri.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.7-04\(19\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1](http://www.xbri.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.7-04(19))-Publisher FASB-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1)

+ Details

Name:us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_Namespace Prefix:us-gaap_Data Type:xbri:monetaryItemType Balance Type:credit Period Type:duration

- Definition

Amount of income (expense) related to nonoperating activities, classified as other.

+ References

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph \(SX 210.5-03\(9\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph (SX 210.5-03(9))-Publisher FASB-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2)

+ Details

Name:us-gaap_OtherNonoperatingIncomeExpense_Namespace Prefix:us-gaap_Data Type:xbri:monetaryItemType Balance Type:credit Period Type:duration

- Definition

The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.

+ References

Reference 1: <http://www.xbri.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 6-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6>**Reference 2:** <http://www.xbri.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 9-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-9>**Reference 3:** [http://www.xbri.org/2003/role/disclosureRef-Topic 805-SubTopic 60-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph \(g\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1](http://www.xbri.org/2003/role/disclosureRef-Topic 805-SubTopic 60-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph (g)-Publisher FASB-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1)**Reference 4:** [http://www.xbri.org/2003/role/disclosureRef-Topic 740-SubTopic 323-Name Accounting Standards Codification-Section 65-Paragraph 2-Subparagraph \(g\)\(3\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2](http://www.xbri.org/2003/role/disclosureRef-Topic 740-SubTopic 323-Name Accounting Standards Codification-Section 65-Paragraph 2-Subparagraph (g)(3)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2)**Reference 5:** [http://www.xbri.org/2003/role/disclosureRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.4-08\(g\)\(1\)\(ii\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbri.org/2003/role/disclosureRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.4-08(g)(1)(ii))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)**Reference 6:** [http://www.xbri.org/2003/role/disclosureRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbri.org/2003/role/disclosureRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3)**Reference 7:** [http://www.xbri.org/2003/role/disclosureRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-Subparagraph \(f\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbri.org/2003/role/disclosureRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-Subparagraph (f)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28)**Reference 8:** [http://www.xbri.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(b\)\(2\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1](http://www.xbri.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (b)(2)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1)**Reference 9:** [http://www.xbri.org/2003/role/disclosureRef-Topic 815-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph \(f\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1](http://www.xbri.org/2003/role/disclosureRef-Topic 815-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph (f)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1)**Reference 10:** <http://www.xbri.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 8-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-8>**Reference 11:** <http://www.xbri.org/2003/role/exampleRef-Topic 946-SubTopic 830-Name Accounting Standards Codification-Section 55-Paragraph 11-Publisher FASB-URI https://asc.fasb.org/1943274/2147479168/946-830-55-1>**Reference 12:** [http://www.xbri.org/2003/role/disclosureRef-Topic 946-SubTopic 205-Name Accounting Standards Codification-Section 45-Paragraph 3-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478009/946-205-45-3](http://www.xbri.org/2003/role/disclosureRef-Topic 946-SubTopic 205-Name Accounting Standards Codification-Section 45-Paragraph 3-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478009/946-205-45-3)**Reference 13:** <http://www.xbri.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section 45-Paragraph 7-Publisher FASB-URI https://asc.fasb.org/1943274/2147479105/946-220-45-7>**Reference 14:** [http://www.xbri.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.7-04\(16\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1](http://www.xbri.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.7-04(16))-Publisher FASB-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1)**Reference 15:** <http://www.xbri.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section 45-Paragraph 7-Publisher FASB-URI https://asc.fasb.org/1943274/2147479105/946-220-45-7>

~~Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.6-07(9)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 16>: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph \(SX 210.6-09\(1\)\(d\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.6-09(1)(d))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 17>: <http://www.xbrl.org/2003/role/disclosureRef-Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 19> -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481231/810-10-45-19Reference 18>: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 6> -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482765/220-10-50-6Reference 19>: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(i\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(i))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 20>: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(ii\)\)](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(ii))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 21>: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\(A\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(iii)(A))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 22>: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(iv))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 23>: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(5\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(5))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1AReference 24>: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(i\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(i))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 25>: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(A\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iii)(A))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 26>: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iii)(B))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 27>: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iv))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28>: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(5\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(5))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29>: [http://www.xbrl.org/2003/role/disclosureRef-Topic 942-SubTopic 235-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.9-05\(b\)\(2\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 942-SubTopic 235-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.9-05(b)(2))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147477314/942-235-S99-1Reference 30>: <http://www.xbrl.org/2003/role/disclosureRef-Topic 205-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 7> -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 31>: <http://www.xbrl.org/2003/role/exampleRef-Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 4J> -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481175/810-10-55-4JReference 32>: <http://www.xbrl.org/2003/role/exampleRef-Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 4K> -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481175/810-10-55-4KReference 33>: [http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1A-Subparagraph \(a\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1A-Subparagraph (a)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 34>: [http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1B-Subparagraph \(a\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1B-Subparagraph (a)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 35>: <http://www.xbrl.org/2003/role/disclosureRef-Topic 230-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 2> -Publisher FASB -URI <https://asc.fasb.org/1943274/2147482740/230-10-45-2Reference 36>: [http://www.xbrl.org/2003/role/disclosureRef-Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1A-Subparagraph \(a\)\(1\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1A-Subparagraph (a)(1)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481203/810-10-50-1AReference 37>: [http://www.xbrl.org/2003/role/disclosureRef-Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1A-Subparagraph \(c\)\(1\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1A-Subparagraph (c)(1)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481203/810-10-50-1A>~~

+ Details

Name:us-gaap_ProfitLoss_Namespace Prefix:us-gaap_Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

- Definition

Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.

+ References

Reference 1: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic 730-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Publisher FASB-URI https://asc.fasb.org/1943274/2147482916/730-10-50-1>

+ Details

Name:us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_Namespace Prefix:us-gaap_Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 41-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41](http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 41-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41)
Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 270-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(i\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 270-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (i)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1)
Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph \(ec\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph (ec)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)
Reference 4: [http://fasb.org/us-gaap/role/ref/otherTransitionRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://fasb.org/us-gaap/role/ref/otherTransitionRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)
Reference 5: [http://fasb.org/us-gaap/role/ref/otherTransitionRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://fasb.org/us-gaap/role/ref/otherTransitionRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)
Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic 924-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SAB Topic 11.L\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 924-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SAB Topic 11.L)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1)
Reference 7: <http://www.xbrl.org/2003/role/disclosureRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 5-Publisher FASB-URI https://asc.fasb.org/1943274/2147479806/606-10-50-5>
Reference 8: [http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 30-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30](http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 30-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30)
Reference 9: <http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 42-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-42>
Reference 10: [http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 22-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22](http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 22-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22)
Reference 11: <http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 40-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40>
Reference 12: [http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 22-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22](http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 22-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22)
Reference 13: [http://www.xbrl.org/2003/role/disclosureRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 4-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479806/606-10-50-4](http://www.xbrl.org/2003/role/disclosureRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 4-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479806/606-10-50-4)

+Details

Name:us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax **Namespace Prefix:**us-gaap **Data Type:**xbri:monetaryItemType **Balance Type:**credit **Period Type:**duration

-Definition

The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.

+References

Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic-260-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-1-Subparagraph-\(a\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482662/260-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic-260-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-1-Subparagraph-(a)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482662/260-10-50-1)**Reference 2:** <http://www.xbrl.org/2003/role/disclosureRef-Topic-260-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-16-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482689/260-10-45-16>

+Details

Name:us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding **Namespace Prefix:**us-gaap **Data Type:**xbri:sharesItemType **Balance Type:**na **Period Type:**duration

-Definition

Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.

+References

Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic-260-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-1-Subparagraph-\(a\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482662/260-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic-260-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-1-Subparagraph-(a)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482662/260-10-50-1)**Reference 2:** <http://www.xbrl.org/2003/role/disclosureRef-Topic-260-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-10-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482689/260-10-45-10>

+Details

Name:us-gaap_WeightedAverageNumberOfSharesOutstandingBasic **Namespace Prefix:**us-gaap **Data Type:**xbri:sharesItemType **Balance Type:**na **Period Type:**duration

-References

No definition available.

+Details

Name:us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract **Namespace Prefix:**us-gaap **Data Type:**xbri:stringItemType **Balance Type:**na **Period Type:**duration **XML 20-R5.htm IDEA:** XBRL DOCUMENT

Consolidated Statements of Stockholders' Equity--USD (\$)-\$ in Total Common

Thousands	Stock	Capital	Additional Paid-In	Accumulated Other Comprehensive Loss	Accumulated Deficit	Non-controlling Interest
Beginning balance at Sep. 30, 2022 \$ 418,339\$ 198\$ 1,219,213\$ (136)\$ (820,755)\$ 19,819 Beginning balance (in shares) at Sep. 30, 2022 105,960,000 Increase (Decrease) in Stockholders' Equity [Roll Forward]						
Stock-based compensation 19,390 19,390 Exercise of stock options 576 576 Exercise of stock options (in shares) 82,000 Common stock--restricted stock units vesting 0\$ 1(1) Common stock--restricted stock units vesting (in shares) 98,000 Foreign currency translation adjustments (122) (122) Net income (loss) (41,811) (41,325) (486) Ending balance at Dec. 31, 2022 396,372\$ 199\$ 1,239,178\$ (258)\$ (862,080)\$ 19,333 Ending balance (in shares) at Dec. 31, 2022 106,140,000						
Beginning balance at Sep. 30, 2022 418,339\$ 198\$ 1,219,213\$ (136)\$ (820,755)\$ 19,819 Beginning balance (in shares) at Sep. 30, 2022 105,960,000 Increase (Decrease) in Stockholders' Equity [Roll Forward]						
Foreign currency translation adjustments (275) Change in unrealized losses on available-for-sale securities 0 Net income (loss) (98,260) Ending balance at Jun. 30, 2023 381,985\$ 199\$ 1,281,393\$ (411)\$ (916,351)\$ 17,155 Ending balance (in shares) at Jun. 30, 2023 107,102,000 Beginning balance at Dec. 31, 2022 396,372\$ 199\$ 1,239,178\$ (258)\$ (862,080)\$ 19,333 Beginning balance (in shares) at Dec. 31, 2022 106,140,000						
Stock-based compensation 20,612 20,612 Exercise of stock options 520 520 Exercise of stock options (in shares) 64,000 Common stock--restricted stock units vesting (in shares) 665,000 Foreign currency translation adjustments (74) (74) Net income (loss) 47,676 48,675 (999) Ending balance at Mar. 31, 2023 465,106\$ 199\$ 1,260,310\$ (332)\$ (813,405)\$ 18,334 Ending balance (in shares) at Mar. 31, 2023 106,869,000 Increase (Decrease) in Stockholders' Equity [Roll Forward]						
Stock-based compensation 19,947 19,947 Exercise of stock options 1,136 1,136 Exercise of stock options (in shares) 198,000 Common stock--restricted stock units vesting (in shares) 35,000 Foreign currency translation adjustments (79) (79) Change in unrealized losses on available-for-sale securities 0 Net income (loss) (104,125) (102,946) (1,179) Ending balance at Jun. 30, 2023 381,985\$ 199\$ 1,281,393\$ (411)\$ (916,351)\$ 17,155 Ending balance (in shares) at Jun. 30, 2023 107,102,000 Beginning balance at Sep. 30, 2023 287,162\$ 200\$ 1,300,395\$ (3,222)\$ (1,026,030)\$ 15,819 Beginning balance (in shares) at Sep. 30, 2023 107,312,000 Increase (Decrease) in Stockholders' Equity [Roll Forward]						
Stock-based compensation 19,694 19,694 Exercise of stock options 267 267 Exercise of stock options (in shares) 34,000 Common stock--restricted stock units vesting (in shares) 154,000 Foreign currency translation adjustments 58 58 Change in unrealized losses on available-for-sale securities 1,909 1,909 Net income (loss) (135,376) (132,864) (2,512) Ending balance at Dec. 31, 2023 173,714\$ 200\$ 1,320,356\$ (1,255)\$ (1,158,894)\$ 13,307 Beginning balance (in shares) at Dec. 31, 2023 107,500,000 Increase (Decrease) in Stockholders' Equity [Roll Forward]						
Stock-based compensation 17,050 17,050 Exercise of stock options 1,512 1,512 Exercise of stock options (in shares) 120,000 Common stock--restricted stock units vesting 0\$ 1(1) Common stock--restricted stock units vesting (in shares) 723,000 Common stock issued, net of offering costs 429,265\$ 164 29,249 Common stock issued, net of offering costs (in shares) 15,790,000 Foreign currency translation adjustments (56) (56) Change in unrealized losses on available-for-sale securities 216 216 Net income (loss) (126,996) (125,300) (1,696) Ending balance at Mar. 31, 2024 495,405\$ 217\$ 1,768,866\$ (1,095)\$ (1,284,194)\$ 11,611 Ending balance (in shares) at Mar. 31, 2024 124,133,000 Increase (Decrease) in Stockholders' Equity [Roll Forward]						
Stock-based compensation 17,050 17,050 Exercise of stock options 1,512 1,512 Exercise of stock options (in shares) 51,000 Foreign currency translation adjustments (141) (141) Change in unrealized losses on available-for-sale securities 249 249 Net income (loss) (173,977) (170,793) (3,184) Ending balance at Jun. 30, 2024 338,974\$ 217\$ 1,786,304\$ (987)\$ (1,454,987)\$ 8,427 Ending balance (in shares) at Jun. 30, 2024 124,227,000						

-Definition

Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.

[+ References](#)

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 35-Paragraph 2-Publisher FASB-URI https://asc.fasb.org/1943274/2147480483/718-10-35-2>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 718-SubTopic 20-Section 55-Paragraph 13-Publisher FASB-URI https://asc.fasb.org/1943274/2147481089/718-20-55-13>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 718-SubTopic 20-Section 55-Paragraph 12-Publisher FASB-URI https://asc.fasb.org/1943274/2147481089/718-20-55-12>

[+ Details](#)

Name:us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_Namespace Prefix:us-gaap_Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

[- Definition](#)

A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.

[+ References](#)

No definition available.

[+ Details](#)

Name:us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_Namespace Prefix:us-gaap_Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

[- Definition](#)

Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.

[+ References](#)

Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.7-04\(19\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.7-04(19))-Publisher FASB-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 10A-Subparagraph \(e\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A](http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 10A-Subparagraph (e)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 10A-Subparagraph \(f\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A](http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 10A-Subparagraph (f)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A)Reference 4: <http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 11-Publisher FASB-URI https://asc.fasb.org/1943274/2147482790/220-10-45-11>

[+ Details](#)

Name:us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax_Namespace Prefix:us-gaap_Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

[- Definition](#)

Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term investment nature.

[+ References](#)

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 45-Paragraph 10A-Subparagraph \(a\)-SubTopic 10-Topic 220-Publisher FASB-URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 45-Paragraph 10A-Subparagraph (a)-SubTopic 10-Topic 220-Publisher FASB-URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A)Reference 2: <http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name>

+Details

Name:us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_Namespace Prefix:us-gaap_Data Type: xbrli:monetaryItemType Balance Type:credit Period Type:duration

-Definition

The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.

+References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 6-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 9-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-9>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 805-SubTopic 60-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph \(g\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 805-SubTopic 60-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph (g)-Publisher FASB-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 323-Name Accounting Standards Codification-Section 65-Paragraph 2-Subparagraph \(g\)\(3\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 323-Name Accounting Standards Codification-Section 65-Paragraph 2-Subparagraph (g)(3)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.4-08\(g\)\(1\)\(ii\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.4-08(g)(1)(ii))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-50-1)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-Subparagraph \(f\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbrl.org/2003/role/disclosureRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-Subparagraph (f)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(b\)\(2\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (b)(2)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph \(f\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph (f)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1)Reference 10: <http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 8-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-8>Reference 11: <http://www.xbrl.org/2003/role/exampleRef-Topic 946-SubTopic 830-Name Accounting Standards Codification-Section 55-Paragraph 11-Publisher FASB-URI https://asc.fasb.org/1943274/2147479168/946-830-55-11>Reference 12: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 205-Name Accounting Standards Codification-Section 45-Paragraph 3-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478009/946-205-45-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 205-Name Accounting Standards Codification-Section 45-Paragraph 3-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478009/946-205-45-3)Reference 13: <http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section 45-Paragraph 7-Publisher FASB-URI https://asc.fasb.org/1943274/2147479105/946-220-45-7>Reference 14: [http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.7-04\(16\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.7-04(16))-Publisher FASB-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1)Reference 15: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.6-07\(9\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.6-07(9))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1)Reference 16: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph \(SX 210.6-09\(1\)\(d\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.6-09(1)(d))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3)Reference 17: <http://www.xbrl.org/2003/role/disclosureRef-Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 19-Publisher FASB-URI https://asc.fasb.org/1943274/2147481231/810-10-45-19>Reference 18: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 6-Publisher FASB-URI https://asc.fasb.org/1943274/2147482765/220-10-50-6>Reference 19: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(i\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(i))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 20: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(ii\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(ii))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 21: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(iii\)\(A\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(iii)(A))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 22: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(iv))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 23: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(5\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(5))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A)Reference 24: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(i\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(i))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 25: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(A\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iii)(A))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 26: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iii)(B))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 27: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iv))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 28: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(5\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(5))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B)Reference 29: [http://www.xbrl.org/2003/role/disclosureRef-Topic 942-SubTopic 235-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.9-05\(b\)\(2\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 942-SubTopic 235-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.9-05(b)(2))-Publisher FASB-URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1)Reference 30: <http://www.xbrl.org/2003/role/disclosureRef-Topic 205-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 7-Publisher FASB-URI https://asc.fasb.org/1943274/2147483499/205-20-50-7>Reference 31: <http://www.xbrl.org/2003/role/exampleRef-Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 4J-Publisher FASB-URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J>Reference 32: <http://www.xbrl.org/2003/role/exampleRef-Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 4K-Publisher FASB-URI https://asc.fasb.org/1943274/2147481175/810-10-55-4K>Reference 33: [http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1A-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1A-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A)Reference 34: [http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1B-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1B-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B)Reference 35: <http://www.xbrl.org/2003/role/disclosureRef-Topic 230-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 2-Publisher FASB-URI https://asc.fasb.org/1943274/2147482740/230-10-45-2>Reference 36: [http://www.xbrl.org/2003/role/disclosureRef-Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1A-Subparagraph \(a\)\(1\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1A-Subparagraph (a)(1)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A)Reference 37: [http://www.xbrl.org/2003/role/disclosureRef-Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1A-Subparagraph \(c\)\(1\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A](http://www.xbrl.org/2003/role/disclosureRef-Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1A-Subparagraph (c)(1)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A)

No definition available.

+ Details

Name:us-gaap_SharesOutstanding_Namespace Prefix:us-gaap_Data Type:xbrli:sharesItemType Balance Type:na Period Type:instant

-Definition

Number of new stock issued during the period.

+ References

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 50-Paragraph 2-SubTopic 10-Topic 505-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-2>Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(28\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(28)))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 3: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(29\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(29)))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 505-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478448/946-505-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 505-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478448/946-505-50-2)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph \(SX 210.6-09\(4\)\(b\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.6-09(4)(b)))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph \(SX 210.6-03\(i\)\(1\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.6-03(i)(1)))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 7: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.3-04\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.3-04))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1

+ Details

Name:us-gaap_StockIssuedDuringPeriodSharesNewIssues_Namespace Prefix:us-gaap_Data Type:xbrli:sharesItemType Balance Type:na Period Type:duration

-Definition

Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.

+ References

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 50-Paragraph 2-SubTopic 10-Topic 505-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-2>Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.3-04\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.3-04))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1

+ Details

Name:us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_Namespace Prefix:us-gaap_Data Type:xbrli:sharesItemType Balance Type:na Period Type:duration

- Definition

Number of share options (or share units) exercised during the current period.

+ References

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 50-Paragraph 2-SubTopic 10-Topic 505-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-2>**Reference 2:** [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(28\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(28))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)**Reference 3:** [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(29\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(29))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)**Reference 4:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\)\(1\)\(iv\)\(02\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c)(1)(iv)(02)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)**Reference 5:** [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.3-04\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.3-04)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1)

+ Details

Name:us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_Namespace Prefix:us-gaap_Data Type:xbrli:sharesItemType Balance Type:na Period Type:duration

- Definition

Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.

+ References

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 50-Paragraph 2-SubTopic 10-Topic 505-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-2>**Reference 2:** [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(28\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(28))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)**Reference 3:** [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(29\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(29))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)**Reference 4:** <http://www.xbrl.org/2003/role/exampleRef-Topic 946-SubTopic 830-Name Accounting Standards Codification-Section 55-Paragraph 11-Publisher FASB-URI https://asc.fasb.org/1943274/2147479168/946-830-55-11>**Reference 5:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 205-Name Accounting Standards Codification-Section 45-Paragraph 4-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478009/946-205-45-4](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 205-Name Accounting Standards Codification-Section 45-Paragraph 4-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478009/946-205-45-4)**Reference 6:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 505-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478448/946-505-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 505-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478448/946-505-50-2)**Reference 7:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph \(SX 210.6-09\(4\)\(b\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.6-09(4)(b))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3)**Reference 8:** [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.3-04\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.3-04)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1)

[+ Details](#)

Name:us-gaap_StockIssuedDuringPeriodValueNewIssues_Namespace Prefix:us-gaap_Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

[- Definition](#)

Aggregate value of stock related to Restricted Stock Awards issued during the period.

[+ References](#)

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 50-Paragraph 2-SubTopic 10-Topic 505-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-2>Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(28\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(28))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 3: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(29\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(29))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 4: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.3-04\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.3-04)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1)

[+ Details](#)

Name:us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_Namespace Prefix:us-gaap_Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

-Definition

Value of stock issued as a result of the exercise of stock options.

+References

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 50-Paragraph 2-SubTopic 10-Topic 505-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-2>**Reference 2:** [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(29\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(29))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)**Reference 3:** [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(30\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(30))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)**Reference 4:** [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(31\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(31))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)**Reference 5:** [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.3-04\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.3-04)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1)

+Details

Name:us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_Namespace Prefix:us-gaap_Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

-Definition

Amount of equity (deficit) attributable to parent and noncontrolling interest. Excludes temporary equity.

+References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 6-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6>**Reference 2:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 805-SubTopic 60-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph \(g\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 805-SubTopic 60-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph (g)-Publisher FASB-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1)**Reference 3:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 805-SubTopic 60-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph \(d\)\(1\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 805-SubTopic 60-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph (d)(1)-Publisher FASB-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1)**Reference 4:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 323-Name Accounting Standards Codification-Section 65-Paragraph 2-Subparagraph \(e\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 323-Name Accounting Standards Codification-Section 65-Paragraph 2-Subparagraph (e)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2)**Reference 5:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 323-Name Accounting Standards Codification-Section 65-Paragraph 2-Subparagraph \(a\)\(3\)\(iii\)\(03\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483550/848-10-65-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 323-Name Accounting Standards Codification-Section 65-Paragraph 2-Subparagraph (a)(3)(iii)(03)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483550/848-10-65-2)**Reference 6:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 323-Name Accounting Standards Codification-Section 65-Paragraph 2-Subparagraph \(d\)\(2\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 323-Name Accounting Standards Codification-Section 65-Paragraph 2-Subparagraph (d)(2)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2)**Reference 7:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 323-Name Accounting Standards Codification-Section 65-Paragraph 2-Subparagraph \(d\)\(1\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 323-Name Accounting Standards Codification-Section 65-Paragraph 2-Subparagraph (d)(1)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2)**Reference 8:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 848-SubTopic 10-Name Accounting Standards Codification-Section 65-Paragraph 8-Subparagraph \(c\)\(3\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479832/842-10-65-8](http://www.xbrl.org/2003/role/disclosureRef-Topic 848-SubTopic 10-Name Accounting Standards Codification-Section 65-Paragraph 8-Subparagraph (c)(3)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479832/842-10-65-8)**Reference 9:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 842-SubTopic 10-Name Accounting Standards Codification-Section 65-Paragraph 8-Subparagraph \(c\)\(3\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479832/842-10-65-8](http://www.xbrl.org/2003/role/disclosureRef-Topic 842-SubTopic 10-Name Accounting Standards Codification-Section 65-Paragraph 8-Subparagraph (c)(3)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479832/842-10-65-8)**Reference 10:** <http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 24-Publisher FASB-URI https://asc.fasb.org/1943274/2147483421/250-10-45-24>**Reference 11:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 23-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483421/250-10-45-23](http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 23-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483421/250-10-45-23)**Reference 12:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 5-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483421/250-10-45-5](http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 5-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483421/250-10-45-5)**Reference 13:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 326-SubTopic 10-Name Accounting Standards Codification-Section 65-Paragraph 5-Subparagraph \(c\)\(2\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479654/326-10-65-5](http://www.xbrl.org/2003/role/disclosureRef-Topic 326-SubTopic 10-Name Accounting Standards Codification-Section 65-Paragraph 5-Subparagraph (c)(2)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479654/326-10-65-5)**Reference 14:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 20-Name Accounting Standards Codification-Section 65-Paragraph 6-Subparagraph \(h\)\(1\)\(iii\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480528/815-20-65-6](http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 20-Name Accounting Standards Codification-Section 65-Paragraph 6-Subparagraph (h)(1)(iii)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480528/815-20-65-6)**Reference 15:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 20-Name Accounting Standards Codification-Section 65-Paragraph 6-Subparagraph \(h\)\(1\)\(iv\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480528/815-20-65-6](http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 20-Name Accounting Standards Codification-Section 65-Paragraph 6-Subparagraph (h)(1)(iv)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480528/815-20-65-6)**Reference 16:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 20-Name Accounting Standards Codification-Section 65-Paragraph 6-Subparagraph \(h\)\(1\)\(i\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480528/815-20-65-6](http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 20-Name Accounting Standards Codification-Section 65-Paragraph 6-Subparagraph (h)(1)(i)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480528/815-20-65-6)**Reference 17:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 20-Name Accounting Standards Codification-Section 65-Paragraph 6-Subparagraph \(h\)\(1\)\(iii\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480528/815-20-65-6](http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 20-Name Accounting Standards Codification-Section 65-Paragraph 6-Subparagraph (h)(1)(iii)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480528/815-20-65-6)**Reference 18:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 20-Name Accounting Standards Codification-Section 65-Paragraph 6-Subparagraph \(d\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480528/815-20-65-6](http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 20-Name Accounting Standards Codification-Section 65-Paragraph 6-Subparagraph (d)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480528/815-20-65-6)**Reference 19:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 20-Name Accounting Standards Codification-Section 65-Paragraph 6-Subparagraph \(i\)\(3\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480528/815-20-65-6](http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 20-Name Accounting Standards Codification-Section 65-Paragraph 6-Subparagraph (i)(3)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480528/815-20-65-6)**Reference 20:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 105-SubTopic 10-Name Accounting Standards Codification-Section 65-Paragraph 6-Subparagraph \(h\)\(1\)\(iii\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479343/105-10-65-6](http://www.xbrl.org/2003/role/disclosureRef-Topic 105-SubTopic 10-Name Accounting Standards Codification-Section 65-Paragraph 6-Subparagraph (h)(1)(iii)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479343/105-10-65-6)**Reference 21:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 105-SubTopic 10-Name Accounting Standards Codification-Section 65-Paragraph 6-Subparagraph \(d\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479343/105-10-65-6](http://www.xbrl.org/2003/role/disclosureRef-Topic 105-SubTopic 10-Name Accounting Standards Codification-Section 65-Paragraph 6-Subparagraph (d)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479343/105-10-65-6)**Reference 22:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 2-Subparagraph \(f\)\(1\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480016/944-40-65-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 2-Subparagraph (f)(1)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480016/944-40-65-2)**Reference 23:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 2-Subparagraph \(f\)\(2\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480016/944-40-65-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 2-Subparagraph (f)(2)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480016/944-40-65-2)**Reference 24:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 8-Subparagraph \(d\)\(2\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482615/740-10-65-8](http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 8-Subparagraph (d)(2)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482615/740-10-65-8)**Reference 25:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section 65-Paragraph 8-Subparagraph \(d\)\(3\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482615/740-10-65-8](http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section 65-Paragraph 8-Subparagraph (d)(3)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482615/740-10-65-8)**Reference 26:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 326-SubTopic 10-Name Accounting Standards Codification-Section 65-Paragraph 6-Subparagraph \(h\)\(1\)\(iii\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480528/815-20-65-6](http://www.xbrl.org/2003/role/disclosureRef-Topic 326-SubTopic 10-Name Accounting Standards Codification-Section 65-Paragraph 6-Subparagraph (h)(1)(iii)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480528/815-20-65-6)

~~Standards Codification –Section 65–Paragraph 4–Subparagraph (d)–Publisher FASB–URI <https://asc.fasb.org/1943274/2147479654/326-10-65-4>Reference 27: [http://www.xbrl.org/2003/role/disclosureRef-Topic-250-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-1-Subparagraph-\(b\)\(3\)-Publisher-FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-250-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-1-Subparagraph-(b)(3)-Publisher-FASB-URI) <https://asc.fasb.org/1943274/2147483443/250-10-50-1>Reference 28: [http://www.xbrl.org/2003/role/disclosureRef-Topic-815-SubTopic-40-Name-Accounting-Standards-Codification-Section-65-Paragraph-1-Subparagraph-\(e\)\(3\)-Publisher-FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-815-SubTopic-40-Name-Accounting-Standards-Codification-Section-65-Paragraph-1-Subparagraph-(e)(3)-Publisher-FASB-URI) <https://asc.fasb.org/1943274/2147480175/815-40-65-1>Reference 29: [http://www.xbrl.org/2003/role/disclosureRef-Topic-250-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-7-Subparagraph-\(b\)-Publisher-FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-250-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-7-Subparagraph-(b)-Publisher-FASB-URI) <https://asc.fasb.org/1943274/2147483443/250-10-50-7>Reference 30: <http://www.xbrl.org/2003/role/disclosureRef-Topic-220-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-5-Publisher-FASB-URI> <https://asc.fasb.org/1943274/2147482765/220-10-50-5>Reference 31: <http://www.xbrl.org/2003/role/disclosureRef-Topic-830-SubTopic-30-Name-Accounting-Standards-Codification-Section-50-Paragraph-1-Publisher-FASB-URI> <https://asc.fasb.org/1943274/2147481674/830-30-50-1>Reference 32: <http://www.xbrl.org/2003/role/disclosureRef-Topic-830-SubTopic-30-Name-Accounting-Standards-Codification-Section-45-Paragraph-17-Publisher-FASB-URI> <https://asc.fasb.org/1943274/2147481694/830-30-45-17>Reference 33: [http://www.xbrl.org/2003/role/disclosureRef-Topic-830-SubTopic-30-Name-Accounting-Standards-Codification-Section-45-Paragraph-20-Subparagraph-\(a\)-Publisher-FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-830-SubTopic-30-Name-Accounting-Standards-Codification-Section-45-Paragraph-20-Subparagraph-(a)-Publisher-FASB-URI) <https://asc.fasb.org/1943274/2147481694/830-30-45-20>Reference 34: <http://www.xbrl.org/2003/role/exampleRef-Topic-946-SubTopic-830-Name-Accounting-Standards-Codification-Section-55-Paragraph-11-Publisher-FASB-URI> <https://asc.fasb.org/1943274/2147479168/946-830-55-11>Reference 35: <http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-205-Name-Accounting-Standards-Codification-Section-45-Paragraph-3-Publisher-FASB-URI> <https://asc.fasb.org/1943274/2147478009/946-205-45-3>Reference 36: <http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-505-Name-Accounting-Standards-Codification-Section-50-Paragraph-3-Publisher-FASB-URI> <https://asc.fasb.org/1943274/2147478448/946-505-50-3>Reference 37: [http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-210-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210.6-04\(19\)\)-Publisher-FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-210-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210.6-04(19))-Publisher-FASB-URI) <https://asc.fasb.org/1943274/2147479170/946-210-S99-1>Reference 38: [http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-210-Name-Accounting-Standards-Codification-Section-S99-Paragraph-2-Subparagraph-\(SX-210.6-05\(4\)\)-Publisher-FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-210-Name-Accounting-Standards-Codification-Section-S99-Paragraph-2-Subparagraph-(SX-210.6-05(4))-Publisher-FASB-URI) <https://asc.fasb.org/1943274/2147479170/946-210-S99-2>Reference 39: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic-946-SubTopic-220-Name-Accounting-Standards-Codification-Section-S99-Paragraph-3-Subparagraph-\(SX-210.6-09\(4\)\(b\)\)-Publisher-FASB-URI](http://www.xbrl.org/2009/role/commonPracticeRef-Topic-946-SubTopic-220-Name-Accounting-Standards-Codification-Section-S99-Paragraph-3-Subparagraph-(SX-210.6-09(4)(b))-Publisher-FASB-URI) <https://asc.fasb.org/1943274/2147479134/946-220-S99-3>Reference 40: [http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-220-Name-Accounting-Standards-Codification-Section-S99-Paragraph-3-Subparagraph-\(SX-210.6-09\(6\)\)-Publisher-FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-220-Name-Accounting-Standards-Codification-Section-S99-Paragraph-3-Subparagraph-(SX-210.6-09(6))-Publisher-FASB-URI) <https://asc.fasb.org/1943274/2147479134/946-220-S99-3>Reference 41: [http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-220-Name-Accounting-Standards-Codification-Section-S99-Paragraph-3-Subparagraph-\(SX-210.6-09\(7\)\)-Publisher-FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-220-Name-Accounting-Standards-Codification-Section-S99-Paragraph-3-Subparagraph-(SX-210.6-09(7))-Publisher-FASB-URI) <https://asc.fasb.org/1943274/2147479134/946-220-S99-3>Reference 42: [http://www.xbrl.org/2003/role/disclosureRef-Topic-505-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210.3-04\)-Publisher-FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-505-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210.3-04)-Publisher-FASB-URI) <https://asc.fasb.org/1943274/2147480008/505-10-S99-1>Reference 43: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic-235-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210.4-08\(g\)\(1\)\(ii\)\)-Publisher-FASB-URI](http://www.xbrl.org/2009/role/commonPracticeRef-Topic-235-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210.4-08(g)(1)(ii))-Publisher-FASB-URI) <https://asc.fasb.org/1943274/2147480678/235-10-S99-1>Reference 44: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic-323-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-3-Subparagraph-\(c\)-Publisher-FASB-URI](http://www.xbrl.org/2009/role/commonPracticeRef-Topic-323-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-3-Subparagraph-(c)-Publisher-FASB-URI) <https://asc.fasb.org/1943274/2147481687/323-10-50-3>Reference 45: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic-825-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-28-Subparagraph-\(f\)-Publisher-FASB-URI](http://www.xbrl.org/2009/role/commonPracticeRef-Topic-825-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-28-Subparagraph-(f)-Publisher-FASB-URI) <https://asc.fasb.org/1943274/2147482907/825-10-50-28>Reference 46: <http://fasb.org/us-gaap/role/ref/legacyRef-Name-Accounting-Standards-Codification-Topic-810-SubTopic-10-Section-45-Paragraph-15-Publisher-FASB-URI> <https://asc.fasb.org/1943274/2147481231/810-10-45-15>Reference 47: <http://fasb.org/us-gaap/role/ref/legacyRef-Name-Accounting-Standards-Codification-Topic-810-SubTopic-10-Section-45-Paragraph-16-Publisher-FASB-URI> <https://asc.fasb.org/1943274/2147481231/810-10-45-16>Reference 48: <http://fasb.org/us-gaap/role/ref/legacyRef-Name-Accounting-Standards-Codification-Topic-810-SubTopic-10-Section-55-Paragraph-41-Publisher-FASB-URI> <https://asc.fasb.org/1943274/2147481175/810-10-55-41>Reference 49: [http://www.xbrl.org/2003/role/disclosureRef-Topic-350-SubTopic-60-Name-Accounting-Standards-Codification-Section-65-Paragraph-1-Subparagraph-\(b\)-Publisher-FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-350-SubTopic-60-Name-Accounting-Standards-Codification-Section-65-Paragraph-1-Subparagraph-(b)-Publisher-FASB-URI) <https://asc.fasb.org/1943274/2147476166/350-60-65-1>~~

[+ Details](#)

Name:us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant XML 21 R6.htm IDEA: XBRL DOCUMENT

Consolidated Statements of Cash Flows - USD (\$) \$ in Thousands 9 Months Ended

Jun. 30, 2024

Jun. 30, 2023

CASH FLOWS FROM OPERATING ACTIVITIES: - Net loss\$ (436,349)\$ (98,260)Adjustments to reconcile net loss to net cash flow from operating activities - Stock-based compensation54,49459,949Depreciation and amortization13,5708,634Amortization (accretion) of note premiums/discounts7,886(1,030)Realized gain on investments(80)0 Non-cash interest expense on liability related to the sale of future royalties17,70513,064Changes in operating assets and liabilities: - Accounts receivable0164Prepaid expenses and other assets(1,746)27,913Accounts payable2,7855,001Accrued expenses13,086(32,082)Deferred revenue(866)(113,144)Operating lease, net3,8801,827Net cash used in operating activities(325,635)(127,964)CASH FLOWS FROM INVESTING ACTIVITIES: - Purchases of property and equipment(117,180)(112,830)Purchases of investments(428,611)(233,984)Proceeds from sales and maturities of investments348,642220,150Net cash used in investing activities(197,149)(126,664)CASH FLOWS FROM FINANCING ACTIVITIES: - Proceeds from the exercises of stock options2,1662,232Proceeds from the issuance of common stock, net of offering costs429,2650Proceeds from the sale of future royalties50,000250,000Net cash provided by financing activities481,431252,232Net decrease in cash, cash equivalents and restricted cash(41,353)(2,396)Effect of exchange rate on cash, cash equivalents and restricted cash(139)(275)CASH, CASH EQUIVALENTS AND RESTRICTED CASH: - BEGINNING OF PERIOD110,891108,005END OF PERIOD69,399105,334Supplementary disclosure of cash flows: - Income taxes paid(3,062)0Supplemental disclosure of non-cash investing activities: - Capital expenditures included in accrued expenses\$ 6,909\$ 15,624

[- Definition](#)

Non-Cash Interest Expense, Liability Related To Sale Of Future Royalties

[+ References](#)

No definition available.

[+ Details](#)

Name:arwr_NonCashInterestExpenseLiabilityRelatedToSaleOffFutureRoyalties Namespace Prefix:arwr_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

[- Definition](#)

Proceeds from Sale of Future Royalties

[+ References](#)

No definition available.

[+ Details](#)

Name:arwr_ProceedsFromSaleOffFutureRoyalties Namespace Prefix:arwr_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

[- References](#)

No definition available.

[+ Details](#)

Name:us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

[- Definition](#)

Future cash outflow to pay for purchases of fixed assets that have occurred.

[+ References](#)

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 50 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4>

~~10-Section 50-Paragraph 3-Publisher FASB-URI <https://asc.fasb.org/1943274/2147482913/230-10-50-3>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 230-SubTopic 10-Section 50-Paragraph 5-Publisher FASB-URI https://asc.fasb.org/1943274/2147482913/230-10-50-5>~~

[+ Details](#)

~~Name:us-gaap-CapitalExpendituresIncurredButNotYetPaid Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration~~

[- Definition](#)

~~Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.~~

[+ References](#)

~~Reference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 230-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 8-Publisher FASB-URI https://asc.fasb.org/1943274/2147482913/230-10-50-8>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 24-Publisher FASB-URI https://asc.fasb.org/1943274/2147482740/230-10-45-24>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 230-SubTopic 10-Section 45-Paragraph 4-Publisher FASB-URI https://asc.fasb.org/1943274/2147482740/230-10-45-4>~~

[+ Details](#)

~~Name:us-gaap-CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant~~

[- References](#)

~~No definition available.~~

[+ Details](#)

~~Name:us-gaap-CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration~~

[- Definition](#)

~~Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.~~

[+ References](#)

~~Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 24-Publisher FASB-URI https://asc.fasb.org/1943274/2147482740/230-10-45-24>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 45-Paragraph 1-SubTopic 230-Topic 830-Publisher FASB-URI https://asc.fasb.org/1943274/2147477401/830-230-45-1>~~

[+ Details](#)

Name:us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect_Namespace-Prefix:us-gaap_Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

-References

No definition available.

+Details

Name:us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_Namespace-Prefix:us-gaap_Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

-Definition

The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.

+References

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 45-Paragraph 28-Subparagraph \(b\)-SubTopic 10-Topic 230-Publisher FASB-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 45-Paragraph 28-Subparagraph (b)-SubTopic 10-Topic 230-Publisher FASB-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28)Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 360-SubTopic 10-Section 50-Paragraph 1-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482099/360-10-50-1](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 360-SubTopic 10-Section 50-Paragraph 1-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482099/360-10-50-1)

+Details

Name:us-gaap_DepreciationAndAmortization_Namespace-Prefix:us-gaap_Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

-Definition

Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.

+References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 830-SubTopic 230-Name Accounting Standards Codification-Section 45-Paragraph 1-Publisher FASB-URI https://asc.fasb.org/1943274/2147477401/830-230-45-1>

+Details

Name:us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_Namespace-Prefix:us-gaap_Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

-Definition

Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.

+References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 230-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2A-Publisher FASB-URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 23-Publisher FASB-URI https://asc.fasb.org/1943274/2147482685/740-10-50-23>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 22-Publisher FASB-URI https://asc.fasb.org/1943274/2147482685/740-10-50-22>Reference 4: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 230-SubTopic 10-Section 50-Paragraph 2-Publisher FASB-URI https://asc.fasb.org/1943274/2147482913/230-10-50-2>

[+ Details](#)

Name:us-gaap_IncomeTaxesPaidNet_Namespace Prefix:us-gaap_Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

[- Definition](#)

The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.

[+ References](#)

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 45-Paragraph 28-Subparagraph (a)-SubTopic 10-Topic 230-Publisher FASB-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28

[+ Details](#)

Name:us-gaap_IncreaseDecreaseInAccountsPayable_Namespace Prefix:us-gaap_Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

[- Definition](#)

The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.

[+ References](#)

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 45-Paragraph 28-Subparagraph (a)-SubTopic 10-Topic 230-Publisher FASB-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28

[+ Details](#)

Name:us-gaap_IncreaseDecreaseInAccountsReceivable_Namespace Prefix:us-gaap_Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

[- Definition](#)

The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.

[+ References](#)

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 45-Paragraph 28-Subparagraph (a)-SubTopic 10-Topic 230-Publisher FASB-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28

[+ Details](#)

Name:us-gaap_IncreaseDecreaseInAccruedLiabilities_Namespace Prefix:us-gaap_Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

[- Definition](#)

Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.

[+ References](#)

Reference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 912-SubTopic 310-Name Accounting Standards Codification-Section 45-Paragraph 11-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478345/912-310-45-11Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 230-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 28-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28

[+ Details](#)

Name:us-gaap_IncreaseDecreaseInContractWithCustomerLiability_Namespace Prefix:us-gaap_Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

[- References](#)

No definition available.

[+ Details](#)

Name:us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_Namespace Prefix:us-gaap_Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

[- Definition](#)

Amount of increase (decrease) in obligation for operating lease.

[+ References](#)

Reference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 230-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 28-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 230-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 28-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28)Reference 2: [http://www.xbrl.org/2009/role/commonPracticeRef-Name Accounting Standards Codification-Section 50-Paragraph 4-Subparagraph \(g\)\(1\)-SubTopic 20-Topic 842-Publisher FASB-URI https://asc.fasb.org/1943274/2147478964/842-20-50-4](http://www.xbrl.org/2009/role/commonPracticeRef-Name Accounting Standards Codification-Section 50-Paragraph 4-Subparagraph (g)(1)-SubTopic 20-Topic 842-Publisher FASB-URI https://asc.fasb.org/1943274/2147478964/842-20-50-4)

+ Details

Name:us-gaap_IncreaseDecreaseInOperatingLeaseLiability_Namespace Prefix:us-gaap_Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

Amount of increase (decrease) in prepaid expenses, and assets classified as other.

+ References

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 45-Paragraph 28-Subparagraph \(a\)-SubTopic 10-Topic 230-Publisher FASB-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 45-Paragraph 28-Subparagraph (a)-SubTopic 10-Topic 230-Publisher FASB-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28)

+ Details

Name:us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_Namespace Prefix:us-gaap_Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

- Definition

Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.

+ References

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph \(SX 210.5-03\(8\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph (SX 210.5-03(8))-Publisher FASB-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2)

+ Details

Name:us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_Namespace Prefix:us-gaap_Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

- Definition

Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.

+ References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 230-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 24-Publisher FASB-URI https://asc.fasb.org/1943274/2147482740/230-10-45-24>

+ Details

Name:us-gaap_NetCashProvidedByUsedInFinancingActivities_Namespace Prefix:us-gaap_Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- References

No definition available.

+ Details

Name:us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_Namespace Prefix:us-gaap_Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

- Definition

Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.

+ References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 230-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 24-Publisher FASB-URI https://asc.fasb.org/1943274/2147482740/230-10-45-24>

[+ Details](#)

Name:us-gaap_NetCashProvidedByUsedInInvestingActivities Namespace Prefix:us-gaap_ Data Type:xbri:monetaryItemType Balance Type:debit Period Type:duration

[- References](#)

No definition available.

[+ Details](#)

Name:us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract Namespace Prefix:us-gaap_ Data Type:xbri:stringItemType Balance Type:na Period Type:duration

[- Definition](#)

Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.

[+ References](#)

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 20-Publisher FASB-URI https://asc.fasb.org/1943274/2147482740/230-10-45-20>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 24-Publisher FASB-URI https://asc.fasb.org/1943274/2147482740/230-10-45-24>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 25-Publisher FASB-URI https://asc.fasb.org/1943274/2147482740/230-10-45-25>

[+ Details](#)

Name:us-gaap_NetCashProvidedByUsedInOperatingActivities Namespace Prefix:us-gaap_ Data Type:xbri:monetaryItemType Balance Type:na Period Type:duration

[- References](#)

No definition available.

[+ Details](#)

Name:us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract Namespace Prefix:us-gaap_ Data Type:xbri:stringItemType Balance Type:na Period Type:duration

[- Definition](#)

The cash outflow associated with the purchase of all investments (debt, security, other) during the period.

[+ References](#)

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 13-Publisher FASB-URI https://asc.fasb.org/1943274/2147482740/230-10-45-13>

[+ Details](#)

Name:us-gaap_PaymentsToAcquireInvestments Namespace Prefix:us-gaap_ Data Type:xbri:monetaryItemType Balance Type:credit Period Type:duration

[- Definition](#)

The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.

[+ References](#)

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 13-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482740/230-10-45-13](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 13-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482740/230-10-45-13)

[+ Details](#)

Name:us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Namespace Prefix:us-gaap_ Data Type:xbri:monetaryItemType Balance Type:credit Period Type:duration

[- Definition](#)

The cash inflow from the additional capital contribution to the entity.

[+ References](#)

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 45-Paragraph 14-Subparagraph \(a\)-SubTopic 10-Topic 230-Publisher FASB-URI https://asc.fasb.org/1943274/2147482740/230-10-45-14](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 45-Paragraph 14-Subparagraph (a)-SubTopic 10-Topic 230-Publisher FASB-URI https://asc.fasb.org/1943274/2147482740/230-10-45-14)

+ Details

Name:us-gaap_ProceedsFromIssuanceOfCommonStock **Namespace Prefix:**us-gaap_ **Data Type:**xbri:monetaryItemType **Balance Type:**debit **Period Type:**duration

- Definition

The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.

+ References

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 230-SubTopic 10-Section 45-Paragraph 12-Publisher FASB-URI https://asc.fasb.org/1943274/2147482740/230-10-45-12>

+ Details

Name:us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments **Namespace Prefix:**us-gaap_ **Data Type:**xbri:monetaryItemType **Balance Type:**debit **Period Type:**duration

- Definition

Amount of cash inflow from exercise of option under share-based payment arrangement.

+ References

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 45-Paragraph 14-Subparagraph \(a\)-SubTopic 10-Topic 230-Publisher FASB-URI https://asc.fasb.org/1943274/2147482740/230-10-45-14](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 45-Paragraph 14-Subparagraph (a)-SubTopic 10-Topic 230-Publisher FASB-URI https://asc.fasb.org/1943274/2147482740/230-10-45-14)**Reference 2:** [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 50-Paragraph 2A-Subparagraph \(a\)-SubTopic 10-Topic 718-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 50-Paragraph 2A-Subparagraph (a)-SubTopic 10-Topic 718-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A)

+ Details

Name:us-gaap_ProceedsFromStockOptionsExercised **Namespace Prefix:**us-gaap_ **Data Type:**xbri:monetaryItemType **Balance Type:**debit **Period Type:**duration

- Definition

The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.

+ References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 6-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6>**Reference 2:** <http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 9-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-9>**Reference 3:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph \(g\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph (g)-Publisher FASB-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1)**Reference 4:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 323-Name Accounting Standards Codification-Section 65-Paragraph 2-Subparagraph \(g\)\(3\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 323-Name Accounting Standards Codification-Section 65-Paragraph 2-Subparagraph (g)(3)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2)**Reference 5:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.4-08\)\(g\)\(1\)\(ii\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.4-08)(g)(1)(ii)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1)**Reference 6:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3)**Reference 7:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-Subparagraph \(f\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28](http://www.xbrl.org/2003/role/disclosureRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-Subparagraph (f)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28)**Reference 8:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(b\)\(2\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (b)(2)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-1)**Reference 9:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph \(f\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph (f)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1)**Reference 10:** <http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 8-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-8>**Reference 11:** [http://www.xbrl.org/2003/role/exampleRef-Topic 946-SubTopic 830-Name Accounting Standards Codification-Section 55-Paragraph 1-Subparagraph \(SX 210.7-04\)\(16\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1](http://www.xbrl.org/2003/role/exampleRef-Topic 946-SubTopic 830-Name Accounting Standards Codification-Section 55-Paragraph 1-Subparagraph (SX 210.7-04)(16))-Publisher FASB-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1)**Reference 12:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 205-Name Accounting Standards Codification-Section 45-Paragraph 3-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/214748009/946-205-45-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 205-Name Accounting Standards Codification-Section 45-Paragraph 3-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/214748009/946-205-45-3)**Reference 13:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.6-07\(9\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.6-07(9))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1)**Reference 14:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.7-04\(16\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482765/220-10-50-6](http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.7-04(16))-Publisher FASB-URI https://asc.fasb.org/1943274/2147482765/220-10-50-6)**Reference 15:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.13-01\(a\)\(4\)\(i\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.13-01(a)(4)(i))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)**Reference 16:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(ii\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(ii))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)**Reference 17:** <http://www.xbrl.org/2003/role/disclosureRef-Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 19-Publisher FASB-URI https://asc.fasb.org/1943274/2147481231/810-10-45-19>**Reference 18:** <http://www.xbrl.org/2009/role/commonPracticeRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 6-Publisher FASB-URI https://asc.fasb.org/1943274/2147482765/220-10-50-6>**Reference 19:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(i\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(i))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)**Reference 20:** [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(ii\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(ii))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)**Reference 21:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iv))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)**Reference 22:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iii)(B))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)**Reference 23:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(A\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iii)(A))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)**Reference 24:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(5\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(5))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)**Reference 25:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(A\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iii)(A))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)**Reference 26:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(B\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iii)(B))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)**Reference 27:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(iv\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iv))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)**Reference 28:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(5\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(5))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1)**Reference 29:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 942-SubTopic 235-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.9-05\(b\)\(2\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 942-SubTopic 235-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.9-05(b)(2))-Publisher FASB-URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1)**Reference 30:** <http://www.xbrl.org/2003/role/disclosureRef-Topic 205-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 7-Publisher FASB-URI https://asc.fasb.org/1943274/2147483499/205-20-50-7>**Reference 31:** <http://www.xbrl.org/2003/role/exampleRef-Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 4J-Publisher FASB-URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J>**Reference 32:** <http://www.xbrl.org/2003/role/exampleRef-Topic 810-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 4J-Publisher FASB-URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J>

Codification -Section 55 -Paragraph 4K -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481175/810-10-55-4K>Reference 33:
[http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification -Section 45-Paragraph 1A-Subparagraph \(a\)-Publisher FASB](http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification -Section 45-Paragraph 1A-Subparagraph (a)-Publisher FASB)
-URI <https://asc.fasb.org/1943274/2147482790/220-10-45-1A>Reference 34: [http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification -Section 45-Paragraph 1B-Subparagraph \(a\)-Publisher FASB](http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification -Section 45-Paragraph 1B-Subparagraph (a)-Publisher FASB)-URI <https://asc.fasb.org/1943274/2147482790/220-10-45-1B>Reference 35:
<http://www.xbrl.org/2003/role/disclosureRef-Topic 230-SubTopic 10-Name Accounting Standards Codification -Section 45-Paragraph 2-Publisher FASB>-URI
<https://asc.fasb.org/1943274/2147482740/230-10-45-2>Reference 36: [http://www.xbrl.org/2003/role/disclosureRef-Topic 810-SubTopic 10-Name Accounting Standards Codification -Section 50-Paragraph 1A-Subparagraph \(a\)\(1\)-Publisher FASB](http://www.xbrl.org/2003/role/disclosureRef-Topic 810-SubTopic 10-Name Accounting Standards Codification -Section 50-Paragraph 1A-Subparagraph (a)(1)-Publisher FASB)-URI <https://asc.fasb.org/1943274/2147481203/810-10-50-1A>Reference 37:
[http://www.xbrl.org/2003/role/disclosureRef-Topic 810-SubTopic 10-Name Accounting Standards Codification -Section 50-Paragraph 1A-Subparagraph \(c\)\(1\)-Publisher FASB](http://www.xbrl.org/2003/role/disclosureRef-Topic 810-SubTopic 10-Name Accounting Standards Codification -Section 50-Paragraph 1A-Subparagraph (c)(1)-Publisher FASB)-URI <https://asc.fasb.org/1943274/2147481203/810-10-50-1A>

+ Details

Name:us-gAAP_ProfitLoss_Namespace-Prefix:us-gAAP_Data-Type:xbrli:monetaryItemType-Balance-Type:credit-Period-Type:duration

- Definition

Amount of realized gain (loss) on investment.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic-944-SubTopic-220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210-7-04(3)(a))-Publisher FASB-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

+ Details

Name:us-gAAP_RealizedInvestmentGainsLosses_Namespace-Prefix:us-gAAP_Data-Type:xbrli:monetaryItemType-Balance-Type:credit-Period-Type:duration

- Definition

Amount of noncash expense for share-based payment arrangement.

+ References

Reference 1: http://fasb.org/us-gAAP/role/ref/legacyRef-Name Accounting Standards Codification-Section 45-Paragraph 28-Subparagraph (a)-SubTopic 10-Topic 230-Publisher FASB-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28

+ Details

Name:us-gAAP_ShareBasedCompensation_Namespace-Prefix:us-gAAP_Data-Type:xbrli:monetaryItemType-Balance-Type:debit-Period-Type:duration

- References

No definition available.

+ Details

Name:us-gAAP_SupplementalCashFlowInformationAbstract_Namespace-Prefix:us-gAAP_Data-Type:xbrli:stringItemType-Balance-Type:na-Period-Type:duration-XML-22-R7.htm

IDEA: XBRL DOCUMENT

Organization and Significant Accounting Policies9 Months Ended

Jun. 30, 2024

Accounting Policies [Abstract] Organization and Significant Accounting PoliciesORGANIZATION AND SIGNIFICANT ACCOUNTING POLICIES

General and Recent Developments

Arrowhead Pharmaceuticals, Inc. and its subsidiaries (referred to herein collectively as the “Company”) are primarily engaged in developing medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, the Company’s therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference (“RNAi”) is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. The Company’s RNAi-based therapeutics may leverage this natural pathway of gene silencing to target and shut down specific disease-causing genes.

The following table presents the Company’s current pipeline:

	Therapeutic Area	Name	Stage	Product Rights	Cardiometabolic
plozasiran (ARO-APOC3)					
Phase 3 Arrowhead					
zodasiran (ARO-ANG2) Phase 2b Arrowhead					
olpasiran Phase 3 Amgen/Pulmonary ARO-RAGE					
Phase 1/2a Arrowhead ARO-MUC5AC Phase 1/2a Arrowhead ARO-MMP7					
Phase 1/2a Arrowhead Liver GSK-4522990 Phase 2b GSK					
fazirsiran Phase 3 Jakeda and Arrowhead					
daplusiran/tomigisiran (GSK5637608, formerly INI-3089) Phase 2 GSK ARO-PNPLA3					
Phase 1 Arrowhead ARO-C3					
Phase 1/2a Arrowhead ARO-CFB Phase 1/2a Arrowhead					
Muscle ARO-DUX4 Phase 1/2a Arrowhead ARO-BM3 Phase 1/2a Arrowhead					
Central Nervous System (CNS) Various Pre-Clinical Arrowhead					

The Company operates lab facilities in California and Wisconsin, where its research and development activities, including the development of RNAi therapeutics, take place. The Company’s principal executive offices are located in Pasadena, California.

Thus far in fiscal 2024, the Company has continued to develop and advance its pipeline and partnered candidates. Several key recent developments include:

- Announced plans to advance investigational plozasiran into a Phase 3 cardiovascular outcomes trial called CAPITAN, which is designed to enroll patients with mixed hyperlipidemia and residual risk of atherosclerotic cardiovascular disease.
- Announced successful top-line results from the pivotal Phase 3 PALISADE study of investigational plozasiran in patients with familial chylomicronemia syndrome (FCS). The Company highlighted recent data for its cardiometabolic pipeline at its June 25, 2024, Cardiometabolic event.
- Presented preclinical data on ARO-INHBE for the treatment of obesity and metabolic diseases at the American Diabetes Association 84th Scientific Sessions. INHBE small interfering RNA (siRNA) administration resulted in multiple promising findings including: (1) 95% reduction in INHBE mRNA expression; (2) 19% suppression of body weight compared to saline controls; (3) 26% loss of fat mass; and (4) preservation of lean mass.
- Announced results from the Phase 2b double-blind, randomized ARCHES-2 study of investigational zodasiran in patients with mixed hyperlipidemia.
- Announced that new interim clinical data on ARO-RAGE achieves high level of gene knockdown in patients with asthma.
- Completed enrollment in Amgen’s Phase 3 OCEAN(a) – outcome trial of olpasiran, triggering a \$50.0 million milestone payment to the Company, which was paid in the third quarter of fiscal 2024.
- Presented final data from the double-blind treatment period of the Company’s Phase 2 SHASTA-2 study of investigational plozasiran in patients with severe Hypertriglyceridemia. Results from the SHASTA-2 study showed dramatic, consistent, and sustained reductions in Apolipoprotein C-III (APOC3) and triglycerides and improvement in multiple atherogenic lipoprotein levels.
- Announced an Expanded Access Program (“EAP”) to make investigational plozasiran available outside of a clinical trial for qualifying patients with FCS.

- Initiated a Phase 1/2a clinical trial of ARO-DM1, being developed as a potential treatment for type 1 myotonic dystrophy (DM1), the most common adult-onset muscular dystrophy;
- Filled an application for clearance to initiate a Phase 1/2a clinical trial of ARO-CFB, being developed as a potential treatment for complement-mediated renal disease;
- Entered into an Amended and Restated License Agreement with GSK, pursuant to which GSK received a worldwide, exclusive license to develop and commercialize daplusiran/tomligisiran (GSK5637608, formerly JN-3989). Daplusiran/tomligisiran had previously been licensed to Janssen Pharmaceuticals, Inc. See Note 2.

Consolidation and Basis of Presentation

The interim Consolidated Financial Statements include the accounts of Arrowhead Pharmaceuticals, Inc. and its subsidiaries (wholly-owned subsidiaries and a variable interest entity for which the Company is the primary beneficiary). Subsidiaries refer to Arrowhead Madison, Inc., Visirna Therapeutics, Inc. ("Visirna"), and Arrowhead Australia Pty Ltd. For subsidiaries in which the Company owns or is exposed to less than 100% of the economics, the Company records net loss attributable to noncontrolling interests in its consolidated statements of operations equal to the percentage of the economic or ownership interests retained in such entity by the respective noncontrolling party.

The interim Consolidated Financial Statements have been prepared in conformity with U.S. generally accepted accounting principles ("GAAP"). The financial data of the Company included herein are unaudited. In the opinion of management, all material adjustments of a normal recurring nature have been made to present fairly the Company's financial position at June 30, 2024 and the results of operations and cash flows for the periods presented. All intercompany transactions and balances have been eliminated. Certain prior period amounts have been reclassified to conform with the current period presentation.

Certain financial information that is normally included in annual financial statements prepared in accordance with GAAP, but that is not required for interim reporting purposes, has been omitted from the accompanying interim consolidated financial statements and related notes. Readers are urged to review the Company's Annual Report on Form 10-K for the year ended September 30, 2023 for more complete descriptions and discussions. Operating results and cash flows for the nine months ended June 30, 2024 are not necessarily indicative of the results that may be expected for the fiscal year ending September 30, 2024.

Liquidity

The Company's primary sources of financing have been through the sale of its equity securities, revenue from its licensing and collaboration agreements and the sale of certain future royalties. Research and development activities have required significant capital investment since the Company's inception and are expected to continue to require significant cash expenditure in the future, particularly as the Company's pipeline of drug candidates and its headcount have both expanded. Additionally, significant capital investment will be required as the Company's pipeline matures into later stage clinical trials.

As of June 30, 2024, the Company had \$69.4 million in cash, cash equivalents and restricted cash (\$2.2 million in restricted cash) and \$367.3 million in available-for-sale securities to fund operations. During the nine months ended June 30, 2024, the Company's cash, cash equivalents and restricted cash and investments balance increased by \$33.0 million which was primarily due to the net proceeds of \$429.3 million from the underwritten offering in January 2024 discussed below, offset by ongoing expenses related to the Company's research and development programs, general and administrative expenses and capital expenditures.

On January 2, 2024, the Company entered into an underwriting agreement with Jefferies LLC, BofA Securities, Inc., and Cowen and Company, LLC, as representatives of the several underwriters. The Company issued 15,790,000 shares of common stock at a price of \$28.50 per share. The aggregate purchase price paid by investors was \$450.0 million and the Company received net proceeds of \$429.3 million after deducting advisory fees and offering expenses.

In total, the Company is eligible to receive up to \$2.7 billion in developmental, regulatory and sales milestones, and may receive various royalties on net sales from its licensing and collaboration agreements, subject to the terms and conditions of those agreements. The revenue recognition for these collaboration agreements is discussed further in Note 2.

Summary of Significant Accounting Policies

There have been no changes to the significant accounting policies disclosed in the Company's most recent Annual Report on Form 10-K for the fiscal year ended September 30, 2023.

Uncertainty in Income Taxes

The Company recorded an income tax benefit of \$3.3 million and expense of \$0.8 million for the nine months ended June 30, 2024 and 2023, respectively. The income tax benefit is primarily due to the discrete change in the Company's uncertain tax positions related to the statute of limitation expiration.

Recent Accounting Pronouncements

In December 2023, the Financial Accounting Standards Board ("FASB") issued Accounting Standard Update ("ASU") 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, to improve its income tax disclosure requirements. Under the guidance, entities must annually (1) disclose specific categories in the rate reconciliation and (2) provide additional information for reconciling items that meet a quantitative threshold. This guidance will become effective for the Company beginning on October 1, 2025. The Company does not expect any material impact on its consolidated financial statements and related disclosures resulting from applying this ASU.

In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, which is intended to improve reportable segment disclosure requirements, primarily through additional disclosures about significant segment expenses. The guidance requires public companies with a single reportable segment to provide all disclosures required under ASC 280. In addition, the guidance requires public companies to include in interim reports all disclosures related to a reportable segment's profit or loss and assets that are currently required in annual reports. The standard is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The amendments should be applied retrospectively to all prior periods presented in the financial statements. The Company does not expect any material impact on its consolidated financial statements and related disclosures resulting from applying this ASU.

-References

No definition available.

+ Details
Name:us-gaap_AccountingPoliciesAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

-Definition

The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements.

+ References

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic-235-Name-Accounting-Standards-Codification-Publisher-FASB-URI>
<https://asc.fasb.org/235/tableOfContent>Reference 2: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic-275-Name-Accounting-Standards-Codification-Publisher-FASB-URI>
<https://asc.fasb.org/275/tableOfContent>Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic-810-Name-Accounting-Standards-Codification-Publisher-FASB-URI>
<https://asc.fasb.org/810/tableOfContent>Reference 4: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic-205-Name-Accounting-Standards-Codification-Publisher-FASB-URI>
<https://asc.fasb.org/205/tableOfContent>

+ Details

Name:us-gaap_OrganizationConsolidationAndPresentationOffFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock Namespace Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration XML 23-R8.htm IDEA: XBRL DOCUMENT
Collaboration and License Agreements9 Months Ended
Jun. 30, 2024
Organization, Consolidation and Presentation of Financial Statements [Abstract] Collaboration and License Agreements
COLLABORATION AND LICENSE AGREEMENTSThe Company also performs manufacturing and development work pursuant to a Clinical Supply Agreement between the parties contemplated by the Visirna License Agreement. The Company received \$0.1 million and \$0.9 million as consideration for this manufacturing and development work for the nine months ended June 30, 2024 and 2023, respectively. There were no contract assets and liabilities recorded as of June 30, 2024.

The following table provides a summary of revenue recognized.

																							Three Months Ended June 30, Nine Months Ended June 30, 2024-2023-2024-2023 (in thousands)								
GSK	\$	—	\$277	\$2,685	\$29,600	Horizon	=	1,539	=	23,206	Takeda	=	14,009	866	146,477	Janssen	=	—	=	355	Amgen	=	—	=	25,000	Total	\$	—	\$15,823	\$3,951	\$224,638
The following table summarizes the balance of receivables and contract liabilities related to the Company's collaboration and license agreements:																															

receivable \$— \$— Contract liabilities included in deferred revenue \$— \$866 June 30, 2024 September 30, 2023 (in thousands) Receivables included in accounts

Glaxosmithkline Intellectual Property (No. 3) Limited ("GSK")
GSK-HSD License Agreement

On November 22, 2021, GSK and the Company entered into an Exclusive License Agreement (the "GSK-HSD License Agreement"). Under the GSK-HSD License Agreement, GSK has received an exclusive license for GSK-4532990 (formerly ARO-HSD). The exclusive license is worldwide with the exception of greater China. GSK is wholly responsible for all clinical development and commercialization of GSK-4532990 in its territory. GSK dosed the first patient in a Phase 2b trial in March 2023 and paid a \$30.0 million milestone payment to the Company in the third quarter of fiscal 2023.

The Company is eligible for an additional payment of \$100.0 million upon achieving the first patient dosed in a Phase 3 trial. Furthermore, should the Phase 3 trial read out positively, and the potential new medicine receives regulatory approval in major markets, the deal provides for commercial milestone payments to the Company of up to \$190.0 million at first commercial sale, and up to \$590.0 million in sales-related milestone payments. The Company is further eligible to receive tiered royalties on net product sales in a range of mid-teens to twenty percent.

GSK-HBV Agreement

On December 11, 2023, the Company entered into an Amended and Restated License Agreement with GSK (the “GSK-HBV Agreement”) pursuant to which GSK received a worldwide, exclusive license to develop and commercialize daplusiran/tomligisiran (GSK5637608, formerly JNJ-3989), the Company’s third-generation subcutaneously administered RNAi therapeutic candidate being developed as a potential therapy for patients with chronic hepatitis B virus infection. GSK5637608 had previously been licensed to Janssen in October 2018.

Under the terms of the GSK-HBV Agreement, the Company received \$2.7 million in December 2023, upon signing the amended GSK-HBV Agreement. The Company is eligible to receive up to \$832.5 million in development and sales milestone payments under the GSK-HBV Agreement.

There were no contract assets and liabilities recorded as of June 30, 2024.

Horizon Therapeutics Ireland DAC (“Horizon”)

In June 2021, Horizon and the Company entered into a collaboration and license agreement (the “Horizon License Agreement”). Under the terms of the Horizon License Agreement, Horizon received a worldwide exclusive license for HZN-457, a clinical-stage medicine being developed by Horizon as a potential treatment for people with uncontrolled gout.

At the inception of the Horizon License Agreement, the Company identified one distinct performance obligation. The Company determined that the key deliverables included the license and certain R&D services, including the Company’s responsibilities to conduct all activities through the preclinical stages of development of HZN-457 (the “Horizon R&D Services”). The Company received a \$40.0 million upfront payment in July 2021. Revenue was recognized on a straight-line basis over the timeframe for completing the Horizon R&D Services, concluding in the first quarter of 2023. Further, the Company received an additional \$15.0 million upon Horizon’s initiation of a Phase 1 clinical trial in January 2023.

On October 6, 2023, Amgen completed its acquisition of Horizon and subsequently notified the Company of Amgen’s intent to terminate the HZN-457 license. Horizon exercised its right to terminate the Horizon License Agreement for convenience, which took effect on December 21, 2023.

Takeda Pharmaceutical Company Limited (“Takeda”)

In October 2020, Takeda and the Company entered into an Exclusive License and Co-Funding Agreement (the “Takeda License Agreement”). Under the Takeda License Agreement, Takeda and the Company will co-develop the Company’s fazirsiran program (formerly TAK-999 and ARO-AAT), the Company’s second-generation subcutaneously administered RNAi therapeutic candidate being developed as a treatment for liver disease associated with alpha-1 antitrypsin deficiency. Within the United States, fazirsiran, if approved, will be co-commercialized under a 50/50 profit sharing structure. Outside the United States, Takeda received an exclusive license to commercialize fazirsiran and will lead the global commercialization strategy, while the Company will be eligible to receive tiered royalties of 20% to 25% on net

sales.

At the inception of the Takeda License Agreement, the Company identified one distinct performance obligation. The Company determined that the key deliverables included the license and certain R&D services including the Company’s responsibilities to complete the initial portion of the SEQUOIA study, to complete the ongoing Phase 2 AROAAT2002 study and to ensure certain manufacturing of fazirsiran drug product is completed and delivered to Takeda (the “Takeda R&D Services”). Due to the specialized and unique nature of these Takeda R&D Services and their direct relationship with the license, the Company determined that these deliverables represent one distinct bundle and, thus, one performance obligation. Beyond the Takeda R&D Services, which are the responsibility of the Company, Takeda will be responsible for managing future clinical development and commercialization outside the United States. Within the United States, the Company will also participate in co-development and co-commercialization efforts and will co-fund these efforts with Takeda as part of the 50/50 profit sharing structure within the United States. The Company considers the collaborative activities, including the co-development and co-commercialization, to be a separate unit of account within Topic 808, and as such, these co-funding amounts are recorded as research and development expenses or general and administrative expenses as appropriate.

Under the terms of the Takeda License Agreement, the Company received \$300.0 million as an upfront payment in January 2021 and an additional \$40.0 million upon Takeda’s initiation of a Phase 3 REDWOOD clinical study of fazirsiran in March 2023, and is eligible to receive up to \$527.5 million in additional potential development, regulatory and commercial milestones.

The Company allocated the total \$300.0 million initial transaction price to its one distinct performance obligation for the fazirsiran license and the associated Takeda R&D Services. Revenue was recognized using the input method (based on actual patient visits completed versus total estimated visits completed for the ongoing SEQUOIA and AROAAT2002 clinical studies). The Phase 2 study visits for patients in the SEQUOIA and AROAAT2002 studies concluded by December 31, 2023, and the Company has substantially completed its performance obligation under the Takeda License Agreement. As such, all revenue has been fully recognized as of December 31, 2023. There were no further deferred revenue and contract liabilities as of June 30, 2024.

The Company recorded \$21.3 million as accrued expenses as of June 30, 2024 that was primarily driven by co-development and co-commercialization activities.

Janssen Pharmaceuticals, Inc. (“Janssen”)

On April 7, 2023, Janssen voluntarily terminated its collaboration agreement with the Company and the Company regained full rights to ARO-PNPLA3, formerly called JNJ-75220795. ARO-PNPLA3 is in Phase 1 clinical trials, which are now being developed by the Company.

Further, on December 11, 2023, the Company entered into the GSK-HBV Agreement, as discussed above, pursuant to which GSK received an exclusive license for daplusiran/tomligisiran (GSK5637608, formerly JNJ-3989). Daplusiran/tomligisiran had previously been licensed to Janssen in October 2018.

Amgen Inc. (“Amgen”)

In September 2016, Amgen and the Company entered into two collaboration and license agreements and a common stock purchase agreement. Under the Second Collaboration and License Agreement (the “Olpasiran Agreement”), Amgen received a worldwide, exclusive license to the Company’s novel RNAi olpasiran (previously referred to as AMG-890 or ARO-LPA) program. These RNAi molecules are designed to reduce elevated lipoprotein(a), which is a genetically validated, independent risk factor for atherosclerotic cardiovascular disease. Under the Olpasiran Agreement, Amgen is wholly responsible for clinical development and commercialization.

Under the Olpasiran Agreement, the Company has received \$35.0 million in upfront payments and \$21.5 million in the form of an equity investment by Amgen in the Company’s common stock. Further, the Company received an additional \$55.0 million in milestone payments, \$10.0 million upon Amgen’s initiation of a Phase 1 study in September 2018, \$20.0 million upon its initiation of a Phase 2 clinical study in July 2020, and \$25.0 million upon its first subject enrollment in a Phase 3 trial in December 2022. The Company has substantially completed its performance obligations under the Olpasiran Agreement. There were no contract assets and liabilities recorded as of June 30, 2024.

In November 2022, Royalty Pharma Investments 2019 ICAV (“Royalty Pharma”) and the Company entered into a Royalty Purchase Agreement with Royalty Pharma (the “Royalty Pharma Agreement”). In consideration for the payments under the Royalty Pharma Agreement, Royalty Pharma is entitled to receive all royalties otherwise payable by Amgen to the Company under the Olpasiran Agreement. The Company remains eligible to receive up to an additional \$485.0 million in remaining development, regulatory and sales milestone payments payable from Amgen and Royalty Pharma. See Note

11.

Visirna Therapeutics, Inc. (“Visirna”)

In April 2022, the Company and Visirna, its subsidiary, entered into a License Agreement (the “Visirna License Agreement”), pursuant to which Visirna received an exclusive license to develop, manufacture and commercialize four of the Company’s RNAi-based investigational cardiometabolic medicines in Greater China (including the People’s Republic of China, Hong Kong, Macau and Taiwan).

-Definition

The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.

+ References

Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(a\)-SubTopic 10-Topic 808-Publisher FASB-URI https://asc.fasb.org/1943274/2147479402/808-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (a)-SubTopic 10-Topic 808-Publisher FASB-URI https://asc.fasb.org/1943274/2147479402/808-10-50-1)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(b\)-SubTopic 10-Topic 808-Publisher FASB-URI https://asc.fasb.org/1943274/2147479402/808-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (b)-SubTopic 10-Topic 808-Publisher FASB-URI https://asc.fasb.org/1943274/2147479402/808-10-50-1)Reference 3: <http://www.xbrl.org/2003/role/disclosureRef-Name Accounting Standards Codification-Topic 808-Publisher FASB-URI https://asc.fasb.org/808/tableOfContent>

+Details

Name:us-gaap_CollaborativeArrangementDisclosureTextBlock Namespace Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration

-References

No definition available.

+Details

Name:us-gaap_OrganizationConsolidationAndPresentationOffFinancialStatementsAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration XML 24-R9.htm IDEA: XBRL DOCUMENT Balance Sheet Accounts9 Months Ended Jun. 30, 2024 Organization, Consolidation and Presentation of Financial Statements [Abstract] Balance Sheet AccountsBALANCE SHEET ACCOUNTS Property, Plant and Equipment

The following table summarizes the Company’s major classes of property, plant and equipment:

	June 30, 2024	September 30, 2023 (in thousands)
Research equipment	64,207	\$6,509
Furniture	5,593	1,540
Computers and software	926	700
Leasehold improvements	104,396	103,813
Construction in progress	175,778	166,655
Less: Accumulated depreciation and amortization	(33,903)	(41,951)
Property, plant and equipment, net	\$25,911	\$290,262

Depreciation and amortization expense for property, plant and equipment for the three months ended June 30, 2024 and 2023 was \$4.4 million and \$2.9 million, respectively. Depreciation and amortization expense for property and equipment for the nine months ended June 30, 2024 and 2023 was \$12.3 million and \$7.4 million, respectively.

During the first quarter of fiscal 2024, the Company completed the build out of one of its laboratory and office facilities in Verona, Wisconsin, which resulted in the reclassification of \$75.9 million from construction in progress to building as of

June 30, 2024. Further, the Company commenced depreciation on the newly completed facility over a 39-year period.

Accrued Expenses

Accrued expenses consist of the following:

Accrued R&D expenses \$17,911, \$16,125
Accrued R&D expenses: co-development 21,280, 5,895
Accrued capital expenditures 6,909, 14,044
Other 1,799, 3,692
Total accrued expenses \$47,899, \$630,763

June 30, 2024, September 30, 2023 (in thousands)

-References

No definition available.

+Details

Name:us-gaap_OrganizationConsolidationAndPresentationOffFinancialStatementsAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

-Definition

The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.

+References

Reference 1: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic 210-Name Accounting Standards Codification-Publisher FASB-URI https://asc.fasb.org/210/tableOfContent>

+Details

Name:us-gaap_SupplementalBalanceSheetDisclosuresTextBlock Namespace Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration XML 25-R10.htm IDEA: XBRL DOCUMENT

Investments 9 Months Ended

Jun. 30, 2024

Investments, Debt and Equity Securities [Abstract] Investments

INVESTMENTS The Company has determined that the available-for-sale securities that were in an unrealized loss position did not have any credit loss impairment as of June 30, 2024 and 2023.

The Company's investments consisted of the following:

As of June 30, 2024 (in thousands) Adjusted Basis Gross Unrealized Gains
Gross Unrealized Losses
Fair Value Available-for-sale securities \$367,862, \$0, \$(598) \$367,272 Total current investments \$367,862, \$0, \$(598) \$367,272

As of September 30, 2023 (in thousands) Adjusted Basis Gross Unrealized Gains
Gross Unrealized Losses
Fair Value Available-for-sale securities \$295,699, \$2, \$(2,967) \$292,735 Total current investments \$295,699, \$2, \$(2,967) \$292,735

-References

No definition available.

+Details

Name:us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

-Definition

The entire disclosure for investments in certain debt and equity securities.

+References

Reference 1: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic 940-SubTopic 320-Name Accounting Standards Codification-Publisher FASB-URI https://asc.fasb.org/940-320/tableOfContent> Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Name Regulation S-K \(SK\)-Number 229-Section 1403-Paragraph b-Publisher SEC](http://www.xbrl.org/2003/role/disclosureRef-Name Regulation S-K (SK)-Number 229-Section 1403-Paragraph b-Publisher SEC) Reference 3: <http://www.xbrl.org/2003/role/disclosureRef-Topic 320-Name Accounting Standards Codification-Publisher FASB-URI https://asc.fasb.org/320/tableOfContent> Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 320-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 10-Subparagraph \(d\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481800/320-10-50-10](http://www.xbrl.org/2003/role/disclosureRef-Topic 320-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 10-Subparagraph (d)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481800/320-10-50-10) Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic 820-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 6B-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6B](http://www.xbrl.org/2003/role/disclosureRef-Topic 820-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 6B-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6B) Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic 820-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 6B-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6B](http://www.xbrl.org/2003/role/disclosureRef-Topic 820-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 6B-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6B) Reference 7: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 942-SubTopic 320-Name Accounting Standards Codification-Publisher FASB-URI https://asc.fasb.org/942-320/tableOfContent>

+ Details

Name:us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock Namespace Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration XML 26 R11.htm IDEA: XBRL DOCUMENT

Intangible Assets 9 Months Ended

Jun. 30, 2024

Goodwill and Intangible Assets Disclosure [Abstract] Intangible AssetsINTANGIBLE ASSETS

Intangible assets subject to amortization include patents and a license agreement capitalized as part of the Novartis rRNAi asset acquisition in March 2015. The following table presents the components of intangible assets:

Gross Carrying Amount Accumulated Amortization Impairment Net Carrying Amount Useful																			
Lives (in thousands) (in years) As of June 30, 2024	Patents	\$21,728	\$14,485	\$—	\$7,243	14	License	3,129	1,385	—	1,744	21	Total intangible assets, net	\$24,857	\$15,870	\$—	\$8,987	As of September 30, 2023	Patents
21,728	\$13,321	\$—	\$8,407	14	License	3,129	1,274	—	1,855	21	Total intangible assets, net	\$24,857	\$14,595	\$—	\$10,262	As of September 30, 2023	Patents		

Intangible assets are reviewed annually for impairment and more frequently if potential impairment indicators exist. No impairment indicators were identified during the nine months ended June 30, 2024 and 2023.

Intangible assets with definite useful lives are amortized on a straight-line basis over their useful lives. Intangible assets amortization expense was \$0.4 million for the three months ended June 30, 2024 and 2023, and \$1.3 million for the nine months ended June 30, 2024 and 2023. None of the intangible assets with definite useful lives are anticipated to have a residual value.

The following table presents the estimated future amortization expense related to intangible assets as of June 30, 2024:

Amortization Expense Year Ending September 30, (in thousands)	2024 (remainder)	\$425	2025	1,700	2026	1,700	2027	1,700	2028	1,700	Thereafter	1,762	Total	\$8,987

- References

No definition available.

+ Details

Name:us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract Namespace Prefix:us-gaap_ Data Type:xbri:stringItemType Balance Type:na Period Type:duration

- Definition

The entire disclosure for all or part of the information related to intangible assets.

+ References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic-350-SubTopic-30-Name-Accounting-Standards-Codification-Publisher-FASB-URI-https://asc.fasb.org/350-30/tableOfContent>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef-Topic-350-SubTopic-30-Name-Accounting-Standards-Codification-Section-50-Paragraph-4-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482665/350-30-50-4>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic-350-SubTopic-30-Name-Accounting-Standards-Codification-Section-50-Paragraph-3-Subparagraph-\(a\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482665/350-30-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic-350-SubTopic-30-Name-Accounting-Standards-Codification-Section-50-Paragraph-3-Subparagraph-(a)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482665/350-30-50-3)Reference 4: <http://www.xbrl.org/2003/role/disclosureRef-Topic-985-SubTopic-20-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481283/985-20-50-2>Reference 5: <http://www.xbrl.org/2003/role/disclosureRef-Topic-985-SubTopic-20-Name-Accounting-Standards-Codification-Publisher-FASB-URI-https://asc.fasb.org/985-20/tableOfContent>

+ Details

Name:us-gaap_IntangibleAssetsDisclosureTextBlock Namespace Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration XML 27 R12.htm IDEA: XBRL DOCUMENT

Stockholders' Equity 9 Months Ended

Jun. 30, 2024

Equity [Abstract] Stockholders' EquitySTOCKHOLDERS' EQUITY

The following table summarizes the Company's shares of common stock and preferred stock:

Value Authorized Issued Outstanding (in thousands) As of June 30, 2024	Common stock \$0.001 200,000 124,227 124,227	Preferred stock \$0.001 5,000 —	As of September 30, 2023	Common stock \$0.001 200,000 107,312 107,312	Preferred stock \$0.001 5,000 —

As of June 30, 2024 and September 30, 2023, respectively, 11,608,148 and 12,709,837 shares of common stock were reserved for issuance upon exercise of options and vesting of restricted stock units granted or available for grant under the Company's 2013 and 2021 Incentive Plans, as well as for other inducement grants made to new employees under Rule 5635(c)(4) of the Nasdaq Listing Rules.

On January 2, 2024, the Company entered into an underwriting agreement with Jefferies LLC, BofA Securities, Inc., and Cowen and Company, LLC, as representatives of the several underwriters. The Company issued 15,790,000 shares of common stock at an offering price of \$28.50 per share. The aggregate purchase price paid by investors was \$450.0 million and the Company received net proceeds of \$429.3 million after deducting advisory fees and offering expenses.

On December 2, 2022, the Company entered into an open market sale agreement (the "Open Market Sale Agreement"), pursuant to which the Company may, from time to time, sell up to \$250,000,000 in shares of the Company's common stock through Jefferies LLC, acting as the sales agent and/or principal, in an at-the-market offering ("ATM Offering"). The Company is not required to sell shares under the Open Market Sale Agreement. The Company will pay Jefferies LLC a commission of up to 3.0% of the aggregate gross proceeds received from all sales of the common stock under the Open Market Sale Agreement. Unless otherwise terminated, the ATM Offering shall terminate upon the earlier of (i) the sale of all shares of common stock subject to the Open Market Sale Agreement and (ii) the termination of the Open Market Sale Agreement as permitted therein. The Company and Jefferies may each terminate the Open Market Sale Agreement at any time upon prior notice. As of June 30, 2024, no shares have been issued under the Open Market Sale Agreement.

- References

No definition available.

[+ Details](#)
Name:us-gaap_EquityAbstract_Namespace Prefix:us-gaap_Data Type:xbrl:stringItemType Balance Type:na Period Type:duration

[- Definition](#)

The entire disclosure for equity.

[+ References](#)

Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic-505-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-13-Subparagraph-\(b\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef-Topic-505-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-13-Subparagraph-(b)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481112/505-10-50-13)**Reference 2:** [http://www.xbrl.org/2003/role/disclosureRef-Topic-505-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-13-Subparagraph-\(b\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef-Topic-505-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-13-Subparagraph-(b)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481112/505-10-50-13)**Reference 3:** [http://www.xbrl.org/2003/role/disclosureRef-Topic-505-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-14-Subparagraph-\(b\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481112/505-10-50-14](http://www.xbrl.org/2003/role/disclosureRef-Topic-505-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-14-Subparagraph-(b)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481112/505-10-50-14)**Reference 4:** [http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-235-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-\(a\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147477968/946-235-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-235-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-(a)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147477968/946-235-50-2)**Reference 5:** [http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-235-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-\(d\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147477968/946-235-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-235-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-(d)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147477968/946-235-50-2)**Reference 6:** <http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-505-Name-Accounting-Standards-Codification-Section-50-Paragraph-6-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147478448/946-505-50-6>**Reference 7:** [http://www.xbrl.org/2003/role/disclosureRef-Topic-815-SubTopic-40-Name-Accounting-Standards-Codification-Section-50-Paragraph-6-Subparagraph-\(a\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480237/815-40-50-6](http://www.xbrl.org/2003/role/disclosureRef-Topic-815-SubTopic-40-Name-Accounting-Standards-Codification-Section-50-Paragraph-6-Subparagraph-(a)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480237/815-40-50-6)**Reference 8:** [http://www.xbrl.org/2003/role/disclosureRef-Topic-505-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210.3-04\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480008/505-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic-505-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210.3-04)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480008/505-10-S99-1)**Reference 9:** [http://www.xbrl.org/2003/role/disclosureRef-Topic-235-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210.4-08\(e\)\(1\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic-235-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210.4-08(e)(1))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480678/235-10-S99-1)**Reference 10:** <http://fasb.org/us-gaap/role/ref/legacyRef-Topic-505-Name-Accounting-Standards-Codification-Publisher-FASB-URI-https://asc.fasb.org/505/tableOfContent>**Reference 11:** <http://www.xbrl.org/2003/role/disclosureRef-Topic-505-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-13-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481112/505-10-50-13>**Reference 12:** [http://www.xbrl.org/2003/role/disclosureRef-Topic-505-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-13-Subparagraph-\(g\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef-Topic-505-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-13-Subparagraph-(g)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481112/505-10-50-13)**Reference 13:** [http://www.xbrl.org/2003/role/disclosureRef-Topic-505-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-13-Subparagraph-\(i\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef-Topic-505-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-13-Subparagraph-(i)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481112/505-10-50-13)**Reference 14:** [http://www.xbrl.org/2003/role/disclosureRef-Topic-505-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-14-Subparagraph-\(a\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481112/505-10-50-14](http://www.xbrl.org/2003/role/disclosureRef-Topic-505-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-14-Subparagraph-(a)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481112/505-10-50-14)**Reference 15:** [http://www.xbrl.org/2003/role/disclosureRef-Topic-505-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-14-Subparagraph-\(c\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481112/505-10-50-14](http://www.xbrl.org/2003/role/disclosureRef-Topic-505-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-14-Subparagraph-(c)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481112/505-10-50-14)**Reference 16:** [http://www.xbrl.org/2003/role/disclosureRef-Topic-505-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-16-Subparagraph-\(b\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481112/505-10-50-16](http://www.xbrl.org/2003/role/disclosureRef-Topic-505-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-16-Subparagraph-(b)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481112/505-10-50-16)**Reference 17:** [http://www.xbrl.org/2003/role/disclosureRef-Topic-505-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-18-Subparagraph-\(a\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481112/505-10-50-18](http://www.xbrl.org/2003/role/disclosureRef-Topic-505-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-18-Subparagraph-(a)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481112/505-10-50-18)**Reference 18:** [http://www.xbrl.org/2003/role/disclosureRef-Topic-505-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-18-Subparagraph-\(b\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481112/505-10-50-18](http://www.xbrl.org/2003/role/disclosureRef-Topic-505-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-18-Subparagraph-(b)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481112/505-10-50-18)**Reference 19:** [http://www.xbrl.org/2003/role/disclosureRef-Topic-505-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-18-Subparagraph-\(d\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481112/505-10-50-18](http://www.xbrl.org/2003/role/disclosureRef-Topic-505-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-18-Subparagraph-(d)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481112/505-10-50-18)

COMMITMENTS AND CONTINGENCIES**As of June 30, 2024, the Company has incurred \$266.0 million and intends to spend an additional \$18.0 million to \$32.0 million to complete the build out of the facilities.**

Litigation

From time to time, the Company may be subject to various claims and legal proceedings in the ordinary course of business. If the potential loss from any claim, asserted or unasserted, or legal proceeding is considered probable and the amount is reasonably estimable, the Company will accrue a liability for the estimated loss. There were no contingent liabilities recorded as of June 30, 2024.

Commitments

The Company owns land in the Verona Technology Park in Verona, Wisconsin, which is being developed into an approximately 160,000 square foot drug manufacturing facility and an approximately 140,000 square foot laboratory and office facility which will support the Company's manufacturing process development and analytical activities. During the first quarter of fiscal 2024, the Company completed the build out of one of its laboratory and office facilities.

-References

No definition available.

+ Details

Name:us-gaap_CommitmentsAndContingenciesDisclosureAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

-Definition

The entire disclosure for commitments and contingencies.

+ References

Reference 1: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic 405-SubTopic 30-Name Accounting Standards Codification-Publisher FASB-URI https://asc.fasb.org/405-30/tableOfContent>**Reference 2:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 440-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 4-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482648/440-10-50-4](http://www.xbrl.org/2003/role/disclosureRef-Topic 440-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 4-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482648/440-10-50-4)**Reference 3:** <http://www.xbrl.org/2009/role/commonPracticeRef-Topic 450-Name Accounting Standards Codification-Publisher FASB-URI https://asc.fasb.org/450/tableOfContent>**Reference 4:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 954-SubTopic 440-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478522/954-440-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 954-SubTopic 440-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478522/954-440-50-1)**Reference 5:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 440-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 4-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482648/440-10-50-4](http://www.xbrl.org/2003/role/disclosureRef-Topic 440-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 4-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482648/440-10-50-4)**Reference 6:** <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 440-Name Accounting Standards Codification-Publisher FASB-URI https://asc.fasb.org/440/tableOfContent>

+ Details

Name:us-gaap_CommitmentsAndContingenciesDisclosureTextBlock Namespace Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration XML 29-R14.htm IDEA: XBRL DOCUMENT Leases 9-Months Ended Jun. 30, 2024 Leases [Abstract] Leases LEASES

Pasadena, California: The Company leases 49,000 square feet of office space located at 177 East Colorado Blvd. for its corporate headquarters from 177 Colorado Owner, LLC, which lease expires on April 30, 2027. The lease contains an option to renew for one additional five-year term. The Company is not reasonably certain that it will exercise this option to renew and therefore it is not included in right-of-use assets and liabilities as of June 30, 2024.

San Diego, California: The Company leases 144,000 square feet of office and research and development laboratory space located at 10102 Hoyt Park from 11404 & 11408 Sorrento Valley Owner, LLC, which lease expires on April 30, 2028. Pursuant to the lease, within twelve months of the expiration of the initial 15-year term, the Company has the option to extend the lease for up to one additional ten-year term, with certain annual increases in base rent. The Company is not reasonably certain that it will exercise this option to renew and therefore it is not included in right-of-use assets and liabilities as of June 30, 2024.

The lease agreement grants the Company the right to receive an Additional Tenant Improvement Allowance ("ATIA") funded by the lessor, with a maximum amount of \$7.2 million, subject to a 7% interest per annum over the base term. Further, on September 25, 2023, the Company executed the first amendment to the lease, which grants a second ATIA with a maximum amount of \$23.6 million, bearing interest at a rate of 9% per annum over the base term. The Company received \$30.8 million ATIA from the lessor during the first quarter of fiscal 2024. As a result, the Company remeasured its lease liability and right-of-use assets to reflect these additional allowances and the related increased lease payments. The Company has further concluded that these ATIAs have no effects on the classification of the lease.

The Company previously subleased additional research and development space in San Diego, California, which sublease ended during the fiscal year of 2023.

Madison, Wisconsin: The Company leases 115,000 square feet space located at 502 South Rosa Road for its office and laboratory facilities, which lease expires on September 30, 2031. The lease contains options to renew for two terms of five years. The Company is not reasonably certain that it will exercise this option and therefore it is not included in right-of-use assets and liabilities as of June 30, 2024.

The components of lease assets and liabilities along with their classification on the Company's consolidated balance sheets were as follows:

		Lease Assets and Liabilities Classification June 30, 2024 September 30, 2023	
thousands	Operating lease assets Right-of-use assets \$44,332 \$45,297	Current operating lease liabilities Lease liabilities 6,052 10,562	Non-current operating lease liabilities Lease liabilities, net of current portion 112,040 104,608
		Three Months Ended June 30, Nine Months Ended June 30, Lease Cost Classification 2024-	
2023-2024-2023	(in thousands)	Operating lease cost Research and development 862 257 2,478 627	General and administrative expense 527 509 1,504 1,542
Variable lease cost ^(H) Research and development		Total: \$64,365 \$64,089 \$612,512 \$69,004	
(H) Variable lease cost is primarily related to operating expenses associated with the Company's operating leases.			
There was no short-term lease cost during the nine months ended June 30, 2024. There was \$0.6 million and \$1.2 million short-term lease cost during the three and nine months ended June 30, 2023, respectively.			
The following table presents maturities of operating lease liabilities on an undiscounted basis as of June 30, 2024:			
		Year Amounts (in thousands)	
15,696 2027 14,869 2028 13,511 2029 and thereafter 128,356 Total \$191,581 Less imputed interest \$(73,488)		Total operating lease liabilities (includes current portion) \$618,093	
Supplemental cash flow and other information related to leases was as follows:			
		Three Months Ended June 30, Nine Months Ended June 30, 2024-2023-2024-2023	
thousands	Cash received for amounts included in the measurement of lease liabilities	Operating cash flows from operating leases \$— \$5,414 \$3,099 \$23,343	

Right-of-use assets adjusted in exchange for new/amended operating lease liabilities \$— \$3,519 \$ (64) \$(19,063) Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases \$3,204 \$1,885 \$7,221 \$4,081

June 30, 2024 2023 Weighted average remaining lease term (in years) 12.8 12.4 Weighted average discount rate 8.0 % 8.0 %

–References

No definition available.

+Details

Name:us-gaap_LeasesAbstract Namespace Prefix:us-gaap_Data Type:xbrl:stringItemType Balance Type:na Period Type:duration

–Definition

The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.

+References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic-842-SubTopic-20-Name Accounting Standards Codification-Publisher FASB-URI https://asc.fasb.org/842-20/tableOfContent>

+Details

Name:us-gaap_LesseeOperatingLeasesTextBlock Namespace Prefix:us-gaap_Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration XML 30 R15.htm

IDEA: XBRL DOCUMENT

Stock-Based Compensation9 Months Ended

Jun. 30, 2024

Share-Based Payment Arrangement [Abstract] Stock-Based CompensationSTOCK-BASED COMPENSATION

Stock Plans

The Company has two plans that provide for equity-based compensation under the 2013 and the 2021 plans. Under the 2013 Incentive Plan (the "2013 Plan"), 2,924,586 shares of the Company's common stock are reserved for grants of stock options and restricted stock awards to employees and directors as of June 30, 2024.

Under the 2021 Incentive Plan (the "2021 Plan"), 8,000,000 shares (subject to certain adjustments) of the Company's common stock are reserved for grants of stock options, stock appreciation rights, restricted and unrestricted stock, performance awards, cash awards and other awards convertible into or otherwise based on shares of the Company's common stock. The maximum number of shares authorized under the 2021 Plan will be (i) reduced by any shares subject to awards made under the 2013 Plan after January 1, 2021, and (ii) increased by any shares subject to outstanding awards under the 2013 Plan as of January 1, 2021 that, after January 1, 2021, are canceled, expired, forfeited or otherwise not issued under such awards (other than as a result of being tendered or withheld to pay the exercise price or withholding taxes in connection with any such awards) or settled in cash. As of June 30, 2024, the total number of shares available for issuance was 4,565,727 shares, which includes 158,928 and 154,139 shares that were forfeited under the 2013 and 2021 Plans, respectively, and 3,697,189 shares have been granted under the 2021 Plan.

In addition, there were 665,020 shares reserved for options and 616,638 shares reserved for restricted stock units issued as inducement grants to new employees granted outside of the Company's equity-based compensation plans under Rule 5635(c)(4) of the Nasdaq Listing Rules.

The following table presents a summary of awards outstanding:

	As of June 30, 2024	2013 Plan	2021 Plan	Inducement Awards	Total Granted and outstanding awards:	Options	Restricted stock units
1,609,260	2,804,026	616,638	5,029,924	Total 1,924,586	2,836,177	1,281,688	7,042,421

The following table summarizes stock-based compensation expenses included in operating expenses:

	Research and development	\$6,221	\$8,982	\$21,634	\$26,129	General and administrative	8,490	10,965	27,350	33,820	Total	(\$14,711)	(\$19,947)	(\$48,984)	(\$59,945)	
												Three Months Ended June 30,	2024	2023	2024	2023

Stock Option Awards

The following table presents a summary of the stock option activity for the nine months ended June 30, 2024:

	Shares	Weighted-Average	Exercise Price	Per Share
Weighted-Average	Remaining	Contractual	Term (Years)	

Aggregate Intrinsic Value

Outstanding at September 30, 2023 2,263,473 \$22.68 Granted — Canceled or expired (53,582) 36.62 Exercised (197,398) 10.98

Outstanding at June 30, 2024 2,012,497 \$23.22 3.8 \$22,486,304

Exercisable at June 30, 2024 2,001,968 \$23.05 3.8 \$22,486,304

The aggregate intrinsic values represent the amount by which the market price of the underlying stock exceeds the exercise price of the option. The total intrinsic value of the options exercised during the three months ended June 30, 2024 and 2023 was \$0.7 million and \$6.5 million, respectively. The total intrinsic value of the options exercised during the nine months ended June 30, 2024 and 2023 was \$3.8 million and \$10.1 million, respectively.

Stock-based compensation expense related to stock options outstanding for the three months ended June 30, 2024 and 2023, was \$0.4 million and \$2.1 million, respectively. Stock-based compensation expense related to stock options outstanding for the nine months ended June 30, 2024 and 2023, was \$2.5 million and \$6.7 million, respectively.

As of June 30, 2024, the pre-tax compensation expense for all outstanding unvested stock options in the amount of \$0.4 million will be recognized in the Company's results of operations over a weighted average period of 3 months.

The fair value of each stock option award is estimated on the date of grant using the Black-Scholes option pricing model. The Black-Scholes option pricing model was developed for use in estimating the fair value of traded options, which do not have vesting restrictions and are fully transferable. The determination of the fair value of each stock option is affected by the Company's stock price on the date of grant, as well as assumptions regarding a number of highly complex and subjective variables. Because the Company's employee stock options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, the existing models do not necessarily provide a reliable single measure of the fair value of its employee stock options.

The following table provides the assumptions used in the calculation of grant-date fair values of these stock options based on the Black-Scholes option pricing model:

Nine Months Ended June 30, 2024	2023
Expected dividend yield ⁽¹⁾ N/A	—
Risk-free interest rate ⁽²⁾ N/A	3.69%
Expected volatility ⁽³⁾ N/A	86.4%
Expected term (in years) ⁽⁴⁾ N/A	6.25

Weighted average grant date fair value per share of options granted N/A \$24.80

(1) The dividend yield is zero as the Company currently does not pay a dividend.

(2) The risk-free interest rate is based on that of the U.S. Treasury yields with equivalent terms in effect at the time of the grant.

(3) Volatility is estimated based on volatility average of the Company's common stock price.

(4) The computation of expected term was determined based on safe harbor rules, considering the contractual terms of the awards and vesting schedules.

(5) No options were granted during the nine months ended June 30, 2024.

Visirma ESOP: On October 1, 2023, Visirma, a subsidiary of the Company, granted 7,500,000 stock options to its employees from the Employee Stock Option Plan (the "Visirma ESOP"), which authorizes 20,000,000 shares for issuance. The Visirma ESOP is independently managed by Visirma, including the valuation process. For the three and nine months ended June 30, 2024, stock-based compensation expense related to the Visirma ESOP was \$2.3 million and \$5.5 million, respectively.

Restricted Stock Units

Restricted Stock Units ("RSUs"), including market-based, time-based and performance-based awards, have been granted under the Company's 2013 and 2021 Plans and as inducements grants granted outside of the Company's equity-based compensation plans. At vesting, each outstanding RSU will be exchanged for one share of the Company's common stock. RSU awards generally vest subject to the satisfaction of service requirements or the satisfaction of both service requirements and achievement of certain performance targets.

The following table summarizes the activity of the Company's RSUs:

	Weighted-Average	Grant Date	Fair Value	Per Share
				Number of RSUs

Outstanding at September 30, 2023 4,241,640 \$58.42 Granted 1,876,825 30.67 Vested (927,766) 53.16 Forfeited (160,775) 41.75

Outstanding at June 30, 2024 5,029,924 \$49.58

The fair value of RSUs was determined based on the closing price of the Company's common stock on the grant date, with consideration given to the probability of achieving service and/or performance conditions for awards.

For the three months ended June 30, 2024 and 2023, the Company recorded \$14.3 million and \$17.8 million of expense related to RSUs, respectively. For the nine months ended June 30, 2024 and 2023, the Company recorded \$46.5 million and \$53.2 million of expense related to RSUs, respectively. As of June 30, 2024, there was \$96.3 million of total unrecognized compensation cost related to RSUs that is expected to be recognized over a weighted average period of 1.6 years.

–Definition

The entire disclosure for share-based payment arrangement.

+References

Reference 1: [http://www.xbrl.org/2003/role/exampleRef-Topic-718-SubTopic-10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(a\)\(1\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/exampleRef-Topic-718-SubTopic-10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (a)(1)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 2: <http://www.xbrl.org/2003/role/disclosureRef-Topic-718-Name Accounting Standards Codification-Publisher FASB-URI https://asc.fasb.org/718/tableOfContent>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic-718-SubTopic-10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic-718-SubTopic-10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic-718-SubTopic-10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(h\)\(2\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic-718-SubTopic-10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (h)(2)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic-718-SubTopic-10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(h\)\(2\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic-718-SubTopic-10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (h)(2)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)

+ Details
Name:us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock Namespace Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na
Period Type:duration

-References
No definition available.

+ Details
Name:us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:
duration XML 31 R16.htm IDEA: XBRL DOCUMENT
Fair Value Measurements9-Months-Ended
Jun. 30, 2024
Fair Value Disclosures [Abstract] Fair Value MeasurementsFAIR VALUE MEASUREMENTS

The Company employs a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The Company's valuation techniques and inputs used to measure fair value and the definition of the three levels (Level 1, Level 2, and Level 3) of the fair value hierarchy are disclosed in Note 10 - Fair Value Measurements of Notes to Consolidated Financial Statements of Part IV, "Item 15. Exhibits and Financial Statement Schedules" of its Annual Report on Form 10-K for the year ended September 30, 2023.

The Company uses prices and inputs that are current as of the measurement date, including during periods of market disruption. In periods of market disruption, the ability to observe prices and inputs may be reduced for many instruments. This condition could cause an instrument to be reclassified from Level 1 to Level 2, or from Level 2 to Level 3. The Company recognizes transfers between levels at either the actual date of the event or a change in circumstances that caused the transfer. At June 30, 2024 and September 30, 2023, the Company did not have any financial assets or financial liabilities based on Level 3 measurements.

The following table presents information about the Company's assets and liabilities measured at fair value on a recurring basis, and indicates the fair value hierarchy of the valuation techniques utilized by the Company:

June 30, 2024 Level 1 Level 2 Level 3 Total (in thousands)									
Available-for-sale securities U.S. government bonds \$ 80,046 \$ 80,046 Commercial notes 114,616 114,616 Corporate debt securities 171,710 171,710 Total available-for-sale securities 367,272 367,272 Cash equivalents Money market instruments 29,495 29,495 Commercial notes 4,986 4,986 Total cash equivalents 29,495 4,986 34,481 Total financial assets 629,495 627,258 6401,753									

September 30, 2023 Level 1 Level 2 Level 3 Total (in thousands)									
Available-for-sale securities U.S. government bonds \$ 31,553 \$ 31,553 Municipal securities 7,093 7,093 Commercial notes 22,205 22,205 Corporate debt securities 231,884 231,884 Total available-for-sale securities 31,553 261,182 292,735 Cash equivalents Money market instruments 39,733 39,733 Total cash equivalents 39,733 39,733 Total financial assets 671,286 6261,182 6332,468									

-References
No definition available.

+ Details
Name:us-gaap_FairValueDisclosuresAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

-Definition
The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity; and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration; (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item; (c) policy for requiring collateral or other security and information as to accessing such collateral or security; and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election; (b) discussion of the effect of fair value changes on earnings; (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef-Topic 820-SubTopic 10-Name Accounting Standards Codification -Section 55-Paragraph 107-Publisher FASB-URI https://asc.fasb.org/1943274/2147482078/820-10-55-107Reference 2: http://www.xbrl.org/2003/role/exampleRef-Topic 820-SubTopic 10-Name Accounting Standards Codification -Section 55-Paragraph 100-Publisher FASB-URI https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference 3: http://www.xbrl.org/2003/role/disclosureRef-Topic 820-SubTopic 10-Name Accounting Standards Codification -Section 50-Paragraph 2-Subparagraph (c)(3)-Publisher

~~FASB-URI <https://asc.fasb.org/1943274/2147482106/820-10-50-2>Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 820-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 6A-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A](http://www.xbrl.org/2003/role/disclosureRef-Topic 820-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 6A-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A)Reference 5: <http://www.xbrl.org/2003/role/disclosureRef-Topic 820-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2E-Publisher FASB-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E>Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic 820-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 6A-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A](http://www.xbrl.org/2003/role/disclosureRef-Topic 820-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 6A-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef-Topic 820-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 6A-Subparagraph \(f\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A](http://www.xbrl.org/2003/role/disclosureRef-Topic 820-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 6A-Subparagraph (f)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef-Topic 820-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 6A-Subparagraph \(e\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A](http://www.xbrl.org/2003/role/disclosureRef-Topic 820-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 6A-Subparagraph (e)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef-Topic 820-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 6A-Subparagraph \(d\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A](http://www.xbrl.org/2003/role/disclosureRef-Topic 820-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 6A-Subparagraph (d)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A)Reference 10: [http://www.xbrl.org/2003/role/disclosureRef-Topic 820-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(h\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 820-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (h)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2)Reference 11: [http://www.xbrl.org/2003/role/disclosureRef-Topic 820-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(g\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 820-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (g)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2)Reference 12: [http://www.xbrl.org/2003/role/disclosureRef-Topic 940-SubTopic 820-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478119/940-820-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 940-SubTopic 820-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478119/940-820-50-1)~~

+Details

Name:us-gaap_FairValueDisclosuresTextBlock_Namespace-Prefix:us-gaap_Data-Type:dtr-types:textBlockItemType Balance-Type:na Period-Type:duration XML:32-R17.htm

IDEA:XBRL-DOCUMENT

Liability-Related to the Sale of Future Royalties9 Months Ended

Jun-30-2024

Liability-Related To The Sale Of Future Royalties [Abstract] Liability-Related to the Sale of Future RoyaltiesLIABILITY RELATED TO THE SALE OF FUTURE ROYALTIES

In November 2022, the Company and Royalty Pharma entered into the Royalty Pharma Agreement, pursuant to which Royalty Pharma agreed to pay up to \$410.0 million in cash to the Company in consideration for the Company's future royalty interest in olpasiran, a siRNA originally developed by the Company and licensed to Amgen in September 2016 under the Olpasiran Agreement.

Pursuant to the Royalty Pharma Agreement, Royalty Pharma paid \$250.0 million upfront and agreed to pay up to an

additional \$160.0 million in aggregate one-time milestone payments due if and when the following milestone events occur: (i) \$50.0 million on completion of enrollment in the OCEAN Phase 3 clinical trial for olpasiran; (ii) \$50.0 million upon receipt of FDA approval of olpasiran for an approved indication (reduction in the risk of myocardial infarction, urgent coronary revascularization, or coronary heart disease death in adults with established cardiovascular disease and elevated Lp(a)); and (iii) \$60.0 million upon Royalty Pharma's receipt of at least \$70.0 million of royalty payments under the Royalty Pharma Agreement in any single calendar year. During the third quarter of fiscal 2024, Amgen completed enrollment of the Phase 3 OCEAN(a) outcomes trial of olpasiran, which triggered a \$50.0 million milestone payment that the Company received in the same quarter.

In consideration for the payment of the foregoing amounts under the Royalty Pharma Agreement, Royalty Pharma is entitled to receive all royalties otherwise payable by Amgen to the Company under the Olpasiran Agreement. The Company remains eligible to receive any milestone payments potentially payable by Amgen under the Olpasiran Agreement.

The Company has evaluated the terms of the Royalty Pharma Agreement and concluded, in accordance with the relevant accounting guidance, that the Company accounted for the transaction as debt and the funding of \$250.0 million and \$50.0 million from Royalty Pharma were recorded as liabilities related to the sale of future royalties on its consolidated balance sheets. The Company is not obligated to repay these funds received under the Royalty Pharma Agreement.

The Company records the obligations at their carrying value using the effective interest method. In order to amortize the sale of future royalties, the Company utilizes the prospective method to estimate the future royalties to be paid by the Company to the counterparty over the life of the arrangement. Under the prospective method, a new effective interest rate is determined based on the revised estimate of remaining cash flows. The new rate is the discount rate that equates the present value of the revised estimate of remaining cash flows with the carrying amount of the debt, and it will be used to recognize non-cash interest expense for the remaining periods. The Company periodically assesses the amount and the timing of expected royalty payments using a combination of internal projections and forecasts from external sources. The estimates of future net product sales (and resulting royalty payments) are based on key assumptions including population, penetration, probability of success and sales price, among others. To the extent such payments are greater or less than the Company's initial estimates or the timing of such payments is different than its original estimates, the Company will prospectively adjust the amortization of the royalty financing obligations and the effective interest rate. As of June 30, 2024, the estimated effective interest rate was 6.3%.

The following table presents the activity with respect to the liability related to the sale of future royalties:

	Carrying Amount (in thousands)	Carrying value as of September 30, 2023	\$268,326
Milestone payment received	50,000	Non-cash interest expense recognized	17,705
		Carrying value as of June 30, 2024	\$336,031

-Definition

Liability-Related To The Sale Of Future Royalties

+References

No definition available.

+Details

Name:arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract_Namespace-Prefix:arwr_Data-Type:xbrl:stringItemType Balance-Type:na Period-Type:duration

-Definition

Liability-Related To The Sale Of Future Royalties

+References

No definition available.

+Details

Name:arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock_Namespace-Prefix:arwr_Data-Type:dtr-types1:textBlockItemType Balance-Type:na Period-Type:duration

XML:33-R18.htm IDEA:XBRL-DOCUMENT

Net Loss Per Share 9 Months Ended

Jun-30-2024

Earnings Per Share [Abstract] Net Loss Per ShareNET LOSS PER SHARE

The following table presents the computation of basic and diluted net loss per share for the three and nine months ended June 30, 2024 and 2023:

	Three Months Ended June 30, Nine Months Ended June 30, 2024-2023-2024-2023									
(in thousands, except per share amounts) Numerator:	Net loss attributable to Arrowhead Pharmaceuticals, Inc. \$(170,793) \$(102,946) \$(428,957) \$(95,596)									
	Denominator: Weighted-average basic shares outstanding 124,199 107,004 118,260 106,592									
	Effect of dilutive securities — — — — Weighted-average diluted shares outstanding 124,199 107,004 118,260 106,592									
	Basic net loss per share \$(1.38) \$(0.96) \$(3.62) \$(0.90) Diluted net loss per share \$(1.38) \$(0.96) \$(3.62) \$(0.90)									

The following table sets forth the potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to include them would be anti-dilutive:

	Three Months Ended June 30, Nine Months Ended June 30, 2024-2023-2024-2023									
(in thousands) Options	753	637	711	768	Restricted stock units	3,976	2,830	4,060	3,256	Total
	4,729	3,467	4,771	4,024						

-References

No definition available.

+Details

Name:us-gaap_EarningsPerShareAbstract_Namespace-Prefix:us-gaap_Data-Type:xbrl:stringItemType Balance-Type:na Period-Type:duration

-Definition

The entire disclosure for earnings per share.

+References

Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic-260-SubTopic-10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482662/260-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic-260-SubTopic-10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482662/260-10-50-1)Reference 2: <http://www.xbrl.org/2003/role/disclosureRef-Topic-260-Name Accounting Standards Codification-Publisher FASB-URI https://asc.fasb.org/260/tableOfContentReference 3: http://www.xbrl.org/2003/role/disclosureRef-Topic-260-SubTopic-10-Name Accounting Standards Codification-Section 50-Paragraph 2-Publisher FASB-URI https://asc.fasb.org/1943274/2147482662/260-10-50-2>Reference 4: <http://www.xbrl.org/2003/role/disclosureRef-Topic-260-SubTopic-10-Name Accounting Standards Codification-Section 50-Paragraph 3-Publisher FASB-URI https://asc.fasb.org/1943274/2147482662/260-10-50-3>

[+ Details](#)

Name:us-gaap_EarningsPerShareTextBlock **Namespace Prefix:**us-gaap_ **Data Type:**dtr-types:textBlockItemType **Balance Type:**na **Period Type:**duration **XML 34 R19.htm IDEA:**

XBRL DOCUMENT

Subsequent Events 9-Months-Ended

Jun. 30, 2024

Subsequent Events [Abstract] [Subsequent Events](#) **SUBSEQUENT EVENTS**

Financing Agreement

On August 7, 2024 (the "Closing Date"), the Company entered into a financing agreement (the "Financing Agreement") with the guarantors party thereto, the lenders party thereto (the "Lenders"), and Sixth Street Lending Partners, as the administrative agent and collateral agent for the Lenders. The Financing Agreement provides for a senior secured term loan facility of \$500.0 million (the "Credit Facility"), which includes \$400.0 million funded on the Closing Date with an additional \$100.0 million at the Company's option, subject to mutual agreement between Sixth Street and the Company, during the seven-year term of the agreement. The Credit Facility matures on August 7, 2031 (the "Maturity Date") and bears interest at an annual rate equal to 15.0%. The Credit Facility does not provide for scheduled amortization payments during the term, and all principal will be due on the Maturity Date. The Company has the right to prepay loans under the Financing Agreement at any time. See Item 5, Other Information of Part II, for more information.

[-References](#)

No definition available.

[+ Details](#)

Name:us-gaap_SubsequentEventsAbstract **Namespace Prefix:**us-gaap_ **Data Type:**xbri:stringItemType **Balance Type:**na **Period Type:**duration

[-Definition](#)

The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.

[+ References](#)

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic-855-Name-Accounting-Standards-Codification-Publisher-FASB-URI>

https://asc.fashb.org/855/tableOfContent**Reference 2:** [http://www.xbrl.org/2003/role/disclosureRef-Topic-855-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-\(a\)-Publisher-FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-855-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-(a)-Publisher-FASB-URI) **https://asc.fashb.org/1943274/2147483399/855-10-50-2**

[+ Details](#)

Name:us-gaap_SubsequentEventsTextBlock **Namespace Prefix:**us-gaap_ **Data Type:**dtr-types:textBlockItemType **Balance Type:**na **Period Type:**duration **XML 35 R20.htm IDEA:**

XBRL DOCUMENT

Pay vs Performance Disclosure - USD (\$) \$ in Thousands3-Months-Ended9-Months-Ended

Jun. 30, 2024

Jun. 30, 2023

Jun. 30, 2024

Jun. 30, 2023

Pay vs Performance Disclosure - Net loss attributable to Arrowhead Pharmaceuticals, Inc.\$ (170,793)\$ (102,946)\$ (428,957)\$ (95,596)

[-References](#)

Reference 1: <http://www.xbrl.org/2003/role/presentationRef-Publisher-SEC-Name-Regulation-S-K-Number-229-Section-402-Subsection-v-Paragraph-1>

[+ Details](#)

Name:ecd_PvpTable **Namespace Prefix:**ecd_ **Data Type:**xbri:stringItemType **Balance Type:**na **Period Type:**duration

[-Definition](#)

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

[+ References](#)

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic-250-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-6-Publisher-FASB-URI> **https://asc.fashb.org/1943274/2147483443/250-10-50-6****Reference 2:** <http://www.xbrl.org/2003/role/disclosureRef-Topic-250-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-9-Publisher-FASB-URI> **https://asc.fashb.org/1943274/2147483443/250-10-50-9****Reference 3:** [http://www.xbrl.org/2003/role/disclosureRef-Topic-805-SubTopic-60-Name-Accounting-Standards-Codification-Section-65-Paragraph-1-Subparagraph-\(g\)-Publisher-FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-805-SubTopic-60-Name-Accounting-Standards-Codification-Section-65-Paragraph-1-Subparagraph-(g)-Publisher-FASB-URI) **https://asc.fashb.org/1943274/2147476176/805-60-65-1****Reference 4:** [http://www.xbrl.org/2003/role/disclosureRef-Topic-740-SubTopic-323-Name-Accounting-Standards-Codification-Section-65-Paragraph-2-Subparagraph-\(g\)\(3\)-Publisher-FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-740-SubTopic-323-Name-Accounting-Standards-Codification-Section-65-Paragraph-2-Subparagraph-(g)(3)-Publisher-FASB-URI) **https://asc.fashb.org/1943274/2147478666/740-323-65-2****Reference 5:** [http://fashb.org/us-gaap/role/ref/legacyRef-Topic-220-SubTopic-10-Name-Accounting-Standards-Codification-Section-599-Paragraph-2-Subparagraph-\(SX-210-5-03\(20\)\)-Publisher-FASB-URI](http://fashb.org/us-gaap/role/ref/legacyRef-Topic-220-SubTopic-10-Name-Accounting-Standards-Codification-Section-599-Paragraph-2-Subparagraph-(SX-210-5-03(20))-Publisher-FASB-URI) **https://asc.fashb.org/1943274/2147483621/220-10-599-2****Reference 6:** [http://www.xbrl.org/2003/role/disclosureRef-Topic-235-SubTopic-10-Name-Accounting-Standards-Codification-Section-599-Paragraph-1-Subparagraph-\(SX-210-4-08\(g\)\(1\)\(ii\)\)-Publisher-FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-235-SubTopic-10-Name-Accounting-Standards-Codification-Section-599-Paragraph-1-Subparagraph-(SX-210-4-08(g)(1)(ii))-Publisher-FASB-URI) **https://asc.fashb.org/1943274/2147480678/235-10-599-1****Reference 7:** [http://www.xbrl.org/2003/role/disclosureRef-Topic-323-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-3-Subparagraph-\(c\)-Publisher-FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-323-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-3-Subparagraph-(c)-Publisher-FASB-URI) **https://asc.fashb.org/1943274/2147481687/323-10-50-3****Reference 8:** [http://www.xbrl.org/2003/role/disclosureRef-Topic-825-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-28-Subparagraph-\(f\)-Publisher-FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-825-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-28-Subparagraph-(f)-Publisher-FASB-URI) **https://asc.fashb.org/1943274/2147482907/825-10-50-28****Reference 9:** <http://www.xbrl.org/2003/role/disclosureRef-Topic-220-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-6-Publisher-FASB-URI> **https://asc.fashb.org/1943274/2147482765/220-10-50-6****Reference 10:** <http://www.xbrl.org/2003/role/disclosureRef-Topic-250-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-3-Publisher-FASB-URI> **https://asc.fashb.org/1943274/2147483443/250-10-50-3****Reference 11:** [http://www.xbrl.org/2003/role/disclosureRef-Topic-250-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-11-Subparagraph-\(a\)-Publisher-FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-250-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-11-Subparagraph-(a)-Publisher-FASB-URI) **https://asc.fashb.org/1943274/2147483443/250-10-50-11****Reference 12:** [http://www.xbrl.org/2003/role/disclosureRef-Topic-815-SubTopic-40-Name-Accounting-Standards-Codification-Section-65-Paragraph-1-Subparagraph-\(f\)-Publisher-FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-815-SubTopic-40-Name-Accounting-Standards-Codification-Section-65-Paragraph-1-Subparagraph-(f)-Publisher-FASB-URI) **https://asc.fashb.org/1943274/2147480175/815-40-65-1****Reference 13:** <http://www.xbrl.org/2003/role/disclosureRef-Topic-250-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-8-Publisher-FASB-URI> **https://asc.fashb.org/1943274/2147483443/250-10-50-8****Reference 14:** [http://www.xbrl.org/2003/role/disclosureRef-Topic-250-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-11-Subparagraph-\(b\)-Publisher-FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-250-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-11-Subparagraph-(b)-Publisher-FASB-URI) **https://asc.fashb.org/1943274/2147483443/250-10-50-11****Reference 15:** [http://www.xbrl.org/2003/role/disclosureRef-Topic-250-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-11-Subparagraph-\(b\)-Publisher-FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-250-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-11-Subparagraph-(b)-Publisher-FASB-URI) **https://asc.fashb.org/1943274/2147483443/250-10-50-11****Reference 16:** <http://www.xbrl.org/2003/role/disclosureRef-Topic-250-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-4-Publisher-FASB-URI> **https://asc.fashb.org/1943274/2147483443/250-10-50-4****Reference 17:** <http://www.xbrl.org/2003/role/exampleRef->

~~Topic 946-SubTopic 830-Name Accounting Standards Codification-Section 55-Paragraph 10-Publisher FASB-URI https://asc.fasb.org/1943274/2147479168/946-830-55-10Reference 18: http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section 45-Paragraph 7-Publisher FASB-URI https://asc.fasb.org/1943274/2147479105/946-220-45-7Reference 19: http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.7-04(18))-Publisher FASB-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1Reference 20: http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.6-07(9))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1Reference 21: http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.6-09(1)(d))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3Reference 22: http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(i))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(ii))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 24: http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(iii)(A))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 25: http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(iv))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 26: http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(5))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1Reference 27: http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(i))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 28: http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iii)(A))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 29: http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iii)(B))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 30: http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iv))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 31: http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(5))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1BReference 32: http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 60B-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60BReference 33: http://www.xbrl.org/2003/role/disclosureRef-Topic 205-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 7-Publisher FASB-URI https://asc.fasb.org/1943274/2147483499/205-20-50-7Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 230-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 28-Publisher FASB-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28Reference 35: http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1A-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1AReference 36: http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1B-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1BReference 37: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 942-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.9-04(22))-Publisher FASB-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1~~

+ Details

Name:us-gaap_NetIncomeLoss Namespace Prefix:us-gaap_ Data Type:xbri:monetaryItem Type Balance Type:credit Period Type:duration XML:36-R21.htm IDEA: XBRL DOCUMENT Insider Trading Arrangements3 Months Ended9 Months Ended Jun. 30, 2024 shares Jun. 30, 2024 shares Trading Arrangements, by Individual- Material Terms of Trading Arrangement This column indicates the total number of shares vesting in connection with equity awards, not the number of shares to be sold. The actual number of shares to be sold will be a smaller number based on whatever is required to satisfy payment of applicable withholding taxes under sell-to-cover arrangements. During the quarter ended June 30, 2024, the following directors and officers (as defined in Exchange Act Rule 16a-1(f)) adopted certain trading plans intended to satisfy Rule 10b5-1(c):

Shares Vesting and Subject to Sell-To-Cover:	Other Shares Being Sold (Subject to Certain Conditions)	Name	Title	Adoption Date	Plan Start Date	Plan End Date

Victoria Vakiener Board Member 5/15/2024 12/16/2024 12/31/2024 n/a 0.9948 Non-Rule 10b5-1 Arrangement Adoptedfalse Rule 10b5-1 Arrangement Terminatedfalse Non-Rule 10b5-1 Arrangement Terminatedfalse Victoria Vakiener [Member]- Trading Arrangements, by Individual- NameVictoria Vakiener TitleBoard Member Rule 10b5-1 Arrangement Adoptedtrue Adoption Date5/15/2024 Expiration Date12/31/2024 Arrangement Duration15 days Aggregate Available8,9948,994

- References

Reference 1: http://www.xbrl.org/2003/role/presentationRef-Publisher SEC-Name Regulation S-K-Number 229-Section 408-Subsection a-Paragraph 1

+ Details

Name:ecd_MtrTermsOffrdArrTextBlock Namespace Prefix:ecd_ Data Type:dtr-types:textBlockItem Type Balance Type:na Period Type:duration

- References

Reference 1: http://www.xbrl.org/2003/role/presentationRef-Publisher SEC-Name Regulation S-K-Number 229-Section 408-Subsection a-Paragraph 1

+ Details

Name:ecd_NonRule10b51ArrAdoptedFlag Namespace Prefix:ecd_ Data Type:xbri:booleanItem Type Balance Type:na Period Type:duration

- References

Reference 1: http://www.xbrl.org/2003/role/presentationRef-Publisher SEC-Name Regulation S-K-Number 229-Section 408-Subsection a-Paragraph 1

[+ Details](#)
Name:ecd_NonRule10b51ArrTrmntdFlag_Namespace Prefix:ecd_Data Type:xbrli:booleanItemType Balance Type:na Period Type:duration

[- References](#)
Reference 1: http://www.xbrl.org/2003/role/presentationRef-Publisher SEC-Name Regulation S-K-Number 229-Section 408-Subsection a-Paragraph 1

[+ Details](#)
Name:ecd_Rule10b51ArrAdoptedFlag_Namespace Prefix:ecd_Data Type:xbrli:booleanItemType Balance Type:na Period Type:duration

[- References](#)
Reference 1: http://www.xbrl.org/2003/role/presentationRef-Publisher SEC-Name Regulation S-K-Number 229-Section 408-Subsection a-Paragraph 1

[+ Details](#)
Name:ecd_Rule10b51ArrTrmntdFlag_Namespace Prefix:ecd_Data Type:xbrli:booleanItemType Balance Type:na Period Type:duration

[- References](#)
Reference 1: http://www.xbrl.org/2003/role/presentationRef-Publisher SEC-Name Regulation S-K-Number 229-Section 408-Subsection a-Paragraph 2-Subparagraph A

[+ Details](#)
Name:ecd_TradingArrByIndTable_Namespace Prefix:ecd_Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

[- References](#)
Reference 1: http://www.xbrl.org/2003/role/presentationRef-Publisher SEC-Name Regulation S-K-Number 229-Section 408-Subsection a-Paragraph 2-Subparagraph B

[+ Details](#)
Name:ecd_TrdArrAdoptionDate_Namespace Prefix:ecd_Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

[- References](#)
Reference 1: http://www.xbrl.org/2003/role/presentationRef-Publisher SEC-Name Regulation S-K-Number 229-Section 408-Subsection a-Paragraph 2-Subparagraph C

[+ Details](#)
Name:ecd_TrdArrDuration_Namespace Prefix:ecd_Data Type:xbrli:durationItemType Balance Type:na Period Type:duration

[- References](#)
Reference 1: http://www.xbrl.org/2003/role/presentationRef-Publisher SEC-Name Regulation S-K-Number 229-Section 408-Subsection a-Paragraph 2-Subparagraph C

[+ Details](#)
Name:ecd_TrdArrExpirationDate_Namespace Prefix:ecd_Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

[- References](#)
Reference 1: http://www.xbrl.org/2003/role/presentationRef-Publisher SEC-Name Regulation S-K-Number 229-Section 408-Subsection a-Paragraph 2-Subparagraph A

[+ Details](#)
Name:ecd_TrdArrIndName_Namespace Prefix:ecd_Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

[- References](#)
Reference 1: http://www.xbrl.org/2003/role/presentationRef-Publisher SEC-Name Regulation S-K-Number 229-Section 408-Subsection a-Paragraph 2-Subparagraph A

+ Details

Name:ecd_TrdArrIndTitle_Namespace Prefix:ecd_Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

-References

Reference 1: http://www.xbrl.org/2003/role/presentationRef-Publisher SEC-Name Regulation S-K-Number 229-Section 408-Subsection a-Paragraph 2-Subparagraph D

+ Details

Name:ecd_TrdArrSecuritiesAggAvailAmt_Namespace Prefix:ecd_Data Type:xbrli:sharesItemType Balance Type:na Period Type:instant

-Details

Name:ecd_IndividualAxis=arwr_VictoriaVakienerMember_Namespace Prefix: Data Type:na Balance Type: Period Type: XML 37-R22.htm IDEA: XBRL DOCUMENT

Organization and Significant Accounting Policies (Policies)9 Months Ended

Jun. 30, 2024

Accounting Policies [Abstract] Recent Accounting Pronouncements

Recent Accounting Pronouncements

In December 2023, the Financial Accounting Standards Board ("FASB") issued Accounting Standard Update ("ASU") 2023-09, Income Taxes (Topic 740), Improvements to Income Tax Disclosures, to improve its income tax disclosure requirements. Under the guidance, entities must annually (1) disclose specific categories in the rate reconciliation and (2) provide additional information for reconciling items that meet a quantitative threshold. This guidance will become effective for the Company beginning on October 1, 2025. The Company does not expect any material impact on its consolidated financial statements and related disclosures resulting from applying this ASU.

In November 2023, the FASB issued ASU 2023-07, Segment Reporting (Topic 280), Improvements to Reportable Segment Disclosures, which is intended to improve reportable segment disclosure requirements, primarily through additional disclosures about significant segment expenses. The guidance requires public companies with a single reportable segment to provide all disclosures required under ASC 280. In addition, the guidance requires public companies to include in interim reports all disclosures related to a reportable segment's profit or loss and assets that are currently required in annual reports. The standard is effective for fiscal years beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024, with early adoption permitted. The amendments should be applied retrospectively to all prior periods presented in the financial statements. The Company does not expect any material impact on its consolidated financial statements and related disclosures resulting from applying this ASU.

-References

No definition available.

+ Details

Name:us-gaap_AccountingPoliciesAbstract_Namespace Prefix:us-gaap_Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

-Definition

Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.

+ References

No definition available.

+ Details

Name:us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_Namespace Prefix:us-gaap_Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:

duration XML 38-R23.htm IDEA: XBRL DOCUMENT

Organization and Significant Accounting Policies (Tables)9 Months Ended

Jun. 30, 2024

Accounting Policies [Abstract] Schedule of Company's Current Pipeline

The following table presents the Company's current pipeline:

	Therapeutic Area Name Stage Product Rights Cardiometabolic
plazasiran (ARO-AP0C3)	
Phase 2 Arrowhead	
zodasiran (ARO-ANG3) Phase 2b Arrowhead	
olpasiran Phase 2 Amgen-Pulmonary ARO-RAGE	
Phase 1/2a Arrowhead ARO-MUC5AC Phase 1/2a Arrowhead ARO-MMP7	
Phase 1/2a Arrowhead Liver GSK-4532990 Phase 2b GSK	
tasasiran Phase 3 Takeda and Arrowhead	
dauphasiran (omilgisiran) (GSK9637608, formerly [IN] 3989) Phase 2 GSK ARO-PNPLA3	
Phase 1 Arrowhead ARO-C3	
Phase 1/2a Arrowhead ARO-CFR Phase 1/2a Arrowhead	
Muscle ARO-DUX4 Phase 1/2a Arrowhead ARO-DM1 Phase 1/2a Arrowhead	

Central Nervous System (CNS): Various Pre-Clinical Arrowhead

-Definition

Schedule of Current Products

+ References

No definition available.

+ Details

Name:arwr_ScheduleOfCurrentProductsTableTextBlock_Namespace Prefix:arwr_Data Type:dtr-types1:textBlockItemType Balance Type:na Period Type:duration

-References

No definition available.

+ Details

Name:us-gaap_AccountingPoliciesAbstract_Namespace Prefix:us-gaap_Data Type:xbrli:stringItemType Balance Type:na Period Type:duration XML 39-R24.htm IDEA: XBRL

DOCUMENT

Collaboration and License Agreements (Tables)9 Months Ended

Jun. 30, 2024

Organization, Consolidation and Presentation of Financial Statements [Abstract] Summary of Revenue

The following table provides a summary of revenue recognized:

	Three Months Ended June 30, Nine Months Ended June 30, 2024-2023-2024-2023 (in thousands)	GSK \$— \$277 \$2,685 \$29,600 Horizon — 1,539 — 23,206 Takeda — 14,009 866 146,477 Janssen — — 355 Amgen — — 25,000	Total \$—;\$15,825;\$23,551;\$224,638;Schedule of Receivables and Contract Liabilities

The following table summarizes the balance of receivables and contract liabilities related to the Company's collaboration and license agreements:

	June 30, 2024 September 30, 2023 (in thousands): Receivables included in accounts receivable \$— \$— Contract liabilities included in deferred revenue \$— \$866

-Definition

Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 10-Publisher FASB

-URI https://asc.fasb.org/1943274/2147479806/606-10-50-10

[+ Details](#)
Name:us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_Namespace Prefix:us-gaap_Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration
-Definition
Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.
[+ References](#)
Reference 1: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 5-Publisher FASB-URI https://asc.fasb.org/1943274/2147479806/606-10-50-5>

[+ Details](#)
Name:us-gaap_DisaggregationOfRevenueTableTextBlock_Namespace Prefix:us-gaap_Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration
-References
No definition available.
[+ Details](#)
Name:us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_Namespace Prefix:us-gaap_Data Type:xbrii:stringItemType Balance Type:na Period Type:duration XML 40 R25.htm IDEA: XBRL DOCUMENT Balance Sheet Accounts (Tables) 9 Months Ended Jun. 30, 2024 Organization, Consolidation and Presentation of Financial Statements [Abstract] [Summary of Property and Equipment](#)
The following table summarizes the Company's major classes of property, plant and equipment:

June 30, 2024 September 30, 2023 (in thousands): Land\$2,996 \$2,996 Building75,868 —
(41,951) Property, plant and equipment, net\$375,911-\$290,262Schedule of Accrued Expenses
Accrued expenses consist of the following:

June 30, 2024 September 30, 2023 (in thousands):
Accrued R&D expenses\$17,911 \$16,125
Accrued R&D expenses: co-development21,280 5,895
Accrued capital expenditures6,909 14,044
Other1,799 2,692
Total accrued expense\$47,899\$639,763

[+ References](#)
No definition available.
[+ Details](#)
Name:us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_Namespace Prefix:us-gaap_Data Type:xbrii:stringItemType Balance Type:na Period Type:duration
-Definition
Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated depreciation.
[+ References](#)
Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 50-Paragraph 1-SubTopic 10-Topic 360-Publisher FASB-URI https://asc.fasb.org/1943274/2147482099/360-10-50-1>

[+ Details](#)
Name:us-gaap_PropertyPlantAndEquipmentTextBlock_Namespace Prefix:us-gaap_Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration
-Definition
Tabular disclosure of the components of accrued liabilities.
[+ References](#)
No definition available.
[+ Details](#)
Name:us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_Namespace Prefix:us-gaap_Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration XML 41 R26.htm IDEA: XBRL DOCUMENT Investments (Tables) 9 Months Ended Jun. 30, 2024 Investments, Debt and Equity Securities [Abstract] [Summary of Short-term and Long-term Investments and Marketable Securities](#)
The Company's investments consisted of the following:

As of June 30, 2024 (in thousands): Adjusted Basis GrossUnrealized Gains
GrossUnrealized Losses
Fair Value Available-for-sale securities\$367,862 \$0 \$(590) \$367,272 Total current investments\$367,862 \$0 \$(590) \$367,272
As of September 30, 2023 (in thousands): Adjusted Basis GrossUnrealized Gains
GrossUnrealized Losses
Fair Value Available-for-sale securities\$295,699 \$3 \$(2,967) \$292,735 Total current investments\$295,699 \$3 \$(2,967) \$292,735

-Definition
Held to maturity securities and marketable securities.
[+ References](#)
No definition available.
[+ Details](#)
Name:arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTableTextBlock_Namespace Prefix:arwr_Data Type:dtr-types1:textBlockItemType Balance Type:na Period Type:duration
[+ References](#)

No definition available.

+ Details

Name:us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration XML 42 R27.htm IDEA: XBRL DOCUMENT Intangible Assets (Tables) 9 Months Ended Jun 30 2024 Goodwill and Intangible Assets Disclosure [Abstract] Schedule of Finite-Lived Intangible AssetsThe following table presents the components of intangible assets:

Gross Carrying Amount Accumulated Amortization Impairment Net Carrying Amount Useful																			
Lives (in thousands) (in years) As of June 30, 2024	Patents	\$21,728	\$14,485	\$—	\$7,243	14	License	3,129	1,385	\$—	1,744	21	Total intangible assets, net	\$24,857	\$15,870	\$—	\$8,987	As of September 30, 2023	Patents
21,728	\$13,321	\$—	\$8,407	14	License	3,129	1,274	\$—	1,855	21	Total intangible assets, net	\$24,857	\$14,595	\$—	\$10,262	Schedule of Intangible Assets Future Amortization Expense			

The following table presents the estimated future amortization expense related to intangible assets as of June 30, 2024:

Amortization Expense Year Ending September 30:	(in thousands)	2024 (remainder)	\$425	2025	1,700	2026	1,700	2027	1,700	2028	1,700	Thereafter	1,762	Total	\$8,987

-References

No definition available.

+ Details

Name:us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

-Definition

Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef-Topic 350-SubTopic 30-Name Accounting Standards Codification-Section 55-Paragraph 40-Publisher FASB-URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 350-SubTopic 30-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482665/350-30-50-2

+ Details

Name:us-gaap_ScheduleOffiniteLivedIntangibleAssetsTableTextBlock Namespace Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration

-Definition

Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef-Topic 350-SubTopic 30-Name Accounting Standards Codification-Section 55-Paragraph 40-Publisher FASB-URI https://asc.fasb.org/1943274/2147482640/350-30-55-40Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 350-SubTopic 30-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (a)(3)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482665/350-30-50-2

+ Details

Name:us-gaap_ScheduleoffiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock Namespace Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration XML 43 R28.htm IDEA: XBRL DOCUMENT Stockholders' Equity (Tables) 9 Months Ended Jun 30 2024 Equity [Abstract] Schedule of Shares of Common Stock and Preferred Stock The following table summarizes the Company's shares of common stock and preferred stock:

Value Authorized Issued Outstanding (in thousands) As of June 30, 2024										Shares Par				
Common stock	\$0.001	290,000	124,227	124,227	Preferred stock	\$0.001	5,000	—	As of September 30, 2023	Common stock	\$0.001	290,000	107,312	107,312
Preferred stock	\$0.001	5,000	—	—										

-References

No definition available.

+ Details

Name:us-gaap_EquityAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

-Definition

Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount; dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from; number of shares authorized, issued, and outstanding.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(27))-SubTopic 10-Topic 210-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(28))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-

1Reference 3: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1-Subparagraph \(SX 210.5-02\(29\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1-Subparagraph (SX 210.5-02(29))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 4: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1-Subparagraph \(SX 210.3-04\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1-Subparagraph (SX 210.3-04)) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480008/505-10-S99-1>Reference 5: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 505-SubTopic 10-Section 50-Paragraph 3> -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-3>Reference 6: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 505-SubTopic 10-Section 50-Paragraph 4> -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-4>Reference 7: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 505-SubTopic 10-Section 50-Paragraph 5> -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-5>Reference 8: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 505-SubTopic 10-Section 45-Paragraph 2> -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481142/505-10-45-2>Reference 9: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 505-SubTopic 10-Section 50-Paragraph 10> -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-10>Reference 10: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 505-SubTopic 10-Section 50-Paragraph 8> -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-8>Reference 11: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 480-SubTopic 10-Section 599-Paragraph 1> -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480244/480-10-S99-1>Reference 12: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 6> -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-6>Reference 13: <http://fasb.org/us-gaap/role/ref/legacyRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 7> -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-7>

+ Details
Name:us-gaap_ScheduleOfStockByClassTextBlock Namespace-Prefix:us-gaap_Data-Type:dtr-types:textBlockItemType Balance-Type:na Period-Type:duration XML-44-R29.htm
IDEA: XBRL-DOCUMENT
Leases (Tables) 9 Months Ended
Jun. 30, 2024
Leases [Abstract] Schedule of Lease Assets and Liabilities and Lease Cost

The components of lease assets and liabilities along with their classification on the Company's consolidated balance sheets were as follows:

thousands)	Operating lease assets	Right-of-use assets	\$44,339	\$45,297	Current operating lease liabilities	Lease liabilities	6,052	10,562	Non-current operating lease liabilities	Lease liabilities, net of current portion	112,040	104,608
Lease Assets and Liabilities Classification June 30, 2024 September 30, 2023 (in thousands)												
Three Months Ended June 30, Nine Months Ended June 30, Lease Cost Classification 2024:												
2023-2024-2023 (in thousands)	Operating lease cost	Research and development	\$2,965	\$3,322	\$8,531	\$7,735	General and administrative expense	537	509	1,504	1,542	
Variable lease cost ⁽¹⁾	Research and development	863	257	2,478	627	General and administrative expense	—	—	—	Total	\$4,265	\$4,089
(1) Variable lease cost is primarily related to operating expenses associated with the Company's operating leases. Summary of Maturities of Operating Lease Liabilities on an Undiscounted Basis												
The following table presents maturities of operating lease liabilities on an undiscounted basis as of June 30, 2024:												

15,696	2027	14,869	2028	13,511	2029 and thereafter	128,356	Total	\$191,581	Less imputed interest	\$(73,488)	Total operating lease liabilities (includes current portion)	\$118,093
Year Amounts (in thousands) 2024 (remainder of fiscal year) 2025 15,356 2026												
Supplemental cash flow and other information related to leases was as follows:												

thousands)	Cash received for amounts included in the measurement of lease liabilities:	Operating cash flows from operating leases	\$—	\$5,414	\$3,090	\$23,342	Three Months Ended June 30, Nine Months Ended June 30, 2024-2023-2024-2023 (in thousands)			
Right-of-use assets adjusted in exchange for new/amended operating lease liabilities	\$—	\$3,519	\$(64)	\$(19,063)	Cash paid for amounts included in the measurement of lease liabilities:	Operating cash flows from operating leases	\$3,204	\$1,885	\$7,221	\$4,081
June 30, 2024-2023	Weighted-average remaining lease term (in years)	12.8	13.4	Weighted-average discount rate	8.0 %	8.0 %				

-Definition
Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 842-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 4-Publisher FASB-URI https://asc.fasb.org/1943274/2147478964/842-20-50-4

+ Details
Name:us-gaap_LeaseCostTableTextBlock Namespace-Prefix:us-gaap_Data-Type:dtr-types:textBlockItemType Balance-Type:na Period-Type:duration

-References
No definition available.

+ Details
Name:us-gaap_LeasesAbstract Namespace-Prefix:us-gaap_Data-Type:xbrli:stringItemType Balance-Type:na Period-Type:duration

-Definition
Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 842-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 6-Publisher FASB-URI https://asc.fasb.org/1943274/2147478964/842-20-50-6

+ Details
Name:us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock Namespace-Prefix:us-gaap_Data-Type:dtr-types:textBlockItemType Balance-Type:na Period-Type:duration XML-45-R30.htm IDEA: XBRL-DOCUMENT
Stock-Based Compensation (Tables) 9 Months Ended
Jun. 30, 2024
Share-Based Payment Arrangement [Abstract] Summary of Awards Outstanding
The following table presents a summary of awards outstanding:

As of June 30, 2024	2013 Plan	2021 Plan	Inducement Awards	Total	Granted and outstanding awards:	Options	1,315,326	22,151	665,020	2,012,497	Restricted stock units
1,609,260	2,804,026	616,638	5,029,024	Total	2,024,586	2,826,177	1,281,658	7,042,421	Share-Based Payment Arrangement, Expensed		

The following table summarizes stock-based compensation expenses included in operating expenses:

Research and development	\$6,221	\$8,982	\$21,634	\$26,129	General and administrative	8,490	10,965	27,350	33,820	Total	\$14,711	\$19,947	\$48,984	\$59,949	Summarized Information about Stock Options
The following table presents a summary of the stock option activity for the nine months ended June 30, 2024:															

Shares	Weighted-Average	Exercise	Price	Per Share
Weighted-Average Remaining Contractual Term (Years)				

AggregateIntrinsicValue

Outstanding at September 30, 2023 2,263,477 \$22.68⁽¹⁾ Granted — Canceled or expired (53,582) 26.62 Exercised (197,398) 10.98
Outstanding at June 30, 2024 2,012,497 \$23.22⁽²⁾ 3.8 \$22,486,304
Exercisable at June 30, 2024 2,001,968 \$23.05⁽³⁾ 3.8 \$22,486,304 **Assumptions Used to Value Stock Options**
The following table provides the assumptions used in the calculation of grant date fair values of these stock options based on the Black-Scholes option pricing model:

Nine Months Ended June 30:
2023-2023
Expected dividend yield⁽⁴⁾ N/A —
Risk-free interest rate⁽⁵⁾ N/A 3.69%
Expected volatility⁽²⁾ N/A 86.4%
Expected term (in years)⁽⁴⁾ N/A 6.25 Weighted average grant date fair value per share of options granted N/A \$24.80
(1) The dividend yield is zero as the Company currently does not pay a dividend.
(2) The risk-free interest rate is based on that of the U.S. Treasury yields with equivalent terms in effect at the time of the grant.
(3) Volatility is estimated based on volatility average of the Company's common stock price.
(4) The computation of expected term was determined based on safe harbor rules, considering the contractual terms of the awards and vesting schedules.
(5) No options were granted during the nine months ended June 30, 2024. **Summary of Share Activity Related to RSUs**
The following table summarizes the activity of the Company's RSUs:

Weighted-AverageGrantDateFair-ValuePer-Share Number ofRSUs

Outstanding at September 30, 2023 4,241,640 \$58.43⁽¹⁾ Granted 1,876,825 30.67⁽²⁾ Vested (927,766) 53.16⁽³⁾ Forfeited (160,775) 41.75⁽⁴⁾
Outstanding at June 30, 2024 5,029,924 \$49.58⁽⁵⁾

-References

No definition available.

+Details

Name:us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

-Definition

Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.

+References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 718-SubTopic 10-Section 50-Paragraph 2-Subparagraph (h)(1)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

+Details

Name:us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock Namespace Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration

-Definition

Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value.

+References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c)(2)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (d)-SubTopic 10-Topic 718-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (e)-SubTopic 10-Topic 718-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

+Details

Name:us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock Namespace Prefix:us-gaap_ Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration

-Definition

Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.

+References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (e)(1)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

+ Details

Name:us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock Namespace Prefix:us-gaap Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration

- Definition

Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 718 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (c)(1)- Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (d) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (e) -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

+ Details

Name:us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock Namespace Prefix:us-gaap Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration

- Definition

Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 718 -SubTopic 10 -Subparagraph (f)(2) -Name Accounting Standards Codification -Paragraph 2 -Section 50 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

+ Details

Name:us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock Namespace Prefix:us-gaap Data Type:dtr-types:textBlockItemType Balance Type:na Period Type:duration XML 46 R31.htm IDEA: XBRL DOCUMENT Fair Value Measurements (Tables)9 Months Ended

Jun 30, 2024

Fair Value Disclosures [Abstract] Fair Value Measurements for Assets and Liabilities Measured at Fair Value on Recurring Basis

The following table presents information about the Company's assets and liabilities measured at fair value on a recurring basis, and indicates the fair value hierarchy of the valuation techniques utilized by the Company.

June 30, 2024 Level 1 Level 2 Level 3 Total (in thousands)									
Available-for-sale securities									
U.S. government bonds \$ — \$80,046 \$ — \$80,046									
Commercial notes — 114,616 — 114,616									
Corporate debt securities — 171,710 — 171,710									
Total available-for-sale securities — 367,272 — 367,272									
Cash equivalents									
Money market instruments 29,495 — 29,495									
Commercial notes — 4,986 — 4,986									
Total cash equivalents 29,495 4,986 — 34,481									
Total financial assets \$29,495 \$372,258 \$ — \$401,753									
September 30, 2023 Level 1 Level 2 Level 3 Total (in thousands)									
Available-for-sale securities									
U.S. government bonds \$31,552 \$ — \$ — \$31,552									
Municipal securities — 7,092 — 7,092									
Commercial notes — 22,205 — 22,205									
Corporate debt securities — 231,884 — 231,884									
Total available-for-sale securities 31,552 261,182 — 292,735									
Cash equivalents									
Money market instruments 39,732 — 39,732									
Total cash equivalents 39,732 — 39,732									
Total financial assets \$71,286 \$261,182 \$ — \$332,468									

- References

No definition available.

+ Details

Name:us-gaap_FairValueDisclosuresAbstract Namespace Prefix:us-gaap Data Type:xbrl:stringItemType Balance Type:na Period Type:duration

- Definition

Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 820 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

[+ Details](#)
Name:us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock **Namespace Prefix:**us-gaap_ **Data Type:**dtr-types:textBlockItemType **Balance Type:**na **Period Type:**duration XML 47 R32.htm IDEA: XBRL DOCUMENT **Liability Related to the Sale of Future Royalties (Tables) 9 Months Ended Jun. 30, 2024**
Liability Related To The Sale Of Future Royalties [Abstract] Schedule of Liability Related to the Sale of Future Royalties
The following table presents the activity with respect to the liability related to the sale of future royalties:

Carrying Amount (in thousands) Carrying value as of September 30, 2023 \$268,326
Milestone payment received 50,000 Non-cash interest expense recognized 17,705 Carrying value as of June 30, 2024 \$236,031

[- Definition](#)
Liability Related To The Sale Of Future Royalties

[+ References](#)
No definition available.

[+ Details](#)
Name:arwr_LiabilityRelatedToTheSaleOfFutureRoyaltiesAbstract **Namespace Prefix:**arwr_ **Data Type:**xbri:stringItemType **Balance Type:**na **Period Type:**duration

[- Definition](#)
Schedule Of Liability Related To The Sale Of Future Royalties

[+ References](#)
No definition available.

[+ Details](#)
Name:arwr_ScheduleOfLiabilityRelatedToTheSaleOfFutureRoyaltiesTableTextBlock **Namespace Prefix:**arwr_ **Data Type:**dtr-types:textBlockItemType **Balance Type:**na **Period Type:**duration XML 48 R33.htm IDEA: XBRL DOCUMENT **Net Loss Per Share (Tables) 9 Months Ended Jun. 30, 2024**
Earnings Per Share [Abstract] Schedule of Earnings Per Share, Basic and Diluted
The following table presents the computation of basic and diluted net loss per share for the three and nine months ended June 30, 2024 and 2023:

Three Months Ended June 30, Nine Months Ended June 30, 2024-2023 2024-2023
(in thousands, except per share amounts) Numerators Net loss attributable to Arrowhead Pharmaceuticals, Inc. \$(170,793) \$(102,946) \$(428,957) \$(95,596) Denominators Weighted-average basic shares outstanding 124,199 107,004 118,260 106,597
Effect of dilutive securities — — — Weighted-average diluted shares outstanding 124,199 107,004 118,260 106,597 Basic net loss per share \$(1.38) \$(0.96) \$(3.63) \$(0.90) Diluted net loss per share \$(1.38) \$(0.96) \$(3.63) \$(0.90)

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share
The following table sets forth the potentially dilutive securities that have been excluded from the calculation of diluted net loss per share because to include them would be anti-dilutive:

Three Months Ended June 30, Nine Months Ended June 30, 2024-2023 2024-2023 (in thousands) Options 752 637 711 768 Restricted stock units 3,976 2,830 4,060 3,256 Total 4,728 3,467 4,771 4,024

[- References](#)
No definition available.

[+ Details](#)
Name:us-gaap_EarningsPerShareAbstract **Namespace Prefix:**us-gaap_ **Data Type:**xbri:stringItemType **Balance Type:**na **Period Type:**duration

[- Definition](#)
Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.

[+ References](#)
Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 260-SubTopic 10-Section 50-Paragraph 1-Subparagraph \(c\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482662/260-10-50-1](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 260-SubTopic 10-Section 50-Paragraph 1-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482662/260-10-50-1)

[+ Details](#)
Name:us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock **Namespace Prefix:**us-gaap_ **Data Type:**dtr-types:textBlockItemType **Balance Type:**na **Period Type:**duration

[- Definition](#)
Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.

[+ References](#)
Reference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482662/260-10-50-1](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482662/260-10-50-1)

[+ Details](#)
Name:us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock **Namespace Prefix:**us-gaap_ **Data Type:**dtr-types:textBlockItemType **Balance Type:**na **Period Type:**duration XML 49 R34.htm IDEA: XBRL DOCUMENT **Organization and Significant Accounting Policies - Narrative (Details) - USD (\$)** \$ / shares in Units, \$ in Thousands 3 Months Ended 9 Months Ended Jan. 02, 2024 Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023

~~Sep. 30, 2023~~

~~Organization And Significant Accounting Policies [Line Items] — Cash, cash equivalents and restricted cash \$ 69,400 \$ 69,400 — Restricted cash 2,200 2,200 — Available-for-sale securities, at fair value 367,272 367,272 \$ 292,735 Increase (decrease) in cash and investments 33,000 — Development regulatory and sales milestones payments 2,700,000 2,700,000 — Income tax expense (benefit) 0 \$ 742(3,313) \$ 759 — Underwriting Agreement — Organization And Significant Accounting Policies [Line Items] — Net proceeds \$ 429,300 — Shares of common stock issued (in shares) 15,790,000 — Common stock offering price (in dollars per share) \$ 28.50 — Aggregate purchase price paid by investors \$ 450,000 — Amgen / Royalty Pharma Agreement — Organization And Significant Accounting Policies [Line Items] — Milestone payment receivable upon achievement of enrollment in phase 3 clinical trial \$ 50,000 \$ 50,000 —~~

~~—Definition~~

~~Development regulatory and sales milestones payments.~~

~~+ References~~

~~No definition available.~~

~~+ Details~~

~~Name:arwr_DevelopmentRegulatoryAndSalesMilestonesPayments_Namespace Prefix:arwr_Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant~~

~~—Definition~~

~~Increase decrease in cash and investments.~~

~~+ References~~

~~No definition available.~~

~~+ Details~~

~~Name:arwr_IncreaseDecreaseInCashAndInvestments_Namespace Prefix:arwr_Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration~~

~~—Definition~~

~~Milestone Payment Receivable, Upon Achievement of Enrollment in Phase 3 Clinical Trial~~

~~+ References~~

~~No definition available.~~

~~+ Details~~

~~Name:arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial_Namespace Prefix:arwr_Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant~~

~~—Definition~~

~~Organization and significant accounting policies.~~

~~+ References~~

~~No definition available.~~

~~+ Details~~

~~Name:arwr_OrganizationAndSignificantAccountingPoliciesLineItems_Namespace Prefix:arwr_Data Type:xbrli:stringItemType Balance Type:na Period Type:duration~~

~~—Definition~~

~~Sale Of Stock, Aggregate Purchase Price~~

~~+ References~~

~~No definition available.~~

~~+ Details~~

~~Name:arwr_SaleOfStockAggregatePurchasePrice_Namespace Prefix:arwr_Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration~~

~~—Definition~~

~~Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.~~

~~+ References~~

~~Reference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 320-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 2-Publisher FASB-URI https://asc.fasb.org/1943274/2147481830/320-10-45-2>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef-Topic 326-SubTopic 30-Name Accounting Standards Codification-Section 45-Paragraph 1-Publisher FASB-URI https://asc.fasb.org/1943274/2147479130/326-30-45-1>~~

~~+ Details~~

~~Name:us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_Namespace Prefix:us-gaap_Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant~~

~~—Definition~~

~~Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.~~

~~+ References~~

~~Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(1\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(1))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)Reference 2: [http://www.xbrl.org/2003/role/exampleRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483467/210-10-45-1](http://www.xbrl.org/2003/role/exampleRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483467/210-10-45-1)Reference 3: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 230-SubTopic 10-Section 45-Paragraph 4-Publisher FASB-URI https://asc.fasb.org/1943274/2147482740/230-10-45-4>~~

+ Details

Name:us-gaap_CashAndCashEquivalentsAtCarryingValue_Namespace Prefix:us-gaap_Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant

- Definition

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.

+ References

Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 270-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(i\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 270-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (i)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1)**Reference 2:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph \(ee\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph (ee)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)**Reference 3:** <http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 12-Publisher FASB-URI https://asc.fasb.org/1943274/2147482685/740-10-50-12>**Reference 4:** <http://www.xbrl.org/2003/role/exampleRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 231-Publisher FASB-URI https://asc.fasb.org/1943274/2147482663/740-10-55-231>**Reference 5:** <http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 9-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-9>**Reference 6:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1-Subparagraph \(SAB Topic 6.f.7\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479360/740-10-599-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section 599-Paragraph 1-Subparagraph (SAB Topic 6.f.7)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479360/740-10-599-1)**Reference 7:** <http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 8-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-8>**Reference 8:** <http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 10-Publisher FASB-URI https://asc.fasb.org/1943274/2147482685/740-10-50-10>**Reference 9:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 22-Subparagraph \(h\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22](http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 22-Subparagraph (h)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22)**Reference 10:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section 599-Paragraph 1-Subparagraph \(SX 210.7-04\(9\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147477250/944-220-599-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section 599-Paragraph 1-Subparagraph (SX 210.7-04(9))-Publisher FASB-URI https://asc.fasb.org/1943274/2147477250/944-220-599-1)**Reference 11:** [http://www.xbrl.org/2003/role/disclosureRef-Name Accounting Standards Codification-Section 45-Paragraph 2-Subparagraph \(a\)-SubTopic 20-Topic 740-Publisher FASB-URI https://asc.fasb.org/1943274/2147482659/740-20-45-2](http://www.xbrl.org/2003/role/disclosureRef-Name Accounting Standards Codification-Section 45-Paragraph 2-Subparagraph (a)-SubTopic 20-Topic 740-Publisher FASB-URI https://asc.fasb.org/1943274/2147482659/740-20-45-2)**Reference 12:** [http://www.xbrl.org/2003/role/disclosureRef-Name Accounting Standards Codification-Section 599-Paragraph 1-Subparagraph \(SX 210.4-08\(h\)\)-SubTopic 10-Topic 235-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-599-1](http://www.xbrl.org/2003/role/disclosureRef-Name Accounting Standards Codification-Section 599-Paragraph 1-Subparagraph (SX 210.4-08(h))-SubTopic 10-Topic 235-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-599-1)

[+ Details](#)

Name:us-gAAP_IncomeTaxExpenseBenefit **Namespace Prefix:**us-gAAP_ **Data Type:**xbri:monetaryItemType **Balance Type:**debit **Period Type:**duration

[- Definition](#)

Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.

[+ References](#)

Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(1\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(1))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)**Reference 2:** <http://www.xbrl.org/2003/role/disclosureRef-Topic 230-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 8-Publisher FASB-URI https://asc.fasb.org/1943274/2147482913/230-10-50-8>**Reference 3:** <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 230-SubTopic 10-Section 45-Paragraph 4-Publisher FASB-URI https://asc.fasb.org/1943274/2147482740/230-10-45-4>

[+ Details](#)

Name:us-gAAP_RestrictedCashAndCashEquivalentsAtCarryingValue **Namespace Prefix:**us-gAAP_ **Data Type:**xbri:monetaryItemType **Balance Type:**debit **Period Type:**instant

[- Definition](#)

Cash received on stock transaction after deduction of issuance costs.

[+ References](#)

No definition available.

[+ Details](#)

Name:us-gAAP_SaleOfStockConsiderationReceivedOnTransaction **Namespace Prefix:**us-gAAP_ **Data Type:**xbri:monetaryItemType **Balance Type:**debit **Period Type:**duration

[- Definition](#)

The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.

[+ References](#)

No definition available.

[+ Details](#)

Name:us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_Namespace-Prefix:us-gaap_Data-Type:xbrl:sharesItemType Balance-Type:na-Period-Type:duration

-Definition

Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.

+References

No definition available.

+Details

Name:us-gaap_SaleOfStockPricePerShare_Namespace-Prefix:us-gaap_Data-Type:dtr-types:perShareItemType Balance-Type:na-Period-Type:instant

-Details

Name:us-gaap_SubsidiarySaleOfStockAxis=arwr_UnderwritingAgreementMember_Namespace-Prefix: Data-Type:na-Balance-Type: Period-Type:

-Details

Name:srt_CounterpartyNameAxis=arwr_AmgenIncorporatedMember_Namespace-Prefix: Data-Type:na-Balance-Type: Period-Type:

-Details

Name:us-gaap_TypeOfArrangementAxis=arwr_RoyaltyPharmaAgreementMember_Namespace-Prefix: Data-Type:na-Balance-Type: Period-Type: XML-50-R35.htm-IDEA: XBRL DOCUMENT

Collaboration and License Agreements - Revenue (Details) - USD (\$) \$ in Thousands3 Months Ended9 Months Ended

Jun-30-2024

Jun-30-2023

Jun-30-2024

Jun-30-2023

Disaggregation of Revenue [Line Items] — Revenue\$ 0\$ 15,825\$ 3,551\$ 224,638GSK — Disaggregation of Revenue [Line Items] — Revenue02772,68529,600Horizon —

Disaggregation of Revenue [Line Items] — Revenue01,539023,206Takeda — Disaggregation of Revenue [Line Items] — Revenue014,009866146,477Janssen — Disaggregation of

Revenue [Line Items] — Revenue000355Amgen — Disaggregation of Revenue [Line Items] — Revenue\$ 0\$ 0\$ 0\$ 25,000

-Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic-606-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-5-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479806/606-10-50-5>Reference 2: [http://www.xbrl.org/2003/role/exampleRef-Topic-606-SubTopic-10-Name-Accounting-Standards-Codification-Section-55-Paragraph-91-Subparagraph-\(a\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479777/606-10-55-91](http://www.xbrl.org/2003/role/exampleRef-Topic-606-SubTopic-10-Name-Accounting-Standards-Codification-Section-55-Paragraph-91-Subparagraph-(a)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479777/606-10-55-91)Reference 3: [http://www.xbrl.org/2003/role/exampleRef-Topic-606-SubTopic-10-Name-Accounting-Standards-Codification-Section-55-Paragraph-91-Subparagraph-\(b\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479777/606-10-55-91](http://www.xbrl.org/2003/role/exampleRef-Topic-606-SubTopic-10-Name-Accounting-Standards-Codification-Section-55-Paragraph-91-Subparagraph-(b)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479777/606-10-55-91)Reference 4: [http://www.xbrl.org/2003/role/exampleRef-Topic-606-SubTopic-10-Name-Accounting-Standards-Codification-Section-55-Paragraph-91-Subparagraph-\(c\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479777/606-10-55-91](http://www.xbrl.org/2003/role/exampleRef-Topic-606-SubTopic-10-Name-Accounting-Standards-Codification-Section-55-Paragraph-91-Subparagraph-(c)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479777/606-10-55-91)Reference 5: [http://www.xbrl.org/2003/role/exampleRef-Topic-606-SubTopic-10-Name-Accounting-Standards-Codification-Section-55-Paragraph-91-Subparagraph-\(d\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479777/606-10-55-91](http://www.xbrl.org/2003/role/exampleRef-Topic-606-SubTopic-10-Name-Accounting-Standards-Codification-Section-55-Paragraph-91-Subparagraph-(d)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479777/606-10-55-91)Reference 6: [http://www.xbrl.org/2003/role/exampleRef-Topic-606-SubTopic-10-Name-Accounting-Standards-Codification-Section-55-Paragraph-91-Subparagraph-\(e\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479777/606-10-55-91](http://www.xbrl.org/2003/role/exampleRef-Topic-606-SubTopic-10-Name-Accounting-Standards-Codification-Section-55-Paragraph-91-Subparagraph-(e)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479777/606-10-55-91)Reference 7: [http://www.xbrl.org/2003/role/exampleRef-Topic-606-SubTopic-10-Name-Accounting-Standards-Codification-Section-55-Paragraph-91-Subparagraph-\(f\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479777/606-10-55-91](http://www.xbrl.org/2003/role/exampleRef-Topic-606-SubTopic-10-Name-Accounting-Standards-Codification-Section-55-Paragraph-91-Subparagraph-(f)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479777/606-10-55-91)Reference 8: [http://www.xbrl.org/2003/role/exampleRef-Topic-606-SubTopic-10-Name-Accounting-Standards-Codification-Section-55-Paragraph-91-Subparagraph-\(g\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479777/606-10-55-91](http://www.xbrl.org/2003/role/exampleRef-Topic-606-SubTopic-10-Name-Accounting-Standards-Codification-Section-55-Paragraph-91-Subparagraph-(g)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479777/606-10-55-91)

+ Details

Name:us-gaap_DisaggregationOfRevenueLineItems **Namespace Prefix:**us-gaap **Data Type:**xbrl:stringItemType **Balance Type:**na **Period Type:**duration

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.

+ References

Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 41-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41](http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 41-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41)**Reference 2:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 270-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(i\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 270-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (i)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1)**Reference 3:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph \(ec\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph (ec)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)**Reference 4:** [http://fasb.org/us-gaap/role/ref/otherTransitionRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://fasb.org/us-gaap/role/ref/otherTransitionRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)**Reference 5:** [http://fasb.org/us-gaap/role/ref/otherTransitionRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://fasb.org/us-gaap/role/ref/otherTransitionRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)**Reference 6:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 924-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SAB Topic 11.L\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 924-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SAB Topic 11.L)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1)**Reference 7:** <http://www.xbrl.org/2003/role/disclosureRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 5-Publisher FASB-URI https://asc.fasb.org/1943274/2147479806/606-10-50-5>**Reference 8:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 30-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30](http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 30-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30)**Reference 9:** <http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 42-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-42>**Reference 10:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 22-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22](http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 22-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22)**Reference 11:** <http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 40-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40>**Reference 12:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 22-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22](http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 22-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22)**Reference 13:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 4-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479806/606-10-50-4](http://www.xbrl.org/2003/role/disclosureRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 4-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479806/606-10-50-4)

[+ Details](#)

Name:us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix:us-gaap Data Type:xbrl:monetaryItemType Balance Type:credit Period Type:duration

[-Details](#)

Name:srt_MajorCustomersAxis=arwr_GlaxosmithklineIntellectualPropertyLimitedMember Namespace Prefix: Data Type:na Balance Type: Period Type:

[-Details](#)

Name:srt_MajorCustomersAxis=arwr_HorizonTherapeuticsIrelandDACMember Namespace Prefix: Data Type:na Balance Type: Period Type:

[-Details](#)

Name:srt_MajorCustomersAxis=arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember Namespace Prefix: Data Type:na Balance Type: Period Type:

[-Details](#)

Name:srt_MajorCustomersAxis=arwr_JanssenPharmaceuticalsIncorporationMember Namespace Prefix: Data Type:na Balance Type: Period Type:

[-Details](#)

Name:srt_MajorCustomersAxis=arwr_AmgenIncorporatedMember Namespace Prefix: Data Type:na Balance Type: Period Type: XML 51 R36.htm IDEA: XBRL DOCUMENT Collaboration and License Agreements - Receivables and Contract Liabilities (Details) - USD (\$) \$ in Thousands Jun. 30, 2024Sep. 30, 2023Organization, Consolidation and Presentation of Financial Statements [Abstract] - Receivables included in accounts receivable\$ 0\$ 0Contract liabilities included in deferred revenue\$ 0\$ 866

[-Definition](#)

Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business.

[+ References](#)

Reference 1: [http://www.xbrl.org/2003/role/exampleRef-Topic-946-SubTopic-310-Name-Accounting-Standards-Codification-Section-45-Paragraph-1-Subparagraph-\(d\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147477802/946-310-45-1](http://www.xbrl.org/2003/role/exampleRef-Topic-946-SubTopic-310-Name-Accounting-Standards-Codification-Section-45-Paragraph-1-Subparagraph-(d)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147477802/946-310-45-1)Reference 2: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic-944-SubTopic-210-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210.7-03\(a\)\(5\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147478777/944-210-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef-Topic-944-SubTopic-210-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210.7-03(a)(5))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147478777/944-210-S99-1)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-210-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210.6-04\(5\)\(b\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479170/946-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic-946-SubTopic-210-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210.6-04(5)(b))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479170/946-210-S99-1)Reference 4: <http://www.xbrl.org/2003/role/disclosureRef-Topic-954-SubTopic-310-Name-Accounting-Standards-Codification-Section-45-Paragraph-1-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479196/954-310-45-1>Reference 5: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic-944-SubTopic-210-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210.7-03\(a\)\(3\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147478777/944-210-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef-Topic-944-SubTopic-210-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210.7-03(a)(3))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147478777/944-210-S99-1)

[+ Details](#)

Name:us-gaap_AccountsReceivableNet **Namespace Prefix:**us-gaap_ **Data Type:**xbrli:monetaryItemType **Balance Type:**debit **Period Type:**instant

[- Definition](#)

Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.

[+ References](#)

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic-606-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-1-Publisher-FASB-URI>
Reference 2: <https://asc.fasb.org/1943274/2147479837/606-10-45-1>
Reference 3: <https://asc.fasb.org/1943274/2147479806/606-10-50-8>
Reference 4: <http://www.xbrl.org/2003/role/disclosureRef-Topic-606-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-2-Publisher-FASB-URI>
Reference 5: <https://asc.fasb.org/1943274/2147479837/606-10-45-2>

[+ Details](#)

Name:us-gaap_ContractWithCustomerLiability **Namespace Prefix:**us-gaap_ **Data Type:**xbrli:monetaryItemType **Balance Type:**credit **Period Type:**instant

[- References](#)

No definition available.

[+ Details](#)

Name:us-gaap_OrganizationConsolidationAndPresentationOffFinancialStatementsAbstract **Namespace Prefix:**us-gaap_ **Data Type:**xbrli:stringItemType **Balance Type:**na **Period**

Type:duration **XML 52-R37.htm IDEA:** XBRL DOCUMENT

Collaboration and License Agreements - Glaxosmithkline Intellectual Property (No. 3) Limited (Details) - USD (\$) 1-Months Ended

Dec. 31, 2023

Jun. 30, 2024

Dec. 11, 2023

Sep. 30, 2023

Jun. 30, 2023

Nov. 22, 2021

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] — Contract liabilities \$ 0 \$ 866,000 — GSK / GSK-HSD License Agreement —
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] — Milestone payment receivable — \$ 30,000,000 Milestone payment receivable
upon achievement of phase two and first patient dosed in phase three — \$ 100,000,000.0 GSK / GSK-HSD License Agreement / Maximum — Collaborative Arrangements And
Noncollaborative Arrangement Transactions [Line Items] — Commercial milestone payments at first commercial sale — 190,000,000.0 Sales-related milestone payments —
\$ 590,000,000.0 GSK / GSK-HBV Agreement — Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] — Initial transaction price
\$ 2,700,000 — Contract assets 0 — Contract liabilities \$ 0 — GSK / GSK-HBV Agreement / Maximum — Collaborative Arrangements And Noncollaborative Arrangement
Transactions [Line Items] — Development and sales milestone payments \$ 832,500,000 —

[- Definition](#)

Commercial milestone payments at first commercial sale.

[+ References](#)

No definition available.

[+ Details](#)

Name:arwr_CommercialMilestonePaymentsAtFirstCommercialSale **Namespace Prefix:**arwr_ **Data Type:**xbrli:monetaryItemType **Balance Type:**debit **Period Type:**instant

[- Definition](#)

Development And Sales Milestones Payments

[+ References](#)

No definition available.

[+ Details](#)

Name:arwr_DevelopmentAndSalesMilestonesPayments **Namespace Prefix:**arwr_ **Data Type:**xbrli:monetaryItemType **Balance Type:**credit **Period Type:**instant

[- Definition](#)

Initial transaction price.

+ References

No definition available.

+ Details

Name:arwr_InitialTransactionPrice_Namespace Prefix:arwr_Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

-Definition

Milestone Payment Receivable

+ References

No definition available.

+ Details

Name:arwr_MilestonePaymentReceivable_Namespace Prefix:arwr_Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant

-Definition

Milestone payment receivable upon achievement of phase two and first patient dosed in phase three.

+ References

No definition available.

+ Details

Name:arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree_Namespace Prefix:arwr_Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant

-Definition

Sales-related milestone payments.

+ References

No definition available.

+ Details

Name:arwr_SalesRelatedMilestonePayments_Namespace Prefix:arwr_Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant

-Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic-808-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-1-Subparagraph-\(d\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479402/808-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic-808-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-1-Subparagraph-(d)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479402/808-10-50-1)

+ Details

Name:us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_Namespace Prefix:us-gaap_Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

-Definition

Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.

+ References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic-606-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-3-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479837/606-10-45-3>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef-Topic-606-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-1-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479837/606-10-45-1>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic-606-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-8-Subparagraph-\(a\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479806/606-10-50-8](http://www.xbrl.org/2003/role/disclosureRef-Topic-606-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-8-Subparagraph-(a)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479806/606-10-50-8)

+ Details

Name:us-gaap_ContractWithCustomerAssetNetCurrent_Namespace Prefix:us-gaap_Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant

-Definition

Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.

+ References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic-606-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-1-Publisher-FASB-URI>

<https://asc.fasb.org/1943274/2147479837/606-10-45-1>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 8-Subparagraph \(a\)-Publisher FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 8-Subparagraph (a)-Publisher FASB-URI) <https://asc.fasb.org/1943274/2147479806/606-10-50-8>Reference 3: <http://www.xbrl.org/2003/role/disclosureRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 2-Publisher FASB-URI> <https://asc.fasb.org/1943274/2147479837/606-10-45-2>

[+ Details](#)

Name:us-gaap_ContractWithCustomerLiabilityCurrent_Namespace Prefix:us-gaap_Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant

[-Details](#)

Name:srt_CounterpartyNameAxis=arwr_GlaxosmithklineIntellectualPropertyLimitedMember_Namespace Prefix: Data Type:na Balance Type: Period Type:

[-Details](#)

Name:us-gaap_TypeOfArrangementAxis=arwr_GSKHSDLicenseAgreementMember_Namespace Prefix: Data Type:na Balance Type: Period Type:

[-Details](#)

Name:srt_RangeAxis=srt_MaximumMember_Namespace Prefix: Data Type:na Balance Type: Period Type:

[-Details](#)

Name:us-gaap_TypeOfArrangementAxis=arwr_GSKHBVAgreementMember_Namespace Prefix: Data Type:na Balance Type: Period Type: XML 53 R38.htm IDEA: XBRL DOCUMENT Collaboration and License Agreements - Horizon Therapeutics Ireland DAC (Details) - Horizon - Horizon License Agreement \$ in Millions 1 Months Ended Jul. 31, 2021 USD (\$)
Jun. 30, 2021 obligation Jan. 31, 2023 USD (\$)

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] - Number of distinct performance obligations / obligation 1 Initial transaction price \$ 40.0 - Milestone payment - \$ 15.0

[-Definition](#)

Initial transaction price.

[+ References](#)

No definition available.

[+ Details](#)

Name:arwr_InitialTransactionPrice_Namespace Prefix:arwr_Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

[-Definition](#)

Milestone payment earned.

[+ References](#)

No definition available.

[+ Details](#)

Name:arwr_MilestonePaymentEarned_Namespace Prefix:arwr_Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant

[-Definition](#)

Number of distinct performance obligations.

[+ References](#)

No definition available.

[+ Details](#)

Name:arwr_NumberOfDistinctPerformanceObligations_Namespace Prefix:arwr_Data Type:xbrli:integerItemType Balance Type:na Period Type:duration

[-Definition](#)

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

[+ References](#)

Reference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 808-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (d)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479402/808-10-50-1

[+ Details](#)

Name:us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_Namespace Prefix:us-gaap_Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

[-Details](#)

Name:srt_CounterpartyNameAxis=arwr_HorizonTherapeuticsIrelandDACMember_Namespace Prefix: Data Type:na Balance Type: Period Type:

[-Details](#)

Name:us-gaap_TypeOfArrangementAxis=arwr_HorizonLicenseAgreementMember_Namespace Prefix: Data Type:na Balance Type: Period Type: XML 54 R39.htm IDEA: XBRL

~~DOCUMENT~~
~~Collaboration and License Agreements - Takeda Pharmaceutical Company Limited (Details) \$ in Thousands 1 Months Ended~~
~~Oct. 31, 2020~~
~~USD (\$)~~
~~bundle~~
~~obligation~~
~~Jun. 30, 2024~~
~~USD (\$)~~
~~Sep. 30, 2023~~
~~USD (\$)~~
~~Mar. 31, 2023~~
~~USD (\$)~~
~~Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] — Development regulatory and sales milestones payments \$ 2,700,000 Accrued expenses 47,899\$ 39,763 Takeda / License and Co-Funding Agreement — Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] — Number of distinct performance obligations / obligation1 — Number of distinct bundle / bundle1 — Initial transaction price\$ 300,000 — Milestone payment — \$ 40,000Accrued expenses 21,300 Takeda / License and Co-Funding Agreement / Minimum — Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] — Percentage of eligible to receive tiered royalties on net sales20.00% — Takeda / License and Co-Funding Agreement / Maximum — Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] — Percentage of eligible to receive tiered royalties on net sales25.00% — Development regulatory and sales milestones payments \$ 527,500 —~~
~~—Definition~~

~~Development regulatory and sales milestones payments.~~

~~+ References~~

~~No definition available.~~

~~+ Details~~
~~Name:arwr_DevelopmentRegulatoryAndSalesMilestonesPayments Namespace Prefix:arwr_ Data Type:xbrii:monetaryItemType Balance Type:credit Period Type:instant~~

~~—Definition~~

~~Initial transaction price.~~

~~+ References~~

~~No definition available.~~

~~+ Details~~
~~Name:arwr_InitialTransactionPrice Namespace Prefix:arwr_ Data Type:xbrii:monetaryItemType Balance Type:credit Period Type:duration~~

~~—Definition~~

~~Milestone payment earned.~~

~~+ References~~

~~No definition available.~~

~~+ Details~~
~~Name:arwr_MilestonePaymentEarned Namespace Prefix:arwr_ Data Type:xbrii:monetaryItemType Balance Type:credit Period Type:instant~~

~~—Definition~~

~~Number of distinct bundle.~~

~~+ References~~

~~No definition available.~~

~~+ Details~~
~~Name:arwr_NumberOfDistinctBundle Namespace Prefix:arwr_ Data Type:xbrii:integerItemType Balance Type:na Period Type:duration~~

~~—Definition~~

~~Number of distinct performance obligations.~~

~~+ References~~

~~No definition available.~~

~~+ Details~~
~~Name:arwr_NumberOfDistinctPerformanceObligations Namespace Prefix:arwr_ Data Type:xbrii:integerItemType Balance Type:na Period Type:duration~~

~~—Definition~~

~~Percentage of eligible to receive tiered royalties on net sales.~~

~~+ References~~

~~No definition available.~~

~~+ Details~~
~~Name:arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales Namespace Prefix:arwr_ Data Type:dtr-types1:percentItemType Balance Type:na Period Type:duration~~

~~—Definition~~

~~Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).~~

~~+ References~~

~~Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1~~

~~+ Details~~
~~Name:us-gaap_AccruedLiabilitiesCurrent Namespace Prefix:us-gaap_ Data Type:xbrii:monetaryItemType Balance Type:credit Period Type:instant~~

~~—Definition~~

~~Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.~~

~~+ References~~

~~Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1~~

[+ Details](#)

Name:us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems **Namespace Prefix:**us-gaap **Data Type:**xbri:stringItemType **Balance Type:**na **Period Type:**duration

[-Details](#)

Name:srt_CounterpartyNameAxis=arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember **Namespace Prefix:** **Data Type:**na **Balance Type:** **Period Type:**

[-Details](#)

Name:us-gaap_TypeOfArrangementAxis=arwr_LicenseAndCoFundingAgreementMember **Namespace Prefix:** **Data Type:**na **Balance Type:** **Period Type:**

[-Details](#)

Name:srt_RangeAxis=srt_MinimumMember **Namespace Prefix:** **Data Type:**na **Balance Type:** **Period Type:**

[-Details](#)

Name:srt_RangeAxis=srt_MaximumMember **Namespace Prefix:** **Data Type:**na **Balance Type:** **Period Type:**XML 55 R40.htm IDEA XBRL DOCUMENT

Collaboration and License Agreements - Amgen, Inc (Details) 1 Months Ended9 Months Ended

Sep. 30, 2016

USD (\$)

agreement

Jun. 30, 2024

USD (\$)

Jun. 30, 2023

USD (\$)

Sep. 30, 2023

USD (\$)

Dec. 31, 2022

USD (\$)

Jul. 31, 2020

USD (\$)

Sep. 30, 2018

USD (\$)

Collaborative Arrangements And Noncollaborative Arrangement Transactions (Line Items) Proceeds from the issuance of common stock, net of offering costs

\$ 429,265,000\$ 0 Contract liabilities 0 \$ 866,000 Amgen / Olpasiran Agreement Collaborative Arrangements And Noncollaborative Arrangement Transactions (Line

Items) Number of agreements + agreement2 Upfront payment\$ 35,000,000 Proceeds from the issuance of common stock, net of offering costs\$ 21,500,000

Milestone payments 55,000,000 \$ 25,000,000\$ 20,000,000\$ 10,000,000Contract assets 0 Contract liabilities 0 Amgen / Olpasiran Agreement / Maximum

Collaborative Arrangements And Noncollaborative Arrangement Transactions (Line Items) Additional remaining development regulatory and sales milestones payments

\$ 485,000,000

[-Definition](#)

Additional remaining development regulatory and sales milestones payments.

[+ References](#)

No definition available.

[+ Details](#)

Name:arwr_AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments **Namespace Prefix:**arwr **Data Type:**xbri:monetaryItemType **Balance Type:**credit **Period Type:**instant

[-Definition](#)

Cash received as due under collaboration agreement.

[+ References](#)

No definition available.

[+ Details](#)

Name:arwr_CashReceivedAsDueUnderCollaborationAgreement **Namespace Prefix:**arwr **Data Type:**xbri:monetaryItemType **Balance Type:**debit **Period Type:**duration

[-Definition](#)

Milestone payment received.

[+ References](#)

No definition available.

[+ Details](#)

Name:arwr_MilestonePaymentReceived **Namespace Prefix:**arwr **Data Type:**xbri:monetaryItemType **Balance Type:**credit **Period Type:**instant

[-Definition](#)

Number of agreements.

[+ References](#)

No definition available.

[+ Details](#)

Name:arwr_NumberOfAgreements **Namespace Prefix:**arwr **Data Type:**xbri:integerItemType **Balance Type:**na **Period Type:**instant

[-Definition](#)

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

[+ References](#)

Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic-808-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-1-Subparagraph-\(d\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479402/808-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic-808-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-1-Subparagraph-(d)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479402/808-10-50-1)

[+ Details](#)

Name:us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems **Namespace Prefix:**us-gaap **Data Type:**xbri:stringItemType **Balance Type:**na **Period Type:**duration

[-Definition](#)

Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than

passage of time, classified as current.

[+ References](#)

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 3-Publisher FASB-URI https://asc.fasb.org/1943274/2147479837/606-10-45-3>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1-Publisher FASB-URI https://asc.fasb.org/1943274/2147479837/606-10-45-1>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 8-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479806/606-10-50-8](http://www.xbrl.org/2003/role/disclosureRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 8-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479806/606-10-50-8)

[+ Details](#)

Name:us-gaap_ContractWithCustomerAssetNetCurrent Namespace Prefix:us-gaap Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant

[- Definition](#)

Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.

[+ References](#)

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1-Publisher FASB-URI https://asc.fasb.org/1943274/2147479837/606-10-45-1>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 8-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479806/606-10-50-8](http://www.xbrl.org/2003/role/disclosureRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 8-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479806/606-10-50-8)Reference 3: <http://www.xbrl.org/2003/role/disclosureRef-Topic 606-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 2-Publisher FASB-URI https://asc.fasb.org/1943274/2147479837/606-10-45-2>

[+ Details](#)

Name:us-gaap_ContractWithCustomerLiabilityCurrent Namespace Prefix:us-gaap Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant

[- Definition](#)

The cash inflow from the additional capital contribution to the entity.

[+ References](#)

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 45-Paragraph 14-Subparagraph \(a\)-SubTopic 10-Topic 230-Publisher FASB-URI https://asc.fasb.org/1943274/2147482740/230-10-45-14](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 45-Paragraph 14-Subparagraph (a)-SubTopic 10-Topic 230-Publisher FASB-URI https://asc.fasb.org/1943274/2147482740/230-10-45-14)

[+ Details](#)

Name:us-gaap_ProceedsFromIssuanceOfCommonStock Namespace Prefix:us-gaap Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

[- Details](#)

Name:srt_CounterpartyNameAxis=arwr_AmgenIncorporatedMember Namespace Prefix: Data Type:na Balance Type: Period Type:

[- Details](#)

Name:us-gaap_TypeOfArrangementAxis=arwr_OlpasiranAgreementMember Namespace Prefix: Data Type:na Balance Type: Period Type:

[- Details](#)

Name:srt_RangeAxis=srt_MaximumMember Namespace Prefix: Data Type:na Balance Type: Period Type: XML 56 R41.htm IDEA: XBRL DOCUMENT Collaboration and License Agreements - Visirna Therapeutics, Inc. (Details) - USD (\$) \$ in Thousands 3 Months Ended 9 Months Ended Jun. 30, 2024 Jun. 30, 2023 Jun. 30, 2024 Jun. 30, 2023

Sep. 30, 2023

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] — Revenue \$ 0 \$ 15,825 \$ 3,551 \$ 224,638 Deferred revenue 0 0 \$ 866 Visirna Therapeutics, Inc. / Visirna License Agreement — Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] — Revenue 100 \$ 900 Contract assets 0 0 Deferred revenue \$ 0 \$ 0 —

—Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic-808-SubTopic-10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(d\)-Publisher FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-808-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-1-Subparagraph-(d)-Publisher-FASB-URI) <https://asc.fasb.org/1943274/2147479402/808-10-50-1>

+ Details

Name: us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems Namespace Prefix: us-gaap_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration

—Definition

Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.

+ References

Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic-606-SubTopic-10-Name Accounting Standards Codification-Section 45-Paragraph 3-Publisher FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-606-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-3-Publisher-FASB-URI) <https://asc.fasb.org/1943274/2147479837/606-10-45-3> Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic-606-SubTopic-10-Name Accounting Standards Codification-Section 45-Paragraph 1-Publisher FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-606-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-1-Publisher-FASB-URI) <https://asc.fasb.org/1943274/2147479837/606-10-45-1> Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic-606-SubTopic-10-Name Accounting Standards Codification-Section 50-Paragraph 8-Subparagraph \(a\)-Publisher FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-606-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-8-Subparagraph-(a)-Publisher-FASB-URI) <https://asc.fasb.org/1943274/2147479806/606-10-50-8>

+ Details

Name: us-gaap_ContractWithCustomerAssetNetCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant

—Definition

Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.

+ References

Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic-606-SubTopic-10-Name Accounting Standards Codification-Section 45-Paragraph 1-Publisher FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-606-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-1-Publisher-FASB-URI) <https://asc.fasb.org/1943274/2147479837/606-10-45-1> Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic-606-SubTopic-10-Name Accounting Standards Codification-Section 50-Paragraph 8-Subparagraph \(a\)-Publisher FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-606-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-8-Subparagraph-(a)-Publisher-FASB-URI) <https://asc.fasb.org/1943274/2147479806/606-10-50-8> Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic-606-SubTopic-10-Name Accounting Standards Codification-Section 45-Paragraph 2-Publisher FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-606-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-2-Publisher-FASB-URI) <https://asc.fasb.org/1943274/2147479837/606-10-45-2>

+ Details

Name: us-gaap_ContractWithCustomerLiabilityCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant

—Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected

~~from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.~~

[+ References](#)

Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-41-Subparagraph-\(a\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482810/280-10-50-41](http://www.xbrl.org/2003/role/disclosureRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-41-Subparagraph-(a)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482810/280-10-50-41)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic-270-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-1-Subparagraph-\(i\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482964/270-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic-270-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-1-Subparagraph-(i)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482964/270-10-50-1)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-32-Subparagraph-\(ee\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2003/role/disclosureRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-32-Subparagraph-(ee)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 4: [http://fasb.org/us-gaap/role/ref/otherTransitionRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-32-Subparagraph-\(b\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://fasb.org/us-gaap/role/ref/otherTransitionRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-32-Subparagraph-(b)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 5: [http://fasb.org/us-gaap/role/ref/otherTransitionRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-32-Subparagraph-\(a\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://fasb.org/us-gaap/role/ref/otherTransitionRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-32-Subparagraph-(a)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482810/280-10-50-32)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic-924-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SAB-Topic-11.L\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479941/924-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic-924-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SAB-Topic-11.L)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479941/924-10-S99-1)Reference 7: <http://www.xbrl.org/2003/role/disclosureRef-Topic-606-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-5-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479806/606-10-50-5>Reference 8: [http://www.xbrl.org/2003/role/disclosureRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-30-Subparagraph-\(a\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482810/280-10-50-30](http://www.xbrl.org/2003/role/disclosureRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-30-Subparagraph-(a)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482810/280-10-50-30)Reference 9: <http://www.xbrl.org/2003/role/disclosureRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-42-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482810/280-10-50-42>Reference 10: [http://www.xbrl.org/2003/role/disclosureRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-22-Subparagraph-\(b\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482810/280-10-50-22](http://www.xbrl.org/2003/role/disclosureRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-22-Subparagraph-(b)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482810/280-10-50-22)Reference 11: <http://www.xbrl.org/2003/role/disclosureRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-40-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482810/280-10-50-40>Reference 12: [http://www.xbrl.org/2003/role/disclosureRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-22-Subparagraph-\(a\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482810/280-10-50-22](http://www.xbrl.org/2003/role/disclosureRef-Topic-280-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-22-Subparagraph-(a)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482810/280-10-50-22)Reference 13: [http://www.xbrl.org/2003/role/disclosureRef-Topic-606-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-4-Subparagraph-\(a\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479806/606-10-50-4](http://www.xbrl.org/2003/role/disclosureRef-Topic-606-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-4-Subparagraph-(a)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479806/606-10-50-4)

[+ Details](#)

Name:us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax Namespace Prefix:us-gaap Data Type:xbri:monetaryItemType Balance Type:credit Period Type:duration

[-Details](#)

Name:srt_CounterpartyNameAxis=arwr_VisirnaTherapeuticsIncMember Namespace Prefix: Data Type:na Balance Type: Period Type:

[-Details](#)

Name:us-gaap_TypeOfArrangementAxis=arwr_VisirnaLicenseAgreementMember Namespace Prefix: Data Type:na Balance Type: Period Type: XML:57 R42.htm IDEA: XBRL DOCUMENT

Balance Sheet Accounts - Summary of Property and Equipment (Details) - USD (\$) \$ in Thousands 3 Months Ended 9 Months Ended

Jun. 30, 2024

Jun. 30, 2023

Jun. 30, 2024

Jun. 30, 2023

Dec. 31, 2023

Sep. 30, 2023

Property, Plant and Equipment [Line Items] — [Property, plant and equipment, gross](#) \$ 429,814 \$ 429,814 \$ 332,213 [Less: Accumulated depreciation and amortization](#) (53,903) (53,903) (41,951) [Property, plant and equipment, net](#) 375,911 375,911 290,262 [Depreciation and amortization expense for property and equipment](#) 4,400 \$ 2,900 12,300 \$ 7,400 [Land](#) — [Property, Plant and Equipment \[Line Items\]](#) — [Property, plant and equipment, gross](#) 2,996 2,996 2,996 [Building](#) — [Property, Plant and Equipment \[Line Items\]](#) — [Property, plant and equipment, gross](#) 75,868 75,868 0 [Property, plant and equipment, reclassification](#) 75,900 [Useful life](#) 39 years [Research equipment](#) — [Property, Plant and Equipment \[Line Items\]](#) — [Property, plant and equipment, gross](#) 64,207 64,207 56,509 [Furniture](#) — [Property, Plant and Equipment \[Line Items\]](#) — [Property, plant and equipment, gross](#) 5,593 5,593 1,540 [Computers and software](#) — [Property, Plant and Equipment \[Line Items\]](#) — [Property, plant and equipment, gross](#) 976 976 700 [Leasehold improvements](#) — [Property, Plant and Equipment \[Line Items\]](#) — [Property, plant and equipment, gross](#) 104,396 104,396 103,813 [Construction in progress](#) — [Property, Plant and Equipment \[Line Items\]](#) — [Property, plant and equipment, gross](#) \$ 175,778 175,778 \$ 166,655 [Property, plant and equipment, reclassification](#) \$ (75,900) —

[-Definition](#)

Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.

[+ References](#)

Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic-944-SubTopic-210-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210-7-03\(a\)\(b\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic-944-SubTopic-210-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210-7-03(a)(b))) - Publisher FASB - URI <https://asc.fasb.org/1943274/2147478777/944-210-S99-1> Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210-5-02\(14\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210-5-02(14))) - Publisher FASB - URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1> Reference 3: [http://fasb.org/us-gaap/role/ref/legacyRef-Name-Accounting-Standards-Codification-Topic-360-SubTopic-10-Section-50-Paragraph-1-Subparagraph-\(c\)](http://fasb.org/us-gaap/role/ref/legacyRef-Name-Accounting-Standards-Codification-Topic-360-SubTopic-10-Section-50-Paragraph-1-Subparagraph-(c)) - Publisher FASB - URI <https://asc.fasb.org/1943274/2147482099/360-10-50-1>

[+ Details](#)

Name:us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment Namespace Prefix:us-gaap Data Type:xbri:monetaryItemType Balance Type:credit Period Type:instant

[-Definition](#)

The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.

[+ References](#)

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 45-Paragraph 28-Subparagraph \(b\)-SubTopic 10-Topic 230-Publisher FASB-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 45-Paragraph 28-Subparagraph (b)-SubTopic 10-Topic 230-Publisher FASB-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28)**Reference 2:** <http://www.xbrl.org/2003/role/exampleRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 48-Publisher FASB-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48>**Reference 3:** <http://www.xbrl.org/2003/role/exampleRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 49-Publisher FASB-URI https://asc.fasb.org/1943274/2147482785/280-10-55-49>**Reference 4:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 270-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(i\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 270-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (i)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1)**Reference 5:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph \(ee\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32](http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 32-Subparagraph (ee)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32)**Reference 6:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 22-Subparagraph \(e\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22](http://www.xbrl.org/2003/role/disclosureRef-Topic 280-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 22-Subparagraph (e)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22)

[+ Details](#)

Name:us-gaap_DepreciationDepletionAndAmortization_Namespace Prefix:us-gaap_Data Type:xbrl:monetaryItemType Balance Type:debit Period Type:duration

[- Definition](#)

Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.

[+ References](#)

Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.7-03\(a\)\(8\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.7-03(a)(8))-Publisher FASB-URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1)**Reference 2:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(13\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(13))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)**Reference 3:** [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 360-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482099/360-10-50-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 360-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482099/360-10-50-1)

[+ Details](#)

Name:us-gaap_PropertyPlantAndEquipmentGross_Namespace Prefix:us-gaap_Data Type:xbri:monetaryItemType Balance Type:debit Period Type:instant

-Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+References

Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic-842-SubTopic-20-Name-Accounting-Standards-Codification-Section-50-Paragraph-7A-Subparagraph-\(a\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147478964/842-20-50-7A](http://www.xbrl.org/2003/role/disclosureRef-Topic-842-SubTopic-20-Name-Accounting-Standards-Codification-Section-50-Paragraph-7A-Subparagraph-(a)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147478964/842-20-50-7A)

+Details

Name:us-gaap_PropertyPlantAndEquipmentLineItems_Namespace Prefix:us-gaap_Data Type:xbri:stringItemType Balance Type:na Period Type:duration

-Definition

Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.

+References

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Name-Accounting-Standards-Codification-Section-50-Paragraph-1-SubTopic-10-Topic-360-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482099/360-10-50-1>**Reference 2:** [http://www.xbrl.org/2003/role/disclosureRef-Topic-842-SubTopic-20-Name-Accounting-Standards-Codification-Section-50-Paragraph-7A-Subparagraph-\(a\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147478964/842-20-50-7A](http://www.xbrl.org/2003/role/disclosureRef-Topic-842-SubTopic-20-Name-Accounting-Standards-Codification-Section-50-Paragraph-7A-Subparagraph-(a)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147478964/842-20-50-7A)**Reference 3:** <http://www.xbrl.org/2003/role/exampleRef-Topic-852-SubTopic-10-Name-Accounting-Standards-Codification-Section-55-Paragraph-10-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481372/852-10-55-10>**Reference 4:** [http://www.xbrl.org/2003/role/disclosureRef-Topic-944-SubTopic-210-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210.7-03\(a\)\(8\)\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147478777/944-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic-944-SubTopic-210-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210.7-03(a)(8))-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147478777/944-210-S99-1)**Reference 5:** <http://www.xbrl.org/2003/role/disclosureRef-Topic-942-SubTopic-360-Name-Accounting-Standards-Codification-Section-50-Paragraph-1-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147478451/942-360-50-1>

+Details

Name:us-gaap_PropertyPlantAndEquipmentNet_Namespace Prefix:us-gaap_Data Type:xbri:monetaryItemType Balance Type:debit Period Type:instant

-Definition

Amount of increase (decrease) of physical assets used in the normal conduct of business and not intended for resale, from reclassification, impairment, donation, or changes classified as other. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.

+References

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name-Accounting-Standards-Codification-Topic-360-SubTopic-10-Section-50-Paragraph-2-Subparagraph-\(a\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482099/360-10-50-2](http://fasb.org/us-gaap/role/ref/legacyRef-Name-Accounting-Standards-Codification-Topic-360-SubTopic-10-Section-50-Paragraph-2-Subparagraph-(a)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482099/360-10-50-2)

+Details

Name:us-gaap_PropertyPlantAndEquipmentTransfersAndChanges_Namespace Prefix:us-gaap_Data Type:xbri:monetaryItemType Balance Type:debit Period Type:duration

-Definition

Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment,

furniture and fixtures, and computer equipment.

[+ References](#)

No definition available.

[+ Details](#)

Name:us-gaap_PropertyPlantAndEquipmentUsefulLife_Namespace Prefix:us-gaap_Data Type:xbri:durationItemType Balance Type:na Period Type:instant

[-Details](#)

Name:us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember_Namespace Prefix: Data Type:na Balance Type: Period Type:

[-Details](#)

Name:us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember_Namespace Prefix: Data Type:na Balance Type: Period Type:

[-Details](#)

Name:us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ResearchEquipmentMember_Namespace Prefix: Data Type:na Balance Type: Period Type:

[-Details](#)

Name:us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember_Namespace Prefix: Data Type:na Balance Type: Period Type:

[-Details](#)

Name:us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ComputerAndSoftwareMember_Namespace Prefix: Data Type:na Balance Type: Period Type:

[-Details](#)

Name:us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember_Namespace Prefix: Data Type:na Balance Type: Period Type:

[-Details](#)

Name:us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember_Namespace Prefix: Data Type:na Balance Type: Period Type: XML 58

R43.htm IDEA: XBRL DOCUMENT

Balance Sheet Accounts - Accrued Expenses (Details) - USD (\$) \$ in Thousands Jun. 30, 2024 Sep. 30, 2023 Organization, Consolidation and Presentation of Financial Statements [Abstract] - Accrued R&D expenses \$ 17,911 \$ 16,125 Accrued R&D expenses; co-development 21,2805,895 Accrued capital expenditures 6,90914,044 Other 1,7993,699 Total accrued expenses \$ 47,899 \$ 39,763

[-Definition](#)

Accrued Capital Expenditure, Current

[+ References](#)

No definition available.

[+ Details](#)

Name:arwr_AccruedCapitalExpenditureCurrent_Namespace Prefix:arwr_Data Type:xbri:monetaryItemType Balance Type:credit Period Type:instant

[-Definition](#)

Accrued Research And Development Co-Development Expense, Current

[+ References](#)

No definition available.

[+ Details](#)

Name:arwr_AccruedResearchAndDevelopmentCoDevelopmentExpenseCurrent_Namespace Prefix:arwr_Data Type:xbri:monetaryItemType Balance Type:credit Period Type:instant

[-Definition](#)

Accrued Research And Development Expense, Current

[+ References](#)

No definition available.

[+ Details](#)

Name:arwr_AccruedResearchAndDevelopmentExpenseCurrent_Namespace Prefix:arwr_Data Type:xbri:monetaryItemType Balance Type:credit Period Type:instant

[-Definition](#)

Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

[+ References](#)

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(20))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

[+ Details](#)

Name:us-gaap_AccruedLiabilitiesCurrent_Namespace Prefix:us-gaap_Data Type:xbri:monetaryItemType Balance Type:credit Period Type:instant

[-References](#)

No definition available.

[+ Details](#)

Name:us-gaap_OrganizationConsolidationAndPresentationOffFinancialStatementsAbstract_Namespace Prefix:us-gaap_Data Type:xbri:stringItemType Balance Type:na Period Type:duration

[-Definition](#)

Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.

[+ References](#)

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(20))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

[+ Details](#)

Name:us-gaap_OtherAccruedLiabilitiesCurrent_Namespace Prefix:us-gaap_Data Type:xbri:monetaryItemType Balance Type:credit Period Type:instant XML 59 R44.htm IDEA: XBRL DOCUMENT

~~Investments – Summary of Short-term, Long-term Investments and Marketable Securities (Details) – USD (\$) \$ in Thousands Jun. 30, 2024 Sep. 30, 2023 Schedule Of Held To Maturity Securities And Marketable Securities [Line Items] – Current investments, Available-for-sale, Adjusted Basis \$ 367,862 \$ 295,699 Current investments, Available-for-sale, Gross Unrealized Gains 83 Current investments, Available-for-sale, Gross Unrealized Losses (598) (2,967) Current investments, Available-for-sale, Fair Value 367,272 292,735 Debt securities – Schedule Of Held To Maturity Securities And Marketable Securities [Line Items] – Current investments, Available-for-sale, Adjusted Basis 367,862 295,699 Current investments, Available-for-sale, Gross Unrealized Gains 83 Current investments, Available-for-sale, Gross Unrealized Losses (598) (2,967) Current investments, Available-for-sale, Fair Value \$ 367,272 \$ 292,735~~

~~– Definition~~

~~Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, Current~~

~~+ References~~

~~No definition available.~~

~~+ Details~~

~~Name: arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent Namespace Prefix: arwr_ Data Type: xbrli:monetaryItemType Balance Type: credit Period Type: instant~~

~~– Definition~~

~~Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, Current~~

~~+ References~~

~~No definition available.~~

~~+ Details~~

~~Name: arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent Namespace Prefix: arwr_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant~~

~~– Definition~~

~~Schedule of held-to maturity securities and marketable securities.~~

~~+ References~~

~~No definition available.~~

~~+ Details~~

~~Name: arwr_ScheduleOfHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems Namespace Prefix: arwr_ Data Type: xbrli:stringItemType Balance Type: na Period Type: duration~~

~~– Definition~~

~~Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.~~

~~+ References~~

~~Reference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 320-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 2-Publisher FASB-URI https://asc.fasb.org/1943274/2147481830/320-10-45-2 Reference 2: http://www.xbrl.org/2003/role/disclosureRef-Topic 326-SubTopic 30-Name Accounting Standards Codification-Section 45-Paragraph 1-Publisher FASB-URI https://asc.fasb.org/1943274/2147479130/326-30-45-1~~

~~+ Details~~

~~Name: us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant~~

~~– Definition~~

~~Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.~~

~~+ References~~

~~Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 320-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481800/320-10-50-2 Reference 2: http://www.xbrl.org/2003/role/disclosureRef-Topic 326-SubTopic 30-Name Accounting Standards Codification-Section 45-Paragraph 1-Publisher FASB-URI https://asc.fasb.org/1943274/2147479130/326-30-45-1~~

~~+ Details~~

~~Name: us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent Namespace Prefix: us-gaap_ Data Type: xbrli:monetaryItemType Balance Type: debit Period Type: instant~~

~~– Details~~

~~Name: us-gaap_FinancialInstrumentAxis=us-gaap_DebtSecuritiesMember Namespace Prefix: Data Type: na Balance Type: Period Type: XML 60 R45.htm IDEA: XBRL DOCUMENT~~

~~Intangible Assets – Schedule of Intangible Assets (Details) – USD (\$) \$ in Thousands 3 Months Ended 9 Months Ended~~

~~Jun. 30, 2024~~

~~Jun. 30, 2023~~

~~Jun. 30, 2024~~

~~Jun. 30, 2023~~

~~Sep. 30, 2023~~

~~Finite Lived Intangible Assets [Line Items] — Net Carrying Amount \$ 8,987 \$ 8,987 \$ 10,262 Amortization expense 400 \$ 400 1,300 \$ 1,300 Novartis — Finite Lived Intangible Assets [Line Items] — Gross Carrying Amount 24,857 24,857 24,857 Accumulated Amortization 15,870 15,870 14,595 Impairment 0 0 0 Net Carrying Amount 8,987 8,987 10,262~~

[Novartis / Patents](#) — [Finite Lived Intangible Assets \[Line Items\]](#) — [Gross Carrying Amount](#)21,728 21,728 21,728[Accumulated Amortization](#)14,485 14,485 13,321[Impairment](#)0 0 0[Net Carrying Amount](#)\$ 7,243 \$ 7,243 \$ 8,407[Useful Lives](#)14 years 14 years 14 years[Novartis / License](#) — [Finite Lived Intangible Assets \[Line Items\]](#) — [Gross Carrying Amount](#)\$ 3,129 \$ 3,129 \$ 3,129[Accumulated Amortization](#)1,385 1,385 1,274[Impairment](#)0 0 0[Net Carrying Amount](#)\$ 1,744 \$ 1,744 \$ 1,855[Useful Lives](#)21 years 21 years 21 years

[-Definition](#)

Finite-Lived Intangible Assets, Impairment

[+References](#)

No definition available.

[+Details](#)

Name:arwr_FiniteLivedIntangibleAssetsImpairment_Namespace-Prefix:arwr_Data-Type:xbrli:monetaryItemType-Balance-Type:credit-Period-Type:instant

[-Definition](#)

The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.

[+References](#)

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph \(b\) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28)Reference 2: <http://www.xbrl.org/2003/role/exampleRef-Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\)\(2\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2)Reference 4: <http://www.xbrl.org/2003/role/disclosureRef-Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482686/350-30-45-2>

[+Details](#)

Name:us-gaap_AmortizationOfIntangibleAssets_Namespace-Prefix:us-gaap_Data-Type:xbrli:monetaryItemType-Balance-Type:debit-Period-Type:duration

[-Definition](#)

Useful life of finite-lived intangible assets, in 'PnYnMnDtnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

[+References](#)

No definition available.

[+Details](#)

Name:us-gaap_FiniteLivedIntangibleAssetUsefulLife_Namespace-Prefix:us-gaap_Data-Type:xbrli:durationItemType-Balance-Type:na-Period-Type:instant

[-Definition](#)

Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.

[+References](#)

Reference 1: <http://www.xbrl.org/2003/role/exampleRef-Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 55 -Paragraph 40 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482640/350-30-55-40>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef-Topic 350 -SubTopic 10 -Name Accounting Standards Codification -Section 545 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480265/350-10-545-1>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph \(a\)\(1\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 350 -SubTopic 30 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Subparagraph (a)(1) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482665/350-30-50-2)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(16\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-599-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(16)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-599-1)

+ Details

Name:us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization **Namespace Prefix:**us-gaap_ **Data Type:**xbri:monetaryItemType **Balance Type:**credit **Period Type:**instant

- Definition

Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.

+ References

Reference 1: <http://www.xbrl.org/2003/role/exampleRef-Topic-350-SubTopic-30-Name-Accounting-Standards-Codification-Section-55-Paragraph-40-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482640/350-30-55-40>**Reference 2:** <http://www.xbrl.org/2003/role/disclosureRef-Topic-350-SubTopic-10-Name-Accounting-Standards-Codification-Section-545-Paragraph-1-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480265/350-10-545-1>**Reference 3:** [http://www.xbrl.org/2003/role/disclosureRef-Topic-350-SubTopic-30-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-\(a\)\(1\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482665/350-30-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic-350-SubTopic-30-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-(a)(1)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482665/350-30-50-2)**Reference 4:** <http://www.xbrl.org/2003/role/disclosureRef-Topic-928-SubTopic-340-Name-Accounting-Standards-Codification-Section-50-Paragraph-1-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147478859/928-340-50-1>

+ Details

Name:us-gaap_FiniteLivedIntangibleAssetsGross **Namespace Prefix:**us-gaap_ **Data Type:**xbri:monetaryItemType **Balance Type:**debit **Period Type:**instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: <http://www.xbrl.org/2003/role/exampleRef-Topic-350-SubTopic-30-Name-Accounting-Standards-Codification-Section-55-Paragraph-40-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482640/350-30-55-40>**Reference 2:** [http://www.xbrl.org/2003/role/disclosureRef-Topic-350-SubTopic-30-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-\(d\)\(2\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482665/350-30-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic-350-SubTopic-30-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-(d)(2)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482665/350-30-50-2)**Reference 3:** [http://www.xbrl.org/2003/role/disclosureRef-Topic-350-SubTopic-30-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-\(d\)\(1\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482665/350-30-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic-350-SubTopic-30-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-(d)(1)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482665/350-30-50-2)**Reference 4:** <http://www.xbrl.org/2003/role/disclosureRef-Topic-350-SubTopic-30-Name-Accounting-Standards-Codification-Section-45-Paragraph-1-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482686/350-30-45-1>**Reference 5:** [http://www.xbrl.org/2003/role/disclosureRef-Topic-350-SubTopic-30-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-\(a\)\(1\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482665/350-30-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic-350-SubTopic-30-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-(a)(1)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482665/350-30-50-2)**Reference 6:** [http://www.xbrl.org/2003/role/disclosureRef-Topic-350-SubTopic-30-Name-Accounting-Standards-Codification-Section-50-Paragraph-3-Subparagraph-\(d\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482665/350-30-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic-350-SubTopic-30-Name-Accounting-Standards-Codification-Section-50-Paragraph-3-Subparagraph-(d)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482665/350-30-50-3)**Reference 7:** <http://www.xbrl.org/2003/role/disclosureRef-Topic-985-SubTopic-20-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481283/985-20-50-2>**Reference 8:** <http://www.xbrl.org/2003/role/disclosureRef-Topic-926-SubTopic-20-Name-Accounting-Standards-Codification-Section-50-Paragraph-5-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147483154/926-20-50-5>

~~Name:us-gAAP_FiniteLivedIntangibleAssetsLineItems Namespace Prefix:us-gAAP_ Data Type:xbri:stringItemType Balance Type:na Period Type:duration~~

Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.

Reference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 350-SubTopic 30-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(a\)\(1\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482665/350-30-50-2](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 350-SubTopic 30-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (a)(1)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482665/350-30-50-2Reference 2: http://www.xbrl.org/2003/role/disclosureRef-Topic 926-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 5-Publisher FASB-URI https://asc.fasb.org/1943274/2147483154/926-20-50-5)Reference 2: <http://www.xbrl.org/2003/role/disclosureRef-Topic 926-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 5-Publisher FASB-URI https://asc.fasb.org/1943274/2147483154/926-20-50-5>

Name:us-gaap_FiniteLivedIntangibleAssetsNet Namespace Prefix:us-gaap Data Type:xbri:monetaryItemType Balance Type:debit Period Type:instant

Name:us-gaap_AssetAcquisitionAxis=arwr_NovartisMember Namespace Prefix: Data Type:na Balance Type: Period Type:

[-Details](#)
Name:us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember Namespace Prefix: Data Type:na Balance Type: Period Type: XML 61
R46.htm IDEA: XBRL DOCUMENT
Intangible Assets - Expected Future Amortization (Details) - USD (\$) \$ in Thousands Jun. 30, 2024Sep. 30, 2023
Goodwill and Intangible Assets Disclosure [Abstract] - 2024
(remainder)\$ 425,202\$1,700,202\$1,700,202\$1,700,202\$1,700,202\$1,762,Net Carrying Amount\$ 0.987\$10.262

~~**Finite-Lived Intangible Asset, Expected Amortization, after Year Four**~~

~~No definition available.~~

Name:arwr_FiniteLivedIntangibleAssetExpectedAmortizationAfterYearFour Namespace Prefix:arwr_ Data Type:xbri:monetaryItemType Balance Type:debit Period Type:instant

Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).

+References

Reference 1: <http://www.xbrl.org/2003/role/exampleRef-Topic-350-SubTopic-30-Name-Accounting-Standards-Codification-Section-55-Paragraph-40-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482640/350-30-55-40>**Reference 2:** [http://www.xbrl.org/2003/role/disclosureRef-Topic-350-SubTopic-30-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-\(a\)\(3\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482665/350-30-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic-350-SubTopic-30-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-(a)(3)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482665/350-30-50-2)**Reference 3:** <http://www.xbrl.org/2003/role/disclosureRef-Topic-985-SubTopic-20-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481283/985-20-50-2>

+ Details

Name:us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths **Namespace Prefix:**us-gaap **Data Type:**xbrli:monetaryItemType **Balance Type:**debit **Period Type:**instant

- Definition

Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year.

+ References

Reference 1: <http://www.xbrl.org/2009/role/commonPracticeRef-Topic-985-SubTopic-20-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481283/985-20-50-2>

+ Details

Name:us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear **Namespace Prefix:**us-gaap **Data Type:**xbrli:monetaryItemType **Balance Type:**debit **Period Type:**instant

- Definition

Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).

+ References

Reference 1: <http://www.xbrl.org/2003/role/exampleRef-Topic-350-SubTopic-30-Name-Accounting-Standards-Codification-Section-55-Paragraph-40-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482640/350-30-55-40>**Reference 2:** [http://www.xbrl.org/2003/role/disclosureRef-Topic-350-SubTopic-30-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-\(a\)\(3\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482665/350-30-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic-350-SubTopic-30-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-(a)(3)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482665/350-30-50-2)**Reference 3:** <http://www.xbrl.org/2003/role/disclosureRef-Topic-985-SubTopic-20-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481283/985-20-50-2>

+ Details

Name:us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour **Namespace Prefix:**us-gaap **Data Type:**xbrli:monetaryItemType **Balance Type:**debit **Period Type:**instant

- Definition

Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).

+ References

Reference 1: <http://www.xbrl.org/2003/role/exampleRef-Topic-350-SubTopic-30-Name-Accounting-Standards-Codification-Section-55-Paragraph-40-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482640/350-30-55-40>**Reference 2:** [http://www.xbrl.org/2003/role/disclosureRef-Topic-350-SubTopic-30-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-\(a\)\(3\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482665/350-30-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic-350-SubTopic-30-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-(a)(3)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482665/350-30-50-2)**Reference 3:** <http://www.xbrl.org/2003/role/disclosureRef-Topic-985-SubTopic-20-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147481283/985-20-50-2>

+ Details

Name:us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_Namespace Prefix:us-gaap_Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant

- Definition

Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).

+ References

Reference 1: <http://www.xbrl.org/2003/role/exampleRef-Topic 350-SubTopic 30-Name Accounting Standards Codification-Section 55-Paragraph 40-Publisher FASB-URI https://asc.fasb.org/1943274/2147482640/350-30-55-40>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 350-SubTopic 30-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(a\)\(3\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482665/350-30-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 350-SubTopic 30-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (a)(3)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482665/350-30-50-2)Reference 3: <http://www.xbrl.org/2003/role/disclosureRef-Topic 985-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 2-Publisher FASB-URI https://asc.fasb.org/1943274/2147481283/985-20-50-2>

+ Details

Name:us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_Namespace Prefix:us-gaap_Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant

- Definition

Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.

+ References

Reference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 350-SubTopic 30-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(a\)\(1\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482665/350-30-50-2](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 350-SubTopic 30-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (a)(1)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482665/350-30-50-2)Reference 2: <http://www.xbrl.org/2003/role/disclosureRef-Topic 926-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 5-Publisher FASB-URI https://asc.fasb.org/1943274/2147483154/926-20-50-5>

+ Details

Name:us-gaap_FiniteLivedIntangibleAssetsNet_Namespace Prefix:us-gaap_Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant

- References

No definition available.

+ Details

Name:us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_Namespace Prefix:us-gaap_Data Type:xbrli:stringItemType Balance Type:na Period Type:duration XML 62 R47.htm IDEA: XBRL DOCUMENT Stockholders' Equity (Details) - USD (\$) Jan. 02, 2024Dec. 02, 2022Jun. 30, 2024Sep. 30, 2023Class Of Stock [Line Items] - Common stock, par value (in dollars per share)

~~\$ 0.001\$ 0.001Common stock, shares authorized (in shares) 290,000,000290,000,000Common stock, shares issued (in shares) 124,227,000107,312,000Common stock, shares outstanding (in shares) 124,227,000107,312,000Preferred stock, par value (in dollars per share) \$ 0.001\$ 0.001Preferred stock, shares authorized (in shares) 5,000,0005,000,000Preferred stock, shares issued (in shares) 00Preferred stock, shares outstanding (in shares) 00Common stock, share reserve for issuance (in shares) 4,563,727Underwriting Agreement Class Of Stock [Line Items] Shares of common stock issued (in shares) 15,790,000 Common stock offering price (in dollars per share) \$ 28.50 Aggregate purchase price paid by investors\$ 450,000,000 Net proceeds\$ 429,300,000 At The Market Agreement Class Of Stock [Line Items] Shares issued 0 At The Market Agreement / Maximum Class Of Stock [Line Items] Common stock shares value reserved for future issuance \$ 250,000,000 Percentage of commission to sales agent 3.00% 2013 and 2021 Incentive Plans and other inducement grants Class Of Stock [Line Items] Common stock, share reserve for issuance (in shares) 11,608,14812,709,837~~
~~-Definition~~

~~Common stock, capital shares value reserved for future issuance.~~

~~+ References~~

~~No definition available.~~

~~+ Details~~

~~Name:arwr_CommonStockCapitalSharesValueReservedForFutureIssuance Namespace Prefix:arwr_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant~~

~~-Definition~~

~~Percentage of commission on aggregate gross proceeds from sale of common stock.~~

~~+ References~~

~~No definition available.~~

~~+ Details~~

~~Name:arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock Namespace Prefix:arwr_ Data Type:dtr-types1:percentItemType Balance Type:na Period Type:duration~~

~~-Definition~~

~~Sale Of Stock, Aggregate Purchase Price~~

~~+ References~~

~~No definition available.~~

~~+ Details~~

~~Name:arwr_SaleOfStockAggregatePurchasePrice Namespace Prefix:arwr_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration~~

~~-Definition~~

~~Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.~~

~~+ References~~

~~Reference 1: http://www.xbrl.org/2003/role/exampleRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph (d)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef-Topic 272-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 3-Publisher FASB-URI https://asc.fasb.org/1943274/2147483014/272-10-45-3Reference 3: http://www.xbrl.org/2003/role/disclosureRef-Topic 272-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Publisher FASB-URI https://asc.fasb.org/1943274/2147482987/272-10-50-1Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.4-08(d))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1Reference 5: http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 6: http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 7: http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 8: http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph (h)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13Reference 9: http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 14-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14Reference 10: http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 18-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-18Reference 11: http://www.xbrl.org/2003/role/disclosureRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(27)(b))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 12: http://www.xbrl.org/2003/role/disclosureRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(28))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 13: http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-2Reference 14: http://www.xbrl.org/2003/role/disclosureRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(29))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1Reference 15: http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.6-03(i)(2))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 16: http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.6-03(i)(1))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 17: http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.6-03(i)(2)(i))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3Reference 18: http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.6-03(i)(2)(ii))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3~~

[+ Details](#)

Name:us-gaap_ClassOfStockLineItems_Namespace Prefix:us-gaap_Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

[- Definition](#)

Face amount or stated value per share of common stock.

[+ References](#)

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(29\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(29)))-Publisher FASB-URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>

[+ Details](#)

Name:us-gaap_CommonStockParOrStatedValuePerShare_Namespace Prefix:us-gaap_Data Type:dtr-types:perShareItemType Balance Type:na Period Type:instant

[- Definition](#)

The maximum number of common shares permitted to be issued by an entity's charter and bylaws.

[+ References](#)

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(29\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(29)))-Publisher FASB-URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.6-04\(16\)\(a\)\)](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.6-04(16)(a)))-Publisher FASB-URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-1>

[+ Details](#)

Name:us-gaap_CommonStockSharesAuthorized_Namespace Prefix:us-gaap_Data Type:xbrli:sharesItemType Balance Type:na Period Type:instant

[- Definition](#)

Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.

[+ References](#)

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(29\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(29)))-Publisher FASB-URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>

[+ Details](#)

Name:us-gaap_CommonStockSharesIssued_Namespace Prefix:us-gaap_Data Type:xbrli:sharesItemType Balance Type:na Period Type:instant

[- Definition](#)

Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.

[+ References](#)

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 50-Paragraph 2-SubTopic 10-Topic 505-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-2>Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(29\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(29)))-Publisher FASB-URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 3:

~~[http://www.xbri.org/2003/role/disclosureRef-Topic-946-SubTopic-210-Name-Accounting-Standards-Codification-Section-S99-Paragraph-2-Subparagraph-\(SX-210.6-05\(4\)\)](http://www.xbri.org/2003/role/disclosureRef-Topic-946-SubTopic-210-Name-Accounting-Standards-Codification-Section-S99-Paragraph-2-Subparagraph-(SX-210.6-05(4)))~~
~~-Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-2>~~
~~Reference 4: [http://www.xbri.org/2009/role/commonPracticeRef-Topic-946-SubTopic-220-Name-Accounting-Standards-Codification-Section-S99-Paragraph-3-Subparagraph-\(SX-210.6-09\(4\)\(b\)\)](http://www.xbri.org/2009/role/commonPracticeRef-Topic-946-SubTopic-220-Name-Accounting-Standards-Codification-Section-S99-Paragraph-3-Subparagraph-(SX-210.6-09(4)(b)))~~
~~-Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3>~~
~~Reference 5: [http://www.xbri.org/2003/role/disclosureRef-Topic-946-SubTopic-210-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210.6-04\(16\)\(a\)\)](http://www.xbri.org/2003/role/disclosureRef-Topic-946-SubTopic-210-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210.6-04(16)(a)))~~
~~-Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-1>~~
~~Reference 6: [http://www.xbri.org/2009/role/commonPracticeRef-Topic-946-SubTopic-220-Name-Accounting-Standards-Codification-Section-S99-Paragraph-3-Subparagraph-\(SX-210.6-09\(7\)\)](http://www.xbri.org/2009/role/commonPracticeRef-Topic-946-SubTopic-220-Name-Accounting-Standards-Codification-Section-S99-Paragraph-3-Subparagraph-(SX-210.6-09(7)))~~
~~-Publisher FASB -URI <https://asc.fasb.org/1943274/2147479134/946-220-S99-3>~~

[+ Details](#)

Name:*us-gaap_CommonStockSharesOutstanding* **Namespace Prefix:***us-gaap_* **Data Type:***xbri:sharesItemType* **Balance Type:***na* **Period Type:***instant*

[- Definition](#)

Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.

[+ References](#)

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210.5-02\(28\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210.5-02(28))) **-Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>**
Reference 2: [http://www.xbri.org/2003/role/disclosureRef-Topic-505-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-13-Subparagraph-\(a\)](http://www.xbri.org/2003/role/disclosureRef-Topic-505-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-13-Subparagraph-(a)) **-Publisher FASB -URI <https://asc.fasb.org/1943274/2147481112/505-10-50-13>**

[+ Details](#)

Name:*us-gaap_PreferredStockParOrStatedValuePerShare* **Namespace Prefix:***us-gaap_* **Data Type:***dtr-types:perShareItemType* **Balance Type:***na* **Period Type:***instant*

[- Definition](#)

The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.

[+ References](#)

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210.5-02\(28\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic-210-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210.5-02(28))) **-Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>**
Reference 2: [http://www.xbri.org/2003/role/disclosureRef-Topic-946-SubTopic-210-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SX-210.6-04\(16\)\(a\)\)](http://www.xbri.org/2003/role/disclosureRef-Topic-946-SubTopic-210-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SX-210.6-04(16)(a))) **-Publisher FASB -URI <https://asc.fasb.org/1943274/2147479170/946-210-S99-1>**

[+ Details](#)

Name:us-gaap_PreferredStockSharesAuthorized **Namespace Prefix:**us-gaap **Data Type:**xbri:sharesItemType **Balance Type:**na **Period Type:**instant

[- Definition](#)

Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.

[+ References](#)

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(20\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(20))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)**Reference 2:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13](http://www.xbrl.org/2003/role/disclosureRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 13-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13)

[+ Details](#)

Name:us-gaap_PreferredStockSharesIssued **Namespace Prefix:**us-gaap **Data Type:**xbri:sharesItemType **Balance Type:**na **Period Type:**instant

[- Definition](#)

Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.

[+ References](#)

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(20\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(20))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)**Reference 2:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph \(SX 210.6-05\(4\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph (SX 210.6-05(4))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2)**Reference 3:** [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph \(SX 210.6-09\(4\)\(b\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.6-09(4)(b))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3)**Reference 4:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.6-04\(16\)\(a\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.6-04(16)(a))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1)**Reference 5:** [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph \(SX 210.6-09\(7\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.6-09(7))-Publisher FASB-URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3)

[+Details](#)

Name:us-gaap_PreferredStockSharesOutstanding_Namespace Prefix:us-gaap_Data Type:xbrli:sharesItemType Balance Type:na Period Type:instant

[-Definition](#)

Cash received on stock transaction after deduction of issuance costs.

[+References](#)

No definition available.

[+Details](#)

Name:us-gaap_SaleOfStockConsiderationReceivedOnTransaction_Namespace Prefix:us-gaap_Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

[-Definition](#)

The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.

[+References](#)

No definition available.

[+Details](#)

Name:us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_Namespace Prefix:us-gaap_Data Type:xbrli:sharesItemType Balance Type:na Period Type:duration

[-Definition](#)

Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.

[+References](#)

No definition available.

[+Details](#)

Name:us-gaap_SaleOfStockPricePerShare_Namespace Prefix:us-gaap_Data Type:dtr-types:perShareItemType Balance Type:na Period Type:instant

[-Definition](#)

The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.

[+References](#)

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 718-SubTopic 10-Section 50-Paragraph 2-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2>

[+Details](#)

Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_Namespace Prefix:us-gaap_Data Type:xbrli:sharesItemType Balance Type:na Period Type:instant

[-Definition](#)

Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.

[+References](#)

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 50-Paragraph 2-SubTopic 10-Topic 505-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-2>

[+Details](#)

Name:us-gaap_SharesIssued_Namespace Prefix:us-gaap_Data Type:xbrli:sharesItemType Balance Type:na Period Type:instant

[-Details](#)

Name:us-gaap_SubsidiarySaleOfStockAxis=arwr_UnderwritingAgreementMember_Namespace Prefix: Data Type:na Balance Type: Period Type:

[-Details](#)

Name:us-gaap_SubsidiarySaleOfStockAxis=arwr_AtTheMarketAgreementMember_Namespace Prefix: Data Type:na Balance Type: Period Type:

[-Details](#)

Name:srt_RangeAxis=srt_MaximumMember_Namespace Prefix: Data Type:na Balance Type: Period Type:

[-Details](#)

Name:us-gaap_PlanNameAxis=arwr_TwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember_Namespace Prefix: Data Type:na Balance Type: Period Type: XML 63 R48.htm IDEA: XBRL DOCUMENT

Commitments and Contingencies - Narrative (Details) ft² in Thousands Jun. 30, 2024Dec. 20, 2021

	USD (\$)	ft ²	Other Commitments [Line Items]	Contingent liabilities\$ 0	Drug Manufacturing Facility / Wisconsin	Other Commitments [Line Items]	Planned area of the site (in sq ft) / ft ² 160	Laboratory and Office Facility / Wisconsin	Other Commitments [Line Items]	Planned area of the site (in sq ft) / ft ² 140	Facilities	Other Commitments [Line Items]	Capital expenditures incurred266,000,000.0	Facilities / Minimum	Other Commitments [Line Items]	Amount intends to invest for buildout of the facilities18,900,000.0	Facilities / Maximum	Other Commitments [Line Items]	Amount intends to invest for buildout of the facilities\$ 32,000,000.0

[-Definition](#)

Amount intends to invest for buildout of facilities.

[+References](#)

No definition available.

[+Details](#)

Name:arwr_AmountIntendsToInvestForBuildoutOffFacilities_Namespace Prefix:arwr_Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant

[-Definition](#)

Commitments, Capital Expenditures Incurred To Date

[+References](#)

No definition available.

+ Details
Name:arwr_CommitmentsCapitalExpendituresIncurredToDate_Namespace Prefix:arwr_Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant

-Definition

Area of land held.

+ References

No definition available.

+ Details
Name:us-gaap_AreaOffLand_Namespace Prefix:us-gaap_Data Type:dtr-types:areaItemType Balance Type:na Period Type:instant

-Definition

Amount of loss contingency liability.

+ References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 450-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 1-Publisher FASB-URI https://asc.fash.org/1943274/2147483076/450-20-50-1>Reference 2: <http://www.xbrl.org/2003/role/recommendedDisclosureRef-Topic 450-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 10-Publisher FASB-URI https://asc.fash.org/1943274/2147483076/450-20-50-10>

+ Details
Name:us-gaap_LossContingencyAccrualAtCarryingValue_Namespace Prefix:us-gaap_Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant

-Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details
Name:us-gaap_OtherCommitmentsLineItems_Namespace Prefix:us-gaap_Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

-Details
Name:us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_DrugManufacturingFacilityMember_Namespace Prefix: Data Type:na Balance Type: Period Type:

-Details
Name:srt_StatementGeographicalAxis=stpr_WI_Namespace Prefix: Data Type:na Balance Type: Period Type:

-Details
Name:us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_LaboratoryAndOfficeFacilityMember_Namespace Prefix: Data Type:na Balance Type: Period Type:

-Details
Name:us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_FacilitiesMember_Namespace Prefix: Data Type:na Balance Type: Period Type:

-Details
Name:srt_RangeAxis=srt_MinimumMember_Namespace Prefix: Data Type:na Balance Type: Period Type:

-Details
Name:srt_RangeAxis=srt_MaximumMember_Namespace Prefix: Data Type:na Balance Type: Period Type: XML 64 R49.htm IDEA: XBRL DOCUMENT

Leases - Narrative (Details) ft² in Thousands, \$ in Millions 3 Months Ended 9 Months Ended

Jun. 30, 2023

USD (\$)

Jun. 30, 2024

USD (\$)

ft²

option

Jun. 30, 2023

USD (\$)

Dec. 31, 2023

USD (\$)

Sep. 25, 2023

USD (\$)

Lessee Lease Description [Line Items] — Short-term lease cost / \$ \$ 0.6 \$ 0.0 \$ 1.2 Corporate Headquarters In Pasadena / California — Lessee Lease Description [Line Items] — Office space leases (in sq ft) / ft² 49 — Corporate Headquarters In Pasadena / California / Colorado Owner, LLC — Lessee Lease Description [Line Items] — Number of options to renew / option 1 — Operating lease renewal term 5 years — Research Facility in San Diego / California — Lessee Lease Description [Line Items] — Office space leases (in sq ft) / ft² 144 — Operating lease renewal term 10 years — Lease term 15 years — Maximum additional tenant improvement allowance / \$ \$ 7.2 \$ 23.6 Additional tenant improvement allowance interest per annum 7.00% 9.00% Additional tenant improvement allowance liability / \$ \$ 30.8 Research Facility in San Diego / California / Maximum — Lessee Lease Description [Line Items] — Number of options to renew / option 1 — Research Facility in Madison / Wisconsin — Lessee Lease Description [Line Items] — Office space leases (in sq ft) / ft² 113 — Number of options to renew / option 2 — Operating lease renewal term 5 years —

-Definition

Additional Tenant Improvement Allowance, Interest Per Annum

+ References

No definition available.

+ Details
Name:arwr_AdditionalTenantImprovementAllowanceInterestPerAnnum_Namespace Prefix:arwr_Data Type:dtr-types:percentItemType Balance Type:na Period Type:instant

-Definition

Additional Tenant Improvement Allowance Liability

+ References

No definition available.

+ Details
Name:arwr_AdditionalTenantImprovementAllowanceLiability_Namespace Prefix:arwr_Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant

-Definition

Maximum Additional Tenant Improvement Allowance

+ References

No definition available.

+ Details

Name:arwr_MaximumAdditionalTenantImprovementAllowance Namespace Prefix:arwr_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant

-Definition

Number of options to renew:

+ References

No definition available.

+ Details

Name:arwr_NumberOfOptionsToRenew Namespace Prefix:arwr_ Data Type:xbrli:integerItemType Balance Type:na Period Type:instant

-Definition

Area of land subject to a ground lease:

+ References

Reference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic-842-SubTopic-20-Name-Accounting-Standards-Codification-Section-50-Paragraph-3-Subparagraph-\(a\)\(1\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147478964/842-20-50-3](http://www.xbrl.org/2009/role/commonPracticeRef-Topic-842-SubTopic-20-Name-Accounting-Standards-Codification-Section-50-Paragraph-3-Subparagraph-(a)(1)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147478964/842-20-50-3)

+ Details

Name:us-gaap_LandSubjectToGroundLeases Namespace Prefix:us-gaap_ Data Type:dtr-types:areaItemType Balance Type:na Period Type:instant

-Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic-842-SubTopic-20-Name-Accounting-Standards-Codification-Section-50-Paragraph-7A-Subparagraph-\(c\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147478964/842-20-50-7A](http://www.xbrl.org/2003/role/disclosureRef-Topic-842-SubTopic-20-Name-Accounting-Standards-Codification-Section-50-Paragraph-7A-Subparagraph-(c)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147478964/842-20-50-7A)Reference 2: <http://www.xbrl.org/2003/role/disclosureRef-Topic-842-SubTopic-20-Name-Accounting-Standards-Codification-Section-50-Paragraph-3-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147478964/842-20-50-3>

+ Details

Name:us-gaap_LesseeLeaseDescriptionLineItems Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

-Definition

Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.

+ References

Reference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic-842-SubTopic-20-Name-Accounting-Standards-Codification-Section-50-Paragraph-3-Subparagraph-\(a\)\(3\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147478964/842-20-50-3](http://www.xbrl.org/2009/role/commonPracticeRef-Topic-842-SubTopic-20-Name-Accounting-Standards-Codification-Section-50-Paragraph-3-Subparagraph-(a)(3)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147478964/842-20-50-3)

+ Details

Name:us-gaap_LesseeOperatingLeaseRenewalTerm Namespace Prefix:us-gaap_ Data Type:xbrli:durationItemType Balance Type:na Period Type:instant

-Definition

Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.

+ References

Reference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic-842-SubTopic-20-Name-Accounting-Standards-Codification-Section-50-Paragraph-3-Subparagraph-\(a\)\(3\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147478964/842-20-50-3](http://www.xbrl.org/2009/role/commonPracticeRef-Topic-842-SubTopic-20-Name-Accounting-Standards-Codification-Section-50-Paragraph-3-Subparagraph-(a)(3)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147478964/842-20-50-3)

+ Details

Name:us-gaap_LesseeOperatingLeaseTermOfContract Namespace Prefix:us-gaap_ Data Type:xbrli:durationItemType Balance Type:na Period Type:instant

-Definition

Amount of short-term lease cost, excluding expense for lease with term of one month or less.

+ References

Reference 1: <http://www.xbrl.org/2003/role/exampleRef-Topic-842-SubTopic-20-Name-Accounting-Standards-Codification-Section-55-Paragraph-53-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479589/842-20-55-53>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic-842-SubTopic-20-Name-Accounting-Standards-Codification-Section-50-Paragraph-4-Subparagraph-\(c\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147478964/842-20-50-4](http://www.xbrl.org/2003/role/disclosureRef-Topic-842-SubTopic-20-Name-Accounting-Standards-Codification-Section-50-Paragraph-4-Subparagraph-(c)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147478964/842-20-50-4)

+ Details

Name:us-gaap_ShortTermLeaseCost_Namespace Prefix:us-gaap_Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

-Details

Name:us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_CorporateHeadquartersInPasadenaMember_Namespace Prefix:_Data Type:na Balance Type:_Period Type:

-Details

Name:srt_StatementGeographicalAxis=stpr_CA_Namespace Prefix:_Data Type:na Balance Type:_Period Type:

-Details

Name:srt_CounterpartyNameAxis=arwr_ColoradoOwnerLLCMember_Namespace Prefix:_Data Type:na Balance Type:_Period Type:

-Details

Name:us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ResearchFacilityInSanDiegoMember_Namespace Prefix:_Data Type:na Balance Type:_Period Type:

-Details

Name:srt_RangeAxis=srt_MaximumMember_Namespace Prefix:_Data Type:na Balance Type:_Period Type:

-Details

Name:us-gaap_PropertyPlantAndEquipmentByTypeAxis=arwr_ResearchFacilityInMadisonMember_Namespace Prefix:_Data Type:na Balance Type:_Period Type:

-Details

Name:srt_StatementGeographicalAxis=stpr_WI_Namespace Prefix:_Data Type:na Balance Type:_Period Type: XML-65-R50.htm IDEA: XBRL DOCUMENT

Leases - Components of Lease Assets and Liabilities (Details) - USD (\$) \$ in Thousands 3 Months Ended 9 Months Ended

Jun. 30, 2024

Jun. 30, 2023

Jun. 30, 2024

Jun. 30, 2023

Sep. 30, 2023

Lease Assets and Liabilities — Right-of-use assets\$ 44,339 \$ 44,339 \$ 45,297Lease liabilities6,053 6,053 10,563Lease liabilities, net of current portion112,040 112,040 \$ 104,608Lease Cost — Total4,365\$ 4,08912,513\$ 9,904 Research and development — Lease Cost — Operating lease cost2,9653,3238,5317,735 Variable lease cost863257 2,478627 General and administrative expense — Lease Cost — Operating lease cost5375091,5041,542 Variable lease cost\$ 0\$ 0\$ 0-

-References

No definition available.

+ Details

Name:us-gaap_AssetsAndLiabilitiesLesseeAbstract_Namespace Prefix:us-gaap_Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

-Definition

Amount of lease cost recognized by lessee for lease contract.

+ References

Reference 1: <http://www.xbrl.org/2003/role/exampleRef-Topic-842-SubTopic-20-Name-Accounting-Standards-Codification-Section-55-Paragraph-53-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479589/842-20-55-53>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef-Topic-842-SubTopic-20-Name-Accounting-Standards-Codification-Section-50-Paragraph-4-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147478964/842-20-50-4>

+ Details

Name:us-gaap_LeaseCost_Namespace Prefix:us-gaap_Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

-References

No definition available.

+ Details

Name:us-gaap_LeaseCostAbstract_Namespace Prefix:us-gaap_Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

-Definition

Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.

+ References

Reference 1: <http://www.xbrl.org/2003/role/exampleRef-Topic-842-SubTopic-20-Name-Accounting-Standards-Codification-Section-55-Paragraph-53-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479589/842-20-55-53>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic-842-SubTopic-20-Name-Accounting-Standards-Codification-Section-50-Paragraph-4-Subparagraph-\(b\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147478964/842-20-50-4](http://www.xbrl.org/2003/role/disclosureRef-Topic-842-SubTopic-20-Name-Accounting-Standards-Codification-Section-50-Paragraph-4-Subparagraph-(b)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147478964/842-20-50-4)

[+ Details](#)

~~Name:us-gaap_OperatingLeaseCost Namespace Prefix:us-gaap_ Data Type:xbri:monetaryItemType Balance Type:debit Period Type:duration~~

[- Definition](#)

~~Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.~~

[+ References](#)

~~Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic-842-SubTopic-20-Name-Accounting-Standards-Codification-Section-45-Paragraph-1-Subparagraph-\(b\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479041/842-20-45-1](http://www.xbrl.org/2003/role/disclosureRef-Topic-842-SubTopic-20-Name-Accounting-Standards-Codification-Section-45-Paragraph-1-Subparagraph-(b)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479041/842-20-45-1)~~

[+ Details](#)

~~Name:us-gaap_OperatingLeaseLiabilityCurrent Namespace Prefix:us-gaap_ Data Type:xbri:monetaryItemType Balance Type:credit Period Type:instant~~

[- Definition](#)

~~Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.~~

[+ References](#)

~~Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic-842-SubTopic-20-Name-Accounting-Standards-Codification-Section-45-Paragraph-1-Subparagraph-\(b\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479041/842-20-45-1](http://www.xbrl.org/2003/role/disclosureRef-Topic-842-SubTopic-20-Name-Accounting-Standards-Codification-Section-45-Paragraph-1-Subparagraph-(b)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479041/842-20-45-1)~~

[+ Details](#)

~~Name:us-gaap_OperatingLeaseLiabilityNoncurrent Namespace Prefix:us-gaap_ Data Type:xbri:monetaryItemType Balance Type:credit Period Type:instant~~

[- Definition](#)

~~Amount of lessee's right to use underlying asset under operating lease.~~

[+ References](#)

~~Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic-842-SubTopic-20-Name-Accounting-Standards-Codification-Section-45-Paragraph-1-Subparagraph-\(a\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479041/842-20-45-1](http://www.xbrl.org/2003/role/disclosureRef-Topic-842-SubTopic-20-Name-Accounting-Standards-Codification-Section-45-Paragraph-1-Subparagraph-(a)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479041/842-20-45-1)~~

[+ Details](#)

~~Name:us-gaap_OperatingLeaseRightOfUseAsset Namespace Prefix:us-gaap_ Data Type:xbri:monetaryItemType Balance Type:debit Period Type:instant~~

[- Definition](#)

~~Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.~~

[+ References](#)

~~Reference 1: <http://www.xbrl.org/2003/role/exampleRef-Topic-842-SubTopic-20-Name-Accounting-Standards-Codification-Section-55-Paragraph-53-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479589/842-20-55-53>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic-842-SubTopic-20-Name-Accounting-Standards-Codification-Section-50-Paragraph-4-Subparagraph-\(d\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147478964/842-20-50-4](http://www.xbrl.org/2003/role/disclosureRef-Topic-842-SubTopic-20-Name-Accounting-Standards-Codification-Section-50-Paragraph-4-Subparagraph-(d)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147478964/842-20-50-4)~~

[+ Details](#)

~~Name:us-gaap_VariableLeaseCost Namespace Prefix:us-gaap_ Data Type:xbri:monetaryItemType Balance Type:debit Period Type:duration~~

[- Details](#)

~~Name:us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember Namespace Prefix: Data Type:na Balance Type: Period Type:~~

[- Details](#)

~~Name:us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember Namespace Prefix: Data Type:na Balance Type: Period Type: XML 66~~

R51.htm IDEA: XBRL DOCUMENT
Leases - Summary of Maturities of Operating Lease Liabilities on an Undiscounted Basis (Details) \$ in Thousands Jun. 30, 2024
USD (\$) Leases (Abstract) 2024 (remainder of fiscal year) \$ 3,793 2025 15,356 2026 15,696 2027 14,869 2028 13,511 2029 and thereafter 128,356 Total 191,581 Less imputed interest (73,488) Total operating lease liabilities (includes current portion) \$ 118,093

-Definition

Lessee operating lease liability payments due year five and after year five.

+References

No definition available.

+Details

Name:arwr_LesseeOperatingLeaseLiabilityPaymentsDueYearFiveAndAfterYearFive_Namespace Prefix:arwr_Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant

-References

No definition available.

+Details

Name:us-gaap_LeasesAbstract_Namespace Prefix:us-gaap_Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

-Definition

Amount of lessee's undiscounted obligation for lease payment for operating lease.

+References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic-842-SubTopic-20-Name Accounting Standards Codification-Section 50-Paragraph 6-Publisher FASB-URI https://asc.fasb.org/1943274/2147478964/842-20-50-6

+Details

Name:us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_Namespace Prefix:us-gaap_Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant

-Definition

Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).

+References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic-842-SubTopic-20-Name Accounting Standards Codification-Section 50-Paragraph 6-Publisher FASB-URI https://asc.fasb.org/1943274/2147478964/842-20-50-6

+Details

Name:us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_Namespace Prefix:us-gaap_Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant

-Definition

Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).

+References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic-842-SubTopic-20-Name Accounting Standards Codification-Section 50-Paragraph 6-Publisher FASB-URI https://asc.fasb.org/1943274/2147478964/842-20-50-6

+Details

Name:us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_Namespace Prefix:us-gaap_Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant

-Definition

Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).

+References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic-842-SubTopic-20-Name Accounting Standards Codification-Section 50-Paragraph 6-Publisher FASB-URI https://asc.fasb.org/1943274/2147478964/842-20-50-6

+Details

Name:us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_Namespace Prefix:us-gaap_Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant

-Definition

Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).

+References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic-842-SubTopic-20-Name Accounting Standards Codification-Section 50-Paragraph 6-Publisher FASB-URI

+ Details

Name:us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_Namespace Prefix:us-gaap_Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant

- Definition

Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef-Topic 842-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 6-Publisher FASB-URI https://asc.fasb.org/1943274/2147478964/842-20-50-6

+ Details

Name:us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOffFiscalYear_Namespace Prefix:us-gaap_Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant

- Definition

Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 842-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 6-Publisher FASB-URI https://asc.fasb.org/1943274/2147478964/842-20-50-6

+ Details

Name:us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_Namespace Prefix:us-gaap_Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant

- Definition

Present value of lessee's discounted obligation for lease payments from operating lease.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 842-SubTopic 20-Name Accounting Standards Codification-Section 45-Paragraph 1-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479041/842-20-45-1

+ Details

Name:us-gaap_OperatingLeaseLiability_Namespace Prefix:us-gaap_Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant XML 67 R52.htm IDEA: XBRL DOCUMENT

Leases-Supplemental Cash Flow and Other Information Related to Leases (Details)-USD (\$) \$ in Thousands3 Months Ended9 Months Ended

Jun. 30, 2024

Jun. 30, 2023

Jun. 30, 2024

Jun. 30, 2023

Cash received for amounts included in the measurement of lease liabilities:—Operating cash flows from operating leases\$ 0\$ 5,414\$ 3,099\$ 23,343Right-of-use assets adjusted in exchange for new/amended operating lease liabilities03,519(64)(19,063)Cash paid for amounts included in the measurement of lease liabilities:—Operating cash flows from operating leases\$ 3,204\$ 1,885\$ 7,221\$ 4,081Weighted-average remaining lease term (in years)12 years 9 months 18 days13 years 4 months 24 days12 years 9 months 18 days13 years 4 months 24 daysWeighted-average discount rate8.00%8.00%8.00%8.00%

- Definition

Cash Flow, Operating Activities, Lessee, Cash Received For Amounts Included In Measurement Of Lease Liabilities

+ References

No definition available.

+ Details

Name:arwr_CashFlowOperatingActivitiesLesseeCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_Namespace Prefix:arwr_Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

- Definition

Operating Lease, Cash Received For Amounts Included In Measurement Of Lease Liabilities

+ References

No definition available.

+ Details

Name:arwr_OperatingLeaseCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilities_Namespace Prefix:arwr_Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

- Definition

Right-Of-Use Asset Adjustment In Exchange For Operating Lease Liability

+ References

No definition available.

+ Details
Name:arwr_RightOfUseAssetAdjustmentInExchangeForOperatingLeaseLiability Namespace Prefix:arwr_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

-References

No definition available.

+ Details
Name:us-gaap_CashFlowOperatingActivitiesLesseeAbstract Namespace Prefix:us-gaap_ Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

-Definition

Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef-Topic 842-SubTopic 20-Name Accounting Standards Codification-Section 45-Paragraph 5-Subparagraph (c)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479041/842-20-45-5Reference 2: http://www.xbrl.org/2003/role/disclosureRef-Topic 842-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 4-Subparagraph (g)(1)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478964/842-20-50-4

+ Details
Name:us-gaap_OperatingLeasePayments Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:duration

-Definition

Weighted average discount rate for operating lease calculated at point in time.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef-Topic 842-SubTopic 20-Name Accounting Standards Codification-Section 55-Paragraph 53-Publisher FASB-URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef-Topic 842-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 4-Subparagraph (g)(4)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478964/842-20-50-4

+ Details
Name:us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent Namespace Prefix:us-gaap_ Data Type:dtr-types:percentItemType Balance Type:na Period Type:instant

-Definition

Weighted average remaining lease term for operating lease, in 'PnYnMnDfnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef-Topic 842-SubTopic 20-Name Accounting Standards Codification-Section 55-Paragraph 53-Publisher FASB-URI https://asc.fasb.org/1943274/2147479589/842-20-55-53Reference 2: http://www.xbrl.org/2003/role/disclosureRef-Topic 842-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 4-Subparagraph (g)(3)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478964/842-20-50-4

+ Details
Name:us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1 Namespace Prefix:us-gaap_ Data Type:xbrli:durationItemType Balance Type:na Period Type:instant
XML 68 R53.htm IDEA: XBRL DOCUMENT
Stock-Based Compensation - Narrative (Details) - USD (\$) \$ in Thousands 3 Months Ended9 Months Ended
Oct. 01, 2023
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Sep. 30, 2021

~~Share Based Compensation Arrangement By Share Based Payment Award [Line Items] — Common stock, share reserve for issuance (in shares) 4,565,727 4,565,727 — Granted (in shares) 0 — Stock-based compensation expense \$ 14,711 \$ 19,947 \$ 48,984 \$ 59,949 — Options — Share Based Compensation Arrangement By Share Based Payment Award [Line Items] — Intrinsic value of options exercised 7006,500 3,800 10,100 — Stock-based compensation expense 4002,100 2,500 6,700 — Unrecognized pre-tax compensation expense 400 \$ 400 — Weighted average period to recognize pre-tax compensation expense 3 months — Restricted stock units — Share Based Compensation Arrangement By Share Based Payment Award [Line Items] — Stock-based compensation expense 14,300 \$ 17,800 \$ 46,500 \$ 53,200 — Weighted average period to recognize pre-tax compensation expense 1 year 7 months 6 days — Unrecognized pre-tax compensation expense \$ 96,300 \$ 96,300 — 2013 Incentive Plan — Share Based Compensation Arrangement By Share Based Payment Award [Line Items] — Shares reserve for issuance (in shares) 2,924,586 2,924,586 — Number of shares forfeited (in shares) 158,928 — 2021 Incentive Plan — Share Based Compensation Arrangement By Share Based Payment Award [Line Items] — Number of shares authorized (in shares) 8,000,000 — Number of shares forfeited (in shares) 154,139 — Granted (in shares) 3,697,189 — Inducement Awards / Options — Share Based Compensation Arrangement By Share Based Payment Award [Line Items] — Shares reserve for issuance (in shares) 665,020 665,020 — Inducement Awards / Restricted stock units — Share Based Compensation Arrangement By Share Based Payment Award [Line Items] — Shares reserve for issuance (in shares) 616,638 616,638 — Visirna ESOP — Share Based Compensation Arrangement By Share Based Payment Award [Line Items] — Number of shares authorized (in shares) 20,000,000 — Granted (in shares) 7,500,000 — Stock-based compensation expense \$ 2,300 \$ 5,500 —~~

-Definition

~~Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.~~

+ References

~~Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SAB Topic 14.F\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SAB Topic 14.F)-Publisher FASB-URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(h\)\(1\)\(i\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (h)(1)(i)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)~~

+Details

~~Name:us-gaap_AllocatedShareBasedCompensationExpense Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration~~

-Definition

~~Aggregate number of common shares reserved for future issuance.~~

+ References

~~Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(29\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(29))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)~~

+Details

~~Name:us-gaap_CommonStockCapitalSharesReservedForFutureIssuance Namespace Prefix:us-gaap_ Data Type:xbrli:sharesItemType Balance Type:na Period Type:instant~~

-Definition

~~Weighted average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'PY5M13D' represents reported fact of one year, five months, and thirteen days.~~

+ References

~~Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(i\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (i)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)~~

+Details

~~Name:us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 Namespace Prefix:us-gaap_ Data Type:xbrli:durationItemType Balance Type:na Period Type:duration~~

-Definition

~~Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.~~

+ References

~~Reference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(i\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (i)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)~~

+Details

~~Name:us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions Namespace Prefix:us-gaap_ Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant~~

-Definition

~~Amount of cost to be recognized for option under share-based payment arrangement.~~

+ References

Reference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(f\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (f)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)

+ Details

Name:us-gaap-EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions **Namespace Prefix:**us-gaap_ **Data Type:** xbrli:monetaryItemType **Balance Type:**debit **Period Type:**instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 35-Paragraph 1D-Publisher FASB-URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D>**Reference 2:** <http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 35-Paragraph 3-Publisher FASB-URI https://asc.fasb.org/1943274/2147480483/718-10-35-3>**Reference 3:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(a\)\(1\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (a)(1)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)**Reference 4:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(a\)\(2\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (a)(2)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)**Reference 5:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(a\)\(3\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (a)(3)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)**Reference 6:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\)\(1\)\(i\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c)(1)(i)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)**Reference 7:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\)\(1\)\(ii\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c)(1)(ii)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)**Reference 8:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\)\(1\)\(iii\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c)(1)(iii)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)**Reference 9:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\)\(1\)\(iv\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c)(1)(iv)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)**Reference 10:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\)\(1\)\(iv\)\(01\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c)(1)(iv)(01)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)**Reference 11:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\)\(1\)\(iv\)\(02\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c)(1)(iv)(02)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)**Reference 12:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\)\(1\)\(iv\)\(03\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c)(1)(iv)(03)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)**Reference 13:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\)\(1\)\(iv\)\(04\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c)(1)(iv)(04)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)**Reference 14:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\)\(2\)\(i\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c)(2)(i)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)**Reference 15:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\)\(2\)\(ii\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c)(2)(ii)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)**Reference 16:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\)\(2\)\(iii\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c)(2)(iii)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)**Reference 17:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\)\(2\)\(iii\)\(01\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c)(2)(iii)(01)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)**Reference 18:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\)\(2\)\(iii\)\(02\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c)(2)(iii)(02)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)**Reference 19:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\)\(2\)\(iii\)\(03\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c)(2)(iii)(03)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)**Reference 20:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(d\)\(1\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (d)(1)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)**Reference 21:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(d\)\(2\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (d)(2)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)**Reference 22:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(e\)\(1\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (e)(1)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)**Reference 23:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(e\)\(2\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (e)(2)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)**Reference 24:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(f\)\(2\)\(i\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (f)(2)(i)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)**Reference 25:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(f\)\(2\)\(ii\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (f)(2)(ii)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)**Reference 26:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(f\)\(2\)\(iii\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (f)(2)(iii)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)**Reference 27:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(f\)\(2\)\(iv\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (f)(2)(iv)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)**Reference 28:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(f\)\(2\)\(v\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (f)(2)(v)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)

[+Details](#)

Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_Namespace Prefix:us-gaap_Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

[-Definition](#)

Number of shares authorized for issuance under share-based payment arrangement.

[+References](#)

Reference 1: [http://www.xbrl.org/2003/role/exampleRef-Topic-718-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-\(a\)\(3\)-Publisher-FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/exampleRef-Topic-718-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-(a)(3)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480429/718-10-50-2)

[+Details](#)

Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_Namespace Prefix:us-gaap_Data Type:xbrli:sharesItemType Balance Type:na Period Type:instant

[-Definition](#)

The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.

[+References](#)

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name-Accounting-Standards-Codification-Topic-718-SubTopic-10-Section-50-Paragraph-2-Publisher-FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://fasb.org/us-gaap/role/ref/legacyRef-Name-Accounting-Standards-Codification-Topic-718-SubTopic-10-Section-50-Paragraph-2-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480429/718-10-50-2)

[+Details](#)

Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_Namespace Prefix:us-gaap_Data Type:xbrli:sharesItemType Balance Type:na Period Type:instant

[-Definition](#)

Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.

[+References](#)

Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic-718-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-\(d\)\(2\)-Publisher-FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic-718-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-(d)(2)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480429/718-10-50-2)

[+Details](#)

Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_Namespace Prefix:us-gaap_Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

[-Definition](#)

The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.

[+References](#)

Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic-718-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-\(c\)\(1\)\(iv\)\(03\)-Publisher-FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic-718-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-(c)(1)(iv)(03)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480429/718-10-50-2)

[+Details](#)

Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_Namespace Prefix:us-gaap_Data Type:xbrli:sharesItemType Balance Type:na Period Type:duration

[-Definition](#)

Gross number of share options (or share units) granted during the period.

[+References](#)

Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic-718-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-\(c\)\(1\)\(iv\)\(01\)-Publisher-FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic-718-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-(c)(1)(iv)(01)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480429/718-10-50-2)

[+Details](#)

Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_Namespace Prefix:us-gaap_Data Type:xbrli:sharesItemType

Balance Type:na Period Type:duration

[-Details](#)

Name:us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type:na Balance Type: Period Type:

[-Details](#)

Name:us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type:na Balance Type: Period Type:

[-Details](#)

Name:us-gaap_PlanNameAxis=arwr_TwoThousandsThirteenIncentivePlanMember Namespace Prefix: Data Type:na Balance Type: Period Type:

[-Details](#)

Name:us-gaap_PlanNameAxis=arwr_TwoThousandTwentyOneIncentivePlanMember Namespace Prefix: Data Type:na Balance Type: Period Type:

[-Details](#)

Name:us-gaap_PlanNameAxis=arwr_InducementAwardsMember Namespace Prefix: Data Type:na Balance Type: Period Type:

[-Details](#)

Name:us-gaap_PlanNameAxis=arwr_VisirnaESOPMember Namespace Prefix: Data Type:na Balance Type: Period Type: XML 69 R54.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation - Summary of Granted and Outstanding Shares (Details) - shares Jun. 30, 2024 Sep. 30, 2023 Share Based Compensation Arrangement By Share Based Payment Award [Line Items] - Number of options outstanding (in shares) 2,012,497 2,263,477 Total (in shares) 7,042,421 Restricted stock units - Share Based Compensation Arrangement By Share Based Payment Award [Line Items] - Share-based payment award (in shares) 5,029,924 4,241,640 2013 Incentive Plan - Share Based Compensation Arrangement By Share Based Payment Award [Line Items] - Number of options outstanding (in shares) 1,315,326 Total (in shares) 2,924,586 2013 Incentive Plan / Restricted stock units - Share Based Compensation Arrangement By Share Based Payment Award [Line Items] - Share-based payment award (in shares) 1,609,260 2021 Incentive Plan - Share Based Compensation Arrangement By Share Based Payment Award [Line Items] - Number of options outstanding (in shares) 32,151 Total (in shares) 2,836,177 2021 Incentive Plan / Restricted stock units - Share Based Compensation Arrangement By Share Based Payment Award [Line Items] - Share-based payment award (in shares) 2,804,026 Inducement Awards - Share Based Compensation Arrangement By Share Based Payment Award [Line Items] - Number of options outstanding (in shares) 665,020 Total (in shares) 1,281,658 Inducement Awards / Restricted stock units - Share Based Compensation Arrangement By Share Based Payment Award [Line Items] - Share-based payment award (in shares) 616,638

[-Definition](#)

Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Equity Instruments Other Than Options, Outstanding

[+References](#)

No definition available.

[+Details](#)

Name:arwr_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding Namespace Prefix:arwr_Data Type:xbrl:sharesItemType Balance Type:na Period Type:instant

[-Definition](#)

The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.

[+References](#)

Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\)\(2\)\(i\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c)(2)(i)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\)\(2\)\(ii\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c)(2)(ii)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)

[+Details](#)

Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber Namespace Prefix:us-gaap_Data Type:xbrl:sharesItemType Balance Type:na Period Type:instant

[-Definition](#)

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

[+References](#)

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 35-Paragraph 1D-Publisher FASB-URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(a\)\(1\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (a)(1)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(a\)\(2\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (a)(2)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(a\)\(3\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (a)(3)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 5: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(a\)\(4\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (a)(4)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(a\)\(5\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (a)(5)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 7: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(a\)\(6\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (a)(6)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(a\)\(7\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (a)(7)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(a\)\(8\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (a)(8)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 10: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(a\)\(9\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (a)(9)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 11: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(a\)\(10\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (a)(10)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 12: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(a\)\(11\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (a)(11)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 13: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(a\)\(12\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (a)(12)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 14: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(a\)\(13\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (a)(13)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 15: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(a\)\(14\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (a)(14)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 16: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(a\)\(15\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (a)(15)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 17: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(a\)\(16\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (a)(16)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 18: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(a\)\(17\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (a)(17)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 19: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(a\)\(18\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (a)(18)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 20: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(a\)\(19\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (a)(19)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 21: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(a\)\(20\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (a)(20)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 22: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(a\)\(21\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (a)(21)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 23: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(a\)\(22\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (a)(22)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 24: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(a\)\(23\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (a)(23)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 25: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(a\)\(24\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (a)(24)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)

~~[http://www.xbrl.org/2003/role/disclosureRef-Topic-718-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-\(f\)\(2\)\(ii\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference-26](http://www.xbrl.org/2003/role/disclosureRef-Topic-718-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-(f)(2)(ii)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference-26); [http://www.xbrl.org/2003/role/disclosureRef-Topic-718-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-\(f\)\(2\)\(iii\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference-27](http://www.xbrl.org/2003/role/disclosureRef-Topic-718-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-(f)(2)(iii)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference-27); [http://www.xbrl.org/2003/role/disclosureRef-Topic-718-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-\(f\)\(2\)\(iv\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference-28](http://www.xbrl.org/2003/role/disclosureRef-Topic-718-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-(f)(2)(iv)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480429/718-10-50-2Reference-28); [http://www.xbrl.org/2003/role/disclosureRef-Topic-718-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-\(f\)\(2\)\(v\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic-718-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-(f)(2)(v)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480429/718-10-50-2)~~

[+ Details](#)

Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems **Namespace Prefix:**us-gaap_ **Data Type:**xbrli:stringItemType **Balance Type:**na **Period Type:**duration

[- Definition](#)

Number of options outstanding, including both vested and non-vested options:

[+ References](#)

Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic-718-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-\(c\)\(1\)\(i\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic-718-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-(c)(1)(i)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480429/718-10-50-2)**Reference 2:** [http://www.xbrl.org/2003/role/disclosureRef-Topic-718-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-\(c\)\(1\)\(ii\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic-718-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-(c)(1)(ii)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480429/718-10-50-2)

[+ Details](#)

Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber **Namespace Prefix:**us-gaap_ **Data Type:**xbrli:sharesItemType **Balance Type:**na **Period Type:**instant

[- Details](#)

Name:us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember **Namespace Prefix:** **Data Type:**na **Balance Type:** **Period Type:**

[- Details](#)

Name:us-gaap_PlanNameAxis=arwr_TwoThousandsThirteenIncentivePlanMember **Namespace Prefix:** **Data Type:**na **Balance Type:** **Period Type:**

[- Details](#)

Name:us-gaap_PlanNameAxis=arwr_TwoThousandTwentyOneIncentivePlanMember **Namespace Prefix:** **Data Type:**na **Balance Type:** **Period Type:**

[- Details](#)

Name:us-gaap_PlanNameAxis=arwr_InducementAwardsMember **Namespace Prefix:** **Data Type:**na **Balance Type:** **Period Type:**XML 70-R55.htm IDEA: XBRL DOCUMENT **Stock-Based Compensation - Expenses Included in Operating Expenses (Details) - USD (\$)** \$ in Thousands **3 Months Ended** **9 Months Ended**

Jun. 30, 2024

Jun. 30, 2023

Jun. 30, 2024

Jun. 30, 2023

Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items] — **Stock-based compensation expense** \$ 14,711 \$ 19,947 \$ 48,984 \$ 59,949 **Research and development** — **Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]** — **Stock-based compensation expense** 6,221 6,982 21,634 26,129 **General and administrative expense** — **Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]** — **Stock-based compensation expense** \$ 8,490 \$ 10,965 \$ 27,350 \$ 33,820

[- Definition](#)

Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.

[+ References](#)

Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic-718-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-\(SAB-Topic-14-F\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479830/718-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic-718-SubTopic-10-Name-Accounting-Standards-Codification-Section-S99-Paragraph-1-Subparagraph-(SAB-Topic-14-F)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147479830/718-10-S99-1)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic-718-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-\(h\)\(1\)\(i\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic-718-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-(h)(1)(i)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480429/718-10-50-2)

[+ Details](#)

Name:us-gaap_AllocatedShareBasedCompensationExpense_Namespace-Prefix:us-gaap_Data-Type:xbrli:monetaryItemType_Balance-Type:debit-Period-Type:duration

[- Definition](#)

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

[+ References](#)

No definition available.

[+ Details](#)

Name:us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_Namespace-Prefix:us-gaap_Data-Type:xbrli:stringItemType_Balance-Type:na-Period-Type:duration

[- Details](#)

Name:us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember_Namespace-Prefix:_Data-Type:na-Balance-Type:_Period-Type:

[- Details](#)

Name:us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember_Namespace-Prefix:_Data-Type:na-Balance-Type:_Period-Type:_XML-71

R56.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation - Summarize Information about Stock Options (Details) - USD (\$) 9 Months Ended

Jun. 30, 2024

Shares_Beginning balance (in shares)2,263,477Granted (in shares)0Cancelled (in shares)(53,582)Exercised (in shares)(197,398)Ending balance (in shares)2,012,497Number of Options Outstanding, Exercisable (in shares)2,001,968Weighted-Average Exercise Price Per Share_Beginning balance (in dollars per share)\$ 22.68Granted (in dollars per share)0Cancelled (in dollars per share)36.62Exercised (in dollars per share)10.98Ending balance (in dollars per share)23.22Weighted-Average Exercise Price Per Share, Exercisable (in dollars per share)\$ 23.05Weighted-Average Remaining Contractual Term (Years)3 years 9 months 18 daysWeighted-Average Remaining Contractual Term, Exercisable3 years 9 months 18 daysAggregate Intrinsic Value\$ 22,486,304Aggregate Intrinsic Value, Exercisable\$ 22,486,304

[- Definition](#)

The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.

[+ References](#)

Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic-718-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-\(c\)\(1\)\(iii\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic-718-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-(c)(1)(iii)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480429/718-10-50-2)

[+ Details](#)

Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_Namespace-Prefix:us-gaap_Data-Type:xbrli:sharesItemType_Balance-Type:na-Period-Type:instant

[- Definition](#)

The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.

[+ References](#)

Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic-718-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-\(c\)\(1\)\(iii\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic-718-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-(c)(1)(iii)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480429/718-10-50-2)

[+ Details](#)

Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_Namespace-Prefix:us-gaap_Data-Type:dtr-types:perShareItemType_Balance-Type:na-Period-Type:instant

[- Definition](#)

Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.

[+ References](#)

Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic-718-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-\(c\)\(1\)\(iv\)\(04\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic-718-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-(c)(1)(iv)(04)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480429/718-10-50-2)

+ Details

Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_**Namespace Prefix:**us-gaap_**Data Type:**xbri:sharesItemType
Balance Type:na **Period Type:**duration

- Definition

Gross number of share options (or share units) granted during the period:

+ References

Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic-718-SubTopic-10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\)\(1\)\(iv\)-\(01\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic-718-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-(c)(1)(iv)-(01)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480429/718-10-50-2)

+ Details

Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_**Namespace Prefix:**us-gaap_**Data Type:**xbri:sharesItemType
Balance Type:na **Period Type:**duration

- Definition

Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding:

+ References

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Topic 718-SubTopic 10-Section 50-Paragraph 2-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://fasb.org/us-gaap/role/ref/legacyRef-Name-Accounting-Standards-Codification-Topic-718-SubTopic-10-Section-50-Paragraph-2-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480429/718-10-50-2)

+ Details

Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_**Namespace Prefix:**us-gaap_**Data Type:**xbri:monetaryItemType **Balance Type:**debit **Period Type:**instant

- Definition

Number of options outstanding, including both vested and non-vested options:

+ References

Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic-718-SubTopic-10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\)\(1\)\(i\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic-718-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-(c)(1)(i)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480429/718-10-50-2)**Reference 2:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\)\(1\)\(ii\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic-718-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-(c)(1)(ii)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480429/718-10-50-2)

+ Details

Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_**Namespace Prefix:**us-gaap_**Data Type:**xbri:sharesItemType
Balance Type:na **Period Type:**instant

- Definition

A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period:

+ References

No definition available:

+ Details

Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_**Namespace Prefix:**us-gaap_**Data Type:**xbri:stringItemType **Balance Type:**na **Period Type:**duration

- Definition

Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan:

+ References

Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic-718-SubTopic-10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\)\(1\)\(i\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic-718-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-(c)(1)(i)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480429/718-10-50-2)**Reference 2:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\)\(1\)\(ii\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic-718-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-(c)(1)(ii)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480429/718-10-50-2)

+ Details

Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice **Namespace Prefix:**us-gaap **Data Type:**dtr-types:perShareItemType **Balance Type:**na **Period Type:**instant

-References

No definition available.

+ Details

Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward **Namespace Prefix:**us-gaap **Data Type:**xbrli:stringItemType **Balance Type:**na **Period Type:**duration

-Definition

Weighted average price at which option holders acquired shares when converting their stock options into shares.

+ References

Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic-718-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-\(c\)\(1\)\(iv\)\(02\)](http://www.xbrl.org/2003/role/disclosureRef-Topic-718-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-(c)(1)(iv)(02)) **Publisher:**FASB **URI:**<https://asc.fasb.org/1943274/2147480429/718-10-50-2>

+ Details

Name:us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice **Namespace Prefix:**us-gaap **Data Type:**dtr-types:perShareItemType **Balance Type:**na **Period Type:**duration

-Definition

Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.

+ References

Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic-718-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-\(c\)\(1\)\(iv\)\(04\)](http://www.xbrl.org/2003/role/disclosureRef-Topic-718-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-(c)(1)(iv)(04)) **Publisher:**FASB **URI:**<https://asc.fasb.org/1943274/2147480429/718-10-50-2>

+ Details

Name:us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice **Namespace Prefix:**us-gaap **Data Type:**dtr-types:perShareItemType **Balance Type:**na **Period Type:**duration

-Definition

Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.

+ References

Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic-718-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-\(c\)\(1\)\(iv\)\(01\)](http://www.xbrl.org/2003/role/disclosureRef-Topic-718-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-(c)(1)(iv)(01)) **Publisher:**FASB **URI:**<https://asc.fasb.org/1943274/2147480429/718-10-50-2>

+ Details

Name:us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice **Namespace Prefix:**us-gaap **Data Type:**dtr-types:perShareItemType **Balance Type:**na **Period Type:**duration

-Definition

Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.

+ References

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Name-Accounting-Standards-Codification-Topic-718-SubTopic-10-Section-50-Paragraph-2-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480429/718-10-50-2>

+ Details

Name:us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 **Namespace Prefix:**us-gaap **Data Type:**xbrli:monetaryItemType **Balance Type:**debit **Period Type:**instant

-Definition

Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Name-Accounting-Standards-Codification-Topic-718-SubTopic-10-Section-50-Paragraph-2-Publisher-FASB-URI>

<https://asc.fasb.org/1943274/2147480429/718-10-50-2>

+ Details

Name:us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_Namespace Prefix:us-gaap_Data Type:xbrli:durationItemType Balance Type:na Period Type:duration

- Definition

Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 718-SubTopic 10-Subparagraph \(c\)\(1\)-Name Accounting Standards Codification-Paragraph 2-Section 50-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 718-SubTopic 10-Subparagraph (c)(1)-Name Accounting Standards Codification-Paragraph 2-Section 50-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)

+ Details

Name:us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_Namespace Prefix:us-gaap_Data Type:xbrli:durationItemType Balance Type:na Period Type:duration

- Definition

Number of share options (or share units) exercised during the current period.

+ References

Reference 1: <http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification-Section 50-Paragraph 2-SubTopic 10-Topic 505-Publisher FASB-URI https://asc.fasb.org/1943274/2147481112/505-10-50-2>**Reference 2:** [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(28\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(28))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)**Reference 3:** [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(29\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(29))-Publisher FASB-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1)**Reference 4:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\)\(1\)\(iv\)\(02\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c)(1)(iv)(02)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)**Reference 5:** [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.3-04\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 505-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.3-04)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1)

+ Details

Name:us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_Namespace Prefix:us-gaap_Data Type:xbrli:sharesItemType Balance Type:na Period Type:duration XML 72-R57.htm IDEA: XBRL DOCUMENT
Stock-Based Compensation - Assumptions Used to Value Stock Options (Details) - \$ / shares 9 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Share-Based Payment Arrangement [Abstract] - Expected dividend yield 0.00% 0.00% Risk-free interest rate 3.69% Expected volatility 86.40% Expected life (in years) 6 years 3 months Weighted average grant date fair value per share of options granted (in dollars per share) \$ 24.80

- References

No definition available.

+ Details

Name:us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_Namespace Prefix:us-gaap_Data Type:xbrli:stringItemType Balance Type:na Period Type:

duration

-Definition

The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.

+References

Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic-718-SubTopic-10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(f\)\(2\)\(iii\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic-718-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-(f)(2)(iii)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480429/718-10-50-2)

+Details

Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate **Namespace Prefix:**us-gaap_ **Data Type:**dtr-types:percentItemType **Balance Type:**na **Period Type:**duration

-Definition

The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.

+References

Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic-718-SubTopic-10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(f\)\(2\)\(ii\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic-718-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-(f)(2)(ii)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480429/718-10-50-2)

+Details

Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate **Namespace Prefix:**us-gaap_ **Data Type:**dtr-types:percentItemType **Balance Type:**na **Period Type:**duration

-Definition

The risk-free interest rate assumption that is used in valuing an option on its own shares.

+References

Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic-718-SubTopic-10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(f\)\(2\)\(iv\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic-718-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-(f)(2)(iv)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480429/718-10-50-2)

+Details

Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate **Namespace Prefix:**us-gaap_ **Data Type:**dtr-types:percentItemType **Balance Type:**na **Period Type:**duration

-Definition

The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.

+References

Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic-718-SubTopic-10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(d\)\(1\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic-718-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-(d)(1)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480429/718-10-50-2)

+Details

Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue **Namespace Prefix:**us-gaap_ **Data Type:**dtr-types:perShareItemType **Balance Type:**na **Period Type:**duration

-Definition

Expected term of award under share-based payment arrangement, in 'PnYnMnDtnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.

+References

Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic-718-SubTopic-10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(f\)\(2\)\(i\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic-718-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-(f)(2)(i)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480429/718-10-50-2)

+Details

Name:us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 **Namespace Prefix:**us-gaap_ **Data Type:**xbrli:durationItemType **Balance Type:**na **Period Type:**duration **XML 73 R58.htm IDEA:** XBRL DOCUMENT Stock-Based Compensation - Summary of RSUs Activity (Details) - Restricted stock units9 Months Ended Jun. 30, 2024

~~$\$/\text{shares}$~~
~~shares~~
~~Number of RSUs: Beginning of period (in shares) / shares~~~~4,241,640~~~~Granted (in shares) / shares~~~~1,876,825~~~~Vested (in shares) / shares~~~~(927,766)~~~~Forfeited (in shares) / shares~~
~~(160,775)~~~~End of period (in shares) / shares~~~~5,029,924~~~~Weighted-Average Grant Date Fair Value Per Share: Beginning balance (in dollars per share) / \$ / shares~~~~\$ 58.43~~~~Granted~~
~~(in dollars per share) / \$ / shares~~~~30.67~~~~Vested (in dollars per share) / \$ / shares~~~~53.16~~~~Forfeited (in dollars per share) / \$ / shares~~~~41.75~~~~Ending balance (in dollars per share) / \$ /~~
~~shares~~~~\$ 49.58~~

~~-Definition~~

~~The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.~~

~~+References~~

~~Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic-718-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-\(c\)\(2\)\(iii\)\(03\)](http://www.xbrl.org/2003/role/disclosureRef-Topic-718-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-(c)(2)(iii)(03))-Publisher FASB-URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>~~

~~+Details~~

~~Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_Namespace-Prefix:us-gaap_Data~~
~~Type:xbrli:sharesItemType Balance-Type:na Period-Type:duration~~

~~-Definition~~

~~Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.~~

~~+References~~

~~Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic-718-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-\(c\)\(2\)\(iii\)\(03\)](http://www.xbrl.org/2003/role/disclosureRef-Topic-718-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-(c)(2)(iii)(03))-Publisher FASB-URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>~~

~~+Details~~

~~Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue~~
~~Namespace-Prefix:us-gaap_Data Type:dtr-types:perShareItemType Balance-Type:na Period-Type:duration~~

~~-Definition~~

~~The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).~~

~~+References~~

~~Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic-718-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-\(c\)\(2\)\(iii\)\(01\)](http://www.xbrl.org/2003/role/disclosureRef-Topic-718-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-(c)(2)(iii)(01))-Publisher FASB-URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>~~

~~+Details~~

~~Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_Namespace-Prefix:us-gaap_Data~~
~~Type:xbrli:sharesItemType Balance-Type:na Period-Type:duration~~

~~-Definition~~

~~The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).~~

~~+References~~

~~Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic-718-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-\(c\)\(2\)\(iii\)\(01\)](http://www.xbrl.org/2003/role/disclosureRef-Topic-718-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-(c)(2)(iii)(01))-Publisher FASB-URI <https://asc.fasb.org/1943274/2147480429/718-10-50-2>~~

~~+Details~~

~~Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue~~
~~Namespace-Prefix:us-gaap_Data Type:dtr-types:perShareItemType Balance-Type:na Period-Type:duration~~

~~-Definition~~

~~The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.~~

~~+References~~

~~Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic-718-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-\(c\)\(2\)\(i\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic-718-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-(c)(2)(i)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic-718-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-\(c\)\(2\)\(ii\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic-718-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-(c)(2)(ii)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147480429/718-10-50-2)~~

+ Details

Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_Namespace Prefix:us-gaap_Data Type:xbrli:sharesItemType Balance Type:na Period Type:instant

- Definition

A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.

+ References

No definition available.

+ Details

Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_Namespace Prefix:us-gaap_Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

- Definition

Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.

+ References

Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\)\(2\)\(i\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c)(2)(i)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\)\(2\)\(ii\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c)(2)(ii)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)

+ Details

Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_Namespace Prefix:us-gaap_Data Type:dtr-types:perShareItemType Balance Type:na Period Type:instant

- References

No definition available.

+ Details

Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_Namespace Prefix:us-gaap_Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

- Definition

The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.

+ References

Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\)\(2\)\(iii\)\(02\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c)(2)(iii)(02)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)

+ Details

Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_Namespace Prefix:us-gaap_Data Type:xbrli:sharesItemType Balance Type:na Period Type:duration

- Definition

The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.

+ References

Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph \(c\)\(2\)\(iii\)\(02\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 718-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2-Subparagraph (c)(2)(iii)(02)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2)

+ Details

Name:us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_Namespace Prefix:us-gaap_Data Type:dtr-types:perShareItemType Balance Type:na Period Type:duration

- Details

Name:us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember_Namespace Prefix: Data Type:na Balance Type: Period Type: XML 74 R59.htm IDEA: XBRL

<u>Fair Value Measurements – Fair Value Measurements for Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) – Fair Value, Measurements – Recurring – USD (\$) – in Thousands</u>	<u>Jun. 30, 2024</u>	<u>Sep. 30, 2023</u>
<u>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] – Available-for-sale securities</u>	<u>\$ 367,272</u>	<u>\$ 292,735</u>
<u>Cash equivalents</u>	<u>34,461</u>	<u>39,733</u>
<u>Total financial assets</u>	<u>401,733</u>	<u>468,000</u>
<u>Money market instruments – Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] – Cash equivalents</u>	<u>29,495</u>	<u>39,733</u>
<u>Commercial notes – Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] – Cash equivalents</u>	<u>4,986</u>	<u>0</u>
<u>U.S. government bonds – Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] – Available-for-sale securities</u>	<u>80,946</u>	<u>31,553</u>
<u>Municipal securities – Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] – Available-for-sale securities</u>	<u>7,093</u>	<u>0</u>
<u>Corporate debt securities – Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] – Available-for-sale securities</u>	<u>114,616</u>	<u>22,205</u>
<u>Level 1 – Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] – Available-for-sale securities</u>	<u>171,710</u>	<u>31,884</u>
<u>Level 2 – Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] – Available-for-sale securities</u>	<u>372,258</u>	<u>261,182</u>
<u>Level 3 – Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] – Available-for-sale securities</u>	<u>0</u>	<u>0</u>
<u>Level 1 – U.S. government bonds – Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] – Available-for-sale securities</u>	<u>0</u>	<u>0</u>
<u>Level 1 – Municipal securities – Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] – Available-for-sale securities</u>	<u>0</u>	<u>0</u>
<u>Level 1 – Corporate debt securities – Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] – Available-for-sale securities</u>	<u>0</u>	<u>0</u>
<u>Level 2 – Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] – Available-for-sale securities</u>	<u>367,272</u>	<u>261,182</u>
<u>Cash equivalents</u>	<u>4,986</u>	<u>0</u>
<u>Total financial assets</u>	<u>372,258</u>	<u>261,182</u>
<u>Level 2 – Money market instruments – Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] – Cash equivalents</u>	<u>0</u>	<u>0</u>
<u>Level 2 – Commercial notes – Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] – Cash equivalents</u>	<u>0</u>	<u>0</u>
<u>Level 2 – U.S. government bonds – Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] – Available-for-sale securities</u>	<u>80,946</u>	<u>0</u>
<u>Level 2 – Municipal securities – Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] – Available-for-sale securities</u>	<u>7,093</u>	<u>0</u>
<u>Level 2 – Commercial notes – Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] – Available-for-sale securities</u>	<u>114,616</u>	<u>22,205</u>
<u>Level 2 – Corporate debt securities – Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] – Available-for-sale securities</u>	<u>171,710</u>	<u>31,884</u>
<u>Level 3 – Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] – Available-for-sale securities</u>	<u>0</u>	<u>0</u>
<u>Level 3 – Cash equivalents</u>	<u>0</u>	<u>0</u>
<u>Level 3 – Commercial notes – Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] – Cash equivalents</u>	<u>0</u>	<u>0</u>
<u>Level 3 – U.S. government bonds – Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] – Available-for-sale securities</u>	<u>0</u>	<u>0</u>
<u>Level 3 – Municipal securities – Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] – Available-for-sale securities</u>	<u>0</u>	<u>0</u>
<u>Level 3 – Corporate debt securities – Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items] – Available-for-sale securities</u>	<u>0</u>	<u>0</u>
<u>– Definition</u>		

+ References

[+ Details](#)

Name:us-gaap_AssetsFairValueDisclosure Namespace Prefix:us-gaap Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant

~~Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).~~

Reference 1: <http://www.xbrl.org/2003/role/exampleRef-Topic-820-SubTopic-10-Name-Accounting-Standards-Codification-Section-55-Paragraph-103-Publisher-FASB-URI>
<https://asc.fasb.org/1943274/2147482078/820-10-55-103Reference> 2: <http://www.xbrl.org/2003/role/exampleRef-Topic-820-SubTopic-10-Name-Accounting-Standards-Codification-Section-55-Paragraph-100-Publisher-FASB-URI>
<https://asc.fasb.org/1943274/2147482078/820-10-55-100Reference> 3: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic-820-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-\(bbb\)\(21\)\(i\)-Publisher-FASB-URI](http://www.xbrl.org/2009/role/commonPracticeRef-Topic-820-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-(bbb)(21)(i)-Publisher-FASB-URI)
<https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference> 4: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic-820-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-\(bbb\)\(2\)-Publisher-FASB-URI](http://www.xbrl.org/2009/role/commonPracticeRef-Topic-820-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-(bbb)(2)-Publisher-FASB-URI)
<https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference> 5: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic-820-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-\(bbb\)\(1\)-Publisher-FASB-URI](http://www.xbrl.org/2009/role/commonPracticeRef-Topic-820-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-(bbb)(1)-Publisher-FASB-URI)
<https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference> 6: [http://www.xbrl.org/2003/role/disclosureRef-Topic-820-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-\(a\)-Publisher-FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-820-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-(a)-Publisher-FASB-URI)
<https://asc.fasb.org/1943274/2147482106/820-10-50-2Reference> 7: [http://www.xbrl.org/2003/role/disclosureRef-Topic-320-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-\(aa\)-Publisher-FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-320-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-(aa)-Publisher-FASB-URI)
<https://asc.fasb.org/1943274/2147481800/320-10-50-2Reference> 8: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic-320-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-1-Subparagraph-\(b\)-Publisher-FASB-URI](http://www.xbrl.org/2009/role/commonPracticeRef-Topic-320-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-1-Subparagraph-(b)-Publisher-FASB-URI)
<https://asc.fasb.org/1943274/2147481830/320-10-45-1Reference> 9: [http://www.xbrl.org/2003/role/disclosureRef-Topic-942-SubTopic-210-Name-Accounting-Standards-Codification-Section-599-Paragraph-1-Subparagraph-\(SX-210-9-03\(6\)\)-Publisher-FASB-URI](http://www.xbrl.org/2003/role/disclosureRef-Topic-942-SubTopic-210-Name-Accounting-Standards-Codification-Section-599-Paragraph-1-Subparagraph-(SX-210-9-03(6))-Publisher-FASB-URI)
<https://asc.fasb.org/1943274/2147478546/942-210-599-1Reference> 10: <http://www.xbrl.org/2003/role/disclosureRef-Topic-326-SubTopic-30-Name-Accounting-Standards-Codification-Section-45-Paragraph-1-Publisher-FASB-URI>
<https://asc.fasb.org/1943274/2147479130/326-30-45-1>

+ Details

Name:us-gAAP_AvailableForSaleSecuritiesDebtSecurities_Namespace-Prefix:us-gAAP_Data-Type:xbrli:monetaryItemType Balance-Type:debit Period-Type:instant

- Definition

Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.

+ References

Reference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic-820-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-\(b\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482106/820-10-50-2](http://www.xbrl.org/2009/role/commonPracticeRef-Topic-820-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-(b)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482106/820-10-50-2)Reference 2: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic-820-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-\(a\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482106/820-10-50-2](http://www.xbrl.org/2009/role/commonPracticeRef-Topic-820-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-(a)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482106/820-10-50-2)

+ Details

Name:us-gAAP_CashAndCashEquivalentsFairValueDisclosure_Namespace-Prefix:us-gAAP_Data-Type:xbrli:monetaryItemType Balance-Type:debit Period-Type:instant

-Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: <http://www.xbrl.org/2003/role/exampleRef-Topic-820-SubTopic-10-Name-Accounting-Standards-Codification-Section-55-Paragraph-100-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482078/820-10-55-100>Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic-820-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-\(b\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482106/820-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic-820-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-(b)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482106/820-10-50-2)Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic-820-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-\(a\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482106/820-10-50-2](http://www.xbrl.org/2003/role/disclosureRef-Topic-820-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-2-Subparagraph-(a)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482106/820-10-50-2)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic-820-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-3-Subparagraph-\(a\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482106/820-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic-820-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-3-Subparagraph-(a)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482106/820-10-50-3)

+ Details

Name:us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_Namespace-Prefix:us-gaap_Data-Type:xbrli:stringItemType-Balance-Type:na-Period-Type:duration

-Details

Name:us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember_Namespace-Prefix:_Data-Type:na-Balance-Type:_Period-Type:

-Details

Name:us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember_Namespace-Prefix:_Data-Type:na-Balance-Type:_Period-Type:

-Details

Name:us-gaap_CashAndCashEquivalentsAxis=arwr_CommercialNotesMember_Namespace-Prefix:_Data-Type:na-Balance-Type:_Period-Type:

-Details

Name:us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember_Namespace-Prefix:_Data-Type:na-Balance-Type:_Period-Type:

-Details

Name:us-gaap_FinancialInstrumentAxis=us-gaap_MunicipalBondsMember_Namespace-Prefix:_Data-Type:na-Balance-Type:_Period-Type:

-Details

Name:us-gaap_FinancialInstrumentAxis=arwr_CommercialNotesMember_Namespace-Prefix:_Data-Type:na-Balance-Type:_Period-Type:

-Details

Name:us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember_Namespace-Prefix:_Data-Type:na-Balance-Type:_Period-Type:

-Details

Name:us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member_Namespace-Prefix:_Data-Type:na-Balance-Type:_Period-Type:

-Details

Name:us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member_Namespace-Prefix:_Data-Type:na-Balance-Type:_Period-Type:

-Details

Name:us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member_Namespace-Prefix:_Data-Type:na-Balance-Type:_Period-Type:XML-75

R60.htm IDEA: XBRL DOCUMENT

Liability-Related to the Sale of Future Royalties - Narrative (Details) - USD (\$) \$ in Thousands1 Months Ended3 Months Ended9 Months Ended

Nov. 30, 2022

Jun. 30, 2024

Jun. 30, 2024

Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] - Milestone payment received - \$ 50,000Royalty Pharma Agreement - Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] - Upfront payment\$ 250,000 - Milestone payment receivable160,000 - Milestone payment receivable upon FDA approval50,000 - Milestone payment receivable upon receipt of royalty payments60,000 - Royalty payment threshold70,000 - Milestone payment received- \$ 50,000 - Liability-related to the sale of future royalties - \$ 250,000\$ 250,000Liability-related to the sale of future royalties, interest rate 6.30%6.30%Royalty Pharma Agreement + Amgen - Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] - Milestone payment receivable upon achievement of enrollment in phase 3 clinical trial - \$ 50,000\$ 50,000Royalty Pharma Agreement + Maximum - Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] - Initial transaction price\$ 410,000-

-Definition

Cash received as due under collaboration agreement.

+ References

No definition available.

+ Details

Name:arwr_CashReceivedAsDueUnderCollaborationAgreement_Namespace-Prefix:arwr_Data-Type:xbrli:monetaryItemType-Balance-Type:debit-Period-Type:duration

-Definition

Initial transaction price.

+ References

No definition available.

+ Details

Name:arwr_InitialTransactionPrice_Namespace-Prefix:arwr_Data-Type:xbrli:monetaryItemType-Balance-Type:credit-Period-Type:duration

-Definition

Liability, Sale of Future Royalties

[**+ References**](#)

No definition available.

[**+ Details**](#)

Name:arwr_LiabilitySaleOfFutureRoyalties_Namespace Prefix:arwr_Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant

[**-Definition**](#)

Liability, Sale Of Future Royalties, Interest Rate

[**+ References**](#)

No definition available.

[**+ Details**](#)

Name:arwr_LiabilitySaleOfFutureRoyaltiesInterestRate_Namespace Prefix:arwr_Data Type:dtr-types:percentItemType Balance Type:na Period Type:instant

[**-Definition**](#)

Milestone Payment Receivable

[**+ References**](#)

No definition available.

[**+ Details**](#)

Name:arwr_MilestonePaymentReceivable_Namespace Prefix:arwr_Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant

[**-Definition**](#)

Milestone Payment Receivable, Upon Achievement of Enrollment in Phase 3 Clinical Trial

[**+ References**](#)

No definition available.

[**+ Details**](#)

Name:arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial_Namespace Prefix:arwr_Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant

[**-Definition**](#)

Milestone Payment Receivable, Upon FDA Approval

[**+ References**](#)

No definition available.

[**+ Details**](#)

Name:arwr_MilestonePaymentReceivableUponFDAApproval_Namespace Prefix:arwr_Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant

[**-Definition**](#)

Milestone Payment Receivable, Upon Receipt Of Royalty Payments

[**+ References**](#)

No definition available.

[**+ Details**](#)

Name:arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments_Namespace Prefix:arwr_Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:instant

[**-Definition**](#)

Milestone Payment Received, Liability Related To Sale Of Future Royalties

[**+ References**](#)

No definition available.

[**+ Details**](#)

Name:arwr_MilestonePaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties_Namespace Prefix:arwr_Data Type:xbrli:monetaryItemType Balance Type:debit Period Type:duration

[**-Definition**](#)

Royalty Payment Threshold

[**+ References**](#)

No definition available.

[**+ Details**](#)

Name:arwr_RoyaltyPaymentThreshold_Namespace Prefix:arwr_Data Type:xbrli:monetaryItemType Balance Type:credit Period Type:instant

[**-Definition**](#)

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

[**+ References**](#)

Reference 1- http://www.xbrl.org/2003/role/disclosureRef-Topic 808-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (d)-Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1

[**+ Details**](#)

Name:us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_Namespace Prefix:us-gaap_Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

[**-Details**](#)

Name:us-gaap_TypeOfArrangementAxis=arwr_RoyaltyPharmaAgreementMember_Namespace Prefix: Data Type:na Balance Type: Period Type:

[**-Details**](#)

Name:srt_CounterpartyNameAxis=arwr_AmgenIncorporatedMember_Namespace Prefix: Data Type:na Balance Type: Period Type:

[**-Details**](#)

Name:srt_RangeAxis=srt_MaximumMember_Namespace Prefix: Data Type:na Balance Type: Period Type: XML 76 R61.htm IDEA: XBRL DOCUMENT
Liability Related to the Sale of Future Royalties – Activity (Details) – USD (\$) \$ in Thousands9 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Liability, Sale Of Future Royalties [Roll Forward] – Carrying value as of September 30, 2023\$ 268,326 **Non-cash interest expense recognized**17,705\$ 13,064**Carrying value as of June 30, 2024**\$ 336,031
–Definition

Liability, Sale Of Future Royalties

+ References

No definition available.

+ Details
Name:arwr_LiabilitySaleOfFutureRoyaltiesRollForward_Namespace Prefix:arwr_ Data Type:xbrl:stringItemType Balance Type:na Period Type:duration

–Definition

Non-Cash Interest Expense, Liability Related To Sale Of Future Royalties

+ References

No definition available.

+ Details
Name:arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties_Namespace Prefix:arwr_ Data Type:xbrl:monetaryItemType Balance Type:debit Period Type:duration

–Definition

Royalties, Liability, Noncurrent

+ References

No definition available.

+ Details
Name:arwr_RoyaltiesLiabilityNoncurrent_Namespace Prefix:arwr_ Data Type:xbrl:monetaryItemType Balance Type:credit Period Type:instant XML 77 R62.htm IDEA: XBRL DOCUMENT
Net Loss Per Share – Basic and Diluted Net Loss Per Share (Details) - USD (\$) \$ / shares in Units, shares in Thousands, \$ in Thousands3 Months Ended9 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Numerator: — Net loss attributable to Arrowhead Pharmaceuticals, Inc.\$ (170,793)\$ (102,946)\$ (428,957)\$ (95,596)**Denominator: — Weighted-average basic shares outstanding (in shares)**124,199107,004118,260106,597**Effect of dilutive securities (in shares)**0000**Weighted-average diluted shares outstanding (in shares)**124,199107,004118,260106,597**Basic net loss per share (in dollars per share)**\$ (1.38)\$ (0.96)\$ (3.63)\$ (0.90)**Diluted net loss per share (in dollars per share)**\$ (1.38)\$ (0.96)\$ (3.63)\$ (0.90)
–Definition

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

+ References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 6-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6>**Reference 2:** <http://www.xbrl.org/2003/role/exampleRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 52-Publisher FASB-URI https://asc.fasb.org/1943274/2147482635/260-10-55-52>**Reference 3:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 805-SubTopic 60-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph \(g\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 805-SubTopic 60-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph (g)-Publisher FASB-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1)**Reference 4:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 323-Name Accounting Standards Codification-Section 65-Paragraph 2-Subparagraph \(g\)\(3\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 323-Name Accounting Standards Codification-Section 65-Paragraph 2-Subparagraph (g)(3)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2)**Reference 5:** <http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3>**Reference 6:** <http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 15-Publisher FASB-URI https://asc.fasb.org/1943274/2147482635/260-10-55-15>**Reference 7:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph \(e\)\(4\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph (e)(4)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1)**Reference 8:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph \(f\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph (f)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1)**Reference 9:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11)**Reference 10:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11)**Reference 11:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 7-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-7](http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 7-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-7)**Reference 12:** <http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 2-Publisher FASB-URI https://asc.fasb.org/1943274/2147482689/260-10-45-2>**Reference 13:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 60B-Subparagraph \(d\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B](http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 60B-Subparagraph (d)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B)**Reference 14:** <http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 4-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-4>**Reference 15:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482662/260-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482662/260-10-50-1)**Reference 16:** <http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 10-Publisher FASB-URI https://asc.fasb.org/1943274/2147482689/260-10-45-10>**Reference 17:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph \(SX 210.5-03\(25\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph (SX 210.5-03(25))-Publisher FASB-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2)**Reference 18:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 942-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.9-04\(27\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 942-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.9-04(27))-Publisher FASB-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1)**Reference 19:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.7-04\(23\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.7-04(23))-Publisher FASB-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1)**Reference 20:** <http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 7-Publisher FASB-URI https://asc.fasb.org/1943274/2147482689/260-10-45-7>

+ Details

Name:us-gaap_EarningsPerShareBasic **Namespace Prefix:**us-gaap_ **Data Type:**dtr-types:perShareItemType **Balance Type:**na **Period Type:**duration

- Definition

The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.

+ References

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 6-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6>Reference 2: <http://www.xbrl.org/2003/role/exampleRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 52-Publisher FASB-URI https://asc.fasb.org/1943274/2147482635/260-10-55-52>Reference 3: [http://www.xbrl.org/2003/role/disclosureRef-Topic 805-SubTopic 60-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph \(g\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 805-SubTopic 60-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph (g)-Publisher FASB-URI https://asc.fasb.org/1943274/2147476176/805-60-65-1)Reference 4: [http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 323-Name Accounting Standards Codification-Section 65-Paragraph 2-Subparagraph \(g\)\(3\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 323-Name Accounting Standards Codification-Section 65-Paragraph 2-Subparagraph (g)(3)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478666/740-323-65-2)Reference 5: <http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-3>Reference 6: <http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 55-Paragraph 15-Publisher FASB-URI https://asc.fasb.org/1943274/2147482635/260-10-55-15>Reference 7: [http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph \(e\)\(4\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph (e)(4)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1)Reference 8: [http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph \(f\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph (f)-Publisher FASB-URI https://asc.fasb.org/1943274/2147480175/815-40-65-1)Reference 9: [http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11)Reference 10: [http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph \(b\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph (b)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-11)Reference 11: [http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 7-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-7](http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 7-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-7)Reference 12: <http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 2-Publisher FASB-URI https://asc.fasb.org/1943274/2147482689/260-10-45-2>Reference 13: [http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 60B-Subparagraph \(d\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B](http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 60B-Subparagraph (d)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B)Reference 14: <http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 4-Publisher FASB-URI https://asc.fasb.org/1943274/2147483443/250-10-50-4>Reference 15: [http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(a\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482662/260-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (a)-Publisher FASB-URI https://asc.fasb.org/1943274/2147482662/260-10-50-1)Reference 16: [http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph \(SX 210.5-03\(25\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph (SX 210.5-03(25))-Publisher FASB-URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2)Reference 17: [http://www.xbrl.org/2003/role/disclosureRef-Topic 942-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.9-04\(27\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 942-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.9-04(27))-Publisher FASB-URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1)Reference 18: [http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.7-04\(23\)\)-Publisher FASB-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.7-04(23))-Publisher FASB-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1)Reference 19: <http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 7-Publisher FASB-URI https://asc.fasb.org/1943274/2147482689/260-10-45-7>

[+ Details](#)

Name:us-gaap_EarningsPerShareDiluted **Namespace Prefix:**us-gaap **Data Type:**dtr-types:perShareItemType **Balance Type:**na **Period Type:**duration

[-Definition](#)

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

[+ References](#)

Reference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 6-Publisher FASB-URI https://asc.fashb.org/1943274/2147483443/250-10-50-6>**Reference 2:** <http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 9-Publisher FASB-URI https://asc.fashb.org/1943274/2147483443/250-10-50-9>**Reference 3:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 805-SubTopic 60-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph \(g\)-Publisher FASB-URI https://asc.fashb.org/1943274/2147476176/805-60-65-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 805-SubTopic 60-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph (g)-Publisher FASB-URI https://asc.fashb.org/1943274/2147476176/805-60-65-1)**Reference 4:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 323-Name Accounting Standards Codification-Section 65-Paragraph 2-Subparagraph \(g\)\(3\)-Publisher FASB-URI https://asc.fashb.org/1943274/2147478666/740-323-65-2](http://www.xbrl.org/2003/role/disclosureRef-Topic 740-SubTopic 323-Name Accounting Standards Codification-Section 65-Paragraph 2-Subparagraph (g)(3)-Publisher FASB-URI https://asc.fashb.org/1943274/2147478666/740-323-65-2)**Reference 5:** [http://fashb.org/us-gaap/role/ref/legacyRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph \(SX 210.5-03\(20\)\)-Publisher FASB-URI https://asc.fashb.org/1943274/2147483621/220-10-S99-2](http://fashb.org/us-gaap/role/ref/legacyRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 2-Subparagraph (SX 210.5-03(20))-Publisher FASB-URI https://asc.fashb.org/1943274/2147483621/220-10-S99-2)**Reference 6:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.4-08\(g\)\(1\)\(ii\)\)-Publisher FASB-URI https://asc.fashb.org/1943274/2147480678/235-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 235-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.4-08(g)(1)(ii))-Publisher FASB-URI https://asc.fashb.org/1943274/2147480678/235-10-S99-1)**Reference 7:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph \(c\)-Publisher FASB-URI https://asc.fashb.org/1943274/2147481687/323-10-50-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 323-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Subparagraph (c)-Publisher FASB-URI https://asc.fashb.org/1943274/2147481687/323-10-50-3)**Reference 8:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-Subparagraph \(f\)-Publisher FASB-URI https://asc.fashb.org/1943274/2147482907/825-10-50-28](http://www.xbrl.org/2003/role/disclosureRef-Topic 825-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 28-Subparagraph (f)-Publisher FASB-URI https://asc.fashb.org/1943274/2147482907/825-10-50-28)**Reference 9:** <http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 6-Publisher FASB-URI https://asc.fashb.org/1943274/2147482765/220-10-50-6>**Reference 10:** <http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 3-Publisher FASB-URI https://asc.fashb.org/1943274/2147483443/250-10-50-3>**Reference 11:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(b\)\(2\)-Publisher FASB-URI https://asc.fashb.org/1943274/2147483443/250-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (b)(2)-Publisher FASB-URI https://asc.fashb.org/1943274/2147483443/250-10-50-1)**Reference 12:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph \(f\)-Publisher FASB-URI https://asc.fashb.org/1943274/2147480175/815-40-65-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 815-SubTopic 40-Name Accounting Standards Codification-Section 65-Paragraph 1-Subparagraph (f)-Publisher FASB-URI https://asc.fashb.org/1943274/2147480175/815-40-65-1)**Reference 13:** <http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 8-Publisher FASB-URI https://asc.fashb.org/1943274/2147483443/250-10-50-8>**Reference 14:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph \(b\)-Publisher FASB-URI https://asc.fashb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph (b)-Publisher FASB-URI https://asc.fashb.org/1943274/2147483443/250-10-50-11)**Reference 15:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph \(b\)-Publisher FASB-URI https://asc.fashb.org/1943274/2147483443/250-10-50-11](http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 11-Subparagraph (b)-Publisher FASB-URI https://asc.fashb.org/1943274/2147483443/250-10-50-11)**Reference 16:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph \(f\)-Publisher FASB-URI https://asc.fashb.org/1943274/2147483443/250-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 250-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 1-Subparagraph (f)-Publisher FASB-URI https://asc.fashb.org/1943274/2147483443/250-10-50-1)**Reference 17:** <http://www.xbrl.org/2003/role/exampleRef-Topic 946-SubTopic 830-Name Accounting Standards Codification-Section 55-Paragraph 10-Publisher FASB-URI https://asc.fashb.org/1943274/2147479168/946-830-55-10>**Reference 18:** <http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section 45-Paragraph 7-Publisher FASB-URI https://asc.fashb.org/1943274/2147479105/946-220-45-7>**Reference 19:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.7-04\(18\)\)-Publisher FASB-URI https://asc.fashb.org/1943274/214747250/944-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 944-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.7-04(18))-Publisher FASB-URI https://asc.fashb.org/1943274/214747250/944-220-S99-1)**Reference 20:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.6-07\(9\)\)-Publisher FASB-URI https://asc.fashb.org/1943274/2147479134/946-220-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.6-07(9))-Publisher FASB-URI https://asc.fashb.org/1943274/2147479134/946-220-S99-1)**Reference 21:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph \(SX 210.6-09\(1\)\(d\)\)-Publisher FASB-URI https://asc.fashb.org/1943274/2147479134/946-220-S99-3](http://www.xbrl.org/2003/role/disclosureRef-Topic 946-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 3-Subparagraph (SX 210.6-09(1)(d))-Publisher FASB-URI https://asc.fashb.org/1943274/2147479134/946-220-S99-3)**Reference 22:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(i\)\)-Publisher FASB-URI https://asc.fashb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(i))-Publisher FASB-URI https://asc.fashb.org/1943274/2147480097/470-10-S99-1)**Reference 23:** [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\)-Publisher FASB-URI https://asc.fashb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(iv))-Publisher FASB-URI https://asc.fashb.org/1943274/2147480097/470-10-S99-1)**Reference 24:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(5\)\)-Publisher FASB-URI https://asc.fashb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(5))-Publisher FASB-URI https://asc.fashb.org/1943274/2147480097/470-10-S99-1)**Reference 25:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-01\(a\)\(4\)\(iv\)\)-Publisher FASB-URI https://asc.fashb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-01(a)(4)(iv))-Publisher FASB-URI https://asc.fashb.org/1943274/2147480097/470-10-S99-1)**Reference 26:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(A\)\)-Publisher FASB-URI https://asc.fashb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1A-Subparagraph (SX 210.13-02(a)(4)(iii)(A))-Publisher FASB-URI https://asc.fashb.org/1943274/2147480097/470-10-S99-1)**Reference 27:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(a\)-Publisher FASB-URI https://asc.fashb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (a)-Publisher FASB-URI https://asc.fashb.org/1943274/2147480097/470-10-S99-1)**Reference 28:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(4\)\(iii\)\(A\)\)-Publisher FASB-URI https://asc.fashb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(4)(iii)(A))-Publisher FASB-URI https://asc.fashb.org/1943274/2147480097/470-10-S99-1)**Reference 29:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(a\)-Publisher FASB-URI https://asc.fashb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (a)-Publisher FASB-URI https://asc.fashb.org/1943274/2147480097/470-10-S99-1)**Reference 30:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(a\)-Publisher FASB-URI https://asc.fashb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (a)-Publisher FASB-URI https://asc.fashb.org/1943274/2147480097/470-10-S99-1)**Reference 31:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph \(SX 210.13-02\(a\)\(5\)\)-Publisher FASB-URI https://asc.fashb.org/1943274/2147480097/470-10-S99-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 470-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1B-Subparagraph (SX 210.13-02(a)(5))-Publisher FASB-URI https://asc.fashb.org/1943274/2147480097/470-10-S99-1)**Reference 32:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 60B-Subparagraph \(a\)-Publisher FASB-URI https://asc.fashb.org/1943274/2147482689/260-10-45-60B](http://www.xbrl.org/2003/role/disclosureRef-Topic 260-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 60B-Subparagraph (a)-Publisher FASB-URI https://asc.fashb.org/1943274/2147482689/260-10-45-60B)**Reference 33:** <http://www.xbrl.org/2003/role/disclosureRef-Topic 205-SubTopic 20-Name Accounting Standards Codification-Section 50-Paragraph 7-Publisher FASB-URI https://asc.fashb.org/1943274/2147483499/205-20-50-7>**Reference 34:** <http://fashb.org/us-gaap/role/ref/legacyRef-Topic 230-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 28-Publisher FASB-URI https://asc.fashb.org/1943274/2147482740/230-10-45-28>**Reference 35:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1A-Subparagraph \(a\)-Publisher FASB-URI https://asc.fashb.org/1943274/2147482790/220-10-45-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1A-Subparagraph (a)-Publisher FASB-URI https://asc.fashb.org/1943274/2147482790/220-10-45-1)**Reference 36:** [http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1B-Subparagraph \(a\)-Publisher FASB-URI https://asc.fashb.org/1943274/2147482790/220-10-45-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 220-SubTopic 10-Name Accounting Standards Codification-Section 45-Paragraph 1B-Subparagraph (a)-Publisher FASB-URI https://asc.fashb.org/1943274/2147482790/220-10-45-1)**Reference 37:** [http://fashb.org/us-gaap/role/ref/legacyRef-Topic 942-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.9-04\(22\)\)-Publisher FASB-URI https://asc.fashb.org/1943274/2147478524/942-220-S99-1](http://fashb.org/us-gaap/role/ref/legacyRef-Topic 942-SubTopic 220-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.9-04(22))-Publisher FASB-URI https://asc.fashb.org/1943274/2147478524/942-220-S99-1)

[+ Details](#)

Name:us-gaap_NetIncomeLoss **Namespace Prefix:**us-gaap_ **Data Type:**xbrii:monetaryItemType **Balance Type:**credit **Period Type:**duration

[- References](#)

No definition available.

[+ Details](#)

Name:us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract **Namespace Prefix:**us-gaap_ **Data Type:**xbrii:stringItemType **Balance Type:**na **Period Type:**duration

[- Definition](#)

The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.

[+ References](#)

Reference 1: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic-260-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-1-Subparagraph-\(a\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482662/260-10-50-1](http://www.xbrl.org/2009/role/commonPracticeRef-Topic-260-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-1-Subparagraph-(a)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482662/260-10-50-1)

[+ Details](#)

Name:us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment **Namespace Prefix:**us-gaap_ **Data Type:**xbrii:sharesItemType **Balance Type:**na **Period Type:**duration

[- Definition](#)

The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.

[+ References](#)

Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic-260-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-1-Subparagraph-\(a\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482662/260-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic-260-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-1-Subparagraph-(a)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482662/260-10-50-1)**Reference 2:** <http://www.xbrl.org/2003/role/disclosureRef-Topic-260-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-16-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482689/260-10-45-16>

[+ Details](#)

Name:us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding **Namespace Prefix:**us-gaap_ **Data Type:**xbrii:sharesItemType **Balance Type:**na **Period Type:**duration

[- Definition](#)

Number of (basic) shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.

[+ References](#)

Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic-260-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-1-Subparagraph-\(a\)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482662/260-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic-260-SubTopic-10-Name-Accounting-Standards-Codification-Section-50-Paragraph-1-Subparagraph-(a)-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482662/260-10-50-1)**Reference 2:** <http://www.xbrl.org/2003/role/disclosureRef-Topic-260-SubTopic-10-Name-Accounting-Standards-Codification-Section-45-Paragraph-10-Publisher-FASB-URI-https://asc.fasb.org/1943274/2147482689/260-10-45-10>

[+ Details](#)

Name:us-gaap_WeightedAverageNumberOfSharesOutstandingBasic **Namespace Prefix:**us-gaap_ **Data Type:**xbrii:sharesItemType **Balance Type:**na **Period Type:**duration

[- References](#)

No definition available.

[+ Details](#)

Name:us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract **Namespace Prefix:**us-gaap_ **Data Type:**xbrii:stringItemType **Balance Type:**na **Period Type:**duration **XML:**78-R63.htm **IDEA:**XBRL-DOCUMENT

Net Loss Per Share – Antidilutive (Details) – shares shares in Thousands 3 Months Ended 9 Months Ended

Jun. 30, 2024

Jun. 30, 2023

Jun. 30, 2024

Jun. 30, 2023

Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] – Potentially dilutive securities excluded from computation of diluted earnings per share (in shares) 4,7293,4674,7714,024 Options – Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] – Potentially dilutive securities excluded from computation of diluted earnings per share (in shares) 753637711768 Restricted stock units – Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] – Potentially dilutive securities excluded from computation of diluted earnings per share (in shares) 3,9762,8304,0603,256

–Definition

Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.

+ References

Reference 1: [http://www.xbrl.org/2003/role/disclosureRef-Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph \(c\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1](http://www.xbrl.org/2003/role/disclosureRef-Topic 260 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1)

+Details

Name:us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Namespace Prefix:us-gaap Data Type:xbrli:sharesItemType Balance Type:na Period Type:duration

–Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+Details

Name:us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems Namespace Prefix:us-gaap Data Type:xbrli:stringItemType Balance Type:na Period Type:duration

–Details

Name:us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember Namespace Prefix: Data Type:na Balance Type: Period Type:

–Details

Name:us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember Namespace Prefix: Data Type:na Balance Type: Period Type: XML 79-R64.htm IDEA: XBRL DOCUMENT

Subsequent Events (Details) – Subsequent Event – Financing Agreement – Line of Credit \$ in Millions Aug. 07, 2024

Interest rate 15.00% Secured Debt Subsequent Event [Line Items] Maximum borrowing capacity \$ 500.0 Long-term line of credit 400.0 Incremental Facility Subsequent Event [Line Items] Maximum borrowing capacity \$ 100.0

–Definition

Contractual interest rate for funds borrowed, under the debt agreement.

+ References

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(22\)\(a\)\(1\)\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)(a)(1)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1) Reference 2: [http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph \(b\) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B](http://www.xbrl.org/2003/role/disclosureRef-Topic 470 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 1B -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B)

+Details

Name:us-gaap_DebtInstrumentInterestRateStatedPercentage Namespace Prefix:us-gaap Data Type:dtr-types:percentItemType Balance Type:na Period Type:instant

–Definition

Period of time between issuance and maturity of debt instrument, in PnYnMnDtnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

No definition available.

+Details

Name:us-gaap_DebtInstrumentTerm Namespace Prefix:us-gaap Data Type:xbrli:durationItemType Balance Type:na Period Type:duration

–Definition

The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long-term obligation to refinance the short-term obligation on a long-term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long-term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.

+ References

Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph \(SX 210.5-02\(22\)\) -SubTopic 10 -](http://fasb.org/us-gaap/role/ref/legacyRef-Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(22)) -SubTopic 10 -)

Topic 210 -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 942-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.9-03\(16\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 942-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.9-03(16))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478546/942-210-S99-1>Reference 3: [http://www.xbrl.org/2009/role/commonPracticeRef-Topic 944-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.7-03\(a\)\(16\)\(a\)\(2\)\)](http://www.xbrl.org/2009/role/commonPracticeRef-Topic 944-SubTopic 210-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.7-03(a)(16)(a)(2))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147478777/944-210-S99-1>

[+ Details](#)
Name:us-gaap_LineOfCredit **Namespace Prefix:**us-gaap_ **Data Type:**xbrli:monetaryItemType **Balance Type:**credit **Period Type:**instant

[-Definition](#)
Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.

[+ References](#)
Reference 1: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(22\)\(b\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(22)(b))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>Reference 2: [http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph \(SX 210.5-02\(19\)\(b\)\)](http://fasb.org/us-gaap/role/ref/legacyRef-Topic 210-SubTopic 10-Name Accounting Standards Codification-Section S99-Paragraph 1-Subparagraph (SX 210.5-02(19)(b))) -Publisher FASB -URI <https://asc.fasb.org/1943274/2147480566/210-10-S99-1>

[+ Details](#)
Name:us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity **Namespace Prefix:**us-gaap_ **Data Type:**xbrli:monetaryItemType **Balance Type:**credit **Period Type:**instant

[-Definition](#)
Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.

[+ References](#)
Reference 1: <http://www.xbrl.org/2003/role/disclosureRef-Topic 830-SubTopic 30-Name Accounting Standards Codification-Section 50-Paragraph 2> -Publisher FASB -URI <https://asc.fasb.org/1943274/2147481674/830-30-50-2>Reference 2: <http://www.xbrl.org/2003/role/disclosureRef-Topic 855-SubTopic 10-Name Accounting Standards Codification-Section 50-Paragraph 2> -Publisher FASB -URI <https://asc.fasb.org/1943274/2147483399/855-10-50-2>

[+ Details](#)
Name:us-gaap_SubsequentEventLineItems **Namespace Prefix:**us-gaap_ **Data Type:**xbrli:stringItemType **Balance Type:**na **Period Type:**duration

[-Details](#)
Name:us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember **Namespace Prefix:** **Data Type:**na **Balance Type:** **Period Type:**

[-Details](#)
Name:us-gaap_DebtInstrumentAxis=arwr_FinancingAgreementMember **Namespace Prefix:** **Data Type:**na **Balance Type:** **Period Type:**

[-Details](#)
Name:us-gaap_LongtermDebtTypeAxis=us-gaap_LineOfCreditMember **Namespace Prefix:** **Data Type:**na **Balance Type:** **Period Type:**

[-Details](#)
Name:us-gaap_CreditFacilityAxis=us-gaap_SecuredDebtMember **Namespace Prefix:** **Data Type:**na **Balance Type:** **Period Type:**

[-Details](#)
Name:us-gaap_CreditFacilityAxis=arwr_IncrementalFacilityMember **Namespace Prefix:** **Data Type:**na **Balance Type:** **Period Type:** EXCEL 80 Financial_Report.xlsx IDEA: XBRL

[illegible]

[illegible]

01:1%V-N5+1#=-GG1:10M63A.73"N.2°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~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~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lt

JL-0:8#RHJ103JHRM&Z5=H<1/!S0P>Q-1)3N%MH MQ+VZWVr:16W^X^V&GJ:8I=9E!OMZ^#RFC/!RH^?P^VA<1ZG7-04S/X^0 MRT8)72,0(K 32+TD^N@ZHL91
CJ37^7LQ,0%J3D)1.O!>PD^Y^7JG+&0 M9+S<A1A1PH2HEU^HXUS^BS,0.\$98&BW15ZC+1WJ_E.Y@K-K1RHJ(89FJ M7+H%ZWT5G=>4&8&1UI3LFE
R2^6+VJ68MOA6UOUBVZVJ^S1-NV2^!MH: M=2% KMJ:25!+1VA4G7LKE6P^L2ZHPMZJHJ^Q^NL(M=NSHDCQ&S9 MIO65< B#% 17%21F37OJH^OD41;4>LX1^*G@D.O.G!
(+SBY(1-MCT<+F5N/(8@1M10N.4@HBD&Q X3S7^+!&S<#&9)9)OKLS87<1VABW4Q!A=GK!_8HJZB(1TP_X7J1^NT6Y%`# M6.W>=QD.DRN9BUV166T?>
OM).9!H!>=B^D&K:IGY46960>!\$TB1.(C=IOL9 M=X^0NET<^7S5B.1O.M5UG/A7XAZCHYTCL^MF>=>HE5^&B^ UW1\$7NAS@<(O31/7X<P6+7%X^..7G9'9BS.O#V41HJZPMJ&
M3=JNW&Y\$=5%+& 2V80S^=US80^X1TX.WJW?^A^CC<2471.NJX^+!&30 M9TW1WY/LCZONO+U+VWGUO!5Z+FM^A&=DZ@_&U^CJRV75SC5N^W3^DZRIOA
M@CZ<4!>=CY3RJPJOY^ETENTHT^:(K0+>2.EVA48JBRJ)O4^?F=(67%21RU1V7V)XAS.\$SDS M^RDJ+!>?E!AX^NJO3!&G^<@eU152K^1OY3VHT^<4NU8H^2%2+15XKP4MK
MM^K+ C2H175>CLO+Z14+UWFL.PM^YV066U6H.Z.M.3X162^M+!>F9GVA4+G6LM7V+&S^JRJOQWR M:U7?>=>SRX;D^UADPZ1=>RKY.S3!\$3)3^2B.C6@TL^%..V2N.HB4^ZP.X5Y
MYS^R+>+1T3G5<N4^N-2!KCFR.LPV^UQ.P65HUKCH(1=)1&C<#&29&6.M4X2MV12^2VX 1O^YMO70G T^M4V/D2H1RQ@!0!>U>=<6.SHN9877D1NY@M^MCO(S.%6^*
PMAQW1/9JHHU.L^X)WV%>^JA8IWF43@=89%HH>[S.Z.S5BS -M7@IX^O>=>QT/H9U>N=#.8.KAJM3PJ37!>LFL4^9P^AJCMIO10PES56^V^M^C16
=H870Q.0=0>R1C@!>.8K^!S!<@L.P3QC!1@S=Z^U3MH5+>Q?M13M2AIG@=(T%>=&17N^OK&=M2M29T.OB!>S^RJB^43^Y.O1TC3AO^AX^X0?>?D M@TN!+&0%HE6E2^1-
9><@R#28>2VEFL1H6G(HEX.Y4 08^V^CMQO&VD\$H.M.HLZ89^AUFJ386F1!>GV1Y4G3!+RM\$!^WK.#MN M^!^NXP=S.PIQ6V7\$X.#5531U^T6.X
IPB^GO%U^H^DBK1=>B\$=MS\$56^?M^M9SYUBF1\$S@B9%P52Z^N4MSA\$K^V^7HJ!<1^?3OR.HJ(1O4C@!>M2^L8WB4(4+JG<M^&J^B1^1^>\$V1^DA^B\$!O) M23!+!>LPLZ?>
F.0>3GUB^O M\$E.O!(NML1W/OL@+1+GESC^Y2K07P6^6ZRD.U-4X=>FIRA&Y6U2ZVX M-B&M@>=>KOMY\$Y5.(FELZ\$<M^<Z^WJZ^MG.O150MBH@DXN>14G!^SNE^JQ
MXC2X^B0=FGG-L2U=%4M9DX43YJH/FTD)J6HCW-.7 220ZR@KB@S!M^Q^TE.M+\$(7P<3WM%75.ZRI&1N^PXX^FVJ^M;7.UZ&F^P%ZRV!^#&PP1R3&2L-WH21290.
^!S>=W>J^JREL 4JE(3W\$0=&M.WZ36K^IMNH^5 1DY7!658 UT^N7A0^&C&BX-NL&H+S0>=LT2Q>VP^H MH5^F&.&L.91CKJX^R@>@/6^+8V7E.6IO^5^J2C^79.7+E?>
X>+38IE^Q^M2WV6Q=>AUYLDXQ20B6^HJ4K 6J(5CYCV 8 9+104.W<+2FLF@!S!\$!M15ZB^W5E(H65T6M!^S^W&A^JYUQWL^!DZXZBQOFT&R!L)OKZ? 2AJS@>8
M^YX1L^N3!^9 8%>D =>O 5XZMAS\$#>=>7HK9.8.NYO+K9VVL&H? 3F<6F.M.NO.SR3-1J6@KNIJX^W>CG>U^LL1B^W^%VW-NOU&_IX5>GJ5XEB3<>AGR^VW
JQ2^O>3 MYSJN@G@N7P150 505)6&WG7^W2PM^YV^N.NODDPV1H^W?_1U=>=5BGJ8L.GC^M^62Z 75\$3=>H1H1G2ZVFYV!H 15^W^H414\$!>H!O (M-&6 ^%EH^P%#Z0.#!^* 9
>&P0=VJR.W-H965T=-1CRLB%GCN9>69Y^DT@X+14UF^MP)F55 4S.^JUTFL%#F^BMRCOC^V^L.%LYC58S=J.9.5R.F&T5T51L/5U!
^!S>=W>J^JREL 4JE(3W\$0=&M.WZ36K^IMNH^5 1DY7!658 UT^N7A0^&C&BX-NL&H+S0>=LT2Q>VP^H MH5^F&.&L.91CKJX^R@>@/6^+8V7E.6IO^5^J2C^79.7+E?>
M6CMJ29B&Y^R9P=>2VF1Z4=DE.R^C^M^B^Z9E/!MU=>N^M!>VX2U+1!>L.6RW1^%EOC&8!BM^O.C>2XL MR9Q3.M2A^U4Z+N\$>C0Z3B.LJ8-UO+77PDC!SG>2
MJM.DKXMS&X55!O<S4W^L1@-W^L=>E2F^M^M^X^2H3B!>L^1^L^71^>XZP.M13^1^WU@DR876@%TFEN0.P9C.N>SHIO5.&F(1^X122H3DUN22^1W.3W^*
M9K 6^PR03HJ^WS8VMG9G(6M)^ET6A^KW:71^OYR@>Q!98!>=>F&S!R)R719P=>E^9 M2^M^J^S508S XADYV5Y^A QOQ3<<S^V1P.GI2<D^K2<@H1^77TDB\$41.2+TRH!O!>L
MH.&^<617@>SHY^A32.NX!@B!RQ!XQI2H0^EP>OKL0.^?2>D!>=1/Z.W2AC M1Z5TF!<=>F&S!MA73&<S^BN.2U^7EX5!3WF7K_P!7>^"KJK;IU^CFHSY
MUL^#1V51C0>@XG.NXGKU&VHEX>=>131D@XH2X=Q2 V M@!O48AN8)20^&ZLHE.#^>0S<^28?%GKNMN9^7E>+1^S^EGDV.N^X7^&+&
M7&B^P0W1^7U46121Q^_9JHL50<+>P^14D/4G82C.U!^QO:L^K12.S5M(W6@&PQ M=VIR.W-H965T!HY6Q=>RY?>@H.ME.C^C^6^V^K^D! MM9.
&@17%#COGUT^O^UM^W^B2FVMP4+U5!M^OR2^F@P^X12.VZ06 2K.G.92X^7AKUOV4CX3^#8X^?>M&N717U@UMLX@+1R9(1.RLHH&Z^XF&3ARV^T^<@9AWCCS-
>Z&Z)X3M8^CR.M9@766S.^W12M4313K^#R02^O9CR:29A+16D^4U2^_R06^G"3^@LX^K MBRR1^#5K4ABB@X^_52H^DQ%\$1V(.7=E.C(KSDG^Y^Q^>V3<7^3YW9+FT.M
NU^L.VY.WFV^W.E2+<#<#Y^>=>8S^Y!<C-INB670Q3+8ASZ9X^!E96W&J4VY? MJG8.U8M&M6U5^4EL^MN
M4Q+27Q\$XJFESJ9^3K%FN>1<1.4N0YD1Q!QU(NB^>X0 3H5+>@>12P^M GS@B>G06JEEG 8MG 2.XF=>=S56 7Q\$R=>=>E/1A5P9^6XU!>H.W6X!Q! MZH.M>KX!H2F>3.H^LV<
<7LMP!>JPH37!H@-G1P8)1LUF&E7^BFI0B!500^M&PQ=VIR.W-H965TCTC1496>1!>H.MRRH8X5!85\$S:K5L^1Q!&L^EWBKP.D!V237^O!J.P.B8+PQ!>5=00Q^Q.OA:IQ!
M^T=SPVJD^M^%71.T7S6G0N)H^Y 90^>M=>P2^Y+Q>V-PGBR5=G233+4!B!P^M^%A8A!&H^HPPD040^14F3^V6G& 97.<^!0 9^TZ+>^!G12R6!>16V.20(DK MU@HIS.X-8?
3!H0R0A2V&S!1@>S4K^&JWAH3@YK^!H!>P/R0)UUB^QO+N+M.L/KLMEB!MA&M^#M.&L@7261Q^EYH1H7DYU>=W^%>2U/&P^!UN^<81CAY.M8N^Y60VM^2!S8LME
75CR!M@<4BM^P7LL3R6_LAS>O9)3MV%&E1P^!>M.8 T^B^&DM\$10+3W-05XZ1MXUTQ+!M2!WYOXUOC164W^26W94@fJZ\$ MJY<B!D?>
4>H4W^M96&M\$?NH(=>=<Z\$H^*+&H)PH4ZQ@=0LU!P^+T=O^K.A M+&B \$S9&IUP2!>4.0CCL/QE!>H21A!X(XCC29AD&K6B9N^2Y=>#10X.%IWFEE^W^Q^>3)X^X^OOG^BL^C
M0+225>OG0K2N^%=>L7^KY4Y-R.60-H 2>Q=&#G6(F5!6^U!S31M2^THOODE!PU7B!<=>A@4>_N4!E^9P^M+?^P<^!P42P1^<70Y.^!L42&8!B\$S=>PA-
7=>=>^!VJG6B>56^5AL!PR2 M^>)&_HC^MP37.89^C^!>WDR9161EGNQGGLSP^%ARIKN/2H3.R!@>0.WV3^M^>DOW^%>Y7^S2>22PCG8>1@>JWTFY!
%9&E@YSJ0W>JF^YB5>_YSME25G@-MAZHEH78^>E^Y^B.N.PIDM^>PDG.M^%>98 (6=81T9Z!0 7B<M^D.JX^!>W4W^K&UO9K.N.Y\$G(2A7^7Q09!
M8AU13!T3G3H^MUMD^3M1=\$+1A!O\$JBEF3M!C#EY04V(50<8>N/H-10 M_\$=#EID M.LV-DKCM6^%OG5^6ML.C-J=&C(X4!L4A3M!Y^>)FBY@9BOKUMVZ_7^9!O
ME+G0^RR.H<4>9G=IG!OUBER!>O>133^!D^WJ!>=&/(AB3)8K.7.3&O M!3Y5W^R7K=EDR+!>C@&035YU9^W^L2+H W=WITH^/3&X<O!>#^_7URSO1 M^<1^1U>^Z
6B1^ORR.M^HJ54^T=-0!2 MEA9.Z7!9\$3!&N<= ZZR336G=>9#M53^NNA5OKECT67H!>M9!>7RB=W^1V^!KH>3^XF@CSM^>@USW^H^KPE(3B@!P2+M1YVZQO;V) 4/8 M!+>
(BG9^C^D 9C&4T560217R9^L.R1V^6+1D<@ORA0H30!1CQXHRF)YH!>M^GCDX^JH4D9^>CJ\$&L^8^8VWV^+!OZOL^>OSVTFW3B/P^Y!>=>L!LYXIE=>K> MYQWSI39WK3?>O>
W^K>^!#IOP2^Y^YQ^!RHR!PBA)N8^ZGN<=>S!>2^!K^M12T^G00DN!>YMA4XKULS0^>4S^&L^%U2^=>^6%K&3&H!>Z>Z=>=>9@P.M^O.68.)^%<EFGJ^HFT<=>W5^
!2.1^7Q.LA6-(54RSXS.F1!L4C^>H>=>M3B/U-18+T<9F84JW^OV+!L47NU&Q.8+OVC7^8+D.D6\$7L!D.LJ!8!<K^MV@<X5=\$^UMW17LHU!
M^>T2=>2^7S CFABEJ^F^T! UYNH\$1N1J3K08.N=WMH! L8R875_9X!M^P=>Y OGZ3!>L9G18T4^>H\$S<@!>9MDS^>5 G@>3 MDVSX&G&ZGHZ)R^A^G10!U=Z^#
IQG09(L\$03^8^6.2@6.FUM10 3!T^DTP^3 M^@&S!T@ W@>^2!2!2H!L8GC-(369X4G1F)H3)W52<Q.G!UB7X4^!O1XL!\$B^M^U04^1=N!IMB60N!L!L2R46\$!UMQEAUF0!
M2\$3B=>_E4\$5J120.10\$1+>2B5<=>EH!D 1 K!&C5E1ATCQ4FHH!>UH M^L.M&E7^J^18U2V^J^0 M^P&GM.G1X.VZ.6!R=&16K!106HMI^15HV..0W/2J>=>CMLQ32^#880.83+>
1 MMB8!GBF0H10!H4AE9!HJH<=>G=>R0^!>B20.10\$1+>2B54D6.FS.MFTM.DH^N.Z!H!M^O&E88B!G^+!N3H2PP^<=>K^NG04Y=>N72!+^UYJ80?
ME1!>TD!L6C4XMF5^>1^TZ8C^E/Q+IOD+C=4+N=>Y(1^OK^50B^X^H^>5YJ2 M.E1.B\$6K!LZV^&GW^>U#FHAS^Y7FH=>15\$!>2@NO<6HVE8!>=>RY^?7JN9K M49.
(B^CM\$^Z^R^+!>_0L\$^SRW&3FO^>Y^Y)K@>.@5A M^W9YRKUQ^C8+E.OP24\$!H!>0^&K^%>DH MG@Y=>@O.T; 9>K&P=VIR.W-H965T^7 2^_M2=>=>X!M+!418-[G2]
(@MZ3^727U2U^VY+2=>=<B)E!>1^TG&N&6\$H8U10 M67R1JTW8N0.E^P^98W^Y^>X4^ACHAF=R!>H!>@&W^L!>EJ^J.V60W MKY.HOU.V<=>B^W+!S3>1RX@P=P-D^Y66?
RCGFV^T!A1.3^6^JOY\$#^V.H.MBC^Y9^DC5B^L(TZ+>=>O.P^%>P\$83!2!H!>7K M^P&U1^3A\$!>E=L^7EHK6G6L12!JWBE13B573!EUB5!>P!>SJM!4!
M^3!>LHR@>X&K!>H530@>KP.IB&G^UJL^?B+!>1^HDMZM.J+>OHRP!>6!OB8S9 M6BBY&+M2^>N&N!>F1^2U!>P^COPC 9B!>H0^X2&6B123!E530NRH<5!>4SH4=>M^T=>QW5Q 0+O)O^!
!>J@>9S!W5Y8^G2.7.WYOH!U@>T\$^2!>=<24D\$6.BHL.MZAG^YNU<=>N3.042)W^WJ!U!U00SRTWP\$N^Q(C.Z<=>0)RC74&?ZXPIG!H MA=PE#F\$84NP7G+>CFAB3YM4H&+?
BV^>Y^WYV(S!>N9C>DAQ8P&O1HWB= M0&51^M^K=>#(H^X&+9F!>=>BUKO(C^UO!H^K^#^>SU7^F^!>O@>B4^1^1 MCHU!>2L46!>1MA=>P^F^>F\$84NP7G+>CFAB3YM4H&+?
!>F1WY1T^ZFDN^2T960@>S@>@>HVEJQ5^29^X^N^Q?N7&G&M^W!M0AYH0K3&L8763B^K<2&5AFW1^B6PNQ3XK!0!>=>100U9V!MGZ^&H&X^M^>L^X^02G.
%>9&OAZWL^N<=>@>Y^C^14^L&B=M^X^F^BUU-U^M^42^>S^>Q^>U^P^>M^G3S^>6^3A6!L^>W^KK^?T.OM1.8^>+>L^T!H5&K9^ZZ^>H^>=>@>=>P!>3QZ9V^>M^DZ.8!U)D\$4^D
NOH&G^FNC^#A!K<50 M4M4ZSD2.G=>6K69^BKE^#QFK^N^Q!>JCG39YTPQ2!O/G!>L41^>Z(M^%>Q@M^K^#M^ZWMV=>5^>=>RUWX^>V>=>IAY59U75<4B^KP^Z!A^2
L!>C!7 M77D7!55!>K!J+Z1^4=C^PP^5E>72X122@0#=>3S.6/RZ;LH^W!F.X^4\$!&L^M!>10 (&6^%G2U^+!APY^#&9>&P0=VIR.W-H965T!D10!KOP>=>S^!>N.Z>?>7 M<1V1B?>
T8>=>K&R0K!H(L=>=>E!>FOX7^&1A82E2!>Q!>H^F\$UHQ>31WGB!G^W^M^P^Y.QH35TFNU!>+W!0S&CH^<PCH^A9P^S\$.(H8QO2<=>MG3!>B?>=>K7 MCK7DS!&H&JOA
M!HWBTFH!>GM^W^M4G^Z211&R0IX^2^H!191^ M!&X^>Q>_>S^K\$9Y^>Y^T^>N!>FU(M^>=>EEP!>2W!U!H!SDQKOW=9DC8Y4-/Q7DKA=MLC=>
N/B!F414D.B!1B!>+>4^1U>BP=>P^HC6^&M^Y^M3M^W1W7^F5^VQZ^FZ!>H!>=>WS.IY(M^0 2M\$A2&6P0=VIR.W-H965T!B1^1YTD0425!P3!>662!8M.U9Y!>P^M6PO0(66>B
051UO&G16^>E=>HC 6X1^>RN3>_2\$P(A!>6&M^RPA13!58\$>3^4NWR M12\$230!>X!^!PS=>=>1A!>G&GDM^MAUWK!L.M@>H2N+1.6.R20!>3!>CEGQOM6>4E#F.2^PHB0SGBW^GOKK^3-
R\$H!VOK M=>K9!>BDSOH3G2OYN&F+2(A^62^P.IK0^>Y!>8^DU8Z^>VYBGK^>W-U^HWO9.MQ.N+F6!>HECXHYV!U:ASV4%SL!>K4YEV!>DN\$!>R(M8^+!>M^W^FAT4K(5D
M41&1&A#1^>+>4!>L4!>O.T!>A!>@!>P^T^>@>ITB^X^NJO&J!>H^>B^&C^H M^>X!>C<B80A45O1K9EWC8(DG4ZYB>=>E^2W<R/HWB0U8N4Q-GDZBQ5
M<7^>BNC\$>190^D8H!UHH5PCZ\$>5^228.D1 P^R8B^E^?D^>=>QU+9HW1^MXO!>4K.GMP^ZC122^423)9PZ!F!>G!BDR!>F\$KHL=>@T!>J5!>U!>1 MPMNA&1^!>EKH<=>5R)9
>S!>F!>T^H!RTOV72!>M^W!>H!>H!>BOLT^XVM=>M^!>K^E.A9A>=>PAW3JC.EZ!HP^>D!>J2LO2G<=>1WQ3>=>4^>OR1^220^6!>EJ&B^K MNJ5!W857?
>=>C^3^G!UFGP^2K16F!>1^MD 126^H^Z0^S^>K<=>=>5&S&KJ^BVP^>=>PAQ^F!>L!>R!>A!>L^X!>N!>L87P.4>1^ED#=#N9^PCQF!>1^S!>UDV+>T!>N!>#50D
M.LJN!>SGP^>8)P&A&SP+29.L6E!>62!>A#B3.A81YX.1KFOF2 6QS@>=>Jm2^" M92C^Y7!6.V3!>H!>L.Z\$>=>F!>C!>M5!>FBE!>KDF!>F1-FL3).R!>A+FO.
12Y!>E!>J&F9^V16=>+HJ=KZ!>=>J!>O!>H^M^35H46WU0(2YD^>#7\$B0!>PGS@>=>U!>Y^O2&=>H!>=>LAK=>=>B9^P!>H(7U^%K62!>H^BC!>L3Y
MH#2 1W5WO!>H0!>9A!>F94K^M^5!>10!>Y^Y3F@>M(A)H!>O!>4B5W MK=>X^F^>YH!>1^OXHS06E>T^X!>6M2U^UOZO+!>3&4Z.Y5^2CAZH<9C^>MP6W2^C.D^NFE!>6.32?
#%K50&D^>=>TNOY353MK3)Q!>K\$>A^>F0O=>=>M^!>KN M^>S^>K!>D!>H4590S.E^5^>T^>N=7J5Y+>1^L!>VYB^M^>O^>TYX\$!>H+E4)H20^A M^4^!>JARO14 R^FF!>ZK^>O^>F9K4^3^3M^?
T^>K50F@>=>1^>K^>G=>=>L!>U!>D^>PDK!>(7ME^TEQO^F=>1^Z!>H!>5N50.8UN!>1)9D)EF3W!>VZ4FXR9^S1^>PHT6T^J4Y.M!>VZ2^5K!>OLFV^!>JO!>XHS8^>BY88.VM!>Q!>V3?>
>@0^YCF6^>+>0!>6BXEOLD6.MTH5!>7P!>=>@>FZ2N.B^9!>#>S8JCFG3Q2V!>QO2)9D^TMG3\$H699LK@>N>=>1P74 M^05C!>F!>TGK!>1<8^W3^>U!>+P04^!>E@>A9T^>XD!>S^#^>9^>0^>0^>A!>
M+W+O=>=>1^>V5!>2!>CZ>L7>3>H!>T5!>=>M!>L!>S^>=>5^>F^MU+ZREL^P+1^5P70H!>+>V!>H!>DV08.90E2C!>RU3!>M^>E!>ZEEH2H!>LZ!>F4!>D=>=<=>1FD M^>4V!>M>6GCI9V^>
(NB8!>F8\$ M^D\$!>1^>Q9M80.L^MX!>B!>N=>S04N0^>VA<N^>N^>Z)J!>D=>=>U^FN^!>P8D>2^Y@>Z!>P!>BG50>M^>NA70/7!>D!>H!>#F%>6!>K!>1<760.8D7R!>O2Y+>64 MY!>N^!>AE
M!>DTOM2^>M^>RKZK^>5^C^>V^>C^!>JDG103!>=>A M2=>=>H!>P5^>S^>QV\$3G^>B\$>H06!>B!>D8(8+!>U.M^%>H!>M6!>9R51=Y0+7!>JF3V^5^>CCP^>?>=>Y!>T!>R!>1^>M^>W!>Q3^>
>=>R7^>4!>N=M0K=>HUMF!>VHGDE.HX^>F!>G!>AMFF27574NE^WTF.M.KH!>G!>4B!>D!>F&Y&Z^>X6A&Q3!>C^#6+>G=T^W^>3XK9D9!>DX46=>
MIE25!>YU@>GOD>P4^F^M^6UWNSVK0A_ZWEL^QD>GJN^XHZEFU.F9YP.MG.144^!>ZBBN^N7JHE57!>H!>K2>=>R^80^>T=>=>3 ME4B5DP\$Z!>FX2K!>H^M^Z^S<52T@!>J2!>SY\$!>
T^NA4R!>E=RZ.A.HU+H!>SD?>=>2EE0=>=>O=>N3P^M2!>Q^!>J7RZA5O!>G>=>W&=>9!>9^>YMF=F^WH+!>D!>1<0TE9BEP M000G^N!>Q>?>6^A^H^R0R!>M!>F1!>60C0M^>B3B!>
L^M\$C2^#2!>B^K57.M^H40^>DNG^M0K^!>H!>H!>7^>+>P!>TQ2!>9!>F!>B!>L^GZ^M^>D>#>#>A!>1D67^>N^Z 9E!>L^MTMK8!>1E0!>F!>C!>A=>=>P&A^N!>V!>9N!>H!>P5Z M!>10^>PVT^P4H^A5
W.G&G^CHN!>D!>H!>E!>S!>G4^K2B4!>J M^>8^>8KR8^>=>M!>F2.V.9^>7!>T^>22C6!>DX!>L.R.52!>I!>H!>5Y3^!>H!>5X^>@N5E!>L!>FXN681 M3N!>0!>R!>V!>P0F^WZFW!>=>E@>Y\$>^>7(7W0%>^>
!>ODN^>P.D!>9MW9) M^M^>B^>@>E!>EA!>H2.C^>XO!>Y!>P.LEN!>H!>M!>R861^3^>=>Y8!>R!>8!>H!>M^>Z M29)O^>3V7S0^U^>F9J2\$>GYLX<=>1^>D!>E2W!>FBH5<=>4.30C9X.KC2DZ!>N
M.5%U8!>=>C2)JG!>G.3^>SG@>F!>N0>=>K!>2!>H!>H!>R^E!>DQ8B 1K^3E!>H!>M!>S8 MZ!>U^F9!>R!>M!>SSA&HAG!>H7!>S&E^>BSYE+>HH9^22!>H!>+VY!>JQ4E6P40DK M^>K2US!>!>Q=>46>=>J^>
EHB 1KJ3!>L5!>A5!>B!>H!>F6!>1N.SUL!>ISKX0HV-MW/P8^PZF3SS!>H!>A YD^JW!>X5^>6L^Y.M0X^F!>U7+!>46!>6JF+BSL7!>H!>R.6 M!>H8!>L^86F+!>DQ8B 1K^7G!>=>E!>M^>=>
<=>D^>J!>W^>9^>QYH!>SD!>T0>=>=>Z^>E^D^K^>NHR!>L^>U^>K!>M0^>Z^>Q!>H2+>2^>6MSUWTF^>Y5G!>P=>=>MR6W!>A2!>13!>H!>G!>7RXY=RS!>Y>=>166+2VOW7P!>H!>O^>9G.SU^>ST
MLY3Q^>O!>106HM^>F!>V1^>3!>UJH!>R6 M^K>WE.9.L6!>WE1^>395KOE!>FYU^>H!>+!>O!>E19B!>T=>I23.A^>Z!>H!>P=>=>K2^>M2@M0.2\$6K.WH
JOV!>G!>G!>4&S^YFFZA+>=>1&S9^R49FKZ0!>D1!>H!>F!>F!>E!>N^>M!>J!>L^>H!>O^>=>CJMX!>L!>H6!>SN!>S^>WQ6Z.PF+>EZ!>H!>+L6AM2^>YNH>4!>=>D3X> M^>JHN3!>J+4^EA5BTMEL<
UD!>O!>F!>AYK^H!>H!>J!>61K!>N!>WB7!>L.W!>S!>Q=>N.M

M=\$@3G.1E<>46G6S\$K!&O:&MF&=91.3N&9K2)H4D)P7!&B3F5374V MG2:&SG-NR(0)50=>D!98KCTSS.5:J6YK2")H4D)P10=>69&ZL3Z#8)M=+4)0WV+?Y56D24\$T20-UH-N\$@&1UO:Q1C=95T\$F52ALZ187Uf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~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~>E8XP80DG30BCFV>P/>P^%4N0^M1UOEF1DIOKMUG^MAK^3XOF4W(K2SZ#4L>K^>O0W.P4JCM1DIO<960)M^N^H^V<3.6RBYX191DDR@>OP8&V4E4YJ1M1MJ.RR<@>W18LW.H.QS25C<MP503U1B#K^<^>715^X24(OH.K8>L^H1LMG7%0YF=ECCG7(KLQ.NWGG)7>@GK.H.2P2S^>2.M^HIEH'65Z<~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

a.while(e&c;e.nodeName!=""TABLE")e=c.nextSibling;if(!e||e.nodeName=="TABLE"){var ref=(window)?w.document.document.getElementById(r):(ref?e=ref.cloneNode(1):e.removeAttribute("id"),a.parentNode.appendChildChild(e))}if(e.style.display=="block";Show.LastAR=e;Show.hideAR=function() {Show.LastAR.style.display="none"};Show.toggleNext=function(a){var e=a;while(e.nodeName!="DIV")e=e.nextSibling;if(!e.style){else if(e.style.display){else{var d,p;if(e.style.display=="none"){d="block;p="+1}else{d="none;p="+-1}}e.style.display=d;if(a.textContent) {fa.textContent+=p+a.textContent.substring(1)}else{a.innerHTMLText=p+a.innerHTMLText.substring(1)}}}XML 82 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ v2.2.0.24 */ DefRef Styles % report table.authRefData background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } report table.authRefData f display: block; font-weight: bold; } report table.authRefData p f margin-top: 0px; } report table.authRefData hide f background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } report table.authRefData hide a hover f background-color: #2F4497; } report table.authRefData body f height: 150px; overflow: auto; width: 400px; } report table.authRefData table f font-size: 1em; } % Report Styles % pl.a.pl.a.visited f color: black; text-decoration: none; } % table % report f background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, sans-serif; margin-bottom: 2em; } report hr f border: 1px solid #acf; } % Top labels % report th f background-color: #acf; color: black; font-weight: bold; text-align: center; } report th void f background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, sans-serif; text-align: left; } report .pl f text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; } word-wrap: break-word; % } report td.pl.a.f cursor: pointer; display: block; width: 200px; overflow: hidden; } report td.pl div a f width: 200px; } report td.pl a hover f background-color: #ffc; } % Header rows... % report tr th f background-color: #acf; color: black; font-weight: bold; } % Calendars... % report rc f background-color: #f0f0f0; } % Even rows... % report re, report reu f background-color: #def; } report reu td f border-bottom: 1px solid black; } % Odd rows... % report ro, report rou f background-color: white; } report rou td f border-bottom: 1px solid black; } report rou table td, report reu table td f border-bottom: 0px solid black; } % styles for footnote marker % report .fn f white-space: nowrap; } % styles for numeric types % report num, report nump f text-align: right; white-space: nowrap; } report nump f padding-left: 2em; } report nump f padding: 0px 0 4em 0px 2em; } % styles for text types % report text f text-align: left; white-space: normal; } report text big f margin-bottom: 1em; width: 17em; } report text more f display: none; } report text note f font-style: italic; font-weight: bold; } report text small f width: 10em; } report sup f font-style: italic; } report outerFootnotes f font-size: 1em; } XML 84 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.2.u1 http://www.xbrl.org/2003/role/disclosure/1 false false R1.htm0000001 - Document - CoverSheethttp://www.arrowheadresearch.com/role/CoverCoverCover1 falsefalseR2.htm9952151 - Statement - Consolidated Balance Sheetshttp://www.arrowheadresearch.com/role/ConsolidatedBalanceSheetsConsolidated Balance SheetsStatements2 falsefalseR3.htm9952152 - Statement - Consolidated Balance Sheets (Parenthetical)Sheethttp://www.arrowheadresearch.com/role/ConsolidatedBalanceSheetsParentheticalConsolidated Balance Sheets (Parenthetical)Statements3 falsefalseR4.htm9952153 - Statement - Consolidated Statements of Operations and Comprehensive LossStatementhttp://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLossConsolidated Statements of Operations and Comprehensive LossStatements4 falsefalseR5.htm9952154 - Statement - Consolidated Statements of Stockholders??? EquitySheethttp://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquityConsolidated Statements of Stockholders??? EquityStatements5 falsefalseR6.htm9952155 - Statement - Consolidated Statements of Cash FlowsSheethttp://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlowsConsolidated Statements of Cash FlowsStatements6 falsefalseR7.htm9952156 - Disclosure - Organization and Significant Accounting PoliciesSheethttp://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesOrganization and Significant Accounting PoliciesNotes7 falsefalseR8.htm9952157 - Disclosure - Collaboration and License AgreementsSheethttp://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsCollaboration and License AgreementsNotes8 falsefalseR9.htm9952158 - Disclosure - Balance Sheet AccountsSheethttp://www.arrowheadresearch.com/role/BalanceSheetAccountsBalance Sheet AccountsNotes9 falsefalseR10.htm9952159 - Disclosure - InvestmentsSheethttp://www.arrowheadresearch.com/role/InvestmentsInvestmentsNotes10 falsefalseR11.htm9952160 - Disclosure - Intangible AssetsSheethttp://www.arrowheadresearch.com/role/IntangibleAssetsIntangible AssetsNotes11 falsefalseR12.htm9952161 - Disclosure - Stockholders' EquitySheethttp://www.arrowheadresearch.com/role/StockholdersEquityStockholders' EquityNotes12 falsefalseR13.htm9952162 - Disclosure - Commitments and ContingenciesSheethttp://www.arrowheadresearch.com/role/CommitmentsandContingenciesCommitments and ContingenciesNotes13 falsefalseR14.htm9952163 - Disclosure - LeasesSheethttp://www.arrowheadresearch.com/role/LeasesLeasesNotes14 falsefalseR15.htm9952164 - Disclosure - Stock-Based CompensationSheethttp://www.arrowheadresearch.com/role/StockBasedCompensationStock-Based Compensation Notes15 falsefalseR16.htm9952165 - Disclosure - Fair Value MeasurementsSheethttp://www.arrowheadresearch.com/role/FairValueMeasurementsFair Value Measurements Notes16 falsefalseR17.htm9952166 - Disclosure - Liability Related to the Sale of Future RoyaltiesSheethttp://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesLiability Related to the Sale of Future RoyaltiesNotes17 falsefalseR18.htm9952167 - Disclosure - Net Loss Per ShareSheethttp://www.arrowheadresearch.com/role/NetLossPerShareNet Loss Per ShareNotes18 falsefalseR19.htm9952168 - Disclosure - Subsequent EventsSheethttp://www.arrowheadresearch.com/role/SubsequentEventsSubsequent EventsNotes19 falsefalseR20.htm995410 - Disclosure - Pay vs Performance DisclosureSheethttp://xbrl.sec.gov/ecd/role/PvpDisclosurePay vs Performance DisclosureNotes20 falsefalseR21.htm995445 - Disclosure - Insider Trading ArrangementsSheethttp://xbrl.sec.gov/ecd/role/InsiderTradingArrangementsInsider Trading ArrangementsNotes21 falsefalseR22.htm9954471 - Disclosure - Organization and Significant Accounting Policies (Policies)Sheethttp://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesPoliciesOrganization and Significant Accounting Policies (Policies)Policiesheethttp://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPolicies22 falsefalseR23.htm9954472 - Disclosure - Organization and Significant Accounting Policies (Tables)Sheethttp://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesTablesOrganization and Significant Accounting Policies (Tables)Tableshthttp://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPolicies23 falsefalseR24.htm9954473 - Disclosure - Collaboration and License Agreements (Tables)Sheethttp://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTablesCollaboration and License Agreements (Tables)Tableshthttp://www.arrowheadresearch.com/role/CollaborationandLicenseAgreements24 falsefalseR25.htm9954474 - Disclosure - Balance Sheet Accounts (Tables)Sheethttp://www.arrowheadresearch.com/role/BalanceSheetAccountsTablesBalance Sheet Accounts (Tables)Tableshthttp://www.arrowheadresearch.com/role/BalanceSheetAccounts25 falsefalseR26.htm9954475 - Disclosure - Investments (Tables)Sheethttp://www.arrowheadresearch.com/role/InvestmentsTablesInvestments (Tables)Tableshthttp://www.arrowheadresearch.com/role/Investments26 falsefalseR27.htm9954476 - Disclosure - Intangible Assets (Tables)Sheethttp://www.arrowheadresearch.com/role/IntangibleAssetsTablesIntangible Assets (Tables)Tableshthttp://www.arrowheadresearch.com/role/IntangibleAssets27 falsefalseR28.htm9954477 - Disclosure - Stockholders' Equity (Tables)Sheethttp://www.arrowheadresearch.com/role/StockholdersEquityTablesStockholders' Equity (Tables)Tableshthttp://www.arrowheadresearch.com/role/StockholdersEquity28 falsefalseR29.htm9954478 - Disclosure - Leases (Tables)Sheethttp://www.arrowheadresearch.com/role/LeasesTablesLeases (Tables)Tableshthttp://www.arrowheadresearch.com/role/Leases29 falsefalseR30.htm9954479 - Disclosure - Stock-Based Compensation (Tables)Sheethttp://www.arrowheadresearch.com/role/StockBasedCompensationTablesStock-Based Compensation (Tables)Tableshthttp://www.arrowheadresearch.com/role/StockBasedCompensation30 falsefalseR31.htm9954480 - Disclosure - Fair Value Measurements (Tables)Sheethttp://www.arrowheadresearch.com/role/FairValueMeasurementsTablesFair Value Measurements (Tables)Tableshthttp://www.arrowheadresearch.com/role/FairValueMeasurements31 falsefalseR32.htm9954481 - Disclosure - Liability Related to the Sale of Future Royalties (Tables)Sheethttp://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesTablesLiability Related to the Sale of Future Royalties (Tables)Tableshthttp://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyalties32 falsefalseR33.htm9954482 - Disclosure - Net Loss Per Share (Tables)Sheethttp://www.arrowheadresearch.com/role/NetLossPerShareTablesNet Loss Per Share (Tables)Tableshthttp://www.arrowheadresearch.com/role/NetLossPerShare33 falsefalseR34.htm9954483 - Disclosure - Organization and Significant Accounting Policies - Narrative (Details)Sheethttp://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetailsOrganization and Significant Accounting Policies - Narrative (Details)Detailshthttp://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesTables34 falsefalseR35.htm9954484 - Disclosure - Collaboration and License Agreements - Revenue (Details)Sheethttp://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsRevenueDetailsCollaboration and License Agreements - Revenue (Details)Details35 falsefalseR36.htm9954485 - Disclosure - Collaboration and License Agreements - Receivables and Contract Liabilities (Details)Sheethttp://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsReceivablesandContractLiabilitiesDetailsCollaboration and License Agreements - Receivables and Contract Liabilities (Details)Details36 falsefalseR37.htm9954486 - Disclosure - Collaboration and License Agreements - Glaxosmithkline Intellectual Property (No. 3) Limited (Details)Sheethttp://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetailsCollaboration and License Agreements - Glaxosmithkline Intellectual Property (No. 3) Limited (Details)Details37 falsefalseR38.htm9954487 - Disclosure - Collaboration and License Agreements - Horizon Therapeutics Ireland DAC (Details)Sheethttp://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetailsCollaboration and License Agreements - Horizon Therapeutics Ireland DAC (Details)Details38 falsefalseR39.htm9954488 - Disclosure - Collaboration and License Agreements - Takeda Pharmaceutical Company Limited (Details)Sheethttp://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetailsCollaboration and License Agreements - Takeda Pharmaceutical Company Limited (Details)Details39 falsefalseR40.htm9954489 - Disclosure - Collaboration and License Agreements - Amgen Inc (Details)Sheethttp://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetailsCollaboration and License Agreements - Amgen Inc (Details)Details40 falsefalseR41.htm9954490 - Disclosure - Collaboration and License Agreements - Visirna Therapeutics, Inc. (Details)Sheethttp://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsVisirnaTherapeuticsIncDetailsCollaboration and License Agreements - Visirna Therapeutics, Inc. (Details)Details41 falsefalseR42.htm9954491 - Disclosure - Balance Sheet Accounts - Summary of Property and Equipment (Details)Sheethttp://www.arrowheadresearch.com/role/BalanceSheetAccountsSummaryofPropertyandEquipmentDetailsBalance Sheet Accounts - Summary of Property and Equipment (Details)Details42 falsefalseR43.htm9954492 - Disclosure - Balance Sheet Accounts - Accrued Expenses (Details)Sheethttp://www.arrowheadresearch.com/role/BalanceSheetAccountsAccruedExpensesDetailsBalance Sheet Accounts - Accrued Expenses (Details)Details43 falsefalseR44.htm9954493 - Disclosure - Investments - Summary of Short-term, Long-term Investments and Marketable Securities (Details)Sheethttp://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetailsInvestments - Summary of Short-term, Long-term Investments and Marketable Securities (Details)Details44 falsefalseR45.htm9954494 - Disclosure - Intangible Assets - Schedule of Intangible Assets (Details)Sheethttp://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetailsIntangible Assets - Schedule of Intangible Assets (Details)Details45 falsefalseR46.htm9954495 - Disclosure - Intangible Assets - Expected Future Amortization (Details)Sheethttp://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetailsIntangible Assets - Expected Future Amortization (Details)Details46 falsefalseR47.htm9954496 - Disclosure - Stockholders' Equity (Details)Sheethttp://www.arrowheadresearch.com/role/StockholdersEquityDetailsStockholders' Equity (Details)Details47 falsefalseR48.htm9954497 - Disclosure - Commitments and Contingencies - Narrative (Details)Sheethttp://www.arrowheadresearch.com/role/CommitmentsandContingenciesNarrativeDetailsCommitments and Contingencies - Narrative (Details)Details48 falsefalseR49.htm9954498 - Disclosure - Leases - Narrative (Details)Sheethttp://www.arrowheadresearch.com/role/LeasesNarrativeDetailsLeases - Narrative (Details)Details49 falsefalseR50.htm9954499 - Disclosure - Leases - Components of Lease Assets and Liabilities (Details)Sheethttp://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetailsLeases - Components of Lease Assets and Liabilities (Details)Details50 falsefalseR51.htm9954500 - Disclosure - Leases - Summary of Maturities of Operating Lease Liabilities on an Undiscounted Basis (Details)Sheethttp://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetailsLeases - Summary of Maturities of Operating Lease Liabilities on an Undiscounted Basis (Details)Details51 falsefalseR52.htm9954501 - Disclosure - Leases - Supplemental Cash Flow and Other Information Related to Leases (Details)Sheethttp://www.arrowheadresearch.com/role/LeasesSupplementalCashFlowandOtherInformationRelatedtoLeasesDetailsLeases - Supplemental Cash Flow and Other Information Related to Leases (Details)Details52 falsefalseR53.htm9954502

Value-Stock Options - DetailsDetails57 falsefalseR58.htm9954507 - Disclosure - Stock-Based Compensation - Summary of RSUs Activity
(Details)Sheethttp://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetailsStock-Based Compensation - Summary of RSUs Activity
(Details)Details58 falsefalseR59.htm9954508 - Disclosure - Fair Value Measurements - Fair Value Measurements for Assets and Liabilities Measured at Fair Value on Recurring Basis
(Details)Sheethttp://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetailsFair Value Measurements - Fair Value Measurements for Assets and Liabilities Measured at Fair Value on Recurring Basis (Details)Details59 falsefalseR60.htm9954509 -
Disclosure - Liability Related to the Sale of Future Royalties - Narrative
(Details)Sheethttp://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleoffutureRoyaltiesNarrativeDetailsLiability Related to the Sale of Future Royalties - Narrative
(Details)Detailshttp://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleoffutureRoyaltiesTables60 falsefalseR61.htm9954510 - Disclosure - Liability Related to the Sale of Future Royalties - Activity (Details)Sheethttp://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleoffutureRoyaltiesActivityDetailsLiability Related to the Sale of Future Royalties - Activity (Details)Detailshttp://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleoffutureRoyaltiesTables61 falsefalseR62.htm9954511 -
Disclosure - Net Loss Per Share - Basic and Diluted Net Loss Per Share
(Details)Sheethttp://www.arrowheadresearch.com/role/NetLossPerShareBasicandDilutedNetLossPerShareDetailsNet Loss Per Share - Basic and Diluted Net Loss Per Share
(Details)Details62 falsefalseR63.htm9954512 - Disclosure - Net Loss Per Share - Antidilutive
(Details)Sheethttp://www.arrowheadresearch.com/role/NetLossPerShareAntidilutiveDetailsNet Loss Per Share - Antidilutive (Details)Details63 falsefalseR64.htm9954513 -
Disclosure - Subsequent Events (Details)Sheethttp://www.arrowheadresearch.com/role/SubsequentEventsDetailsSubsequent Events
(Details)Detailshttp://www.arrowheadresearch.com/role/SubsequentEvents64 falsefalseAll ReportsBookAll Reports arwr-20240630.htmarwr-20240630.xsdarwr-20240630-cal.xmlarwr-20240630-def.xmlarwr-20240630-lab.xmlarwr-20240630-pre.xml http://fasb.org/us-gaap/2024http://xbrl.sec.gov/dei/2024http://xbrl.sec.gov/ecd/2024true true JSON-87 MetaLinks.json IDEA-XBRL DOCUMENT { "version": "2.2", "instance": { "arwr-20240630.htm": { "nsPrefix": "arwr", "nsURI": "http://www.arrowheadresearch.com/20240630", "dts": { "inline": { "local": { "arwr-20240630.htm": { "schema": { "local": { "arwr-20240630.xsd": { "remote": { "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd": { "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd": { "http://www.xbrl.org/2003/xl-2003-12-31.xsd": { "http://www.xbrl.org/2003/xlink-2003-12-31.xsd": { "http://www.xbrl.org/2005/xbrldt-2005.xsd": { "http://www.xbrl.org/2006/ref-2006-02-27.xsd": { "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd": { "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd": { "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd": { "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd": { "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd": { "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd": { "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd": { "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd": { "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd": { "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd": { "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd": { "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd": { "https://xbrl.sec.gov/country/2024/country-2024.xsd": { "https://xbrl.sec.gov/dei/2024/dei-2024.xsd": { "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd": { "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd": { "calculationLink": { "local": { "arwr-20240630-cal.xml": { "definitionLink": { "local": { "arwr-20240630-def.xml": { "labelLink": { "local": { "arwr-20240630-lab.xml": { "presentationLink": { "local": { "arwr-20240630-pre.xml": { "keyStandard": 247, "keyCustom": 50, "axisStandard": 23, "axisCustom": 0, "memberStandard": 32, "memberCustom": 34, "hidden": { "total": 7, "http://xbrl.sec.gov/dei/2024": 5, "http://xbrl.sec.gov/ecd/2024": 2, "contextCount": 277, "entityCount": 1, "segmentCount": 73, "elementCount": 581, "unitCount": 9, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 747, "http://xbrl.sec.gov/dei/2024": 30, "http://xbrl.sec.gov/ecd/2024": 12, "report": { "R1": { "role": "http://www.arrowheadresearch.com/role/Cover", "longName": "0000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body", "html": { "reportCount": 1, "baseRef": "arwr-20240630.htm", "first": true, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body", "html": { "reportCount": 1, "baseRef": "arwr-20240630.htm", "first": true, "unique": true } }, "R2": { "role": "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets", "longName": "9952151 - Statement - Consolidated Balance Sheets", "shortName": "Consolidated Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr", "table", "div", "body", "html": { "reportCount": 1, "baseRef": "arwr-20240630.htm", "first": true, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:PrepaidExpenseCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr", "table", "div", "body", "html": { "reportCount": 1, "baseRef": "arwr-20240630.htm", "unique": true } }, "R3": { "role": "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheetsParenthetical", "longName": "9952152 - Statement - Consolidated Balance Sheets (Parenthetical)", "shortName": "Consolidated Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": { "span": "div", "body", "html": { "reportCount": 1, "baseRef": "arwr-20240630.htm", "first": true, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr", "table", "div", "body", "html": { "reportCount": 1, "baseRef": "arwr-20240630.htm", "unique": true } }, "R5": { "role": "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss", "longName": "9952153 - Statement - Consolidated Statements of Operations and Comprehensive Loss", "shortName": "Consolidated Statements of Operations and Comprehensive Loss", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr", "table", "div", "body", "html": { "reportCount": 1, "baseRef": "arwr-20240630.htm", "first": true, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr", "table", "div", "body", "html": { "reportCount": 1, "baseRef": "arwr-20240630.htm", "unique": true } }, "R6": { "role": "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows", "longName": "9952155 - Statement - Consolidated Statements of Cash Flows", "shortName": "Consolidated Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ProfitLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr", "table", "div", "body", "html": { "reportCount": 1, "baseRef": "arwr-20240630.htm", "first": true, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ShareBasedCompensation", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": { "span": "td", "tr", "table", "div", "body", "html": { "reportCount": 1, "baseRef": "arwr-20240630.htm", "unique": true } }, "R7": { "role": "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPolicies", "longName": "9952156 - Disclosure - Organization and Significant Accounting Policies", "shortName": "Organization and Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationAndPresentationOffinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body", "html": { "reportCount": 1, "baseRef": "arwr-20240630.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:OrganizationConsolidationAndPresentationOffinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body", "html": { "reportCount": 1, "baseRef": "arwr-20240630.htm", "first": true, "unique": true } }, "R8": { "role": "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreements", "longName": "9952157 - Disclosure - Collaboration and License Agreements", "shortName": "Collaboration and License Agreements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body", "html": { "reportCount": 1, "baseRef": "arwr-20240630.htm", "first": true, "unique": true } }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": { "span": "div", "body", "html": { "reportCount": 1, "baseRef": "arwr

```

"us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html", "1", "reportCount": 1, "baseRef": "arwr-20240630.htm", "first": true, "unique": true }, "R16": { "role": "http://www.arrowheadresearch.com/role/FairValueMeasurements", "longName": "9952165 - Disclosure - Fair Value Measurements", "shortName": "Fair Value Measurements", "isDefault": "false", "groupType": "disclosure", "subGroupType": null, "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html", "1", "reportCount": 1, "baseRef": "arwr-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html", "1", "reportCount": 1, "baseRef": "arwr-20240630.htm", "first": true, "unique": true }, "R17": { "role": "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyalties", "longName": "9952166 - Disclosure - Liability Related to the Sale of Future Royalties", "shortName": "Liability Related to the Sale of Future Royalties", "isDefault": "false", "groupType": "disclosure", "subGroupType": null, "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "c-1", "name": "arwr:LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html", "1", "reportCount": 1, "baseRef": "arwr-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "arwr:LiabilityRelatedToTheSaleOfFutureRoyaltiesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html", "1", "reportCount": 1, "baseRef": "arwr-20240630.htm", "first": true, "unique": true }, "R18": { "role": "http://www.arrowheadresearch.com/role/NetLossPerShare", "longName": "9952167 - Disclosure - Net Loss Per Share", "shortName": "Net Loss Per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": null, "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html", "1", "reportCount": 1, "baseRef": "arwr-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html", "1", "reportCount": 1, "baseRef": "arwr-20240630.htm", "first": true, "unique": true }, "R19": { "role": "http://www.arrowheadresearch.com/role/SubsequentEvents", "longName": "9952168 - Disclosure - Subsequent Events", "shortName": "Subsequent Events", "isDefault": "false", "groupType": "disclosure", "subGroupType": null, "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html", "1", "reportCount": 1, "baseRef": "arwr-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html", "1", "reportCount": 1, "baseRef": "arwr-20240630.htm", "first": true, "unique": true }, "R20": { "role": "http://xbrl.sec.gov/ecd/role/PyPDisclosure", "longName": "9954110 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": null, "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html", "1", "reportCount": 1, "baseRef": "arwr-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:NetIncomeLoss", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "3", "ancestors": [ "span", "td", "tr", "table", "div", "ix:continuation", "ix:continuation", "body", "html", "1", "reportCount": 1, "baseRef": "arwr-20240630.htm", "first": true, "unique": true }, "R21": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "9954445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": null, "menuCat": "Notes", "order": "21", "firstAnchor": { "contextRef": "c-1", "name": "ecd:MtrTermsOfFrdArrTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html", "1", "reportCount": 1, "baseRef": "arwr-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "ecd:MtrTermsOfFrdArrTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html", "1", "reportCount": 1, "baseRef": "arwr-20240630.htm", "first": true, "unique": true }, "R22": { "role": "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPolicies(Policies)", "longName": "9954471 - Disclosure - Organization and Significant Accounting Policies (Policies)", "shortName": "Organization and Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "22", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:NewAccountingPronouncementsPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html", "1", "reportCount": 1, "baseRef": "arwr-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:NewAccountingPronouncementsPolicyTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html", "1", "reportCount": 1, "baseRef": "arwr-20240630.htm", "first": true, "unique": true }, "R23": { "role": "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesTables", "longName": "9954472 - Disclosure - Organization and Significant Accounting Policies (Tables)", "shortName": "Organization and Significant Accounting Policies (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "23", "firstAnchor": { "contextRef": "c-1", "name": "arwr:ScheduleOfCurrentProductsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html", "1", "reportCount": 1, "baseRef": "arwr-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "arwr:ScheduleOfCurrentProductsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html", "1", "reportCount": 1, "baseRef": "arwr-20240630.htm", "first": true, "unique": true }, "R24": { "role": "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTables", "longName": "9954473 - Disclosure - Collaboration and License Agreements (Tables)", "shortName": "Collaboration and License Agreements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html", "1", "reportCount": 1, "baseRef": "arwr-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:DisaggregationOfRevenueTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html", "1", "reportCount": 1, "baseRef": "arwr-20240630.htm", "first": true, "unique": true }, "R25": { "role": "http://www.arrowheadresearch.com/role/BalanceSheetAccountsTables", "longName": "9954474 - Disclosure - Balance Sheet Accounts (Tables)", "shortName": "Balance Sheet Accounts (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html", "1", "reportCount": 1, "baseRef": "arwr-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:PropertyPlantAndEquipmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "body", "html", "1", "reportCount": 1, "baseRef": "arwr-20240630.htm", "first": true, "unique": true }, "R26": { "role": "http://www.arrowheadresearch.com/role/InvestmentsTables", "longName": "9954475 - Disclosure - Investments (Tables)", "shortName": "Investments (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "c-1", "name": "arwr:HeldToMaturitySecuritiesAndMarketableSecuritiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html", "1", "reportCount": 1, "baseRef": "arwr-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "arwr:HeldToMaturitySecuritiesAndMarketableSecuritiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html", "1", "reportCount": 1, "baseRef": "arwr-20240630.htm", "first": true, "unique": true }, "R27": { "role": "http://www.arrowheadresearch.com/role/IntangibleAssetsTables", "longName": "9954476 - Disclosure - Intangible Assets (Tables)", "shortName": "Intangible Assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html", "1", "reportCount": 1, "baseRef": "arwr-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "body", "html", "1", "reportCount": 1, "baseRef": "arwr-20240630.htm", "first": true, "unique": true }, "R28": { "role": "http://www.arrowheadresearch.com/role/LeasesTables", "longName": "9954477 - Disclosure - Leases (Tables)", "shortName": "Leases (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables",
```


and License Agreements – Receivables and Contract Liabilities (Details)", "shortName": "Collaboration and License Agreements – Receivables and Contract Liabilities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:AccountsReceivableNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": { "span": "td", "tr": "table", "div": "ix:continuation", "ix:continuation": "body", "html": "1", "reportCount": "1", "baseRef": "arwr-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:AccountsReceivableNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": { "span": "td", "tr": "table", "div": "ix:continuation", "ix:continuation": "body", "html": "1", "reportCount": "1", "baseRef": "arwr-20240630.htm", "first": true, "unique": true }, "R37": { "role": "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails", "longName": "9954486 – Disclosure – Collaboration and License Agreements – Glaxosmithkline Intellectual Property (No. 3) Limited (Details)", "shortName": "Collaboration and License Agreements – Glaxosmithkline Intellectual Property (No. 3) Limited (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:ContractWithCustomerLiabilityCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": { "span": "td", "tr": "table", "div": "ix:continuation", "ix:continuation": "body", "html": "1", "reportCount": "1", "baseRef": "arwr-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-111", "name": "arwr:MilestonePaymentReceivable", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": { "span": "div", "ix:continuation", "body": "html", "1", "reportCount": "1", "baseRef": "arwr-20240630.htm", "unique": true }, "R38": { "role": "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails", "longName": "9954487 – Disclosure – Collaboration and License Agreements – Horizon Therapeutics Ireland DAC (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "c-117", "name": "arwr:NumberOfDistinctPerformanceObligations", "unitRef": "obligation", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": { "span": "div", "ix:continuation", "body": "html", "1", "reportCount": "1", "baseRef": "arwr-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-117", "name": "arwr:NumberOfDistinctPerformanceObligations", "unitRef": "obligation", "xsiNil": "false", "lang": "en-US", "decimals": "INF", "ancestors": { "span": "div", "ix:continuation", "body": "html", "1", "reportCount": "1", "baseRef": "arwr-20240630.htm", "first": true, "unique": true }, "R39": { "role": "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails", "longName": "9954488 – Disclosure – Collaboration and License Agreements – Takeda Pharmaceutical Company Limited (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "c-3", "name": "arwr:DevelopmentRegulatoryAndSalesMilestonesPayments", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-8", "ancestors": { "span": "div", "ix:continuation", "body": "html", "1", "reportCount": "1", "baseRef": "arwr-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-122", "name": "arwr:NumberOfDistinctPerformanceObligations", "unitRef": "obligation", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": { "span": "div", "ix:continuation", "body": "html", "1", "reportCount": "1", "baseRef": "arwr-20240630.htm", "unique": true }, "R40": { "role": "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails", "longName": "9954489 – Disclosure – Collaboration and License Agreements – Amgen, Inc (Details)", "shortName": "Collaboration and License Agreements – Amgen, Inc (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "c-1", "name": "us-gaap:ProceedsFromIssuanceOfCommonStock", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": { "span": "td", "tr": "table", "div": "ix:continuation", "ix:continuation": "body", "html": "1", "reportCount": "1", "baseRef": "arwr-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-126", "name": "arwr:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": { "span": "div", "ix:continuation", "body": "html", "1", "reportCount": "1", "baseRef": "arwr-20240630.htm", "unique": true }, "R41": { "role": "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsVisirnaTherapeuticsIncDetails", "longName": "9954490 – Disclosure – Collaboration and License Agreements – Visirna Therapeutics, Inc. (Details)", "shortName": "Collaboration and License Agreements – Visirna Therapeutics, Inc. (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "c-5", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": { "span": "td", "tr": "table", "div": "ix:continuation", "body": "html", "1", "reportCount": "1", "baseRef": "arwr-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-133", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": { "span": "div", "ix:continuation", "body": "html", "1", "reportCount": "1", "baseRef": "arwr-20240630.htm", "unique": true }, "R42": { "role": "http://www.arrowheadresearch.com/role/BalanceSheetAccountsSummaryofPropertyandEquipmentDetails", "longName": "9954491 – Disclosure – Balance Sheet Accounts – Summary of Property and Equipment (Details)", "shortName": "Balance Sheet Accounts – Summary of Property and Equipment (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": { "span": "td", "tr": "table", "div": "ix:continuation", "body": "html", "1", "reportCount": "1", "baseRef": "arwr-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-4", "name": "us-gaap:PropertyPlantAndEquipmentGross", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": { "span": "td", "tr": "table", "div": "ix:continuation", "body": "html", "1", "reportCount": "1", "baseRef": "arwr-20240630.htm", "unique": true }, "R43": { "role": "http://www.arrowheadresearch.com/role/BalanceSheetAccountsAccruedExpensesDetails", "longName": "9954492 – Disclosure – Balance Sheet Accounts – Accrued Expenses (Details)", "shortName": "Balance Sheet Accounts – Accrued Expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "c-3", "name": "arwr:AccruedResearchAndDevelopmentExpenseCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": { "span": "td", "tr": "table", "div": "ix:continuation", "body": "html", "1", "reportCount": "1", "baseRef": "arwr-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "arwr:AccruedResearchAndDevelopmentExpenseCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": { "span": "td", "tr": "table", "div": "ix:continuation", "body": "html", "1", "reportCount": "1", "baseRef": "arwr-20240630.htm", "first": true, "unique": true }, "R44": { "role": "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShortTermLongtermInvestmentsandMarketableSecuritiesDetails", "longName": "9954493 – Disclosure – Investments – Summary of Short-term, Long-term Investments and Marketable Securities (Details)", "shortName": "Investments – Summary of Short-term, Long-term Investments and Marketable Securities (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": { "span": "td", "tr": "table", "div": "ix:continuation", "body": "html", "1", "reportCount": "1", "baseRef": "arwr-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostCurrent", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": { "span": "td", "tr": "table", "div": "ix:continuation", "body": "html", "1", "reportCount": "1", "baseRef": "arwr-20240630.htm", "first": true, "unique": true }, "R45": { "role": "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails", "longName": "9954494 – Disclosure – Intangible Assets – Schedule of Intangible Assets (Details)", "shortName": "Intangible Assets – Schedule of Intangible Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:FiniteLivedIntangibleAssetsNet", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": { "span": "td", "tr": "table", "div": "ix:continuation", "body": "html", "1", "reportCount": "1", "baseRef": "arwr-20240630.htm", "first": true }, "uniqueAnchor": { "contextRef": "c-5", "name": "us-gaap:AmortizationOfIntangibleAssets", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-5", "ancestors": { "span": "div", "ix:continuation", "body": "html", "1", "reportCount": "1", "baseRef": "arwr-20240630.htm", "unique": true }, "R46": { "role": "http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails", "longName": "9954495 – Disclosure – Intangible Assets – Expected Future Amortization (Details)", "shortName": "Intangible Assets – Expected Future Amortization (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "c-3", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": { "span": "td", "tr": "table", "div": "ix:continuation", "body": "html", "1", "reportCount": "1", "baseRef": "arwr-20240630.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-3", "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear", "unitRef": "usd", "xsiNil": "false", "lang": "en-US", "decimals": "-3", "ancestors": { "span": "td", "tr": "table", "div": "ix:continuation", "body": "html", "1", "reportCount": "1", "baseRef": "arwr-20240630.htm", "first": true, "unique": true }, "R47": { "role": "http://www.arrowheadresearch.com/role/StockholdersEquity

[illegible]

"monetaryItemType": "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesCurrent", "crdr": "credit", "calculation": {
"http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap:LiabilitiesCurrent", "weight": 1.0, "order": 1.0 },
"http://www.arrowheadresearch.com/role/BalanceSheetAccountsAccruedExpensesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": {
"http://www.arrowheadresearch.com/role/BalanceSheetAccountsAccruedExpensesDetails":
"http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails",
"http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": { "lang": { "en-us": { "role": { "terseLabel": "Accrued expenses", "totalLabel": "Total accrued expenses",
"label": "Accrued Liabilities, Current", "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory
in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes,
interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). } } }, "auth_ref": { "r49" }
}, "arwr:AccruedResearchAndDevelopmentCoDevelopmentExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://www.arrowheadresearch.com/20240630",
"localname": "AccruedResearchAndDevelopmentCoDevelopmentExpenseCurrent", "crdr": "credit", "calculation": {
"http://www.arrowheadresearch.com/role/BalanceSheetAccountsAccruedExpensesDetails": { "parentTag": "us-gaap:AccruedLiabilitiesCurrent", "weight": 1.0, "order": 4.0 } },
"presentation": { "http://www.arrowheadresearch.com/role/BalanceSheetAccountsAccruedExpensesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Accrued R&D
expenses: co-development", "label": "Accrued Research And Development Co-Development Expense, Current", "documentation": "Accrued Research And Development Co-
Development Expense, Current" } } }, "auth_ref": { } }, "arwr:AccruedResearchAndDevelopmentExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.arrowheadresearch.com/20240630", "localname": "AccruedResearchAndDevelopmentExpenseCurrent", "crdr": "credit", "calculation": {
"http://www.arrowheadresearch.com/role/BalanceSheetAccountsAccruedExpensesDetails": { "parentTag": "us-gaap:AccruedLiabilitiesCurrent", "weight": 1.0, "order": 2.0 } },
"presentation": { "http://www.arrowheadresearch.com/role/BalanceSheetAccountsAccruedExpensesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Accrued R&D
expenses", "label": "Accrued Research And Development Expense, Current", "documentation": "Accrued Research And Development Expense, Current" } } }, "auth_ref": { } },
"us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment", "crdr": "credit", "calculation": {
"http://www.arrowheadresearch.com/role/BalanceSheetAccountsSummaryofPropertyandEquipmentDetails": { "parentTag": "us-gaap:PropertyPlantAndEquipmentNet",
"weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.arrowheadresearch.com/role/BalanceSheetAccountsSummaryofPropertyandEquipmentDetails": { "lang": { "en-us":
"role": { "negatedLabel": "Less: Accumulated depreciation and amortization", "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and
Equipment", "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods
and services." } } }, "auth_ref": { "r25", "r122", "r537" } }, "us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax", "crdr": "credit", "calculation": {
"http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap:StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": {
"http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": { "lang": { "en-us": { "role": { "terseLabel": "Accumulated other comprehensive loss", "label":
"Accumulated Other Comprehensive Income (Loss), Net of Tax", "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other
event and circumstance from nonowner source." } } }, "auth_ref": { "r14", "r15", "r64", "r129", "r533", "r557", "r558" } }, "us-
gaap:AccumulatedOtherComprehensiveIncomeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname":
"AccumulatedOtherComprehensiveIncomeMember", "presentation": { "http://www.arrowheadresearch.com/role/ConsolidatedStatementsOfStockholdersEquity": { "lang": { "en-
us": { "role": { "terseLabel": "Accumulated Other Comprehensive Loss", "label": "AOCI Attributable to Parent [Member]", "documentation": "Accumulated increase (decrease)
in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in
equity from transactions resulting from investments by owners and distributions to owners." } } }, "auth_ref": { "r1", "r7", "r15", "r392", "r395", "r451", "r553", "r554", "r624",
"r825", "r826", "r832", "r833", "r834", "r835" } }, "ecd:Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024",
"localname": "Additional402vDisclosureTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Additional
402(v) Disclosure", "label": "Additional 402(v) Disclosure [Text Block]" } } }, "auth_ref": { "r763" } }, "us-gaap:AdditionalPaidInCapitalCommonStock": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalCommonStock", "crdr": "credit", "calculation": {
"http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap:StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": {
"http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": { "lang": { "en-us": { "role": { "terseLabel": "Additional paid-in capital", "label": "Additional Paid in
Capital, Common Stock", "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and
amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital,
capital in excess of par, capital surplus, or paid-in capital." } } }, "auth_ref": { "r59" } }, "us-gaap:AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": {
"http://www.arrowheadresearch.com/role/ConsolidatedStatementsOfStockholdersEquity": { "lang": { "en-us": { "role": { "terseLabel": "Additional Paid-In Capital", "label":
"Additional Paid-In Capital [Member]", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other
transactions involving the entity's stock or stockholders." } } }, "auth_ref": { "r568", "r832", "r833", "r834", "r835", "r906" } }, "arwr:AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments": { "xbrltype": "monetaryItemType", "nsuri": "http://www.arrowheadresearch.com/20240630",
"localname": "AdditionalRemainingDevelopmentRegulatoryAndSalesMilestonesPayments", "crdr": "credit", "presentation": {
"http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails": { "lang": { "en-us": { "role": { "terseLabel": "Additional remaining
development regulatory and sales milestones payments", "label": "Additional Remaining Development Regulatory And Sales Milestones Payments", "documentation":
"Additional remaining development regulatory and sales milestones payments." } } }, "auth_ref": { } }, "arwr:AdditionalTenantImprovementAllowanceInterestPerAnnum": {
"xbrltype": "percentItemType", "nsuri": "http://www.arrowheadresearch.com/20240630", "localname": "AdditionalTenantImprovementAllowanceInterestPerAnnum",
"presentation": { "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Additional tenant improvement allowance
interest per annum", "label": "Additional Tenant Improvement Allowance, Interest Per Annum", "documentation": "Additional Tenant Improvement Allowance, Interest Per
Annum" } } }, "auth_ref": { } }, "arwr:AdditionalTenantImprovementAllowanceLiability": { "xbrltype": "monetaryItemType", "nsuri":
"http://www.arrowheadresearch.com/20240630", "localname": "AdditionalTenantImprovementAllowanceLiability", "crdr": "credit", "presentation": {
"http://www.arrowheadresearch.com/role/LeasesNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Additional tenant improvement allowance liability", "label":
"Additional Tenant Improvement Allowance Liability", "documentation": "Additional Tenant Improvement Allowance Liability" } } }, "auth_ref": { } }, "ecd:AdjToCompAmt": {
"xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang":
"en-us": { "role": { "terseLabel": "Adjustment to Compensation, Amount", "label": "Adjustment to Compensation Amount" } } }, "auth_ref": { "r776" } }, "ecd:AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": {
"http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Compensation:", "label": "Adjustment to Compensation [Axis]" } } },
"auth_ref": { "r776" } }, "ecd:AdjToNonPeeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"AdjToNonPeeoNeoCompFnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Adjustment to Non-PEO NEO
Compensation Footnote", "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]" } } }, "auth_ref": { "r776" } }, "ecd:AdjToPeeoCompFnTextBlock": {
"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeeoCompFnTextBlock", "presentation": {
"http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Adjustment To PEO Compensation, Footnote", "label": "Adjustment To PEO
Compensation, Footnote [Text Block]" } } }, "auth_ref": { "r776" } }, "us-
gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "xbrltype": "monetaryItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "crdr": "credit",
"presentation": { "http://www.arrowheadresearch.com/role/ConsolidatedStatementsOfStockholdersEquity": { "lang": { "en-us": { "role": { "terseLabel": "Stock-based
compensation", "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition", "documentation": "Amount of increase to additional paid-in capital (APIC)
for recognition of cost for award under share-based payment arrangement." } } }, "auth_ref": { "r37", "r38", "r332" } }, "us-
gaap:AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024",
"localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": {
"http://www.arrowheadresearch.com/role/ConsolidatedStatementsOfCashFlows": { "lang": { "en-us": { "role": { "terseLabel": "Adjustments to reconcile net loss to net cash flow
from operating activities", "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]" } } }, "auth_ref": { } },
"ecd:AggtChngPnsnValnInSummaryCompstnTblForApblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"AggtChngPnsnValnInSummaryCompstnTblForApblYrMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel":
"Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table", "label": "Aggregate Change in Present Value of
Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]" } } }, "auth_ref": { "r809" } }, "ecd:AggtErrCompAmt": { "xbrltype":
"monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": {
"en-us": { "role": { "terseLabel": "Aggregate Erroneous Compensation Amount", "label": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": { "r735", "r745",
"r755", "r787" } }, "ecd:AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"AggtErrCompNotYetDeterminedTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Aggregate
Erroneous Compensation Not Yet Determined", "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]" } } }, "auth_ref": { "r738", "r748", "r758",
"r790" } }, "ecd:AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdjsSvcCstMember",
"presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Aggregate Pension Adjustments Service Cost", "label": "Aggregate
Pension Adjustments Service Cost [Member]" } } }, "auth_ref": { "r810" } }, "ecd:AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri":
"http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel":
"All Adjustments to Compensation", "label": "All Adjustments to Compensation [Member]" } } }, "auth_ref": { "r776" } }, "ecd:AllExecutiveCategoriesMember": { "xbrltype":
"domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": {
"lang": { "en-us": { "role": { "terseLabel": "All Executive Categories", "label": "All Executive Categories [Member]" } } }, "auth_ref": { "r783" } }, "ecd:AllIndividualsMember": {
"xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": {
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
"http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "All Individuals", "label": "All Individuals [Member]" } } }, "auth_ref": { "r739", "r749",
"r759", "r783", "r791", "r795", "r803" } }, "ecd:AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname":
"AllTradingArrangementsMember", "presentation": { "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements": { "lang": { "en-us": { "role": { "terseLabel": "All Trading
Arrangements", "label": "All Trading Arrangements [Member]" } } }, "auth_ref": { "r801" } }, "us-gaap:AllocatedShareBasedCompensationExpense": { "xbrltype":
"monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AllocatedShareBasedCompensationExpense", "crdr": "debit", "presentation": {
"http://www.arrowheadresearch.com/role/StockBasedCompensationExpensesIncludedInOperatingExpensesDetails":
"http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation expense", "label":
"Share-Based Payment Arrangement, Expense", "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized." } } },
"auth_ref": { "r361", "r366" } }, "dei:AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag",
"presentation": { "http://www.arrowheadresearch.com/role/Cover": { "lang": { "en-us": { "role": { "verboseLabel": "Amendment Flag", "label": "Amendment Flag",
"documentation": "Boolean flag that is true when the XBRL content amends previously filed or accepted submission." } } }, "auth_ref": { } },
"arwr:AmgenIncorporatedMember": { "xbrltype": "domainItemType", "nsuri": "http://www.arrowheadresearch.com/20240630", "localname": "AmgenIncorporatedMember",
"presentation": { "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails",
"http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsRevenueDetails",
"http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleoffutureRoyaltiesNarrativeDetails",
"http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Amgen", "label":


```

"Amgen Incorporated [Member]", "documentation": "Amgen Incorporated." } }, "auth_ref": [ ], "us-gaap_AmortizationOfIntangibleAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AmortizationOfIntangibleAssets", "crdr": "debit", "presentation": [ "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" ] }, "lang": { "en-us": { "role": { "terseLabel": "Amortization expense", "label": "Amortization of Intangible Assets", "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method." } } }, "auth_ref": [ "r5", "r247", "r254", "r666" ] }, "arw_AmountIntendsToInvestForBuildoutOffacilities": { "xbrltype": "monetaryItemType", "nsuri": "http://www.arrowheadresearch.com/20240630", "localname": "AmountIntendsToInvestForBuildoutOffacilities", "crdr": "debit", "presentation": [ "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesNarrativeDetails" ] }, "lang": { "en-us": { "role": { "terseLabel": "Amount intends to invest for buildout of the facilities", "label": "Amount Intends To Invest For Buildout Of Facilities", "documentation": "Amount intends to invest for buildout of facilities." } } }, "auth_ref": [ ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://www.arrowheadresearch.com/role/NetLossPerShareAntidilutiveDetails" ] }, "lang": { "en-us": { "role": { "terseLabel": "Potentially dilutive securities excluded from computation of diluted earnings per share (in shares)", "label": "Antidilutive Securities Excluded From Computation of Earnings Per Share, Amount", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r176" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [ "http://www.arrowheadresearch.com/role/NetLossPerShareAntidilutiveDetails" ] }, "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities [Axis]", "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r22" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [ "http://www.arrowheadresearch.com/role/NetLossPerShareAntidilutiveDetails" ] }, "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ ] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [ "http://www.arrowheadresearch.com/role/NetLossPerShareAntidilutiveDetails" ] }, "lang": { "en-us": { "role": { "terseLabel": "Antidilutive Securities, Name [Domain]", "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r22" ] }, "us-gaap_AreaOffLand": { "xbrltype": "areaItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AreaOffLand", "presentation": [ "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesNarrativeDetails" ] }, "lang": { "en-us": { "role": { "terseLabel": "Planned area of the site (in sq ft)", "label": "Area of Land", "documentation": "Area of land held." } } }, "auth_ref": [ ] }, "us-gaap_ArrangementsAndNonarrangementTransactionsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ArrangementsAndNonarrangementTransactionsMember", "presentation": [ "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails", "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails", "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails", "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails", "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsVisirnaTherapeuticsIncDetails", "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleoffutureRoyaltiesNarrativeDetails", "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetails" ] }, "lang": { "en-us": { "role": { "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]", "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." } } }, "auth_ref": [ "r383" ] }, "us-gaap_AssetAcquisitionAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionAxis", "presentation": [ "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" ] }, "lang": { "en-us": { "role": { "terseLabel": "Asset Acquisition", "label": "Asset Acquisition [Axis]", "documentation": "Information by asset acquisition." } } }, "auth_ref": [ "r248", "r249", "r250", "r251", "r252", "r905" ] }, "us-gaap_AssetAcquisitionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetAcquisitionDomain", "presentation": [ "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails" ] }, "lang": { "en-us": { "role": { "terseLabel": "Asset Acquisition", "label": "Asset Acquisition [Domain]", "documentation": "Asset acquisition." } } }, "auth_ref": [ "r248", "r249", "r250", "r251", "r252", "r905" ] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": { "parentTag": null, "weight": null, "order": null, "root": true }, "presentation": [ "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets" ] }, "lang": { "en-us": { "role": { "totalLabel": "Total Assets", "label": "Assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r96", "r108", "r125", "r150", "r180", "r183", "r190", "r191", "r230", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r385", "r389", "r424", "r530", "r595", "r662", "r663", "r701", "r726", "r869", "r870", "r922" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": [ "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets" ] }, "lang": { "en-us": { "role": { "terseLabel": "ASSETS", "label": "Assets [Abstract]" } } }, "auth_ref": [ ] }, "us-gaap_AssetsAndLiabilitiesLesseeAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAndLiabilitiesLesseeAbstract", "presentation": [ "http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails" ] }, "lang": { "en-us": { "role": { "terseLabel": "Lease Assets and Liabilities", "label": "Assets and Liabilities, Lessee [Abstract]" } } }, "auth_ref": [ ] }, "us-gaap_AssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets Current", "crdr": "debit", "calculation": { "parentTag": null, "weight": null, "order": null, "root": true }, "presentation": [ "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ] }, "lang": { "en-us": { "role": { "totalLabel": "Total financial assets", "label": "Assets, Fair Value Disclosure", "documentation": "Fair value portion of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r403", "r404", "r689" ] }, "arw_AtTheMarketAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.arrowheadresearch.com/20240630", "localname": "AtTheMarketAgreementMember", "presentation": [ "http://www.arrowheadresearch.com/role/StockholdersEquityDetails" ] }, "lang": { "en-us": { "role": { "terseLabel": "At The Market Agreement", "label": "At The Market Agreement [Member]", "documentation": "At-the-market agreement." } } }, "auth_ref": [ ] }, "us-gaap_AvailableForSaleSecuritiesDebtSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtSecurities", "crdr": "debit", "calculation": { "parentTag": null, "weight": null, "order": null, "root": true }, "presentation": [ "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" ] }, "lang": { "en-us": { "role": { "terseLabel": "Available for sale securities", "label": "Debt Securities, Available-for-Sale", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for sale)." } } }, "auth_ref": [ "r202", "r238", "r403", "r524", "r689", "r692", "r842", "r910", "r911", "r912" ] }, "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent", "crdr": "debit", "calculation": { "parentTag": null, "weight": null, "order": null, "root": true }, "presentation": [ "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets" ] }, "lang": { "en-us": { "role": { "terseLabel": "Available for Sale Securities Current", "label": "Debt Securities Current", "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for sale)." } } }, "auth_ref": [ "r202", "r238", "r403", "r524", "r689", "r692", "r842", "r910", "r911", "r912" ] }, "us-gaap_AwardExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbri.sec.gov/ecd/2024", "localname": "AwardExercisePrice", "presentation": [ "http://xbri.sec.gov/ecd/role/AwardTimingDisclosure" ] }, "lang": { "en-us": { "role": { "terseLabel": "Exercise Price", "label": "Award Exercise Price" } } }, "auth_ref": [ "r798" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbri.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbri.sec.gov/ecd/role/AwardTimingDisclosure" ] }, "lang": { "en-us": { "role": { "terseLabel": "Fair Value as of Grant Date", "label": "Award Grant Date Fair Value" } } }, "auth_ref": [ "r799" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbri.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]" } } }, "auth_ref": [ "r794" ] }, "ecd_AwardTmgHowMnpiCnsrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbri.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsrdTextBlock", "presentation": [ "http://xbri.sec.gov/ecd/role/AwardTimingDisclosure" ] }, "lang": { "en-us": { "role": { "terseLabel": "Award Timing, How MNPI Considered", "label": "Award Timing, How MNPI Considered", "documentation": "Award Timing, How MNPI Considered [Text Block]" } } }, "auth_ref": [ "r794" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbri.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbri.sec.gov/ecd/role/AwardTimingDisclosure" ] }, "lang
```

```

AwardUnderlySecuritiesAmt": "presentation": "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": "en-us", "role": "terseLabel": "Underlying Securities", "label": "Award Underlying Securities Amount", "auth_ref": "r797", "ecd_AwardsCloseToMnpiDiscIndName": "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": "en-us", "role": "terseLabel": "Name", "label": "Awards Close in Time to MNPI Disclosures, Individual Name", "auth_ref": "r796", "ecd_AwardsCloseToMnpiDiscTable": "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": "en-us", "role": "terseLabel": "Awards Close in Time to MNPI Disclosures", "label": "Awards Close in Time to MNPI Disclosures", "auth_ref": "r795", "ecd_AwardsCloseToMnpiDiscTableTextBlock": "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": "en-us", "role": "terseLabel": "Awards Close in Time to MNPI Disclosures, Table", "label": "Awards Close in Time to MNPI Disclosures Table Text Block", "auth_ref": "r795", "us-gaap_BuildingMember": "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BuildingMember", "presentation": "http://www.arrowheadresearch.com/role/BalanceSheetAccountsSummaryofPropertyandEquipmentDetails", "lang": "en-us", "role": "terseLabel": "Building", "label": "Building Member", "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities.", "auth_ref": "r81", "stpr_CA": "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/stpr/2024", "localname": "CA", "presentation": "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails", "lang": "en-us", "role": "terseLabel": "California", "label": "CALIFORNIA", "auth_ref": "us-gaap_CapitalExpendituresIncurredButNotYetPaid": "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CapitalExpendituresIncurredButNotYetPaid", "crdr": "credit", "presentation": "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows", "lang": "en-us", "role": "terseLabel": "Capital expenditures included in accrued expenses", "label": "Capital Expenditures Incurred but Not yet Paid", "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.", "auth_ref": "r19", "r20", "r21", "us-gaap_CashAndCashEquivalentsAtCarryingValue": "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetails", "lang": "en-us", "role": "terseLabel": "Cash, cash equivalents and restricted cash", "label": "Cash and Cash Equivalents, at Carrying Value", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "auth_ref": "r17", "r120", "r655", "us-gaap_CashAndCashEquivalentsAxis": "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAxis", "presentation": "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "lang": "en-us", "role": "terseLabel": "Cash and Cash Equivalents Axis", "label": "Cash and Cash Equivalents Axis", "documentation": "Information by type of cash and cash equivalent balance.", "auth_ref": "r120", "us-gaap_CashAndCashEquivalentsFairValueDisclosure": "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsFairValueDisclosure", "crdr": "debit", "calculation": "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 2.0, "presentation": "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "lang": "en-us", "role": "terseLabel": "Cash equivalents", "label": "Cash and Cash Equivalents, Fair Value Disclosure", "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "auth_ref": "r908", "r909", "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "calculation": "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets", "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 2.0, "presentation": "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets", "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows", "lang": "en-us", "role": "terseLabel": "Cash, cash equivalents and restricted cash, periodStartLabel", "label": "BEGINNING OF PERIOD", "periodEndLabel": "END OF PERIOD", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "auth_ref": "r17", "r75", "r148", "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract": "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperationsAbstract", "presentation": "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows", "lang": "en-us", "role": "terseLabel": "CASH, CASH EQUIVALENTS AND RESTRICTED CASH", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Including Disposal Group and Discontinued Operations Abstract", "auth_ref": "r17", "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect": "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "crdr": "debit", "calculation": "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows", "parentTag": null, "weight": null, "order": null, "root": true, "presentation": "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows", "lang": "en-us", "role": "totalLabel": "Net decrease in cash, cash equivalents and restricted cash", "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect", "documentation": "Amount of increase (decrease) in cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; excluding effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "auth_ref": "r0", "r75", "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract", "presentation": "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows", "lang": "en-us", "role": "terseLabel": "Supplemental disclosure of non-cash investing activities", "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure Abstract", "auth_ref": "us-gaap_CashFlowOperatingActivitiesLesseeAbstract": "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashFlowOperatingActivitiesLesseeAbstract", "presentation": "http://www.arrowheadresearch.com/role/LeasesSupplementalCashFlowandOtherInformationRelatedtoLeasesDetails", "lang": "en-us", "role": "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities", "label": "Cash Flow, Operating Activities, Lessee Abstract", "auth_ref": "arwr_CashFlowOperatingActivitiesLesseeCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract": "xbrltype": "stringItemType", "nsuri": "http://www.arrowheadresearch.com/20240630", "localname": "CashFlowOperatingActivitiesLesseeCashReceivedForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract", "presentation": "http://www.arrowheadresearch.com/role/LeasesSupplementalCashFlowandOtherInformationRelatedtoLeasesDetails", "lang": "en-us", "role": "terseLabel": "Cash received for amounts included in the measurement of lease liabilities", "label": "Cash Flow, Operating Activities, Lessee, Cash Received For Amounts Included In Measurement Of Lease Liabilities Abstract", "documentation": "Cash Flow, Operating Activities, Lessee, Cash Received For Amounts Included In Measurement Of Lease Liabilities", "auth_ref": "arwr_CashReceivedAsDueUnderCollaborationAgreement": "xbrltype": "monetaryItemType", "nsuri": "http://www.arrowheadresearch.com/20240630", "localname": "CashReceivedAsDueUnderCollaborationAgreement", "crdr": "debit", "presentation": "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails", "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails", "lang": "en-us", "role": "terseLabel": "Upfront payment", "label": "Cash Received As Due Under Collaboration Agreement", "documentation": "Cash received as due under collaboration agreement.", "auth_ref": "ecd_ChangedPeerGroupFnTextBlock": "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": "en-us", "role": "terseLabel": "Changed Peer Group, Footnote", "label": "Changed Peer Group, Footnote Text Block", "auth_ref": "r74", "ecd_ChngInFrValAsOfYstngDtOPPrYrEqtyAwrdsVstldInCvrdYrMember": "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfYstngDtOPPrYrEqtyAwrdsVstldInCvrdYrMember", "presentation": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": "en-us", "role": "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year", "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year Member", "auth_ref": "r74", "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrYrsMember": "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrYrsMember", "presentation": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": "en-us", "role": "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested", "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested Member", "auth_ref": "r769", "dei_CityAreaCode": "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": "http://www.arrowheadresearch.com/role/Cover", "lang": "en-us", "role": "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city", "auth_ref": "us-gaap_ClassOfStockLineItems": "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockLineItems", "presentation": "http://www.arrowheadresearch.com/role/StockholdersEquityDetails", "lang": "en-us", "role": "terseLabel": "Class Of Stock Line Items", "label": "Class of Stock Line Items", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "auth_ref": "r126", "r127", "r128", "r182", "r300", "r301", "r302", "r304", "r307", "r312", "r314", "r561", "r562", "r563", "r564", "r672", "r813", "r829", "ecd_CoSelectedMeasureAmt": "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": "en-us", "role": "terseLabel": "Company Selected Measure Amount", "label": "Company Selected Measure Amount", "auth_ref": "r775", "ecd_CoSelectedMeasureName": "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "
```

Arrangements And Noncollaborative Arrangement Transactions [Line Items], "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r383" } }, "arwr_ColoradoOwnerLLCMember": { "xbrltype": "domainItemType", "nsuri": "http://www.arrowheadresearch.com/20240630", "localname": "ColoradoOwnerLLCMember", "presentation": { "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Colorado Owner, LLC", "label": "Colorado Owner LLC [Member]", "documentation": "Colorado Owner, LLC." } } }, "auth_ref": { "r383" } }, "arwr_CommercialMilestonePaymentsAtFirstCommercialSale": { "xbrltype": "monetaryItemType", "nsuri": "http://www.arrowheadresearch.com/20240630", "localname": "CommercialMilestonePaymentsAtFirstCommercialSale", "crdr": "debit", "presentation": { "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails": { "lang": { "en-us": { "role": { "terseLabel": "Commercial milestone payments at first commercial sale", "label": "Commercial Milestone Payments At First Commercial Sale", "documentation": "Commercial milestone payments at first commercial sale." } } }, "auth_ref": { "r383" } }, "arwr_CommercialNotesMember": { "xbrltype": "domainItemType", "nsuri": "http://www.arrowheadresearch.com/20240630", "localname": "CommercialNotesMember", "presentation": { "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": { "lang": { "en-us": { "role": { "terseLabel": "Commercial notes", "label": "Commercial Notes [Member]", "documentation": "Commercial Notes." } } }, "auth_ref": { "r383" } }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": { "lang": { "en-us": { "role": { "terseLabel": "Commitments and contingencies (Note 7)", "label": "Commitments and Contingencies", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": { "r55", "r99", "r531", "r581" } }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies Disclosure [Abstract]", "label": "Commitments and Contingencies Disclosure [Abstract]", "documentation": "Commitments and Contingencies Disclosure [Abstract]" } } }, "auth_ref": { "r383" } }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": { "http://www.arrowheadresearch.com/role/CommitmentsandContingencies": { "lang": { "en-us": { "role": { "terseLabel": "Commitments and Contingencies", "label": "Commitments and Contingencies Disclosure [Text Block]", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": { "r82", "r265", "r266", "r640", "r861", "r866" } }, "arwr_CommitmentsCapitalExpendituresIncurredToDate": { "xbrltype": "monetaryItemType", "nsuri": "http://www.arrowheadresearch.com/20240630", "localname": "CommitmentsCapitalExpendituresIncurredToDate", "crdr": "debit", "presentation": { "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Capital expenditures incurred", "label": "Commitments, Capital Expenditures Incurred To Date", "documentation": "Commitments, Capital Expenditures Incurred To Date" } } }, "auth_ref": { "r383" } }, "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockCapitalSharesReservedForFutureIssuance", "presentation": { "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Shares reserve for issuance (in shares)", "label": "Common Stock, Capital Shares Reserved For Future Issuance", "documentation": "Aggregate number of common shares reserved for future issuance." } } }, "auth_ref": { "r58" } }, "arwr_CommonStockCapitalSharesValueReservedForFutureIssuance": { "xbrltype": "monetaryItemType", "nsuri": "http://www.arrowheadresearch.com/20240630", "localname": "CommonStockCapitalSharesValueReservedForFutureIssuance", "crdr": "credit", "presentation": { "http://www.arrowheadresearch.com/role/StockholdersEquityDetails": { "lang": { "en-us": { "role": { "terseLabel": "Common stock shares value reserved for future issuance", "label": "Common Stock Capital Shares Value Reserved For Future Issuance", "documentation": "Common stock, capital shares value reserved for future issuance." } } }, "auth_ref": { "r383" } }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": { "http://www.arrowheadresearch.com/role/ConsolidatedStatementsOfStockholdersEquity": { "lang": { "en-us": { "role": { "terseLabel": "Common Stock", "label": "Common Stock [Member]", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": { "r716", "r717", "r718", "r720", "r721", "r722", "r723", "r832", "r833", "r835", "r906", "r965", "r966" } }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": { "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheetsParentetical": { "http://www.arrowheadresearch.com/role/StockholdersEquityDetails": { "lang": { "en-us": { "role": { "terseLabel": "Common stock, par value (in dollars per share)", "label": "Common Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": { "r58" } }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": { "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheetsParentetical": { "http://www.arrowheadresearch.com/role/StockholdersEquityDetails": { "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares authorized (in shares)", "label": "Common Stock, Shares Authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": { "r58", "r582" } }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": { "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheetsParentetical": { "http://www.arrowheadresearch.com/role/StockholdersEquityDetails": { "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares issued (in shares)", "label": "Common Stock, Shares, Issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": { "r58" } }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": { "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheetsParentetical": { "http://www.arrowheadresearch.com/role/StockholdersEquityDetails": { "lang": { "en-us": { "role": { "terseLabel": "Common stock, shares outstanding (in shares)", "label": "Common Stock, Shares, Outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": { "r8", "r58", "r582", "r601", "r966", "r967" } }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": { "lang": { "en-us": { "role": { "terseLabel": "Common stock, \$0.001 par value: Authorized 290,000 shares; issued and outstanding 124,227 and 107,312 shares", "label": "Common Stock, Value, Issued", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": { "r58", "r532", "r701" } }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Company Selected Measure", "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]" } } }, "auth_ref": { "r780" } }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Net Income", "label": "Compensation Actually Paid vs. Net Income [Text Block]" } } }, "auth_ref": { "r779" } }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Other Measure", "label": "Compensation Actually Paid vs. Other Measure [Text Block]" } } }, "auth_ref": { "r781" } }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return", "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]" } } }, "auth_ref": { "r778" } }, "us-gaap_ComprehensiveIncomeNetOfTaxAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTaxAbstract", "presentation": { "http://www.arrowheadresearch.com/role/ConsolidatedStatementsOfOperationsandComprehensiveLoss": { "lang": { "en-us": { "role": { "terseLabel": "Other comprehensive loss, net of tax", "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent [Abstract]" } } }, "auth_ref": { "r383" } }, "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "crdr": "credit", "calculation": { "http://www.arrowheadresearch.com/role/ConsolidatedStatementsOfOperationsandComprehensiveLoss": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.arrowheadresearch.com/role/ConsolidatedStatementsOfOperationsandComprehensiveLoss": { "lang": { "en-us": { "role": { "totalLabel": "Comprehensive loss", "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest", "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners." } } }, "auth_ref": { "r44", "r94", "r137", "r139", "r143", "r525", "r545" } }, "arwr_ComputerAndSoftwareMember": { "xbrltype": "domainItemType", "nsuri": "http://www.arrowheadresearch.com/20240630", "localname": "ComputerAndSoftwareMember", "presentation": { "http://www.arrowheadresearch.com/role/BalanceSheetAccountsSummaryofPropertyandEquipmentDetails": { "lang": { "en-us": { "role": { "terseLabel": "Computers and software", "label": "Computer And Software [Member]", "documentation": "Computer And Software" } } }, "auth_ref": { "r383" } }, "us-gaap_ConstructionInProgressMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ConstructionInProgressMember", "presentation": { "http://www.arrowheadresearch.com/role/BalanceSheetAccountsSummaryofPropertyandEquipmentDetails": { "lang": { "en-us": { "role": { "terseLabel": "Construction in progress", "label": "Construction in Progress [Member]", "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service." } } }, "auth_ref": { "r383" } }, "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock", "presentation": { "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTables": { "lang": { "en-us": { "role": { "terseLabel": "Schedule of Receivables and Contract Liabilities", "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]", "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability." } } }, "auth_ref": { "r872" } }, "us-gaap_ContractWithCustomerAssetNetCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerAssetNetCurrent", "crdr": "debit", "presentation": { "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails": { "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails": { "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsVisirnaTherapeuticsIncDetails": { "lang": { "en-us": { "role": { "terseLabel": "Contract assets", "label": "Contract with Customer, Asset, after Allowance for Credit Loss, Current", "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current." } } }, "auth_ref": { "r316", "r318", "r321" } }, "us-gaap_ContractWithCustomerLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiability", "crdr": "credit", "presentation": { "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsReceivablesandContractLiabilitiesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Contract liabilities included in deferred revenue", "label": "Contract with Customer, Liability", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": { "r316", "r317", "r321" } }, "us-gaap_ContractWithCustomerLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ContractWithCustomerLiabilityCurrent", "crdr": "credit", "calculation": { "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails": { "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails": { "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": { "lang": { "en-us": { "role": { "terseLabel": "Deferred revenue", "verboseLabel": "Contract liabilities", "label": "Contract with Customer, Liability, Current", "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current." } } }, "auth_ref": { "r316", "r317", "r321" } }, "us-gaap_CorporateDebtSecuritiesMember": { "xbrltype": "domainItemType",

```

"nsuri": "http://fasb.org/us-gaap/2024", "localname": "CorporateDebtSecuritiesMember", "presentation": "nsuri", "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "lang": "en-us", "role": "terseLabel", "CorporateDebtSecurities", "label": "CorporateDebtSecurities", "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.", "auth_ref": "r680", "r682", "r689", "r702", "r715", "r962", "arwr_CorporateHeadquartersInPasadenaMember", "xbrltype": "domainItemType", "nsuri": "http://www.arrowheadresearch.com/20240630", "localname": "CorporateHeadquartersInPasadenaMember", "presentation": "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails", "lang": "en-us", "role": "terseLabel", "CorporateHeadquartersInPasadena", "label": "CorporateHeadquartersInPasadena", "documentation": "CorporateHeadquartersInPasadena", "auth_ref": "H", "srt_CounterpartyNameAxis", "xbrltype": "stringItemType", "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "CounterpartyNameAxis", "presentation": "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails", "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails", "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails", "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails", "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsVisirnaTherapeuticsIncDetails", "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails", "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleoffutureRoyaltiesNarrativeDetails", "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetails", "lang": "en-us", "role": "terseLabel", "CounterpartyName", "label": "CounterpartyName", "auth_ref": "r151", "r152", "r205", "r302", "r452", "r472", "r529", "r657", "r659", "dei_CoverAbstract", "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": "en-us", "role": "terseLabel", "Cover", "label": "Cover", "documentation": "Cover page.", "auth_ref": "I", "us-gaap_CreditFacilityAxis", "xbrltype": "stringItemType", "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityAxis", "presentation": "http://www.arrowheadresearch.com/role/SubsequentEventsDetails", "lang": "en-us", "role": "terseLabel", "CreditFacility", "label": "CreditFacility", "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "auth_ref": "r272", "r867", "us-gaap_CreditFacilityDomain", "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CreditFacilityDomain", "presentation": "http://www.arrowheadresearch.com/role/SubsequentEventsDetails", "lang": "en-us", "role": "terseLabel", "CreditFacility", "label": "CreditFacility", "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.", "auth_ref": "r272", "r867", "dei_CurrentFiscalYearEndDate", "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": "http://www.arrowheadresearch.com/role/Cover", "lang": "en-us", "role": "terseLabel", "CurrentFiscalYearEnd Date", "label": "CurrentFiscalYearEnd Date", "documentation": "End date of current fiscal year in the format --MM-DD--", "auth_ref": "I", "us-gaap_DebtInstrumentAxis", "xbrltype": "stringItemType", "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentAxis", "presentation": "http://www.arrowheadresearch.com/role/SubsequentEventsDetails", "lang": "en-us", "role": "terseLabel", "DebtInstrument", "label": "DebtInstrument", "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.", "auth_ref": "r12", "r48", "r49", "r97", "r98", "r153", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r667", "r668", "r669", "r670", "r671", "r699", "r830", "r862", "r863", "r864", "r916", "r917", "us-gaap_DebtInstrumentInterestRateStatedPercentage", "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentInterestRateStatedPercentage", "presentation": "http://www.arrowheadresearch.com/role/SubsequentEventsDetails", "lang": "en-us", "role": "terseLabel", "Interest rate", "label": "DebtInstrumentInterestRateStatedPercentage", "documentation": "Contractual interest rate for funds borrowed under the debt agreement.", "auth_ref": "r51", "r283", "us-gaap_DebtInstrumentNameDomain", "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentNameDomain", "presentation": "http://www.arrowheadresearch.com/role/SubsequentEventsDetails", "lang": "en-us", "role": "terseLabel", "DebtInstrumentName", "label": "DebtInstrumentName", "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.", "auth_ref": "r12", "r153", "r282", "r283", "r284", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r297", "r667", "r668", "r669", "r670", "r671", "r699", "r830", "r862", "r863", "r864", "r916", "r917", "us-gaap_DebtInstrumentTerm", "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtInstrumentTerm", "presentation": "http://www.arrowheadresearch.com/role/SubsequentEventsDetails", "lang": "en-us", "role": "terseLabel", "Debt instrument term", "label": "DebtInstrumentTerm", "documentation": "Period of time between issuance and maturity of debt instrument, in PnYnMnDnHnMnS format, for example, "P1Y5M13D" represents the reported fact of one year, five months, and thirteen days.", "auth_ref": "I", "arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent", "xbrltype": "monetaryItemType", "nsuri": "http://www.arrowheadresearch.com/20240630", "localname": "DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainCurrent", "crdr": "credit", "calculation": "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails", "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent", "weight": 1.0, "order": 1.0, "presentation": "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails", "lang": "en-us", "role": "terseLabel", "Current investments, Available for sale, Gross Unrealized Gains", "label": "DebtSecurities, Available for Sale, Accumulated Gross Unrealized Gain, Current", "documentation": "DebtSecurities, Available for Sale, Accumulated Gross Unrealized Gain, Current", "auth_ref": "I", "arwr_DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent", "xbrltype": "monetaryItemType", "nsuri": "http://www.arrowheadresearch.com/20240630", "localname": "DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedLossCurrent", "crdr": "debit", "calculation": "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails", "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent", "weight": 1.0, "order": 2.0, "presentation": "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails", "lang": "en-us", "role": "terseLabel", "Current investments, Available for sale, Gross Unrealized Losses", "label": "DebtSecurities, Available for Sale, Accumulated Gross Unrealized Loss, Current", "documentation": "DebtSecurities, Available for Sale, Accumulated Gross Unrealized Loss, Current", "auth_ref": "I", "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostCurrent", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesAvailableForSaleAmortizedCostCurrent", "crdr": "debit", "calculation": "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails", "parentTag": null, "weight": null, "order": null, "root": true, "presentation": "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails", "lang": "en-us", "role": "totalLabel", "Current investments, Available for sale, Adjusted Basis", "label": "DebtSecurities, Available for Sale, Amortized Cost, Current", "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for sale), classified as current.", "auth_ref": "r238", "r843", "us-gaap_DebtSecuritiesMember", "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DebtSecuritiesMember", "presentation": "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails", "lang": "en-us", "role": "terseLabel", "DebtSecurities", "label": "DebtSecurities", "documentation": "Debt instrument issued by corporations, governments and governmental agencies, municipalities, and other institutions.", "auth_ref": "r23", "r718", "r968", "us-gaap_DepreciationAndAmortization", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationAndAmortization", "crdr": "debit", "calculation": "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows", "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0, "presentation": "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows", "lang": "en-us", "role": "terseLabel", "Depreciation and amortization", "label": "Depreciation, Depletion and Amortization, Nonproduction", "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset, or to reflect consumption during the period of an asset that is not used in production.", "auth_ref": "r15", "r24", "us-gaap_DepreciationDepletionAndAmortization", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DepreciationDepletionAndAmortization", "crdr": "debit", "presentation": "http://www.arrowheadresearch.com/role/BalanceSheetAccountsSummaryofPropertyandEquipmentDetails", "lang": "en-us", "role": "terseLabel", "Depreciation and amortization expense for property and equipment", "label": "Depreciation, Depletion and Amortization", "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "auth_ref": "r5", "r180", "r187", "r191", "r662", "r663", "arwr_DevelopmentAndSalesMilestonesPayments", "xbrltype": "monetaryItemType", "nsuri": "http://www.arrowheadresearch.com/20240630", "localname": "DevelopmentAndSalesMilestonesPayments", "crdr": "credit", "presentation": "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails", "lang": "en-us", "role": "terseLabel", "Development and sales milestone payments", "label": "DevelopmentAndSalesMilestonesPayments", "documentation": "DevelopmentAndSalesMilestonesPayments", "auth_ref": "I", "arwr_DevelopmentRegulatoryAndSalesMilestonesPayments", "xbrltype": "monetaryItemType", "nsuri": "http://www.arrowheadresearch.com/20240630", "localname": "DevelopmentRegulatoryAndSalesMilestonesPayments", "crdr": "credit", "presentation": "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails", "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetails", "lang": "en-us", "role": "terseLabel", "Development regulatory and sales milestones payments", "label": "DevelopmentRegulatoryAndSalesMilestonesPayments", "documentation": "Development regulatory and sales milestones payments.", "auth_ref": "I", "us-gaap_DisaggregationOfRevenueLineItems", "xbrltype": "stringItemType", "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisaggregationOfRevenueLineItems", "presentation": "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsRevenueDetails", "lang": "en-us", "role": "terseLabel", "Disaggregation of Revenue", "label": "Disaggregation of Revenue", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "auth_ref": "r320", "r673", "r674", "r675", "r676", "r677", "r678", "r679", "us-gaap_DisaggregationOfRevenueTable", "xbrltype": "stringItemType", "stringItemType", "nsuri": "http://fasb.org/us-gaap/
```

"http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": { "http://www.arrowheadresearch.com/role/Cover" }, "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K, the date of the report, the date of the earliest event reported, for the EDGAR submission types of Form N-1A, the filing date; for all other submission types, the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": { } }, "dei.DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentQuarterlyReport", "presentation": { "http://www.arrowheadresearch.com/role/Cover" }, "lang": { "en-us": { "role": { "terseLabel": "Document Quarterly Report", "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": { "r730" } }, "dei.DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": { "http://www.arrowheadresearch.com/role/Cover" }, "lang": { "en-us": { "role": { "terseLabel": "Document Transition Report", "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": { "r762" } }, "dei.DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": { "http://www.arrowheadresearch.com/role/Cover" }, "lang": { "en-us": { "role": { "verboseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": { "arw_DrugManufacturingFacilityMember" }, "xbrltype": "domainItemType", "nsuri": "http://www.arrowheadresearch.com/20240630", "localname": "DrugManufacturingFacilityMember", "presentation": { "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesNarrativeDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Drug Manufacturing Facility", "label": "Drug Manufacturing Facility [Member]", "documentation": "Drug manufacturing facility." } } }, "auth_ref": { } }, "ecd_DvdsOrOthrErngsPdOnEqtyAwrdsNtOthrRsRfctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "DvdsOrOthrErngsPdOnEqtyAwrdsNtOthrRsRfctdInTtlCompForCvrdYrMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PyvDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year", "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": { "r144", "r159", "r160", "r161", "r162", "r163", "r164", "r169", "r171", "r173", "r174", "r175", "r179", "r379", "r382", "r400", "r401", "r526", "r546", "r660" } }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "label": "Earnings Per Share Abstract" } } }, "auth_ref": { } }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": { "http://www.arrowheadresearch.com/role/ConsolidatedStatementsOfOperationsandComprehensiveLoss" }, "lang": { "en-us": { "role": { "terseLabel": "Basic (in dollars per share)", "label": "Basic (in dollars per share)", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": { "r144", "r159", "r160", "r161", "r162", "r163", "r164", "r169", "r171", "r173", "r174", "r175", "r179", "r379", "r382", "r400", "r401", "r526", "r546", "r660" } }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": { "http://www.arrowheadresearch.com/role/ConsolidatedStatementsOfOperationsandComprehensiveLoss" }, "lang": { "en-us": { "role": { "terseLabel": "Diluted (in dollars per share)", "label": "Diluted (in dollars per share)", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": { "r144", "r159", "r160", "r161", "r162", "r163", "r164", "r169", "r171", "r173", "r174", "r175", "r179", "r379", "r382", "r400", "r401", "r526", "r546", "r660" } }, "us-gaap_EarningsPerShareReconciliationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareReconciliationAbstract", "presentation": { "http://www.arrowheadresearch.com/role/ConsolidatedStatementsOfOperationsandComprehensiveLoss" }, "lang": { "en-us": { "role": { "terseLabel": "Net loss per share attributable to Arrowhead Pharmaceuticals, Inc.", "label": "Earnings Per Share Reconciliation Abstract" } } }, "auth_ref": { } }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": { "http://www.arrowheadresearch.com/role/NetLossPerShare" }, "lang": { "en-us": { "role": { "terseLabel": "Net Loss Per Share", "label": "Earnings Per Share [Text Block]", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": { "r168", "r176", "r177", "r178" } }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": { "http://www.arrowheadresearch.com/role/ConsolidatedStatementsOfCashFlows" }, "lang": { "en-us": { "role": { "terseLabel": "Effect of exchange rate on cash, cash equivalents and restricted cash", "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations", "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": { "r425" } }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": { "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets" }, "lang": { "en-us": { "role": { "terseLabel": "Accrued payroll and benefits", "label": "Employee-related Liabilities, Current", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": { "r49" } }, "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems", "presentation": { "http://www.arrowheadresearch.com/role/StockBasedCompensationExpensesIncludedinOperatingExpensesDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { } }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": { "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Weighted average period to recognize pre-tax compensation expense", "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in PnYnMnDnHnMnS format, for example, P1Y5M13D represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": { "r364" } }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions", "crdr": "debit", "presentation": { "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Unrecognized pre-tax compensation expense", "label": "Share-Based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount", "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": { "r902" } }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "crdr": "debit", "presentation": { "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails" }, "lang": { "en-us": { "role": { "terseLabel": "Unrecognized pre-tax compensation expense", "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "documentation": "Amount of cost to be recognized for option under share-based payment arrangement." } } }, "auth_ref": { "r902" } }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": { "http://www.arrowheadresearch.com/role/NetLossPerShareAntidilutiveDetails", "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" }, "lang": { "en-us": { "role": { "terseLabel": "Options", "label": "Share-Based Payment Arrangement, Option [Member]", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": { } }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": { "http://www.arrowheadresearch.com/role/Cover" }, "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": { } }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine2", "presentation": { "http://www.arrowheadresearch.com/role/Cover" }, "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line Two", "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": { } }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": { "http://www.arrowheadresearch.com/role/Cover" }, "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": { } }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": { "http://www.arrowheadresearch.com/role/Cover" }, "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": { } }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": { "http://www.arrowheadresearch.com/role/Cover" }, "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": { } }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": { "http://www.arrowheadresearch.com/role/Cover" }, "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": { "r728" } }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": { "http://www.arrowheadresearch.com/role/Cover" }, "lang": { "en-us": { "role": { "terseLabel": "Entity Common Stock, Shares Outstanding", "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": { } }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": { "http://www.arrowheadresearch.com/role/Cover" }, "lang": { "en-us": { "role": { "terseLabel": "Entity Current Reporting Status", "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": { } }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": { "http://www.arrowheadresearch.com/role/Cover" }, "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": { "r728" } }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": { "http://www.arrowheadresearch.com/role/Cover" }, "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } } }

"auth_ref": {} }, {"dei_EntityFilerCategory": {"xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": {"http://www.arrowheadresearch.com/role/Cover"}}, {"lang": "en-us", "role": "terseLabel", "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, {"auth_ref": {"r728"}}, {"dei_EntityIncorporationStateCountryCode": {"xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": {"http://www.arrowheadresearch.com/role/Cover"}}, {"lang": "en-us", "role": "terseLabel", "Entity Incorporation State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, {"auth_ref": {} }, {"dei_EntityInteractiveDataCurrent": {"xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": {"http://www.arrowheadresearch.com/role/Cover"}}, {"lang": "en-us", "role": "terseLabel", "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-F during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."} } }, {"auth_ref": {"r812"}}, {"dei_EntityRegistrantName": {"xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": {"http://www.arrowheadresearch.com/role/Cover"}}, {"lang": "en-us", "role": "terseLabel", "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, {"auth_ref": {"r728"}}, {"dei_EntityShellCompany": {"xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": {"http://www.arrowheadresearch.com/role/Cover"}}, {"lang": "en-us", "role": "terseLabel", "Entity Shell Company", "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, {"auth_ref": {"r728"}}, {"dei_EntitySmallBusiness": {"xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": {"http://www.arrowheadresearch.com/role/Cover"}}, {"lang": "en-us", "role": "terseLabel", "Entity Small Business", "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."} } }, {"auth_ref": {"r728"}}, {"dei_EntityTaxIdentificationNumber": {"xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": {"http://www.arrowheadresearch.com/role/Cover"}}, {"lang": "en-us", "role": "terseLabel", "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, {"auth_ref": {"r728"}}, {"ecd_EqtyAwrdsAdjFnTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": {"http://xbrl.sec.gov/ecd/role/PvpDisclosure"}}, {"lang": "en-us", "role": "terseLabel", "Equity Awards Adjustments, Footnote", "label": "Equity Awards Adjustments, Footnote [Text Block]"} } }, {"auth_ref": {"r767"}}, {"ecd_EqtyAwrdsAdjExclgValRprtdInSummryCompstnTblMember": {"xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjExclgValRprtdInSummryCompstnTblMember", "presentation": {"http://xbrl.sec.gov/ecd/role/PvpDisclosure"}}, {"lang": "en-us", "role": "terseLabel", "Equity Awards Adjustments, Excluding Value Reported in Compensation Table", "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]"} } }, {"auth_ref": {"r808"}}, {"ecd_EqtyAwrdsAdjJsMember": {"xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjJsMember", "presentation": {"http://xbrl.sec.gov/ecd/role/PvpDisclosure"}}, {"lang": "en-us", "role": "terseLabel", "Equity Awards Adjustments [Member]"} } }, {"auth_ref": {"r808"}}, {"ecd_EqtyAwrdsInSummryCompstnTblForApblYrMember": {"xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsInSummryCompstnTblForApblYrMember", "presentation": {"http://xbrl.sec.gov/ecd/role/PvpDisclosure"}}, {"lang": "en-us", "role": "terseLabel", "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table", "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]"} } }, {"auth_ref": {"r808"}}, {"us-gaap_EquityAbstract": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityAbstract", "lang": "en-us", "role": "terseLabel", "Equity Abstract", "label": "Equity Abstract"} } }, {"auth_ref": {} }, {"us-gaap_EquityComponentDomain": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": {"http://www.arrowheadresearch.com/role/ConsolidatedStatementsOfStockholdersEquity"}}, {"lang": "en-us", "role": "terseLabel", "Equity Component [Domain]", "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, {"auth_ref": {"r8", "r15", "r140", "r141", "r142", "r154", "r155", "r156", "r158", "r163", "r165", "r167", "r181", "r231", "r232", "r261", "r315", "r373", "r374", "r376", "r377", "r378", "r380", "r381", "r382", "r391", "r392", "r393", "r394", "r395", "r396", "r399", "r426", "r427", "r428", "r429", "r430", "r431", "r433", "r436", "r451", "r543", "r553", "r554", "r555", "r568", "r621"}}, {"ecd_EquityValuationAssumptionDifferenceFnTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": {"http://xbrl.sec.gov/ecd/role/PvpDisclosure"}}, {"lang": "en-us", "role": "terseLabel", "Equity Valuation Assumption Difference, Footnote", "label": "Equity Valuation Assumption Difference, Footnote [Text Block]"} } }, {"auth_ref": {"r777"}}, {"ecd_ErrCompAnalysisTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": {"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"}}, {"lang": "en-us", "role": "terseLabel", "Erroneous Compensation Analysis", "label": "Erroneous Compensation Analysis [Text Block]"} } }, {"auth_ref": {"r735", "r745", "r755", "r787"}}, {"ecd_ErrCompRecoveryTable": {"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": {"http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"}}, {"lang": "en-us", "role": "terseLabel", "Erroneously Awarded Compensation Recovery", "label": "Erroneously Awarded Compensation Recovery [Table]"} } }, {"auth_ref": {"r732", "r742", "r752", "r784"}}, {"ecd_ExecutiveCategoryAxis": {"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": {"http://xbrl.sec.gov/ecd/role/PvpDisclosure"}}, {"lang": "en-us", "role": "terseLabel", "Executive Category", "label": "Executive Category [Axis]"} } }, {"auth_ref": {"r783"}}, {"arwr_FacilitiesMember": {"xbrltype": "domainItemType", "nsuri": "http://www.arrowheadresearch.com/20240630", "localname": "FacilitiesMember", "presentation": {"http://www.arrowheadresearch.com/role/CommitmentsAndContingenciesNarrativeDetails"}}, {"lang": "en-us", "role": "terseLabel", "Facilities", "label": "Facilities [Member]", "documentation": "Facilities." } } }, {"auth_ref": {} }, {"us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": {"http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"}}, {"lang": "en-us", "role": "terseLabel", "Fair Value Assets and Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]", "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, {"auth_ref": {"r403", "r404", "r414", "r689"}}, {"us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": {"http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"}}, {"lang": "en-us", "role": "terseLabel", "Fair Value Assets and Liabilities Measured On Recurring And Nonrecurring Basis [Table]", "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, {"auth_ref": {"r403", "r404", "r414", "r689"}}, {"us-gaap_FairValueByFairValueHierarchyLevelAxis": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": {"http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"}}, {"lang": "en-us", "role": "terseLabel", "Fair Value Hierarchy and NAV", "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, {"auth_ref": {"r290", "r323", "r324", "r325", "r326", "r327", "r328", "r402", "r403", "r404", "r405", "r406", "r407", "r413", "r414", "r416", "r459", "r460", "r461", "r668", "r669", "r680", "r681", "r682", "r689", "r692"}}, {"us-gaap_FairValueByMeasurementFrequencyAxis": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByMeasurementFrequencyAxis", "presentation": {"http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"}}, {"lang": "en-us", "role": "terseLabel", "Measurement Frequency", "label": "Measurement Frequency [Axis]", "documentation": "Information by measurement frequency." } } }, {"auth_ref": {"r403", "r404", "r405", "r407", "r689", "r911", "r914"}}, {"us-gaap_FairValueDisclosuresAbstract": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresAbstract", "lang": "en-us", "role": "terseLabel", "Fair Value Disclosures Abstract", "label": "Fair Value Disclosures Abstract [Abstract]"} } }, {"auth_ref": {} }, {"us-gaap_FairValueDisclosuresTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresTextBlock", "presentation": {"http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"}}, {"lang": "en-us", "role": "terseLabel", "Fair Value Disclosures [Text Block]", "label": "Fair Value Disclosures [Text Block]", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration; (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item; (c) policy for requiring collateral or other security and information as to accessing such collateral or security; and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election; (b) discussion of the effect of fair value changes on earnings; (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, {"auth_ref": {"r409", "r411", "r412", "r413", "r416", "r417", "r418", "r419", "r420", "r523", "r689", "r693"}}, {"us-gaap_FairValueInputsLevel1Member": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1Member", "presentation": {"http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"}}, {"lang": "en-us", "role": "terseLabel", "Level 1", "label": "Fair Value, Inputs, Level 1 [Member]", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, {"auth_ref": {"r290", "r323", "r328", "r404", "r414", "r459", "r680", "r681", "r682", "r689"}}, {"us-gaap_FairValueInputsLevel2Member": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel2Member", "presentation": {"http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"}}, {"lang": "en-us", "role": "terseLabel", "Level 2", "label": "Fair Value, Inputs, Level 2 [Member]", "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets." } } }, {"auth_ref": {"r290", "r323", "r328", "r404", "r405", "r414", "r460", "r668", "r669", "r680", "r681", "r682", "r689"}}, {"us-gaap_FairValueInputsLevel3Member": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel3Member", "presentation": {"http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"}}, {"lang": "en-us", "role": "terseLabel", "Level 3", "label": "Fair Value, Inputs, Level 3 [Member]", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, {"auth_ref": {"r290", "r323", "r324", "r325", "r326", "r327", "r328", "r404", "r405", "r406", "r407", "r414", "r461", "r668", "r669", "r680", "r681", "r682", "r689", "r692"}}, {"us-gaap_FairValueMeasurementFrequencyDomain": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementFrequencyDomain", "presentation": {"http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"}}, {"lang": "en-us", "role": "terseLabel", "Measurement Frequency", "label": "Measurement Frequency [Domain]", "documentation": "Measurement frequency." } } }, {"auth_ref": {"r403", "r404", "r405", "r407", "r689", "r911", "r914"}}, {"us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": {"http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails"}}, {"lang": "en-us", "role": "terseLabel", "Fair Value Hierarchy and NAV", "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, {"auth_ref": {"r290", "r323", "r324", "r325", "r326", "r327", "r328", "r402", "r404", "r405", "r406", "r407", "r413"}}

```

"r416", "r459", "r460", "r461", "r668", "r669", "r690", "r681", "r682", "r689", "r692" ] }, "us-gaap_FairValueMeasurementsRecurringMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsRecurringMember", "presentation": { "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsForAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": { "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurements Recurring", "label": "Fair Value Recurring [Member]", "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value." } } }, "auth_ref": { "r689", "r908", "r909", "r910", "r911", "r912", "r914" } }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialInstrumentAxis", "presentation": { "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsForAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": { "lang": { "en-us": { "role": { "terseLabel": "Financial Instrument Axis", "label": "Financial Instrument Axis", "documentation": "Information by type of financial instrument." } } }, "auth_ref": { "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r233", "r234", "r235", "r236", "r237", "r239", "r240", "r241", "r298", "r312", "r397", "r421", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r544", "r665", "r689", "r690", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r702", "r816", "r817", "r818", "r819", "r820", "r821", "r822", "r844", "r845", "r846", "r847", "r907", "r910", "r911", "r912", "r913", "r914" } } }, "arwr_FinancingAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://www.arrowheadresearch.com/20240630", "localname": "FinancingAgreementMember", "presentation": { "http://www.arrowheadresearch.com/role/SubsequentEventsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Financing Agreement", "label": "Financing Agreement [Member]", "documentation": "Financing Agreement" } } }, "auth_ref": { "r11", "arwr_FiniteLivedIntangibleAssetsExpectedAmortizationAfterYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://www.arrowheadresearch.com/20240630", "localname": "FiniteLivedIntangibleAssetsExpectedAmortizationAfterYearFour", "crdr": "debit", "calculation": { "http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails": { "lang": { "en-us": { "role": { "terseLabel": "Thereafter", "label": "Finite-Lived Intangible Asset, Expected Amortization, after Year Four", "documentation": "Finite-Lived Intangible Asset, Expected Amortization, after Year Four" } } }, "auth_ref": { "r11", "us-gaap_FiniteLivedIntangibleAssetsUsefulLife": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsUsefulLife", "presentation": { "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Useful Lives", "label": "Finite-Lived Intangible Asset, Useful Life", "documentation": "Useful life of finite-lived intangible assets, in PnYnMnDnHnMnS format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": { "r11", "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization", "crdr": "credit", "calculation": { "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Accumulated Amortization", "label": "Finite-Lived Intangible Assets, Accumulated Amortization", "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": { "r123", "r244", "r253", "r666" } } }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths", "crdr": "debit", "calculation": { "http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 5.0 } }, "presentation": { "http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails": { "lang": { "en-us": { "role": { "terseLabel": "2025", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year One", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": { "r255", "r653", "r666" } } } }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOffiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOffiscalYear", "crdr": "debit", "calculation": { "http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails": { "lang": { "en-us": { "role": { "terseLabel": "2024 (remainder)", "label": "Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in remainder of current fiscal year." } } }, "auth_ref": { "r969" } } } }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour", "crdr": "debit", "calculation": { "http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 6.0 } }, "presentation": { "http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails": { "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Four", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": { "r255", "r653", "r666" } } } }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree", "crdr": "debit", "calculation": { "http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 2.0 } }, "presentation": { "http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails": { "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Three", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": { "r255", "r653", "r666" } } } }, "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo", "crdr": "debit", "calculation": { "http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 4.0 } }, "presentation": { "http://www.arrowheadresearch.com/role/IntangibleAssetsExpectedFutureAmortizationDetails": { "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Finite-Lived Intangible Asset, Expected Amortization, Year Two", "documentation": "Amount of amortization for assets, excluding financial assets and goodwill, lacking physical substance with finite life expected to be recognized in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)." } } }, "auth_ref": { "r255", "r653", "r666" } } } }, "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis", "presentation": { "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Finite-Lived Intangible Assets by Major Class", "label": "Finite-Lived Intangible Assets by Major Class [Axis]", "documentation": "Information by major type or class of finite-lived intangible assets." } } }, "auth_ref": { "r246", "r248", "r249", "r250", "r252", "r253", "r256", "r257", "r491", "r492", "r653" } } } }, "us-gaap_FiniteLivedIntangibleAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FiniteLivedIntangibleAssetsGross", "crdr": "debit", "calculation": { "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Gross Carrying Amount", "label": "Finite-Lived Intangible Assets, Gross", "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life." } } }, "auth_ref": { "r244", "r253", "r492", "r666" } } } }, "arwr_FiniteLivedIntangibleAssetsImpairment": { "xbrltype": "monetaryItemType", "nsuri": "http://www.arrowheadresearch.com/20240630", "localname": "FiniteLivedIntangibleAssetsImpairment", "crdr": "credit", "calculation": { "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails": { "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleofIntangibleAssetsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Impairment", "label": "Finite-Lived Intangible Assets, Impairment", "documentation": "Finite-Lived Intangible Assets, Impairment" } } }, "auth_ref": { "r11", "us-gaap_FiniteLivedIntangibleAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fas
```

"nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "FrValAsOfPrYrEndOffEqtyAwrdsGrntdInPrYrsFldVstngCondsDrngCvrdYrMember", "presentation": {
"http://xbrl.sec.gov/ecd/role/PrpDisclosure": {
"lang": {
"en-us": {
"role": {
"terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year", "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]", "auth_ref": {
"r772": {
"us-gaap_FurnitureAndFixturesMember": {
"xbrltype": "domainItemType", "nsuri":
"http://fasb.org/us-gaap/2024", "localname": "FurnitureAndFixturesMember", "presentation": {
"http://www.arrowheadresearch.com/role/BalanceSheetAccountsSummaryofPropertyandEquipmentDetails": {
"lang": {
"en-us": {
"role": {
"terseLabel": "Furniture", "label":
"Furniture and Fixtures [Member]", "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases." } } }, "auth_ref": {
"r1": {
"arwr_GSKHBVAgreementMember": {
"xbrltype": "domainItemType", "nsuri": "http://www.arrowheadresearch.com/20240630", "localname": "GSKHBVAgreementMember", "presentation": {
"http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails": {
"lang": {
"en-us": {
"role": {
"terseLabel": "GSK-HBV Agreement", "label": "GSK-HBV Agreement [Member]", "documentation": "GSK-HBV Agreement" } } }, "auth_ref": {
"r1": {
"arwr_GSKHSDLicenseAgreementMember": {
"xbrltype": "domainItemType", "nsuri": "http://www.arrowheadresearch.com/20240630", "localname": "GSKHSDLicenseAgreementMember", "presentation": {
"http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails": {
"lang": {
"en-us": {
"role": {
"terseLabel": "GSK-HSD License Agreement", "label": "GSK-HSD License Agreement [Member]", "documentation": "GSK-HSD License Agreement" } } }, "auth_ref": {
"r1": {
"us-gaap_GeneralAndAdministrativeExpense": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": {
"http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
"parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 } } }, "presentation": {
"http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
"lang": {
"en-us": {
"role": {
"terseLabel": "General and administrative", "label": "General and Administrative Expense", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": {
"r67": {
"r605": {
"us-gaap_GeneralAndAdministrativeExpenseMember": {
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": {
"http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails": {
"http://www.arrowheadresearch.com/role/StockBasedCompensationExpensesIncludedinOperatingExpensesDetails": {
"lang": {
"en-us": {
"role": {
"terseLabel": "General and administrative expense", "label": "General and Administrative Expense [Member]", "documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth_ref": {
"r67": {
"arwr_GlaxosmithklineIntellectualPropertyLimitedMember": {
"xbrltype": "domainItemType", "nsuri": "http://www.arrowheadresearch.com/20240630", "localname": "GlaxosmithklineIntellectualPropertyLimitedMember", "presentation": {
"http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails": {
"http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsRevenueDetails": {
"lang": {
"en-us": {
"role": {
"terseLabel": "GSK", "label": "Glaxosmithkline Intellectual Property Limited [Member]", "documentation": "Glaxosmithkline Intellectual Property Limited." } } }, "auth_ref": {
"r1": {
"us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract", "lang": {
"en-us": {
"role": {
"terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]", "label": "Goodwill and Intangible Assets Disclosure [Abstract]", "auth_ref": {
"r1": {
"arwr_HeldToMaturitySecuritiesAndMarketableSecuritiesTableTextBlock": {
"xbrltype": "textBlockItemType", "nsuri": "http://www.arrowheadresearch.com/20240630", "localname": "HeldToMaturitySecuritiesAndMarketableSecuritiesTableTextBlock", "presentation": {
"http://www.arrowheadresearch.com/role/InvestmentsTables": {
"lang": {
"en-us": {
"role": {
"terseLabel": "Summary of Short-term and Long-term Investments and Marketable Securities", "label": "Held To Maturity Securities And Marketable Securities Table [Table Text Block]", "documentation": "Held to maturity securities and marketable securities." } } }, "auth_ref": {
"r1": {
"arwr_HorizonLicenseAgreementMember": {
"xbrltype": "domainItemType", "nsuri": "http://www.arrowheadresearch.com/20240630", "localname": "HorizonLicenseAgreementMember", "presentation": {
"http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails": {
"lang": {
"en-us": {
"role": {
"terseLabel": "Horizon License Agreement", "label": "Horizon License Agreement [Member]", "documentation": "Horizon License Agreement" } } }, "auth_ref": {
"r1": {
"arwr_HorizonTherapeuticsIrelandDACMember": {
"xbrltype": "domainItemType", "nsuri": "http://www.arrowheadresearch.com/20240630", "localname": "HorizonTherapeuticsIrelandDACMember", "presentation": {
"http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails": {
"http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsRevenueDetails": {
"lang": {
"en-us": {
"role": {
"terseLabel": "Horizon Therapeutics Ireland DAC [Member]", "label": "Horizon Therapeutics Ireland DAC", "documentation": "Horizon Therapeutics Ireland DAC." } } }, "auth_ref": {
"r1": {
"us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "crdr": "credit", "calculation": {
"http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
"parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 1.0 } } }, "presentation": {
"http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
"lang": {
"en-us": {
"role": {
"totalLabel": "Loss before income tax expense (benefit) and noncontrolling interest", "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest", "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest." } } }, "auth_ref": {
"r65": {
"r102": {
"r107": {
"r527": {
"r539": {
"r661": {
"r662": {
"r37": {
"r838": {
"r839": {
"r840": {
"r841": {
"us-gaap_IncomeStatementAbstract": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": {
"en-us": {
"role": {
"terseLabel": "Income Statement [Abstract]", "label": "Income Statement [Abstract]", "auth_ref": {
"r1": {
"us-gaap_IncomeStatementLocationAxis": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": {
"http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails": {
"http://www.arrowheadresearch.com/role/StockBasedCompensationExpensesIncludedinOperatingExpensesDetails": {
"lang": {
"en-us": {
"role": {
"terseLabel": "Income Statement Location [Axis]", "label": "Statement of Income Location, Balance [Axis]", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": {
"r262": {
"r263": {
"r264": {
"r408": {
"r410": {
"r415": {
"r550": {
"r552": {
"r606": {
"r653": {
"r691": {
"r936": {
"us-gaap_IncomeStatementLocationDomain": {
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": {
"http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails": {
"http://www.arrowheadresearch.com/role/StockBasedCompensationExpensesIncludedinOperatingExpensesDetails": {
"lang": {
"en-us": {
"role": {
"terseLabel": "Income Statement Location [Domain]", "label": "Statement of Income Location, Balance [Domain]", "documentation": "Location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": {
"r263": {
"r264": {
"r408": {
"r410": {
"r415": {
"r550": {
"r552": {
"r606": {
"r653": {
"r691": {
"r936": {
"us-gaap_IncomeTaxExpenseBenefit": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExpenseBenefit", "crdr": "debit", "calculation": {
"http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
"parentTag": "us-gaap_ProfitLoss", "weight": 1.0, "order": 2.0 } } }, "presentation": {
"http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
"http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetails": {
"lang": {
"en-us": {
"role": {
"terseLabel": "Income tax expense (benefit)", "label": "Income Tax Expense (Benefit)", "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": {
"r109": {
"r112": {
"r166": {
"r167": {
"r180": {
"r188": {
"r191": {
"r369": {
"r370": {
"r375": {
"r548": {
"r686": {
"us-gaap_IncomeTaxesPaidNet": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxesPaidNet", "crdr": "credit", "presentation": {
"http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
"lang": {
"en-us": {
"role": {
"terseLabel": "Income taxes paid", "label": "Income Taxes Paid, Net", "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax." } } }, "auth_ref": {
"r18": {
"r147": {
"r371": {
"r372": {
"us-gaap_IncreaseDecreaseInAccountsPayable": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "calculation": {
"http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 9.0 } } }, "presentation": {
"http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
"lang": {
"en-us": {
"role": {
"terseLabel": "Accounts payable", "label": "Increase (Decrease) in Accounts Payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": {
"r4": {
"us-gaap_IncreaseDecreaseInAccountsReceivable": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsReceivable", "crdr": "credit", "calculation": {
"http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 10.0 } } }, "presentation": {
"http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
"lang": {
"en-us": {
"role": {
"negatedLabel": "Accounts receivable", "label": "Increase (Decrease) in Accounts Receivable", "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services." } } }, "auth_ref": {
"r4": {
"us-gaap_IncreaseDecreaseInAccruedLiabilities": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccruedLiabilities", "crdr": "debit", "calculation": {
"http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 8.0 } } }, "presentation": {
"http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
"lang": {
"en-us": {
"role": {
"terseLabel": "Accrued expenses", "label": "Increase (Decrease) in Accrued Liabilities", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid." } } }, "auth_ref": {
"r4": {
"arwr_IncreaseDecreaseInCashAndInvestments": {
"xbrltype": "monetaryItemType", "nsuri": "http://www.arrowheadresearch.com/20240630", "localname": "IncreaseDecreaseInCashAndInvestments", "crdr": "credit", "presentation": {
"http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetails": {
"lang": {
"en-us": {
"role": {
"terseLabel": "Increase (decrease) in cash and investments", "label": "Increase (Decrease) In Cash And Investments", "documentation": "Increase decrease in cash and investments." } } }, "auth_ref": {
"r1": {
"us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInContractWithCustomerLiability", "crdr": "debit", "calculation": {
"http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } } }, "presentation": {
"http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
"lang": {
"en-us": {
"role": {
"terseLabel": "Deferred revenue", "label": "Increase (Decrease) in Contract with Customer, Liability", "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable." } } }, "auth_ref": {
"r489": {
"r828": {
"us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": {
"http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
"lang": {
"en-us": {
"role": {
"terseLabel": "Changes in operating assets and liabilities", "label": "Increase (Decrease) in Operating Capital [Abstract]", "auth_ref": {
"r1": {
"us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingLeaseLiability", "crdr": "debit", "calculation": {
"http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } } }, "presentation": {
"http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
"lang": {
"en-us": {
"role": {
"terseLabel": "Operating lease, net", "label": "Increase (Decrease) in Operating Lease Liability", "documentation": "Amount of increase (decrease) in obligation for operating lease." } } }, "auth_ref": {
"r815": {
"r828": {
"us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": {
"http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } } }, "presentation": {
"http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": {
"lang": {
"en-us": {
"role": {
"negatedLabel": "Prepaid expenses and other assets", "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": {
"r4": {
"us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": {
"http://www.arrowheadresearch.com/role/ConsolidatedStatementsofStockholdersEquity": {
"lang": {
"en-us": {
"role": {
"terseLabel": "Increase (Decrease) in Stockholders'


```
"@context": "http://www.arrowheadresearch.com/role/IncrementalFacilityMember", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." }, { "auth_ref": [1], "arwr_incrementalfacilitymember": { "xbrltype": "domainItemType", "nsuri": "http://www.arrowheadresearch.com/20240630", "localname": "IncrementalFacilityMember", "presentation": [ "http://www.arrowheadresearch.com/role/SubsequentEventsDetails", "lang": { "en-us": { "role": { "terseLabel": "Incremental Facility", "label": "Incremental Facility (Member)", "documentation": "Incremental Facility" } } }, "auth_ref": [1], "ecd_individualaxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ] }, "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PypDisclosure", "lang": { "en-us": { "role": { "terseLabel": "Individual", "label": "Individual Axis" } } }, "auth_ref": [739, 749, 759, 783, 791, 795, 803] }, "arwr_inducementawardsmember": { "xbrltype": "domainItemType", "nsuri": "http://www.arrowheadresearch.com/20240630", "localname": "InducementAwardsMember", "presentation": [ "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails", "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails", "lang": { "en-us": { "role": { "terseLabel": "Inducement Awards", "label": "Inducement Awards (Member)", "documentation": "Inducement Awards" } } }, "auth_ref": [1], "arwr_initialtransactionprice": { "xbrltype": "monetaryItemType", "nsuri": "http://www.arrowheadresearch.com/20240630", "localname": "InitialTransactionPrice", "crdr": "credit", "presentation": [ "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails", "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails", "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails", "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleoffutureRoyaltiesNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Initial transaction price", "label": "Initial Transaction Price", "documentation": "Initial transaction price" } } }, "auth_ref": [1], "ecd_insidertradingarrlineitems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements Line Items" } } }, "auth_ref": [801-1], "ecd_insidertradingpoliciesproclineitems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Line Items" } } }, "auth_ref": [731, 807] }, "ecd_insidertrdpoliciesprocadoptedflag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc", "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Adopted", "label": "Insider Trading Policies and Procedures Adopted Flag" } } }, "auth_ref": [731, 807] }, "ecd_insidertrdpoliciesprocnotadoptedtextblock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc", "lang": { "en-us": { "role": { "terseLabel": "Insider Trading Policies and Procedures Not Adopted", "label": "Insider Trading Policies and Procedures Not Adopted Text Block" } } }, "auth_ref": [731, 807] }, "us-gaap_intangibleassetsdisclosuretextblock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IntangibleAssetsDisclosureTextBlock", "presentation": [ "http://www.arrowheadresearch.com/role/IntangibleAssets", "lang": { "en-us": { "role": { "terseLabel": "Intangible Assets", "label": "Intangible Assets Disclosure Text Block", "documentation": "The entire disclosure for all or part of the information related to intangible assets." } } }, "auth_ref": [245, 258, 260, 652, 653] }, "us-gaap_interestexpensenonoperating": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InterestExpenseNonoperating", "crdr": "debit", "calculation": [ "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss", "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 2.0 ], "presentation": [ "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss", "lang": { "en-us": { "role": { "negatedTerseLabel": "Interest expense", "label": "Interest Expense, Nonoperating", "documentation": "Amount of interest expense classified as nonoperating." } } }, "auth_ref": [186, 827] }, "us-gaap_investmentincomelinterestanddividend": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentIncomeInterestAndDividend", "crdr": "credit", "calculation": [ "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss", "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 3.0 ], "presentation": [ "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss", "lang": { "en-us": { "role": { "terseLabel": "Interest income", "label": "Investment Income, Interest and Dividend", "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income and dividend income on nonoperating securities." } } }, "auth_ref": [68, 69] }, "us-gaap_investmentincomeNetAmortizationOfDiscountAndPremium": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentIncomeNetAmortizationOfDiscountAndPremium", "crdr": "credit", "calculation": [ "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows", "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 6.0 ], "presentation": [ "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows", "lang": { "en-us": { "role": { "negatedLabel": "Amortization (accretion) of note premiums/discounts", "label": "Investment Income, Net, Amortization of Discount and Premium", "documentation": "Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities." } } }, "auth_ref": [71] }, "us-gaap_investmentsDebtAndEquitySecuritiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentsDebtAndEquitySecuritiesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Investments, Debt and Equity Securities Abstract", "label": "Investments, Debt and Equity Securities Abstract" } } }, "auth_ref": [1], "us-gaap_investmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock", "presentation": [ "http://www.arrowheadresearch.com/role/Investments", "lang": { "en-us": { "role": { "terseLabel": "Investments", "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure Text Block", "documentation": "The entire disclosure for investments in certain debt and equity securities." } } }, "auth_ref": [104, 114, 197, 199, 422, 423, 930-1], "arwr_janssenpharmaceuticalsincorporationmember": { "xbrltype": "domainItemType", "nsuri": "http://www.arrowheadresearch.com/20240630", "localname": "JanssenPharmaceuticalsIncorporationMember", "presentation": [ "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsRevenueDetails", "lang": { "en-us": { "role": { "terseLabel": "Janssen", "label": "Janssen Pharmaceuticals Incorporation (Member)", "documentation": "Janssen Pharmaceuticals, Incorporation" } } }, "auth_ref": [1], "arwr_laboratoryandofficefacilitymember": { "xbrltype": "domainItemType", "nsuri": "http://www.arrowheadresearch.com/20240630", "localname": "LaboratoryAndOfficeFacilityMember", "presentation": [ "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Laboratory and Office Facility", "label": "Laboratory And Office Facility (Member)", "documentation": "Laboratory and office facility." } } }, "auth_ref": [1], "us-gaap_landmember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LandMember", "presentation": [ "http://www.arrowheadresearch.com/role/BalanceSheetAccountsSummaryofPropertyandEquipmentDetails", "lang": { "en-us": { "role": { "terseLabel": "Land", "label": "Land (Member)", "documentation": "Part of earth's surface not covered by water." } } }, "auth_ref": [1874] }, "us-gaap_landSubjectToGroundLeases": { "xbrltype": "areaItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LandSubjectToGroundLeases", "presentation": [ "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Office space leases (in sq ft)", "label": "Land Subject to Ground Leases", "documentation": "Area of land subject to a ground lease." } } }, "auth_ref": [918] }, "us-gaap_leaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCost", "crdr": "debit", "calculation": [ "http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails", "parentTag": null, "weight": null, "order": null, "root": true ], "presentation": [ "http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails", "lang": { "en-us": { "role": { "totalLabel": "Total", "label": "Lease, Cost", "documentation": "Amount of lease cost recognized by lessee for lease contract." } } }, "auth_ref": [441, 700] }, "us-gaap_leaseCostAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCostAbstract", "presentation": [ "http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails", "lang": { "en-us": { "role": { "terseLabel": "Lease Cost", "label": "Lease, Cost Abstract", "documentation": "Schedule of Lease Assets and Liabilities and Lease Cost", "label": "Lease, Cost Table Text Block", "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income." } } }, "auth_ref": [920] }, "us-gaap_leaseholdImprovementsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseholdImprovementsMember", "presentation": [ "http://www.arrowheadresearch.com/role/BalanceSheetAccountsSummaryofPropertyandEquipmentDetails", "lang": { "en-us": { "role": { "terseLabel": "Leasehold improvements", "label": "Leasehold Improvements (Member)", "documentation": "Additions or improvements to assets held under a lease arrangement." } } }, "auth_ref": [81, 449] }, "us-gaap_leasesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeasesAbstract", "lang": { "en-us": { "role": { "terseLabel": "Leases Abstract", "label": "Leases Abstract" } } }, "auth_ref": [1], "us-gaap_lesseeLeaseDescriptionLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeaseDescriptionLineItems", "presentation": [ "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Lessee Lease Description Line Items", "label": "Lessee, Lease, Description Line Items", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [440, 450] }, "us-gaap_lesseeLeaseDescriptionTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeLeaseDescriptionTable", "presentation": [ "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Lessee Lease Description Table", "label": "Lessee, Lease, Description Table", "documentation": "Disclosure of information about lessee's leases." } } }, "auth_ref": [440, 450] }, "us-gaap_lesseeOperatingLeaseLiabilityMaturityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock", "presentation": [ "http://www.arrowheadresearch.com/role/LeasesTables", "lang": { "en-us": { "role": { "terseLabel": "Summary of Maturities of Operating Lease Liabilities on an Undiscounted Basis", "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity Table Text Block", "documentation": "Tabular
```

```

"http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 4.0 } }, "presentation": {
"http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails": { "lang": { "en-us": { "role": { "terseLabel": "2028", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). } } }, "auth_ref": { "r448" } }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree", "crdr": "credit", "calculation": {
"http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 6.0 } }, "presentation": {
"http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails": { "lang": { "en-us": { "role": { "terseLabel": "2027", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). } } }, "auth_ref": { "r448" } }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo", "crdr": "credit", "calculation": {
"http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 1.0 } }, "presentation": {
"http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails": { "lang": { "en-us": { "role": { "terseLabel": "2026", "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach). } } }, "auth_ref": { "r448" } }, "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear", "crdr": "credit", "calculation": {
"http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 3.0 } }, "presentation": {
"http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails": { "lang": { "en-us": { "role": { "terseLabel": "2024 (remainder of fiscal year)", "label": "Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year", "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year. } } }, "auth_ref": { "r921" } }, "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount", "crdr": "credit", "calculation": {
"http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails": { "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue", "weight": 1.0, "order": 2.0 } }, "presentation": {
"http://www.arrowheadresearch.com/role/LeasesSummaryofMaturitiesofOperatingLeaseLiabilitiesonanUndiscountedBasisDetails": { "lang": { "en-us": { "role": { "negatedLabel": "Less imputed interest", "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount", "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease. } } }, "auth_ref": { "r448" } }, "us-gaap_LesseeOperatingLeaseRenewalTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseRenewalTerm", "presentation": { "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Operating lease renewal term", "label": "Lessee, Operating Lease, Renewal Term", "documentation": "Term of lessee's operating lease renewal in 'PnYnMnDnTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. } } }, "auth_ref": { "r919" } }, "us-gaap_LesseeOperatingLeaseTermOfContract": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeaseTermOfContract", "presentation": {
"http://www.arrowheadresearch.com/role/LeasesNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Lease term", "label": "Lessee, Operating Lease, Term of Contract", "documentation": "Term of lessee's operating lease in 'PnYnMnDnTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. } } }, "auth_ref": { "r919" } }, "us-gaap_LesseeOperatingLeasesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LesseeOperatingLeasesTextBlock", "presentation": { "http://www.arrowheadresearch.com/role/Leases": { "lang": { "en-us": { "role": { "terseLabel": "Leases", "label": "Lessee, Operating Leases [Text Block]", "documentation": "The entire disclosure for operating leases of lessee, includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability. } } }, "auth_ref": { "r435" } }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": {
"http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": {
"http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": { "lang": { "en-us": { "role": { "totalLabel": "Total Liabilities, Noncontrolling Interest and Stockholders Equity 2019", "label": "Liabilities and Equity", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any. } } }, "auth_ref": { "r63", "r101", "r536", "r701", "r831", "r848", "r915" } }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": {
"http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": { "lang": { "en-us": { "role": { "terseLabel": "LIABILITIES, NONCONTROLLING INTEREST AND STOCKHOLDERS' EQUITY", "label": "Liabilities and Equity [Abstract]", "documentation": "The entire disclosure for operating leases of lessee, includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability. } } }, "auth_ref": { "r919" } }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": {
"http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": { "lang": { "en-us": { "role": { "totalLabel": "Total current liabilities", "label": "Liabilities, Current", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. } } }, "auth_ref": { "r50", "r119", "r150", "r230", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r386", "r389", "r390", "r424", "r701", "r869", "r922", "r923" } }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": { "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": { "lang": { "en-us": { "role": { "terseLabel": "Current liabilities", "label": "Liabilities, Current [Abstract]", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. } } }, "auth_ref": { "r50", "r119", "r150", "r230", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r386", "r389", "r390", "r424", "r701", "r869", "r922", "r923" } }, "us-gaap_LiabilitiesNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesNoncurrentAbstract", "presentation": { "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": { "lang": { "en-us": { "role": { "terseLabel": "Long-term liabilities", "label": "Liabilities, Noncurrent [Abstract]", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. } } }, "auth_ref": { "r50", "r119", "r150", "r230", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r386", "r389", "r390", "r424", "r701", "r869", "r922", "r923" } }, "us-gaap_LiabilitiesNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesNoncurrentAbstract", "presentation": { "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": { "lang": { "en-us": { "role": { "terseLabel": "Long-term liabilities", "label": "Liabilities, Noncurrent [Abstract]", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. } } }, "auth_ref": { "r50", "r119", "r150", "r230", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r386", "r389", "r390", "r424", "r701", "r869", "r922", "r923" } }, "us-gaap_LiabilitiesNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesNoncurrentAbstract", "presentation": { "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": { "lang": { "en-us": { "role": { "terseLabel": "Long-term liabilities", "label": "Liabilities, Noncurrent [Abstract]", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. } } }, "auth_ref": { "r50", "r119", "r150", "r230", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r386", "r389", "r390", "r424", "r701", "r869", "r922", "r923" } }, "us-gaap_LiabilitiesNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesNoncurrentAbstract", "presentation": { "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": { "lang": { "en-us": { "role": { "terseLabel": "Long-term liabilities", "label": "Liabilities, Noncurrent [Abstract]", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer. } } }, "auth_ref": { "r50", "r119", "r150", "r230", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r386", "r389", "r39
```

"domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LongtermDebtTypeDomain", "presentation": {
"http://www.arrowheadresearch.com/role/SubsequentEventsDetails": {
"lang": {
"en-us": {
"role": {
"terseLabel": "Long-Term Debt Type {Domain}", "label": "Long-Term Debt Type {Domain}", "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer." } } }
"auth_ref": {
"r12", "r27", "r862", "r863", "r864" } }
"us-gaap_LossContingencyAccrualAtCarryingValue": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LossContingencyAccrualAtCarryingValue", "crdr": "credit", "presentation": {
"http://www.arrowheadresearch.com/role/CommitmentsandContingenciesNarrativeDetails": {
"lang": {
"en-us": {
"role": {
"terseLabel": "Contingent Liabilities", "label": "Loss Contingency Accrual", "documentation": "Amount of loss contingency liability." } } }
"auth_ref": {
"r267", "r814" } }
"srt_MajorCustomersAxis": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MajorCustomersAxis", "presentation": {
"http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsRevenueDetails": {
"lang": {
"en-us": {
"role": {
"terseLabel": "Customer {Axis}", "label": "Customer {Axis}" } } }
"auth_ref": {
"r195", "r675", "r711", "r714", "r873", "r935", "r937", "r938", "r939", "r940", "r941", "r942", "r943", "r944", "r945", "r946", "r947", "r948", "r949", "r950", "r951", "r952", "r953", "r954", "r955", "r956", "r957", "r958", "r959", "r960", "r961", "r963", "r964" } }
"arwr_MaximumAdditionalTenantImprovementAllowance": {
"xbrltype": "monetaryItemType", "nsuri": "http://www.arrowheadresearch.com/20240630", "localname": "MaximumAdditionalTenantImprovementAllowance", "crdr": "debit", "presentation": {
"http://www.arrowheadresearch.com/role/LeasesNarrativeDetails": {
"lang": {
"en-us": {
"role": {
"terseLabel": "Maximum additional tenant improvement allowance", "label": "Maximum Additional Tenant Improvement Allowance", "documentation": "Maximum Additional Tenant Improvement Allowance." } } }
"auth_ref": {
"srt_MaximumMember": {
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MaximumMember", "presentation": {
"http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails": {
"http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails": {
"http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails": {
"http://www.arrowheadresearch.com/role/CommitmentsandContingenciesNarrativeDetails": {
"http://www.arrowheadresearch.com/role/LeasesNarrativeDetails": {
"http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails": {
"http://www.arrowheadresearch.com/role/StockholdersEquityDetails": {
"lang": {
"en-us": {
"role": {
"terseLabel": "Maximum", "label": "Maximum {Member}" } } }
"auth_ref": {
"r268", "r269", "r270", "r271", "r329", "r367", "r407", "r488", "r549", "r551", "r559", "r573", "r574", "r626", "r628", "r630", "r631", "r633", "r650", "r651", "r664", "r672", "r683", "r692", "r693", "r697", "r698", "r712", "r871", "r924", "r925", "r926", "r927", "r928", "r929" } }
"ecd_MeasureAxis": {
"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": {
"http://xbrl.sec.gov/ecd/role/PvpDisclosure": {
"lang": {
"en-us": {
"role": {
"terseLabel": "Measure", "label": "Measure {Axis}" } } }
"auth_ref": {
"r775" } }
"ecd_MeasureName": {
"xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": {
"http://xbrl.sec.gov/ecd/role/PvpDisclosure": {
"lang": {
"en-us": {
"role": {
"terseLabel": "Name", "label": "Measure Name" } } }
"auth_ref": {
"r775" } }
"arwr_MilestonePaymentEarned": {
"xbrltype": "monetaryItemType", "nsuri": "http://www.arrowheadresearch.com/20240630", "localname": "MilestonePaymentEarned", "crdr": "credit", "presentation": {
"http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails": {
"http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails": {
"lang": {
"en-us": {
"role": {
"terseLabel": "Milestone payment", "label": "Milestone Payment Earned", "documentation": "Milestone payment earned." } } }
"auth_ref": {
"arwr_MilestonePaymentReceivable": {
"xbrltype": "monetaryItemType", "nsuri": "http://www.arrowheadresearch.com/20240630", "localname": "MilestonePaymentReceivable", "crdr": "debit", "presentation": {
"http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails": {
"http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails": {
"http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails": {
"lang": {
"en-us": {
"role": {
"terseLabel": "Milestone payment receivable", "label": "Milestone Payment Receivable", "documentation": "Milestone Payment Receivable." } } }
"auth_ref": {
"arwr_MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial": {
"xbrltype": "monetaryItemType", "nsuri": "http://www.arrowheadresearch.com/20240630", "localname": "MilestonePaymentReceivableUponAchievementOfEnrollmentInPhase3ClinicalTrial", "crdr": "debit", "presentation": {
"http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails": {
"http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetails": {
"lang": {
"en-us": {
"role": {
"terseLabel": "Milestone payment receivable upon achievement of enrollment in phase 3 clinical trial", "label": "Milestone Payment Receivable, Upon Achievement of Enrollment in Phase 3 Clinical Trial", "documentation": "Milestone Payment Receivable, Upon Achievement of Enrollment in Phase 3 Clinical Trial." } } }
"auth_ref": {
"arwr_MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree": {
"xbrltype": "monetaryItemType", "nsuri": "http://www.arrowheadresearch.com/20240630", "localname": "MilestonePaymentReceivableUponAchievementOfPhaseTwoAndFirstPatientDosedInPhaseThree", "crdr": "debit", "presentation": {
"http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails": {
"lang": {
"en-us": {
"role": {
"terseLabel": "Milestone payment receivable upon achievement of phase two and first patient dosed in phase three", "label": "Milestone Payment Receivable Upon Achievement Of Phase Two And First Patient Dosed In Phase Three", "documentation": "Milestone payment receivable upon achievement of phase two and first patient dosed in phase three." } } }
"auth_ref": {
"arwr_MilestonePaymentReceivableUponFDAApproval": {
"xbrltype": "monetaryItemType", "nsuri": "http://www.arrowheadresearch.com/20240630", "localname": "MilestonePaymentReceivableUponFDAApproval", "crdr": "debit", "presentation": {
"http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails": {
"lang": {
"en-us": {
"role": {
"terseLabel": "Milestone payment receivable upon FDA approval", "label": "Milestone Payment Receivable, Upon FDA Approval", "documentation": "Milestone Payment Receivable, Upon FDA Approval." } } }
"auth_ref": {
"arwr_MilestonePaymentReceivableUponReceiptOfRoyaltyPayments": {
"xbrltype": "monetaryItemType", "nsuri": "http://www.arrowheadresearch.com/20240630", "localname": "MilestonePaymentReceivableUponReceiptOfRoyaltyPayments", "crdr": "debit", "presentation": {
"http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails": {
"lang": {
"en-us": {
"role": {
"terseLabel": "Milestone payment receivable upon receipt of royalty payments", "label": "Milestone Payment Receivable, Upon Receipt Of Royalty Payments", "documentation": "Milestone Payment Receivable, Upon Receipt Of Royalty Payments." } } }
"auth_ref": {
"arwr_MilestonePaymentReceived": {
"xbrltype": "monetaryItemType", "nsuri": "http://www.arrowheadresearch.com/20240630", "localname": "MilestonePaymentReceived", "crdr": "credit", "presentation": {
"http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails": {
"lang": {
"en-us": {
"role": {
"terseLabel": "Milestone payments", "label": "Milestone Payment Received", "documentation": "Milestone payment received." } } }
"auth_ref": {
"arwr_MilestonePaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties": {
"xbrltype": "monetaryItemType", "nsuri": "http://www.arrowheadresearch.com/20240630", "localname": "MilestonePaymentReceivedLiabilityRelatedToSaleOfFutureRoyalties", "crdr": "debit", "presentation": {
"http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails": {
"lang": {
"en-us": {
"role": {
"terseLabel": "Milestone payment received", "label": "Milestone Payment Received, Liability Related To Sale Of Future Royalties", "documentation": "Milestone Payment Received, Liability Related To Sale Of Future Royalties." } } }
"auth_ref": {
"srt_MinimumMember": {
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": {
"http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails": {
"http://www.arrowheadresearch.com/role/CommitmentsandContingenciesNarrativeDetails": {
"lang": {
"en-us": {
"role": {
"terseLabel": "Minimum", "label": "Minimum {Member}" } } }
"auth_ref": {
"r268", "r269", "r270", "r271", "r329", "r367", "r407", "r488", "r549", "r551", "r559", "r573", "r574", "r626", "r628", "r630", "r631", "r633", "r650", "r651", "r664", "r672", "r683", "r692", "r693", "r697", "r712", "r871", "r924", "r925", "r926", "r927", "r928", "r929" } }
"us-gaap_MinorityInterest": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MinorityInterest", "crdr": "credit", "calculation": {
"http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
"parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 } }
"presentation": {
"http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": {
"lang": {
"en-us": {
"role": {
"terseLabel": "Noncontrolling interest", "label": "Equity, Attributable to Noncontrolling Interest", "documentation": "Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity." } } }
"auth_ref": {
"r62", "r100", "r150", "r230", "r273", "r275", "r276", "r277", "r280", "r281", "r424", "r535", "r584" } }
"ecd_MnpiDiscTimedForCompValFlag": {
"xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": {
"http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": {
"lang": {
"en-us": {
"role": {
"terseLabel": "MNPI Disclosure Timed for Compensation Value", "label": "MNPI Disclosure Timed for Compensation Value {Flag}" } } }
"auth_ref": {
"r794" } }
"us-gaap_MoneyMarketFundsMember": {
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MoneyMarketFundsMember", "presentation": {
"http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": {
"lang": {
"en-us": {
"role": {
"terseLabel": "Money market instruments", "label": "Money Market Funds {Member}", "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities." } } }
"auth_ref": {
"r875" } }
"ecd_MtrlTermsOfTrdArrTextBlock": {
"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": {
"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements": {
"lang": {
"en-us": {
"role": {
"terseLabel": "Material Terms of Trading Arrangement", "label": "Material Terms of Trading Arrangement {Text Block}" } } }
"auth_ref": {
"r802" } }
"us-gaap_MunicipalBondsMember": {
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MunicipalBondsMember", "presentation": {
"http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails": {
"lang": {
"en-us": {
"role": {
"terseLabel": "Municipal securities", "label": "Municipal Bonds {Member}", "documentation": "Long-term debt securities issued by state, city or local governments or the agencies operated by state, city or local governments." } } }
"auth_ref": {
"srt_NameOfMajorCustomerDomain": {
"xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "NameOfMajorCustomerDomain", "presentation": {
"http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsRevenueDetails": {
"lang": {
"en-us": {
"role": {
"terseLabel": "Customer {Domain}", "label": "Customer {Domain}" } } }
"auth_ref": {
"r195", "r675", "r711", "r714", "r873", "r935", "r937", "r938", "r939", "r940", "r941", "r942", "r943", "r944", "r945", "r946", "r947", "r948", "r949", "r950", "r951", "r952", "r953", "r954", "r955", "r956", "r957", "r958", "r959", "r960", "r961", "r963", "r964" } }
"ecd_NamedExecutiveOfficersFnTextBlock": {
"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": {
"http://xbrl.sec.gov/ecd/role/PvpDisclosure": {
"lang": {
"en-us": {
"role": {
"terseLabel": "Named Executive Officers, Footnote", "label": "Named Executive Officers, Footnote {Text Block}" } } }
"auth_ref": {
"r776" } }
"us-gaap_NetCashProvidedByUsedInFinancingActivities": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": {
"http://www.arrowheadresearch.com/role/ConsolidatedStatementsOfCashFlows": {
"parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0, "order": 3.0 } }
"presentation": {
"http://www.arrowheadresearch.com/role/ConsolidatedStatementsOfCashFlows": {
"lang": {
"en-us": {
"role": {
"totalLabel": "Net cash provided by financing activities", "label": "Net Cash Provided by (Used in) Financing Activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }
"auth_ref": {
"r146" } }
"us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": {
"http://www.arrowheadresearch.com/role/ConsolidatedStatementsOfCashFlows": {
"lang": {
"en-us": {
"role": {
"terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES", "label": "Net Cash Provided by (Used in) Financing Activities {Abstract}" } } }
"auth_ref": {
"us-gaap_NetCashProvidedByUsedInInvestingActivities": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivities", "crdr": "debit", "calculation": {
"http://www.arrowheadresearch.com/role/ConsolidatedStatementsOfCashFlows": {
"parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }
"presentation": {
"http://www.arrowheadresearch.com/role/ConsolidatedStatementsOfCashFlows": {
"lang": {
"en-us": {
"role": {
"totalLabel": "Net cash used in investing activities", "label": "Net Cash Provided by (Used in) Investing Activities", "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets." } } }
"auth_ref": {
"r146" } }
"us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract", "presentation": {
"http://www.arrowheadresearch.com/role/ConsolidatedStatementsOfCashFlows": {
"lang": {
"en-us": {
"role": {
"terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES", "label": "Net Cash Provided by (Used in) Investing Activities {Abstract}" } } }
"auth_ref": {
"us-gaap_NetCashProvidedByUsedInOperatingActivities": {
"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": {

http://www.arrowheadresearch.com/role/ConsolidatedStatementsOfCashFlows": {"parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect", "weight": 1.0, "order": 1.0 }, {"presentation": "http://www.arrowheadresearch.com/role/ConsolidatedStatementsOfCashFlows"}], "lang": "en-us", "role": "totalLabel", "Net cash used in operating activities", "label": "Net Cash Provided by (Used in) Operating Activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." }, {"auth_ref": "r75", "r76", "r77"}], "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": "http://www.arrowheadresearch.com/role/ConsolidatedStatementsOfCashFlows"}], "lang": "en-us", "role": "totalLabel", "CASH FLOWS FROM OPERATING ACTIVITIES", "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "auth_ref": "r75", "r76", "r77"}, {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": {"http://www.arrowheadresearch.com/role/ConsolidatedStatementsOfOperationsandComprehensiveLoss": {"parentTag": null, "weight": null, "order": null, "root": true }}, "presentation": "http://www.arrowheadresearch.com/role/ConsolidatedStatementsOfOperationsandComprehensiveLoss"}, {"http://www.arrowheadresearch.com/role/NetLossPerShareBasicandDilutedNetLossPerShareDetails": {"http://xbrl.sec.gov/ecd/role/PvpDisclosure"}], "lang": "en-us", "role": "totalLabel", "Net loss attributable to Arrowhead Pharmaceuticals, Inc.", "terseLabel": "Net loss attributable to Arrowhead Pharmaceuticals, Inc.", "label": "Net Income (Loss) Attributable to Parent", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." }, {"auth_ref": "r66", "r77", "r103", "r117", "r136", "r138", "r142", "r150", "r157", "r159", "r160", "r161", "r162", "r163", "r166", "r167", "r172", "r230", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r379", "r382", "r401", "r424", "r542", "r603", "r619", "r620", "r724", "r869"}], "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAttributableToNoncontrollingInterest", "crdr": "debit", "calculation": {"http://www.arrowheadresearch.com/role/ConsolidatedStatementsOfOperationsandComprehensiveLoss": {"parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 2.0 }}, "presentation": "http://www.arrowheadresearch.com/role/ConsolidatedStatementsOfOperationsandComprehensiveLoss"}], "lang": "en-us", "role": "totalLabel", "Net loss attributable to noncontrolling interest, net of tax", "label": "Net Income (Loss) Attributable to Noncontrolling Interest", "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest." }, {"auth_ref": "r43", "r95", "r136", "r138", "r163", "r166", "r167", "r541", "r826"}], "us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAvailableToCommonStockholdersDilutedAbstract", "presentation": "http://www.arrowheadresearch.com/role/NetLossPerShareBasicandDilutedNetLossPerShareDetails"}], "lang": "en-us", "role": "terseLabel", "Numerator", "label": "Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]", "auth_ref": "r43", "r95", "r136", "r138", "r163", "r166", "r167", "r541", "r826"}, {"http://www.arrowheadresearch.com/role/AccountingPronouncementsPolicyPolicyTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": "http://www.arrowheadresearch.com/role/AccountingPronouncementsPolicyPolicyTextBlock"}], "lang": "en-us", "role": "terseLabel", "Recent Accounting Pronouncements", "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." }, {"auth_ref": "r11"}, {"arwr_NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties": {"xbrltype": "monetaryItemType", "nsuri": "http://www.arrowheadresearch.com/20240630", "localname": "NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties", "crdr": "debit", "calculation": {"http://www.arrowheadresearch.com/role/ConsolidatedStatementsOfCashFlows": {"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 5.0 }}, "presentation": "http://www.arrowheadresearch.com/role/ConsolidatedStatementsOfCashFlows"}, {"http://www.arrowheadresearch.com/role/LiabilityRelatedToTheSaleOfFutureRoyaltiesActivityDetails": {"http://xbrl.sec.gov/ecd/2024", "localname": "NonCashInterestExpenseLiabilityRelatedToSaleOfFutureRoyalties", "documentation": "Non-Cash Interest Expense, Liability Related To Sale Of Future Royalties", "auth_ref": "r11"}, {"ecd_NonGaapMeasureDescriptionTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": "http://xbrl.sec.gov/ecd/role/PvpDisclosure"}], "lang": "en-us", "role": "terseLabel", "Non-GAAP Measure Description", "label": "Non-GAAP Measure Description [Text Block]", "auth_ref": "r775", "r776"}, {"http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation": "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"}], "lang": "en-us", "role": "terseLabel", "Non-NEOs", "label": "Non-NEOs [Member]", "auth_ref": "r739", "r749", "r759", "r783", "r791"}, {"ecd_NonPeoNeoAvgCompActuallyPaidAmt": {"xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": "http://xbrl.sec.gov/ecd/role/PvpDisclosure"}], "lang": "en-us", "role": "terseLabel", "Non-PEO NEO Average Total Compensation Amount", "label": "Non-PEO NEO Average Total Compensation Amount", "auth_ref": "r765"}, {"ecd_NonPeoNeoMember": {"xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": "http://xbrl.sec.gov/ecd/role/PvpDisclosure"}], "lang": "en-us", "role": "terseLabel", "Non-PEO NEO", "label": "Non-PEO NEO [Member]", "auth_ref": "r783"}, {"ecd_NonRule10b51ArrAdoptedFlag": {"xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "documentation": "Non-Rule 10b5-1 Arrangement Adopted", "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "auth_ref": "r802"}, {"ecd_NonRule10b51ArrTrmndFlag": {"xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmndFlag", "presentation": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"}], "lang": "en-us", "role": "terseLabel", "Non-Rule 10b5-1 Arrangement Terminated", "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]", "auth_ref": "r802"}, {"us-gaap_NoncontrollingInterestMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NoncontrollingInterestMember", "presentation": "http://www.arrowheadresearch.com/role/ConsolidatedStatementsOfStockholdersEquity"}], "lang": "en-us", "role": "terseLabel", "Non-controlling Interest", "label": "Noncontrolling Interest [Member]", "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest." }, {"auth_ref": "r40", "r41", "r832", "r833", "r834", "r835", "r966"}], "us-gaap_NonoperatingIncomeExpense": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": {"http://www.arrowheadresearch.com/role/ConsolidatedStatementsOfOperationsandComprehensiveLoss": {"parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest", "weight": 1.0, "order": 1.0 }}, "presentation": "http://www.arrowheadresearch.com/role/ConsolidatedStatementsOfOperationsandComprehensiveLoss"}], "lang": "en-us", "role": "totalLabel", "Total other income (expense)", "label": "Nonoperating Income (Expense)", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).", "auth_ref": "r70"}, {"us-gaap_NonoperatingIncomeExpenseAbstract": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": "http://www.arrowheadresearch.com/role/ConsolidatedStatementsOfOperationsandComprehensiveLoss"}], "lang": "en-us", "role": "terseLabel", "Other income (expense)", "label": "Nonoperating Income (Expense) [Abstract]", "auth_ref": "r11"}, {"arwr_NovartisMember": {"xbrltype": "domainItemType", "nsuri": "http://www.arrowheadresearch.com/20240630", "localname": "NovartisMember", "presentation": "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleOfIntangibleAssetsDetails"}], "lang": "en-us", "role": "terseLabel", "Novartis", "label": "Novartis [Member]", "documentation": "Novartis." }, {"auth_ref": "r11"}, {"arwr_NumberOfAgreements": {"xbrltype": "integerItemType", "nsuri": "http://www.arrowheadresearch.com/20240630", "localname": "NumberOfAgreements", "presentation": "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails"}], "lang": "en-us", "role": "terseLabel", "Number of agreements", "label": "Number of Agreements", "documentation": "Number of agreements." }, {"auth_ref": "r11"}, {"arwr_NumberOfDistinctBundles": {"xbrltype": "integerItemType", "nsuri": "http://www.arrowheadresearch.com/20240630", "localname": "NumberOfDistinctBundles", "presentation": "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails"}], "lang": "en-us", "role": "terseLabel", "Number of distinct bundle", "label": "Number of Distinct Bundle", "documentation": "Number of distinct bundle." }, {"auth_ref": "r11"}, {"arwr_NumberOfDistinctPerformanceObligations": {"xbrltype": "integerItemType", "nsuri": "http://www.arrowheadresearch.com/20240630", "localname": "NumberOfDistinctPerformanceObligations", "presentation": "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails"}], "lang": "en-us", "role": "terseLabel", "Number of distinct performance obligations", "label": "Number of Distinct Performance Obligations", "documentation": "Number of distinct performance obligations." }, {"auth_ref": "r11"}, {"arwr_NumberOfOptionsToRenew": {"xbrltype": "integerItemType", "nsuri": "http://www.arrowheadresearch.com/20240630", "localname": "NumberOfOptionsToRenew", "presentation": "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails"}], "lang": "en-us", "role": "terseLabel", "Number of options to renew", "label": "Number of Options To Renew", "documentation": "Number of options to renew." }, {"auth_ref": "r11"}, {"arwr_OlpasiranAgreementMember": {"xbrltype": "domainItemType", "nsuri": "http://www.arrowheadresearch.com/20240630", "localname": "OlpasiranAgreementMember", "presentation": "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails"}], "lang": "en-us", "role": "terseLabel", "Olpasiran Agreement", "label": "Olpasiran Agreement [Member]", "documentation": "Olpasiran agreement." }, {"auth_ref": "r11"}, {"us-gaap_OperatingExpenses": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "crdr": "debit", "calculation": {"http://www.arrowheadresearch.com/role/ConsolidatedStatementsOfOperationsandComprehensiveLoss": {"parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 2.0 }}, "presentation": "http://www.arrowheadresearch.com/role/ConsolidatedStatementsOfOperationsandComprehensiveLoss"}], "lang": "en-us", "role": "totalLabel", "Total operating expenses", "label": "Operating Expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." }, {"auth_ref": "r11"}, {"us-gaap_OperatingExpensesAbstract": {"xbrltype": "stringItemType", "nsuri": "http://fasb

```

for lease payments from operating lease." } } } , "auth ref": { "r438" } } , "us-gaap-OperatingLeaseLiabilityCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityCurrent", "crdr": "credit", "calculation": { "parentTag": "us-gaap-LiabilitiesCurrent", "weight": 1.0, "order": 6.0 } } , "presentation": { "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets", "lang": { "en-us": { "role": { "terseLabel": "Lease liabilities", "label": "Operating Lease, Liability, Current", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current." } } } , "auth ref": { "r438" } } , "us-gaap-OperatingLeaseLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseLiabilityNoncurrent", "crdr": "credit", "calculation": { "parentTag": "us-gaap-LiabilitiesNoncurrent", "weight": 1.0, "order": 2.0 } } , "presentation": { "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets", "lang": { "en-us": { "role": { "terseLabel": "Lease liabilities, net of current portion", "label": "Operating Lease, Liability, Noncurrent", "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent." } } } , "auth ref": { "r438" } } , "us-gaap-OperatingLeasePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeasePayments", "crdr": "credit", "presentation": { "http://www.arrowheadresearch.com/role/LeasesSupplementalCashFlowAndOtherInformationRelatedtoLeasesDetails", "lang": { "en-us": { "role": { "terseLabel": "Operating cash flows from operating leases", "label": "Operating Lease, Payments", "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use." } } } , "auth ref": { "r439", "r445" } } , "us-gaap-OperatingLeaseRightOfUseAsset": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseRightOfUseAsset", "crdr": "debit", "calculation": { "parentTag": "us-gaap-Assets", "weight": 1.0, "order": 3.0 } } , "presentation": { "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets", "lang": { "en-us": { "role": { "terseLabel": "Right of use assets", "label": "Operating Lease, Right of Use Asset", "documentation": "Amount of lessee's right to use underlying asset under operating lease." } } } , "auth ref": { "r437" } } , "us-gaap-OperatingLeaseWeightedAverageDiscountRatePercent": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageDiscountRatePercent", "presentation": { "http://www.arrowheadresearch.com/role/LeasesSupplementalCashFlowAndOtherInformationRelatedtoLeasesDetails", "lang": { "en-us": { "role": { "terseLabel": "Weighted average discount rate", "label": "Operating Lease, Weighted Average Discount Rate, Percent", "documentation": "Weighted average discount rate for operating lease calculated at point in time." } } } , "auth ref": { "r447", "r700" } } , "us-gaap-OperatingLeaseWeightedAverageRemainingLeaseTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm", "presentation": { "http://www.arrowheadresearch.com/role/LeasesSupplementalCashFlowAndOtherInformationRelatedtoLeasesDetails", "lang": { "en-us": { "role": { "terseLabel": "Weighted average remaining lease term (in years)", "label": "Operating Lease, Weighted Average Remaining Lease Term", "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDnFnHnMns' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } } , "auth ref": { "r446", "r700" } } , "us-gaap-OperatingLeasedAssetsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeasedAssetsLineItems", "presentation": { "http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails", "lang": { "en-us": { "role": { "terseLabel": "Operating Leased Assets (Line Items)", "label": "Operating Leased Assets (Line Items)", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } } , "auth ref": { "arwr-OrganizationAndSignificantAccountingPoliciesLineItems", "xbrltype": "stringItemType", "nsuri": "http://www.arrowheadresearch.com/20240630", "localname": "OrganizationAndSignificantAccountingPoliciesLineItems", "presentation": { "http://www.arrowheadresearch.com/role/OrganizationAndSignificantAccountingPoliciesNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Organization And Significant Accounting Policies (Line Items)", "label": "Organization And Significant Accounting Policies (Line Items)", "documentation": "Organization and significant accounting policies." } } } , "auth ref": { "arwr-OrganizationAndSignificantAccountingPoliciesTable", "xbrltype": "stringItemType", "nsuri": "http://www.arrowheadresearch.com/20240630", "localname": "OrganizationAndSignificantAccountingPoliciesTable", "presentation": { "http://www.arrowheadresearch.com/role/OrganizationAndSignificantAccountingPoliciesNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Organization And Significant Accounting Policies (Table)", "label": "Organization And Significant Accounting Policies (Table)", "documentation": "Organization and significant accounting policies." } } } , "auth ref": { "us-gaap-OrganizationConsolidationAndPresentationOffFinancialStatementsAbstract", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOffFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Organization Consolidation and Presentation of Financial Statements (Abstract)" } } } , "auth ref": { "us-gaap-OrganizationConsolidationAndPresentationOffFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOffFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock", "presentation": { "http://www.arrowheadresearch.com/role/OrganizationAndSignificantAccountingPolicies", "lang": { "en-us": { "role": { "terseLabel": "Organization and Significant Accounting Policies", "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies (Text Block)", "documentation": "The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows. Describes procedure if disclosures are provided in more than one note to the financial statements." } } } , "auth ref": { "r45", "r78", "r79", "r93" } } , "us-gaap-OtherAccruedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAccruedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.arrowheadresearch.com/role/BalanceSheetAccountsAccruedExpensesDetails", "parentTag": "us-gaap-AccruedLiabilitiesCurrent", "weight": 1.0, "order": 3.0 } } , "presentation": { "http://www.arrowheadresearch.com/role/BalanceSheetAccountsAccruedExpensesDetails", "lang": { "en-us": { "role": { "terseLabel": "Other", "label": "Other Accrued Liabilities, Current", "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer." } } } , "auth ref": { "r49" } } , "us-gaap-OtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsCurrent", "crdr": "debit", "calculation": { "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets", "parentTag": "us-gaap-AssetsCurrent", "weight": 1.0, "order": 4.0 } } , "presentation": { "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets", "lang": { "en-us": { "role": { "terseLabel": "Other current assets", "label": "Other Assets, Current", "documentation": "Amount of current assets classified as other." } } } , "auth ref": { "r131", "r701" } } , "us-gaap-OtherAssetsNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherAssetsNoncurrent", "crdr": "debit", "calculation": { "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets", "parentTag": "us-gaap-Assets", "weight": 1.0, "order": 5.0 } } , "presentation": { "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets", "lang": { "en-us": { "role": { "terseLabel": "Other assets", "label": "Other Assets, Noncurrent", "documentation": "Amount of noncurrent assets classified as other." } } } , "auth ref": { "r124" } } , "us-gaap-OtherCommitmentsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherCommitmentsLineItems", "presentation": { "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Other Commitments (Line Items)", "label": "Other Commitments (Line Items)", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } } , "auth ref": { "us-gaap-OtherCommitmentsTable", "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherCommitmentsTable", "presentation": { "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesNarrativeDetails", "lang": { "en-us": { "role": { "terseLabel": "Other Commitments (Table)", "label": "Other Commitments (Table)", "documentation": "Disclosure of information about obligations resulting from other commitments." } } } , "auth ref": { "us-gaap-OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax", "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax", "crdr": "credit", "calculation": { "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss", "parentTag": "us-gaap-ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 3.0 } } , "presentation": { "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss", "lang": { "en-us": { "role": { "terseLabel": "Change in unrealized losses on available for-sale securities", "label": "OCI, Debt Securities, Available for Sale, Gain (Loss), after Adjustment and Tax", "documentation": "Amount, after tax and adjustment, of unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available for-sale) and unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available for sale." } } } , "auth ref": { "r133", "r134", "r135", "r543" } } , "us-gaap-OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax", "crdr": "credit", "calculation": { "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss", "parentTag": "us-gaap-ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 2.0 } } , "presentation": { "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss", "lang": { "en-us": { "role": { "terseLabel": "Foreign currency translation adjustments", "label": "Foreign currency translation adjustments", "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term investment nature." } } } , "auth ref": { "r2", "r543" } } , "us-gaap-OtherLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets", "parentTag": "us-gaap-LiabilitiesCurrent", "weight": 1.0, "order": 2.0 } } , "presentation": { "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets", "lang": { "en-us": { "role": { "terseLabel": "Other liabilities", "label": "Other Liabilities, Current", "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer." } } } , "auth ref": { "r49", "r701" } } , "us-gaap-OtherNonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss", "parentTag": "us-gaap-NonoperatingIncomeExpense", "weight": 1.0, "order": 1.0 } } , "presentation": { "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss", "lang": { "en-us": { "role": { "terseLabel": "Other, net", "label
```


Items": {} }, "auth_ref": { "r764" } }, "us-gaap_PaymentsToAcquireInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquireInvestments", "crdr": "credit", "calculation": { "http://www.arrowheadresearch.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 2.0 } }, "presentation": { "http://www.arrowheadresearch.com/role/ConsolidatedStatementsOfCashFlows": { "lang": { "en-us": { "role": { "negatedLabel": "Purchases of investments", "label": "Payments to Acquire Investments", "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period." } } }, "auth_ref": { "r73" } }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "crdr": "credit", "calculation": { "http://www.arrowheadresearch.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0, "order": 1.0 } }, "presentation": { "http://www.arrowheadresearch.com/role/ConsolidatedStatementsOfCashFlows": { "lang": { "en-us": { "role": { "negatedLabel": "Purchases of property and equipment", "label": "Payments to Acquire Property, Plant, and Equipment", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": { "r74" } }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Peer Group Issuers, Footnote", "label": "Peer Group Issuers, Footnote [Text Block]", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": { "r774" } }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Peer Group Total Shareholder Return Amount", "label": "Peer Group Total Shareholder Return Amount", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": { "r774" } }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "PEO Actually Paid Compensation Amount", "label": "PEO Actually Paid Compensation Amount", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": { "r783" } }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "PEO Name", "label": "PEO Name", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": { "r776" } }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "PEO Total Compensation Amount", "label": "PEO Total Compensation Amount", "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets." } } }, "auth_ref": { "r765" } }, "arwr_PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock": { "xbrltype": "percentItemType", "nsuri": "http://www.arrowheadresearch.com/20240630", "localname": "PercentageOfCommissionOnAggregateGrossProceedsFromSaleOfCommonStock", "presentation": { "http://www.arrowheadresearch.com/role/StockholdersEquityDetails": { "lang": { "en-us": { "role": { "terseLabel": "Percentage of commission to sales agent", "label": "Percentage of Commission On Aggregate Gross Proceeds From Sale Of Common Stock", "documentation": "Percentage of commission on aggregate gross proceeds from sale of common stock." } } }, "auth_ref": { "r777" } }, "arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales": { "xbrltype": "percentItemType", "nsuri": "http://www.arrowheadresearch.com/20240630", "localname": "PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales", "presentation": { "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails": { "lang": { "en-us": { "role": { "terseLabel": "Percentage of eligible to receive tiered royalties on net sales", "label": "Percentage Of Eligible To Receive Tiered Royalties On Net Sales", "documentation": "Percentage of eligible to receive tiered royalties on net sales." } } }, "auth_ref": { "r778" } }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameAxis", "presentation": { "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Plan Name", "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": { "r876", "r877", "r878", "r879", "r880", "r881", "r882", "r883", "r884", "r885", "r886", "r887", "r888", "r889", "r890", "r891", "r892", "r893", "r894", "r895", "r896", "r897", "r898", "r899", "r900", "r901" } }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameDomain", "presentation": { "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Plan Name", "label": "Plan Name [Domain]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": { "r876", "r877", "r878", "r879", "r880", "r881", "r882", "r883", "r884", "r885", "r886", "r887", "r888", "r889", "r890", "r891", "r892", "r893", "r894", "r895", "r896", "r897", "r898", "r899", "r900", "r901" } }, "ecd_PnsnAdjsPrvSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrvSvcCstMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Pension Adjustments Prior Service Cost", "label": "Pension Adjustments Prior Service Cost [Member]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": { "r767" } }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Pension Adjustments Service Cost", "label": "Pension Adjustments Service Cost [Member]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": { "r811" } }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/PvpDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Pension Benefits Adjustments, Footnote", "label": "Pension Benefits Adjustments, Footnote [Text Block]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": { "r766" } }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": { "http://www.arrowheadresearch.com/role/StockholdersEquityDetails": { "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, par value (in dollars per share)", "label": "Preferred Stock, Par or Stated Value Per Share", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": { "r57", "r300" } }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": { "http://www.arrowheadresearch.com/role/StockholdersEquityDetails": { "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares authorized (in shares)", "label": "Preferred Stock, Shares Authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": { "r57", "r582" } }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesIssued", "presentation": { "http://www.arrowheadresearch.com/role/StockholdersEquityDetails": { "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares issued (in shares)", "label": "Preferred Stock, Shares Issued", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } } }, "auth_ref": { "r57", "r300" } }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesOutstanding", "presentation": { "http://www.arrowheadresearch.com/role/StockholdersEquityDetails": { "lang": { "en-us": { "role": { "terseLabel": "Preferred stock, shares outstanding (in shares)", "label": "Preferred Stock, Shares Outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock for preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": { "r57", "r582", "r601", "r666", "r676" } }, "us-gaap_PrepaidExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidExpenseCurrent", "crdr": "debit", "calculation": { "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": { "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets": { "lang": { "en-us": { "role": { "terseLabel": "Prepaid expenses", "label": "Prepaid Expense, Current", "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": { "r130", "r242", "r243", "r656" } }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "calculation": { "http://www.arrowheadresearch.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails": { "lang": { "en-us": { "role": { "terseLabel": "Proceeds from the issuance of common stock, net of offering costs", "label": "Proceeds from Issuance of Common Stock", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": { "r3" } }, "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments", "crdr": "debit", "calculation": { "http://www.arrowheadresearch.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": { "http://www.arrowheadresearch.com/role/ConsolidatedStatementsOfCashFlows": { "lang": { "en-us": { "role": { "terseLabel": "Proceeds from sales and maturities of investments", "label": "Proceeds from Sale, Maturity and Collection of Investments", "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period." } } }, "auth_ref": { "r16" } }, "arwr_ProceedsFromSaleOfFutureRoyalties": { "xbrltype": "monetaryItemType", "nsuri": "http://www.arrowheadresearch.com/20240630", "localname": "ProceedsFromSaleOfFutureRoyalties", "crdr": "debit", "calculation": { "http://www.arrowheadresearch.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.arrowheadresearch.com/role/ConsolidatedStatementsOfCashFlows": { "lang": { "en-us": { "role": { "terseLabel": "Proceeds from the sale of future royalties", "label": "Proceeds from Sale of Future Royalties", "documentation": "Proceeds from Sale of Future Royalties" } } }, "auth_ref": { "r1" } }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "calculation": { "http://www.arrowheadresearch.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.arrowheadresearch.com/role/ConsolidatedStatementsOfCashFlows": { "lang": { "en-us": { "role": { "terseLabel": "Proceeds from the exercises of stock options", "label": "Proceeds from Stock Options Exercised", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth_ref": { "r3", "r11" } }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://www.arrowheadresearch.com/role/ConsolidatedStatementsOfOperationsandComprehensiveLoss": { "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.arrowheadresearch.com/role/ConsolidatedStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 11.0 } }, "presentation": { "http://www.arrowheadresearch.com/role/ConsolidatedStatementsOfOperationsandComprehensiveLoss": { "lang": { "en-us": { "role": { "totalLabel": "Net loss including noncontrolling interest", "label": "Net loss (loss)", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": { "r117", "r136", "r138", "r145", "r150", "r157", "r163", "r166", "r167", "r230", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r280", "r281", "r379", "r382", "r384", "r387", "r388", "r401", "r424", "r527", "r540", "r567", "r603", "r619", "r620", "r687", "r688", "r725", "r826", "r869" } }, "us-gaap_PropertyPlantAndEquipmentByTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentByTypeAxis", "presentation": { "http://www.arrowheadresearch.com/role/BalanceSheetAccountsSummaryofPropertyandEquipmentDetails": { "lang": { "en-us": { "role": { "terseLabel": "Property, plant and equipment, gross", "label": "Property, Plant and Equipment, Gross", "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } } }, "auth_ref": { "r91", "r121", "r538" } }, "us-gaap_PropertyPlantAndEquipmentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentLineItems", "presentation": {

"http://www.arrowheadresearch.com/role/BalanceSheetAccountsSummaryofPropertyandEquipmentDetails" }, {"lang": "en-us", "role": "terseLabel", "Property, Plant and Equipment [Line Items]", "label": "Property, Plant and Equipment [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, {"auth_ref": "r449" }, {"us-gaap_PropertyPlantAndEquipmentNet", {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentNet", "crdr": "debit", "calculation": "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets", {"parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 } }, {"http://www.arrowheadresearch.com/role/BalanceSheetAccountsSummaryofPropertyandEquipmentDetails", {"parentTag": null, "weight": null, "order": null, "root": true } }, {"presentation": "http://www.arrowheadresearch.com/role/BalanceSheetAccountsSummaryofPropertyandEquipmentDetails", {"http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets" }, {"lang": "en-us", "role": "terseLabel", "Property, plant and equipment, net", "totalLabel", "Property, plant and equipment, net", "label": "Property, Plant and Equipment, Net", "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } }, {"auth_ref": "r6", "r449", "r528", "r538", "r701" }, {"us-gaap_PropertyPlantAndEquipmentTextBlock", {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTextBlock", "presentation": "http://www.arrowheadresearch.com/role/BalanceSheetAccountsTables" }, {"lang": "en-us", "role": "terseLabel", "Summary of Property and Equipment", "label": "Property, Plant and Equipment [Table Text Block]", "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated depreciation." } }, {"auth_ref": "r6" }, {"us-gaap_PropertyPlantAndEquipmentTransfersAndChanges", {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTransfersAndChanges", "crdr": "debit", "presentation": "http://www.arrowheadresearch.com/role/BalanceSheetAccountsSummaryofPropertyandEquipmentDetails" }, {"lang": "en-us", "role": "terseLabel", "Property, plant and equipment, reclassification", "label": "Property, Plant and Equipment, Transfers and Changes", "documentation": "Amount of increase (decrease) of physical assets used in the normal conduct of business and not intended for resale, from reclassification, impairment, donation, or changes classified as other. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures." } }, {"auth_ref": "r26" }, {"us-gaap_PropertyPlantAndEquipmentTypeDomain", {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentTypeDomain", "presentation": "http://www.arrowheadresearch.com/role/BalanceSheetAccountsSummaryofPropertyandEquipmentDetails", {"http://www.arrowheadresearch.com/role/CommitmentsandContingenciesNarrativeDetails", {"http://www.arrowheadresearch.com/role/LeasesNarrativeDetails" }, {"en-us", "role": "terseLabel", "Long-Lived Tangible Asset [Domain]", "label": "Long-Lived Tangible Asset [Domain]", "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, {"auth_ref": "r81", "r449" }, {"us-gaap_PropertyPlantAndEquipmentUsefulLife", {"xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PropertyPlantAndEquipmentUsefulLife", "presentation": "http://www.arrowheadresearch.com/role/BalanceSheetAccountsSummaryofPropertyandEquipmentDetails" }, {"lang": "en-us", "role": "terseLabel", "Useful life", "label": "Property, Plant and Equipment, Useful Life", "documentation": "Useful life of long-lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDnFnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment." } } }, {"auth_ref": "H", "ecd_PvpTable", {"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": "http://xbrl.sec.gov/ecd/PvpDisclosure" }, {"lang": "en-us", "role": "terseLabel", "Pay vs Performance Disclosure", "label": "Pay vs Performance Disclosure [Table]", "auth_ref": "r764" }, {"ecd_PvpTableTextBlock", {"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": "http://xbrl.sec.gov/ecd/PvpDisclosure" }, {"lang": "en-us", "role": "terseLabel", "Pay vs Performance Disclosure, Table", "label": "Pay vs Performance [Table Text Block]", "auth_ref": "r764" }, {"srt_RangeAxis", {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails", {"http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails", {"http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails", {"http://www.arrowheadresearch.com/role/CommitmentsandContingenciesNarrativeDetails", {"http://www.arrowheadresearch.com/role/LeasesNarrativeDetails", {"http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleoffutureRoyaltiesNarrativeDetails", {"http://www.arrowheadresearch.com/role/StockholdersEquityDetails" }, {"lang": "en-us", "role": "terseLabel", "Statistical Measurement [Axis]", "label": "Statistical Measurement [Axis]", "auth_ref": "r268", "r269", "r270", "r271", "r322", "r329", "r357", "r358", "r359", "r367", "r407", "r462", "r471", "r488", "r549", "r551", "r559", "r573", "r574", "r626", "r628", "r630", "r631", "r633", "r650", "r651", "r664", "r672", "r683", "r692", "r693", "r697", "r698", "r712", "r718", "r865", "r871", "r911", "r925", "r926", "r927", "r928", "r929" }, {"srt_RangeMember", {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails", {"http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails", {"http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails", {"http://www.arrowheadresearch.com/role/CommitmentsandContingenciesNarrativeDetails", {"http://www.arrowheadresearch.com/role/LeasesNarrativeDetails", {"http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleoffutureRoyaltiesNarrativeDetails", {"http://www.arrowheadresearch.com/role/StockholdersEquityDetails" }, {"lang": "en-us", "role": "terseLabel", "Statistical Measurement [Domain]", "label": "Statistical Measurement [Domain]", "auth_ref": "r268", "r269", "r270", "r271", "r322", "r329", "r357", "r358", "r359", "r367", "r407", "r462", "r471", "r488", "r549", "r551", "r559", "r573", "r574", "r626", "r628", "r630", "r631", "r633", "r650", "r651", "r664", "r672", "r683", "r692", "r693", "r697", "r698", "r712", "r718", "r865", "r871", "r911", "r925", "r926", "r927", "r928", "r929" }, {"us-gaap_RealizedInvestmentGainsLosses", {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RealizedInvestmentGainsLosses", "crdr": "credit", "calculation": "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows", {"parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 12.0 } }, {"presentation": "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows" }, {"lang": "en-us", "role": "negatedTerseLabel", "Realized gain on investments", "label": "Realized Investment Gains (Losses)", "documentation": "Amount of realized gain (loss) on investment." } }, {"auth_ref": "r547" }, {"ecd_RecoveryOfErrCompDisclosureLineItems", {"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": "en-us", "role": "label", "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]", "auth_ref": "r732", "r742", "r752", "r784" }, {"srt_RepurchaseAgreementCounterpartyNameDomain", {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RepurchaseAgreementCounterpartyNameDomain", "presentation": "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails", {"http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails", {"http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails", {"http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails", {"http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsVisirnaTherapeuticsIncDetails", {"http://www.arrowheadresearch.com/role/LeasesNarrativeDetails", {"http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleoffutureRoyaltiesNarrativeDetails", {"http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetails" }, {"lang": "en-us", "role": "terseLabel", "Counterparty Name [Domain]", "label": "Counterparty Name [Domain]", "auth_ref": "r151", "r152", "r285", "r302", "r452", "r472", "r529", "r658", "r659" }, {"us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost", {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost", "crdr": "debit", "calculation": "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss", {"parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } }, {"presentation": "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" }, {"lang": "en-us", "role": "terseLabel", "Research and development", "label": "Research and Development Expense (Excluding Acquired in Process Cost)", "documentation": "Amount of expense for research and development. Excludes cost for computer software product to be sold, leased, or otherwise marketed, writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both, and write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, {"auth_ref": "r903" }, {"us-gaap_ResearchAndDevelopmentExpenseMember", {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": "http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails", {"http://www.arrowheadresearch.com/role/StockBasedCompensationExpensesIncludedinOperatingExpensesDetails" }, {"lang": "en-us", "role": "terseLabel", "Research and development", "label": "Research and Development Expense [Member]", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, {"auth_ref": "H", "arwr_ResearchEquipmentMember", {"xbrltype": "domainItemType", "nsuri": "http://www.arrowheadresearch.com/20240630", "localname": "ResearchEquipmentMember", "presentation": "http://www.arrowheadresearch.com/role/BalanceSheetAccountsSummaryofPropertyandEquipmentDetails" }, {"lang": "en-us", "role": "terseLabel", "Research equipment", "label": "Research Equipment [Member]", "documentation": "Research Equipment" } } }, {"auth_ref": "H", "arwr_ResearchFacilityInMadisonMember", {"xbrltype": "domainItemType", "nsuri": "http://www.arrowheadresearch.com/20240630", "localname": "ResearchFacilityInMadisonMember", "presentation": "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails" }, {"lang": "en-us", "role": "terseLabel", "Research facility in Madison", "label": "Research Facility In Madison [Member]", "documentation": "Research facility in Madison." } } }, {"auth_ref": "H", "arwr_ResearchFacilityInSanDiegoMember", {"xbrltype": "domainItemType", "nsuri": "http://www.arrowheadresearch.com/20240630", "localname": "ResearchFacilityInSanDiegoMember", "presentation": "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails" }, {"lang": "en-us", "role": "terseLabel", "Research facility in San Diego", "label": "Research Facility In San Diego [Member]", "documentation": "Research Facility in San Diego." } } }, {"auth_ref": "H", "ecd_RestatementDateAxis", {"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" }, {"lang": "en-us", "role": "terseLabel", "Restatement Determination Date", "label": "Restatement Determination Date [Axis]", "auth_ref": "r733", "r743", "r753", "r785" }, {"ecd_RestatementDeterminationDate", {"xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" }, {"lang": "en-us", "role": "terseLabel", "Restatement Determination Date", "label": "Restatement Determination Date" } } }, {"auth_ref": "r734", "r744", "r754", "r786" }, {"ecd_RestatementDoesNotRequireRecoveryTextBlock", {"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" }, {"lang": "en-us", "role": "terseLabel", "Restatement does not require recovery", "label": "Restatement Does Not Require Recovery [Text Block]", "auth_ref": "r741", "r751", "r761", "r793" }, {"us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue", {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "presentation": "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetails" }, {"lang": "en-us", "role": "terseLabel", "Restricted cash", "label": "Restricted Cash and Cash Equivalents, Current", "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, {"auth_ref": "r17", "r120", "r148" }, {"us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember", "presentation": "http://www.arrowheadresearch.com/role/FairValueMeasurementsFairValueMeasurementsforAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails" }, {"lang": "en-us", "role": "terseLabel", "Cash and Cash Equivalents [Domain]", "label": "Cash and Cash Equivalents [Domain]", "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, {"auth_ref": "r120" }, {"us-gaap_RestrictedStockUnitsRSUMember", {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RestrictedStockUnitsRSUMember", "presentation": "http://www.arrowheadresearch.com/role/RestrictedStockUnitsRSUMember", "presentation": "http://www.arrowheadresearch.com/role/RestrictedStockUnitsRSUMember" } }

"http://www.arrowheadresearch.com/role/NetLossPerShareAntidilutiveDetails", "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails", "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryOfGrantedandOutstandingSharesDetails", "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryOfRSUsActivityDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "lang": "en-us", "role": "Restricted stock units", "label": "Restricted Stock Units (RSUs) [Member]", "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.", "auth_ref": [], "us-gaap_RetainedEarningsAccumulatedDeficit": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets", "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0}, "presentation": "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets", "lang": "en-us", "role": "Retained Earnings (Accumulated Deficit)", "label": "Retained Earnings (Accumulated Deficit)", "documentation": "Amount of accumulated undistributed earnings (deficit).", "auth_ref": ["r60", "r87", "r534", "r556", "r558", "r565", "r583", "r701"], "us-gaap_RetainedEarningsMember": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": "http://www.arrowheadresearch.com/role/ConsolidatedStatementsOfStockholdersEquity", "lang": "en-us", "role": "Retained Earnings (Accumulated Deficit)", "label": "Retained Earnings [Member]", "documentation": "Accumulated undistributed earnings (deficit).", "auth_ref": ["r115", "r154", "r155", "r156", "r158", "r163", "r165", "r167", "r231", "r232", "r261", "r373", "r374", "r376", "r377", "r378", "r380", "r381", "r382", "r391", "r393", "r394", "r396", "r399", "r433", "r436", "r437", "r553", "r555", "r558", "r966"], "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "debit", "presentation": "http://www.arrowheadresearch.com/role/ConsolidatedStatementsOfOperationsandComprehensiveLoss", "parentTag": "us-gaap_OperatingIncomeLoss", "weight": 1.0, "order": 1.0}, "presentation": "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsRevenueDetails", "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsVisirnaTherapeuticsIncDetails", "http://www.arrowheadresearch.com/role/ConsolidatedStatementsOfOperationsandComprehensiveLoss", "lang": "en-us", "role": "Revenue", "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.", "auth_ref": ["r105", "r106", "r180", "r184", "r185", "r189", "r191", "r192", "r193", "r195", "r319", "r320", "r490"], "arwr_RightOfUseAssetAdjustmentInExchangeForOperatingLeaseLiability": {"xbrltype": "monetaryItemType", "nsuri": "http://www.arrowheadresearch.com/20240630", "localname": "RightOfUseAssetAdjustmentInExchangeForOperatingLeaseLiability", "crdr": "debit", "presentation": "http://www.arrowheadresearch.com/role/LeasesSupplementalCashFlowandOtherInformationRelatedtoLeasesDetails", "lang": "en-us", "role": "Right-of-use assets adjusted in exchange for new/amended operating lease liabilities", "label": "Right-Of-Use Asset Adjustment In Exchange For Operating Lease Liability", "documentation": "Right-Of-Use Asset Adjustment In Exchange For Operating Lease Liability", "auth_ref": [], "arwr_RoyaltiesLiabilityNoncurrent": {"xbrltype": "monetaryItemType", "nsuri": "http://www.arrowheadresearch.com/20240630", "localname": "RoyaltiesLiabilityNoncurrent", "crdr": "credit", "calculation": "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets", "parentTag": "us-gaap_LiabilitiesNoncurrent", "weight": 1.0, "order": 1.0}, "presentation": "http://www.arrowheadresearch.com/role/ConsolidatedBalanceSheets", "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesActivityDetails", "lang": "en-us", "role": "Liability related to the sale of future royalties", "periodStartLabel": "Carrying value as of June 30, 2024", "label": "Royalties, Liability, Noncurrent", "documentation": "Royalties, Liability, Noncurrent", "auth_ref": [], "arwr_RoyaltyPaymentThreshold": {"xbrltype": "monetaryItemType", "nsuri": "http://www.arrowheadresearch.com/20240630", "localname": "RoyaltyPaymentThreshold", "crdr": "credit", "presentation": "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails", "lang": "en-us", "role": "Royalty payment threshold", "label": "Royalty Payment Threshold", "documentation": "Royalty Payment Threshold", "auth_ref": [], "arwr_RoyaltyPharmaAgreementMember": {"xbrltype": "domainItemType", "nsuri": "http://www.arrowheadresearch.com/20240630", "localname": "RoyaltyPharmaAgreementMember", "presentation": "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails", "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetails", "lang": "en-us", "role": "Royalty Pharma Agreement", "label": "Royalty Pharma Agreement [Member]", "documentation": "Royalty Pharma Agreement", "auth_ref": [], "ecd_Rule10b51ArrAdoptedFlag": {"xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "lang": "en-us", "role": "Rule 10b5-1 Arrangement Adopted", "label": "Rule 10b5-1 Arrangement Adopted [Flag]", "auth_ref": ["r802"], "ecd_Rule10b51ArrTrmndFlag": {"xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmndFlag", "presentation": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "lang": "en-us", "role": "Rule 10b5-1 Arrangement Terminated", "label": "Rule 10b5-1 Arrangement Terminated [Flag]", "auth_ref": ["r802"], "arwr_SaleOfStockAggregatePurchasePrice": {"xbrltype": "monetaryItemType", "nsuri": "http://www.arrowheadresearch.com/20240630", "localname": "SaleOfStockAggregatePurchasePrice", "crdr": "debit", "presentation": "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetails", "http://www.arrowheadresearch.com/role/StockholdersEquityDetails", "lang": "en-us", "role": "Aggregate purchase price paid by investors", "label": "Sale Of Stock, Aggregate Purchase Price", "documentation": "Sale Of Stock, Aggregate Purchase Price", "auth_ref": [], "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {"xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockConsiderationReceivedOnTransaction", "crdr": "debit", "presentation": "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetails", "http://www.arrowheadresearch.com/role/StockholdersEquityDetails", "lang": "en-us", "role": "Net proceeds", "label": "Sale of Stock, Consideration Received on Transaction", "documentation": "Cash received on stock transaction after deduction of issuance costs.", "auth_ref": [], "us-gaap_SaleOfStockNameOfTransactionDomain": {"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetails", "http://www.arrowheadresearch.com/role/StockholdersEquityDetails", "lang": "en-us", "role": "Sale of Stock [Domain]", "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "auth_ref": [], "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {"xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNumberOfSharesIssuedInTransaction", "presentation": "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetails", "http://www.arrowheadresearch.com/role/StockholdersEquityDetails", "lang": "en-us", "role": "Shares of common stock issued (in shares)", "label": "Sale of Stock, Number of Shares Issued in Transaction", "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.", "auth_ref": [], "us-gaap_SaleOfStockPricePerShare": {"xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockPricePerShare", "presentation": "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetails", "http://www.arrowheadresearch.com/role/StockholdersEquityDetails", "lang": "en-us", "role": "Common stock offering price (in dollars per share)", "label": "Sale of Stock, Price Per Share", "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.", "auth_ref": [], "arwr_SalesRelatedMilestonePayments": {"xbrltype": "monetaryItemType", "nsuri": "http://www.arrowheadresearch.com/20240630", "localname": "SalesRelatedMilestonePayments", "crdr": "debit", "presentation": "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails", "lang": "en-us", "role": "Sales-related milestone payments", "label": "Sales Related Milestone Payments", "documentation": "Sales-related milestone payments.", "auth_ref": [], "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "presentation": "http://www.arrowheadresearch.com/role/BalanceSheetAccountsTables", "lang": "en-us", "role": "Schedule of Accrued Expenses", "label": "Schedule of Accrued Liabilities [Table Text Block]", "documentation": "Tabular disclosure of the components of accrued liabilities.", "auth_ref": [], "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": "http://www.arrowheadresearch.com/role/NetLossPerShareAntidilutiveDetails", "lang": "en-us", "role": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]", "label": "Antidilutive Security, Excluded EPS Calculation [Table]", "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS.", "auth_ref": ["r22"], "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTableTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTableTextBlock", "presentation": "http://www.arrowheadresearch.com/role/NetLossPerShareTables", "lang": "en-us", "role": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share", "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.", "auth_ref": ["r22"], "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable", "presentation": "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails", "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails", "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails", "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails", "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsVisirnaTherapeuticsIncDetails", "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesNarrativeDetails", "lang": "en-us", "role": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]", "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.", "auth_ref": ["r383"], "arwr_ScheduleOfCurrentProductsTableTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://www.arrowheadresearch.com/20240630", "localname": "ScheduleOfCurrentProductsTableTextBlock", "presentation": "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesTables", "lang": "en-us", "role": "Schedule of Company's Current Pipeline", "label": "Schedule of Current Products [Table Text Block]", "documentation": "Schedule of Current Products", "auth_ref": [], "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": "http://www.arrowheadresearch.com/role/NetLossPerShareTables", "lang": "en-us", "role": "Schedule of Earnings Per Share, Basic and Diluted", "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.", "auth_ref": ["r836"], "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable", "presentation": "http://www.arrowheadresearch.com/role/StockBasedCompensationExpensesIncludedInOperatingExpensesDetails", "lang": "en-us", "role": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table]", "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.", "auth_ref": ["r36"], "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock": {"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTableTextBlock", "presentation": "http://www.arrowheadresearch.com/role/StockBasedCompensationTables", "lang": "en-us", "role": "Share-Based Payment Arrangement, Expensed", "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not

limited to, corresponding line item in financial statement." } } }, "auth_ref": { "r36" } } }, "us-gaap_ScheduleOffFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOffFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "presentation": { "http://www.arrowheadresearch.com/role/FairValueMeasurementsTables": { "lang": { "en-us": { "role": { "terseLabel": "Fair Value Measurements for Assets and Liabilities Measured at Fair Value on Recurring Basis", "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3). } } }, "auth_ref": { "r908", "r909" } } }, "us-gaap_ScheduleOffFiniteLivedIntangibleAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOffFiniteLivedIntangibleAssetsTable", "presentation": { "http://www.arrowheadresearch.com/role/IntangibleAssetsScheduleoffIntangibleAssetsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Finite Lived Intangible Assets [Table]", "label": "Intangible Asset, Finite Lived [Table]", "documentation": "Disclosure of information about finite-lived intangible asset. Excludes indefinite-lived intangible asset." } } }, "auth_ref": { "r246", "r253", "r256", "r257", "r259", "r491", "r653", "r666" } } }, "us-gaap_ScheduleOffFiniteLivedIntangibleAssetsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOffFiniteLivedIntangibleAssetsTableTextBlock", "presentation": { "http://www.arrowheadresearch.com/role/IntangibleAssetsTables": { "lang": { "en-us": { "role": { "terseLabel": "Schedule of Finite Lived Intangible Assets", "label": "Schedule of Finite Lived Intangible Assets [Table Text Block]", "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment." } } }, "auth_ref": { "r666", "r855" } } }, "arwr_ScheduleOffHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://www.arrowheadresearch.com/20240630", "localname": "ScheduleOffHeldToMaturitySecuritiesAndMarketableSecuritiesLineItems", "presentation": { "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Held To Maturity Securities And Marketable Securities [Line Items]", "label": "Schedule Of Held To Maturity Securities And Marketable Securities [Line Items]", "documentation": "Schedule of held to maturity securities and marketable securities." } } }, "auth_ref": { "r11" } }, "arwr_ScheduleOffHeldToMaturitySecuritiesAndMarketableSecuritiesTable": { "xbrltype": "stringItemType", "nsuri": "http://www.arrowheadresearch.com/20240630", "localname": "ScheduleOffHeldToMaturitySecuritiesAndMarketableSecuritiesTable", "presentation": { "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Held To Maturity Securities And Marketable Securities [Table]", "label": "Schedule Of Held To Maturity Securities And Marketable Securities [Table]", "documentation": "Schedule of held to maturity securities and marketable securities." } } }, "auth_ref": { "r11" } }, "arwr_ScheduleOffLiabilityRelatedToTheSaleOfFutureRoyaltiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://www.arrowheadresearch.com/20240630", "localname": "ScheduleOffLiabilityRelatedToTheSaleOfFutureRoyaltiesTableTextBlock", "presentation": { "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleofFutureRoyaltiesTables": { "lang": { "en-us": { "role": { "terseLabel": "Schedule of Liability Related to the Sale of Future Royalties", "label": "Schedule Of Liability Related To The Sale Of Future Royalties [Table Text Block]", "documentation": "Schedule Of Liability Related To The Sale Of Future Royalties" } } }, "auth_ref": { "r11" } }, "us-gaap_ScheduleOfOperatingLeasedAssetsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfOperatingLeasedAssetsTable", "presentation": { "http://www.arrowheadresearch.com/role/LeasesComponentsofLeaseAssetsandLiabilitiesDetails": { "lang": { "en-us": { "role": { "terseLabel": "Schedule of Operating Leased Assets [Table]", "label": "Schedule of Operating Leased Assets [Table]", "documentation": "Disclosure of information about long-lived, depreciable assets that are subject to operating lease agreements and are used in the normal conduct of business to produce goods and services. Examples may include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software." } } }, "auth_ref": { "r11" } }, "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfPropertyPlantAndEquipmentTable", "presentation": { "http://www.arrowheadresearch.com/role/BalanceSheetAccountsSummaryofPropertyandEquipmentDetails": { "lang": { "en-us": { "role": { "terseLabel": "Property, Plant and Equipment [Table]", "label": "Property, Plant and Equipment [Table]", "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated depreciation." } } }, "auth_ref": { "r6", "r449" } } }, "us-gaap_ScheduleOfShareBasedCompensationActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationActivityTableTextBlock", "presentation": { "http://www.arrowheadresearch.com/role/StockBasedCompensationTables": { "lang": { "en-us": { "role": { "terseLabel": "Summary of Awards Outstanding", "label": "Share-Based Payment Arrangement, Activity [Table Text Block]", "documentation": "Tabular disclosure of activity for award under share-based payment arrangement. Includes, but is not limited to, outstanding award at beginning and end of year, granted, exercised, forfeited, and weighted-average grant date fair value." } } }, "auth_ref": { "r9", "r10", "r89" } } }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": { "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails": { "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails", "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetails": { "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]", "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": { "r331", "r333", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360" } } }, "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock", "presentation": { "http://www.arrowheadresearch.com/role/StockBasedCompensationTables": { "lang": { "en-us": { "role": { "terseLabel": "Summary of Share Activity Related to RSUs", "label": "Share-Based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]", "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year." } } }, "auth_ref": { "r88" } } }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": { "http://www.arrowheadresearch.com/role/StockBasedCompensationTables": { "lang": { "en-us": { "role": { "terseLabel": "Summarized Information about Stock Options", "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": { "r9", "r10", "r89" } } }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": { "http://www.arrowheadresearch.com/role/StockBasedCompensationTables": { "lang": { "en-us": { "role": { "terseLabel": "Assumptions Used to Value Stock Options", "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": { "r91" } } }, "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockByClassTable", "presentation": { "http://www.arrowheadresearch.com/role/StockholdersEquityDetails": { "lang": { "en-us": { "role": { "terseLabel": "Schedule Of Stock By Class [Table]", "label": "Stock, Class of Stock [Table]", "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks." } } }, "auth_ref": { "r29", "r30", "r31", "r32", "r33", "r34", "r83", "r85", "r86", "r87", "r126", "r127", "r128", "r182", "r300", "r301", "r302", "r304", "r307", "r312", "r314", "r561", "r562", "r563", "r564", "r672", "r813", "r829" } } }, "us-gaap_ScheduleOfStockByClassTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockByClassTextBlock", "presentation": { "http://www.arrowheadresearch.com/role/StockholdersEquityTables": { "lang": { "en-us": { "role": { "terseLabel": "Schedule of Shares of Common Stock and Preferred Stock", "label": "Schedule of Stock by Class [Table Text Block]", "documentation": "Tabular disclosure of an entity's stock, including par or stated value per share, number and dollar amount of share subscriptions, shares authorized, shares issued, shares outstanding, number and dollar amount of shares held in an employee trust, dividend per share, total dividends, share conversion features, par value plus additional paid in capital, the value of treasury stock and other information necessary to a fair presentation, and EPS information. Stock by class includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. Includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity. If more than one issue is outstanding, state the title of each issue and the corresponding dollar amount, dollar amount of any shares subscribed but unissued and the deduction of subscriptions receivable there from, number of shares authorized, issued, and outstanding." } } }, "auth_ref": { "r13", "r28", "r29", "r30", "r31", "r32", "r33", "r34", "r57", "r58", "r85", "r86", "r87" } } }, "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock", "presentation": { "http://www.arrowheadresearch.com/role/IntangibleAssetsTables": { "lang": { "en-us": { "role": { "terseLabel": "Schedule of Intangible Assets Future Amortization Expense", "label": "Schedule of Finite Lived Intangible Assets, Future Amortization Expense [Table Text Block]", "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets." } } }, "auth_ref": { "r666", "r857" } } }, "us-gaap_SecuredDebtMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SecuredDebtMember", "presentation": { "http://www.arrowheadresearch.com/role/SubsequentEventsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Secured Debt", "label": "Secured Debt [Member]", "documentation": "Collateralized debt obligation backed by, for example, but not limited to, pledge, mortgage or other lien on the entity's assets." } } }, "auth_ref": { "r11" } }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": { "http://www.arrowheadresearch.com/role/Cover": { "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": { "r727" } } }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": { "http://www.arrowheadresearch.com/role/Cover": { "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": { "r729" } } }, "srt_SegmentGeographicalDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "SegmentGeographicalDomain", "presentation": { "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesNarrativeDetails": { "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Geographical [Domain]", "label": "Geographical [Domain]", "documentation": "Geographical [Domain]" } } }, "auth_ref": { "r193", "r194", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r523", "r524", "r525", "r526", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r536", "r537", "r538", "r539", "r540", "r541", "r542", "r543", "r544", "r545", "r546", "r547", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r560", "r561", "r562", "r563", "r564" } } }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "documentation": "debit", "calculation": { "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": { "http://www.arrowheadresearch.com/role/ConsolidatedStatementsofCashFlows": { "lang": { "en-us": { "role": { "terseLabel": "Stock-based compensation", "label": "Share-Based Payment Arrangement, Noncash Expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": { "r4" } } }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod", "presentation": { "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetails": { "lang": { "en-us": { "role": { "negatedLabel": "Forfeited (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period." } } }, "auth_ref": {

"r351"}}, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue", "presentation": "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetails", "lang": { "en-us": { "role": { "terseLabel": "Forfeited (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value", "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event." } } }, "auth_ref": { "r351"}}, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod", "presentation": "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetails", "lang": { "en-us": { "role": { "verboseLabel": "Granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period", "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": { "r349"}}, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetails", "lang": { "en-us": { "role": { "terseLabel": "Granted (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)." } } }, "auth_ref": { "r349"}}, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber", "calculation": { "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails": { "parentTag": "arwt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding", "weight": 1.0, "order": 2.0 } }, "presentation": "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails", "lang": { "en-us": { "role": { "terseLabel": "Share-based payment award (in shares)", "periodStartLabel": "Beginning of period (in shares)", "periodEndLabel": "End of period (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number", "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date." } } }, "auth_ref": { "r346", "r347"}}, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward", "presentation": { "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetails": { "lang": { "en-us": { "role": { "terseLabel": "Number of RSUs", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares {Roll Forward}", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": { "r346", "r347"}}, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue", "presentation": { "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetails": { "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance (in dollars per share)", "periodEndLabel": "Ending balance (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value", "documentation": "Per share or unit weighted average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options." } } }, "auth_ref": { "r346", "r347"}}, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward", "presentation": { "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetails": { "lang": { "en-us": { "role": { "terseLabel": "Weighted Average Grant Date Fair Value Per Share", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value {Abstract}" } } }, "auth_ref": { "r346", "r347"}}, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod", "presentation": { "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetails": { "lang": { "en-us": { "role": { "negatedLabel": "Vested (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period", "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period." } } }, "auth_ref": { "r350"}}, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue", "presentation": { "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetails": { "lang": { "en-us": { "role": { "terseLabel": "Vested (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement." } } }, "auth_ref": { "r350"}}, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": { "http://www.arrowheadresearch.com/role/StockBasedCompensationAssumptionsUsedtoValueStockOptionsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Expected dividend yield", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": { "r358"}}, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": { "http://www.arrowheadresearch.com/role/StockBasedCompensationAssumptionsUsedtoValueStockOptionsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Expected volatility", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": { "r357"}}, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": { "http://www.arrowheadresearch.com/role/StockBasedCompensationAssumptionsUsedtoValueStockOptionsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Risk-free interest rate", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": { "r359"}}, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": { "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails", "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails", "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofRSUsActivityDetails": { "lang": { "en-us": { "role": { "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award {Line Items}", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award {Line Items}", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r331", "r333", "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360"}}, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "presentation": { "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Number of shares authorized (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized", "documentation": "Number of shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": { "r685"}}, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": { "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails", "http://www.arrowheadresearch.com/role/StockholdersEquityDetails": { "lang": { "en-us": { "role": { "terseLabel": "Common stock, share reserve for issuance (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": { "r35"}}, "arwt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://www.arrowheadresearch.com/20240630", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding", "calculation": { "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": { "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails": { "lang": { "en-us": { "role": { "totalLabel": "Total (in shares)", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Equity Instruments Other Than Options, Outstanding", "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options And Equity Instruments Other Than Options, Outstanding" } } }, "auth_ref": { "r35"}}, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": { "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofInformationaboutStockOptionsDetails": { "lang": { "en-us": { "role": { "terseLabel": "Number of Options Outstanding, Exercisable (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the

option plan." } } },"auth_ref":{ "r340" } },"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice":{ "xbrltype": "perShareItem Type", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation":{ "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetails" } },"lang":{ "en-us":{ "role":{ "terseLabel": "Weighted-Average Exercise Price Per Share, Exercisable (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted-Average Exercise Price", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } },"auth_ref":{ "r340" } },"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue":{ "xbrltype": "monetaryItem Type", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "crdr": "debit", "presentation":{ "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails" } },"lang":{ "en-us":{ "role":{ "terseLabel": "Intrinsic value of options exercised", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value", "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares." } } },"auth_ref":{ "r353" } },"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod":{ "xbrltype": "sharesItem Type", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod", "presentation":{ "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetails" } },"lang":{ "en-us":{ "role":{ "negatedLabel": "Cancelled (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period", "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements." } } },"auth_ref":{ "r345" } },"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod":{ "xbrltype": "sharesItem Type", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation":{ "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails" } },"lang":{ "en-us":{ "role":{ "terseLabel": "Number of shares forfeited (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } },"auth_ref":{ "r344" } },"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross":{ "xbrltype": "sharesItem Type", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation":{ "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetails" } },"lang":{ "en-us":{ "role":{ "terseLabel": "Granted (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "documentation": "Gross number of share options (or share units) granted during the period." } } },"auth_ref":{ "r342" } },"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue":{ "xbrltype": "perShareItem Type", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation":{ "http://www.arrowheadresearch.com/role/StockBasedCompensationAssumptionsUsedtoValueStockOptionsDetails" } },"lang":{ "en-us":{ "role":{ "terseLabel": "Weighted average grant date fair value per share of options granted (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } },"auth_ref":{ "r352" } },"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue":{ "xbrltype": "monetaryItem Type", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation":{ "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetails" } },"lang":{ "en-us":{ "role":{ "terseLabel": "Aggregate Intrinsic Value", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } },"auth_ref":{ "r35" } },"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber":{ "xbrltype": "sharesItem Type", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "calculation":{ "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails" } },"parentTag": "arwt_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndEquityInstrumentsOtherThanOptionsOutstanding", "weight": 1.0, "order": 1.0 } },"presentation":{ "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetails" } },"http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails" } },"lang":{ "en-us":{ "role":{ "terseLabel": "Number of options outstanding (in shares)", "periodStartLabel": "Beginning balance (in shares)", "periodEndLabel": "Ending balance (in shares)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "documentation": "Number of options outstanding, including both vested and non-vested options." } } },"auth_ref":{ "r338", "r339" } },"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward":{ "xbrltype": "stringItem Type", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "presentation":{ "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetails" } },"lang":{ "en-us":{ "role":{ "terseLabel": "Shares", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding (Roll Forward)", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } },"auth_ref":{ "r338", "r339" } },"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice":{ "xbrltype": "perShareItem Type", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation":{ "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetails" } },"lang":{ "en-us":{ "role":{ "periodStartLabel": "Beginning balance (in dollars per share)", "periodEndLabel": "Ending balance (in dollars per share)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } },"auth_ref":{ "r338", "r339" } },"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward":{ "xbrltype": "stringItem Type", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "presentation":{ "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetails" } },"lang":{ "en-us":{ "role":{ "Weighted-Average Exercise Price (Abstract)" } } },"auth_ref":{ "r338", "r339" } },"us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain":{ "xbrltype": "domainItem Type", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation":{ "http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails" } },"http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails", "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofFRSUsActivityDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" } },"lang":{ "en-us":{ "role":{ "terseLabel": "Award Type", "label": "Award Type (Domain)", "documentation": "Award under share-based payment arrangement." } } },"auth_ref":{ "r335", "r336", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r346", "r347", "r348", "r349", "r350", "r351", "r352", "r353", "r354", "r355", "r356", "r357", "r358", "r359", "r360" } },"us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice":{ "xbrltype": "perShareItem Type", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation":{ "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetails" } },"lang":{ "en-us":{ "role":{ "terseLabel": "Exercised (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } },"auth_ref":{ "r343" } },"us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice":{ "xbrltype": "perShareItem Type", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice", "presentation":{ "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetails" } },"lang":{ "en-us":{ "role":{ "terseLabel": "Cancelled (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired." } } },"auth_ref":{ "r345" } },"us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice":{ "xbrltype": "perShareItem Type", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation":{ "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetails" } },"lang":{ "en-us":{ "role":{ "terseLabel": "Granted (in dollars per share)", "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } },"auth_ref":{ "r342" } },"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTerm1":{ "xbrltype": "durationItem Type", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation":{ "http://www.arrowheadresearch.com/role/StockBasedCompensationAssumptionsUsedtoValueStockOptionsDetails" } },"lang":{ "en-us":{ "role":{ "terseLabel": "Expected life (in years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDnTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } },"auth_ref":{ "r356" } },"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableIntrinsicValue1":{ "xbrltype": "monetaryItem Type", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableIntrinsicValue1", "crdr": "debit", "presentation":{ "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetails" } },"lang":{ "en-us":{ "role":{ "terseLabel": "Aggregate Intrinsic Value, Exercisable", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable." } } },"auth_ref":{ "r35" } },"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1":{ "xbrltype": "durationItem Type", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "presentation":{ "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetails" } },"lang":{ "en-us":{ "role":{ "terseLabel": "Weighted-Average Remaining Contractual Term, Exercisable", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDnTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } },"auth_ref":{ "r35" } },"us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2":{ "xbrltype": "durationItem Type", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation":{ "http://www.arrowheadresearch.com/role/StockBasedCompensationSummarizeInformationaboutStockOptionsDetails" } },"lang":{ "en-us":{ "role":{ "terseLabel": "Weighted-Average Remaining Contractual Term (Years)", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average

```

Remaining Contractual Term", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDnTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": { "r90" }, "us-gaap_SharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesIssued", "presentation": { "http://www.arrowheadresearch.com/role/StockholdersEquityDetails": { "lang": { "en-us": { "role": { "verboseLabel": "Shares issued", "label": "Shares_Issued", "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury." } } }, "auth_ref": { "r8" }, "us-gaap_SharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesOutstanding", "presentation": { "http://www.arrowheadresearch.com/role/ConsolidatedStatementsOfStockholdersEquity": { "lang": { "en-us": { "role": { "periodStartLabel": "Beginning balance (in shares)", "periodEndLabel": "Ending balance (in shares)", "label": "Shares_Outstanding", "documentation": "Number of shares issued which are neither cancelled nor held in the treasury." } } }, "auth_ref": { "r1" }, "us-gaap_ShortTermLeaseCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShortTermLeaseCost", "crdr": "debit", "presentation": { "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails": { "lang": { "en-us": { "role": { "terseLabel": "Short-term lease cost", "label": "Short-Term Lease, Cost", "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less." } } }, "auth_ref": { "r443", "r700" }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": { "http://www.arrowheadresearch.com/role/ConsolidatedStatementsOfStockholdersEquity": { "lang": { "en-us": { "role": { "terseLabel": "Equity Components [Axis]", "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": { "r8", "r58", "r61", "r62", "r115", "r140", "r141", "r142", "r154", "r155", "r156", "r158", "r163", "r165", "r167", "r181", "r231", "r232", "r261", "r315", "r373", "r374", "r376", "r377", "r378", "r380", "r381", "r382", "r391", "r392", "r393", "r394", "r395", "r396", "r399", "r426", "r427", "r428", "r429", "r430", "r431", "r433", "r436", "r451", "r543", "r553", "r554", "r555", "r568", "r621" } } }, "srt_StatementGeographicalAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "StatementGeographicalAxis", "presentation": { "http://www.arrowheadresearch.com/role/CommitmentsandContingenciesNarrativeDetails": "http://www.arrowheadresearch.com/role/LeasesNarrativeDetails" } } }, "lang": { "en-us": { "role": { "terseLabel": "Geographical [Axis]", "label": "Geographical [Axis]" } } }, "auth_ref": { "r193", "r194", "r493", "r494", "r495", "r496", "r497", "r498", "r499", "r500", "r501", "r502", "r503", "r504", "r505", "r506", "r507", "r508", "r509", "r510", "r511", "r512", "r513", "r514", "r515", "r516", "r517", "r518", "r519", "r520", "r521", "r522", "r570", "r571", "r572", "r627", "r629", "r632", "r634", "r638", "r641", "r642", "r643", "r644", "r645", "r646", "r647", "r648", "r649", "r654", "r674", "r703", "r704", "r705", "r706", "r707", "r708", "r709", "r710", "r713", "r718", "r873", "r935", "r937", "r938", "r939", "r940", "r941", "r942", "r943", "r944", "r945", "r946", "r947", "r948", "r949", "r950", "r951", "r952", "r953", "r954", "r955", "r956", "r957", "r958", "r959", "r960", "r961", "r963", "r964" } } }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": { "http://www.arrowheadresearch.com/role/ConsolidatedStatementsOfStockholdersEquity": { "lang": { "en-us": { "role": { "terseLabel": "Statement Line Items", "label": "Statement Line Items", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": { "r154", "r155", "r156", "r181", "r436", "r490", "r560", "r569", "r575", "r576", "r577", "r578", "r579", "r580", "r582", "r585", "r586", "r587", "r588", "r589", "r591", "r592", "r593", "r594", "r596", "r597", "r598", "r599", "r600", "r602", "r604", "r605", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r621", "r719" } } }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Cash Flows [Abstract]", "label": "Statement of Cash Flows [Abstract]" } } }, "auth_ref": { "r1" }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Financial Position [Abstract]", "label": "Statement of Financial Position [Abstract]" } } }, "auth_ref": { "r1" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "terseLabel": "Statement of Stockholders' Equity [Abstract]", "label": "Statement of Stockholders' Equity [Abstract]" } } }, "auth_ref": { "r1" }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": { "http://www.arrowheadresearch.com/role/ConsolidatedStatementsOfStockholdersEquity": { "lang": { "en-us": { "role": { "terseLabel": "Statement Table", "label": "Statement Table", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": { "r154", "r155", "r156", "r181", "r196", "r436", "r490", "r560", "r569", "r575", "r576", "r577", "r578", "r579", "r580", "r582", "r585", "r586", "r587", "r588", "r589", "r591", "r592", "r593", "r594", "r596", "r597", "r598", "r599", "r600", "r602", "r604", "r605", "r607", "r608", "r609", "r610", "r611", "r612", "r613", "r614", "r615", "r616", "r617", "r618", "r621", "r719" } } }, "us-gaap_StockPriceorTSREstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StockPrCStkPrCtsrEstimationMethodTextBlock", "presentation": { "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Stock Price or TSR Estimation Method", "label": "Stock Price or TSR Estimation Method [Text Block]" } } }, "auth_ref": { "r736", "r746", "r756", "r788" } } }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockAppreciationRightsSARSMember", "presentation": { "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure": { "lang": { "en-us": { "role": { "terseLabel": "Stock Appreciation Rights (SARs)", "label": "Stock Appreciation Rights (SARs) [Member]", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": { "r1" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": { "http://www.arrowheadresearch.com/role/ConsolidatedStatementsOfStockholdersEquity": { "lang": { "en-us": { "role": { "terseLabel": "Common stock issued, net of offering costs (in shares)", "label": "Stock Issued During Period, Shares, New Issues", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": { "r8", "r57", "r58", "r87", "r561", "r621", "r635" } } }, "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross", "presentation": { "http://www.arrowheadresearch.com/role/ConsolidatedStatementsOfStockholdersEquity": { "lang": { "en-us": { "role": { "terseLabel": "Common stock - restricted stock units vesting (in shares)", "label": "Stock Issued During Period, Shares, Restricted Stock Award, Gross", "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards." } } }, "auth_ref": { "r8", "r87" } } }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": { "http://www.arrowheadresearch.com/role/ConsolidatedStatementsOfStockholdersEquity": { "lang": { "en-us": { "role": { "terseLabel": "Exercise of stock options (in shares)", "label": "Stock Issued During Period, Value, Restricted Stock Award, Gross", "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period." } } }, "auth_ref": { "r8", "r57", "r58", "r87" } } }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": { "http://www.arrowheadresearch.com/role/ConsolidatedStatementsOfStockholdersEquity": { "lang": { "en-us": { "role": { "terseLabel": "Common stock issued, net of offering costs", "label": "Stock Issued During Period, Value, New Issues", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": { "r8", "r57", "r58", "r87", "r568", "r621", "r635", "r725" } } }, "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross", "crdr": "credit", "presentation": { "http://www.arrowheadresearch.com/role/ConsolidatedStatementsOfStockholdersEquity": { "lang": { "en-us": { "role": { "terseLabel": "Common stock - restricted stock units vesting", "label": "Stock
```

```

SubsequentEventsTextBlock", "presentation": f"http://www.arrowheadresearch.com/role/SubsequentEvents", "lang": f"en-us", f"role": f"terseLabel", "SubsequentEvents", "label": "Subsequent Events [Text Block]", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." }, { "auth_ref": f"r453", "r455" }, { "us-gaap:SubsidiarySaleOfStockAxis": f"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiarySaleOfStockAxis", "presentation": f"http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetails", "http://www.arrowheadresearch.com/role/StockholdersEquityDetails", "lang": f"en-us", f"role": f"terseLabel", "Sale of Stock [Axis]", "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." }, { "auth_ref": f"r823" }, { "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock": f"xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalBalanceSheetDisclosuresTextBlock", "presentation": f"http://www.arrowheadresearch.com/role/BalanceSheetAccounts", "lang": f"en-us", f"role": f"terseLabel", "Balance Sheet Accounts", "label": "Supplemental Balance Sheet Disclosures [Text Block]", "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity." }, { "auth_ref": f"r823" }, { "us-gaap:SupplementalCashFlowInformationAbstract": f"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowInformationAbstract", "presentation": f"http://www.arrowheadresearch.com/role/ConsolidatedStatementsOfCashFlows", "lang": f"en-us", f"role": f"terseLabel", "Supplementary disclosure of cash flows", "label": "Supplemental Cash Flow Information [Abstract]", "auth_ref": f"r781" }, { "ecd:TabularListTableTextBlock": f"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": f"http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": f"en-us", f"role": f"terseLabel", "Tabular List Table", "label": "Tabular List [Table Text Block]", "auth_ref": f"r782" }, { "arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember": f"xbrltype": "domainItemType", "nsuri": "http://www.arrowheadresearch.com/20240630", "localname": "TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember", "presentation": f"http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsRevenueDetails", "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails", "lang": f"en-us", f"role": f"terseLabel", "Takeda", "label": "Takeda Pharmaceuticals United States Of America Incorporated [Member]", "documentation": "Takeda Pharmaceuticals United States of America Incorporated." }, { "auth_ref": f"r823" }, { "ecd:TotalShareholderRtnAmt": f"xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": f"http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": f"en-us", f"role": f"terseLabel", "Total Shareholder Return Amount", "label": "Total Shareholder Return Amount", "auth_ref": f"r774" }, { "ecd:TotalShareholderRtnVsPeerGroupTextBlock": f"xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": f"http://xbrl.sec.gov/ecd/role/PvpDisclosure", "lang": f"en-us", f"role": f"terseLabel", "Total Shareholder Return Vs Peer Group", "label": "Total Shareholder Return Vs Peer Group [Text Block]", "auth_ref": f"r781" }, { "ecd:TradingArrAxis": f"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": f"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "lang": f"en-us", f"role": f"terseLabel", "Trading Arrangement", "label": "Trading Arrangement [Axis]", "auth_ref": f"r801" }, { "ecd:TradingArrByIndTable": f"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": f"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "lang": f"en-us", f"role": f"terseLabel", "Trading Arrangements by Individual", "label": "Trading Arrangements by Individual [Table]", "auth_ref": f"r803" }, { "dei:TradingSymbol": f"xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": f"http://www.arrowheadresearch.com/role/Cover", "lang": f"en-us", f"role": f"terseLabel", "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." }, { "auth_ref": f"r804" }, { "us-gaap:TransfersAndServicingOffFinancialInstrumentsTypesOffFinancialInstrumentsDomain": f"xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TransfersAndServicingOffFinancialInstrumentsTypesOffFinancialInstrumentsDomain", "presentation": f"http://www.arrowheadresearch.com/role/FairValueMeasurementsForAssetsandLiabilitiesMeasuredatFairValueonRecurringBasisDetails", "http://www.arrowheadresearch.com/role/InvestmentsSummaryofShorttermLongtermInvestmentsandMarketableSecuritiesDetails", "lang": f"en-us", f"role": f"terseLabel", "Financial Instruments [Domain]", "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." }, { "auth_ref": f"r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r222", "r223", "r224", "r225", "r226", "r227", "r228", "r229", "r298", "r312", "r397", "r421", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r464", "r465", "r466", "r467", "r468", "r469", "r470", "r473", "r474", "r475", "r476", "r477", "r478", "r479", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r544", "r689", "r690", "r692", "r693", "r694", "r695", "r696", "r697", "r698", "r702", "r816", "r817", "r818", "r819", "r820", "r821", "r822", "r844", "r845", "r846", "r847", "r907", "r910", "r911", "r912", "r913", "r914" }, { "ecd:TrdArrAdoptionDate": f"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": f"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "lang": f"en-us", f"role": f"terseLabel", "Adoption Date", "label": "Trading Arrangement Adoption Date", "auth_ref": f"r804" }, { "ecd:TrdArrDuration": f"xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": f"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "lang": f"en-us", f"role": f"terseLabel", "Arrangement Duration", "label": "Trading Arrangement Duration", "auth_ref": f"r805" }, { "ecd:TrdArrExpirationDate": f"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": f"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "lang": f"en-us", f"role": f"terseLabel", "Expiration Date", "label": "Trading Arrangement Expiration Date", "auth_ref": f"r805" }, { "ecd:TrdArrIndName": f"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": f"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "lang": f"en-us", f"role": f"terseLabel", "Name", "label": "Trading Arrangement Individual Name", "auth_ref": f"r803" }, { "ecd:TrdArrIndTitle": f"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": f"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "lang": f"en-us", f"role": f"terseLabel", "Title", "label": "Trading Arrangement Individual Title", "auth_ref": f"r803" }, { "ecd:TrdArrSecuritiesAggAvailAmt": f"xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": f"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "lang": f"en-us", f"role": f"terseLabel", "Aggregate Available", "label": "Trading Arrangement Securities Aggregate Available Amount", "auth_ref": f"r806" }, { "ecd:TrdArrTerminationDate": f"xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": f"http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "lang": f"en-us", f"role": f"terseLabel", "Termination Date", "label": "Trading Arrangement Termination Date", "auth_ref": f"r804" }, { "arwr:TwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember": f"xbrltype": "domainItemType", "nsuri": "http://www.arrowheadresearch.com/20240630", "localname": "TwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember", "presentation": f"http://www.arrowheadresearch.com/role/StockholdersEquityDetails", "lang": f"en-us", f"role": f"terseLabel", "2013 and 2021 Incentive Plans and other inducement grants", "label": "Two Thousand Thirteen Equity Incentive Plan, Two Thousand Twenty One Equity Incentive Plan And Inducement Grants [Member]", "documentation": "Two Thousand Thirteen Equity Incentive Plan, Two Thousand Twenty One Equity Incentive Plan And Inducement Grants", "auth_ref": f"r804" }, { "arwr:TwoThousandTwentyOneEquityIncentivePlanMember": f"xbrltype": "domainItemType", "nsuri": "http://www.arrowheadresearch.com/20240630", "localname": "TwoThousandTwentyOneEquityIncentivePlanMember", "presentation": f"http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails", "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails", "lang": f"en-us", f"role": f"terseLabel", "2021 Incentive Plan", "label": "Two Thousand Twenty One Incentive Plan [Member]", "documentation": "Two thousand twenty one incentive plan", "auth_ref": f"r804" }, { "arwr:TwoThousandThirteenIncentivePlanMember": f"xbrltype": "domainItemType", "nsuri": "http://www.arrowheadresearch.com/20240630", "localname": "TwoThousandThirteenIncentivePlanMember", "presentation": f"http://www.arrowheadresearch.com/role/StockBasedCompensationNarrativeDetails", "http://www.arrowheadresearch.com/role/StockBasedCompensationSummaryofGrantedandOutstandingSharesDetails", "lang": f"en-us", f"role": f"terseLabel", "2013 Incentive Plan", "label": "Two Thousands Thirteen Incentive Plan [Member]", "documentation": "Two thousands thirteen incentive plan", "auth_ref": f"r804" }, { "us-gaap:TypeOfArrangementAxis": f"xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TypeOfArrangementAxis", "presentation": f"http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsAmgenIncDetails", "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsGlaxosmithklineIntellectualPropertyNo3LimitedDetails", "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsHorizonTherapeuticsIrelandDACDetails", "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsTakedaPharmaceuticalCompanyLimitedDetails", "http://www.arrowheadresearch.com/role/CollaborationandLicenseAgreementsVisirnaTherapeuticsIncDetails", "http://www.arrowheadresearch.com/role/LiabilityRelatedtotheSaleoffutureRoyaltiesNarrativeDetails", "http://www.arrowheadresearch.com/role/OrganizationandSignificantAccountingPoliciesNarrativeDetails", "lang": f"en-us", f"role": f"terseLabel", "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]", "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations." }, { "auth_ref": f"r833" }, { "us
```



```

http://www.arrowheadresearch.com/role/CommitmentsandContingenciesNarrativeDetails", "http://www.arrowheadresearch.com/role/LeasesandContingenciesNarrativeDetails", "lang": "en-us", "role": "terseLabel": "Wisconsin", "label": "WISCONSIN", "auth ref": "11", "us-gaap-WeightedAverageNumberDilutedSharesOutstandingAdjustment": "xbrltype": "sharesItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "calculation": "http://www.arrowheadresearch.com/role/NetLossPerShareBasicandDilutedNetLossPerShareDetails": "parentTag": "us-gaap-WeightedAverageNumberDilutedSharesOutstanding", "weight": "1.0", "order": "1.0", "presentation": "http://www.arrowheadresearch.com/role/NetLossPerShareBasicandDilutedNetLossPerShareDetails", "lang": "en-us", "role": "terseLabel": "Effect of dilutive securities (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment", "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per share or per unit computation.", "auth ref": "r836", "us-gaap-WeightedAverageNumberDilutedSharesOutstanding": "xbrltype": "sharesItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberDilutedSharesOutstanding", "calculation": "http://www.arrowheadresearch.com/role/NetLossPerShareBasicandDilutedNetLossPerShareDetails": "parentTag": null, "weight": null, "order": null, "root": true, "presentation": "http://www.arrowheadresearch.com/role/ConsolidatedStatementsOfOperationsandComprehensiveLoss", "http://www.arrowheadresearch.com/role/NetLossPerShareBasicandDilutedNetLossPerShareDetails", "lang": "en-us", "role": "terseLabel": "Diluted (in shares)", "totalLabel": "Weighted-average diluted shares outstanding (in shares)", "label": "Weighted Average Number of Shares Outstanding, Diluted", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.", "auth ref": "r170", "r175", "us-gaap-WeightedAverageNumberDilutedSharesOutstandingBasic": "xbrltype": "sharesItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberDilutedSharesOutstandingBasic", "calculation": "http://www.arrowheadresearch.com/role/NetLossPerShareBasicandDilutedNetLossPerShareDetails": "parentTag": "us-gaap-WeightedAverageNumberDilutedSharesOutstanding", "weight": "1.0", "order": "2.0", "presentation": "http://www.arrowheadresearch.com/role/ConsolidatedStatementsOfOperationsandComprehensiveLoss", "http://www.arrowheadresearch.com/role/NetLossPerShareBasicandDilutedNetLossPerShareDetails", "lang": "en-us", "role": "terseLabel": "Basic (in shares)", "verboseLabel": "Weighted-average basic shares outstanding (in shares)", "label": "Weighted Average Number of Shares Outstanding, Basic", "documentation": "Number of basic shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "auth ref": "r169", "r175", "us-gaap-WeightedAverageNumberDilutedSharesOutstandingDilutedDisclosureItemsAbstract": "xbrltype": "stringItem", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberDilutedSharesOutstandingDilutedDisclosureItemsAbstract", "presentation": "http://www.arrowheadresearch.com/role/ConsolidatedStatementsOfOperationsandComprehensiveLoss", "http://www.arrowheadresearch.com/role/NetLossPerShareBasicandDilutedNetLossPerShareDetails", "lang": "en-us", "role": "terseLabel": "Weighted-average shares used in calculating", "verboseLabel": "Denominator", "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]", "auth ref": "11", "ecd-YrEndFairValOfEqtyAwardsGrntdInCvrdYrOutsdngAndUnvstMember": "xbrltype": "domainItem", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "YrEndFairValOfEqtyAwardsGrntdInCvrdYrOutsdngAndUnvstMember", "presentation": "http://xbrl.sec.gov/ecd/2024", "lang": "en-us", "role": "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested", "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]", "auth ref": "r768", "std ref": "r0", "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/214747701/830-230-45-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "220", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10A", "Subparagraph": "(a
```

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

Subparagraph. "(a)". "Publisher": "FASB". "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4". "r966": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Text": "Subparagraph. "(SX 210.6-09(4)(b))". "Publisher": "FASB". "URI": "https://asc.fasb.org/1943274/2147479134/946-220-599-3". "r967": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Text": "Subparagraph. "(SX 210.6-09(7))". "Publisher": "FASB". "URI": "https://asc.fasb.org/1943274/2147479134/946-220-599-3". "r968": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Text": "Subparagraph. "(SX 210.12-12(Column A)(Footnote 2))". "Publisher": "FASB". "URI": "https://asc.fasb.org/1943274/214747721/946-320-599-1". "r969": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Text": "Publisher": "FASB". "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2". "r970": { "role": "0001628280-24-036104-xbrl-jp-M4SL#110 L&6 <M>DKAPK&C&G&L Y&6 1 87WV MOHJ ZL 1&WLMWG7 L2&6 1 WY2W ZO7 79P(UQYVFT)W5H&1?>17 LA&H-/5?1=?&#0@#P2-Z/JMYTZWGOOT#<=5%4K3%98M?2 4M3 MJJ15?5ZRSJ?73-7=R2ZTK6EO5H:D9\$K3\$YMFLJ4\$EMZLFF?UC5)?<KM MM@KJZL4EY1V4JLFLA=CBBR@C5576VWU:UHKXSNM14H&C9S98VBYHJSA MJS&A2LZH7M.K8+1OKI?>7H<1 M1#4 SSSPC@XG)H6LKNR94!-IO/WLL%<N\$>DV QX2RH/P75JL L&3 65J MPl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gt

KMSG8U6N1GVX>ZKM&E+1HJZK*Q.M-DZ4%3<.T@>+|YB8:CIUP/S2=LE(R\$U2XL?R@T+Y.OI/R^Z=8;@YC.MH4I-
 +|IQG0<=>2S5323K*3W:KA*VKJ3U>3OU^VZ-C@.NYK2K1N 5IG6R M8VHWK#WJERK9+3R>GP8H1NSWQ>>0FTA-4/GHICIRSCB:<>VE++RE=M:TH-07D,2UC?<
 Z58UHWYWB>=FF297C9B1>JLL^TQ6BHS:IKC<1SBW13>#G%W.M@KS<4C^TEZX2KR&>A|@NFAIVDX#MKG06W3|PR<01L0=1\$%E?>F.90@M\$1+
 (\$6^X=932?>Q0X?FPMJX1J39K4V9SRHAI4>V:8-G.Y@G.MQZ,FTS MZ-B|B\$4ABX@NFF?3>7YQVOOW.ZO)5F(6;V\$2>-2\$C5R%<9R&51<-M\$511%114>.<2.E.=<
 @V9:8KSMDKIXF>A:NGM.6B+1J^XEIK 5G#DJE.M1+2SCT^+7D2.M\$A:VK,1<-N^=4.T6^F+7>9\$K>UH1+L9^+FVRS1
 MJ744\$5DGBTLAE+SDT+C%8<L\$S%59\$U4BEF27HY0Z&H+TJ3RIBP.M59:K6*BI*TKS<FJ=YHT+RP'E)6MBZRAM79L/19.CVL9D1-L.EW.M2?>9)4.Y#M3@SE'FMEQ'?<
 6%#E1+XOC^N1ZPK:1=4I.M+XG'B.9^X<0=06X01^1^J>+>@.IY-HU+0B-12K?Y2K@BU0^<0-M.JYF/MHT=3\$<4/743E?FM?>=TT%1Y670&40?HLYVPY130(6X28+V.9QFT0
 M6K2T0N.PX<+N.YPIESPMPOY@>=RL^H^1+BA)2?W0+9HSH10<?>=N.MNF<@>(QRH&62H\$1W.1WYK:28KG#NDN1DLNXXH?W00A<=>9^+VJW&S<
 M\$1K0X&+G#N<YPIG#N<Y1Y^2?>=5NVO7F8N<^2?Q0^>=5QD(2?#<=>=MYPIGSEIPY@=0-1&J1>?F96ZS3.2>+4#8A0!<^YPIE3.91+15.U4H1.Y.MGVY22.EQL1IAH^<0-1#<
 XH45Z2^WB.01<=>@LWE^W^X^0+0=0718N-MVG-1^Y2J1H^ZQKG.M|WL@>|C|@9QVZ1P^IBNYA4.M6:"ULB1^H02M^1H1JVCB.V41D\$<1H1Y?FPDW3R1L>.(DE8S1\$5615
 MCY33^QV1?>=<G>@>MSFH&2^L.EP.N1A&8J@>D.C5142P+16.HHDIHVD8<@>EEAQ1.4A1+1=H.15.ME^>165.59K(5E3Q>6E^HEH(FB2UY6S6Y1+>6
 NZNP80Z010^7-7X^XG%72H51^L^S0R61WE1^M55M%OFF2P^CGV=ITVP<@>P%OC8HWM/O15:QNG&J87YW&5JHD\$1^VYCB^607:~<+<+<
 <=>8@H=1."0A(O1L.4=>=>MYC@P^1+9<#2?6BA2OEJUD8Y17V^?F^C>:FH(9+14R5P4C&H&L&A>:FTXXU+1/C+4>06CR00.GM\$CG100&|HMFH/61Y?>#Q#+A
 +21=>EY.ML(QSAW.<@>TIN%|MSM41^FD@>#6.<K?J&=<5555F\$7@>B%11WOX(JBXCB^5H6.V1#F#42P3WG.4DU?3/U7MN%<8A.M=<=&165JHNLR58W^55).7C^2Y2P=Y
 MDWN<+Y7QZ+15.WR0HIC^VWDH|K3LA+9KC.5=>9BGA.MTNW&WVP46<+<M=>#12J015(SVGU+5CTT11&@F75147A1^HKD\$3?<44Z
 M:9GFI<3MB.5.DW>=56110%<8R\$PIG#N<YPIG#N<^?G73G6:LE.G17GBMEY.M.B2^XZIP.CAGAW>?1%SDAM2JK?>=1^B8X<D.06:5.0H1WY?55SAW^?N:UW~P^33A#C@>J.
 (RSIG#N5-YDN.A#>6KI^Y1M9)=TNU=&@>=>MCWUQIG#N<YPIG#N5<=>7%|H1JK125TD2=2-Y4KH0H^GD2?D+1TZIU.M5%N%YZC?<
 \$5\$S20N1?>#&2#JHFCR58FTM2G0GLK@00C1CRG.M645^OB4?<@Y^ZYQ>+<YES.PEXHDT4#4.MZ+HJQ^Y1E1XN=8OVC6B9V7F0HF7D^46?<
 3MJ7JW54M2T.O=1^>J1R1^RH1.HIDOG.M^IG-H1MEIQ7W0175V+^F(1^061-A'4=7B1<+<+9P=0AT0)70A.M-WY)GQIN3E^<1+1+KYRZMMA>+<
 +PYBT6B&C:Q1K&X^E5N2^>S^ZJH15F.MOY2YXV3MG^0-ELG.R.M8C2Y^IX.4.AJO2-R9^E.Y.MCCKO)0^ATJFJ5M0Q7HLE7Y1H1+N1+1+L^Y8^NL9+1<1-
 M82<2\$;1%1D0=FLR<1(3-10^>241HZ^S9.Q+41+>181B3ZP^ZS<=>5\$5^?N.MHEH9L(HLTYQ.9@1<=>#2@P@YX@>N#>X3\$X1OU4V1<@>KE^<S1XPI^<+<
 MJ48(768ZG>4LA8FJ6@M.O.FJ=MB^>KJO19)+<2F4LH\$5>+>#%#C1X:(AMF>?7^DEP54^4571714@5^M^G^04Q7(M8XFMT55Y1JHXE5797?)"L/X\$XME.FM-2>
 <9WHV\$U^FW<+<M.V.9)4.Y43(SF0^5(CUKIK)S62.1BK1R4^YPIG#N<R1PPO^>MU-A^U)5MZZS^YBFS+8J+1+1+H1W0%>#C1&DBPK>#|S1JAY\$RC.YH
 M4T21<D\$0S^U1^Q6(F61>27LDBZB(1+>5)H0.WL8HOA<@>8Y>17SRQ09MS.MASTG?8MPD4Q4WLVPW:YVFGDR.X^<ASCY+1+XBMT+1^XOIGH<X^J)PYC@>1LRL<@>G7^ATJ0
 M+>+1A14LH<1BR2<3K2.3NKELKE^M501<1^>0SO1H<@>1JWLJ@.Y35PSAW.SPJA&~WVUD.M2U<Q1^150158K1+>+@H1\$B0J0&<3Q0<+<N4H1@>X^E1Z^9FD2\$=<6^4BH
 M+1+U0C^L+M+UP<=>S+UP.M^WE.CM@>PN^H1ZRC1^#5>OH1Q54^9=J^M+>+356D>1OJ9^<1O1D1^RMOQ^N0-47\$55JZ\$61&P@B>@BYD1<8^RBBCWLE9U7^M73.Y?<
 +AP<+YPIG#N<Y41^61C^1JZOLC.OY12<@>|KPUHWE^<M^X^X^>P9PIG#N<YPIG#N<^?G73WJEE@A70BJZ-80X5JRI.M1+>=>YPIG#N<G
 =WATCSEK1&CURMM&K.G\$OJX3PG<+<U<+<YXQ2CU0.MU.C.D.C0T3L<13K1R0^@F^%1Q.51\$19^S173Y1+KGBW:%04+>+X0=1+Y4>MCI/>|A3K004<~
 Y1PDP2>3H1Q3U1.UU&NJZ&BW2^ZOE8^L^LGN#>@0S#>M4A0DBP(CD^KX2^>JH=>N2K@|N^>B+|J+I9ACIP)5DFH=MK=4489GEO.NZX\$1C^GW^>+Y.P.M+J&PU1CQ^WGK\$1
 IZLZKLGB76CYK4H4.M2>7RVN.MB<B^T03.WRHP+1^M4>=>C?715E1N@YNA1\$YJ5AW.X55.MAW.TVC%RGDR^<M00G#N<=>=PIHV1=>2J38>?+JL
 MP#P1&L^1+OYXMSA.MW.1^MM&3J+1<J.DBD63%3+1.M.7881@T.F0<+<719.T45>5D^<1K>#C=09ZN^O1U<+<A2?TJ(CHE#ER<+1+1+MUJXV
 716@>(KR.KZ2):NME+BX1621M20DZE1&QRK^1.D1LM2.5541.M.O6GT.F1P<+<F5-DJ42Q1K1BLKDDT+1ED7514^F>X7JF>B9.68#0>2J2159ZVBR7^K<~
 17)5Y3P3K0EHZA>BRJU.OY:HMKD1LEG1R08^MLHJAWPT=>N8^A00\$;#W\$1U^X@>#Q1&01(Q24T.M17C#R^:1KHBI\$7YISXTE1^3^IZUD0CGWH1=QJZ4.<?<
 T^OIS.5CB<ME^AQQ6B8CY+>UO>SQK1+Q^RV^+TNI\$U(K6Z28OU^>#HLG<1N34175.M=DO1GD:JDZ\$3K0T.FMELJ^M.EM1+GHTIA^>#GF^IR8?>ISH8H0E>N<5MS..TW5
 (D^NS1.H02^1+1+>=>#62M^>+B8DF1^JISJ&P1+NOP^B1H.MB+0&H14Z7.L13^WKKX<1>=>R6M^H1CQ<U>LXXK<3>30^Y2J2^X<+>#EHD1^>#1&G1+>QQQ?<
 +#J8.F3^+ADIN>+F1^A8.M6F&A1^1.D=>#>#>#&gt

SDMY704;+U.0&K&E?ZINC6Z7Z\$7=N1Q0U0P.D;_SF^?H+>;_GH@MEI-Q1XXYH14W;?IFED-D5(Z8YAXQ2GIMRR7(MH-B^U&ON)H17%ACI-M(I
FEI)6^~29H(GP#H~06TH.P5-LXAA#GJ#D+YICEF-WH+V90P.5WJJKR80M8C/\$TD?)/!\$~GJN.G=Y:5AA^FY.2V@S\$TS0H1^K&E?/9@+&+IA;H
M;HE516^~2L;+1L5;2L;~BUIM^BMVCX;U3U9K74.D3JRZE?T644\$M_HR(Q)~#XW1^INM;ZNI2D;FMH9H=\$&~3J#;M^Q)0\$^CATP43GD
MHUFA^C82WYH4@4E1S^P7V0B^G/C1+JZHE&H?#F0NN~QLP2^P7.9BCQ@P.ME2^Y3(HBPB6B;T2BS;S.67)PL1229&?<_R^L^C+M+64CIA^O.2ZR70(+2^~<M^B;2ZX;XR61
1BP.490%QV+DK&E^I^T^S_#M<~276114ZFRMKF0#~LHS8<^0TH~HK8)~.N;7;6^GVMRFJ8M(1.D.M.D?1^I><U>?051&AE<7
W>GHE3;LVM(OEEDR8G6G8K=AD6B7F2UDYU1MA00?0999D0G;YH>~648I;CTPAGI^H?<2ER&H/Z^/IGN^H44TTE^U?/12.M2G=B40^#B7LFFYL^Q.7^9WEH(X#)2^1MJ.D5#
JZ547D3W+DBI.M^Q12@~1VB@.1.9B@.R.8X^@.7&Z3B~B9F0219CPE;_K2=^95WZFRIAJ7;U)D4(C@10Q.Z^O)0VY>B>@;~OY9RVADM>f.M.NNDV.G>OE^F.F^\$*=fM2-HCC
+6U)7UP>PVAP+L7L.F%QNG8>Y>~&MDTH~80IYAL+THXWTD74H&V1+8V1L.N/2U.5R7?_96AEMPR9+P^KM2UEI;Z9YR7F;?6)N00<959N1WSI^M.VYA^TJ63919KBEI
PH(+2V3?96%K@<OJF4(2.5H>+>?GA4I.M^H;IR&A^#4=Z91\$5GGGLP^\$ECEKA90+X+HEL8UJ>~23=1V20AR^H.M^CKCC>G.R^R;~<X^R
QI(C#)MR@L^P^OKLH^PMSH>O^F^C(PJC^PV7^I^R.DDHH^HK;OJ(BOU^80^Q^L&5;ERF5RP1Z2#?F.ML+406+H^TJ6690HOI^V>E78Z;Q;D;I
M)A#JA;H8S1P?Z.OEYN;IXIS^>~&O.K^H;_H.L^>ZD7U1G;FEXL7D129+QF821E=EL841^JHJH5E^VRE2%+>YCLM9@/ENI
C9)~1^2J9A9N;N4PHB6YR;A1RKR0E@WIPZD4V2DQ?~3FE^M^U?>;_DL(5^S&5C0+RZ;EB;~#F2Y;L&6>R>E>+EK<@IUC@19G4M51FBDE;O;C6B6I#5U^I?
T+N9P^UEMR2@~\$S5XGCOA5E_MRY86<@SL+I^~K^UFO.M.Q^J&3^U)A);OBZTE2P@FHH;OJD.9?7#6^M1ZY1420&^XUZB+BOH@<f>7Y280?^A7R_6AC^\$S1=&WW^<
M5@<A^YV;?2PHQ^O@ED5^\$&5LGS5V;3\$+>M1#&A6Z+&GP;_7D%;_LBN1^5D02@L@1OP_10PZ.MP)8H\$PDLZX+L>@GRS\$SHL@~\$WM;TD;RQH;_@5
C%;WJ2NDQ@~UR.DV0+MM;MOEW+L@U^715_R5?6I^_AH6M;HAI.RDUP;O;XXF9J1KBS1LR5M^M+FY;YCG3B9^CABY^93TXAH;KRFP_SKHIN;N&JC/S
^4F<O)M2544^M^Q\$0D;EO1^2IG&^8A91AE;3K(LI951^EJ^HIB;BOU^2^WAGIE;B7TWI.M6IT;UE2EIV^6/6P+4WCOIZ7FUSYPIQ^UHI2^JDPVE5.L&V4J6KU35Z5C.MG^H?
DRZKG;H5E)VULAY4R50J2>C^M^WOJQAIT^%N^Q~MY9N.2CO^F1^_M2P>+>+ZVU@=IO16LAI^PWLWIE^W+Y^T^RI+ICFP\$A17118M.O.RJLJ3
MNV+JW.SMH2LG.3VE^%U36W3L(LAHK^FB4?2^IOPC(S)5W9LZ+P.HU2.MH4M^J^I^I^K2^#A1^E;FTWV796D^&YJ.E;IBJZ.MJ9N^FJ)DJOITS9.S.M?
PMRYWAMJ@DF+FO40^&LN;82DQ0#H.L.GVUY+N@~1^@CX#P10^OX.MAPVTK3173^1^19KN1M;8#5%9@R7^@S)OQ55JFK^5UHDLNRH7^@CLJDY^M9^+IBE1^I
W2EFIEQM03?Q>F5V.Y^I^T?Z^07S3A^B)F^T800DQ^H2LA.M1;28L+8V5SR05@OD7@TRH.6HRVY.GLPDN3IBHTH1HM6I&SUD^_MI92ZDLOHPCS^=9
K1=N1^W6L^&W^P)Y9G^UGF^FWW=4ZO.P.S=Z1^M^VGK4V^8.SL6GM^FIEB77^IY39<F^_Z5;ELH;EPN1514F29G^H^H860KX^O&E3P7B^3^_AR09ZN
M.X310^<(K;8=LP^I)NP#^2G.WAY&P^X6&E1V^#<1UX?<R;1^O^F^LJ1.M.9HJIEB7.WNN716%0%Q;E^f+L&H.6^33K3EE^I^R^D>E^#&R;R56I
MWLY^RT+7N>~.84Q25^GLM;TS)X;0F@W6&25T^1^14D.O)AY^I^R1.MKE_YLBP^AT8IXSYORGC;T.DL2^<7N>+R3G6Z5S^OJ2^=IYIT5+M=
(81352DLBEA921M6;6NNH5;1^U1#^#TX1^A74LM.M0P^DF^6A.DNE^60X^KJ6>2^E1U^#GF;IW6&1KM^BZNBC^+K3R~1.OJ81R1R1YK58I9.MX^%M;.>?~?&@Y#1
<IR^I^J&5@.5%551W31^P^7^F+346~0.Q214^MORLB95V.MT#36^J35R^FAPKHA99>~\$750S10M0ELK.M+HM^E%>Y#~\$JW&E^F>U
MCGU/6&^Y1\$53XP.E@7LEGH^2KHHR<OY8AGM&BIGXCTW@B^LMU;H19U.M3^H^8>J&6.M^Q>H>~M^YJHW^9E6LZ6G^YWI^YGP0N^525FTY+
&ZTO+AZ7Q3ZABAH;7Z1K7W;WB9>K;75;991^XJHEF=BXFXETM;M7589@.D3;L;L;D6G6^EX4KYU5W15^M1T38F544X;HFPH2^I1992J
MG5M.14ZP3ZPP19A;KW=4WT^4&6~6DV6G^&2310)S@~\$B9?OHLKJH1661.MP4^VIG<6^U(OHX;VJH\$G^5#9.W3Z1^PVLK1K1^TTL^TBCL^U\$&X445>[3J~MR7^3.982XDAQO>
IX<@YHRR&L;IYQ9>~<#H5IWS&+L11.B>BUT6.P=>MA6W>G.B^T^M^&GK9U.Y3^HJNIT^71^L.6J6)J8P^W^#^_A2^Q3&L&KCM^+=+>M^X09P^9VZS(4^ML^2JX4)X<.
&58\$G^H<~HLS;1(GXU>1^MEQO^3YVG+FL^CY+31^1MER1<#C#^MWMFV+ZWJH^KK6LACRN>~74LGR9>+JRP^O+>S1LZ8^IGW(KH&855.M9ZCUP4NNR@QH>
I7#&^U^MUNZR+I2?>[5EJ^=780QY0IPKW51^NA4^MPTSO^HH^JX^T0Y6CV02>H18@OD9L4^>@&01.O^FT^>=H&K^HMO.WIXX^Q.MZM^E4FUVI^=W41^);FR2
UNXSPM5VD6TP.9FEFO>FE1G20.1G\$7+U.W@ATK.M9SSI=7VZY5V39R21U;U;E@59+PK.5^0BVVJZ?7TDOBHQ5>GHCV;P.MIZ+>@KXBS(E^KR12K;7G^
M^Z8~DB^1.69M;ENE89^)#K>LX7;ORHOV\$2D^WOI;J&8DG.C;IV.M@<^Y.K;=EH5W~7^_*J&62@S;2YF3G~F24<=&OUJL6WQ+00Y-Q@10X
MH1Z^%CCHH8^9KM<1^&N&N19ZCYV^N@_YXX14GYXO3RSN@>@W\$S0.CD)MH^D^B@YCY^CSZPPOJL<DXWQ(HUWUOL@MIBF2A2U)GJ^MYZCC^QKZ<M.;IK5L=.)
2635+93<29D9I61^+0H6MT^99.NYMM>+LX;66GM9Y26G.FCV9?>JCCM5D;D(AEK\$M^H8Y.MJL-66=RD1.FQNP285UE>@RR8M^69ZSCA2^8^MYZC^U^V^H72
X(NZ1.BPOY00+M5^<<~<W&H5L^P)PRJOIT0H^5455F<@.MF>GRH^Y1^WH@<~<XKBH1<1<~PH+PI81JBJ@N8XC)7%~1^EY=P\$1.M+71^WX1.T
X@0Z1.9^U4RW9IT9FSE^D8@1J322KXJFBC6Y1^I^S^H^M=X9.M6CBL@KXW518>@C96A1YJ2=SB\$OSXL^I^YQ5PONH1M28L;H;@>?UJ^7U<8>EZ;P%~\$M.Q
XIGB+KN^XX1>6U^?IS^_G2+>N1P%>D^V#~0EF9&2&F^ZH^QYO^0.MJ1^IF\$=\$V%N2BIBEIT1CPB6YBH0R4IF#98&S(14.8@GIAN^IYA6>~>^
%HJ>?PQ^>>CK3^TJG1>5.M.J^K^Q1S^=9PQ(NOH^5W^YXCKA)@0LJ8J^XWYO^C.H53+>C^J3.QP2H2%>#A<@&3^YCBH

[illegible]

[illegible]

GIG +R#DGDG@121+L+3%EN+8J2P#B2 MG+2+H2B+T59Q/7RCAIQX82WXXHX+@T.A.U#0A2DMJWH+0015-M35)CM+@EPGMN=(6M.P.TP(2+M\$0+25745&
BOFU87P#6M9)S);Y=R.MQ(C&G)=40>1/4QOPV)RXIZB+3=YQ M MLN(0H)P+P+@=@I=ITI#1\$2#6@F>GFTTML4IRBNAP)VIE JJI="E M5;N3J0+V9BYA
JR/IE2A/GJF#H+X="OOS1+M>17Q>LQ:0HWX+@+1(MS,UOZYIYV)ICAP+@+LZL+@2PTI\$A#Y%G%,"V9BYB@P8 B7@R+@I-WOTY7#5#10N
7#>BBJ6G/GI2R)AT5(W96ZP\$G5;16W6HLKN9D U 195H1 M +0B+X99ZV+OUFW+3Y#97KM;Y1(KJZEGEZK6H)JKW+@FZN 71+1-M+Y1+9
1)SBOIWE6+KK-Y=7W55W\$S&(W5)OKVP3-2\$534-M6\$6LPGX-M1+U/LGO+H5>S7MYR3Z+VPS/UTUYE)@JH#28L516K3W3P3@H4PQVYSC-R)J7#3#8+FOYJ+
MY06274%#PNH7J2W1969)-MTJLZ4IGMSVIBU IY L O-M.N565YD-B#ZW04JHEK6UY;FW0#D9\$A@*T.M.C.O7W 1%2GR I0\$+940L23@QX#P IZ>= OIYIYQES01@I
L3>17<=<M3%WFS3HYI5P-KIHGG+L+G64J15T1-<IG<8G1="XXIA)IS@N14T-ML2-C4ESIBYIY\$S,S1K=C J-A=L L19J#>=V#HIAH "L F4L1A09>7E1>O1R+M8WRR=
L WOIY+H-HR1B8=F6R181M81/CP0IK XY1A M&HC)S9;F&EKM90QL X82Z2YN521&KERE AWHTU>N+O3N57B6=O>1&R="M620036"=O>25
@E2,ITY3==>F2Y#K7H15 W91V 21H<@<3(U7G# MIVY<O.R)YVVG@QOO35FER&Y1Y0HJH BW76#63TVF)G-6N)D=I050BK1M.#1#4&#WW80JHWF85&E J75W5.WI
(1H1)=,U1U+OHHYVW8L+LKKOW+8 M(D9JUI34J%WASFA809<5+DGMG6)Y1(CYLPHEM,9Z2J1+4YPTIUIJZ+MLSGDFE1H5U02G%>+H>JLCPVYSC-R)J7#3#8+FOYJ+
XPP-3WJES HJ.MJL+PC H2AR-R67V/C QJ8R4023YVOMRT5#=(H+L WCM7>3751R1N2M.QO.M5214A00Y/18 +1<=1W3R 7%4(XS3RL9%,"2>=^%62^LXV632T75T
MK9+V5LNN4 D\$J@T HYIM6E.EB)157K%YWG)CRH671E L=2V5#7>+JN.M10GY#BIZG&L(10-I%U#F)P#T1B@=ZPP+0+X@+C12DGHN60Q+02&8&@U.MQ9?
G10#9FL5#2#ZJYR/H EIM+050B210+1+19I+U+M@.HJRPJ@S B& MB4?PTVY1JRTI+&#EL2L#E#P+##%S+<=ZN-R=RO491@F(O)OP=80FT.MZ151G21HJ)O>7Y1+<H
RCQ.RV<=ZODP1B+N6SEVUV2B5+3CZB JHYX FVVR+01GR?#E#2P\$=TR.94#<88C#QNNR@S1!)=@<1"X=XKU2)NA+IBBD6 M<TF HIA0YJ
IE53#R)S@Q.S&L&R10+17CL>E0B MC#>J Y=OVR#>T M OAA%<EFAKIB13D\$T1L EX W+?CCE\$C%<1(C5\$&C)C&F H%Q39 QD.HW+M2KJNT?
2GJZ9U6Z5026B\$S+R<5+QCL7#&3Y<09RT2DW1+&BYR P=I?P1.MQ00>@9HJMOG01JFX&P>LJY8Y@&T421Z1@)SDAV142B#6R*7HLONL%<M-
CJE.T+&JW<+*3+P1@<=(Z)0A)H6.666+4)6.SX BW1+H2D25(L@ MN4\$*?T%&@&I&<=SJS<B2+I&0Y75%T51XW1V+R/C_95)D.R.M
<6R=L23G.&#>T+&#JHU1M1X\$8U0+R+JCFJZ+YIBH(P)OMGP%-M F-YA?+Y@ 3A"MB8%K61\$S=PHZ%>T #4<3.9YX.IP+Y1H1#GTY1M6X
\$8\$1#1A4X80T6F3_KG>+Q1Q0B9#KZD)G#U\$C L 251L1&S&S MD+MXAV0=>#F1C51HMOGDU2.LC=GCCA@I76M\$S.3MJJ#>B.2>2GEAN5D#B+1
ME9IEFY2>LXA0Q<R>=<S)@L12>F4E.BDB0IS.C1C<@D>8L5N3VEX&C MD M=4-8#D9@JHGT6715%Q(RH9-9J MB-N+0I-W7#8RB6G43C)K1@7YV#5#UUVK2;RQ
<8&P"EB MKLZ\$S=I.V.8+22 GS&+R-2E1XHXDPZHUI+Z1-M52#8YX@80Y1>D)H PM MKH0Y@&66X2-(?C8Y3R14=8R18K>DL#>="SFCSL2Q1*O.S)Q>2H3.&MIA+
I/G9E@S1\$SHVOTIO%O GM;Z4&4B1P.9JINA+1CX74616GOS0V MSCGFO1M7.O&I+99S1-/B#>9HC@-J7>-(2FWF78FON551KFTKT7>="M8A5M1HW>B?&br/>&I6.#47KKYB#IU#0#1#K8&E4>1+&W?<U5D.23>OH M.ZS(KS3B3KHL102 FV123=VMN<5%<@ MORBIGYIB7BLS Y6PDF=U C1R*V21="HWFK27O&7SQV V0 R-C>
@#(R1 MUI+FRH9>S@QZG#<1.OW.DN1J.KJ0YHB#H1D)J1+1+908X95Q?C&D4ES1K+>+51+457L2)48H+H/Y>JRXA\$<9)I&F M(RW0E&7K16B9>6YK13E823
HTN4Y G+1+BHP89T0+>ENA>E 7HD.A.ME1J IBTG6CG819#7#D1 M"Z6"8YVO OLCG)E4V+1A(L@&O376 8HD>O?7VFD01E%<KO M%>?
X7B8ND\$>B2F140_K2>ZD90>=TA(T"8"5X U.PESA?ZG142)ZV1 M.HD<=TU.L2FL5QM#P1=IH FK UOKH#M@0@IET1-L>S1-4Y<=7%4+J913
MS\$<1+IM#B4GAP66K=36H>GT6FRNT3ITD0)Q.NG1@K6328GA=<=5F.89& MYZA1=54O-K.3%CAK14#JA9ZR=DS+P2DQX5Q107P5Q10WDK749&ET3TR
M65UCWP&EY>BGA(+FJ)>=>1#J%KYL+HFP#EGRRH.Q3 ES7YUEA2M1MET=3VGC+IM<JZC14H1=IFK.RNE V.U+1&S135X5EWE&K.R>06R#MM\$?
MFK46CG9K1&5QTU(7X UEOYMD)D#B1#<3ZLPY7=92AUK1XCF>XAM1IWR22P12A#MZF7X&DS=4J9+AS9(MQ#U2M&TAN@8<6G7L2)H1J>HW?=>6KJ(=+?
F7#8K"Z8U2EY#EJXZ"1T"=SSMC MY31-630N>=D141.9ZAKU3RO/U+FC<+1HCEAWE"3AJ"=1CGE.AINIS MC@NAE.O3-ZDLA 22
X+9101.61+1+D1XQ&GX5801P6 7<0BGRCG#G) M591K32LZB JHPRRLP19?T1F000+I91K4C&RPO\$#1478X1#>X\$;779E3KYR M25L4_A7H@%T">M.031SS+1\$H1S1;
(&Y+F1)<1AW79=I3GH9JH2P M0.TJ V<7L\$&WDX1ET)@8C2V1XV.C.5<=4L7>19RWUG1K7H%MM@G1H4A3B\$H<6WBWF?
G#MERCIC61\$5/05\$<5%<4J4+<4E)A91S1 MYD9=>S.DQ9>8K81PYD;HD/D3B\$?2P3V2W=>=W"G1SK#8/R9PC\$3 M5W1P?
4W15+010#<EKHP8D 2_HKS2JH01&1&7YVN13A1=ZG@<N ML3?98HJ5%8QZPV.EB-JH@<1)KY1+KQ<X"PKY3E0.ZFFCVH18+R+1+&1AU\$P851M\$1L53PTTB#>RJ
M+ZE2=763<1O@+1WGHU1>=KX@61(O&1&7YVN13A1=ZG@<N ML3?98HJ5%8QZPV.EB-JH@<1)KY1+KQ<X"PKY3E0.ZFFCVH18+R+1+&1AU\$P851M\$1L53PTTB#>RJ
16:12A.RU>ZL(R1E52NADJ6ZG1M.E@I5QD&71)1/25<@&6LS12TFNUN:1=2*PNM1G.ADPYV#RA19N+M.N21*UOWOHP.25D4FFGW)F5\$ZEN+NPC.YR:R
OCTB-L5=V1@H+V+>L ML8NIBT.N.GVO1Z5J5EJO3071M5+T\$F>#>#>ZEACX.LC@P\$."P.Z+I9D1.MO<21S%>+4-R6W3Q.OI@<1A.05011671LURX11#&0536XO16<6&4L
MYV3J:80D7Y1&H(5%2B&H17E1#>=HJ00M-1\$FA.)?TU<MX55.45+15Y61K6L1M2551PK141=GIU5@3X>35\$<WFM.FW@D4 (CZ+1N6)1E7IYV1LVU=>+1Q8.OVTFX1T?
05SY+QJ&KEC&YBD M DU+7OXPP93P1@<K893PB7&+P1&+9R41TO0X.NW+4YQ?2&+1JPM.OH1Y+>AW7PKIE.TQZS27X0&E(6BX4UK<EKX%>

WIS0:GN.DI.V0BQX37Y:6T14V3-6H*GB&#xVA1H66.DFIR=1MI50K.MI*NF6:JQI=A1:7JHVTV6U*U*VCL.ZSEFS:IQM:1<1>(8GLU&:OI:89GLI:7>71R
M49&3921FYI>5VCAYI@DBB?P21<H4A:08>1<ZT*VYGAH1K<103F<912M.M.YP.UC/HK:CHW6/9/C3C>1BF71EZL@L-K9R178&9<0&T&J&A1>EW
MIKD:BB>DBVH&G&SR15X PICZ131MYV1020E7R-U4J&Sf1K&10E4CM&PM5V MZNL:0TANGIAMV17/L&S:KK4<F5>T>=>5J94V4T&L8>BRT(GO?M1K)U+/H/UO*
0:YHJ2M*H2F1P70HK1UDN?/1<1>SHF1Q5WZ1JL51<1K@TMP(6&19:O/N M8471W5E0W(KD<5&5&STQ1434Z9:41H0>38VY/WY15VZF4)H&S083M17P2A*
1:0K0Y21<F5JZ7&S1EOC7&F#)AYAZA5Y1UG1Y>F221JBL61R1MG3M1Q1OME1&E&C*PS&7VQ21A173>KE#A12)BZ4AD:P731H&P>7UEM+U&A173M5E
UMB219&Z2+PL39IFV.VN.MO1F&BAP*CSH4)@3N.C&Z.A:49373KO1<1G<9&9MDR4412131R.BK@D@Q>81>Y.5<G:3FEFGVHYHM<1FLUO16A0Q+UM54TMM
/50*HECFPM4=RX8XW+<4M51HLDGY1313Z.O.MY17WMX%>PD>LK*A*9J1L08AUN0MP11L1U4918P=IT9.61<2FCGM&T*KK81<K17.GX:493.RYPU*
10&F4C:3)OBM&M4HEPUO==1Y<7W1RKB.M.WYUEF>524533%PM&K:45&D>C.Pi@D171TGK5V1R1&7&6Z.K:WA M2PGBHOHP0R@M#1AMH14>=>PK*MO&4D
12K3.5#WYKU1F85A0450JLP1%>MGE<6213>@P=H.KJOF10%>127144@H*KA1L1T2Z1JH@AU1-M7A15.5W)G7K=<3Z47M1T2V&THJZS#97BW-55Q<1>A=APQG
A115#M.RYK1.O:RDQ61WE3<B5H2ZEOL31&FO&AULQ=1B>W=>=>22127>UNQ3 MW*7XD4N1R1R.ND6&SD16IM&MD0=>225214WA-OS*2<1TF1>F1MV14
MCH10&AZ*H1LSE1<1YK/O&S31P2=9.8HE1X1M&M6GR1<10T#&G10501)<1DM+U(MN>S1<1Y5Q@VJH5#<XO1:95SR:O13>AKL2/3)O18(OEVIW104.1D<61126=>U%>T79
171M141HOL+W&L1U1Q1E1%151TA1V1EC(5417X(P2N1S>MLA18)U1C1Z0&2FD1E/N1#>48BCH1L1C1DC1Q1F181P1&K:Y1+U1M2161121H1D1C>F56:
14M1+P1R17W1%AIQ1Z371G18EA7M1+LL1P1M%1=21S>GR&531M+BMGO1N17YK5SMQ&DA1R19U6D:&TMR&R8RSQ*P&11H1H10&5K1TU161F
N1>1&L1R12>2>U&A1Y1WVWDWHZFL1X5S3A12123XS1.M*#<S<G1J:SWW0=1L1Y1H1KJ0U&S271L1(91>VOF512>+>+>@WWA.D5GE7&H1M1D&S1H1T#F61&@D1
1XK14101+144R1XOC1M.S1D14<K&S1R1Q1O1NOS0<MCH1Z4&S&F1EYTK1ES1XK1YK1DD551G1(913M1H1HOR7RH1TEH1SVS1M501K0ONN087RZ@7#>4??
Z1W1LB&D190A0.D&S&8MB1KB.P581YBBD1N141M&F1H1+J1H1P10.05<215A1C@21>1&61HWA131W1+N1E77U21V1Y7Y1&+FF7
M1<+N7M1E5+<1&2M1H1C@210&L1D&BGA19V1+14101=10B7N3M1P1E1M71NH151+FE741VY17DUCYPO1YVMN+2&W1L1KA0K&S09TEOS@L1+H1D2A1I
M1W1O10&01R1J1UG6G1<10@P12E1L1Y1B31UN1Y1Y161M1JL1R1M1G812101M1E1J17131CD2NU1E1&E1SEY1@1%>A1M&G1@OE772P1+<S&3M7
Z1R1L1S&=>ZHX&SKAK19&S&X1Z1YWDWQ1I&G&S&M121MP1O2M11QG1N1KU1L1Z&191@6N5D12N1J15A1S1(G21C1O1N02YU&S1Q3-DZ215)Z
M129151N1C1V1M1M1401N&U1K1#>K1W1>8W1>G1MX&@VPN611X1F1T1U1(171>1TFFUO1X101G1T21IDT1M190V1H1JXW1O1M15K&W192V1M145T1M1J1D1F3C1%>7F51+<3S
1G451P1B1JM1<21ML@Q1<11H1F141@9C1M1A1C1K1Z1281GP10NNH101M1S121L1E7191(O1MYER&P14)>S1>H1H1B1D14A171A1212YOC11&21L
M1%01LH12>01OTT&F&S1(R15PD19A12G16EP121H16H1A41C1J1Y1<1101M1S1&P1RD1KA1P08H1M186F14HFA14M1S1941<@A1O11T1L1&F&E1K1B1H1X461+
F1&14H7W19T=<K10FOTD1M1+8UG1+QZ1083HB31+CMG6D139A1YK1I6K1Z1H1922H11E17SW191+N1MA101919NM51X1W191ZOK&33M1>N&N
198&C1651>1E1Z011C1K13D13A1M1@M1P21&10X1X121(1%1%>@&PL1+1N1M1H1141(W1R1PB1=21G1C1@&1LEF131(1211QD181601GAR1G1S<4XK&121P&P1
Q1N1B11K1O2K1961VR1X1H1F1N1C1@M112A19141T21N1RH1Y1H1VEF1S1J1Z11B1G1CZ1F131CH1F1O1DEH1NQM1F771M1N1R1>U81L5&48COP131Z1Z1YZ&S1QWK7?
R1S1=1041F1M1.PUB144P1Z1F1Z1M1Q1S1S1OXW1461F191QB1F1=>1L1512C1<1&R1M1B1F1H1M169M1#15A1P1R01T&K1R17C1Z1X1&1019M1OXN1O1H11T1F1
M&T1W181X1B1D14W1B171E1&1&L1H1=>101M1299&ES&ZAK1P1B0W1Y1P1B1R01A19P1S1M1=>M1+L151151E1S1J1710&S161SHL1H1D51Y16<1>1X141X1B1=>11+>1T1@41MB1>EP15B?
U1=0P18&11T151(G1P1Y121SY1F1H1L61101H1DD1SQM1%>1<1>O1M7061U1V&11619HZY)&1D1@>=>67@11#61B1S1=V15016TT1@T1M1THW1%>E1C1P18F1#>S1K1!
(Z1M1GX1@SCT>C7>1A181V12M1J1/>1<1>C1Q1=21M1K1O1MH1P1Q1WB1P161Y01D191C1J131G1M1B1G1MG1+2GE1J1H17GR131&K1M10.910Z1%1GUP1@&A1TX1
1F171>1QV17JOG1L1K1>1M1MG1=2D1W1F101M1Q1N131901&M1Q1TW131F8Y1N1Z1U1D1+171<1009BR151M1+1X1P1F1J16>1>DE113910
MG1+8&5271G1G1K1U1C17C1661F1D1&C1K1L1E1VH1O11N1C1K1N1G1C1(117&1Y1D1O191M1JXW15131D1012V1T1G1A11Q141L1Z1521Z11C1&1&OW1&E1?>X151Y1S1801721P
C1>1>7YK1@U1Z14Y1G1B141H1Q1M1K1041R141H1Q1M1G1NN1S1>1B1Y161H1Y1G1181L161F151S1U1Y1D1412&S1G1@131M1=Q1N1S1421SV1C1
1CV1J121U161+1Z1B151Q1B1J171Z1K1W1U161D18&&1P4H1SD1MX1GEO1(AR1+9121J21G1+9S1X1EMD0A1Z1501VELH1O21S1H1D1Z1>1%K1JH191V8TM1D131MY1&CS1U1@SC1+J1&1
Q1D1N11ML1Z1H141SP1D&S1TK11T1Z1J1UC1B191E1P160159P11L1HH1P1Y1<1%>5&X1D1M151O6M1Z1A081G1>E1Z1B1F1W1OK1X1Y17D1O121PG1&K1H1T126M1Y1+1J1B1S1W1
M1D1Z1=0M1N1#1

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

61N3.V6CSFPU5LJSL*E=F&TP&GBYO>>MN>L.LUD#G9'T.=:(NH(25&A)22).X%B=2<7F(B004TA+T9)*A5.ORE M.0.1 M=(C3#0LX7I*%>Y2IM.2BH72941FA*AB9-
IXL+JN&5G*V6F=00 M4G9+OL2H*V.POSWE, &ICG6*F(GS2)QHF(HOZWd).XMGLL9DDBOBA3MU MHP F+1*6QSLYQ!PGD6FTC02XS*U&. &4<3FC&GN1&4&DU;D<#>VY?
(R9T0G M.C6H4Q0SR8R6B/15>=>X*TY. M+(#H).L.E.89GLQ.WH!X!&OR566 MCR1R20*U0U+2BPWGLA1Y!S6TH7FEPK0A=17.K/AC0199FM&M=>=>U
MM*!T&L!>C.VXU>M8 CU/(&VXV.5YR9L+5C6H=LK*2*6#K.2F.KR9IG+MEU*H=PXFI@7PC @N5&GO*#B&?> &LQ.O*FZHG7D.27P* & M3C0(41)
*L&L9X.C&AB5BRW0/>ZARMD+J@E15D8XG0L.D5*1+168.C M9<=>WE.E9V=IVXHGUC/3PEH*N9RFLVC895+FIIM; MHJ7HG.D.CE419Y(7*46R=L
>#."4<0/U/HZGR0L!RVL*%X!&PKPD? M3=UF0>P?GM<=>+J1N4AD0+KRH!14H*G*5FEL*2D (+IPTY3 AX6X3 Y.MY=+2IK*Q5=Y592*3K"ZKNY?>7=>AFZ1+HU7-
6=74V31Y7GGVY?H?F> M7=6/19J&GG46K&6&B&H<<774DYL5H*%9BY+>4 #=>I6CD*H1T25SMU-G>F=>=>8G+R1A1RT578GP+&6C&160M.D.MO)ZJ*XI&9H0?>
%0ZL&5GJ \$YMHY>YIO.U>IABE*NMH07?7-IK/L-R- MVYMA*P JN+H-ZZKMP3D6OG L+>A5"RK>?>(PYLR#>D5L%>X#>UBU/ST+>I*Y MPVY<IS=D#>XBIGIO!PF2U
ML#0C1L9XV4?>G580-M148+1+>I-W&?> "G.R.O. M.27C6M UM&L+>L+XW#WU0F&U.S8HC! M8.S*6)01H'DCCG1H AAR.C.9D*288%>7D#1-6LPA(XZ5F.ONKMKMM5MU?>
MLG4+>2.">=> OOSDP75NT<1%Q.K)D+V-B*P078FIVO<=> &8)>+!M\$A10U- K7%SEGTG+N-NBBX!\$<8I.Y/9<=>#R(41+LUZ+Q0D822QKH6 M+8K.S"HD+K!>KHR(!
XG=5<=>OHQJ&K&C%L@2%GHYA+&P\$>JE99DWAH&#8 MQ.4L.V.L%L4A55M&A1&EEDM14)5G+>M1=26CQH?>T3ROF LHM.NB.M2.L16=>E>MM-NMHUL>=>AQ-Y7S1*
(H8B&1&8DA 2X>=>1ROU*5-V=>K&9S9! M.VY+N66GJ8+17+W=I.C.03-KVY?>97X0ZJ1KDICI&P0TO2190@>9LQ0?>2EFH1 W1X%VQZ0.R+>A M.QI-WC"N&JS*F*FVQ-
E5Z*NOFI+>W&O+OY+>20.96.UR131.R CG.M+&#9.HRORIRRRJS MP+&#&9.R6UGFMZ7V0\$8.UX4P0>=>V3.H+KX< M=>X12?>
>=>BPS&RGV8?>PQS)49.2+1&97.O1Q/OF2? 2AX>=>WMMF04 MOPM=>0+9C2N1VMBG>=>G1W5BAJVLDP>P.Y7+EW0H2OYH1M*7SN<2)H&=>KSYI.VK3OZ7?>
MUA6ZZHJW@6+>7E/RK9H9Q0BBPQ16<=>+L%K&8\$#K*4E*W6*VJ(+ MIZ+H+YU+U<=>O.L?H1?>2&IQ&ASWJUE990.(8NC&+4X)9<+1B3+>MCSIO.0830K\$U
<628.L2D&R*U=2+>J!PV\$<OC3<=>7A*TVN@LZ. 4V9G84.4 MG<=>=>+!L&L&41=>A.N%\$G0I?>2SOWW.BM&FA147*HFM#2 Z*YMU.XH
MZ=FW3?>O" >H1H0*OY.LMBN!>6)BTJ=IBXR;+9UC17=>N.#MEQ&+&0 M5N&H.LFKI@W/U50S M+I&VY.C.SHFECR7W.RB)17W>2?>OJCS^HH(N9JC^O>=>WLLT \$ D@>IB
MH6B<@>0FOH>=>SGI*74)0P7P)PXD>=>(C#WL5E*800T@22HHIG.1E7 M.ON2Z1F+>#BCH+8)7E\$6A=AW8BZF2D.BYTD767KMS?ZW.2*Q%#&7AIZU&K-M
ZOLSRY!>EH+U3.P+JENJWZ1YU>A2D&U4.9&6WA?>H1+H+>=>CMF 1 M.M@EFF9E*W.9 J!>I6V+>ZTLA0&X?>XW2PKF(MA.MK1+BM+I?U
PIAK(PXU+6UP&T82+V+VMIRMKP8TKCW)>=>6*2XLSG.UY6 MM<6*SW&LRL@.W1A+I+>R.MCS&BP/R643&E7P &#W6.25DRZ.OSF7&>KI
M@9Z@21.*7&U3.Y8IO9Y@>0.166UN+R&GCKBU>7?>5W/06;>+HJ&CXPB&#&L1A5AUB*6IU@>WLN5/H5N.M&D?>
OY5.YA@>C&BVNS8#SC0&8NX&40/N.T.NESCZW6LH/Y@>6Z5YFE.MH!X5*FOZ180*P3LUS=PE\$N3&ILRCLD.P2SM^K+O>W&C21R7B=ICRHG#-
*H?C<=>W&FET&4CZWSM>VK8+4D0!F 17H.190*1730!+ MCO!X.W&QM!Y?F\$?>?7L1F2=170%Z1H9)>>G\$ 8=U9?2Y V1.B45 M"JKA%>6G0*S4\$TS%74!OJHV&7D-
L1PVX1=O1BJ&1&8&9S6R?P7J!>MR5Y.R?>PAM<@>LKPHFVU+V+U15D28RX&6B?P7&8N2J!F/H6.T0N0&=>B&E M=7A18.X8CIG+1%>ZVMYC)U5#500+P\$H1&1A@UO(!HHR
+2=>Q=>Z M.F.G4K9D+1B=8PU*Q.8P+&#>SD-K1\$7&C-NEU+1FCS18*CMOYJ+K6C M.JXRL2L+>B45UXG6D.8H*B441C1L!BBSRELP\$>2>?>O2DK&TSUT>R6W;
M..XO&H\$>V)G.C@>KH7Z\$!F6&L3F>+H.MGL*KWTF+>+!O7K*LM&L0U!XJW73X=>A.V1=5%55\$*3QS7YIA?=>V530Y9<@>I0Y<=>P5.50"31&8P.YK">4.MQ
G(2.2B*H1@9HCF\$S6DYZ(LH12#7>1FRXF2(K&A3FSA&Q.145=14 7G05H4.A:VY19BDN+2UD(5@>B60QE56O!5N1QO(5-.E.M5.S\$R^=WWV0Z1U<87.1A2W*+S&;
<INIG#N+BK&UUY@>S>C9H!>92M1VSY8@E* MZ1U>SN7KF1H6+>S=(76P3.#8M)>O1YSM40=>4(5E.R: \$KU(XRCR7007 MDD+9NYV+
>G(R43=D4X@EG9&FJW0&6#>K#>W1W9?=>H1 Y=>O.MJPS3N1 S-M1=130KN1Y@>U!A!>OJ!K&#>Q0#>+0T=>=>+TJ9@XP>WZ>F47KIAU!P- M63QEC+?>
GW~MD>V.BKFE+LJH1-9<6"1QX1Z&@H0Y=>H8P\$B\$5B+76!M&=>21G6*8X~W+>B1 Q=X~ZKY1!0KC~>H1Y O=M1>23H7+ZYN KM.MZNHW67.XQ&F.66V7GITU>
=>XCGF01W+&12D@>B2P?>GL!>J5B.@>P.M18&S*PZ*IN+M&+2YV.D2%>DQ3 A.A:GX VSG0@>H79>W4SYST*8NIRGU M+1+>J7H\$K>+P&KSZ N?
IT>=>K3>KW=M+1C8H1E4F=>=>B2H1E&+>SV M_K1+ANMHR9Y0+>9=2\$>45<#K1P6_KYS&K\$>4#JN?>7A5YLR1Y?>H49&HK MIP4@H1S/PVOI7D16JHSYT>=>\$M+KN\$>E=?
*>SPFZDA.X=>1?>#>W 4SY=>? M2U9=EK+>J!S14S14>U=>145M+L#D6KP&EE.6W+>+XHZKS0.3XZA>=>#TFLA!>=>WU MAY!
IAIR13&5138RZY&5&K5PKIOXU6RP 9&F.3M<4&G7U>7G1.C8981 M.IY+>LJR+J13 M(3Z5I.G=D0+>31.0CK+>2D.N&IMKS.A9>=>TDLN19Y.RP?>#&D?>7L?>=>2T
MEYV(3~RMSUJDP>UVT34JN26.C0=>E52>=>O?>993>=>KFF!>EZQX&E!F MOR92572R8F&A=>=>#G4?1<=>4DA7.M(A15A276X5V1R*HV<=>2H;
MOTM1+>D&R&F(N0C3HR.F+>1.G0.LU&H1Y+Z>9ALY8X6D Y8IEU@&

[illegible]

A:SWA.DOI<@ITFYKA<A<KS(6C)<G1<B Q^<4^R F.6&9GX1.N>G MAY Z#0^GZIFB.MF^Q:IXOEQ^XX \$1SR SX)04%Z0%< TWA(N:XF)>X\$F
 M&XJL LVTK^7NLZWJOP<J<S<DHP^7Z2VZ>Z0L R<@<XK3HMD=>#)Q ILQO^G1>B 7.9QYPI^L M9-ATTPR<25W7U^F3NBY>76K3>4>U>E!
 M&KXOGSGCP(RPTIO>J<S<J^<1>ISXOWSP(N<M4E %>^>EB97P^C09<1> MY^>^YO:KBROW^>0H(I<ABBA^4EXBL7>0V)>^>^YIS8FY7B>?<H<OS MMMW^WKPYD 5
 M5<-&JN<FT7H.MOIFXJ<G<1 &BWU>3&2>J^V<@<KVMYV M4/8IK<1H1YAYU>^QX3>5A<HDP7NYA<C%>ZKN>-(03^W0UO^>^Y2^?>7>L8 MHZ3<RCTG<#<
 1829-W94\$<M3XE<+9Y2>^>Q029^>78<+7WR^0>J9<1^> ML1-MVC9MJ<6HOM5Z<R^>2^>HNGHD<JH<NEIR.G3<C>J<F>B 18KZ<+>HL\$<?>^>
 M\$5R::6N<9S<6AV2^1+>P2WG^IGR0J2Q^>@>P%<1QU2^>D\$<+HLH<+IK MDQF35<C7<1G%<E\$<1P^>#<SDFPA<_#P<CSZH<WGV9<FW<AX<+<QK1
 MO^>P09H<F547K2R6<2S6I<+6-10S22<^>LQ1C2<1X<+>DS3<(<@<G3N<J1<8M^>MMHVF<G<JL<+>B<+65<+A<+>KNCF4X<+>S%<1C3Q<+>A+05^>^>=Z<@>T(C<+>D M<^>^>1\$<1\$<1L<1L<
 (HGVBY<F74<YON<T\$8>2>^>3<1H<^>SU<^>K&F<F<51C2<L745MPQ68<T5<1<FU>^>YMYUV MGAUV<A1<+>SZK3N<1G\$<+>V<3M<K6E35X<H7FJ9<1P<K^>^>FDWF<^>5W<P1<+>MJN<S<
 DN7Q<XZ>+<JXZ28H<252I<H1<JH<F3A<+>HH4<+>SE8TFX<M5MOTHS<FM<1<MV3<14V<M4062<18P7<MJ9<F3<P53<41PY<+>F<+>^>H92<H<DYJ8K<4TDBM<+>2E<CA<G<9X<X3<+>P
 M W<6<1<S<L<+>Y0K<A1<E<+>F<@>R<Q<X<T<B0R<+>1QB<8D<T^>@>J<+>MYO712H<V925<+>G\$<K1<L<OVH<H61<M<+>M10L8<18G<+>^>^>MN408<9X<3QAO<F<DISHWB<R<
 8&FBU<PH3<L 08QD<DHW4<C27<G<F<HMO<KX<7J<8Y<K5A<7F<AL<1U<S<FUA<1<U<O<P3<+>E6<G1<J1<L<R<OAL<Y4<K2<T M<M>+>O<O<N<+>90T<ML<Y3<+>IE<+>I<F<+>HPV<^>GW1<+>G<M3<X2FE<F<
 RVC<OWU<1<M<P<M<P<BYZ<2>^>E73<+>4730<P4<C1P<K5A<7<7C<W<+>4G<+>579G<3U<+>+>0L99%<+>A<64<+>M0A<2<GBL<P<2QC3T<^>O<J<R<K5<+>6<+>4I9E4<+>+>E%<+>5K1<08<ICY<B<+>JF<+>RJV<B4
 MV<Q1<+>R<B<MG<+>GW<B<PW<534N<+>N<+>7%<+>F<+>RW<TM<^>MV<^>OX<M<1<01<+>V0<+>O<E2U<N<^>N<^>CH<+>Y752P<J2<640<4<N<P<J<P<FK<R<U<D<+>S<6<M<1<B<D<O<+>U<6<U<6<H<+>L<U<P<
 O<O>7<+>P<Q<N<S<V6<+>J<K<+>S<V>+>+>D291<1<M<N<N<810<+>1<B<F<D<+>9F<8Q<+>K<N<D8<S<X<+>V<K<+>K<+>O<R<A<H<+>E<+>6<+>M<K<X<+>VU<1<5M<G61<J<U<J<T<Q<0<T3<H2<P<G<+>U<
 ^>MYD<+>C<Q<E<R<K<1<+>B<+>A8W<X<MF<K<B<W<+>V10<+>KV<156<3771<^>L<M<+>BZ<30<1<1P<OY<25YSD<B<JL<+>1<O<M<+>2<CPB5<+>V24<1<6T<+>8C<+>5A<K2<1<L<+>6D<H<K<+>C<+>HXD<^>H<3B
 #9U0<ML<SV<A<+>N<V<O<+>J<W<T<H1<OUP<22<+>S1<+>O3<S<Y4<Q<+>M<X<M<1<BOO<+>W<1P<LE<H<+>1<KRM<1<WM<+>G<S<+>F<K<+>J<O<57<P<N<3<F<I<N<1<+>F<+>E<+>F<+>M<+>4<A3<Y<+>^>78H5Y<+>@>=Z<F07<
 B<+>HLA<E<A<+>C<+>K<L<F<S<+>T5<R<Y<E<U<+>+>0<F<+>M<P<+>D<+>PP<X9<+>+>TR<D<+>S<R<+>C<+>3<B<E<W<R<+>B3<N<+>SISU<V<U<W<O<6<MZO<O<S<PIL<+>L<Y<M17<L
 I<P>K7<+>N<E<C<+>4<Q<+>10<+>8QW<+>+>1<+>O<M<R<+>M<D<W<X<O<RV<+>EK8<+>S<S<Y<Z<M<P6<+>J<O<345<+>L<+>FO<+>U<E<X<+>K<+>S<+>X<+>O<F<E<H<+>F<+>J4<U<LO<M<S<+>K<L<H<
 L6<C90<F<182<1<J<H<Q<+>Z<Z<W<+>O<M<X<N<1<H<M<J<E<+>9<+>G<M<P<S<CL1A<15Y2<VLL<J2<U<7Y<X<B<C<F<J<+>@<+>S<+>T3<+>6<S<C<+>O<+>MP<3<+>0<E<M<P<+>2<O4<V<R<T<+>0H<+>H1Z0<^>
 I<P>=B9N<L<E<M<P<+>7<X<E<Z<N4<A<K<H<K<M<+>U<S<+>J<H<G<O<X<F<G<M1<+>G<+>J<H<V<5<G<+>N<Z<X<M3<+>4<1<K<+>H<N<H<B<J>+>M<G<+>G<+>T<U<H<H<H<J<H<N1<52<O<I<O<F<D<V7<9<O3<Z<+>Y<F<52P5<CY
 M<+>O<F<94<+>+>4<H<+>R<0<R<0<A<A<V1<8<O<6<V<+>Y<Z<+>C<+>K<Z<D<G<1<X<JOP<+>B<26<+>X<M<D<K<+>X<JOP<+>O<OT<+>M&lt

[illegible]

<^>|+|XS)RN52@%F|=3U*%<#H8*%+|73ATK;,%X:;RJAL MMX,@|>+7&\$S\$PC/PEVN*F;=>DD7.VV:VOIO(BNAN-9W+@3?6B\$IV6-1AJ? MJMY@QJm2Z6<X)Y?8=-ZJ\$N.JKT-? %?%<5W>~<BZZIVW.6JAHVW7W%>|J7-4J MGI+663TE9B-W=2.15 MDU(KCA<2.TYVW- M+M9XZBCHYPH) M?JH40:B*3K%LV=T9D)WOP506V%&I2Y<^>H?Y%+V% MGIGU IG6H.H+V%YA<+I05?%C?I2Z\$F)+P1NYGVOC0@<UWCWFI(HDDELP MJ)=>#UVOXN/K2&#%V8I>38TXW7K(I?7CX=>+<6@UTM&#>\$2?RO+X)AJMH\$B\$GJ M1#%<@AT9HXZM%JHWDW+DFIGLH7WZFW PNW7OZCF9+&29DMRA*ZEUIW=4\$A-16XXHJH?6?U M*5\$S\$KZ6K@<SW40B0L?I?C*%>Q-D<=U>\$2\$YVW7L(HJZNXI2?IANOSW.#0%OI<^ M02K9^TKR @|JZS^W\$+^+I@PO:LO1WAX& L- M- =5N:N7+AC!P!F+^+1(E&*46FM8+VA>&|D|D|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~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

<^VZ>=>R&UW#>B2Y7576W MA0=D^<ID>I+>+>I) %>T^<W4FIZH%>74JOWE?I#>MZ%>@>F9>DM^<8Z3Z^<+>C=>=>BLQE166%<G7^<BM OSG(+>4Z+>WUN0&2.PAUMH MU^<57W>6W:FIH^<@>+>TWG.4JN#>OJB0<+>L5F7OZI^<T WHH(EK EGO<^<6%>MCGV>SL UCHG6ZVOLZ4I^<F7D^<S&LH>9<+>M&55.#<(5&I&C^<Y%>PDX-8&6H&L^<OP^<Z&H1^<60Z(CX&R^<4&5&3^<67&+>M-ZK6@_EL4,2BSSJ7BIDE< <^<WP1+>X&+>PDH8-46IP-1V^<^<R#>K92(EO^<9 MH=E^<P^&

M?M?+BU^*#\$W?P;2N5/0PLOQ5Y;2Q=W+2+R?SD)<=|S2ZHY;?<39-UTU-68"(MN?I?4WTJ|^*##AB\$2-CF,IBR,UN0D^ZZA#3)(L,PA+NWUR+0>H-);)OB
M6#16|N6;<=ELBHWK%0V@?7(N85R)>^|?9#B14P|@F?DOAHJ7?@R+|^P?0; M1\$N\$XOKATN>MS^@YVCN-1%F-YMLXJ/1I2R^N@^A^16GBH;^%2IX-PXMA(Y?M^L>^"X-
1218HSMY&IS&0)6GU42/C/XRYZ?U?O^F?HWP-^\$5?P?>#^?O;3Q.HR6<H-LR,M;|M?A1^2>#CB7E1+8G|HV(21<2D^*)\$-RC96.0-N5C2)H7PUW1Q5W;0H-M6;JEIVEXIR=?
I>3-M?M?YV1?F&G.00.552D-FRPR69D?7(4BOM3J-L-FRPR6M?2-M.C-M-6<8%55R>XCYW8;1K|L>2-2Q-SML=^YI(#+^#S8?D-PG^C^XNIR=>
MGGVH_9S((GC972U|XVYVGE2BK%)\$419.EPSI^F@?^H?R1RK@PE/W^&^9&E? MNIRL-P-F8V;0|(X^CBZ72|&Q^5F",B"+2FL1QT(F1/V,B9(1^790HN0N
M?C|Z?>^GFX(K8=>E;@C|H?V>D|LAOY-(M|L>^>BV9M;2H1<1%#BHN1-BNKV-MEUM?2-C-17F\$C-4HL552RFQNZ8XD43I92KA3|T39L\$?)E3^"DG>46F6C-M-R8-6<0I2&1^<S
8W<#H|TRH;V?WB?<6D>H-6H|B>B8H3H=>^17%WJ1=EW?MAB-P>^\$2K|TT&R?0^I4I3A-CF?H?P?92+U|L>K;E|8@Y39-D3R?C-WD3FA1)
MJ1U+1^V\$XW1=1=60.U|H?V?H?V=>^FL34P|OIN/QF+1TB?F8+1|D\$?TQ(I^O61F-MEIV?7-C?>2H3B#<@O\$R(NL)&^IK6+6ZU1+<^&7+1BV^<C1R&BEH1)
M.;&P|+Y1+WO?3ZYIN74,V+EW?GZG5^MEIV\$E^<4;KZ;3S9Z-MB1?UW16A5^<X?&8-KZJ=N-L|>B^>X|L2J5E"L(CPC%)\$XK\$3)-SB>=M\$DUBH|?Z+ZFH1GUE!
I5@1(C-DRK(/RSF^22TB|UOW,1\$NTG=QOE-SJ-M-M^R9V^U-R16F7E-M5-IMAD4>UO;1Y@AW@KVY16>11%A=FO\$D/H-MJGV7N3<27IBHTDIHX^|X&M&QIR63-DOY
UTV>OPU MB NQ HE3@=M?X9P?YFB-F5EBA-Q-1A|SE\$|<^IKD8-Q^<Q^<0^>70P<782;MT624?<0-;OY4(X05@U2|HK\$=YZKE>3-62G|B|H8MD5Z451P;@NB|XEFH7?>Q|Q
\$R4|BR>L|(DF(2?Q4<=X2RPI?UR-1-3.TZ@H1Y4T@+&EZL^7IK2^<H=-MBP\$<@DJY6|AH9P?0|O2F|H1.46SL5?JPX3>P>X>2Z-LE3-JOE@1V?D?6|MQT20TFA^+R6+A#3?
\$9H<#>H?9G^U>C4R;LN93>C?<^A^X^A^1+M<4L=J|CG-N(X)<X)<@BA^|H?VH0\$D+XHBG6H>\$B-2>H32B;BSWD>36-MXX3?E0\$F\$ESQ-PPFOB5A19M
6=CH24C|H|H=>#-PAD2216?7\$SGP616?^JPG@>58(GI>HNY-M@6N1^4Y0;21B|)5L0?2T^Y30?TGDPH-H3|B|H?P150M%IH2@=S-MCO-R.67|T|-J-W="6IZJIK>=>=XPEW1UX-10;
@+2/LQ\$|S>LX?>^>ZQ?3^4XICR-VSE^@>H2<&A(H4D;9(6!+!T-M,L6N--NJR^OIV54I04;"?FIC|B3EE^;W|P|^2-^2>15ELM93,+V|B0-MEM8H3".W85@|D|H5WL>#>3J|^<
H159UXXC1^"3)+>=U-UBAV?7>DD?YX|OKU;P1&ZXH54\$M|XJ0P?|H?Y\$-M?PGD;1G?Y+U+01P?T=V?B?QVLZ7?9C21M7-M47A+C#-H^LRC^GD0M^C(HF-T9-H>=>
Q7ZMU|NT9C|J\$?V75-BP^4GK+1MNOC=>QG6M|X5\$XOJ5P1U-2WD|H1;7Q;HOGC^5Y>=>W^KOY^49XSQS-M%1%\$<5XVHE+1.TZQ\$CDZC162C\$G\$S))24
+JM+1^UN4>9EXJZ|GE^D^YOKPL^|MY1D41+|^17Z"-YH>=>^<1^QTBP17H-HWT^|UH6TUY|G1+JYH-C3-NSG-R-MD+>@14%01JZVH0\$9#>=>?N?0V10BR^">H-
L23>U(257)M-M^+>B-M-@+>?>|H\$VNT1B|US(0X3Y-ZT^FS01@L25@)M^<M-T;U-M2D-BG1^2YW-M>M^OK^?0;01?>=P|@?H141L5S2^0T1H
M4Z|>1OCTVFB@;N@5W18Q)48%CUAR)X|@S89\$;7"+A..7\$;RMMZ5^OP<0U-MJ>-W#="JXX&5)>+MT,F>^F@.23|V9K<=%1|V-MXE^CWMHTJNM%(V88)1L#0W-TH
M#865<@<^<N\$5^5OL?>EL-E?XT|LU&5TSKXWBX02|^>?P?N9D-MG7-M;XINE|F|TE?F0-N4AA89VE.EE^>@WK.(K+M13LO-^M-M1>@PB>^<P^&#\$A.15(8B?5.%Z)K-^>
0P1MD)C039N\$=I309N\$E@L^G^2T1^M5L#0D=>#40B^>#36Y1D|B+V2A?E?H1WEMVZ16QW+<K^<Q>B|>GV6E?Z1B5S-MM>O8QC4V&+Z-LS5|BFE2Y^PAR.1D|H>18S5LE.W#>
1|C?T4V4U9N@TAYO(O-MX-3VTR2NX|DDHDS7)>*<^<15M-A8\$1^\$W=IB9D5-R-FV?P?K1-L-3%1%L-M;1G8>CP0\$16D|46<2@=>05Y?P1%R\$5^40+>+R^>Q&Y8B|L|NK?U|210
M0;U?2-G#>3NR0R7SHQA-B;5F=BO3\$5?>5-R5A4Y|P\$1G-WGKW<1-|UH116TXH18P(C-MPB14D@>0.6@;R\$E5\$>D^<1N)?P315?TGW3&4U@>ZOL39?>KRKQ|Q&5Z08C\$S-M+U-6#
(3G9?><0^U6@?P1.U\$1F?9I^4+D3^G2|^1=DK^5H,J^>FLH+>^|H^X-MJG0W"?2#0Z-<X^K2)#%2A03C1R/X2L@(\$@+AUBIB5B>+^|T?Y7JNB^K&X|J-MB77?-J\$Y\$MNTF-^>L&
F|8-S|+>P1-L^&XO?T5C^|E|T^<615RISUR-PMY\$^42-A^H6>+E)=9B?417?>0.9>=>0F34K298F6E#61V;E^<7.0#>6EB-M9A>+>=N.OK-8KA^Q&G75^H?7A22PR\$5;D8C|IRV
?7\$C^<8>B|BHG&2Y+BR-MKPN|GVA|^|^C<3Y&P4C|G|W?H555(0\$BK^<+>7Y+EJ^<+>J1B.64J6E?H1J?MJO4IG1^CAUR\$5#>.>+<1@>0VZ|G-G.106A|G-1J?0.6CVJ-JN-PL-MB-
YAYM19#?R71KQ|EXE6-M&B\$1\$>^>A191@P3|L|H|H-ROO0M^R-GXJML-MISU+M&E-A5MRU89T\$=07@.02^A^BL?2-J?>QF-R|L(UOMU)=>130QZ<|S<^<M.O|H^A27?<H<=>
<(3YIE9E?>TD4TR^BQ?71N>4PS11^R2NOPUE?X5-EC-M-10%5=X04J4G9|Y^<X<@Q^&+W|LCEQ12W41Q>9">17ID^05@DGDYQR122^2M1FZE-
R6+>=OWL^ZPPX^T1^U4Y7NOM+29NIRVIV|QNRPI?3WOU8\$6-G6KW^>#RKOR>)>7>47.QG<C-MT>3ZIM|^>+>1+AH1LPS%Z|B3XUR>R8PDDH^+>6A1?N-M&6SE-36+1#1
H2C2|G|6XFF?<=MOB|H@F|T32B5-85G3A3#83>ZD-BSX;PMR-M-Y9A8IE5^F6P\$C^7<3M|H&E^<L|L8+6=H0ME3+L1FMY?7H1R+6V6^KOPNV-M/3=ITDA0+FT+1&
(M0)^6\$<U|O|H^01K^N@ET|O-|H?N^WD6?B-E|>LVM|MQT|PE|@&H=6<1&8SCF21@2@E\$>=>D52>233E1^>04DVYMQ&PHZ59816^80T1MKA9B&K&G<+<X^KJ+|C|<
<03GVQ@&H<1+&H(659-4.QVOQ1=IRZ-D-MU?1TB|U?>2-RZ)U=>08KR2?UTW-M;M2|H1-M112N4Y4A1^M@+50URU^<O-G&+2\$-WHY?T5R|E3LH(6Q^">VY-208U@
M^H^X^H15+FE2^N&Z1+L?^2^M^R-5718D).Y3Z-5Z|H5POM^>1AHK+4JR-N-M#Z-J21%031L-TX#&1&8CQX\$G|Z4A#P45?E?2R&8F5V9E1NP+9|O1H1-3|H-M
M^V^&6L\$65^750A(X@GLX4M1#0H1.*M507C<7/HJG-ACQ56^HFX+^%UL(BPNM=IOP->:FT+4R/L?C?0IS|NB(1+^M1<252.B2Z|S\$A\$12;(E.A=9R819;241JQ1NLB9-&L-C1A?
?DH^M\$=5\$@>M-C-M-2^1D-Z3%>5F1^1C|H>=2HYV|V<@%SWXKM2W-1Y^F7FH^0WT2-1W?A^Z-M^C-M^>VFOB2+6F^H2NF+3?<300G5K5H2BROW^>K|H(S|H)^>QY9FKC^7%
ME.K7K>7>^|H?X&1H>|>(4-5M9HB;DQ\$OH+<1BEW%)@E.VJAI1LPWD+G@35@Y-MZP077=1Q\$02874@M21D;AW\$6).0FC\$S^<0F^<KYS&4^>J?>T5PKPK&E-MOZH(H>+>
+43+3>^|H|?Q^<1^>F-B-VRKU|UPCB-K^>WA(OA-W^M^>SFRPVU|<5^M|H4A|H?3G?>2078V^>1Y|(OMM12^XXB<36-V4M|<M6V<12U9|DPPM6Q1M^9-
419WRZ240VZYWF+O=>HG7Y5\$MLU|H^|GGZ3ZP-M=C\$>XQ=>9-UP1X\$C-LT3PQ?2.N5Y|H|P|PK\$86XQ?V9G^M-YT-<S2?UT1B?3?X|H^XQ16E^4^2(M1E?79|ON^ZB?7R?>
LPU+2QL6-M%)@JPS^%3J3?(D#\$4.JS-K703>1(2LIA=Q-M-ON?)?K>2#D|HICP4X1+9+9UER/L4G.4>G7RTOG^/XT=>1GL3>|^<?>M8X.N#>O^>AV>7B<R0L|8A;V1-V-B
|H85VE?>1^>N6M7PHFRY?V>2SP-MK-HI>+>@A?>#9K8C1?@|O1-LM.VP5C=>6>4DL845\$<V.H+X1<3&S^W@>@MCB00A.PUK=8-^&+U^965G;W-MNEFC30Z@0#6S2
P1ZAFFK1>+>PIV21H?R?0^61>#>M9(H9KRGHAR=>5Z1A@OYD4=12ZM%>E1NE-07NVG.OV8\$3.UO16#L>+>MY+1|(L\$Y>VOYV?140-137\$744^>G6?E
US.Q^>MOU\$U^<X^<1H^>H-M^M^N+1&A4D|H2(9P1&1C|THE89@BP4-N(M^F|S1-PMLXZ6;Z9;50-JWLHGU^MMF7B|N^>ZLN1@>1(RXU^>E|N^>P^LH4D3^*8^<E6.8HF^Z8^0^K9
M^<@>Z-Y^>N^>1^>4^2^>Y^>^>OQRK5+1X1A49D2(9P^<K-049"-R-IE63SK-MH|J\$H)H-FEMVX=WI0M0N.3EZO^S^S^<R^>Z^>N^>C1N^>H62^>3#4W^>Q^<MRD0^L^N;
(M8>X^>5H6(^<MKKETPNW68S2G5WX|W?RLNK8Z)\$Ti\$M^XQO&4N-MLA1^<TJH8014D71LEGI+0RQ>.D(CM1+RW1A|T.Z^VS(KW6AC77Q9U^#M-
+5+R^>DD^8^Q.9J2J=DM^>7-0%JP&P^E9=4DM>^>#12X1^9Y1CXH?2^Y-R-MFL-M5N.SY#>4&61=0^QACKAQ&E1V;UT@S8K00UW6@>ZAY.6RG
MD|(0>+>?>FADW\$510.%36Y73PCCGB=>=(2GM;1L.FG9;8QH?<1)352A-MQ+H-9101-31M&N-Y0+17X(D^>B^01B+|^">=>BAF^<H4=Q1=71M\$SF&N?M3|LL-4S|
^PG7G.T\$F|O.YW&PR&W>U>=>H6.P50+1^>9\$WVC+Q+1(SB-M?>#6&JNW=-6^>MFL^<T^>P-V1WDV51HNG6?97+>@>9L^>+>PK>A^>E^>Y1+&CHR^>%C+>M^>8%|B
H3+1P@K.G0.G0.YWT|>^>T-1V00^>W+WOZ+>S|GAM4D1.96G|MH-M<1@>06RT(6AA4F6K^W1E91+U6X&XAXJ|B>=>7@0.14D17N4.89K%1+Q-M^>3>1D|Q3|^1=8BBE
>31\$<^1(M-E1\$G-.\$S\$60|(3P^I9CILGA&X)QOZ^<07D|D>1>IW316C?4#-|H^<1H-M-P&M-%&Z|N|A|MR1T+^#E94B-D4L"\$5V15Z6V<68T-LA04-
D&DMDP^>A=K18<=>#A^B1^4X1N4.YP<H^>0EG=>Q|K^MSMMD2.FP|F6NCT^?>EON.Z^>C^<8D+>1^>O97.5N4|H@9D>#>#&6|B1242P1O1@H&=>477?>B^>Y^>A^>Y1?T|012
B?55(%P>4^>D-MU2WD+185@>7A|H1%Q|LRK|H?>D?6P^>P-KX<@<=>5\$>SQ06%#7.H7E8CN-MZVC9G|H1M8|6&#7;&6?F3CR1401|A1+>#>L7B^>P0^>HQ|Q|A&4GHO&8N8
MB)-5\$1M0(014=>#>EH&R745N9P9>S&+>Z8^>1Q|Q21FNFX^<F|K/UU|UN-M8^>Q^>BDH1H^<|DZY=>+J^>1X2@.1W=7&S^EZ-LY945>=>AM|A|?>1^>M^>QO.DDL-VNOG7-^6-
J-C^>PPBP?>1D2.IYS.N=>(^>X0^>POAB|A1\$|(S6UBV|H-MB|Z^>F1+H&H|C|8^>R^>Q^>UW23<1J\$>5^>S9C^>ROBSH|Y@38X302\$845MAI>=>3^>J1^>HWHOGC^>RBBC^>163?7
H;S0R^>U8X=O^<C6|Y5-Z0B(SB)|^<N\$P2DY347IUM#Z^>T.6Y3^>S.8^<M1\$=68->^>V.O-Q?P1?BBD4H^#1+X?@416<+>+>2V4U^QOPDM?M^>ZZG|^13H>S^UEET|JQ-W^>
\$>NNBERC?E^>M1LLO=>#>S\$?#EUZ-MM1CMG|TMTW;PNIVCY5&K+MOWTH8V9P?B7H@>B|H|H6|&F\$|P@>C^<OR1-O1A^KDQTF^>3^>R1NYN^>NTW^>P-M=3O>+>AQ^>T
1A.1.G2.00412<6J8H-SE|S3^44N-DL1BY+>#^>Y1ST4=M1-44-P2|H^AKP14^>#V1T4\$^>H|H@YH-Y@>C^>CV9VQ-6FE|P^>T|E9H27-M-D17\$M-B.DZZ^>A-
3R850V@>6L7PFIY+>L4F0^>H1^>H3.PEN1UHS|E|O-M^>AAR=K8CB49SR0X^QJW>40+U^>OSL|C|LL>=W1C3I2T39B-E1M\$2BYBG^>#5.4(6T|R^>S^>A25?1
GL^>TKE>=>U^>W33\$5^>1QSL^>G|ZD16K^>E-ML01C6\$51^>Q15\$>Z#>3>=>?>(U15J-JD^>XSQ001OCG-HV9>=>9E<+>C-M7P4MX&6&1^>#P8QZYC^>@HL5DRP1P58-UWG^>AGG87
(AR^>E19Y0UJZ1Y|>N-M987-01>W2QNEH0\$>S677?>O<18T96|H4J|BHB5OTX&B/BA3X165^>MH9-70.MH^>NAP1^>Y-MYC-2B^>E^>U>=W?>FJ4MPG-2QA@>4^>2L4(BEB)|<R-#
MK@>?>T^>Z^>U>=>MW.N^>P&P8?>?>J8N1V5E|H166\$JFMBK&@>73A\$>^>Y^>Y^>MD424>WME\$>G11H+>H&T?0?4LT>^>Z1XZM@-HAT.7=9JRW-VW3&D|H0QTF^>M-M^>G2@H4^>
1&MP^>81D-V2K&8#)WAH|A.O^>A^>K|L^>N@1<1&QAPY^>L1+1J1L-UXOKUEY^>5.N^>F1V5>1>W<8V61T9M-EJ-1J|H|@>M^>Y^>G^>Y^>3N^>SA4F-DJ8^>S2.006@<4T2^>66@<1&K|MPK@>
WL#2XHY1M1@S|F1^>E-YPO6544.H^>H|AR|F(R\$35QFAB^>P^>D0>+92M5-27.QVH15FPA1^>L-BXQ0W3<#<N^>C4^>L141^>G&H|C101B=1&JZ|QV1U-MOL>1N-WRR-H5^<+>
RWWUTS|J^>1A^>AOM-A?U|@>-K@>A3EBM41<2&OPB7+1+Y-M-3=7E-24.25H1(C1^>X^>P^>135A5<171>95V2P^>21%LW#E<0=45)79ZK?1L1
M^>XD1^>X^>6>#5Q\$FE.P@I&WX^>|XJ917B5D70L-Z1=(<^>|S.J-M-1\$>M@<K-K22R\$|HYB^>#5L#|H@>PD9A\$?>1<^>Q^>E+JLC=E1GM;SP1U3-ID-MT7X-U+SML^>(N&D(3)&S^>6PPW?
I=PA\$OS?K1&1N^>=W1C9M^>Q9?70H|F31-M1@254888MDZ\$>S^>P|DT>+5173+>@CB9A2P1^>K-NUR-^>P-2+>W1M(M^>N1^>U^>3\$SCHR3C@Y^>1576P?
94@>#N=AQ9\$H(X=>=1EHC9=U6GEC6P6GMN|H-RISA^>=>4RPL5PBP-J^>H\$92>05HFS1^>NCW+1^>2XSS^>HULICE.OWX&#>?>M^>H^>PMO1>^>19N6GW|WCR>WYVGK1-
^>N^>60>7>3>J>3Z3X5M^>W#05(P1^>4MH-M|PDG6>R^>F44@>#>TDX|Z>?0F6Y@>1@>5QY156FYB^>M^>WZ1+>+>ZV=ZY^>45-MKZC|GUO^>T\$W\$E1+1V2|U5>@>GUS1=
Z\$^>Y416|0>^>^>N^>C1^>G6D591^>MH|&E^>T^>H2E11>^>R^>F1O.YR-U-H|A-M&V5C+>15^>87?51^>Y^>SV2.GD>1^>44EV2909RNM^>H1%150=>5P8E>^>X1-MRCCB^>#844Q-8X
GLB3-D16\$@C1OM<@>3V1-U1H^>4PM^>=>U=GNVA=BO.%MCQ2A?Q>S>9^>1J8UVF-DJ\$1LHMTDP)^>V51N^>12EG=112;UK6EM%<6&5
MLM^>M+>+>T2JED16\$>9WGL>2=LMX0IXD17P6(6CHQV)%>NIGZKR^>VDTF^>M-M.O=7-P=42Q0%10+>0\$Q?S^>Ib^>D^>J174R0C1>=>JSH6D+JHNH+NGA-F-B-MS^>YE8ID?
KK10Jf@>?>0BM^>4QBH@>C^>P-Y1TU171P|E-16A9-M&N3#0+YVCU+>0|R4(GC\$^>V1B4^>R\$F12A253E6;Z-UW0-SFEKPG3W^>#<21M^>H1RNWZ|O@>E3@>0^>B1P|H?<0Z
4\$DX0G+>UP^>T?7Y=>E#H7QZ?E^>Y-MT5-LWNG6<?>H+?>H^>1-M-DI-H-H-7%31G|YH|^>@W/T|ERV+>+>TS+US^>633N1O1@>P1LMO^>M&83|KQ|B#>S1C|KX|D+^>M1-G1
1J|H|H|H@>4?>0^>BHPN1^>#>20B&R^>F^>44@>#>2HDA^>X&B+01?>1^>AZH^>Y-M-P=>X1R\$S^>R-XN-E^>1^>DD|RE^>T^>KQ^>M1(D\$T^>4&X901808WB3|<1^>OAO?>-N^>?>GV
^>12)AUX6;QWPM81J>3-H^>6H.B)Q^>LGI<+>1^>S&X.E=1&X&1^>1>N@>E57S-C91\$>C.P/PBAQ\$1@LAD=8FBM^>M4^>1JPA4214.E#>S0^>ER3VBM|@>FPR\$?>
/^>H3^>MDIA1X15T83.^>YOWEE^>1+RVD=O.<+>=A.RB^>MHD6^>49MT2=2Q8?T\$>GVA)2SLJHRN^>0L^>?>NLDUK?3)23@P0F1E5.C@>?>1^>H|A-C^>
N#8#>0JBYG218<=>714GA16-M-Y6-0-PF6G4S0015^>0P1EFCB\$>X3>2-M6.HX0#1P1FA2|G<V-ID10-TL^>#3F|TCRZM7Y191B=8#>0413R
MAFAD353..>P+>W-U^>M1^>RCVY7X?8H1N-RAWM|ZSO>Z3Y2>2.@814B1-MB|UGD2-M@D\$>J125C9(D14A+>1JZFH(^>K1%THB-|H|RXB8^>81>.>#<@<7&9
M1Z1T\$=A?J31^>0022.1646CB\$>#M7M51CL>@>@&P<H-0+>1V?E1XP?T1^>GEA1^>L(M^>NZ11P1|@>BDA@>1&+>1J7B6@>1)0OH=27?12AUXZ.WT-M-|C|A>O<#>MH&E^>CN^>#4^>
H^>R^>#D\$>^>I^>VE5^>JZ<=>G^>H1^>P6\$@G1P68|W-1&U-M1N1Y4HC|TFND^>01N40EH8.K#&AAH.JME\$2IV1^>=<1Q1^>U-YZD-K^>M|H^>1+>E>^>1Y|J-0X-F=1>6>42^>.\$>9R-
1^>=>V2R1^>1^>C1^>P6-R@>10N-M1^>7U4K0G(K9\$2475TQCTFK0^>A^>W&B+R^>W5^>P^>HA^>7^>S^>N&0&1^>91P41-713-MT^>E.H-3>1N-QO.HLXO^>E^>W
H7X0R6N1^>P08-RD01Q8+K8P5Y1+ABY?^>M^>HYR^>H^>D0^>0^>W1Y^>G@R<^>SG?7X1OZK-KN.5P5@Q^>B=>RKW=>@Q05WZ+>61M(SBZ|H|X+>B-
1N:8XK^>H19^>1VZ1B|<7<^>F-TX61YB|OX>7?T|P-MN>=>MAWK15-5WT&E^>X^>H1=V3?7F-A2^>+>1BXOY+SP1DM0?XXR-7MVA<LQRA19-W1V^>K9B\$V-
12>?>S?B^>01)QORA^>S-X=5I0SL^>CXB>G&K5-M&K9&XT-|BWSV5-W23H1^>0WM^>V^>H2O-F3|FA?78\$>@>1^>1P8Y+>U-M^>M\$>#^>JHM17^>22\$67ZAE1
M^>1^>A0Q6&R|H1+16\$HUU>^>X-Y-9F93TJ252^>Q-W22UDTHJC-ZZYZ1^>1^>L-M=RP=1?+>1&MUTVE17X<=>^>EXUTVSA-BG1^>U-W:M6V6Z^>TZJ&R^>51C>=>M1
W\$G&R>R^>W1%>O>H|GZ5>J|H1A4F6GT=28YVAXX6TUXC2WD^>Z-9MHW8+5+1YVMT-33P-M-O1X|H^>1^>N^>S5H.39VG66^>Y4&1^>M0BOKY^>U6U^>FAARS.O^>G#>7W-20+>0;
M1^>9WR1OG57F=1QZV8Z^>P>?H1^>E\$S^>Z^>P>?H1O7H#B16>53>0X3P&B12W-M1N1|3/7-8A1X7W@<#>S1L1N1X\$5N2>D&NCF83J^>0712179F&K\$>UJZ
MR+>3C^>E1K|H65|K&WU|>+3KR12^>ZU^>E-M^>T|H+YEO0R&P1L5^>VGE19732-M1^>UX44-U18^>10112V?>9GFM90-@U1:FI32D%1-8DVCVODCP^>Q-MC|O1
<@>MB1^>Q18N^>#61571%41N^>131B55^>T@>1^>DUA9JHNMB|H\$>=>H8U-M^>4.HYH+H-KK3&KPD|H=1VCLM1H1J^>703^>V^>V5G1^>SZ7C^>T^>YUN
M1P^>45R10NRU2^>ZVQ^>NF1^>291A+7M&L7H99N|N+M&15E1R-9H1^>T+T-M6ZL^>N^>F^>2GDFC^>1^>G1X1^>=<E1^>W1W>3P1VW73FM6R1G33TR1B1RPHCWD-M&K1FRUC-
=U1Z8)HP@>U+>@Q65S^>#Y^>KELZ&Z^>S^>T@<C&E^>L^>R^>L^>M^>7R9R+71S-U^>X4N1M&41^>REL^>XZ35WN@|H|J^>T^>C>C^>Y^>H5>7<7>Z^>P^>MUG^>1^>?K0U1^>?>
01-22H19>#23-71&H10U-0%6\$52P5+TW-GV4LRJ-MBM3R)?>P^>OKBAQV^>U1VUK9N09?Y212V53.MOLW-NV+TH4-7E2D>=>XEA-MNL-^>?HNO1Q1^>OL1O?>C6^>R3LYTP/<^>
1VW6Y2OUQ@G|JF1M@M^>

CPUBS.5& @502P.% @ 98 (65\$4&S I 0 ^0Y^ 18 M I A190IPG3 V^%YP/9MX>|A/I^Z MOXE#W9 3H;7KH145O&R;5L5XH(4&; HJH08(IB; <6GD0)V;03XTS;=4UQ(MTLI&ASLHHD%4N@YLSJ+J+WAZ>;GYT^((VK8U4E)^Z|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s /D1-6^3); PIA M;R.ZYH=&E0 M2P\$%^_4^I^E@ A9;5E%SL^#Y 0 %@ @ \$@7@;L87)W&5X.S(R+FA7;51+I08^@*)H^ /7P^ end XML 89 arwr:20240630 htm.xml IDEA: XBRL DOCUMENT 0000879407 2023-10-012024-06-30 0000879407 2024-08-012024-06-30 0000879407 2024-06-30 0000879407 2023-09-30 0000879407 2024-01-012024-06-30 0000879407 2024-04-012024-06-30 0000879407 2022-10-012023-06-30 0000879407 us-gaap:CommonStockMember 2023-09-30 0000879407 us-gaap:AdditionalPaidInCapitalMember 2023-09-30 0000879407 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-09-30 0000879407 us-gaap:RetainedEarningsMember 2023-09-30 0000879407 us-gaap:NoncontrollingInterestMember 2023-09-30 0000879407 us-gaap:AdditionalPaidInCapitalMember 2023-10-012023-12-31 0000879407 us-gaap:CommonStockMember 2023-10-012023-12-31 0000879407 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-10-012023-12-31 0000879407 us-gaap:RetainedEarningsMember 2023-10-012023-12-31 0000879407 us-gaap:NoncontrollingInterestMember 2023-10-012023-12-31 0000879407 us-gaap:CommonStockMember 2023-12-31 0000879407 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0000879407 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0000879407 us-gaap:RetainedEarningsMember 2023-12-31 0000879407 us-gaap:NoncontrollingInterestMember 2023-12-31 0000879407 2023-12-31 0000879407 us-gaap:AdditionalPaidInCapitalMember 2024-01-012024-03-31 0000879407 2024-01-012024-03-31 0000879407 us-gaap:CommonStockMember 2024-01-012024-03-31 0000879407 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-01-012024-03-31 0000879407 us-gaap:RetainedEarningsMember 2024-01-012024-03-31 0000879407 us-gaap:NoncontrollingInterestMember 2024-01-012024-03-31 0000879407 us-gaap:CommonStockMember 2024-03-31 0000879407 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0000879407 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-03-31 0000879407 us-gaap:RetainedEarningsMember 2024-03-31 0000879407 us-gaap:NoncontrollingInterestMember 2024-03-31 0000879407 2024-03-31 0000879407 us-gaap:AdditionalPaidInCapitalMember 2024-04-012024-06-30 0000879407 us-gaap:CommonStockMember 2024-04-012024-06-30 0000879407 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-04-012024-06-30 0000879407 us-gaap:RetainedEarningsMember 2024-04-012024-06-30 0000879407 us-gaap:NoncontrollingInterestMember 2024-04-012024-06-30 0000879407 us-gaap:CommonStockMember 2024-06-30 0000879407 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0000879407 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-06-30 0000879407 us-gaap:RetainedEarningsMember 2024-06-30 0000879407 us-gaap:NoncontrollingInterestMember 2022-09-30 0000879407 us-gaap:AdditionalPaidInCapitalMember 2022-09-30 0000879407 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-09-30 0000879407 us-gaap:RetainedEarningsMember 2022-09-30 0000879407 us-gaap:NoncontrollingInterestMember 2022-09-30 0000879407 2022-09-30 0000879407 us-gaap:AdditionalPaidInCapitalMember 2022-10-012022-12-31 0000879407 2022-10-012022-12-31 0000879407 us-gaap:CommonStockMember 2022-10-012022-12-31 0000879407 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-10-012022-12-31 0000879407 us-gaap:RetainedEarningsMember 2022-10-012022-12-31 0000879407 us-gaap:NoncontrollingInterestMember 2022-10-012022-12-31 0000879407 us-gaap:CommonStockMember 2022-12-31 0000879407 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0000879407 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0000879407 us-gaap:RetainedEarningsMember 2022-12-31 0000879407 us-gaap:NoncontrollingInterestMember 2022-12-31 0000879407 2022-12-31 0000879407 us-gaap:AdditionalPaidInCapitalMember 2023-01-012023-03-31 0000879407 2023-01-012023-03-31 0000879407 us-gaap:CommonStockMember 2023-01-012023-03-31 0000879407 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-012023-03-31 0000879407 us-gaap:RetainedEarningsMember 2023-01-012023-03-31 0000879407 us-gaap:NoncontrollingInterestMember 2023-01-012023-03-31 0000879407 us-gaap:CommonStockMember 2023-03-31 0000879407 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0000879407 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0000879407 us-gaap:RetainedEarningsMember 2023-03-31 0000879407 us-gaap:NoncontrollingInterestMember 2023-03-31 0000879407 2023-03-31 0000879407 us-gaap:AdditionalPaidInCapitalMember 2023-04-012023-06-30 0000879407 us-gaap:CommonStockMember 2023-04-012023-06-30 0000879407 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-04-012023-06-30 0000879407 us-gaap:RetainedEarningsMember 2023-04-012023-06-30 0000879407 us-gaap:NoncontrollingInterestMember 2023-04-012023-06-30 0000879407 us-gaap:CommonStockMember 2023-06-30 0000879407 us-gaap:AdditionalPaidInCapitalMember 2023-06-30 0000879407 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-06-30 0000879407 us-gaap:RetainedEarningsMember 2023-06-30 0000879407 us-gaap:NoncontrollingInterestMember 2023-06-30 0000879407 2023-06-30 0000879407 arwr:AmgenIncorporatedMemberarwr:RoyaltyPharmaAgreementMember 2024-06-30 0000879407 arwr:UnderwritingAgreementMember 2024-01-022024-01-02 0000879407 arwr:UnderwritingAgreementMember 2024-01-02 0000879407 arwr:GlaxosmithklineIntellectualPropertyLimitedMember 2024-04-012024-06-30 0000879407 arwr:GlaxosmithklineIntellectualPropertyLimitedMember 2023-04-012023-06-30 0000879407 arwr:GlaxosmithklineIntellectualPropertyLimitedMember 2023-10-012024-06-30 0000879407 arwr:GlaxosmithklineIntellectualPropertyLimitedMember 2022-10-012023-06-30 0000879407 arwr:HorizonTherapeuticsIrelandDACMember 2024-04-012024-06-30 0000879407 arwr:HorizonTherapeuticsIrelandDACMember 2023-04-012023-06-30 0000879407 arwr:HorizonTherapeuticsIrelandDACMember 2023-10-012024-06-30 0000879407 arwr:HorizonTherapeuticsIrelandDACMember 2022-10-012023-06-30 0000879407 arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember 2024-04-012024-06-30 0000879407 arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember 2023-04-012023-06-30 0000879407 arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember 2023-10-012024-06-30 0000879407 arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember 2022-10-012023-06-30 0000879407 arwr:JanssenPharmaceuticalsIncorporationMember 2024-04-012024-06-30 0000879407 arwr:JanssenPharmaceuticalsIncorporationMember 2023-04-012023-06-30 0000879407 arwr:JanssenPharmaceuticalsIncorporationMember 2023-10-012024-06-30 0000879407 arwr:JanssenPharmaceuticalsIncorporationMember 2022-10-012023-06-30 0000879407 arwr:AmgenIncorporatedMember 2024-04-012024-06-30 0000879407 arwr:AmgenIncorporatedMember 2023-04-012023-06-30 0000879407 arwr:AmgenIncorporatedMember 2023-10-012024-06-30 0000879407 arwr:AmgenIncorporatedMember 2022-10-012023-06-30 0000879407 arwr:GlaxosmithklineIntellectualPropertyLimitedMemberarwr:GSKHSDLicenseAgreementMember 2023-06-30 0000879407 arwr:GlaxosmithklineIntellectualPropertyLimitedMemberarwr:GSKHSDLicenseAgreementMember 2021-11-22 0000879407 arwr:GlaxosmithklineIntellectualPropertyLimitedMembersrt:MaximumMemberarwr:GSKHSDLicenseAgreementMember 2021-11-22 0000879407 arwr:GlaxosmithklineIntellectualPropertyLimitedMemberarwr:GSKHBVAgreementMember 2023-12-012023-12-31 0000879407 arwr:GlaxosmithklineIntellectualPropertyLimitedMembersrt:MaximumMemberarwr:GSKHBVAgreementMember 2023-12-11 0000879407 arwr:GlaxosmithklineIntellectualPropertyLimitedMemberarwr:GSKHBVAgreementMember 2024-06-30 0000879407 arwr:HorizonTherapeuticsIrelandDACMemberarwr:HorizonLicenseAgreementMember 2021-06-012021-06-30 0000879407 arwr:HorizonTherapeuticsIrelandDACMemberarwr:HorizonLicenseAgreementMember 2021-07-012021-07-31 0000879407 arwr:HorizonTherapeuticsIrelandDACMemberarwr:HorizonLicenseAgreementMember 2023-01-31 0000879407 arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMembersrt:MinimumMemberarwr:LicenseAndCoFundingAgreementMember 2020-10-012020-10-31 0000879407 arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMembersrt:MaximumMemberarwr:LicenseAndCoFundingAgreementMember 2020-10-012020-10-31 0000879407 arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMemberarwr:LicenseAndCoFundingAgreementMember 2020-10-012020-10-31 0000879407 arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMemberarwr:LicenseAndCoFundingAgreementMember 2023-03-31 0000879407 arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMembersrt:MaximumMemberarwr:LicenseAndCoFundingAgreementMember 2024-06-30 0000879407 arwr:TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMemberarwr:LicenseAndCoFundingAgreementMember 2024-06-30 0000879407 arwr:AmgenIncorporatedMemberarwr:OlpasiranAgreementMember 2016-09-30 0000879407 arwr:AmgenIncorporatedMemberarwr:OlpasiranAgreementMember 2016-09-012016-09-30 0000879407 arwr:AmgenIncorporatedMemberarwr:OlpasiranAgreementMember 2024-06-30 0000879407 arwr:AmgenIncorporatedMemberarwr:OlpasiranAgreementMember 2018-09-30 0000879407 arwr:AmgenIncorporatedMemberarwr:OlpasiranAgreementMember 2020-07-31 0000879407 arwr:AmgenIncorporatedMemberarwr:OlpasiranAgreementMember 2022-12-31 0000879407 arwr:AmgenIncorporatedMembersrt:MaximumMemberarwr:OlpasiranAgreementMember 2024-06-30 0000879407 arwr:VisirnaTherapeuticsIncMemberarwr:VisirnaLicenseAgreementMember 2023-10-012024-06-30 0000879407 arwr:VisirnaTherapeuticsIncMemberarwr:VisirnaLicenseAgreementMember 2022-10-012023-06-30 0000879407 arwr:VisirnaTherapeuticsIncMemberarwr:VisirnaLicenseAgreementMember 2024-06-30 0000879407 us-gaap:LandMember 2024-06-30 0000879407 us-gaap:LandMember 2023-09-30 0000879407 us-gaap:BuildingMember 2024-06-30 0000879407 us-gaap:BuildingMember 2023-09-30 0000879407 arwr:ResearchEquipmentMember 2024-06-30 0000879407 arwr:ResearchEquipmentMember 2023-09-30 0000879407 us-gaap:FurnitureAndFixturesMember 2024-06-30 0000879407 us-gaap:FurnitureAndFixturesMember 2023-09-30 0000879407 arwr:ComputerAndSoftwareMember 2024-06-30 0000879407 arwr:ComputerAndSoftwareMember 2023-09-30 0000879407 us-gaap:LeaseholdImprovementsMember 2024-06-30 0000879407 us-gaap:LeaseholdImprovementsMember 2023-09-30 0000879407 us-gaap:ConstructionInProgressMember 2024-06-30 0000879407 us-gaap:ConstructionInProgressMember 2023-10-012024-06-30 0000879407 us-gaap:BuildingMember 2023-10-012024-06-30 0000879407 us-gaap:BuildingMember 2023-12-31 0000879407 us-gaap:DebtSecuritiesMember 2024-06-30 0000879407 us-gaap:DebtSecuritiesMember 2023-09-30 0000879407 arwr:NovartisMemberus-gaap:PatentsMember 2024-06-30 0000879407 arwr:NovartisMemberus-gaap:PatentsMember 2023-09-30 0000879407 arwr:NovartisMemberus-gaap:PatentsMember 2023-09-30 0000879407 us-gaap:PatentsMember 2023-09-30 0000879407 arwr:NovartisMember 2023-09-30 0000879407 arwr:TwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember 2024-06-30 0000879407 arwr:TwoThousandThirteenEquityIncentivePlanTwoThousandTwentyOneEquityIncentivePlanAndInducementGrantsMember 2023-09-30 0000879407 srt:MaximumMemberarwr:AtTheMarketAgreementMember 2022-12-02 0000879407 srt:MaximumMemberarwr:AtTheMarketAgreementMember 2022-12-022022-12-02 0000879407 arwr:AtTheMarketAgreementMember 2024-06-30 0000879407 stpr:Wiarwr:DrugManufacturingFacilityMember 2021-12-20 0000879407 stpr:Wiarwr:LaboratoryAndOfficeFacilityMember 2021-12-20 0000879407 arwr:FacilitiesMember 2024-06-30 0000879407 srt:MaximumMemberarwr:FacilitiesMember 2024-06-30 0000879407 srt:MaximumMemberarwr:FacilitiesMember 2024-06-30 0000879407 stpr:MaximumMemberarwr:FacilitiesMember 2024-06-30 0000879407 stpr:CAarwr:CorporateHeadquartersInPasadenaMember 2024-06-30 0000879407 stpr:CAarwr:ResearchFacilityInSanDiegoMember 2024-06-30 0000879407 stpr:MaximumMemberstpr:CAarwr:ResearchFacilityInSanDiegoMember 2024-06-30 0000879407 stpr:CAarwr:ResearchFacilityInSanDiegoMember 2023-09-25 0000879407 stpr:CAarwr:ResearchFacilityInMadisonMember 2024-06-30 0000879407 us-gaap:ResearchAndDevelopmentExpenseMember 2024-04-012024-06-30 0000879407 us-gaap:ResearchAndDevelopmentExpenseMember 2023-04-012023-06-30 0000879407 us-gaap:ResearchAndDevelopmentExpenseMember 2023-10-012024-06-30 0000879407 us-gaap:ResearchAndDevelopmentExpenseMember 2022-10-012023-06-30 0000879407 us-gaap:GeneralAndAdministrativeExpenseMember 2024-04-012024-06-30 0000879407 us-gaap:GeneralAndAdministrativeExpenseMember 2023-04-012023-06-30 0000879407 us-gaap:GeneralAndAdministrativeExpenseMember 2023-10-012024-06-30 0000879407 us-gaap:GeneralAndAdministrativeExpenseMember 2022-10-012023-06-30 0000879407 arwr:TwoThousandThirteenIncentivePlanMember 2024-06-30 0000879407 arwr:TwoThousandTwentyOneIncentivePlanMember 2021-09-30 0000879407 arwr:TwoThousandThirteenIncentivePlanMember 2023-10-012024-06-30 0000879407 arwr:TwoThousandTwentyOneIncentivePlanMember 2023-10-012024-06-30 0000879407 us-gaap:EmployeeStockOptionMemberarwr:InducementAwardsMember 2024-06-30 0000879407 us-gaap:RestrictedStockUnitsRSUMemberarwr:InducementAwardsMember 2024-06-30 0000879407 arwr:TwoThousandTwentyOneIncentivePlanMember 2024-06-30 0000879407 arwr:InducementAwardsMember 2024-06-30 0000879407 us-gaap:RestrictedStockUnitsRSUMemberarwr:TwoThousandThirteenIncentivePlanMember 2024-06-30 0000879407 us-gaap:RestrictedStockUnitsRSUMemberarwr:TwoThousandTwentyOneIncentivePlanMember 2024-06-30 0000879407 us-gaap:RestrictedStockUnitsRSUMember 2024-06-30 0000879407 us-gaap:EmployeeStockOptionMember 2024-04-012024-06-30 0000879407 us-gaap:EmployeeStockOptionMember 2023-04-012023-06-30 0000879407 us-gaap:EmployeeStockOptionMember 2023-10-012024-06-30 0000879407 us-gaap:EmployeeStockOptionMember 2022-10-012023-06-30 0000879407 us-gaap:EmployeeStockOptionMember 2024-06-30 0000879407 arwr:VisirnaESOPMember 2023-10-012023-10-01 0000879407 arwr:VisirnaESOPMember 2023-10-01 0000879407 arwr:VisirnaESOPMember 2023-10-012024-06-30 0000879407 us-gaap:RestrictedStockUnitsRSUMember 2023-09-30 0000879407 us-gaap:RestrictedStockUnitsRSUMember 2023-10-012024-06-30 0000879407 us-gaap:RestrictedStockUnitsRSUMember 2024-04-012024-06-30 0000879407 us-gaap:RestrictedStockUnitsRSUMember 2023-04-012023-06-30 0000879407 us-gaap:RestrictedStockUnitsRSUMember 2022-10-012023-06-30 0000879407 us-gaap:FairValueInputsLevel11Memberus-gaap:FairValueMeasurementsRecurringMemberus-

gaap:USGovernmentDebtSecuritiesMember 2024-06-30 0000879407 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentDebtSecuritiesMember 2024-06-30 0000879407 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentDebtSecuritiesMember 2024-06-30 0000879407 us-gaap:FairValueMeasurementsRecurringMember arwr:CommercialNotesMember 2024-06-30 0000879407 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember arwr:CommercialNotesMember 2024-06-30 0000879407 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember arwr:CommercialNotesMember 2024-06-30 0000879407 us-gaap:FairValueMeasurementsRecurringMember arwr:CommercialNotesMember 2024-06-30 0000879407 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2024-06-30 0000879407 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2024-06-30 0000879407 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2024-06-30 0000879407 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2024-06-30 0000879407 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0000879407 us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0000879407 us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0000879407 us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0000879407 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0000879407 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0000879407 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0000879407 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0000879407 arwr:CommercialNotesMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0000879407 arwr:CommercialNotesMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0000879407 arwr:CommercialNotesMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0000879407 arwr:CommercialNotesMember us-gaap:FairValueMeasurementsRecurringMember 2024-06-30 0000879407 us-gaap:USGovernmentDebtSecuritiesMember 2023-09-30 0000879407 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentDebtSecuritiesMember 2023-09-30 0000879407 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentDebtSecuritiesMember 2023-09-30 0000879407 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentDebtSecuritiesMember 2023-09-30 0000879407 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2023-09-30 0000879407 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2023-09-30 0000879407 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2023-09-30 0000879407 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MunicipalBondsMember 2023-09-30 0000879407 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember arwr:CommercialNotesMember 2023-09-30 0000879407 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember arwr:CommercialNotesMember 2023-09-30 0000879407 us-gaap:FairValueMeasurementsRecurringMember arwr:CommercialNotesMember 2023-09-30 0000879407 us-gaap:FairValueMeasurementsRecurringMember arwr:CommercialNotesMember 2023-09-30 0000879407 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2023-09-30 0000879407 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2023-09-30 0000879407 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2023-09-30 0000879407 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2023-09-30 0000879407 us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0000879407 us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0000879407 us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0000879407 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel1Member us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0000879407 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0000879407 us-gaap:MoneyMarketFundsMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0000879407 us-gaap:MoneyMarketFundsMember us-gaap:FairValueMeasurementsRecurringMember 2023-09-30 0000879407 srt:MaximumMember arwr:RoyaltyPharmaAgreementMember 2022-11-01 2022-11-30 0000879407 arwr:RoyaltyPharmaAgreementMember 2022-11-01 2022-11-30 0000879407 arwr:RoyaltyPharmaAgreementMember 2024-04-01 2024-06-30 0000879407 arwr:RoyaltyPharmaAgreementMember 2024-06-30 0000879407 us-gaap:EmployeeStockOptionMember 2024-04-01 2024-06-30 0000879407 us-gaap:EmployeeStockOptionMember 2023-04-01 2023-06-30 0000879407 us-gaap:EmployeeStockOptionMember 2023-10-01 2023-06-30 0000879407 us-gaap:EmployeeStockOptionMember 2022-10-01 2023-06-30 0000879407 us-gaap:RestrictedStockUnitsRSUMember 2024-04-01 2024-06-30 0000879407 us-gaap:RestrictedStockUnitsRSUMember 2023-04-01 2023-06-30 0000879407 us-gaap:RestrictedStockUnitsRSUMember 2023-10-01 2024-06-30 0000879407 us-gaap:RestrictedStockUnitsRSUMember 2022-10-01 2023-06-30 0000879407 us-gaap:SecuredDebtMember arwr:FinancingAgreementMember us-gaap:LineOfCreditMember us-gaap:SubsequentEventMember 2024-08-07 0000879407 arwr:IncrementalFacilityMember arwr:FinancingAgreementMember us-gaap:LineOfCreditMember us-gaap:SubsequentEventMember 2024-08-07 0000879407 arwr:FinancingAgreementMember us-gaap:LineOfCreditMember us-gaap:SubsequentEventMember 2024-08-07 0000879407 arwr:VictoriaVakienerMember 2024-04-01 2024-06-30 0000879407 arwr:VictoriaVakienerMember 2024-06-30 shares iso4217:USD iso4217:USD shares arwr:obligation pure arwr:bundle arwr:agreement utr:sft arwr:option0000879407--09-302024Q3false12/31/2024P15D10-Qtrue2024-06-30false001-38042ARROWHEAD PHARMACEUTICALS, INC.DE F4048024177 E. Colorado BlvdSuite 700PasadenaCA91105626304-3400Common Stock par value \$0.001 per shareARWRNSDAQYesYesLarge Accelerated Filerfalsefalse12431527469399000011089100063672200092273500092070008813000418400040330004500620004164720003759110002906200089870001026200044330.0018.00129000000002900000001242278000124227800010731200010731200021700020000017863040001360395000.987000.3222000.1454987000.1026030000330547000271343000842700015819000338974000287162000883759000765552000015825000355100022463800015243100094757000370044000253333000237176141000.102703000.438877000.9667200064980004172000155500000114140005094000515800011705100013064000760000306000137000082100002164000.680000.785000.829000.173977000.103383000.439662000.975010000742000.3313000759000.173977000.104125000.436349000.98260000.3184000.1179000.7392000.2664000.1907193000.102946000.428957000.95596000.138.96.6.33.9.0.138.96.6.33.0.90124199000107004000118260000106597000124199000107004000118260000106597000249000023740000.141000.79000.139000.275000.173869000.104204000.434114000.985350001073120002000001300395000.3222000.1026030001581

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

[illegible]

Related to the Sale of Future Royalties

On November 22, 2022, the Company and Royalty Pharma entered into the Royalty Pharma Agreement, pursuant to which Royalty Pharma agreed to pay up to \$410.0 million in cash to the Company in consideration for the Company's future royalty interest in olpasiran, a siRNA originally developed by the Company and licensed to Amgen in September 2016 under the Olpasiran Agreement. Pursuant to the Royalty Pharma Agreement, Royalty Pharma paid \$250.0 million upfront and agreed to pay up to an additional \$160.0 million in aggregate one-time milestone payments due if and when the following milestone events occur: (i) \$50.0 million on completion of enrollment in the OCEAN Phase 3 clinical trial for olpasiran, (ii) \$50.0 million upon receipt of FDA approval of olpasiran for an approved indication (reduction in the risk of myocardial infarction, urgent coronary revascularization, or coronary heart disease death in adults with established cardiovascular disease and elevated Lp(a)), and (iii) \$60.0 million upon Royalty Pharma's receipt of at least \$70.0 million of royalty payments under the Royalty Pharma Agreement in any single calendar year. During the third quarter of fiscal 2024, Amgen completed enrollment of the Phase 3 OCEAN(a) outcomes trial of olpasiran, which triggered a \$50.0 million milestone payment that the Company received in the same quarter.

In consideration for the payment of the foregoing amounts under the Royalty Pharma Agreement, Royalty Pharma is entitled to receive all royalties otherwise payable by Amgen to the Company under the Olpasiran Agreement. The Company remains eligible to receive any milestone payments potentially payable by Amgen under the Olpasiran Agreement.

The Company has evaluated the terms of the Royalty Pharma Agreement and concluded, in accordance with the relevant accounting guidance, that the Company accounted for the transaction as debt and the funding of \$250.0 million and \$50.0 million from Royalty Pharma were recorded as liabilities related to the sale of future royalties on its consolidated balance sheets. The Company is not obligated to repay these funds received under the Royalty Pharma Agreement.

[illegible]

[illegible]

Weighted-Average Diluted Net Loss Per Share

Period	Diluted Net Loss Per Share
Three Months Ended June 30, 2024	\$0.00
Nine Months Ended June 30, 2024	\$0.00
Three Months Ended June 30, 2023	\$0.00
Nine Months Ended June 30, 2023	\$0.00

The following table presents the computation of basic and diluted net loss per share for the three and nine months ended June 30, 2024 and 2023.

Period	Net Loss	Diluted Shares	Diluted Net Loss Per Share
Three Months Ended June 30, 2024	\$0.00	114,253,333	\$0.00
Nine Months Ended June 30, 2024	\$0.00	114,253,333	\$0.00
Three Months Ended June 30, 2023	\$0.00	114,253,333	\$0.00
Nine Months Ended June 30, 2023	\$0.00	114,253,333	\$0.00

Basic shares outstanding are 114,253,333 as of June 30, 2024 and 114,253,333 as of June 30, 2023. Weighted-average dilutive securities include 0 shares as of June 30, 2024 and 0 shares as of June 30, 2023.

[illegible]

[illegible]

[illegible]

[illegible]

!C~>26Q?P2WEHEM=,8XR9= MCS@=BX\$G9SS54!%ZFEFLV,YISE=46\$,YC7#C)KLVIG6VL7UEFUL,F0:52X^G63J3DC<2.D.I.G%=10!SVF^>L>M1:M=7S7=7%>
!B0Q?C.A/L/MSD?>V1?4?M0ZUX0.K.S+J4&KWL=A/!9289A0.K+P.TY0C1?>B#>EX.M0/HB:4M/J<F32%T1HUP,X1C0R>.E0OX9522TUF1MFM/73IFR?T485
MBIX#>GD?IKP?>P1<0R.9P1.B&LKFSL10)8X\$S5Y@>PR<GK65.M1@HVNWYH=32&I@AA>.3G.E<N2ZDG560I4C>I/P/EGXGDU+&HWB+JDF#<M<.<Y4
(RHB:>C9P190W6MW=NQB25858BH+VH0839E1H\$>N16:10\$NG=>MSIOIC<72%O1+L9+>=&S/GMSG/G1+&3127BCX#6VTS28+J5VJO=>L.GDWB:1M+&EED+<RG(22P?
L@>#G#X21M26+DUKYEY.LQ1=>10?7#MN+D1CGL.U7K/M1WL?>T.BP7BL+L?UBNE4L9UW60TR,X*.*2G!6IU9ZS+>NEQJ0K+L1-M!L85HFW(P7D5YZDLA?>
K<0ZTMJK5Y<2ZKY+RS.GC.2+&QTV@>8P,=>H.MB@FEFVW+64<=>WKWM>7?>.XGFI<8B.54(N)>IZGUCZ8T1F/3M3U6I25G.M49DF=2.5\$HJ8?>.TJ?>.6E1(2W?
B+V2U19DM+IKF55.8+&F00(S+G)09.M1@=>Z513X?V1C1HL?>V<6G7TEU:HUL558L=K.M4(N)>8(1)2NWHXNS1
M1362Z.U4R5?>7\$E40V9.LLV=>P(Z.N3WZ5.TOPA=>J16:77.M=65YTFW8.MN=>B21YGVW6F23M1<=>OW^GWSBH.M.CP*)+13.M<6VHPZA-J%O>>L&I.3RDEFY6@H%Y/H0T:4+
15.M9IR1TWSR9715\$QF1<4<=>51@>2V50H1=>GK4T3Z9.L1#>#G.MXE6P6I9E.GB0\$4+R.T.MG+H/L/6.5YV.M+I/135.3P9K%WH%YHF=>YKHS1Q00R\$S11%>B
G.#1\$>IDFN5H1YK7?>M1J.M6VL5KTA@>29HT5+1(M2T4%%>%%>1110444%%>%%>1110444%%>20P\$>H/L/53U1%>MW.T<E>X.O+H%EC+Y4G+M197AW+>
F.USK5H***>BBB@>HHHHH.M***>BBB@>HHHHH.M***>H/L/53U1%>MW.T<E>X.O+H%EC+Y4G+M197AW+>
/X?>P06XGD@>L4.MAPZ\$H.L4U93.HC.M&SMSNZGQX\$1?>9.W0FG.G^>EYRW+V7F10QE.O.KI.MEPT.C<#>Y\$>E.E4UC&BSU2.YFR&6(PDBDC7EAQ6.C1*=>.D1.V:1CMHC
M+>[GU].\$R@F>LEVIX'M.D@>N^BU'POJUY=>MKL-BT=>V^L6M1H=>4.5PQ%>M.2#M+PD1<2<512)10ISGB13.6?#>VJK.HUWY10.86D'R2#>#1<P-?>.MMJ\$GC?
I/1&WKVYHEDR.R8U@>8TZUZ?>10IQ12+J^K<+>S4U1O.NG.P#>MB?>MSPN<35&9PDS4D&JLJR1SPUXEG1:WH1?>H16I.1G071T33J%>7<L10U@KOA<MG?>F7IU%
'FNH+>+B.OJQMW=>=&8-BL1%>XIGNQ&MMMM0#>PD0G=>#(X1HFF).MKEO\$55<2.3.8K371=>(89X4@>W&X@>FX.9.026YZXZKX1V@>#SBTTC7+>73=M.N
GG65HUCW7C25?>=>O@>N.W2.12A154I9U2SUF1>>31X1GBOXL.M2Q8?>#GENA@>X203**>1/667M0+XKN1B0G.4.G3HH.12(7EB3)E5SS.M@>X.TXGCMU&IX-G676
6EN:4175-HRYXOM1QIRHHC789NF.WUWPU=>W0B>=>Y4+31-31VM.5\$>HFW+@>I.W&I2.M1&RMD1QO-6E7Z>60B39GL2D5.BBV6D#>@2.U5.XXP3X5>
MM=310!R1FF3XFC49.R6DFDK1<50)(LK.5/<9!\$C1Q15R<@>Z\$UAI#PWO.MA6^GU\$SDGF2>.I9K>0<5.8+G1.@>OJ3Z5A10!Y)J)M)J%EX(UT?>1P18.MK2W%M%?
P.LT3Q\$S?>QO51C1K-71P.>#EUKT1JZC1>ERV.R9P0M.R@>VW192.M75S3(4<=>4+U5VJ2H1JBL1<=>B1VY?>EDWE7>B6+6+1=>M.ZE.7#00@>H1B.V1GFL24
/1/6?>H1VLEWVP.ER.E51MD9KT8B#>#F3NG7-YX&N.Y2Z2N15AMJC1YD1<=>#U4U5JZ9H1WZ.YCT.M=>H01ACMEEO\$5.8E.YZ@>E.1H803**>+>
12KB34<=>H?>7&URU+13K.16(MEVB)89.0TF3UKKJ.MZHEKKF.5?>H5VP1=>5=D+H%>H'G=>M.G.M1.LW1MW+DZ9+>PAT\$>T.MR1O1P23\$51V1R@>8K12=>5=Z>.0T&
JEM?>47519B99.9K9B698Y.L2&=>M1K9R.95B0A1?>(U21-P1C.8Z7.98/&N&K>+>L<=>K.O3IR.UH1LH4M1S1.6<5%>YH1+Q1%>M02N#A1.C1R1J.CCG17H%
'F>BI?>X1%>VESX>U.M&6721)*<3M&+5C\$8IX8'D>?>Q571>)>Y-0L?>T75K.2Y12M85G@>GBM1&2.R.M'LBJ>#C8PZCAO>N1HH.X5Q/I=M.7K0T&ZBTLZ?>FRM8?>V9Y%
<S0>=>X.M.S@G1K?>F?>E>=>@>PL19=>5TYEFMF1A6'M#>YW0<92P?>7B02P1>=>9T.M1.19M'N1/4H1XHT051R219S@>O12XC968@>P(S@>96=>111>=>P6M
M1+MM2%>+>21'>60W.95W&GVYN3L.XS7H.>#DVA<+>@>3265Y1U>N67.4WE.M7AMS1C1GW8E0ELS&N5N0>205JRSKPHN\$S.Z.MK=1227.J(LR1\$1)9YD@>6.3/2TH
773S1>D6H1AEU21T2H22.2SL2Y1.MO.<O/L.1B72'>NGW>CWO>R<O>YUW&V.6.31XPSRZ<1.8UZE10Y17H.M5Y3H.MTR12&OHEHC6V\$Y3AT4+QGI*Q
ITPC71S1+U&B75+34910T@>CYKIF9A(C1V.N2<1272.MJBD94Q&1H>=>@OWPA.V1H.X322+512.DFNKMG1JQ9D#1#(K1AM7+>M1TQ661V\$Q10.PB<GK1MU:YU^TFH2O.NJE
D@D252-K1V8D)SD>E>A1-MMH>E0>9L(AW?>+>IP>=>Y%>#=>S#>8UPFJOQ/85O/NV.MO&P.UBIZ>HY%>=>66L36?@>PI=>=>K.OJLTT(EN+N286DVXX.I2>=>LH
.EHBK1?>UC>.>TLMG<61B.9P1+HJ67RT.M&X?>4D<=>6/U1#3M80#40B79>2.RVE1+HCSQ0&=>S?>F&91P&QWV=M?>5.MC.EKKV1YVP.8V37M+1P2T7F?>L'G/G?>V
M4EWS>R1HX0H1G1.O1?>TJMH1F6DC1D9>R1XS1H0P>QQG1.SHKD1>QT1Y2&Z8-M=>GJH0Y&DDPS+N10C.2A.TYK>T4YU:UFN#(HUN)8H1W148K01.OD.M@>U<=>U<=>C171^>
>N&AN:1'WC249TU1Y1YDNN:>+>3%>LBDY<1ZG1K2BL027E.MM&VE715M.7/1S7F19U81P&S181P?>X1L'545R1OXU@>MW.P1'525N39.MO?
ADYK+O1O1F=O7=>ON1>+>J7GCR2PT041?>TR1GRV1?>2N(FNERIMMYR9OT.M1.N.GM01V1=>U2U2)SE%>E#>JL1R5R1310Q316E>=>L&158M/N.BU:4?>\$(#H5@>
MKM8X1S1V>H&S.\$@>645R*.\$3101.7#>)(LER.03(Z\$B4\$@Y3.X+D\$>B.O.M1O.ZX1.F.'BO+>CQ&K&IV&D71MK+9+>ENJVMUG11OD5D8.C1L>=>=>Z
M1/NF.V3E.B1M.O@>C1J2DNRX.M#>881.#9@>IGB@>TVBN5N&5MRKQZ?>J)>H1D>H.8PC.V1R1689.Y23M12.MF1
4.V.EZ710.S09K061=W).B#>11R>=>#98>+>F@>#H?>Y57?>H1=VYV.MT54.G

[illegible]

[illegible]

[illegible]

[illegible]